drug1,drug2,text,interacts,type
DDI-DrugBank.d466.s0.e0,DDI-DrugBank.d466.s0.e1,Drug Interaction with drug1 and drug2 drug0,False, 
DDI-DrugBank.d466.s0.e0,DDI-DrugBank.d466.s0.e2,Drug Interaction with drug1 and drug0 drug2,False, 
DDI-DrugBank.d466.s1.e0,DDI-DrugBank.d466.s1.e1,"However, co  administration of drug1 with either drug2 or drug0 led to increased plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d466.s1.e0,DDI-DrugBank.d466.s1.e2,"However, co  administration of drug1 with either drug0 or drug2 led to increased plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d466.s1.e0,DDI-DrugBank.d466.s1.e3,"However, co  administration of drug1 with either drug0 or drug0 led to increased plasma concentrations of drug2",False, 
DDI-DrugBank.d466.s1.e1,DDI-DrugBank.d466.s1.e2,"However, co  administration of drug0 with either drug1 or drug2 led to increased plasma concentrations of drug0",False, 
DDI-DrugBank.d466.s2.e0,DDI-DrugBank.d466.s2.e1,drug1 had no effect on the pharmacokinetics of either drug2 or drug0,False, 
DDI-DrugBank.d466.s2.e0,DDI-DrugBank.d466.s2.e2,drug1 had no effect on the pharmacokinetics of either drug0 or drug2,False, 
DDI-DrugBank.d466.s3.e0,DDI-DrugBank.d466.s3.e1,"In 2 separate studies, drug1 120 mg twice daily (240 mg total daily dose) was co-administered with either drug2 500 mg every 8 hours or drug0",False, 
DDI-DrugBank.d466.s3.e0,DDI-DrugBank.d466.s3.e2,"In 2 separate studies, drug1 120 mg twice daily (240 mg total daily dose) was co-administered with either drug0 500 mg every 8 hours or drug2",False, 
DDI-DrugBank.d466.s4.e0,DDI-DrugBank.d466.s4.e1,No differences in adverse events or QTc interval were observed when subjects were administered drug1 alone or in combination with either drug2 or drug0,False, 
DDI-DrugBank.d466.s4.e0,DDI-DrugBank.d466.s4.e2,No differences in adverse events or QTc interval were observed when subjects were administered drug1 alone or in combination with either drug0 or drug2,False, 
DDI-DrugBank.d466.s5.e0,DDI-DrugBank.d466.s5.e1,The findings of these studies are summarized in the following table: Effects on steady-state drug1 pharmacokinetics after 7 days of co-administration with drug2,False, 
DDI-DrugBank.d466.s17.e0,DDI-DrugBank.d466.s17.e1,These studies indicate that drug1 or drug2 co-administration enhances drug0,False, 
DDI-DrugBank.d466.s17.e0,DDI-DrugBank.d466.s17.e2,These studies indicate that drug1 or drug0 co-administration enhances drug2,True,mechanism
DDI-DrugBank.d466.s17.e1,DDI-DrugBank.d466.s17.e2,These studies indicate that drug0 or drug1 co-administration enhances drug2,True,mechanism
DDI-DrugBank.d466.s18.e0,DDI-DrugBank.d466.s18.e1,"This observed increase in the bioavailability of drug1 may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, drug2 decreases drug0 gastrointestinal secretion, while drug0",False, 
DDI-DrugBank.d466.s18.e0,DDI-DrugBank.d466.s18.e2,"This observed increase in the bioavailability of drug1 may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, drug0 decreases drug2 gastrointestinal secretion, while drug0",False, 
DDI-DrugBank.d466.s18.e1,DDI-DrugBank.d466.s18.e2,"This observed increase in the bioavailability of drug0 may be due to transport-related effects, such as p-glycoprotein. in vivo animal studies also suggest that in addition to enhancing absorption, drug1 decreases drug2 gastrointestinal secretion, while drug0",True,mechanism
DDI-DrugBank.d466.s19.e0,DDI-DrugBank.d466.s19.e1,Drug Interactions with drug1 Administration of 120 mg of drug2 (2 x 60 mg capsule) within 15 minutes of an drug0 and drug0 containing drug0 (drug0 ) decreased drug0,False, 
DDI-DrugBank.d466.s19.e0,DDI-DrugBank.d466.s19.e2,Drug Interactions with drug1 Administration of 120 mg of drug0 (2 x 60 mg capsule) within 15 minutes of an drug2 and drug0 containing drug0 (drug0 ) decreased drug0,False, 
DDI-DrugBank.d466.s19.e1,DDI-DrugBank.d466.s19.e2,Drug Interactions with drug0 Administration of 120 mg of drug1 (2 x 60 mg capsule) within 15 minutes of an drug2 and drug0 containing drug0 (drug0 ) decreased drug0,True,mechanism
DDI-DrugBank.d466.s19.e1,DDI-DrugBank.d466.s19.e3,Drug Interactions with drug0 Administration of 120 mg of drug1 (2 x 60 mg capsule) within 15 minutes of an drug0 and drug2 containing drug0 (drug0 ) decreased drug0,True,mechanism
DDI-DrugBank.d466.s19.e1,DDI-DrugBank.d466.s19.e4,Drug Interactions with drug0 Administration of 120 mg of drug1 (2 x 60 mg capsule) within 15 minutes of an drug0 and drug0 containing drug2 (drug0 ) decreased drug0,True,mechanism
DDI-DrugBank.d466.s19.e1,DDI-DrugBank.d466.s19.e5,Drug Interactions with drug0 Administration of 120 mg of drug1 (2 x 60 mg capsule) within 15 minutes of an drug0 and drug0 containing drug0 (drug2 ) decreased drug0,True,mechanism
DDI-DrugBank.d466.s20.e0,DDI-DrugBank.d466.s20.e1,drug1 should not be taken closely in time with drug2 and drug0 containing drug0,True,advise
DDI-DrugBank.d466.s20.e0,DDI-DrugBank.d466.s20.e2,drug1 should not be taken closely in time with drug0 and drug2 containing drug0,True,advise
DDI-DrugBank.d466.s20.e0,DDI-DrugBank.d466.s20.e3,drug1 should not be taken closely in time with drug0 and drug0 containing drug2,False, 
DDI-DrugBank.d466.s20.e1,DDI-DrugBank.d466.s20.e2,drug0 should not be taken closely in time with drug1 and drug2 containing drug0,False, 
DDI-DrugBank.d466.s27.e0,DDI-DrugBank.d466.s27.e1,"Therefore, to maximize the effects of drug1, it is recommended that drug2",False, 
DDI-DrugBank.d153.s0.e0,DDI-DrugBank.d153.s0.e1,The administration of local drug1 containing drug2 or drug0 to patients receiving drug0 or drug0,False, 
DDI-DrugBank.d153.s0.e0,DDI-DrugBank.d153.s0.e2,The administration of local drug1 containing drug0 or drug2 to patients receiving drug0 or drug0,False, 
DDI-DrugBank.d153.s0.e1,DDI-DrugBank.d153.s0.e3,The administration of local drug0 containing drug1 or drug0 to patients receiving drug2 or drug0,True,effect
DDI-DrugBank.d153.s0.e1,DDI-DrugBank.d153.s0.e4,The administration of local drug0 containing drug1 or drug0 to patients receiving drug0 or drug2,True,effect
DDI-DrugBank.d153.s0.e2,DDI-DrugBank.d153.s0.e3,The administration of local drug0 containing drug0 or drug1 to patients receiving drug2 or drug0,True,effect
DDI-DrugBank.d153.s0.e2,DDI-DrugBank.d153.s0.e4,The administration of local drug0 containing drug0 or drug1 to patients receiving drug0 or drug2,True,effect
DDI-DrugBank.d153.s3.e0,DDI-DrugBank.d153.s3.e1,Concurrent administration of drug1 and of drug2,False, 
DDI-DrugBank.d153.s4.e0,DDI-DrugBank.d153.s4.e1,drug1 and drug2 may reduce or reverse the pressor effect of drug0,False, 
DDI-DrugBank.d153.s4.e0,DDI-DrugBank.d153.s4.e2,drug1 and drug0 may reduce or reverse the pressor effect of drug2,True,effect
DDI-DrugBank.d153.s4.e1,DDI-DrugBank.d153.s4.e2,drug0 and drug1 may reduce or reverse the pressor effect of drug2,True,effect
DDI-DrugBank.d309.s0.e0,DDI-DrugBank.d309.s0.e1,"Additive CNS depression may occur when drug1 are administered concomitantly with other drug2 including drug0, drug0, and drug0",True,effect
DDI-DrugBank.d309.s0.e0,DDI-DrugBank.d309.s0.e2,"Additive CNS depression may occur when drug1 are administered concomitantly with other drug0 including drug2, drug0, and drug0",True,effect
DDI-DrugBank.d309.s0.e0,DDI-DrugBank.d309.s0.e3,"Additive CNS depression may occur when drug1 are administered concomitantly with other drug0 including drug0, drug2, and drug0",True,effect
DDI-DrugBank.d309.s0.e0,DDI-DrugBank.d309.s0.e4,"Additive CNS depression may occur when drug1 are administered concomitantly with other drug0 including drug0, drug0, and drug2",True,effect
DDI-DrugBank.d309.s0.e1,DDI-DrugBank.d309.s0.e2,"Additive CNS depression may occur when drug0 are administered concomitantly with other drug1 including drug2, drug0, and drug0",False, 
DDI-DrugBank.d309.s0.e1,DDI-DrugBank.d309.s0.e3,"Additive CNS depression may occur when drug0 are administered concomitantly with other drug1 including drug0, drug2, and drug0",False, 
DDI-DrugBank.d309.s1.e0,DDI-DrugBank.d309.s1.e1,Patients receiving drug1 should be advised against the concurrent use of other drug2,True,advise
DDI-DrugBank.d309.s2.e0,DDI-DrugBank.d309.s2.e1,drug1 prolong and intensify the anticholinergic effects of drug2,True,effect
DDI-DrugBank.d307.s1.e0,DDI-DrugBank.d307.s1.e1,"In addition, several drug1 s that are cytochrome P450 inducers can decrease plasma concentrations of drug2 and drug0",True,mechanism
DDI-DrugBank.d307.s1.e0,DDI-DrugBank.d307.s1.e2,"In addition, several drug1 s that are cytochrome P450 inducers can decrease plasma concentrations of drug0 and drug2",False, 
DDI-DrugBank.d307.s1.e1,DDI-DrugBank.d307.s1.e2,"In addition, several drug0 s that are cytochrome P450 inducers can decrease plasma concentrations of drug1 and drug2",False, 
DDI-DrugBank.d307.s3.e0,DDI-DrugBank.d307.s3.e1,Results demonstrate that drug1 and its pharmacologically active 10-monohydroxy metabolite (drug2,False, 
DDI-DrugBank.d307.s4.e0,DDI-DrugBank.d307.s4.e1,Although inhibition of CYP 3A4/5 by drug1 and drug2,False, 
DDI-DrugBank.d307.s5.e0,DDI-DrugBank.d307.s5.e1,The inhibition of CYP-2C19 by drug1 and drug2,False, 
DDI-DrugBank.d307.s7.e0,DDI-DrugBank.d307.s7.e1,Increases of 22% with drug1 and 47% with drug2,False, 
DDI-DrugBank.d307.s8.e0,DDI-DrugBank.d307.s8.e1,"As drug1, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., drug2, drug0",False, 
DDI-DrugBank.d307.s8.e0,DDI-DrugBank.d307.s8.e2,"As drug1, the predominant plasma substrate, is only a weak inducer of UDP-glucuronyl transferase, it is unlikely to have an effect on drugs that are mainly eliminated by conjugation through UDP-glucuronyl transferase (e.g., drug0, drug2",False, 
DDI-DrugBank.d307.s9.e0,DDI-DrugBank.d307.s9.e1,"In addition, drug1 and drug2 induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of drug0 and oral drug0",False, 
DDI-DrugBank.d307.s9.e0,DDI-DrugBank.d307.s9.e2,"In addition, drug1 and drug0 induce a subgroup of the cytochrome P450 3A family (CYP3A4 and CYP3A5) responsible for the metabolism of drug2 and oral drug0",False, 
DDI-DrugBank.d307.s11.e0,DDI-DrugBank.d307.s11.e1,drug1: Potential interactions between drug2 and other drug0,False, 
DDI-DrugBank.d307.s11.e0,DDI-DrugBank.d307.s11.e2,drug1: Potential interactions between drug0 and other drug2,False, 
DDI-DrugBank.d307.s16.e0,DDI-DrugBank.d307.s16.e1,Influence of drug1 on drug2,False, 
DDI-DrugBank.d307.s17.e0,DDI-DrugBank.d307.s17.e1,Influence of drug1 On drug2,False, 
DDI-DrugBank.d307.s35.e0,DDI-DrugBank.d307.s35.e1,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high drug1 doses In vivo, the plasma levels of drug2 increased by up to 40%, when drug0",False, 
DDI-DrugBank.d307.s35.e0,DDI-DrugBank.d307.s35.e2,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high drug1 doses In vivo, the plasma levels of drug0 increased by up to 40%, when drug2",False, 
DDI-DrugBank.d307.s35.e1,DDI-DrugBank.d307.s35.e2,"1- nc denotes a mean change of less than 10% 2- Pediatrics 3- Mean increase in adults at high drug0 doses In vivo, the plasma levels of drug1 increased by up to 40%, when drug2",True,mechanism
DDI-DrugBank.d307.s36.e0,DDI-DrugBank.d307.s36.e1,"Therefore, when using doses of drug1 greater than 1200 mg/day during adjunctive therapy, a decrease in the dose of drug2",True,advise
DDI-DrugBank.d307.s37.e0,DDI-DrugBank.d307.s37.e1,"The increase of drug1 level, however, is small (15%) when given with drug2",True,mechanism
DDI-DrugBank.d307.s38.e0,DDI-DrugBank.d307.s38.e1,"Strong inducers of cytochrome P450 enzymes (i.e. drug1, drug2 and drug0) have been shown to decrease the plasma levels of drug0",False, 
DDI-DrugBank.d307.s38.e0,DDI-DrugBank.d307.s38.e2,"Strong inducers of cytochrome P450 enzymes (i.e. drug1, drug0 and drug2) have been shown to decrease the plasma levels of drug0",False, 
DDI-DrugBank.d307.s40.e0,DDI-DrugBank.d307.s40.e1,"Hormonal drug1 Co-administration of drug2 with an oral drug0 has been shown to influence the plasma concentrations of the two hormonal components, drug0 (EE) and drug0",False, 
DDI-DrugBank.d307.s40.e0,DDI-DrugBank.d307.s40.e2,"Hormonal drug1 Co-administration of drug0 with an oral drug2 has been shown to influence the plasma concentrations of the two hormonal components, drug0 (EE) and drug0",False, 
DDI-DrugBank.d307.s40.e1,DDI-DrugBank.d307.s40.e2,"Hormonal drug0 Co-administration of drug1 with an oral drug2 has been shown to influence the plasma concentrations of the two hormonal components, drug0 (EE) and drug0",True,mechanism
DDI-DrugBank.d307.s43.e0,DDI-DrugBank.d307.s43.e1,"Therefore, concurrent use of drug1 with drug2 may render these drug0",True,effect
DDI-DrugBank.d307.s43.e0,DDI-DrugBank.d307.s43.e2,"Therefore, concurrent use of drug1 with drug0 may render these drug2",False, 
DDI-DrugBank.d307.s43.e1,DDI-DrugBank.d307.s43.e2,"Therefore, concurrent use of drug0 with drug1 may render these drug2",False, 
DDI-DrugBank.d307.s45.e0,DDI-DrugBank.d307.s45.e1,"drug1s: After repeated co-administration of drug2, the AUC of drug0",False, 
DDI-DrugBank.d307.s45.e0,DDI-DrugBank.d307.s45.e2,"drug1s: After repeated co-administration of drug0, the AUC of drug2",False, 
DDI-DrugBank.d307.s45.e1,DDI-DrugBank.d307.s45.e2,"drug0s: After repeated co-administration of drug1, the AUC of drug2",True,mechanism
DDI-DrugBank.d307.s46.e0,DDI-DrugBank.d307.s46.e1,drug1 produced a decrease of 20% [90% CI: 18-27] of the plasma levels of drug2,False, 
DDI-DrugBank.d307.s47.e0,DDI-DrugBank.d307.s47.e1,"Other drug interactions drug1, drug2 and drug0 had no effect on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d307.s47.e0,DDI-DrugBank.d307.s47.e2,"Other drug interactions drug1, drug0 and drug2 had no effect on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d307.s48.e0,DDI-DrugBank.d307.s48.e1,Results with drug1 wshow no evidence of interaction with either single or repeated doses of drug2,False, 
DDI-DrugBank.d111.s0.e0,DDI-DrugBank.d111.s0.e1,"drug1 including drug2, drug0, and drug0 HC1: Concomitant use of drug0 and non-selective drug0",False, 
DDI-DrugBank.d111.s0.e0,DDI-DrugBank.d111.s0.e2,"drug1 including drug0, drug2, and drug0 HC1: Concomitant use of drug0 and non-selective drug0",False, 
DDI-DrugBank.d111.s0.e4,DDI-DrugBank.d111.s0.e5,"drug0 including drug0, drug0, and drug0 HC1: Concomitant use of drug1 and non-selective drug2",True,effect
DDI-DrugBank.d174.s1.e0,DDI-DrugBank.d174.s1.e1,Caution should be exercised when administering drug1 with drug2 since interactions have been seen with other drug0,True,advise
DDI-DrugBank.d174.s1.e0,DDI-DrugBank.d174.s1.e2,Caution should be exercised when administering drug1 with drug0 since interactions have been seen with other drug2,False, 
DDI-DrugBank.d174.s1.e1,DDI-DrugBank.d174.s1.e2,Caution should be exercised when administering drug0 with drug1 since interactions have been seen with other drug2,True,int
DDI-DrugBank.d174.s2.e0,DDI-DrugBank.d174.s2.e1,Concomitant administration of an drug1-containing drug2 had no significant effect in the bioavailability of drug0,False, 
DDI-DrugBank.d174.s2.e0,DDI-DrugBank.d174.s2.e2,Concomitant administration of an drug1-containing drug0 had no significant effect in the bioavailability of drug2,False, 
DDI-DrugBank.d184.s0.e0,DDI-DrugBank.d184.s0.e1,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), drug1 (drug2s), drug0, drug0 (drug0 may decrease the effects of these medicines), drug0 (using these medicines with drug0 may result in increased CNS depressant effects), drug0, drug0 (using these medicines with drug0 may change the amount of either medicine that you need to take), and oral drug0 containing drug0 (drug0 may decrease the effectiveness of these oral drug0",False, 
DDI-DrugBank.d184.s0.e0,DDI-DrugBank.d184.s0.e2,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), drug1 (drug0s), drug2, drug0 (drug0 may decrease the effects of these medicines), drug0 (using these medicines with drug0 may result in increased CNS depressant effects), drug0, drug0 (using these medicines with drug0 may change the amount of either medicine that you need to take), and oral drug0 containing drug0 (drug0 may decrease the effectiveness of these oral drug0",False, 
DDI-DrugBank.d184.s0.e12,DDI-DrugBank.d184.s0.e13,"Interactions may occur with the following: adrenocorticoids (cortisone-like medicine), drug0 (drug0s), drug0, drug0 (drug0 may decrease the effects of these medicines), drug0 (using these medicines with drug0 may result in increased CNS depressant effects), drug0, drug0 (using these medicines with drug0 may change the amount of either medicine that you need to take), and oral drug0 containing drug0 (drug1 may decrease the effectiveness of these oral drug2",True,effect
DDI-DrugBank.d358.s0.e0,DDI-DrugBank.d358.s0.e1,"Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when drug2 is coadministered with inhibitors of C.P.A. such as drug0 and drug0 or inhibitors of CYP2C19 such as drug0",False, 
DDI-DrugBank.d358.s0.e0,DDI-DrugBank.d358.s0.e2,"Since drug1 is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when drug0 is coadministered with inhibitors of C.P.A. such as drug2 and drug0 or inhibitors of CYP2C19 such as drug0",False, 
DDI-DrugBank.d358.s0.e1,DDI-DrugBank.d358.s0.e2,"Since drug0 is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when drug1 is coadministered with inhibitors of C.P.A. such as drug2 and drug0 or inhibitors of CYP2C19 such as drug0",True,advise
DDI-DrugBank.d358.s0.e1,DDI-DrugBank.d358.s0.e3,"Since drug0 is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when drug1 is coadministered with inhibitors of C.P.A. such as drug0 and drug2 or inhibitors of CYP2C19 such as drug0",True,advise
DDI-DrugBank.d358.s0.e1,DDI-DrugBank.d358.s0.e4,"Since drug0 is extensively metabolized by cytochrome P-450 isoenzymes, caution should be exercised when drug1 is coadministered with inhibitors of C.P.A. such as drug0 and drug0 or inhibitors of CYP2C19 such as drug2",True,advise
DDI-DrugBank.d358.s1.e0,DDI-DrugBank.d358.s1.e1,Pharmacokinetic studies have demonstrated that drug1 and drug2 significantly increased the systemic exposure of drug0,False, 
DDI-DrugBank.d358.s1.e0,DDI-DrugBank.d358.s1.e2,Pharmacokinetic studies have demonstrated that drug1 and drug0 significantly increased the systemic exposure of drug2,True,mechanism
DDI-DrugBank.d358.s1.e1,DDI-DrugBank.d358.s1.e2,Pharmacokinetic studies have demonstrated that drug0 and drug1 significantly increased the systemic exposure of drug2,True,mechanism
DDI-DrugBank.d358.s2.e0,DDI-DrugBank.d358.s2.e1,Population pharmacokinetic studies showed higher concentrations of drug1 among patients concurrently treated with drug2,True,mechanism
DDI-DrugBank.d358.s3.e0,DDI-DrugBank.d358.s3.e1,"drug1 does not, however, appear to cause increased blood levels of drugs metabolized by CYP3A4, as it had no effect on drug2",False, 
DDI-DrugBank.d12.s0.e0,DDI-DrugBank.d12.s0.e1,Caution should be exercised when drug1 are given in conjunction with drug2,True,advise
DDI-DrugBank.d12.s3.e0,DDI-DrugBank.d12.s3.e1,drug1 may displace acidic drugs such as drug2 or drug0,True,mechanism
DDI-DrugBank.d12.s3.e0,DDI-DrugBank.d12.s3.e2,drug1 may displace acidic drugs such as drug0 or drug2,True,mechanism
DDI-DrugBank.d12.s3.e1,DDI-DrugBank.d12.s3.e2,drug0 may displace acidic drugs such as drug1 or drug2,False, 
DDI-DrugBank.d12.s5.e0,DDI-DrugBank.d12.s5.e1,The hypoglycemic effect of drug1 has been reported to increase when drug2,True,effect
DDI-DrugBank.d12.s6.e0,DDI-DrugBank.d12.s6.e1,Fulminant rhabdomyolysis has been seen as early as three weeks after initiation of combined therapy with another drug1 and drug2,True,effect
DDI-DrugBank.d12.s7.e0,DDI-DrugBank.d12.s7.e1,"For these reasons, it is felt that, in most subjects who have had an unsatisfactory lipid response to either drug alone, the possible benefits of combined therapy with drug1 and a drug2",True,effect
DDI-DrugBank.d12.s8.e0,DDI-DrugBank.d12.s8.e1,"While it is not known whether this interaction occurs with drug1 other than drug2, myopathy and rhabdomyolysis have occasionally been associated with the use of drug0 alone, including drug0",False, 
DDI-DrugBank.d12.s8.e0,DDI-DrugBank.d12.s8.e2,"While it is not known whether this interaction occurs with drug1 other than drug0, myopathy and rhabdomyolysis have occasionally been associated with the use of drug2 alone, including drug0",False, 
DDI-DrugBank.d12.s9.e0,DDI-DrugBank.d12.s9.e1,"Therefore, the combined use of drug1 with drug2",True,advise
DDI-DrugBank.d437.s4.e0,DDI-DrugBank.d437.s4.e1,drug1: The effect of drug2 on total drug concentrations of other drug0,False, 
DDI-DrugBank.d437.s4.e0,DDI-DrugBank.d437.s4.e2,drug1: The effect of drug0 on total drug concentrations of other drug2,False, 
DDI-DrugBank.d437.s5.e0,DDI-DrugBank.d437.s5.e1,"drug1 steady-state Cmax, A.C. and Cmin were decreased by 22%, 38%, and 27%, respectively, by concomitant drug2",True,mechanism
DDI-DrugBank.d437.s7.e0,DDI-DrugBank.d437.s7.e1,"drug1 steady-state Cmax, A.C. and Cmin were increased 21%, decreased 19%, and decreased 48%, respectively, by concomitant drug2",True,mechanism
DDI-DrugBank.d437.s8.e0,DDI-DrugBank.d437.s8.e1,"drug1 steady-state Cmax, A.C. and Cmin were increased by 12%, 15%, and 14%, respectively, by concomitant drug2",True,mechanism
DDI-DrugBank.d437.s9.e0,DDI-DrugBank.d437.s9.e1,drug1: Coadministration of drug2 and drug0 can decrease plasma levels of drug0,False, 
DDI-DrugBank.d437.s9.e0,DDI-DrugBank.d437.s9.e2,drug1: Coadministration of drug0 and drug2 can decrease plasma levels of drug0,False, 
DDI-DrugBank.d437.s9.e1,DDI-DrugBank.d437.s9.e2,drug0: Coadministration of drug1 and drug2 can decrease plasma levels of drug0,True,effect
DDI-DrugBank.d437.s10.e0,DDI-DrugBank.d437.s10.e1,"Coadministration of drug1 and drug2 as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum drug0",True,mechanism
DDI-DrugBank.d437.s10.e0,DDI-DrugBank.d437.s10.e2,"Coadministration of drug1 and drug0 as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum drug2",False, 
DDI-DrugBank.d437.s10.e1,DDI-DrugBank.d437.s10.e2,"Coadministration of drug0 and drug1 as compared to a non-matched historicalcontrol group resulted in a 30%, 27%, and 25% decrease in serum drug2",False, 
DDI-DrugBank.d437.s13.e0,DDI-DrugBank.d437.s13.e1,Laboratory Tests: The combination of drug1 and low-dose drug2,True,effect
DDI-DrugBank.d437.s14.e0,DDI-DrugBank.d437.s14.e1,Appropriate laboratory testing should be considered prior to initiating combination therapy with drug1 and drug2,True,advise
DDI-DrugBank.d437.s15.e0,DDI-DrugBank.d437.s15.e1,"For comprehensive information concerning laboratory test alterations associated with drug1, physicians should refer to the complete prescribing information for drug2 (drug0",False, 
DDI-DrugBank.d437.s15.e0,DDI-DrugBank.d437.s15.e2,"For comprehensive information concerning laboratory test alterations associated with drug1, physicians should refer to the complete prescribing information for drug0 (drug2",False, 
DDI-DrugBank.d395.s0.e0,DDI-DrugBank.d395.s0.e1,"drug1: drug2, given concomitantly with drug0 or 60 minutes following drug0 administration, decreased drug0",False, 
DDI-DrugBank.d395.s0.e0,DDI-DrugBank.d395.s0.e2,"drug1: drug0, given concomitantly with drug2 or 60 minutes following drug0 administration, decreased drug0",False, 
DDI-DrugBank.d395.s0.e1,DDI-DrugBank.d395.s0.e2,"drug0: drug1, given concomitantly with drug2 or 60 minutes following drug0 administration, decreased drug0",True,mechanism
DDI-DrugBank.d395.s1.e0,DDI-DrugBank.d395.s1.e1,"Thus, concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d395.s2.e0,DDI-DrugBank.d395.s2.e1,drug1: drug2 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug0,False, 
DDI-DrugBank.d395.s2.e0,DDI-DrugBank.d395.s2.e2,drug1: drug0 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug2,False, 
DDI-DrugBank.d395.s2.e1,DDI-DrugBank.d395.s2.e2,drug0: drug1 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug2,True,mechanism
DDI-DrugBank.d395.s3.e0,DDI-DrugBank.d395.s3.e1,"In a multiple-dose study, drug1 caused a dose-related increase in the mean elimination half-life of drug2, thereby decreasing the clearance of drug0 by up to 80% and leading to a five-fold increase in the AUC and the half-life of drug0",True,mechanism
DDI-DrugBank.d395.s3.e0,DDI-DrugBank.d395.s3.e2,"In a multiple-dose study, drug1 caused a dose-related increase in the mean elimination half-life of drug0, thereby decreasing the clearance of drug2 by up to 80% and leading to a five-fold increase in the AUC and the half-life of drug0",False, 
DDI-DrugBank.d395.s3.e0,DDI-DrugBank.d395.s3.e3,"In a multiple-dose study, drug1 caused a dose-related increase in the mean elimination half-life of drug0, thereby decreasing the clearance of drug0 by up to 80% and leading to a five-fold increase in the AUC and the half-life of drug2",False, 
DDI-DrugBank.d395.s4.e0,DDI-DrugBank.d395.s4.e1,Trough plasma drug1 levels were also 20% higher when drug2 and drug0,False, 
DDI-DrugBank.d395.s4.e0,DDI-DrugBank.d395.s4.e2,Trough plasma drug1 levels were also 20% higher when drug0 and drug2,False, 
DDI-DrugBank.d395.s4.e1,DDI-DrugBank.d395.s4.e2,Trough plasma drug0 levels were also 20% higher when drug1 and drug2,True,mechanism
DDI-DrugBank.d395.s5.e0,DDI-DrugBank.d395.s5.e1,drug1-related adverse effects have occurred in patients consuming drug2 while on therapy with drug0,False, 
DDI-DrugBank.d395.s5.e0,DDI-DrugBank.d395.s5.e2,drug1-related adverse effects have occurred in patients consuming drug0 while on therapy with drug2,False, 
DDI-DrugBank.d395.s5.e1,DDI-DrugBank.d395.s5.e2,drug0-related adverse effects have occurred in patients consuming drug1 while on therapy with drug2,True,effect
DDI-DrugBank.d395.s6.e0,DDI-DrugBank.d395.s6.e1,drug1: Elevated serum levels of drug2 have been reported with concomitant use of drug0 with other members of the drug0,False, 
DDI-DrugBank.d395.s6.e0,DDI-DrugBank.d395.s6.e2,drug1: Elevated serum levels of drug0 have been reported with concomitant use of drug2 with other members of the drug0,False, 
DDI-DrugBank.d395.s6.e2,DDI-DrugBank.d395.s6.e3,drug0: Elevated serum levels of drug0 have been reported with concomitant use of drug1 with other members of the drug2,True,mechanism
DDI-DrugBank.d395.s7.e0,DDI-DrugBank.d395.s7.e1,drug1: drug2 may raise serum drug0,False, 
DDI-DrugBank.d395.s7.e0,DDI-DrugBank.d395.s7.e2,drug1: drug0 may raise serum drug2,False, 
DDI-DrugBank.d395.s7.e1,DDI-DrugBank.d395.s7.e2,drug0: drug1 may raise serum drug2,True,mechanism
DDI-DrugBank.d395.s8.e0,DDI-DrugBank.d395.s8.e1,"If signs and symptoms suggestive of drug1 toxicity occur when drug2 and drug0 are given concomitantly, physicians are advised to obtain serum drug0 levels and adjust drug0",False, 
DDI-DrugBank.d395.s8.e0,DDI-DrugBank.d395.s8.e2,"If signs and symptoms suggestive of drug1 toxicity occur when drug0 and drug2 are given concomitantly, physicians are advised to obtain serum drug0 levels and adjust drug0",False, 
DDI-DrugBank.d395.s8.e1,DDI-DrugBank.d395.s8.e2,"If signs and symptoms suggestive of drug0 toxicity occur when drug1 and drug2 are given concomitantly, physicians are advised to obtain serum drug0 levels and adjust drug0",True,effect
DDI-DrugBank.d395.s9.e0,DDI-DrugBank.d395.s9.e1,drug1: Seizures have been reported in patients taking drug2 concomitantly with the drug0 drug0,False, 
DDI-DrugBank.d395.s9.e0,DDI-DrugBank.d395.s9.e2,drug1: Seizures have been reported in patients taking drug0 concomitantly with the drug2 drug0,False, 
DDI-DrugBank.d395.s9.e1,DDI-DrugBank.d395.s9.e3,drug0: Seizures have been reported in patients taking drug1 concomitantly with the drug0 drug2,True,effect
DDI-DrugBank.d395.s12.e0,DDI-DrugBank.d395.s12.e1,drug1 and drug2: drug0,False, 
DDI-DrugBank.d395.s12.e0,DDI-DrugBank.d395.s12.e2,drug1 and drug0: drug2,False, 
DDI-DrugBank.d395.s13.e0,DDI-DrugBank.d395.s13.e1,"Therefore, administration of drug1 with drug2 containing drug0, drug0, or drug0",False, 
DDI-DrugBank.d395.s13.e0,DDI-DrugBank.d395.s13.e2,"Therefore, administration of drug1 with drug0 containing drug2, drug0, or drug0",False, 
DDI-DrugBank.d395.s16.e0,DDI-DrugBank.d395.s16.e1,or with drug1 containing drug2 may substantially interfere with drug absorption and result in insufficient plasma and tissue drug0,False, 
DDI-DrugBank.d395.s16.e0,DDI-DrugBank.d395.s16.e2,or with drug1 containing drug0 may substantially interfere with drug absorption and result in insufficient plasma and tissue drug2,False, 
DDI-DrugBank.d395.s16.e1,DDI-DrugBank.d395.s16.e2,or with drug0 containing drug1 may substantially interfere with drug absorption and result in insufficient plasma and tissue drug2,True,mechanism
DDI-DrugBank.d395.s17.e0,DDI-DrugBank.d395.s17.e1,drug1 containing drug2 and drug0 reduce the oral absorption of drug0,False, 
DDI-DrugBank.d395.s17.e0,DDI-DrugBank.d395.s17.e2,drug1 containing drug0 and drug2 reduce the oral absorption of drug0,False, 
DDI-DrugBank.d395.s17.e1,DDI-DrugBank.d395.s17.e3,drug0 containing drug1 and drug0 reduce the oral absorption of drug2,True,mechanism
DDI-DrugBank.d395.s17.e2,DDI-DrugBank.d395.s17.e3,drug0 containing drug0 and drug1 reduce the oral absorption of drug2,True,mechanism
DDI-DrugBank.d395.s18.e0,DDI-DrugBank.d395.s18.e1,The oral bioavailability of drug1 is reduced by 60% with coadministration of drug2,True,mechanism
DDI-DrugBank.d395.s20.e0,DDI-DrugBank.d395.s20.e1,drug1: drug2 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug0,False, 
DDI-DrugBank.d395.s20.e0,DDI-DrugBank.d395.s20.e2,drug1: drug0 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug2,False, 
DDI-DrugBank.d395.s20.e1,DDI-DrugBank.d395.s20.e2,drug0: drug1 is a potent inhibitor of the cytochrome P-450 isozymes responsible for the metabolism of drug2,True,mechanism
DDI-DrugBank.d395.s21.e0,DDI-DrugBank.d395.s21.e1,drug1 interferes with the metabolism of drug2 resulting in a 42% to 74% dose-related decrease in drug0,True,mechanism
DDI-DrugBank.d395.s21.e0,DDI-DrugBank.d395.s21.e2,drug1 interferes with the metabolism of drug0 resulting in a 42% to 74% dose-related decrease in drug2,False, 
DDI-DrugBank.d395.s21.e1,DDI-DrugBank.d395.s21.e2,drug0 interferes with the metabolism of drug1 resulting in a 42% to 74% dose-related decrease in drug2,False, 
DDI-DrugBank.d395.s22.e0,DDI-DrugBank.d395.s22.e1,drug1-related adverse effects have occurred in patients when drug2 and drug0,False, 
DDI-DrugBank.d395.s22.e0,DDI-DrugBank.d395.s22.e2,drug1-related adverse effects have occurred in patients when drug0 and drug2,False, 
DDI-DrugBank.d395.s22.e1,DDI-DrugBank.d395.s22.e2,drug0-related adverse effects have occurred in patients when drug1 and drug2,True,effect
DDI-DrugBank.d395.s23.e0,DDI-DrugBank.d395.s23.e1,"drug1: drug2, including drug0, decrease the clearance of drug0, the less active isomer of racemic drug0",False, 
DDI-DrugBank.d395.s23.e0,DDI-DrugBank.d395.s23.e2,"drug1: drug0, including drug2, decrease the clearance of drug0, the less active isomer of racemic drug0",False, 
DDI-DrugBank.d395.s23.e1,DDI-DrugBank.d395.s23.e3,"drug0: drug1, including drug0, decrease the clearance of drug2, the less active isomer of racemic drug0",True,mechanism
DDI-DrugBank.d395.s23.e2,DDI-DrugBank.d395.s23.e3,"drug0: drug0, including drug1, decrease the clearance of drug2, the less active isomer of racemic drug0",True,mechanism
DDI-DrugBank.d395.s24.e0,DDI-DrugBank.d395.s24.e1,"drug1 does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when drug2 and drug0",False, 
DDI-DrugBank.d395.s24.e0,DDI-DrugBank.d395.s24.e2,"drug1 does not affect the clearance of the active S-isomer, and changes in clotting time have not been observed when drug0 and drug2",False, 
DDI-DrugBank.d395.s25.e0,DDI-DrugBank.d395.s25.e1,"Nevertheless, the prothrombin time or other suitable coagulation test should be monitored when drug1 or its derivatives and drug2",True,advise
DDI-DrugBank.d91.s2.e0,DDI-DrugBank.d91.s2.e1,"When you are using drug1, it is especially important that your health care professional know if you are using the following: Eye product containing drug2",True,advise
DDI-DrugBank.d91.s3.e0,DDI-DrugBank.d91.s3.e1,drug1 may interact with the drug2 preparation causing a gritty substance to form or may interact with the preservative in the drug0,True,mechanism
DDI-DrugBank.d91.s3.e0,DDI-DrugBank.d91.s3.e2,drug1 may interact with the drug0 preparation causing a gritty substance to form or may interact with the preservative in the drug2,False, 
DDI-DrugBank.d91.s3.e1,DDI-DrugBank.d91.s3.e2,drug0 may interact with the drug1 preparation causing a gritty substance to form or may interact with the preservative in the drug2,False, 
DDI-DrugBank.d196.s0.e0,DDI-DrugBank.d196.s0.e1,Treatment with drug1 once weekly for 4 weeks in healthy subjects was associated with an inhibition of P450 1A2 and a 25% increase in drug2,True,mechanism
DDI-DrugBank.d196.s1.e0,DDI-DrugBank.d196.s1.e1,drug1 serum levels should be monitored and appropriate dose adjustments considered for patients given both drug2 and drug0,False, 
DDI-DrugBank.d196.s1.e0,DDI-DrugBank.d196.s1.e2,drug1 serum levels should be monitored and appropriate dose adjustments considered for patients given both drug0 and drug2,False, 
DDI-DrugBank.d196.s1.e1,DDI-DrugBank.d196.s1.e2,drug0 serum levels should be monitored and appropriate dose adjustments considered for patients given both drug1 and drug2,True,advise
DDI-DrugBank.d196.s3.e0,DDI-DrugBank.d196.s3.e1,"In patients with chronic hepatitis C treated with drug1 in combination with drug2, drug0 treatment did not affect drug0",False, 
DDI-DrugBank.d196.s3.e0,DDI-DrugBank.d196.s3.e2,"In patients with chronic hepatitis C treated with drug1 in combination with drug0, drug2 treatment did not affect drug0",False, 
DDI-DrugBank.d196.s4.e0,DDI-DrugBank.d196.s4.e1,Nucleoside Analogues drug1 Co-administration of drug2 and drug0,False, 
DDI-DrugBank.d196.s4.e0,DDI-DrugBank.d196.s4.e2,Nucleoside Analogues drug1 Co-administration of drug0 and drug2,False, 
DDI-DrugBank.d196.s4.e1,DDI-DrugBank.d196.s4.e2,Nucleoside Analogues drug0 Co-administration of drug1 and drug2,True,advise
DDI-DrugBank.d196.s6.e0,DDI-DrugBank.d196.s6.e1,drug1 and drug2 drug0 can antagonize the in vitro antiviral activity of drug0 and drug0,False, 
DDI-DrugBank.d196.s6.e0,DDI-DrugBank.d196.s6.e2,drug1 and drug0 drug2 can antagonize the in vitro antiviral activity of drug0 and drug0,False, 
DDI-DrugBank.d196.s6.e2,DDI-DrugBank.d196.s6.e3,drug0 and drug0 drug1 can antagonize the in vitro antiviral activity of drug2 and drug0,True,effect
DDI-DrugBank.d196.s6.e2,DDI-DrugBank.d196.s6.e4,drug0 and drug0 drug1 can antagonize the in vitro antiviral activity of drug0 and drug2,True,effect
DDI-DrugBank.d196.s10.e0,DDI-DrugBank.d196.s10.e1,Use With drug1 drug2,False, 
DDI-DrugBank.d196.s29.e0,DDI-DrugBank.d196.s29.e1,Pregnancy: Category X: Use With drug1 (see CONTRAINDICATIONS) Significant teratogenic and/or embryocidal effects have been demonstrated in all animal species exposed to drug2,False, 
DDI-DrugBank.d196.s32.e0,DDI-DrugBank.d196.s32.e1,Nursing Mothers It is not known whether drug1 or drug2,False, 
DDI-DrugBank.d196.s33.e0,DDI-DrugBank.d196.s33.e1,The effect of orally ingested drug1 or drug2,False, 
DDI-DrugBank.d196.s34.e0,DDI-DrugBank.d196.s34.e1,"Because of the potential for adverse reactions from the drugs in nursing infants, a decision must be made whether to discontinue nursing or discontinue drug1 and drug2",False, 
DDI-DrugBank.d196.s35.e0,DDI-DrugBank.d196.s35.e1,"Pediatric Use The safety and effectiveness of drug1, alone or in combination with drug2",False, 
DDI-DrugBank.d196.s36.e0,DDI-DrugBank.d196.s36.e1,drug1 contains drug2,False, 
DDI-DrugBank.d196.s39.e0,DDI-DrugBank.d196.s39.e1,Clinical studies of drug1 alone or in combination with drug2,False, 
DDI-DrugBank.d196.s40.e0,DDI-DrugBank.d196.s40.e1,"Adverse reactions related to drug1s, such as CNS, cardiac, and systemic (eg, flu-like) effects may be more severe in the elderly and caution should be exercised in the use of drug2",False, 
DDI-DrugBank.d196.s41.e0,DDI-DrugBank.d196.s41.e1,drug1 and drug2,False, 
DDI-DrugBank.d196.s43.e0,DDI-DrugBank.d196.s43.e1,drug1 should be used with caution in patients with creatinine clearance  50 mL/min and drug2,False, 
DDI-DrugBank.d512.s1.e0,DDI-DrugBank.d512.s1.e1,Effect of drug1 on other drugs: Drugs metabolized by cytochrome P450 2D6 (CYP2D6): drug2,False, 
DDI-DrugBank.d512.s2.e0,DDI-DrugBank.d512.s2.e1,"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., drug1, drug2, drug0 and most drug0",False, 
DDI-DrugBank.d512.s2.e0,DDI-DrugBank.d512.s2.e2,"Therefore, dose adjustments of concomitant medications that are predominantly metabolized by CYP2D6 and have a narrow therapeutic index (e.g., drug1, drug0, drug2 and most drug0",False, 
DDI-DrugBank.d512.s3.e0,DDI-DrugBank.d512.s3.e1,drug1: Concurrent administration of 25 mg or 100 mg drug2 with 50 mg drug0 increased drug0 exposure and drug0,False, 
DDI-DrugBank.d512.s3.e0,DDI-DrugBank.d512.s3.e2,drug1: Concurrent administration of 25 mg or 100 mg drug0 with 50 mg drug2 increased drug0 exposure and drug0,False, 
DDI-DrugBank.d512.s3.e1,DDI-DrugBank.d512.s3.e2,drug0: Concurrent administration of 25 mg or 100 mg drug1 with 50 mg drug2 increased drug0 exposure and drug0,True,mechanism
DDI-DrugBank.d512.s4.e0,DDI-DrugBank.d512.s4.e1,Effect of other drugs on drug1 : drug2,False, 
DDI-DrugBank.d512.s5.e0,DDI-DrugBank.d512.s5.e1,drug1: drug2,False, 
DDI-DrugBank.d512.s6.e0,DDI-DrugBank.d512.s6.e1,"Co-administration of drug1, a strong inhibitor of CYP3A4, increased drug2 exposure following a single 90 mg dose of drug0",True,mechanism
DDI-DrugBank.d512.s6.e0,DDI-DrugBank.d512.s6.e2,"Co-administration of drug1, a strong inhibitor of CYP3A4, increased drug0 exposure following a single 90 mg dose of drug2",False, 
DDI-DrugBank.d512.s6.e1,DDI-DrugBank.d512.s6.e2,"Co-administration of drug0, a strong inhibitor of CYP3A4, increased drug1 exposure following a single 90 mg dose of drug2",False, 
DDI-DrugBank.d512.s7.e0,DDI-DrugBank.d512.s7.e1,"Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., drug2, drug0, drug0",True,advise
DDI-DrugBank.d512.s7.e0,DDI-DrugBank.d512.s7.e2,"Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., drug0, drug2, drug0",True,advise
DDI-DrugBank.d512.s7.e0,DDI-DrugBank.d512.s7.e3,"Dose adjustment of drug1 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., drug0, drug0, drug2",True,advise
DDI-DrugBank.d512.s7.e1,DDI-DrugBank.d512.s7.e2,"Dose adjustment of drug0 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., drug1, drug2, drug0",False, 
DDI-DrugBank.d512.s7.e1,DDI-DrugBank.d512.s7.e3,"Dose adjustment of drug0 may be required and PTH and serum calcium concentrations should be closely monitored if a patient initiates or discontinues therapy with a strong CYP3A4 inhibitor (e.g., drug1, drug0, drug2",False, 
DDI-DrugBank.d275.s1.e0,DDI-DrugBank.d275.s1.e1,Toxicologic and toxicokinetic studies in rats did not demonstrate any alterations in the clearance or toxicologic profile of either drug1 or drug2,False, 
DDI-DrugBank.d275.s2.e0,DDI-DrugBank.d275.s2.e1,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug1 and drug2 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug0",True,effect
DDI-DrugBank.d275.s2.e0,DDI-DrugBank.d275.s2.e2,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug1 and drug0 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug2",False, 
DDI-DrugBank.d275.s2.e1,DDI-DrugBank.d275.s2.e2,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug0 and drug1 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug2",False, 
DDI-DrugBank.d275.s3.e0,DDI-DrugBank.d275.s3.e1,Two percent of patients treated concurrently with drug1 and drug2,True,effect
DDI-DrugBank.d525.s0.e0,DDI-DrugBank.d525.s0.e1,drug1 has been shown to have no effect on the pharmacokinetics of drug2 and the pharmacodynamics of drug0 and drug0,False, 
DDI-DrugBank.d525.s0.e0,DDI-DrugBank.d525.s0.e2,drug1 has been shown to have no effect on the pharmacokinetics of drug0 and the pharmacodynamics of drug2 and drug0,False, 
DDI-DrugBank.d525.s2.e0,DDI-DrugBank.d525.s2.e1,"Because drug1 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and drug2 and drug0, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on drug0",False, 
DDI-DrugBank.d525.s2.e0,DDI-DrugBank.d525.s2.e2,"Because drug1 is not metabolized by the cytochrome P450 system, inhibitors of CYP450 enzyme would not be expected to affect its metabolism, and drug0 and drug2, potent inhibitors of CYP3A and 2C9, respectively, have been shown to have no effect on drug0",False, 
DDI-DrugBank.d525.s3.e0,DDI-DrugBank.d525.s3.e1,drug1 also has no effect on drug2,False, 
DDI-DrugBank.d525.s4.e0,DDI-DrugBank.d525.s4.e1,drug1 (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a drug2 (drug0,False, 
DDI-DrugBank.d525.s4.e0,DDI-DrugBank.d525.s4.e2,drug1 (up to 400 mg b.i.d. or 800 mg q.d.) doses have been safely used concomitantly with a drug0 (drug2,False, 
DDI-DrugBank.d525.s5.e0,DDI-DrugBank.d525.s5.e1,drug1 doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release drug2 (sustained-release drug0,False, 
DDI-DrugBank.d525.s5.e0,DDI-DrugBank.d525.s5.e2,drug1 doses of up to 300 mg b.i.d. have been safely used concomitantly with sustained-release drug0 (sustained-release drug2,False, 
DDI-DrugBank.d501.s4.e0,DDI-DrugBank.d501.s4.e1,In patients using drug1 (drug2,False, 
DDI-DrugBank.d501.s5.e0,DDI-DrugBank.d501.s5.e1,drug1: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of drug2 on drug0 absorption from the peritoneal cavity or on drug0s ability to control blood glucose when drug0 was administered intraperitoneally with drug0,False, 
DDI-DrugBank.d501.s5.e0,DDI-DrugBank.d501.s5.e2,drug1: A clinical study in 6 insulin-dependent diabetic patients demonstrated no effect of drug0 on drug2 absorption from the peritoneal cavity or on drug0s ability to control blood glucose when drug0 was administered intraperitoneally with drug0,False, 
DDI-DrugBank.d501.s6.e0,DDI-DrugBank.d501.s6.e1,"However, appropriate monitoring of blood glucose should be performed when initiating drug1 in diabetic patients and drug2",True,advise
DDI-DrugBank.d501.s7.e0,DDI-DrugBank.d501.s7.e1,drug1: No human drug interaction studies with drug2,False, 
DDI-DrugBank.d501.s8.e0,DDI-DrugBank.d501.s8.e1,In vitro studies demonstrated no evidence of incompatibility of drug1 with drug2,False, 
DDI-DrugBank.d501.s9.e0,DDI-DrugBank.d501.s9.e1,drug1: No human drug interaction studies with drug2,False, 
DDI-DrugBank.d501.s10.e0,DDI-DrugBank.d501.s10.e1,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of drug1, drug2, drug0, drug0/flucoxacillin, drug0, drug0, and drug0 demonstrated no evidence of incompatibility of these drug0 with drug0",False, 
DDI-DrugBank.d501.s10.e0,DDI-DrugBank.d501.s10.e2,"In vitro studies evaluating the minimum inhibitory concentration (MIC) of drug1, drug0, drug2, drug0/flucoxacillin, drug0, drug0, and drug0 demonstrated no evidence of incompatibility of these drug0 with drug0",False, 
DDI-DrugBank.d308.s0.e0,DDI-DrugBank.d308.s0.e1,"THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug2 SUCH AS drug0, drug0 AND drug0",True,effect
DDI-DrugBank.d308.s0.e0,DDI-DrugBank.d308.s0.e2,"THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug0 SUCH AS drug2, drug0 AND drug0",True,effect
DDI-DrugBank.d308.s0.e0,DDI-DrugBank.d308.s0.e3,"THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug0 SUCH AS drug0, drug2 AND drug0",True,effect
DDI-DrugBank.d308.s0.e0,DDI-DrugBank.d308.s0.e4,"THE POTENTIATING ACTION OF drug1 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug0 SUCH AS drug0, drug0 AND drug2",True,effect
DDI-DrugBank.d308.s0.e1,DDI-DrugBank.d308.s0.e2,"THE POTENTIATING ACTION OF drug0 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug1 SUCH AS drug2, drug0 AND drug0",False, 
DDI-DrugBank.d308.s0.e1,DDI-DrugBank.d308.s0.e3,"THE POTENTIATING ACTION OF drug0 MUST BE CONSIDERED WHEN THE DRUG IS USED IN CONJUNCTION WITH drug1 SUCH AS drug0, drug2 AND drug0",False, 
DDI-DrugBank.d308.s1.e0,DDI-DrugBank.d308.s1.e1,Therefore when drug1 are administered concomitantly with drug2,True,advise
DDI-DrugBank.d308.s3.e0,DDI-DrugBank.d308.s3.e1,"Patients should be advised against the simultaneous use of other drug1, and cautioned that the effect of drug2",False, 
DDI-DrugBank.d327.s0.e0,DDI-DrugBank.d327.s0.e1,There have been isolated reports of patients experiencing increases in their prothrombin times when drug1 was added to drug2,True,effect
DDI-DrugBank.d412.s0.e0,DDI-DrugBank.d412.s0.e1,"In one survey, 2.3% of patients taking drug1 in combination with drug2 experienced tremor, as compared to 0.7% reported to occur with drug0",True,effect
DDI-DrugBank.d412.s0.e0,DDI-DrugBank.d412.s0.e2,"In one survey, 2.3% of patients taking drug1 in combination with drug0 experienced tremor, as compared to 0.7% reported to occur with drug2",False, 
DDI-DrugBank.d412.s0.e1,DDI-DrugBank.d412.s0.e2,"In one survey, 2.3% of patients taking drug0 in combination with drug1 experienced tremor, as compared to 0.7% reported to occur with drug2",False, 
DDI-DrugBank.d412.s4.e0,DDI-DrugBank.d412.s4.e1,drug1 has been shown to increase the bioavailability of drug2,True,mechanism
DDI-DrugBank.d412.s6.e0,DDI-DrugBank.d412.s6.e1,Synergism has been shown between drug1 anesthesia and intravenously administered drug2,True,effect
DDI-DrugBank.d412.s7.e0,DDI-DrugBank.d412.s7.e1,"During controlled hypotensive anesthesia using drug1 in association with drug2, high concentrations (3% or above) of drug0",True,effect
DDI-DrugBank.d412.s7.e0,DDI-DrugBank.d412.s7.e2,"During controlled hypotensive anesthesia using drug1 in association with drug0, high concentrations (3% or above) of drug2",False, 
DDI-DrugBank.d412.s7.e1,DDI-DrugBank.d412.s7.e2,"During controlled hypotensive anesthesia using drug0 in association with drug1, high concentrations (3% or above) of drug2",False, 
DDI-DrugBank.d412.s9.e0,DDI-DrugBank.d412.s9.e1,drug1 blunts the reflex tachycardia produced by drug2,True,effect
DDI-DrugBank.d412.s10.e0,DDI-DrugBank.d412.s10.e1,If drug1 is used with drug2,True,effect
DDI-DrugBank.d412.s11.e0,DDI-DrugBank.d412.s11.e1,Care should be taken if drug1 is used concomitantly with drug2s of the drug0,True,advise
DDI-DrugBank.d412.s11.e0,DDI-DrugBank.d412.s11.e2,Care should be taken if drug1 is used concomitantly with drug0s of the drug2,False, 
DDI-DrugBank.d412.s11.e1,DDI-DrugBank.d412.s11.e2,Care should be taken if drug0 is used concomitantly with drug1s of the drug2,False, 
DDI-DrugBank.d412.s16.e0,DDI-DrugBank.d412.s16.e1,drug1 has also been reported to produce a false positive test for drug2,False, 
DDI-DrugBank.d412.s17.e0,DDI-DrugBank.d412.s17.e1,When patients being treated with drug1 have a positive urine test for drug2,False, 
DDI-DrugBank.d510.s0.e0,DDI-DrugBank.d510.s0.e1,"The concurrent use of drug1 Injection with other drug2 or medications with anticholinergic activity, such as drug0, drug0, or drug0",True,effect
DDI-DrugBank.d510.s0.e0,DDI-DrugBank.d510.s0.e2,"The concurrent use of drug1 Injection with other drug0 or medications with anticholinergic activity, such as drug2, drug0, or drug0",True,effect
DDI-DrugBank.d510.s0.e0,DDI-DrugBank.d510.s0.e3,"The concurrent use of drug1 Injection with other drug0 or medications with anticholinergic activity, such as drug0, drug2, or drug0",True,effect
DDI-DrugBank.d510.s0.e0,DDI-DrugBank.d510.s0.e4,"The concurrent use of drug1 Injection with other drug0 or medications with anticholinergic activity, such as drug0, drug0, or drug2",True,effect
DDI-DrugBank.d510.s0.e1,DDI-DrugBank.d510.s0.e2,"The concurrent use of drug0 Injection with other drug1 or medications with anticholinergic activity, such as drug2, drug0, or drug0",False, 
DDI-DrugBank.d510.s0.e1,DDI-DrugBank.d510.s0.e3,"The concurrent use of drug0 Injection with other drug1 or medications with anticholinergic activity, such as drug0, drug2, or drug0",False, 
DDI-DrugBank.d510.s1.e0,DDI-DrugBank.d510.s1.e1,Concomitant administration of drug1 Injection and drug2,True,mechanism
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e1,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug2 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",False, 
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e2,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug2 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e3,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug2, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e4,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug2 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e5,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug2, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e6,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug2, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e7,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug2 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e8,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug2 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e0,DDI-DrugBank.d401.s0.e9,"Drug Interactions: The central drug1 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug2",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e2,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug2 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e3,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug2, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e4,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug2 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e5,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug2, drug0, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e6,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug2, certain drug0 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e7,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug2 such as the drug0 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e8,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug2 salts, and drug0",True,effect
DDI-DrugBank.d401.s0.e1,DDI-DrugBank.d401.s0.e9,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug1 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug0 such as drug0, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug2",True,effect
DDI-DrugBank.d401.s0.e2,DDI-DrugBank.d401.s0.e3,"Drug Interactions: The central drug0 syndrome can occur when anticholinergic agents such as drug0 are administered concomitantly with drugs that have secondary anticholinergic actions, e.g., certain drug1 such as drug2, the drug0 and other drug0, drug0, certain drug0 such as the drug0 salts, and drug0",False, 
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e1,"drug1 can interact with drug2 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,int
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e2,"drug1 can interact with drug0 or other drug2 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,int
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e3,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug2), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e4,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,int
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e5,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug2), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d62.s0.e0,DDI-DrugBank.d62.s0.e6,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug2 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,int
DDI-DrugBank.d290.s1.e0,DDI-DrugBank.d290.s1.e1,"Standard therapy includes drug1, such as drug2 and drug0",False, 
DDI-DrugBank.d290.s1.e0,DDI-DrugBank.d290.s1.e2,"Standard therapy includes drug1, such as drug0 and drug2",False, 
DDI-DrugBank.d290.s2.e0,DDI-DrugBank.d290.s2.e1,"drug1, such as drug2 and drug0",False, 
DDI-DrugBank.d290.s2.e0,DDI-DrugBank.d290.s2.e2,"drug1, such as drug0 and drug2",False, 
DDI-DrugBank.d290.s4.e0,DDI-DrugBank.d290.s4.e1,"and drug1, such as drug2",False, 
DDI-DrugBank.d290.s5.e0,DDI-DrugBank.d290.s5.e1,drug1: The potential for pharmacokinetic drug-drug interactions between drug2,False, 
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e1,"drug1 may interact with drug2, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e2,"drug1 may interact with drug0, drug2, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e3,"drug1 may interact with drug0, drug0, drug2, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e4,"drug1 may interact with drug0, drug0, drug0, drug2, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e5,"drug1 may interact with drug0, drug0, drug0, drug0, drug2 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e6,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e7,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e8,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e9,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e10,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e11,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e12,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,int
DDI-DrugBank.d446.s0.e0,DDI-DrugBank.d446.s0.e13,"drug1 may interact with drug0, drug0, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,int
DDI-DrugBank.d446.s0.e1,DDI-DrugBank.d446.s0.e2,"drug0 may interact with drug1, drug2, drug0, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d446.s0.e1,DDI-DrugBank.d446.s0.e3,"drug0 may interact with drug1, drug0, drug2, drug0, drug0 supplements, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d515.s0.e0,DDI-DrugBank.d515.s0.e1,"The physician should be alert for possible combined drug actions, desirable or undesirable, involving drug1 even though drug2",False, 
DDI-DrugBank.d278.s0.e0,DDI-DrugBank.d278.s0.e1,drug1 dosed as a 1.0 mg/kg subcutaneous injection q12h for four doses did not alter the pharmacokinetics of drug2,False, 
DDI-DrugBank.d369.s1.e0,DDI-DrugBank.d369.s1.e1,"These would include a variety of preparations which contain drug1, drug2, drug0, or drug0",False, 
DDI-DrugBank.d369.s1.e0,DDI-DrugBank.d369.s1.e2,"These would include a variety of preparations which contain drug1, drug0, drug2, or drug0",False, 
DDI-DrugBank.d369.s2.e0,DDI-DrugBank.d369.s2.e1,"The gonadotropin levels may be transiently elevated by drug1, minimally elevated by drug2, and suppressed by oral drug0 and drug0",False, 
DDI-DrugBank.d369.s2.e0,DDI-DrugBank.d369.s2.e2,"The gonadotropin levels may be transiently elevated by drug1, minimally elevated by drug0, and suppressed by oral drug2 and drug0",False, 
DDI-DrugBank.d369.s3.e0,DDI-DrugBank.d369.s3.e1,The response to drug1 may be blunted by drug2 and drug0,True,effect
DDI-DrugBank.d369.s3.e0,DDI-DrugBank.d369.s3.e2,The response to drug1 may be blunted by drug0 and drug2,True,effect
DDI-DrugBank.d369.s3.e1,DDI-DrugBank.d369.s3.e2,The response to drug0 may be blunted by drug1 and drug2,False, 
DDI-DrugBank.d248.s0.e0,DDI-DrugBank.d248.s0.e1,"May interact drug1 (altered hypo-prothrombinemic effect), drug2, drug0 and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of drug0), drug0 (increased effect of drug0",False, 
DDI-DrugBank.d248.s0.e0,DDI-DrugBank.d248.s0.e2,"May interact drug1 (altered hypo-prothrombinemic effect), drug0, drug2 and other inducers of hepatic microsomal enzyme oxidation system (decreased effect of drug0), drug0 (increased effect of drug0",False, 
DDI-DrugBank.d482.s1.e0,DDI-DrugBank.d482.s1.e1,"Talk to your doctor if you are taking certain drug1 such as drug2, drug0 or drug0",False, 
DDI-DrugBank.d482.s1.e0,DDI-DrugBank.d482.s1.e2,"Talk to your doctor if you are taking certain drug1 such as drug0, drug2 or drug0",False, 
DDI-DrugBank.d482.s3.e0,DDI-DrugBank.d482.s3.e1,"Caution should be exercised when taking this medicine certain drug1, such as drug2, drug0, or drug0",False, 
DDI-DrugBank.d482.s3.e0,DDI-DrugBank.d482.s3.e2,"Caution should be exercised when taking this medicine certain drug1, such as drug0, drug2, or drug0",False, 
DDI-DrugBank.d482.s9.e0,DDI-DrugBank.d482.s9.e1,Wait 5 weeks after stopping drug1 before starting a drug2,True,advise
DDI-DrugBank.d482.s10.e0,DDI-DrugBank.d482.s10.e1,Wait 2 weeks after stopping an drug1 before starting drug2,True,advise
DDI-DrugBank.d482.s14.e0,DDI-DrugBank.d482.s14.e1,Tell your doctor if you are taking any of the following drugs: drug1s (drug2) other drug0 drug0 drug0 drug0 (drug0) drug0 (drug0) drug0 drug0 (drug0) intraconazole (drug0) drug0 (drug0) drug0 drug0 drug0,False, 
DDI-DrugBank.d482.s14.e0,DDI-DrugBank.d482.s14.e2,Tell your doctor if you are taking any of the following drugs: drug1s (drug0) other drug2 drug0 drug0 drug0 (drug0) drug0 (drug0) drug0 drug0 (drug0) intraconazole (drug0) drug0 (drug0) drug0 drug0 drug0,False, 
DDI-DrugBank.d9.s0.e0,DDI-DrugBank.d9.s0.e1,"drug1 should not be administered concomitantly with drug2, drug0, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d9.s0.e0,DDI-DrugBank.d9.s0.e2,"drug1 should not be administered concomitantly with drug0, drug2, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d9.s0.e0,DDI-DrugBank.d9.s0.e3,"drug1 should not be administered concomitantly with drug0, drug0, drug2, drug0, or drug0",True,advise
DDI-DrugBank.d9.s0.e0,DDI-DrugBank.d9.s0.e4,"drug1 should not be administered concomitantly with drug0, drug0, drug0, drug2, or drug0",True,advise
DDI-DrugBank.d9.s0.e0,DDI-DrugBank.d9.s0.e5,"drug1 should not be administered concomitantly with drug0, drug0, drug0, drug0, or drug2",True,advise
DDI-DrugBank.d9.s0.e1,DDI-DrugBank.d9.s0.e2,"drug0 should not be administered concomitantly with drug1, drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d9.s0.e1,DDI-DrugBank.d9.s0.e3,"drug0 should not be administered concomitantly with drug1, drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d324.s1.e0,DDI-DrugBank.d324.s1.e1,"CNS-Active Drugs drug1: drug2 10 mg potentiated the CNS-impairing effects of drug0 0.75 g/kg on balance testing and reaction time for 1 hour after drug0 administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after drug0",False, 
DDI-DrugBank.d324.s1.e0,DDI-DrugBank.d324.s1.e2,"CNS-Active Drugs drug1: drug0 10 mg potentiated the CNS-impairing effects of drug2 0.75 g/kg on balance testing and reaction time for 1 hour after drug0 administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after drug0",False, 
DDI-DrugBank.d324.s1.e1,DDI-DrugBank.d324.s1.e2,"CNS-Active Drugs drug0: drug1 10 mg potentiated the CNS-impairing effects of drug2 0.75 g/kg on balance testing and reaction time for 1 hour after drug0 administration and on the digit symbol substitution test (DSST), symbol copying test, and the variability component of the divided attention test for 2.5 hours after drug0",True,effect
DDI-DrugBank.d324.s3.e0,DDI-DrugBank.d324.s3.e1,drug1 did not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d324.s4.e0,DDI-DrugBank.d324.s4.e1,drug1: Coadministration of single doses of drug2 20 mg and drug0,False, 
DDI-DrugBank.d324.s4.e0,DDI-DrugBank.d324.s4.e2,drug1: Coadministration of single doses of drug0 20 mg and drug2,False, 
DDI-DrugBank.d324.s4.e1,DDI-DrugBank.d324.s4.e2,drug0: Coadministration of single doses of drug1 20 mg and drug2,True,effect
DDI-DrugBank.d324.s6.e0,DDI-DrugBank.d324.s6.e1,drug1: Coadministration of a single dose of drug2 20 mg and drug0,False, 
DDI-DrugBank.d324.s6.e0,DDI-DrugBank.d324.s6.e2,drug1: Coadministration of a single dose of drug0 20 mg and drug2,False, 
DDI-DrugBank.d324.s7.e0,DDI-DrugBank.d324.s7.e1,"Additionally, drug1 did not alter the pharmacokinetics of drug2, reflecting the absence of a role of CYP2D6 in drug0",False, 
DDI-DrugBank.d324.s7.e0,DDI-DrugBank.d324.s7.e2,"Additionally, drug1 did not alter the pharmacokinetics of drug0, reflecting the absence of a role of CYP2D6 in drug2",False, 
DDI-DrugBank.d324.s8.e0,DDI-DrugBank.d324.s8.e1,drug1: Coadministration of single doses of drug2 20 mg and drug0,False, 
DDI-DrugBank.d324.s8.e0,DDI-DrugBank.d324.s8.e2,drug1: Coadministration of single doses of drug0 20 mg and drug2,False, 
DDI-DrugBank.d324.s8.e1,DDI-DrugBank.d324.s8.e2,drug0: Coadministration of single doses of drug1 20 mg and drug2,True,effect
DDI-DrugBank.d324.s10.e0,DDI-DrugBank.d324.s10.e1,drug1: Coadministration of a single dose of drug2 10 mg and multiple doses of drug0 ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either drug0 or drug0,False, 
DDI-DrugBank.d324.s10.e0,DDI-DrugBank.d324.s10.e2,drug1: Coadministration of a single dose of drug0 10 mg and multiple doses of drug2 ER (extended release) 150 mg did not result in any significant changes in the pharmacokinetics of either drug0 or drug0,False, 
DDI-DrugBank.d324.s11.e0,DDI-DrugBank.d324.s11.e1,"In addition, there was no pharmacodynamic interaction as a result of coadministration of drug1 and drug2",False, 
DDI-DrugBank.d324.s12.e0,DDI-DrugBank.d324.s12.e1,"drug1: Coadministration of a single dose of drug2 and drug0 (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of drug0",False, 
DDI-DrugBank.d324.s12.e0,DDI-DrugBank.d324.s12.e2,"drug1: Coadministration of a single dose of drug0 and drug2 (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of drug0",False, 
DDI-DrugBank.d324.s12.e1,DDI-DrugBank.d324.s12.e2,"drug0: Coadministration of a single dose of drug1 and drug2 (10 and 25 mg, respectively) resulted in a 15% decrease in maximal plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d324.s13.e0,DDI-DrugBank.d324.s13.e1,"However, the pharmacodynamics of coadministration of drug1 and drug2",False, 
DDI-DrugBank.d324.s15.e0,DDI-DrugBank.d324.s15.e1,Drugs That Induce CYP3A4 drug1: CYP3A4 is ordinarily a minor metabolizing enzyme of drug2,False, 
DDI-DrugBank.d324.s16.e0,DDI-DrugBank.d324.s16.e1,"Multiple-dose administration of the potent CYP3A4 inducer drug1 (600 mg every 24 hours, q24h, for 14 days), however, reduced drug2",True,mechanism
DDI-DrugBank.d324.s18.e0,DDI-DrugBank.d324.s18.e1,"An alternative non-CYP3A4 substrate drug1 may be considered in patients taking CYP3A4 inducers such as drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d324.s18.e0,DDI-DrugBank.d324.s18.e2,"An alternative non-CYP3A4 substrate drug1 may be considered in patients taking CYP3A4 inducers such as drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d324.s19.e0,DDI-DrugBank.d324.s19.e1,"Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of drug1 because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, drug2 and drug0, account for only 9% of the urinary recovery of a drug0",False, 
DDI-DrugBank.d324.s19.e0,DDI-DrugBank.d324.s19.e2,"Drugs That Inhibit CYP3A4 CYP3A4 is a minor metabolic pathway for the elimination of drug1 because the sum of desethylzaleplon (formed via CYP3A4 in vitro) and its metabolites, drug0 and drug2, account for only 9% of the urinary recovery of a drug0",False, 
DDI-DrugBank.d324.s20.e0,DDI-DrugBank.d324.s20.e1,"Coadministration of single, oral doses of drug1 with drug2 (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in drug0",True,mechanism
DDI-DrugBank.d324.s20.e0,DDI-DrugBank.d324.s20.e2,"Coadministration of single, oral doses of drug1 with drug0 (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in drug2",False, 
DDI-DrugBank.d324.s20.e1,DDI-DrugBank.d324.s20.e2,"Coadministration of single, oral doses of drug0 with drug1 (10 mg and 800 mg, respectively), a strong, selective CYP3A4 inhibitor produced a 34% increase in drug2",False, 
DDI-DrugBank.d324.s22.e0,DDI-DrugBank.d324.s22.e1,Other strong selective CYP3A4 inhibitors such as drug1 can also be expected to increase the exposure of drug2,True,mechanism
DDI-DrugBank.d324.s25.e0,DDI-DrugBank.d324.s25.e1,drug1: drug2,False, 
DDI-DrugBank.d324.s26.e0,DDI-DrugBank.d324.s26.e1,There is no pharmacokinetic interaction between drug1 and drug2,False, 
DDI-DrugBank.d324.s28.e0,DDI-DrugBank.d324.s28.e1,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 drug1: drug2 inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for drug0",False, 
DDI-DrugBank.d324.s28.e0,DDI-DrugBank.d324.s28.e2,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 drug1: drug0 inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for drug2",False, 
DDI-DrugBank.d324.s28.e1,DDI-DrugBank.d324.s28.e2,"Drugs That Inhibit Both Aldehyde Oxidase and CYP3A4 drug0: drug1 inhibits both aldehyde oxidase (in vitro) and CYP3A4 (in vitro and in vivo), the primary and secondary enzymes, respectively, responsible for drug2",True,mechanism
DDI-DrugBank.d324.s29.e0,DDI-DrugBank.d324.s29.e1,Concomitant administration of drug1 (10 mg) and drug2 (800 mg) produced an 85% increase in the mean Cmax and AUC of drug0,True,mechanism
DDI-DrugBank.d324.s29.e0,DDI-DrugBank.d324.s29.e2,Concomitant administration of drug1 (10 mg) and drug0 (800 mg) produced an 85% increase in the mean Cmax and AUC of drug2,False, 
DDI-DrugBank.d324.s29.e1,DDI-DrugBank.d324.s29.e2,Concomitant administration of drug0 (10 mg) and drug1 (800 mg) produced an 85% increase in the mean Cmax and AUC of drug2,False, 
DDI-DrugBank.d324.s34.e0,DDI-DrugBank.d324.s34.e1,Drugs with a Narrow Therapeutic Index drug1: drug2 (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of drug0,False, 
DDI-DrugBank.d324.s34.e0,DDI-DrugBank.d324.s34.e2,Drugs with a Narrow Therapeutic Index drug1: drug0 (10 mg) did not affect the pharmacokinetic or pharmacodynamic profile of drug2,False, 
DDI-DrugBank.d324.s35.e0,DDI-DrugBank.d324.s35.e1,drug1: Multiple oral doses of drug2 (20 mg q24h for 13 days) did not affect the pharmacokinetics of drug0 (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of drug0,False, 
DDI-DrugBank.d324.s35.e0,DDI-DrugBank.d324.s35.e2,drug1: Multiple oral doses of drug0 (20 mg q24h for 13 days) did not affect the pharmacokinetics of drug2 (R+)- or (S-)-enantiomers or the pharmacodynamics (prothrombin time) following a single 25-mg oral dose of drug0,False, 
DDI-DrugBank.d324.s36.e0,DDI-DrugBank.d324.s36.e1,Drugs That Alter Renal Excretion drug1: drug2,False, 
DDI-DrugBank.d324.s37.e0,DDI-DrugBank.d324.s37.e1,There was no apparent pharmacokinetic interaction between drug1 and drug2,False, 
DDI-DrugBank.d324.s38.e0,DDI-DrugBank.d324.s38.e1,This was expected because drug1 is primarily metabolized and renal excretion of unchanged drug2,False, 
DDI-DrugBank.d522.s0.e0,DDI-DrugBank.d522.s0.e1,"drug1: In a prospective study involving six-healthy-male volunteers, drug2 did not affect the metabolism of drug0",False, 
DDI-DrugBank.d522.s0.e0,DDI-DrugBank.d522.s0.e2,"drug1: In a prospective study involving six-healthy-male volunteers, drug0 did not affect the metabolism of drug2",False, 
DDI-DrugBank.d522.s1.e0,DDI-DrugBank.d522.s1.e1,"These six volunteers received drug1 alone (60 mg twice daily) for 8 days, followed by drug2 in combination with drug0",False, 
DDI-DrugBank.d522.s1.e0,DDI-DrugBank.d522.s1.e2,"These six volunteers received drug1 alone (60 mg twice daily) for 8 days, followed by drug0 in combination with drug2",False, 
DDI-DrugBank.d522.s3.e0,DDI-DrugBank.d522.s3.e1,"The pharmacokinetics of drug1 and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with drug2 alone, and with drug0 plus drug0",False, 
DDI-DrugBank.d522.s3.e0,DDI-DrugBank.d522.s3.e2,"The pharmacokinetics of drug1 and its acid metabolite and the electrocardiographic QT c interval were measured during both periods: with drug0 alone, and with drug2 plus drug0",False, 
DDI-DrugBank.d522.s5.e0,DDI-DrugBank.d522.s5.e1,"in one man, the C max of drug1 was 8.1 ng/mL with drug2 alone and 7.2 ng/mL with drug0 plus drug0",False, 
DDI-DrugBank.d522.s5.e0,DDI-DrugBank.d522.s5.e2,"in one man, the C max of drug1 was 8.1 ng/mL with drug0 alone and 7.2 ng/mL with drug2 plus drug0",False, 
DDI-DrugBank.d522.s5.e2,DDI-DrugBank.d522.s5.e3,"in one man, the C max of drug0 was 8.1 ng/mL with drug0 alone and 7.2 ng/mL with drug1 plus drug2",True,mechanism
DDI-DrugBank.d522.s7.e0,DDI-DrugBank.d522.s7.e1,The mean QT c interval (msec) was 369 with drug1 alone and 367 with drug2 plus drug0,False, 
DDI-DrugBank.d522.s7.e0,DDI-DrugBank.d522.s7.e2,The mean QT c interval (msec) was 369 with drug1 alone and 367 with drug0 plus drug2,False, 
DDI-DrugBank.d522.s7.e1,DDI-DrugBank.d522.s7.e2,The mean QT c interval (msec) was 369 with drug0 alone and 367 with drug1 plus drug2,True,effect
DDI-DrugBank.d522.s8.e0,DDI-DrugBank.d522.s8.e1,"Also, in vitro experiments demonstrated a lack of interaction between drug1 and drug2",False, 
DDI-DrugBank.d522.s9.e0,DDI-DrugBank.d522.s9.e1,"Thus, the interaction observed between drug1 and drug2 is not expected for drug0",True,int
DDI-DrugBank.d522.s9.e0,DDI-DrugBank.d522.s9.e2,"Thus, the interaction observed between drug1 and drug0 is not expected for drug2",False, 
DDI-DrugBank.d522.s9.e1,DDI-DrugBank.d522.s9.e2,"Thus, the interaction observed between drug0 and drug1 is not expected for drug2",False, 
DDI-DrugBank.d522.s10.e0,DDI-DrugBank.d522.s10.e1,"Serious cardiac dysrhythmias, some resulting in death, have occurred in patients receiving drug1 concomitantly with other drug2",True,effect
DDI-DrugBank.d522.s11.e0,DDI-DrugBank.d522.s11.e1,"In addition, most drug1 are contraindicated in patients receiving drug2",True,advise
DDI-DrugBank.d522.s12.e0,DDI-DrugBank.d522.s12.e1,"drug1: Following co-administration of two 250-mg drug2 tablets administered once daily with 200-mg drug0 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of drug0",False, 
DDI-DrugBank.d522.s12.e0,DDI-DrugBank.d522.s12.e2,"drug1: Following co-administration of two 250-mg drug0 tablets administered once daily with 200-mg drug2 tablets administered twice daily for 10 days to 14 healthy subjects, the steady-state plasma concentration of drug0",False, 
DDI-DrugBank.d522.s13.e0,DDI-DrugBank.d522.s13.e1,"In general, most patients treated with drug1 who are receiving concomitant drug2 therapy may not require empiric adjustment of drug0 dosage or monitoring of drug0",False, 
DDI-DrugBank.d522.s13.e0,DDI-DrugBank.d522.s13.e2,"In general, most patients treated with drug1 who are receiving concomitant drug0 therapy may not require empiric adjustment of drug2 dosage or monitoring of drug0",False, 
DDI-DrugBank.d522.s14.e0,DDI-DrugBank.d522.s14.e1,"However, drug1 plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given drug2 plasma concentration for optimal pulmonary function or in patients with drug0",False, 
DDI-DrugBank.d522.s14.e0,DDI-DrugBank.d522.s14.e2,"However, drug1 plasma concentrations should be monitored, with dosage adjustment as appropriate, in patients whose pulmonary disease requires maintaining a given drug0 plasma concentration for optimal pulmonary function or in patients with drug2",False, 
DDI-DrugBank.d522.s15.e0,DDI-DrugBank.d522.s15.e1,"drug1 or drug2: When drug0 is administered immediately following drug0 or drug0, the absorption of drug0",False, 
DDI-DrugBank.d522.s15.e0,DDI-DrugBank.d522.s15.e2,"drug1 or drug0: When drug2 is administered immediately following drug0 or drug0, the absorption of drug0",False, 
DDI-DrugBank.d522.s15.e2,DDI-DrugBank.d522.s15.e3,"drug0 or drug0: When drug1 is administered immediately following drug2 or drug0, the absorption of drug0",True,mechanism
DDI-DrugBank.d522.s15.e2,DDI-DrugBank.d522.s15.e4,"drug0 or drug0: When drug1 is administered immediately following drug0 or drug2, the absorption of drug0",True,mechanism
DDI-DrugBank.d522.s19.e0,DDI-DrugBank.d522.s19.e1,"drug1: drug2 has been reported to decrease the clearance of drug0 and, thus, may increase the pharmacologic effect of drug0",False, 
DDI-DrugBank.d522.s19.e0,DDI-DrugBank.d522.s19.e2,"drug1: drug0 has been reported to decrease the clearance of drug2 and, thus, may increase the pharmacologic effect of drug0",False, 
DDI-DrugBank.d522.s19.e1,DDI-DrugBank.d522.s19.e2,"drug0: drug1 has been reported to decrease the clearance of drug2 and, thus, may increase the pharmacologic effect of drug0",True,mechanism
DDI-DrugBank.d522.s19.e1,DDI-DrugBank.d522.s19.e3,"drug0: drug1 has been reported to decrease the clearance of drug0 and, thus, may increase the pharmacologic effect of drug2",True,effect
DDI-DrugBank.d522.s20.e0,DDI-DrugBank.d522.s20.e1,drug1: Concomitant administration of drug2 and drug0 has been reported to result in elevated drug0,False, 
DDI-DrugBank.d522.s20.e0,DDI-DrugBank.d522.s20.e2,drug1: Concomitant administration of drug0 and drug2 has been reported to result in elevated drug0,False, 
DDI-DrugBank.d522.s20.e1,DDI-DrugBank.d522.s20.e2,drug0: Concomitant administration of drug1 and drug2 has been reported to result in elevated drug0,True,mechanism
DDI-DrugBank.d522.s21.e0,DDI-DrugBank.d522.s21.e1,drug1: There have been reports of increased anticoagulant effects when drug2 and oral drug0,False, 
DDI-DrugBank.d522.s21.e0,DDI-DrugBank.d522.s21.e2,drug1: There have been reports of increased anticoagulant effects when drug0 and oral drug2,False, 
DDI-DrugBank.d522.s21.e1,DDI-DrugBank.d522.s21.e2,drug0: There have been reports of increased anticoagulant effects when drug1 and oral drug2,True,effect
DDI-DrugBank.d522.s23.e0,DDI-DrugBank.d522.s23.e1,drug1: Concurrent use of drug2 and drug0 or drug0,False, 
DDI-DrugBank.d522.s23.e0,DDI-DrugBank.d522.s23.e2,drug1: Concurrent use of drug0 and drug2 or drug0,False, 
DDI-DrugBank.d522.s23.e1,DDI-DrugBank.d522.s23.e2,drug0: Concurrent use of drug1 and drug2 or drug0,True,effect
DDI-DrugBank.d522.s23.e1,DDI-DrugBank.d522.s23.e3,drug0: Concurrent use of drug1 and drug0 or drug2,True,effect
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e1,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e2,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e3,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e4,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e5,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e6,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e7,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e8,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e9,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,int
DDI-DrugBank.d522.s24.e0,DDI-DrugBank.d522.s24.e10,"Other drugs Drug interactions have been reported with concomitant administration of drug1 and other medications, including drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,int
DDI-DrugBank.d522.s24.e1,DDI-DrugBank.d522.s24.e2,"Other drugs Drug interactions have been reported with concomitant administration of drug0 and other medications, including drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d522.s24.e1,DDI-DrugBank.d522.s24.e3,"Other drugs Drug interactions have been reported with concomitant administration of drug0 and other medications, including drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d463.s0.e0,DDI-DrugBank.d463.s0.e1,"It is recommended that drug1 not be used concomitantly with drug2 Because the effects of concomitant administration of drug0 with most other drug0 have not been studied, the concomitant use of drug0",True,advise
DDI-DrugBank.d463.s0.e0,DDI-DrugBank.d463.s0.e2,"It is recommended that drug1 not be used concomitantly with drug0 Because the effects of concomitant administration of drug2 with most other drug0 have not been studied, the concomitant use of drug0",False, 
DDI-DrugBank.d463.s0.e0,DDI-DrugBank.d463.s0.e3,"It is recommended that drug1 not be used concomitantly with drug0 Because the effects of concomitant administration of drug0 with most other drug2 have not been studied, the concomitant use of drug0",False, 
DDI-DrugBank.d463.s1.e0,DDI-DrugBank.d463.s1.e1,There is one report suggesting that the concomitant use of drug1 (drug2) and drug0,False, 
DDI-DrugBank.d463.s1.e0,DDI-DrugBank.d463.s1.e2,There is one report suggesting that the concomitant use of drug1 (drug0) and drug2,True,effect
DDI-DrugBank.d463.s1.e1,DDI-DrugBank.d463.s1.e2,There is one report suggesting that the concomitant use of drug0 (drug1) and drug2,True,effect
DDI-DrugBank.d463.s3.e0,DDI-DrugBank.d463.s3.e1,"In a study in normal volunteers, concomitant administration of drug1 and drug2 resulted in increased serum drug0",True,mechanism
DDI-DrugBank.d463.s3.e0,DDI-DrugBank.d463.s3.e2,"In a study in normal volunteers, concomitant administration of drug1 and drug0 resulted in increased serum drug2",False, 
DDI-DrugBank.d463.s3.e1,DDI-DrugBank.d463.s3.e2,"In a study in normal volunteers, concomitant administration of drug0 and drug1 resulted in increased serum drug2",False, 
DDI-DrugBank.d463.s5.e0,DDI-DrugBank.d463.s5.e1,"In vitro, drug1 does not displace tightly bound drugs like drug2, drug0, and drug0",False, 
DDI-DrugBank.d463.s5.e0,DDI-DrugBank.d463.s5.e2,"In vitro, drug1 does not displace tightly bound drugs like drug0, drug2, and drug0",False, 
DDI-DrugBank.d463.s6.e0,DDI-DrugBank.d463.s6.e1,"However, there has been one report of prolonged prothrombin time when drug1 was added to the regimen of a patient treated with drug2",True,effect
DDI-DrugBank.d463.s7.e0,DDI-DrugBank.d463.s7.e1,"The patient was also chronically receiving drug1, drug2, drug0, and drug0",False, 
DDI-DrugBank.d463.s7.e0,DDI-DrugBank.d463.s7.e2,"The patient was also chronically receiving drug1, drug0, drug2, and drug0",False, 
DDI-DrugBank.d463.s8.e0,DDI-DrugBank.d463.s8.e1,"In vitro, drug1 may displace less firmly bound drugs like drug2",True,mechanism
DDI-DrugBank.d61.s0.e0,DDI-DrugBank.d61.s0.e1,"In clinical studies, drug1 has been co-administered with other anti-asthma medications, including inhaled and oral drug2, and inhaled drug0",False, 
DDI-DrugBank.d61.s0.e0,DDI-DrugBank.d61.s0.e2,"In clinical studies, drug1 has been co-administered with other anti-asthma medications, including inhaled and oral drug0, and inhaled drug2",False, 
DDI-DrugBank.d523.s1.e0,DDI-DrugBank.d523.s1.e1,Interactions attributed to the combined use of drug1 injection and epidural drug2,True,effect
DDI-DrugBank.d523.s2.e0,DDI-DrugBank.d523.s2.e1,SIDE EFFECTS (drug1) The most common adverse reaction during treatment with drug2,False, 
DDI-DrugBank.d523.s16.e0,DDI-DrugBank.d523.s16.e1,The adverse experience profile seen with drug1 was similar to that seen with drug2,False, 
DDI-DrugBank.d414.s0.e0,DDI-DrugBank.d414.s0.e1,drug1 generally should not be given with drug2 because they reduce its renal clearance and add a high risk of drug0,True,mechanism
DDI-DrugBank.d414.s0.e0,DDI-DrugBank.d414.s0.e2,drug1 generally should not be given with drug0 because they reduce its renal clearance and add a high risk of drug2,False, 
DDI-DrugBank.d414.s0.e1,DDI-DrugBank.d414.s0.e2,drug0 generally should not be given with drug1 because they reduce its renal clearance and add a high risk of drug2,False, 
DDI-DrugBank.d414.s2.e0,DDI-DrugBank.d414.s2.e1,drug1 may increase the ototoxic potential of other drugs such as drug2 and some drug0,True,effect
DDI-DrugBank.d414.s2.e0,DDI-DrugBank.d414.s2.e2,drug1 may increase the ototoxic potential of other drugs such as drug0 and some drug2,True,effect
DDI-DrugBank.d414.s2.e1,DDI-DrugBank.d414.s2.e2,drug0 may increase the ototoxic potential of other drugs such as drug1 and some drug2,False, 
DDI-DrugBank.d414.s4.e0,DDI-DrugBank.d414.s4.e1,"A number of drugs, including drug1, have been shown to displace drug2",True,mechanism
DDI-DrugBank.d414.s6.e0,DDI-DrugBank.d414.s6.e1,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",True,effect
DDI-DrugBank.d414.s6.e0,DDI-DrugBank.d414.s6.e2,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2 and drug0",True,effect
DDI-DrugBank.d414.s6.e0,DDI-DrugBank.d414.s6.e3,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug2",True,effect
DDI-DrugBank.d414.s6.e1,DDI-DrugBank.d414.s6.e2,"In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug2 and drug0",False, 
DDI-DrugBank.d414.s6.e1,DDI-DrugBank.d414.s6.e3,"In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug0 and drug2",False, 
DDI-DrugBank.d414.s7.e0,DDI-DrugBank.d414.s7.e1,"Therefore, when drug1 and drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",True,effect
DDI-DrugBank.d414.s7.e0,DDI-DrugBank.d414.s7.e2,"Therefore, when drug1 and drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d414.s7.e1,DDI-DrugBank.d414.s7.e2,"Therefore, when drug0 and drug1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d442.s0.e0,DDI-DrugBank.d442.s0.e1,Increases in prothrombin time have been noted in patients receiving long- term drug1 therapy after drug2,True,effect
DDI-DrugBank.d442.s1.e0,DDI-DrugBank.d442.s1.e1,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the drug1 dose may be necessary when drug2 Capsules are administered concomitantly with drug0",False, 
DDI-DrugBank.d442.s1.e0,DDI-DrugBank.d442.s1.e2,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the drug1 dose may be necessary when drug0 Capsules are administered concomitantly with drug2",False, 
DDI-DrugBank.d442.s1.e1,DDI-DrugBank.d442.s1.e2,"Therefore, close monitoring of prothrombin time is recommended and adjustment of the drug0 dose may be necessary when drug1 Capsules are administered concomitantly with drug2",True,advise
DDI-DrugBank.d163.s0.e0,DDI-DrugBank.d163.s0.e1,"drug1: Because of the relationship of drug2 to drug0, patients should be advised against taking drug0 containing drug0",False, 
DDI-DrugBank.d163.s0.e0,DDI-DrugBank.d163.s0.e2,"drug1: Because of the relationship of drug0 to drug2, patients should be advised against taking drug0 containing drug0",False, 
DDI-DrugBank.d163.s0.e1,DDI-DrugBank.d163.s0.e2,"drug0: Because of the relationship of drug1 to drug2, patients should be advised against taking drug0 containing drug0",True,effect
DDI-DrugBank.d163.s2.e0,DDI-DrugBank.d163.s2.e1,"drug1: Concomitant treatment with drug2 and drug0 should be avoided because drug0 use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of drug0",False, 
DDI-DrugBank.d163.s2.e0,DDI-DrugBank.d163.s2.e2,"drug1: Concomitant treatment with drug0 and drug2 should be avoided because drug0 use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of drug0",False, 
DDI-DrugBank.d163.s2.e1,DDI-DrugBank.d163.s2.e2,"drug0: Concomitant treatment with drug1 and drug2 should be avoided because drug0 use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of drug0",True,advise
DDI-DrugBank.d163.s2.e3,DDI-DrugBank.d163.s2.e4,"drug0: Concomitant treatment with drug0 and drug0 should be avoided because drug1 use has been associated with a number of cases of pseudotumor cerebri (benign intracranial hypertension), some of which involved concomitant use of drug2",True,effect
DDI-DrugBank.d163.s4.e0,DDI-DrugBank.d163.s4.e1,Micro-dosed drug1 Preparations: Micro-dosed drug2 preparations (minipills that do not contain an drug0) may be an inadequate method of contraception during drug0,False, 
DDI-DrugBank.d163.s4.e0,DDI-DrugBank.d163.s4.e2,Micro-dosed drug1 Preparations: Micro-dosed drug0 preparations (minipills that do not contain an drug2) may be an inadequate method of contraception during drug0,False, 
DDI-DrugBank.d163.s4.e1,DDI-DrugBank.d163.s4.e3,Micro-dosed drug0 Preparations: Micro-dosed drug1 preparations (minipills that do not contain an drug0) may be an inadequate method of contraception during drug2,True,effect
DDI-DrugBank.d163.s5.e0,DDI-DrugBank.d163.s5.e1,"Although other drug1 are highly effective, there have been reports of pregnancy from women who have used drug2",False, 
DDI-DrugBank.d163.s7.e0,DDI-DrugBank.d163.s7.e1,It is not known if drug1 differ in their effectiveness when used with drug2,False, 
DDI-DrugBank.d163.s10.e0,DDI-DrugBank.d163.s10.e1,drug1: drug2 has not been shown to alter the pharmacokinetics of drug0,False, 
DDI-DrugBank.d163.s10.e0,DDI-DrugBank.d163.s10.e2,drug1: drug0 has not been shown to alter the pharmacokinetics of drug2,False, 
DDI-DrugBank.d163.s13.e0,DDI-DrugBank.d163.s13.e1,No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between drug1 and drug2,False, 
DDI-DrugBank.d163.s16.e0,DDI-DrugBank.d163.s16.e1,drug1: drug2,False, 
DDI-DrugBank.d163.s17.e0,DDI-DrugBank.d163.s17.e1,No formal clinical studies have been conducted to assess if there is an interactive effect on bone loss between drug1 and drug2,False, 
DDI-DrugBank.d570.s0.e0,DDI-DrugBank.d570.s0.e1,Drug/ Laboratory Test Interactions Certain endocrine and liver function tests may be affected by drug1-containing oral drug2,False, 
DDI-DrugBank.d524.s0.e0,DDI-DrugBank.d524.s0.e1,"drug1, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d524.s0.e0,DDI-DrugBank.d524.s0.e2,"drug1, drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d530.s0.e0,DDI-DrugBank.d530.s0.e1,"drug1 - including drug2, drug0 and drug0",False, 
DDI-DrugBank.d530.s0.e0,DDI-DrugBank.d530.s0.e2,"drug1 - including drug0, drug2 and drug0",False, 
DDI-DrugBank.d530.s1.e0,DDI-DrugBank.d530.s1.e1,Concomitant use of drug1 and drug2,True,effect
DDI-DrugBank.d530.s2.e0,DDI-DrugBank.d530.s2.e1,drug1 - drug2 and the drug0 drug0,False, 
DDI-DrugBank.d530.s2.e0,DDI-DrugBank.d530.s2.e2,drug1 - drug0 and the drug2 drug0,False, 
DDI-DrugBank.d530.s2.e1,DDI-DrugBank.d530.s2.e3,drug0 - drug1 and the drug0 drug2,True,effect
DDI-DrugBank.d530.s3.e0,DDI-DrugBank.d530.s3.e1,drug1 - drug2 may potentiate the tardive dyskinesia side reactions of drug0,True,effect
DDI-DrugBank.d530.s3.e0,DDI-DrugBank.d530.s3.e2,drug1 - drug0 may potentiate the tardive dyskinesia side reactions of drug2,False, 
DDI-DrugBank.d530.s3.e1,DDI-DrugBank.d530.s3.e2,drug0 - drug1 may potentiate the tardive dyskinesia side reactions of drug2,False, 
DDI-DrugBank.d323.s0.e0,DDI-DrugBank.d323.s0.e1,"Co-administration of drug1 and drug2 or other agents interfering with neuromuscular transmission (e.g., drug0) should only be performed with caution as the effect of the drug0",True,advise
DDI-DrugBank.d323.s0.e0,DDI-DrugBank.d323.s0.e2,"Co-administration of drug1 and drug0 or other agents interfering with neuromuscular transmission (e.g., drug2) should only be performed with caution as the effect of the drug0",True,advise
DDI-DrugBank.d323.s0.e0,DDI-DrugBank.d323.s0.e3,"Co-administration of drug1 and drug0 or other agents interfering with neuromuscular transmission (e.g., drug0) should only be performed with caution as the effect of the drug2",False, 
DDI-DrugBank.d323.s0.e1,DDI-DrugBank.d323.s0.e2,"Co-administration of drug0 and drug1 or other agents interfering with neuromuscular transmission (e.g., drug2) should only be performed with caution as the effect of the drug0",False, 
DDI-DrugBank.d279.s0.e0,DDI-DrugBank.d279.s0.e1,"The adverse effects of drug1, such as myelosuppression and diarrhea, would be expected to be exacerbated by other drug2",True,effect
DDI-DrugBank.d279.s3.e0,DDI-DrugBank.d279.s3.e1,"Lymphocytopenia has been reported in patients receiving drug1, and it is possible that the administration of drug2",True,effect
DDI-DrugBank.d279.s8.e0,DDI-DrugBank.d279.s8.e1,"The incidence of akathisia in clinical trials of the weekly dosage schedule was greater (8.5%, 4/47 patients) when drug1 was administered on the same day as drug2",True,effect
DDI-DrugBank.d279.s10.e0,DDI-DrugBank.d279.s10.e1,It would be expected that drug1 use during therapy with drug2,True,effect
DDI-DrugBank.d279.s11.e0,DDI-DrugBank.d279.s11.e1,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by drug1, the physician may wish to withhold drug2 during dosing with drug0",False, 
DDI-DrugBank.d279.s11.e0,DDI-DrugBank.d279.s11.e2,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by drug1, the physician may wish to withhold drug0 during dosing with drug2",False, 
DDI-DrugBank.d279.s11.e1,DDI-DrugBank.d279.s11.e2,"In view of the potential risk of dehydration secondary to vomiting and/or diarrhea induced by drug0, the physician may wish to withhold drug1 during dosing with drug2",True,effect
DDI-DrugBank.d122.s0.e0,DDI-DrugBank.d122.s0.e1,Nephrotoxicity has been reported following concomitant administration of drug1 with drug2 or potent drug0 such as drug0,True,effect
DDI-DrugBank.d122.s0.e0,DDI-DrugBank.d122.s0.e2,Nephrotoxicity has been reported following concomitant administration of drug1 with drug0 or potent drug2 such as drug0,True,effect
DDI-DrugBank.d122.s0.e0,DDI-DrugBank.d122.s0.e3,Nephrotoxicity has been reported following concomitant administration of drug1 with drug0 or potent drug0 such as drug2,True,effect
DDI-DrugBank.d122.s0.e1,DDI-DrugBank.d122.s0.e2,Nephrotoxicity has been reported following concomitant administration of drug0 with drug1 or potent drug2 such as drug0,False, 
DDI-DrugBank.d122.s0.e1,DDI-DrugBank.d122.s0.e3,Nephrotoxicity has been reported following concomitant administration of drug0 with drug1 or potent drug0 such as drug2,False, 
DDI-DrugBank.d122.s1.e0,DDI-DrugBank.d122.s1.e1,"Renal function should be carefully monitored, especially if higher dosages of the drug1 are to be administered or if therapy is prolonged, because of the potential nephrotoxicity and ototoxicity of drug2",False, 
DDI-DrugBank.d122.s3.e0,DDI-DrugBank.d122.s3.e1,"drug1 has been shown to be antagonistic to drug2, including drug0",True,effect
DDI-DrugBank.d122.s3.e0,DDI-DrugBank.d122.s3.e2,"drug1 has been shown to be antagonistic to drug0, including drug2",True,effect
DDI-DrugBank.d122.s3.e1,DDI-DrugBank.d122.s3.e2,"drug0 has been shown to be antagonistic to drug1, including drug2",False, 
DDI-DrugBank.d390.s0.e0,DDI-DrugBank.d390.s0.e1,drug1 such as drug2 or drug0,False, 
DDI-DrugBank.d390.s0.e0,DDI-DrugBank.d390.s0.e2,drug1 such as drug0 or drug2,False, 
DDI-DrugBank.d32.s0.e0,DDI-DrugBank.d32.s0.e1,drug1: Twelve healthy male volunteers were administered one 200-mg drug2,False, 
DDI-DrugBank.d32.s1.e0,DDI-DrugBank.d32.s1.e1,"With the morning dose of drug1 on day 6, each volunteer received a single intravenous infusion of drug2",False, 
DDI-DrugBank.d32.s3.e0,DDI-DrugBank.d32.s3.e1,The effect of drug1 on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d32.s4.e0,DDI-DrugBank.d32.s4.e1,drug1 or drug2: The effect of increased gastric pH on the bioavailability of drug0,False, 
DDI-DrugBank.d32.s4.e0,DDI-DrugBank.d32.s4.e2,drug1 or drug0: The effect of increased gastric pH on the bioavailability of drug2,False, 
DDI-DrugBank.d32.s6.e0,DDI-DrugBank.d32.s6.e1,A single dose of liquid drug1 did not affect the C max or AUC of drug2,False, 
DDI-DrugBank.d32.s7.e0,DDI-DrugBank.d32.s7.e1,"however, 150 mg of drug1 q12h for 3 days increased the drug2 C max by 23% and drug0",True,mechanism
DDI-DrugBank.d32.s7.e0,DDI-DrugBank.d32.s7.e2,"however, 150 mg of drug1 q12h for 3 days increased the drug0 C max by 23% and drug2",True,mechanism
DDI-DrugBank.d32.s7.e1,DDI-DrugBank.d32.s7.e2,"however, 150 mg of drug0 q12h for 3 days increased the drug1 C max by 23% and drug2",False, 
DDI-DrugBank.d32.s12.e0,DDI-DrugBank.d32.s12.e1,The results of assays using red cells from healthy subjects to determine whether drug1 would cause direct Coombs reactions in vitro showed no positive reaction at drug2,False, 
DDI-DrugBank.d146.s0.e0,DDI-DrugBank.d146.s0.e1,drug1 is inhibited by drug2,True,mechanism
DDI-DrugBank.d146.s1.e0,DDI-DrugBank.d146.s1.e1,The action of drug1 is potentiated by drug2,True,mechanism
DDI-DrugBank.d146.s2.e0,DDI-DrugBank.d146.s2.e1,drug1 may increase sensitivity to the drug2,True,effect
DDI-DrugBank.d146.s3.e0,DDI-DrugBank.d146.s3.e1,Response to drug1 may be enhanced by drug2,True,effect
DDI-DrugBank.d97.s3.e0,DDI-DrugBank.d97.s3.e1,"Drugs that induce CYP3A4 activity would be expected to increase the clearance of drug1, resulting in lowered plasma concentrations of drug2",False, 
DDI-DrugBank.d97.s4.e0,DDI-DrugBank.d97.s4.e1,Coadministration of drug1 and other drugs that inhibit CYP3A4 may decrease the clearance of drug2 and may result in increased plasma concentrations of drug0,False, 
DDI-DrugBank.d97.s4.e0,DDI-DrugBank.d97.s4.e2,Coadministration of drug1 and other drugs that inhibit CYP3A4 may decrease the clearance of drug0 and may result in increased plasma concentrations of drug2,False, 
DDI-DrugBank.d97.s8.e0,DDI-DrugBank.d97.s8.e1,drug1: drug2,False, 
DDI-DrugBank.d97.s10.e0,DDI-DrugBank.d97.s10.e1,"Ergot derivatives: drug1, drug2, drug0, drug0",False, 
DDI-DrugBank.d97.s10.e0,DDI-DrugBank.d97.s10.e2,"Ergot derivatives: drug1, drug0, drug2, drug0",False, 
DDI-DrugBank.d97.s12.e0,DDI-DrugBank.d97.s12.e1,"drug1/drug2: drug0, drug0",False, 
DDI-DrugBank.d97.s12.e0,DDI-DrugBank.d97.s12.e2,"drug1/drug0: drug2, drug0",False, 
DDI-DrugBank.d97.s16.e0,DDI-DrugBank.d97.s16.e1,drug1: drug2,False, 
DDI-DrugBank.d97.s19.e0,DDI-DrugBank.d97.s19.e1,May lead to loss of virologic response and possible resistance to drug1 or to the class of drug2,False, 
DDI-DrugBank.d97.s20.e0,DDI-DrugBank.d97.s20.e1,drug1: drug2,False, 
DDI-DrugBank.d97.s21.e0,DDI-DrugBank.d97.s21.e1,May lead to loss of virologic response and possible resistance to drug1 or to the class of drug2 or other coadministered drug0,False, 
DDI-DrugBank.d97.s21.e0,DDI-DrugBank.d97.s21.e2,May lead to loss of virologic response and possible resistance to drug1 or to the class of drug0 or other coadministered drug2,False, 
DDI-DrugBank.d97.s22.e0,DDI-DrugBank.d97.s22.e1,"drug1: drug2, drug0",False, 
DDI-DrugBank.d97.s22.e0,DDI-DrugBank.d97.s22.e2,"drug1: drug0, drug2",False, 
DDI-DrugBank.d97.s24.e0,DDI-DrugBank.d97.s24.e1,drug1: drug2,False, 
DDI-DrugBank.d97.s25.e0,DDI-DrugBank.d97.s25.e1,Both drug1 and drug2,False, 
DDI-DrugBank.d97.s26.e0,DDI-DrugBank.d97.s26.e1,Combinations of these drugs have not been studied and coadministration of drug1 and drug2,True,advise
DDI-DrugBank.d97.s35.e0,DDI-DrugBank.d97.s35.e1,Dose reduction of drug1 to 600 mg every 8 hours should be considered when taking drug2,True,advise
DDI-DrugBank.d97.s37.e0,DDI-DrugBank.d97.s37.e1,drug1 and drug2,True,advise
DDI-DrugBank.d97.s40.e0,DDI-DrugBank.d97.s40.e1,"The optimal dose of drug1, when given in combination with drug2",False, 
DDI-DrugBank.d97.s41.e0,DDI-DrugBank.d97.s41.e1,Increasing the drug1 dose to 1000 mg every 8 hours does not compensate for the increased drug2 metabolism due to drug0,False, 
DDI-DrugBank.d97.s41.e0,DDI-DrugBank.d97.s41.e2,Increasing the drug1 dose to 1000 mg every 8 hours does not compensate for the increased drug0 metabolism due to drug2,False, 
DDI-DrugBank.d97.s41.e1,DDI-DrugBank.d97.s41.e2,Increasing the drug0 dose to 1000 mg every 8 hours does not compensate for the increased drug1 metabolism due to drug2,True,mechanism
DDI-DrugBank.d97.s47.e0,DDI-DrugBank.d97.s47.e1,drug1 concentrations may be decreased in the presence of drug2,True,mechanism
DDI-DrugBank.d97.s50.e0,DDI-DrugBank.d97.s50.e1,drug1 concentration   drug2,False, 
DDI-DrugBank.d97.s52.e0,DDI-DrugBank.d97.s52.e1,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drug1 in combination with drug2 than those receiving drug0,True,effect
DDI-DrugBank.d97.s52.e0,DDI-DrugBank.d97.s52.e2,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drug1 in combination with drug0 than those receiving drug2,False, 
DDI-DrugBank.d97.s52.e1,DDI-DrugBank.d97.s52.e2,Preliminary clinical data suggest that the incidence of nephrolithiasis is higher in patients receiving drug0 in combination with drug1 than those receiving drug2,False, 
DDI-DrugBank.d97.s57.e0,DDI-DrugBank.d97.s57.e1,"drug1: drug2, drug0 (systemic) and drug0",False, 
DDI-DrugBank.d97.s57.e0,DDI-DrugBank.d97.s57.e2,"drug1: drug0, drug2 (systemic) and drug0",False, 
DDI-DrugBank.d97.s59.e0,DDI-DrugBank.d97.s59.e1,Caution is warranted and therapeutic concentration monitoring is recommended for drug1 when coadministered with drug2,True,advise
DDI-DrugBank.d97.s60.e0,DDI-DrugBank.d97.s60.e1,"drug1: drug2, drug0, drug0",False, 
DDI-DrugBank.d97.s60.e0,DDI-DrugBank.d97.s60.e2,"drug1: drug0, drug2, drug0",False, 
DDI-DrugBank.d97.s63.e0,DDI-DrugBank.d97.s63.e1,drug1 may not be effective due to decreased drug2,True,effect
DDI-DrugBank.d97.s64.e0,DDI-DrugBank.d97.s64.e1,"drug1, drug2: e.g., drug0, drug0, drug0",False, 
DDI-DrugBank.d97.s64.e0,DDI-DrugBank.d97.s64.e2,"drug1, drug0: e.g., drug2, drug0, drug0",False, 
DDI-DrugBank.d97.s68.e0,DDI-DrugBank.d97.s68.e1,drug1 concentration   drug2,False, 
DDI-DrugBank.d97.s70.e0,DDI-DrugBank.d97.s70.e1,drug1: drug2,False, 
DDI-DrugBank.d97.s72.e0,DDI-DrugBank.d97.s72.e1,"Use lowest possible dose of drug1 with careful monitoring, or consider drug2 that are not primarily metabolized by CYP3A4, such as drug0, drug0, or drug0 in combination with drug0",False, 
DDI-DrugBank.d97.s72.e0,DDI-DrugBank.d97.s72.e2,"Use lowest possible dose of drug1 with careful monitoring, or consider drug0 that are not primarily metabolized by CYP3A4, such as drug2, drug0, or drug0 in combination with drug0",False, 
DDI-DrugBank.d97.s72.e0,DDI-DrugBank.d97.s72.e5,"Use lowest possible dose of drug1 with careful monitoring, or consider drug0 that are not primarily metabolized by CYP3A4, such as drug0, drug0, or drug0 in combination with drug2",True,advise
DDI-DrugBank.d97.s72.e1,DDI-DrugBank.d97.s72.e5,"Use lowest possible dose of drug0 with careful monitoring, or consider drug1 that are not primarily metabolized by CYP3A4, such as drug0, drug0, or drug0 in combination with drug2",True,advise
DDI-DrugBank.d97.s73.e0,DDI-DrugBank.d97.s73.e1,"drug1: drug2, drug0, drug0",False, 
DDI-DrugBank.d97.s73.e0,DDI-DrugBank.d97.s73.e2,"drug1: drug0, drug2, drug0",False, 
DDI-DrugBank.d97.s78.e0,DDI-DrugBank.d97.s78.e1,Dose reduction of drug1 to 600 mg every 8 hours is recommended when administering drug2,True,advise
DDI-DrugBank.d97.s83.e0,DDI-DrugBank.d97.s83.e1,drug1 concentration   drug2,False, 
DDI-DrugBank.d97.s84.e0,DDI-DrugBank.d97.s84.e1,Dose reduction of drug1 to half the standard dose and a dose increase of drug2 to 1000 mg (three 333-mg capsules) every 8 hours are recommended when drug0 and drug0,False, 
DDI-DrugBank.d97.s84.e0,DDI-DrugBank.d97.s84.e2,Dose reduction of drug1 to half the standard dose and a dose increase of drug0 to 1000 mg (three 333-mg capsules) every 8 hours are recommended when drug2 and drug0,False, 
DDI-DrugBank.d97.s84.e2,DDI-DrugBank.d97.s84.e3,Dose reduction of drug0 to half the standard dose and a dose increase of drug0 to 1000 mg (three 333-mg capsules) every 8 hours are recommended when drug1 and drug2,True,advise
DDI-DrugBank.d97.s87.e0,DDI-DrugBank.d97.s87.e1,drug1 dose should not exceed a maximum of 25 mg in a 48- hour period in patients receiving concomitant drug2,True,advise
DDI-DrugBank.d97.s90.e0,DDI-DrugBank.d97.s90.e1,drug1 dose should not exceed a maximum of 10 mg in a 72- hour period in patients receiving concomitant drug2,True,advise
DDI-DrugBank.d97.s93.e0,DDI-DrugBank.d97.s93.e1,drug1 dose should not exceed a maximum of 2.5 mg in a 24-hour period in patients receiving concomitant drug2,True,advise
DDI-DrugBank.d341.s1.e0,DDI-DrugBank.d341.s1.e1,"However, it was observed that the pharmacokinetics of drug1  was unaltered by concomitant drug2",False, 
DDI-DrugBank.d341.s2.e0,DDI-DrugBank.d341.s2.e1,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug1  and drug2 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug0",True,effect
DDI-DrugBank.d341.s2.e0,DDI-DrugBank.d341.s2.e2,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug1  and drug0 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug2",False, 
DDI-DrugBank.d341.s2.e1,DDI-DrugBank.d341.s2.e2,"In a study in which patients with active RA were treated for up to 24 weeks with concurrent drug0  and drug1 therapy, a 7% rate of serious infections was observed, which was higher than that observed with drug2",False, 
DDI-DrugBank.d341.s3.e0,DDI-DrugBank.d341.s3.e1,Two percent of patients treated concurrently with drug1  and drug2,True,effect
DDI-DrugBank.d341.s4.e0,DDI-DrugBank.d341.s4.e1,"Patients in a clinical study who were on established therapy with drug1, to which drug2 was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drug0 CI or drug0",True,effect
DDI-DrugBank.d341.s4.e0,DDI-DrugBank.d341.s4.e2,"Patients in a clinical study who were on established therapy with drug1, to which drug0 was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drug2 CI or drug0",False, 
DDI-DrugBank.d341.s4.e0,DDI-DrugBank.d341.s4.e3,"Patients in a clinical study who were on established therapy with drug1, to which drug0 was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either drug0 CI or drug2",False, 
DDI-DrugBank.d355.s2.e0,DDI-DrugBank.d355.s2.e1,Concurrent administration of drug1 and drug2 may result in elevated serum levels of drug0,True,mechanism
DDI-DrugBank.d355.s2.e0,DDI-DrugBank.d355.s2.e2,Concurrent administration of drug1 and drug0 may result in elevated serum levels of drug2,False, 
DDI-DrugBank.d355.s2.e1,DDI-DrugBank.d355.s2.e2,Concurrent administration of drug0 and drug1 may result in elevated serum levels of drug2,False, 
DDI-DrugBank.d355.s3.e0,DDI-DrugBank.d355.s3.e1,"In diabetic patients, the metabolic effects of drug1 may decrease blood glucose and therefore, drug2",True,effect
DDI-DrugBank.d177.s1.e0,DDI-DrugBank.d177.s1.e1,"Consequently, drugs with a low therapeutic margin, such as drug1, drug2, and drug0",False, 
DDI-DrugBank.d177.s1.e0,DDI-DrugBank.d177.s1.e2,"Consequently, drugs with a low therapeutic margin, such as drug1, drug0, and drug2",False, 
DDI-DrugBank.d177.s3.e0,DDI-DrugBank.d177.s3.e1,"For example, when drug1 are administered concomitantly with drug2, prothrombin time should be carefully monitored and if necessary, the dosage of drug0",True,advise
DDI-DrugBank.d177.s3.e0,DDI-DrugBank.d177.s3.e2,"For example, when drug1 are administered concomitantly with drug0, prothrombin time should be carefully monitored and if necessary, the dosage of drug2",False, 
DDI-DrugBank.d177.s3.e1,DDI-DrugBank.d177.s3.e2,"For example, when drug0 are administered concomitantly with drug1, prothrombin time should be carefully monitored and if necessary, the dosage of drug2",False, 
DDI-DrugBank.d370.s1.e0,DDI-DrugBank.d370.s1.e1,"Particular caution should be exercised in using preparations containing drug1, drug2, or drug0 in combination with drug0",False, 
DDI-DrugBank.d370.s1.e0,DDI-DrugBank.d370.s1.e2,"Particular caution should be exercised in using preparations containing drug1, drug0, or drug2 in combination with drug0",False, 
DDI-DrugBank.d535.s1.e0,DDI-DrugBank.d535.s1.e1,drug1: No drug interactions with other drug2 have been identified that would warrant alteration of either the drug0 dose or the dose of the other drug0,False, 
DDI-DrugBank.d535.s1.e0,DDI-DrugBank.d535.s1.e2,drug1: No drug interactions with other drug0 have been identified that would warrant alteration of either the drug2 dose or the dose of the other drug0,False, 
DDI-DrugBank.d550.s0.e0,DDI-DrugBank.d550.s0.e1,"Oral drug1 Multiple doses of drug2 had no effect on the pharmacokinetics of drug0, the estrogenic component in most oral drug0",False, 
DDI-DrugBank.d550.s0.e0,DDI-DrugBank.d550.s0.e2,"Oral drug1 Multiple doses of drug0 had no effect on the pharmacokinetics of drug2, the estrogenic component in most oral drug0",False, 
DDI-DrugBank.d550.s1.e0,DDI-DrugBank.d550.s1.e1,"Although the clinical significance is not known, it is not recommended that drug1 be taken concomitantly with drug2",True,advise
DDI-DrugBank.d550.s2.e0,DDI-DrugBank.d550.s2.e1,drug1: Co-administration of a single dose of intravenously administered drug2 (20 mg) reduced the oral absorption of a single 400 mg dose of drug0,False, 
DDI-DrugBank.d550.s2.e0,DDI-DrugBank.d550.s2.e2,drug1: Co-administration of a single dose of intravenously administered drug0 (20 mg) reduced the oral absorption of a single 400 mg dose of drug2,False, 
DDI-DrugBank.d550.s2.e1,DDI-DrugBank.d550.s2.e2,drug0: Co-administration of a single dose of intravenously administered drug1 (20 mg) reduced the oral absorption of a single 400 mg dose of drug2,True,mechanism
DDI-DrugBank.d550.s3.e0,DDI-DrugBank.d550.s3.e1,"Although the clinical significance is not known, it is not recommended that drug1 be taken concomitantly with drug2",False, 
DDI-DrugBank.d550.s4.e0,DDI-DrugBank.d550.s4.e1,"drug1: As with other drug2, co-administration of drug0 with drug0 resulted in an increase in the plasma exposure of drug0",False, 
DDI-DrugBank.d550.s4.e0,DDI-DrugBank.d550.s4.e2,"drug1: As with other drug0, co-administration of drug2 with drug0 resulted in an increase in the plasma exposure of drug0",False, 
DDI-DrugBank.d550.s4.e1,DDI-DrugBank.d550.s4.e3,"drug0: As with other drug1, co-administration of drug0 with drug2 resulted in an increase in the plasma exposure of drug0",True,mechanism
DDI-DrugBank.d550.s4.e2,DDI-DrugBank.d550.s4.e3,"drug0: As with other drug0, co-administration of drug1 with drug2 resulted in an increase in the plasma exposure of drug0",True,mechanism
DDI-DrugBank.d488.s0.e0,DDI-DrugBank.d488.s0.e1,Drug Interactions: a. Drugs Enhancing drug1 Effect: Oral drug2: drug0,False, 
DDI-DrugBank.d488.s0.e0,DDI-DrugBank.d488.s0.e2,Drug Interactions: a. Drugs Enhancing drug1 Effect: Oral drug0: drug2,False, 
DDI-DrugBank.d488.s1.e0,DDI-DrugBank.d488.s1.e1,"Therefore, when drug1 is given with drug2 or drug0",True,advise
DDI-DrugBank.d488.s1.e0,DDI-DrugBank.d488.s1.e2,"Therefore, when drug1 is given with drug0 or drug2",True,advise
DDI-DrugBank.d488.s1.e1,DDI-DrugBank.d488.s1.e2,"Therefore, when drug0 is given with drug1 or drug2",False, 
DDI-DrugBank.d488.s2.e0,DDI-DrugBank.d488.s2.e1,"drug1: Drugs such as drug2, drug0, drug0, drug0, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug0",False, 
DDI-DrugBank.d488.s2.e0,DDI-DrugBank.d488.s2.e2,"drug1: Drugs such as drug0, drug2, drug0, drug0, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug0",False, 
DDI-DrugBank.d488.s2.e1,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug1, drug0, drug0, drug0, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e2,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug1, drug0, drug0, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e3,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug0, drug1, drug0, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e4,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug0, drug0, drug1, drug0, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e5,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug0, drug0, drug0, drug1, drug0, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e6,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug0, drug0, drug0, drug0, drug1, drug0 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s2.e7,DDI-DrugBank.d488.s2.e8,"drug0: Drugs such as drug0, drug0, drug0, drug0, drug0, drug0, drug1 and others that interfere with platelet-aggregation reactions (the main hemostatic defense of heparinized patients) may induce bleeding and should be used with caution in patients receiving drug2",True,effect
DDI-DrugBank.d488.s3.e0,DDI-DrugBank.d488.s3.e1,The anticoagulant effect of drug1 is enhanced by concurrent treatment with drug2,True,effect
DDI-DrugBank.d488.s4.e0,DDI-DrugBank.d488.s4.e1,"Thus in order to avoid bleeding, reduced dosage of drug1 is recommended during treatment with drug2",True,advise
DDI-DrugBank.d488.s6.e0,DDI-DrugBank.d488.s6.e1,"Drugs Decreasing drug1 Effect: drug2, drug0, drug0, or drug0 may partially counteract the anticoagulant action of drug0",False, 
DDI-DrugBank.d488.s6.e0,DDI-DrugBank.d488.s6.e2,"Drugs Decreasing drug1 Effect: drug0, drug2, drug0, or drug0 may partially counteract the anticoagulant action of drug0",False, 
DDI-DrugBank.d488.s6.e1,DDI-DrugBank.d488.s6.e5,"Drugs Decreasing drug0 Effect: drug1, drug0, drug0, or drug0 may partially counteract the anticoagulant action of drug2",True,effect
DDI-DrugBank.d488.s6.e2,DDI-DrugBank.d488.s6.e5,"Drugs Decreasing drug0 Effect: drug0, drug1, drug0, or drug0 may partially counteract the anticoagulant action of drug2",True,effect
DDI-DrugBank.d488.s6.e3,DDI-DrugBank.d488.s6.e5,"Drugs Decreasing drug0 Effect: drug0, drug0, drug1, or drug0 may partially counteract the anticoagulant action of drug2",True,effect
DDI-DrugBank.d488.s6.e4,DDI-DrugBank.d488.s6.e5,"Drugs Decreasing drug0 Effect: drug0, drug0, drug0, or drug1 may partially counteract the anticoagulant action of drug2",True,effect
DDI-DrugBank.d488.s7.e0,DDI-DrugBank.d488.s7.e1,"drug1 Injection should not be mixed with drug2, drug0, drug0, or drug0, since it has been reported that these drugs are incompatible with drug0",False, 
DDI-DrugBank.d488.s7.e0,DDI-DrugBank.d488.s7.e2,"drug1 Injection should not be mixed with drug0, drug2, drug0, or drug0, since it has been reported that these drugs are incompatible with drug0",False, 
DDI-DrugBank.d429.s0.e0,DDI-DrugBank.d429.s0.e1,drug1 and drug2: drug0 and drug0 can reduce absorption of drug0,False, 
DDI-DrugBank.d429.s0.e0,DDI-DrugBank.d429.s0.e2,drug1 and drug0: drug2 and drug0 can reduce absorption of drug0,False, 
DDI-DrugBank.d429.s0.e2,DDI-DrugBank.d429.s0.e4,drug0 and drug0: drug1 and drug0 can reduce absorption of drug2,True,mechanism
DDI-DrugBank.d429.s0.e3,DDI-DrugBank.d429.s0.e4,drug0 and drug0: drug0 and drug1 can reduce absorption of drug2,True,mechanism
DDI-DrugBank.d429.s2.e0,DDI-DrugBank.d429.s2.e1,drug1: drug2 can inhibit the metabolism of drug0,False, 
DDI-DrugBank.d429.s2.e0,DDI-DrugBank.d429.s2.e2,drug1: drug0 can inhibit the metabolism of drug2,False, 
DDI-DrugBank.d429.s2.e1,DDI-DrugBank.d429.s2.e2,drug0: drug1 can inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d429.s4.e0,DDI-DrugBank.d429.s4.e1,"drug1: In a study of healthy volunteers, drug2 significantly reduced the bioavailability of drug0",False, 
DDI-DrugBank.d429.s4.e0,DDI-DrugBank.d429.s4.e2,"drug1: In a study of healthy volunteers, drug0 significantly reduced the bioavailability of drug2",False, 
DDI-DrugBank.d429.s4.e1,DDI-DrugBank.d429.s4.e2,"drug0: In a study of healthy volunteers, drug1 significantly reduced the bioavailability of drug2",True,mechanism
DDI-DrugBank.d429.s6.e0,DDI-DrugBank.d429.s6.e1,"drug1: After introduction of drug2 (oral form), a sudden increase in serum drug0",False, 
DDI-DrugBank.d429.s6.e0,DDI-DrugBank.d429.s6.e2,"drug1: After introduction of drug0 (oral form), a sudden increase in serum drug2",False, 
DDI-DrugBank.d429.s6.e1,DDI-DrugBank.d429.s6.e2,"drug0: After introduction of drug1 (oral form), a sudden increase in serum drug2",True,mechanism
DDI-DrugBank.d429.s7.e0,DDI-DrugBank.d429.s7.e1,"Therefore, close monitoring of serum drug1 level is recommended and, if necessary, drug2",False, 
DDI-DrugBank.d331.s0.e0,DDI-DrugBank.d331.s0.e1,"- Drugs with ototoxic potential: Especially in the presence of impaired renal function, the use of parenterally administered drug1 in patients to whom drug2",True,advise
DDI-DrugBank.d331.s3.e0,DDI-DrugBank.d331.s3.e1,- drug1: drug2 should generally not be given with drug0 (such as drug0) because they reduce its renal clearance and add a high risk of drug0,False, 
DDI-DrugBank.d331.s3.e0,DDI-DrugBank.d331.s3.e2,- drug1: drug0 should generally not be given with drug2 (such as drug0) because they reduce its renal clearance and add a high risk of drug0,False, 
DDI-DrugBank.d331.s3.e1,DDI-DrugBank.d331.s3.e2,- drug0: drug1 should generally not be given with drug2 (such as drug0) because they reduce its renal clearance and add a high risk of drug0,True,advise
DDI-DrugBank.d331.s3.e1,DDI-DrugBank.d331.s3.e3,- drug0: drug1 should generally not be given with drug0 (such as drug2) because they reduce its renal clearance and add a high risk of drug0,True,advise
DDI-DrugBank.d331.s4.e0,DDI-DrugBank.d331.s4.e1,- drug1: Pretreatment with drug2 reduces both the natriuresis and hyperreninemia produced by drug0,False, 
DDI-DrugBank.d331.s4.e0,DDI-DrugBank.d331.s4.e2,- drug1: Pretreatment with drug0 reduces both the natriuresis and hyperreninemia produced by drug2,False, 
DDI-DrugBank.d331.s4.e1,DDI-DrugBank.d331.s4.e2,- drug0: Pretreatment with drug1 reduces both the natriuresis and hyperreninemia produced by drug2,True,effect
DDI-DrugBank.d331.s5.e0,DDI-DrugBank.d331.s5.e1,This antagonistic effect of drug1 on drug2 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drug0,True,mechanism
DDI-DrugBank.d331.s5.e0,DDI-DrugBank.d331.s5.e2,This antagonistic effect of drug1 on drug0 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drug2,False, 
DDI-DrugBank.d331.s5.e1,DDI-DrugBank.d331.s5.e2,This antagonistic effect of drug0 on drug1 natriuresis is not due to a direct action on sodium excretion but is probably secondary to its inhibitory effect on renal tubular secretion of drug2,False, 
DDI-DrugBank.d331.s6.e0,DDI-DrugBank.d331.s6.e1,"Thus, drug1 should not be administered concurrently with drug2",True,advise
DDI-DrugBank.d331.s7.e0,DDI-DrugBank.d331.s7.e1,- drug1: drug2 blunts the increases in urine volume and sodium excretion seen during drug0 treatment and inhibits the drug0,False, 
DDI-DrugBank.d331.s7.e0,DDI-DrugBank.d331.s7.e2,- drug1: drug0 blunts the increases in urine volume and sodium excretion seen during drug2 treatment and inhibits the drug0,False, 
DDI-DrugBank.d331.s7.e1,DDI-DrugBank.d331.s7.e2,- drug0: drug1 blunts the increases in urine volume and sodium excretion seen during drug2 treatment and inhibits the drug0,True,mechanism
DDI-DrugBank.d331.s7.e1,DDI-DrugBank.d331.s7.e3,- drug0: drug1 blunts the increases in urine volume and sodium excretion seen during drug0 treatment and inhibits the drug2,True,effect
DDI-DrugBank.d331.s9.e0,DDI-DrugBank.d331.s9.e1,- drug1: drug2 may potentiate the effect of various drug0,False, 
DDI-DrugBank.d331.s9.e0,DDI-DrugBank.d331.s9.e2,- drug1: drug0 may potentiate the effect of various drug2,False, 
DDI-DrugBank.d331.s9.e1,DDI-DrugBank.d331.s9.e2,- drug0: drug1 may potentiate the effect of various drug2,True,effect
DDI-DrugBank.d331.s10.e0,DDI-DrugBank.d331.s10.e1,- drug1: Interaction studies in humans have shown no effect on drug2,False, 
DDI-DrugBank.d331.s11.e0,DDI-DrugBank.d331.s11.e1,- drug1: Interaction studies in humans have shown drug2 to have no effect on drug0,False, 
DDI-DrugBank.d331.s11.e0,DDI-DrugBank.d331.s11.e2,- drug1: Interaction studies in humans have shown drug0 to have no effect on drug2,False, 
DDI-DrugBank.d209.s2.e0,DDI-DrugBank.d209.s2.e1,"Compounds that have been tested in man include drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d209.s2.e0,DDI-DrugBank.d209.s2.e2,"Compounds that have been tested in man include drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d209.s3.e0,DDI-DrugBank.d209.s3.e1,"Other concomitant therapy Although specific interaction studies were not performed, drug1 doses of 1 mg or more were concomitantly used in clinical studies with drug2, drug0, a-blockers, drug0, drug0, drug0, drug0, drug0, drug0, cardiac drug0, drug0, drug0, drug0, drug0 (also referred to as drug0), and drug0",False, 
DDI-DrugBank.d209.s3.e0,DDI-DrugBank.d209.s3.e2,"Other concomitant therapy Although specific interaction studies were not performed, drug1 doses of 1 mg or more were concomitantly used in clinical studies with drug0, drug2, a-blockers, drug0, drug0, drug0, drug0, drug0, drug0, cardiac drug0, drug0, drug0, drug0, drug0 (also referred to as drug0), and drug0",False, 
DDI-DrugBank.d209.s7.e0,DDI-DrugBank.d209.s7.e1,In clinical studies with drug1 (drug2,False, 
DDI-DrugBank.d209.s8.e0,DDI-DrugBank.d209.s8.e1,"Further, in clinical studies with drug1 (drug2",False, 
DDI-DrugBank.d31.s0.e0,DDI-DrugBank.d31.s0.e1,drug1 should be used with caution in patients receiving drug2,True,advise
DDI-DrugBank.d31.s1.e0,DDI-DrugBank.d31.s1.e1,"When other potent parental drug1, such as drug2, are used in combination with drug0",True,effect
DDI-DrugBank.d31.s1.e0,DDI-DrugBank.d31.s1.e2,"When other potent parental drug1, such as drug0, are used in combination with drug2",True,effect
DDI-DrugBank.d31.s1.e1,DDI-DrugBank.d31.s1.e2,"When other potent parental drug0, such as drug1, are used in combination with drug2",False, 
DDI-DrugBank.d31.s2.e0,DDI-DrugBank.d31.s2.e1,Profound hypotensive episodes may occur when drug1 infection and drug2,True,effect
DDI-DrugBank.d31.s3.e0,DDI-DrugBank.d31.s3.e1,"drug1 (drug2, drug0",False, 
DDI-DrugBank.d31.s3.e0,DDI-DrugBank.d31.s3.e2,"drug1 (drug0, drug2",False, 
DDI-DrugBank.d31.s5.e0,DDI-DrugBank.d31.s5.e1,drug1 increases drug2,True,mechanism
DDI-DrugBank.d31.s6.e0,DDI-DrugBank.d31.s6.e1,"drug1, drug2, and drug0",False, 
DDI-DrugBank.d31.s6.e0,DDI-DrugBank.d31.s6.e2,"drug1, drug0, and drug2",False, 
DDI-DrugBank.d31.s7.e0,DDI-DrugBank.d31.s7.e1,drug1 may decrease the hemodynamic effects of drug2,True,effect
DDI-DrugBank.d84.s0.e0,DDI-DrugBank.d84.s0.e1,The concomitant administration of drug1 and drug2-containing drug0,False, 
DDI-DrugBank.d84.s0.e0,DDI-DrugBank.d84.s0.e2,The concomitant administration of drug1 and drug0-containing drug2,False, 
DDI-DrugBank.d84.s1.e0,DDI-DrugBank.d84.s1.e1,"Although drug1 has a lower affinity for drug2 than for drug0, drug0 should not be taken with drug0-containing drug0",False, 
DDI-DrugBank.d84.s1.e0,DDI-DrugBank.d84.s1.e2,"Although drug1 has a lower affinity for drug0 than for drug2, drug0 should not be taken with drug0-containing drug0",False, 
DDI-DrugBank.d84.s1.e3,DDI-DrugBank.d84.s1.e4,"Although drug0 has a lower affinity for drug0 than for drug0, drug1 should not be taken with drug2-containing drug0",True,advise
DDI-DrugBank.d84.s2.e0,DDI-DrugBank.d84.s2.e1,"In healthy volunteers, drug1 had no effect on the pharmacokinetics of drug2",False, 
DDI-DrugBank.d84.s3.e0,DDI-DrugBank.d84.s3.e1,The effect of drug1 on drug2,False, 
DDI-DrugBank.d84.s4.e0,DDI-DrugBank.d84.s4.e1,The concomitant administration of drug1 and drug2,False, 
DDI-DrugBank.d84.s6.e0,DDI-DrugBank.d84.s6.e1,The interaction of drug1 with drug2,False, 
DDI-DrugBank.d84.s7.e0,DDI-DrugBank.d84.s7.e1,No inhibition of drug1 metabolism by drug2,False, 
DDI-DrugBank.d568.s1.e0,DDI-DrugBank.d568.s1.e1,"drug1 - Although drug2 did not potentiate the cognitive and motor effects of drug0 in a clinical trial, as with other drug0, the use of drug0 by patients taking drug0",False, 
DDI-DrugBank.d568.s1.e0,DDI-DrugBank.d568.s1.e2,"drug1 - Although drug0 did not potentiate the cognitive and motor effects of drug2 in a clinical trial, as with other drug0, the use of drug0 by patients taking drug0",False, 
DDI-DrugBank.d568.s1.e3,DDI-DrugBank.d568.s1.e5,"drug0 - Although drug0 did not potentiate the cognitive and motor effects of drug0 in a clinical trial, as with other drug1, the use of drug0 by patients taking drug2",True,advise
DDI-DrugBank.d568.s1.e4,DDI-DrugBank.d568.s1.e5,"drug0 - Although drug0 did not potentiate the cognitive and motor effects of drug0 in a clinical trial, as with other drug0, the use of drug1 by patients taking drug2",True,advise
DDI-DrugBank.d568.s2.e0,DDI-DrugBank.d568.s2.e1,drug1 (drug2,False, 
DDI-DrugBank.d568.s3.e0,DDI-DrugBank.d568.s3.e1,"Drugs That Interfere With Hemostasis (drug1, drug2, drug0",False, 
DDI-DrugBank.d568.s3.e0,DDI-DrugBank.d568.s3.e2,"Drugs That Interfere With Hemostasis (drug1, drug0, drug2",False, 
DDI-DrugBank.d568.s5.e0,DDI-DrugBank.d568.s5.e1,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drug1 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drug2 or drug0,True,effect
DDI-DrugBank.d568.s5.e0,DDI-DrugBank.d568.s5.e2,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drug1 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drug0 or drug2,True,effect
DDI-DrugBank.d568.s5.e1,DDI-DrugBank.d568.s5.e2,Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of drug0 that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an drug1 or drug2,False, 
DDI-DrugBank.d568.s7.e0,DDI-DrugBank.d568.s7.e1,"drug1 - In subjects who had received 21 days of 40 mg/day racemic drug2, combined administration of 400 mg/day drug0 for 8 days resulted in an increase in drug0",False, 
DDI-DrugBank.d568.s7.e0,DDI-DrugBank.d568.s7.e2,"drug1 - In subjects who had received 21 days of 40 mg/day racemic drug0, combined administration of 400 mg/day drug2 for 8 days resulted in an increase in drug0",False, 
DDI-DrugBank.d568.s7.e1,DDI-DrugBank.d568.s7.e2,"drug0 - In subjects who had received 21 days of 40 mg/day racemic drug1, combined administration of 400 mg/day drug2 for 8 days resulted in an increase in drug0",True,mechanism
DDI-DrugBank.d568.s9.e0,DDI-DrugBank.d568.s9.e1,"drug1 - In subjects who had received 21 days of 40 mg/day racemic drug2, combined administration of drug0 and drug0 (single dose of 1 mg) did not significantly affect the pharmacokinetics of either drug0 or drug0",False, 
DDI-DrugBank.d568.s9.e0,DDI-DrugBank.d568.s9.e2,"drug1 - In subjects who had received 21 days of 40 mg/day racemic drug0, combined administration of drug2 and drug0 (single dose of 1 mg) did not significantly affect the pharmacokinetics of either drug0 or drug0",False, 
DDI-DrugBank.d568.s10.e0,DDI-DrugBank.d568.s10.e1,drug1 - Coadministration of racemic drug2 (40 mg/day for 10 days) and drug0 (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of drug0 or drug0,False, 
DDI-DrugBank.d568.s10.e0,DDI-DrugBank.d568.s10.e2,drug1 - Coadministration of racemic drug0 (40 mg/day for 10 days) and drug2 (30 mmol/day for 5 days) had no significant effect on the pharmacokinetics of drug0 or drug0,False, 
DDI-DrugBank.d568.s11.e0,DDI-DrugBank.d568.s11.e1,"Nevertheless, plasma drug1 levels should be monitored with appropriate adjustment to the drug2",False, 
DDI-DrugBank.d568.s12.e0,DDI-DrugBank.d568.s12.e1,"Because drug1 may enhance the serotonergic effects of drug2, caution should be exercised when drug0 and drug0",True,effect
DDI-DrugBank.d568.s12.e0,DDI-DrugBank.d568.s12.e2,"Because drug1 may enhance the serotonergic effects of drug0, caution should be exercised when drug2 and drug0",False, 
DDI-DrugBank.d568.s12.e0,DDI-DrugBank.d568.s12.e3,"Because drug1 may enhance the serotonergic effects of drug0, caution should be exercised when drug0 and drug2",False, 
DDI-DrugBank.d568.s12.e2,DDI-DrugBank.d568.s12.e3,"Because drug0 may enhance the serotonergic effects of drug0, caution should be exercised when drug1 and drug2",True,advise
DDI-DrugBank.d568.s13.e0,DDI-DrugBank.d568.s13.e1,"drug1 and drug2 - In a controlled study, a single dose of drug0 2 mg co-administered with racemic drug0 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to drug0",False, 
DDI-DrugBank.d568.s13.e0,DDI-DrugBank.d568.s13.e2,"drug1 and drug0 - In a controlled study, a single dose of drug2 2 mg co-administered with racemic drug0 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to drug0",False, 
DDI-DrugBank.d568.s13.e2,DDI-DrugBank.d568.s13.e3,"drug0 and drug0 - In a controlled study, a single dose of drug1 2 mg co-administered with racemic drug2 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to drug0",True,effect
DDI-DrugBank.d568.s14.e0,DDI-DrugBank.d568.s14.e1,Racemic drug1 did not alter the mean AUC or Cmax of drug2,False, 
DDI-DrugBank.d568.s16.e0,DDI-DrugBank.d568.s16.e1,"drug1 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a drug2 (drug0) and drug0",False, 
DDI-DrugBank.d568.s16.e0,DDI-DrugBank.d568.s16.e2,"drug1 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a drug0 (drug2) and drug0",False, 
DDI-DrugBank.d568.s16.e1,DDI-DrugBank.d568.s16.e3,"drug0 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a drug1 (drug0) and drug2",True,effect
DDI-DrugBank.d568.s16.e2,DDI-DrugBank.d568.s16.e3,"drug0 - There have been rare postmarketing reports describing patients with weakness, hyperreflexia, and incoordination following the use of a drug0 (drug1) and drug2",True,effect
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e1,"If concomitant treatment with drug1 and an drug2 (e.g., drug0, drug0, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e2,"If concomitant treatment with drug1 and an drug0 (e.g., drug2, drug0, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e3,"If concomitant treatment with drug1 and an drug0 (e.g., drug0, drug2, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e4,"If concomitant treatment with drug1 and an drug0 (e.g., drug0, drug0, drug2, drug0, drug0, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e5,"If concomitant treatment with drug1 and an drug0 (e.g., drug0, drug0, drug0, drug2, drug0, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e6,"If concomitant treatment with drug1 and an drug0 (e.g., drug0, drug0, drug0, drug0, drug2, drug0",True,advise
DDI-DrugBank.d568.s17.e0,DDI-DrugBank.d568.s17.e7,"If concomitant treatment with drug1 and an drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug2",True,advise
DDI-DrugBank.d568.s17.e1,DDI-DrugBank.d568.s17.e2,"If concomitant treatment with drug0 and an drug1 (e.g., drug2, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d568.s17.e1,DDI-DrugBank.d568.s17.e3,"If concomitant treatment with drug0 and an drug1 (e.g., drug0, drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d568.s18.e0,DDI-DrugBank.d568.s18.e1,drug1 - Combined administration of racemic drug2 (40 mg/day for 21 days) and the CYP1A2 substrate drug0 (single dose of 300 mg) did not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d568.s18.e0,DDI-DrugBank.d568.s18.e2,drug1 - Combined administration of racemic drug0 (40 mg/day for 21 days) and the CYP1A2 substrate drug2 (single dose of 300 mg) did not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d568.s19.e0,DDI-DrugBank.d568.s19.e1,The effect of drug1 on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d568.s20.e0,DDI-DrugBank.d568.s20.e1,drug1 - Administration of 40 mg/day racemic drug2 for 21 days did not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d568.s20.e0,DDI-DrugBank.d568.s20.e2,drug1 - Administration of 40 mg/day racemic drug0 for 21 days did not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d568.s22.e0,DDI-DrugBank.d568.s22.e1,drug1 - Combined administration of racemic drug2 (40 mg/day for 14 days) and drug0 (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d568.s22.e0,DDI-DrugBank.d568.s22.e2,drug1 - Combined administration of racemic drug0 (40 mg/day for 14 days) and drug2 (titrated to 400 mg/day for 35 days) did not significantly affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d568.s23.e0,DDI-DrugBank.d568.s23.e1,"Although trough drug1 plasma levels were unaffected, given the enzyme-inducing properties of drug2, the possibility that drug0 might increase the clearance of drug0",False, 
DDI-DrugBank.d568.s23.e0,DDI-DrugBank.d568.s23.e2,"Although trough drug1 plasma levels were unaffected, given the enzyme-inducing properties of drug0, the possibility that drug2 might increase the clearance of drug0",False, 
DDI-DrugBank.d568.s23.e2,DDI-DrugBank.d568.s23.e3,"Although trough drug0 plasma levels were unaffected, given the enzyme-inducing properties of drug0, the possibility that drug1 might increase the clearance of drug2",True,mechanism
DDI-DrugBank.d568.s24.e0,DDI-DrugBank.d568.s24.e1,drug1 - Combined administration of racemic drug2 (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate drug0 (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either drug0 or drug0,False, 
DDI-DrugBank.d568.s24.e0,DDI-DrugBank.d568.s24.e2,drug1 - Combined administration of racemic drug0 (titrated to 40 mg/day for 28 days) and the CYP3A4 substrate drug2 (single dose of 0.25 mg) did not significantly affect the pharmacokinetics of either drug0 or drug0,False, 
DDI-DrugBank.d568.s25.e0,DDI-DrugBank.d568.s25.e1,"drug1 - Combined administration of racemic drug2 (40 mg) and drug0 (200 mg) decreased the Cmax and AUC of drug0 by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d568.s25.e0,DDI-DrugBank.d568.s25.e2,"drug1 - Combined administration of racemic drug0 (40 mg) and drug2 (200 mg) decreased the Cmax and AUC of drug0 by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d568.s25.e1,DDI-DrugBank.d568.s25.e2,"drug0 - Combined administration of racemic drug1 (40 mg) and drug2 (200 mg) decreased the Cmax and AUC of drug0 by 21% and 10%, respectively, and did not significantly affect the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d568.s26.e0,DDI-DrugBank.d568.s26.e1,"drug1 - Combined administration of a single dose of drug2 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and drug0 (20 mg) did not affect the pharmacokinetics of either drug0 or drug0",False, 
DDI-DrugBank.d568.s26.e0,DDI-DrugBank.d568.s26.e2,"drug1 - Combined administration of a single dose of drug0 (600 mg), both a CYP3A4 substrate and a potent inhibitor of CYP3A4, and drug2 (20 mg) did not affect the pharmacokinetics of either drug0 or drug0",False, 
DDI-DrugBank.d568.s28.e0,DDI-DrugBank.d568.s28.e1,"However, coadministration of drug1 (20 mg) and drug2 (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of drug0",False, 
DDI-DrugBank.d568.s28.e0,DDI-DrugBank.d568.s28.e2,"However, coadministration of drug1 (20 mg) and drug0 (600 mg), a potent inhibitor of CYP3A4, did not significantly affect the pharmacokinetics of drug2",False, 
DDI-DrugBank.d568.s29.e0,DDI-DrugBank.d568.s29.e1,"Because drug1 is metabolized by multiple enzyme systems, inhibition of a single enzyme may not appreciably decrease drug2",False, 
DDI-DrugBank.d568.s31.e0,DDI-DrugBank.d568.s31.e1,"In addition, steady state levels of racemic drug1 were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of drug2, suggesting that coadministration, with drug0, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on drug0",False, 
DDI-DrugBank.d568.s31.e0,DDI-DrugBank.d568.s31.e2,"In addition, steady state levels of racemic drug1 were not significantly different in poor metabolizers and extensive CYP2D6 metabolizers after multiple-dose administration of drug0, suggesting that coadministration, with drug2, of a drug that inhibits CYP2D6, is unlikely to have clinically significant effects on drug0",False, 
DDI-DrugBank.d568.s32.e0,DDI-DrugBank.d568.s32.e1,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for drug1, i.e., coadministration of drug2 (20 mg/day for 21 days) with the drug0 drug0 (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of drug0",False, 
DDI-DrugBank.d568.s32.e0,DDI-DrugBank.d568.s32.e2,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for drug1, i.e., coadministration of drug0 (20 mg/day for 21 days) with the drug2 drug0 (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of drug0",False, 
DDI-DrugBank.d568.s32.e1,DDI-DrugBank.d568.s32.e3,"However, there are limited in vivo data suggesting a modest CYP2D6 inhibitory effect for drug0, i.e., coadministration of drug1 (20 mg/day for 21 days) with the drug0 drug2 (single dose of 50 mg), a substrate for CYP2D6, resulted in a 40% increase in Cmax and a 100% increase in AUC of drug0",True,mechanism
DDI-DrugBank.d568.s35.e0,DDI-DrugBank.d568.s35.e1,drug1 - Administration of 20 mg/day drug2 for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the drug0 drug0,False, 
DDI-DrugBank.d568.s35.e0,DDI-DrugBank.d568.s35.e2,drug1 - Administration of 20 mg/day drug0 for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the drug2 drug0,False, 
DDI-DrugBank.d568.s35.e1,DDI-DrugBank.d568.s35.e3,drug0 - Administration of 20 mg/day drug1 for 21 days in healthy volunteers resulted in a 50% increase in Cmax and 82% increase in AUC of the drug0 drug2,True,mechanism
DDI-DrugBank.d568.s37.e0,DDI-DrugBank.d568.s37.e1,Coadministration of drug1 and drug2,False, 
DDI-DrugBank.d568.s39.e0,DDI-DrugBank.d568.s39.e1,Concomitant Administration with Racemic drug1 drug2 - Since drug0 is the active isomer of racemic drug0 (drug0,False, 
DDI-DrugBank.d568.s39.e0,DDI-DrugBank.d568.s39.e2,Concomitant Administration with Racemic drug1 drug0 - Since drug2 is the active isomer of racemic drug0 (drug0,False, 
DDI-DrugBank.d568.s39.e2,DDI-DrugBank.d568.s39.e3,Concomitant Administration with Racemic drug0 drug0 - Since drug1 is the active isomer of racemic drug2 (drug0,True,advise
DDI-DrugBank.d568.s39.e2,DDI-DrugBank.d568.s39.e4,Concomitant Administration with Racemic drug0 drug0 - Since drug1 is the active isomer of racemic drug0 (drug2,True,advise
DDI-DrugBank.d533.s0.e0,DDI-DrugBank.d533.s0.e1,"Effects of Other Drugs on drug1 Based on in-vitro studies, drug2",False, 
DDI-DrugBank.d533.s1.e0,DDI-DrugBank.d533.s1.e1,"Co-administration of drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 and drug0 did not result in clinically significant increases in drug0",False, 
DDI-DrugBank.d533.s1.e0,DDI-DrugBank.d533.s1.e2,"Co-administration of drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 and drug0 did not result in clinically significant increases in drug0",False, 
DDI-DrugBank.d533.s2.e0,DDI-DrugBank.d533.s2.e1,Co-administration of drug1 reduced drug2,True,mechanism
DDI-DrugBank.d533.s3.e0,DDI-DrugBank.d533.s3.e1,Co-administration of drug1 resulted in about a 50% increase in drug2,True,mechanism
DDI-DrugBank.d533.s4.e0,DDI-DrugBank.d533.s4.e1,drug1: Co-administration of 200 mg twice-daily drug2 with drug0 resulted in an approximate 80% increase in plasma levels of drug0,False, 
DDI-DrugBank.d533.s4.e0,DDI-DrugBank.d533.s4.e2,drug1: Co-administration of 200 mg twice-daily drug0 with drug2 resulted in an approximate 80% increase in plasma levels of drug0,False, 
DDI-DrugBank.d533.s4.e1,DDI-DrugBank.d533.s4.e2,drug0: Co-administration of 200 mg twice-daily drug1 with drug2 resulted in an approximate 80% increase in plasma levels of drug0,True,mechanism
DDI-DrugBank.d533.s6.e0,DDI-DrugBank.d533.s6.e1,Effects of drug1 on Other Drugs drug2,False, 
DDI-DrugBank.d533.s7.e0,DDI-DrugBank.d533.s7.e1,"Co-administration of drug1 did not significantly affect the pharmacokinetics of drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d533.s7.e0,DDI-DrugBank.d533.s7.e2,"Co-administration of drug1 did not significantly affect the pharmacokinetics of drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d533.s8.e0,DDI-DrugBank.d533.s8.e1,drug1: The effects of drug2 on drug0,False, 
DDI-DrugBank.d533.s8.e0,DDI-DrugBank.d533.s8.e2,drug1: The effects of drug0 on drug2,False, 
DDI-DrugBank.d533.s9.e0,DDI-DrugBank.d533.s9.e1,"drug1: When drug2 was co-administered with drug0, the AUC and Cmax of drug0",False, 
DDI-DrugBank.d533.s9.e0,DDI-DrugBank.d533.s9.e2,"drug1: When drug0 was co-administered with drug2, the AUC and Cmax of drug0",False, 
DDI-DrugBank.d533.s9.e1,DDI-DrugBank.d533.s9.e2,"drug0: When drug1 was co-administered with drug2, the AUC and Cmax of drug0",True,mechanism
DDI-DrugBank.d14.s0.e0,DDI-DrugBank.d14.s0.e1,The vasodilating effects of drug1 may be additive with those of other drug2,True,effect
DDI-DrugBank.d14.s2.e0,DDI-DrugBank.d14.s2.e1,Marked symptomatic orthostatic hypotension has been reported when drug1 and organic drug2,True,effect
DDI-DrugBank.d136.s0.e0,DDI-DrugBank.d136.s0.e1,"drug1 (increases bioavailability by 50%), drug2",False, 
DDI-DrugBank.d158.s0.e0,DDI-DrugBank.d158.s0.e1,"Urinary acidifying agents These agents (drug1, drug2, etc.) increase the concentration of the ionized species of the drug0",False, 
DDI-DrugBank.d158.s0.e0,DDI-DrugBank.d158.s0.e2,"Urinary acidifying agents These agents (drug1, drug0, etc.) increase the concentration of the ionized species of the drug2",True,mechanism
DDI-DrugBank.d158.s0.e1,DDI-DrugBank.d158.s0.e2,"Urinary acidifying agents These agents (drug0, drug1, etc.) increase the concentration of the ionized species of the drug2",True,mechanism
DDI-DrugBank.d158.s2.e0,DDI-DrugBank.d158.s2.e1,drug1 drug2 are inhibited by drug0,False, 
DDI-DrugBank.d158.s2.e0,DDI-DrugBank.d158.s2.e2,drug1 drug0 are inhibited by drug2,False, 
DDI-DrugBank.d158.s2.e1,DDI-DrugBank.d158.s2.e2,drug0 drug1 are inhibited by drug2,True,effect
DDI-DrugBank.d158.s3.e0,DDI-DrugBank.d158.s3.e1,"drug1, drug2 drug0 may enhance the activity of drug0 or drug0",False, 
DDI-DrugBank.d158.s3.e0,DDI-DrugBank.d158.s3.e2,"drug1, drug0 drug2 may enhance the activity of drug0 or drug0",False, 
DDI-DrugBank.d158.s3.e2,DDI-DrugBank.d158.s3.e3,"drug0, drug0 drug1 may enhance the activity of drug2 or drug0",True,effect
DDI-DrugBank.d158.s3.e2,DDI-DrugBank.d158.s3.e4,"drug0, drug0 drug1 may enhance the activity of drug0 or drug2",True,effect
DDI-DrugBank.d158.s4.e0,DDI-DrugBank.d158.s4.e1,drug1 with drug2 or drug0 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d158.s4.e0,DDI-DrugBank.d158.s4.e2,drug1 with drug0 or drug2 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d158.s4.e0,DDI-DrugBank.d158.s4.e3,drug1 with drug0 or drug0 and possibly other drug2 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d158.s4.e0,DDI-DrugBank.d158.s4.e4,drug1 with drug0 or drug0 and possibly other drug0 cause striking and sustained increases in the concentration of drug2,False, 
DDI-DrugBank.d158.s4.e1,DDI-DrugBank.d158.s4.e2,drug0 with drug1 or drug2 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,False, 
DDI-DrugBank.d158.s6.e0,DDI-DrugBank.d158.s6.e1,"drug1 drug2, as well as a metabolite of drug0, slow drug0",False, 
DDI-DrugBank.d158.s6.e0,DDI-DrugBank.d158.s6.e2,"drug1 drug0, as well as a metabolite of drug2, slow drug0",False, 
DDI-DrugBank.d158.s6.e1,DDI-DrugBank.d158.s6.e3,"drug0 drug1, as well as a metabolite of drug0, slow drug2",True,mechanism
DDI-DrugBank.d158.s6.e2,DDI-DrugBank.d158.s6.e3,"drug0 drug0, as well as a metabolite of drug1, slow drug2",True,mechanism
DDI-DrugBank.d158.s10.e0,DDI-DrugBank.d158.s10.e1,drug1: drug2 may counteract the sedative effect of drug0,False, 
DDI-DrugBank.d158.s10.e0,DDI-DrugBank.d158.s10.e2,drug1: drug0 may counteract the sedative effect of drug2,False, 
DDI-DrugBank.d158.s10.e1,DDI-DrugBank.d158.s10.e2,drug0: drug1 may counteract the sedative effect of drug2,True,effect
DDI-DrugBank.d158.s11.e0,DDI-DrugBank.d158.s11.e1,drug1: drug2 may antagonize the hypotensive effects of drug0,False, 
DDI-DrugBank.d158.s11.e0,DDI-DrugBank.d158.s11.e2,drug1: drug0 may antagonize the hypotensive effects of drug2,False, 
DDI-DrugBank.d158.s11.e1,DDI-DrugBank.d158.s11.e2,drug0: drug1 may antagonize the hypotensive effects of drug2,True,effect
DDI-DrugBank.d158.s12.e0,DDI-DrugBank.d158.s12.e1,"drug1: drug2 blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of drug0 and can be used to treat drug0",False, 
DDI-DrugBank.d158.s12.e0,DDI-DrugBank.d158.s12.e2,"drug1: drug0 blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of drug2 and can be used to treat drug0",False, 
DDI-DrugBank.d158.s12.e1,DDI-DrugBank.d158.s12.e2,"drug0: drug1 blocks dopamine and norepinephrine receptors, thus inhibiting the central stimulant effects of drug2 and can be used to treat drug0",True,effect
DDI-DrugBank.d158.s13.e0,DDI-DrugBank.d158.s13.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d158.s13.e0,DDI-DrugBank.d158.s13.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d158.s13.e1,DDI-DrugBank.d158.s13.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d158.s14.e0,DDI-DrugBank.d158.s14.e1,"drug1: drug2 blocks dopamine receptors, thus inhibiting the central stimulant effects of drug0",False, 
DDI-DrugBank.d158.s14.e0,DDI-DrugBank.d158.s14.e2,"drug1: drug0 blocks dopamine receptors, thus inhibiting the central stimulant effects of drug2",False, 
DDI-DrugBank.d158.s14.e1,DDI-DrugBank.d158.s14.e2,"drug0: drug1 blocks dopamine receptors, thus inhibiting the central stimulant effects of drug2",True,effect
DDI-DrugBank.d158.s15.e0,DDI-DrugBank.d158.s15.e1,drug1: The anorectic and stimulatory effects of drug2 may be inhibited by drug0,False, 
DDI-DrugBank.d158.s15.e0,DDI-DrugBank.d158.s15.e2,drug1: The anorectic and stimulatory effects of drug0 may be inhibited by drug2,False, 
DDI-DrugBank.d158.s15.e1,DDI-DrugBank.d158.s15.e2,drug0: The anorectic and stimulatory effects of drug1 may be inhibited by drug2,True,effect
DDI-DrugBank.d158.s16.e0,DDI-DrugBank.d158.s16.e1,drug1: drug2 potentiate the analgesic effect of drug0,False, 
DDI-DrugBank.d158.s16.e0,DDI-DrugBank.d158.s16.e2,drug1: drug0 potentiate the analgesic effect of drug2,False, 
DDI-DrugBank.d158.s16.e1,DDI-DrugBank.d158.s16.e2,drug0: drug1 potentiate the analgesic effect of drug2,True,effect
DDI-DrugBank.d158.s17.e0,DDI-DrugBank.d158.s17.e1,"drug1 therapy Urinary excretion of drug2 is increased, and efficacy is reduced by acidifying agents used in drug0",False, 
DDI-DrugBank.d158.s17.e0,DDI-DrugBank.d158.s17.e2,"drug1 therapy Urinary excretion of drug0 is increased, and efficacy is reduced by acidifying agents used in drug2",False, 
DDI-DrugBank.d158.s17.e1,DDI-DrugBank.d158.s17.e2,"drug0 therapy Urinary excretion of drug1 is increased, and efficacy is reduced by acidifying agents used in drug2",True,mechanism
DDI-DrugBank.d158.s18.e0,DDI-DrugBank.d158.s18.e1,drug1: drug2 enhance the adrenergic effect of drug0,False, 
DDI-DrugBank.d158.s18.e0,DDI-DrugBank.d158.s18.e2,drug1: drug0 enhance the adrenergic effect of drug2,False, 
DDI-DrugBank.d158.s18.e1,DDI-DrugBank.d158.s18.e2,drug0: drug1 enhance the adrenergic effect of drug2,True,effect
DDI-DrugBank.d158.s19.e0,DDI-DrugBank.d158.s19.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d158.s19.e0,DDI-DrugBank.d158.s19.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d158.s19.e1,DDI-DrugBank.d158.s19.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d158.s21.e0,DDI-DrugBank.d158.s21.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d158.s21.e0,DDI-DrugBank.d158.s21.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d158.s21.e1,DDI-DrugBank.d158.s21.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d158.s23.e0,DDI-DrugBank.d158.s23.e1,"drug1: In cases of drug2 overdosage, drug0",False, 
DDI-DrugBank.d158.s23.e0,DDI-DrugBank.d158.s23.e2,"drug1: In cases of drug0 overdosage, drug2",False, 
DDI-DrugBank.d158.s23.e1,DDI-DrugBank.d158.s23.e2,"drug0: In cases of drug1 overdosage, drug2",True,effect
DDI-DrugBank.d158.s24.e0,DDI-DrugBank.d158.s24.e1,drug1: drug2 inhibit the hypotensive effect of drug0,False, 
DDI-DrugBank.d158.s24.e0,DDI-DrugBank.d158.s24.e2,drug1: drug0 inhibit the hypotensive effect of drug2,False, 
DDI-DrugBank.d158.s24.e1,DDI-DrugBank.d158.s24.e2,drug0: drug1 inhibit the hypotensive effect of drug2,True,effect
DDI-DrugBank.d120.s1.e0,DDI-DrugBank.d120.s1.e1,drug1 or other medications with anticholinergic activity - anticholinergic effects may be potentiated when these medications are used concurrently with drug2,False, 
DDI-DrugBank.d120.s2.e0,DDI-DrugBank.d120.s2.e1,drug1 - prior ingestion of drug2 may decrease the drug0 response to drug0,False, 
DDI-DrugBank.d120.s2.e0,DDI-DrugBank.d120.s2.e2,drug1 - prior ingestion of drug0 may decrease the drug2 response to drug0,False, 
DDI-DrugBank.d120.s2.e1,DDI-DrugBank.d120.s2.e3,drug0 - prior ingestion of drug1 may decrease the drug0 response to drug2,True,effect
DDI-DrugBank.d34.s0.e0,DDI-DrugBank.d34.s0.e1,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with drug1, these disturbances have been reported with oral drug2 and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose drug0",True,effect
DDI-DrugBank.d34.s0.e0,DDI-DrugBank.d34.s0.e2,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with drug1, these disturbances have been reported with oral drug0 and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose drug2",False, 
DDI-DrugBank.d34.s0.e1,DDI-DrugBank.d34.s0.e2,"Although acid-base and electrolyte disturbances were not reported in the clinical trials with drug0, these disturbances have been reported with oral drug1 and have, in some instances, resulted in drug interactions (e.g., toxicity associated with high-dose drug2",False, 
DDI-DrugBank.d151.s0.e0,DDI-DrugBank.d151.s0.e1,"drug1 in large amounts may counteract the antiepileptic effect of drug2, drug0 and drug0",True,effect
DDI-DrugBank.d151.s0.e0,DDI-DrugBank.d151.s0.e2,"drug1 in large amounts may counteract the antiepileptic effect of drug0, drug2 and drug0",True,effect
DDI-DrugBank.d151.s0.e0,DDI-DrugBank.d151.s0.e3,"drug1 in large amounts may counteract the antiepileptic effect of drug0, drug0 and drug2",True,effect
DDI-DrugBank.d151.s0.e1,DDI-DrugBank.d151.s0.e2,"drug0 in large amounts may counteract the antiepileptic effect of drug1, drug2 and drug0",False, 
DDI-DrugBank.d151.s0.e1,DDI-DrugBank.d151.s0.e3,"drug0 in large amounts may counteract the antiepileptic effect of drug1, drug0 and drug2",False, 
DDI-DrugBank.d151.s1.e0,DDI-DrugBank.d151.s1.e1,"Preliminary animal and human studies have shown that small quantities of systemically administered drug1 enter the CSF primarily as 5-methyltetrahydro-folate and, in humans, remain 1 to 3 orders of magnitude lower than the usual drug2",False, 
DDI-DrugBank.d151.s2.e0,DDI-DrugBank.d151.s2.e1,"However, high doses of drug1 may reduce the efficacy of intrathecally administered drug2",True,effect
DDI-DrugBank.d151.s3.e0,DDI-DrugBank.d151.s3.e1,drug1 may enhance the toxicity of drug2,True,effect
DDI-DrugBank.d410.s0.e0,DDI-DrugBank.d410.s0.e1,"drug1: drug2  (drug0) Injection, USP should not be used with drug0",False, 
DDI-DrugBank.d410.s0.e0,DDI-DrugBank.d410.s0.e2,"drug1: drug0  (drug2) Injection, USP should not be used with drug0",False, 
DDI-DrugBank.d410.s0.e1,DDI-DrugBank.d410.s0.e3,"drug0: drug1  (drug0) Injection, USP should not be used with drug2",True,effect
DDI-DrugBank.d410.s0.e2,DDI-DrugBank.d410.s0.e3,"drug0: drug0  (drug1) Injection, USP should not be used with drug2",True,effect
DDI-DrugBank.d410.s1.e0,DDI-DrugBank.d410.s1.e1,"drug1: drug2 has been reported to cause coronary artery vasospasm, and its effect could be additive with drug0  (drug0",False, 
DDI-DrugBank.d410.s1.e0,DDI-DrugBank.d410.s1.e2,"drug1: drug0 has been reported to cause coronary artery vasospasm, and its effect could be additive with drug2  (drug0",False, 
DDI-DrugBank.d410.s1.e1,DDI-DrugBank.d410.s1.e2,"drug0: drug1 has been reported to cause coronary artery vasospasm, and its effect could be additive with drug2  (drug0",True,effect
DDI-DrugBank.d410.s1.e1,DDI-DrugBank.d410.s1.e3,"drug0: drug1 has been reported to cause coronary artery vasospasm, and its effect could be additive with drug0  (drug2",True,effect
DDI-DrugBank.d410.s2.e0,DDI-DrugBank.d410.s2.e1,drug1 and drug2  (drug0,True,advise
DDI-DrugBank.d410.s2.e0,DDI-DrugBank.d410.s2.e2,drug1 and drug0  (drug2,True,advise
DDI-DrugBank.d410.s2.e1,DDI-DrugBank.d410.s2.e2,drug0 and drug1  (drug2,False, 
DDI-DrugBank.d410.s3.e0,DDI-DrugBank.d410.s3.e1,"drug1: Although the results of a clinical study did not indicate a safe problem associated with the administration of drug2  (drug0) Injection, USP to subjects already receiving drug0, there have been reports that drug0 may potentiate the vasoconstrictive action of drug0",False, 
DDI-DrugBank.d410.s3.e0,DDI-DrugBank.d410.s3.e2,"drug1: Although the results of a clinical study did not indicate a safe problem associated with the administration of drug0  (drug2) Injection, USP to subjects already receiving drug0, there have been reports that drug0 may potentiate the vasoconstrictive action of drug0",False, 
DDI-DrugBank.d410.s3.e4,DDI-DrugBank.d410.s3.e5,"drug0: Although the results of a clinical study did not indicate a safe problem associated with the administration of drug0  (drug0) Injection, USP to subjects already receiving drug0, there have been reports that drug1 may potentiate the vasoconstrictive action of drug2",True,effect
DDI-DrugBank.d410.s4.e0,DDI-DrugBank.d410.s4.e1,"drug1: drug2 may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to drug0",False, 
DDI-DrugBank.d410.s4.e0,DDI-DrugBank.d410.s4.e2,"drug1: drug0 may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to drug2",False, 
DDI-DrugBank.d410.s4.e1,DDI-DrugBank.d410.s4.e2,"drug0: drug1 may provoke vasoconstriction in some patients, predisposing to a greater ischemic response to drug2",True,effect
DDI-DrugBank.d410.s5.e0,DDI-DrugBank.d410.s5.e1,"drug1 (e. g. drug2 and drug0): Agents of the drug0, of which drug0  (drug0) Injection, USP is a member, have been shown to interact with drug0 of the drug0",False, 
DDI-DrugBank.d410.s5.e0,DDI-DrugBank.d410.s5.e2,"drug1 (e. g. drug0 and drug2): Agents of the drug0, of which drug0  (drug0) Injection, USP is a member, have been shown to interact with drug0 of the drug0",False, 
DDI-DrugBank.d410.s5.e3,DDI-DrugBank.d410.s5.e7,"drug0 (e. g. drug0 and drug0): Agents of the drug1, of which drug0  (drug0) Injection, USP is a member, have been shown to interact with drug0 of the drug2",True,mechanism
DDI-DrugBank.d410.s5.e4,DDI-DrugBank.d410.s5.e7,"drug0 (e. g. drug0 and drug0): Agents of the drug0, of which drug1  (drug0) Injection, USP is a member, have been shown to interact with drug0 of the drug2",True,mechanism
DDI-DrugBank.d410.s5.e5,DDI-DrugBank.d410.s5.e7,"drug0 (e. g. drug0 and drug0): Agents of the drug0, of which drug0  (drug1) Injection, USP is a member, have been shown to interact with drug0 of the drug2",True,mechanism
DDI-DrugBank.d410.s6.e0,DDI-DrugBank.d410.s6.e1,Vasospastic reactions have been reported with therapeutic doses of drug1-containing drugs when co-administered with these drug2,True,effect
DDI-DrugBank.d410.s7.e0,DDI-DrugBank.d410.s7.e1,"drug1: Weakness hyperreflexia, and incoordination have been reported rarely when drug2 have been co-administered with drug0",False, 
DDI-DrugBank.d410.s7.e0,DDI-DrugBank.d410.s7.e2,"drug1: Weakness hyperreflexia, and incoordination have been reported rarely when drug0 have been co-administered with drug2",False, 
DDI-DrugBank.d410.s7.e1,DDI-DrugBank.d410.s7.e2,"drug0: Weakness hyperreflexia, and incoordination have been reported rarely when drug1 have been co-administered with drug2",True,effect
DDI-DrugBank.d410.s8.e0,DDI-DrugBank.d410.s8.e1,"drug1, drug2, drug0, drug0",False, 
DDI-DrugBank.d410.s8.e0,DDI-DrugBank.d410.s8.e2,"drug1, drug0, drug2, drug0",False, 
DDI-DrugBank.d410.s9.e0,DDI-DrugBank.d410.s9.e1,There have been no reported cases from spontaneous reports of drug interaction between drug1 and drug2  (drug0,False, 
DDI-DrugBank.d410.s9.e0,DDI-DrugBank.d410.s9.e2,There have been no reported cases from spontaneous reports of drug interaction between drug1 and drug0  (drug2,False, 
DDI-DrugBank.d410.s10.e0,DDI-DrugBank.d410.s10.e1,Oral drug1: The effect of oral drug2 on the pharmacokinetics of drug0  (drug0,False, 
DDI-DrugBank.d410.s10.e0,DDI-DrugBank.d410.s10.e2,Oral drug1: The effect of oral drug0 on the pharmacokinetics of drug2  (drug0,False, 
DDI-DrugBank.d427.s0.e0,DDI-DrugBank.d427.s0.e1,Elevated plasma levels of drug1 have been reported with concomitant drug2,True,mechanism
DDI-DrugBank.d427.s1.e0,DDI-DrugBank.d427.s1.e1,There have been reports of drug1-related side effects in patients on concomitant therapy with drug2 and drug0,False, 
DDI-DrugBank.d427.s1.e0,DDI-DrugBank.d427.s1.e2,There have been reports of drug1-related side effects in patients on concomitant therapy with drug0 and drug2,False, 
DDI-DrugBank.d427.s1.e1,DDI-DrugBank.d427.s1.e2,There have been reports of drug0-related side effects in patients on concomitant therapy with drug1 and drug2,True,effect
DDI-DrugBank.d427.s2.e0,DDI-DrugBank.d427.s2.e1,"Therefore, monitoring of drug1 plasma levels should be considered and dosage of drug2",False, 
DDI-DrugBank.d427.s3.e0,DDI-DrugBank.d427.s3.e1,drug1 have been shown to interfere with the metabolism of drug2,True,mechanism
DDI-DrugBank.d427.s5.e0,DDI-DrugBank.d427.s5.e1,"drug1, including drug2, may enhance the effects of the oral drug0 drug0",False, 
DDI-DrugBank.d427.s5.e0,DDI-DrugBank.d427.s5.e2,"drug1, including drug0, may enhance the effects of the oral drug2 drug0",False, 
DDI-DrugBank.d427.s5.e0,DDI-DrugBank.d427.s5.e3,"drug1, including drug0, may enhance the effects of the oral drug0 drug2",True,effect
DDI-DrugBank.d427.s5.e1,DDI-DrugBank.d427.s5.e3,"drug0, including drug1, may enhance the effects of the oral drug0 drug2",True,effect
DDI-DrugBank.d427.s7.e0,DDI-DrugBank.d427.s7.e1,drug1 interferes with the therapeutic action of drug2,True,effect
DDI-DrugBank.d427.s8.e0,DDI-DrugBank.d427.s8.e1,"drug1 containing drug2, drug0, or drug0",False, 
DDI-DrugBank.d427.s8.e0,DDI-DrugBank.d427.s8.e2,"drug1 containing drug0, drug2, or drug0",False, 
DDI-DrugBank.d427.s9.e0,DDI-DrugBank.d427.s9.e1,drug1 or divalent or trivalent cations such as drug2,False, 
DDI-DrugBank.d427.s10.e0,DDI-DrugBank.d427.s10.e1,drug1 containing drug2,False, 
DDI-DrugBank.d427.s11.e0,DDI-DrugBank.d427.s11.e1,"and drug1 , (drug2), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drug0",False, 
DDI-DrugBank.d427.s11.e0,DDI-DrugBank.d427.s11.e2,"and drug1 , (drug0), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drug2",True,mechanism
DDI-DrugBank.d427.s11.e1,DDI-DrugBank.d427.s11.e2,"and drug0 , (drug1), chewable/buffered tablets or the pediatric powder for oral solution may substantially interfere with the absorption of drug2",True,mechanism
DDI-DrugBank.d427.s13.e0,DDI-DrugBank.d427.s13.e1,Elevated serum levels of drug1 have been reported with the concomitant use of some drug2 and drug0,False, 
DDI-DrugBank.d427.s13.e0,DDI-DrugBank.d427.s13.e2,Elevated serum levels of drug1 have been reported with the concomitant use of some drug0 and drug2,False, 
DDI-DrugBank.d427.s13.e1,DDI-DrugBank.d427.s13.e2,Elevated serum levels of drug0 have been reported with the concomitant use of some drug1 and drug2,True,mechanism
DDI-DrugBank.d427.s14.e0,DDI-DrugBank.d427.s14.e1,"Therefore, drug1 serum levels should be monitored and appropriate drug2",False, 
DDI-DrugBank.d247.s1.e0,DDI-DrugBank.d247.s1.e1,All drug1 should be used cautiously in patients taking drug2,True,advise
DDI-DrugBank.d247.s2.e0,DDI-DrugBank.d247.s2.e1,drug1 should not be administered concomitantly with other drug2 (such as drug0,True,advise
DDI-DrugBank.d247.s2.e0,DDI-DrugBank.d247.s2.e2,drug1 should not be administered concomitantly with other drug0 (such as drug2,True,advise
DDI-DrugBank.d247.s2.e1,DDI-DrugBank.d247.s2.e2,drug0 should not be administered concomitantly with other drug1 (such as drug2,False, 
DDI-DrugBank.d247.s5.e0,DDI-DrugBank.d247.s5.e1,Administration of drug1 to patients receiving drug2 or drug0 such as drug0,True,effect
DDI-DrugBank.d247.s5.e0,DDI-DrugBank.d247.s5.e2,Administration of drug1 to patients receiving drug0 or drug2 such as drug0,True,effect
DDI-DrugBank.d247.s5.e0,DDI-DrugBank.d247.s5.e3,Administration of drug1 to patients receiving drug0 or drug0 such as drug2,True,effect
DDI-DrugBank.d247.s5.e1,DDI-DrugBank.d247.s5.e2,Administration of drug0 to patients receiving drug1 or drug2 such as drug0,False, 
DDI-DrugBank.d247.s5.e1,DDI-DrugBank.d247.s5.e3,Administration of drug0 to patients receiving drug1 or drug0 such as drug2,False, 
DDI-DrugBank.d247.s7.e0,DDI-DrugBank.d247.s7.e1,"drug1 also should be used cautiously with other drugs (e.g., drug2, drug0) that sensitize the myocardium to the actions of drug0",True,advise
DDI-DrugBank.d247.s7.e0,DDI-DrugBank.d247.s7.e2,"drug1 also should be used cautiously with other drugs (e.g., drug0, drug2) that sensitize the myocardium to the actions of drug0",True,advise
DDI-DrugBank.d247.s7.e0,DDI-DrugBank.d247.s7.e3,"drug1 also should be used cautiously with other drugs (e.g., drug0, drug0) that sensitize the myocardium to the actions of drug2",False, 
DDI-DrugBank.d247.s7.e1,DDI-DrugBank.d247.s7.e2,"drug0 also should be used cautiously with other drugs (e.g., drug1, drug2) that sensitize the myocardium to the actions of drug0",False, 
DDI-DrugBank.d247.s8.e0,DDI-DrugBank.d247.s8.e1,drug1 may decrease vascular response to pressor drugs such as drug2,True,effect
DDI-DrugBank.d247.s9.e0,DDI-DrugBank.d247.s9.e1,drug1 may antagonize the neuron blockade produced by drug2,True,effect
DDI-DrugBank.d74.s0.e0,DDI-DrugBank.d74.s0.e1,drug1 augments the action of drug2s and the muscle relaxant effects of drug0,True,effect
DDI-DrugBank.d74.s0.e0,DDI-DrugBank.d74.s0.e2,drug1 augments the action of drug0s and the muscle relaxant effects of drug2,True,effect
DDI-DrugBank.d74.s0.e1,DDI-DrugBank.d74.s0.e2,drug0 augments the action of drug1s and the muscle relaxant effects of drug2,False, 
DDI-DrugBank.d74.s1.e0,DDI-DrugBank.d74.s1.e1,drug1 may augment the hypotension caused by the ganglionic-blocking effect of drug2,True,effect
DDI-DrugBank.d74.s2.e0,DDI-DrugBank.d74.s2.e1,Caution should be exercised during the administration of drug1 to patients anaesthetised with drug2,True,advise
DDI-DrugBank.d74.s3.e0,DDI-DrugBank.d74.s3.e1,For this reason the dose of drug1 should be restricted and an drug2,False, 
DDI-DrugBank.d74.s4.e0,DDI-DrugBank.d74.s4.e1,"Caution should also be applied for other drug1, and for drug2 and drug0 and drug0",False, 
DDI-DrugBank.d74.s4.e0,DDI-DrugBank.d74.s4.e2,"Caution should also be applied for other drug1, and for drug0 and drug2 and drug0",False, 
DDI-DrugBank.d462.s0.e0,DDI-DrugBank.d462.s0.e1,drug1: The mixing of drug2 with an drug0 in vitro can result in substantial inactivation of the drug0,False, 
DDI-DrugBank.d462.s0.e0,DDI-DrugBank.d462.s0.e2,drug1: The mixing of drug0 with an drug2 in vitro can result in substantial inactivation of the drug0,False, 
DDI-DrugBank.d462.s0.e1,DDI-DrugBank.d462.s0.e2,drug0: The mixing of drug1 with an drug2 in vitro can result in substantial inactivation of the drug0,True,effect
DDI-DrugBank.d462.s1.e0,DDI-DrugBank.d462.s1.e1,"drug1: When used in the perioperative period, drug2 has been implicated in the prolongation of the neuromuscular blockade of drug0",False, 
DDI-DrugBank.d462.s1.e0,DDI-DrugBank.d462.s1.e2,"drug1: When used in the perioperative period, drug0 has been implicated in the prolongation of the neuromuscular blockade of drug2",False, 
DDI-DrugBank.d462.s1.e1,DDI-DrugBank.d462.s1.e2,"drug0: When used in the perioperative period, drug1 has been implicated in the prolongation of the neuromuscular blockade of drug2",True,effect
DDI-DrugBank.d462.s3.e0,DDI-DrugBank.d462.s3.e1,"In one controlled clinical study, the ureidopenicillins, including drug1, were reported to prolong the action of drug2",True,effect
DDI-DrugBank.d462.s4.e0,DDI-DrugBank.d462.s4.e1,"Due to their similar mechanism of action, it is expected that the neuromuscular blockade produced by any of the drug1 could be prolonged in the presence of drug2",True,effect
DDI-DrugBank.d462.s5.e0,DDI-DrugBank.d462.s5.e1,drug1: The oral combination of drug2 before intramuscular injection of drug0 produces an increase in drug0,False, 
DDI-DrugBank.d462.s5.e0,DDI-DrugBank.d462.s5.e2,drug1: The oral combination of drug0 before intramuscular injection of drug2 produces an increase in drug0,False, 
DDI-DrugBank.d462.s5.e1,DDI-DrugBank.d462.s5.e2,drug0: The oral combination of drug1 before intramuscular injection of drug2 produces an increase in drug0,True,mechanism
DDI-DrugBank.d462.s6.e0,DDI-DrugBank.d462.s6.e1,"drug1: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of drug2, oral drug0",False, 
DDI-DrugBank.d462.s6.e0,DDI-DrugBank.d462.s6.e2,"drug1: Coagulation parameters should be tested more frequently and monitored regularly during simultaneous administration of high doses of drug0, oral drug2",False, 
DDI-DrugBank.d462.s7.e0,DDI-DrugBank.d462.s7.e1,drug1: drug2 may reduce the excretion of drug0,False, 
DDI-DrugBank.d462.s7.e0,DDI-DrugBank.d462.s7.e2,drug1: drug0 may reduce the excretion of drug2,False, 
DDI-DrugBank.d462.s7.e1,DDI-DrugBank.d462.s7.e2,drug0: drug1 may reduce the excretion of drug2,True,mechanism
DDI-DrugBank.d462.s9.e0,DDI-DrugBank.d462.s9.e1,"Drug/Laboratory Test Interactions As with other drug1, the administration of drug2",False, 
DDI-DrugBank.d462.s11.e0,DDI-DrugBank.d462.s11.e1,There have been reports of positive test results using the Bio-Rad Laboratories Platelia Aspergillus EIA test in patients receiving drug1/drug2,False, 
DDI-DrugBank.d359.s1.e0,DDI-DrugBank.d359.s1.e1,Considerable caution should be exercised if drug1 is administered concurrently with drug2 (drug0,True,advise
DDI-DrugBank.d359.s1.e0,DDI-DrugBank.d359.s1.e2,Considerable caution should be exercised if drug1 is administered concurrently with drug0 (drug2,True,advise
DDI-DrugBank.d359.s1.e1,DDI-DrugBank.d359.s1.e2,Considerable caution should be exercised if drug0 is administered concurrently with drug1 (drug2,False, 
DDI-DrugBank.d359.s2.e0,DDI-DrugBank.d359.s2.e1,"A two-way interaction between the drug1, drug2, and the drug0",True,int
DDI-DrugBank.d359.s2.e0,DDI-DrugBank.d359.s2.e2,"A two-way interaction between the drug1, drug0, and the drug2",True,int
DDI-DrugBank.d359.s2.e1,DDI-DrugBank.d359.s2.e2,"A two-way interaction between the drug0, drug1, and the drug2",False, 
DDI-DrugBank.d359.s3.e0,DDI-DrugBank.d359.s3.e1,"Presumably, drug1 acts as a stimulator of drug2 metabolism and has been reported to cause decreased serum levels of the drug0",True,mechanism
DDI-DrugBank.d359.s3.e0,DDI-DrugBank.d359.s3.e2,"Presumably, drug1 acts as a stimulator of drug0 metabolism and has been reported to cause decreased serum levels of the drug2",True,mechanism
DDI-DrugBank.d359.s3.e1,DDI-DrugBank.d359.s3.e2,"Presumably, drug0 acts as a stimulator of drug1 metabolism and has been reported to cause decreased serum levels of the drug2",False, 
DDI-DrugBank.d359.s4.e0,DDI-DrugBank.d359.s4.e1,"Conversely, the drug1 have been reported to increase the serum levels and prolong the serum half-life of drug2",True,mechanism
DDI-DrugBank.d359.s5.e0,DDI-DrugBank.d359.s5.e1,"Although there is no documentation of such, a similar interaction between drug1 and the drug2",False, 
DDI-DrugBank.d359.s6.e0,DDI-DrugBank.d359.s6.e1,Caution is therefore advised when administering drug1 to patients receiving drug2,True,advise
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e1,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug2 drug0, drug0, and drug0, and the drug0 drug0",False, 
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e2,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug0 drug2, drug0, and drug0, and the drug0 drug0",True,effect
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e3,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug0 drug0, drug2, and drug0, and the drug0 drug0",True,effect
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e4,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug0 drug0, drug0, and drug2, and the drug0 drug0",True,effect
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e5,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug0 drug0, drug0, and drug0, and the drug2 drug0",False, 
DDI-DrugBank.d306.s0.e0,DDI-DrugBank.d306.s0.e6,"The effectiveness of drug1-only pills is reduced by hepatic enzyme-inducing drugs such as the drug0 drug0, drug0, and drug0, and the drug0 drug2",True,effect
DDI-DrugBank.d207.s1.e0,DDI-DrugBank.d207.s1.e1,In patients receiving a potent CYP3A4 inducer such as drug1 or drug2,False, 
DDI-DrugBank.d207.s2.e0,DDI-DrugBank.d207.s2.e1,International Normalized Ratio (INR) elevations and/or bleeding events have been reported in some patients taking drug1 while on drug2,True,effect
DDI-DrugBank.d207.s4.e0,DDI-DrugBank.d207.s4.e1,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug1 and drug2) decrease drug0 metabolism and increase drug0",False, 
DDI-DrugBank.d207.s4.e0,DDI-DrugBank.d207.s4.e2,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug1 and drug0) decrease drug2 metabolism and increase drug0",True,mechanism
DDI-DrugBank.d207.s4.e0,DDI-DrugBank.d207.s4.e3,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug1 and drug0) decrease drug0 metabolism and increase drug2",True,mechanism
DDI-DrugBank.d207.s4.e1,DDI-DrugBank.d207.s4.e2,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug0 and drug1) decrease drug2 metabolism and increase drug0",True,mechanism
DDI-DrugBank.d207.s4.e1,DDI-DrugBank.d207.s4.e3,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug0 and drug1) decrease drug0 metabolism and increase drug2",True,mechanism
DDI-DrugBank.d207.s4.e2,DDI-DrugBank.d207.s4.e3,"Substances that are potent inhibitors of CYP3A4 activity (eg, drug0 and drug0) decrease drug1 metabolism and increase drug2",False, 
DDI-DrugBank.d207.s7.e0,DDI-DrugBank.d207.s7.e1,Drugs that cause significant sustained elevation in gastric pH (drug1 such as drug2 or drug0) may reduce plasma concentrations of drug0,False, 
DDI-DrugBank.d207.s7.e0,DDI-DrugBank.d207.s7.e2,Drugs that cause significant sustained elevation in gastric pH (drug1 such as drug0 or drug2) may reduce plasma concentrations of drug0,False, 
DDI-DrugBank.d207.s7.e0,DDI-DrugBank.d207.s7.e3,Drugs that cause significant sustained elevation in gastric pH (drug1 such as drug0 or drug0) may reduce plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d207.s7.e1,DDI-DrugBank.d207.s7.e3,Drugs that cause significant sustained elevation in gastric pH (drug0 such as drug1 or drug0) may reduce plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d207.s7.e2,DDI-DrugBank.d207.s7.e3,Drugs that cause significant sustained elevation in gastric pH (drug0 such as drug0 or drug1) may reduce plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d207.s8.e0,DDI-DrugBank.d207.s8.e1,"Phase II clinical trial data, where drug1 and drug2 have been used concomitantly, indicate that drug0 may exacerbate the neutropenic effect of drug0",False, 
DDI-DrugBank.d207.s8.e0,DDI-DrugBank.d207.s8.e2,"Phase II clinical trial data, where drug1 and drug0 have been used concomitantly, indicate that drug2 may exacerbate the neutropenic effect of drug0",False, 
DDI-DrugBank.d207.s8.e2,DDI-DrugBank.d207.s8.e3,"Phase II clinical trial data, where drug0 and drug0 have been used concomitantly, indicate that drug1 may exacerbate the neutropenic effect of drug2",True,effect
DDI-DrugBank.d75.s1.e0,DDI-DrugBank.d75.s1.e1,"In vivo interaction studies in humans have demonstrated that drug1 and drug2 do not affect the PK properties of drug0, nor does drug0 affect the PK properties of drug0 or drug0",False, 
DDI-DrugBank.d75.s1.e0,DDI-DrugBank.d75.s1.e2,"In vivo interaction studies in humans have demonstrated that drug1 and drug0 do not affect the PK properties of drug2, nor does drug0 affect the PK properties of drug0 or drug0",False, 
DDI-DrugBank.d75.s2.e0,DDI-DrugBank.d75.s2.e1,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with drug1 in clinical trials were drug2, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d75.s2.e0,DDI-DrugBank.d75.s2.e2,"Although additional drug interaction studies have not been conducted, the most common medications used concomitantly with drug1 in clinical trials were drug0, drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d75.s4.e0,DDI-DrugBank.d75.s4.e1,An in vivo interaction study in humans demonstrated that a single 1mg dose of drug1 administered concomitantly with a single 900 mg dose of drug2,False, 
DDI-DrugBank.d75.s6.e0,DDI-DrugBank.d75.s6.e1,No clinically relevant pharmacokinetic interactions between drug1 and drug2,False, 
DDI-DrugBank.d75.s8.e0,DDI-DrugBank.d75.s8.e1,"drug1 alone had no effect on platelet aggregation, but did slightly enhance the inhibition of platelet aggregation by drug2",True,effect
DDI-DrugBank.d75.s10.e0,DDI-DrugBank.d75.s10.e1,"It is known that CYP1A2 is inhibited by several medicinal products, including drug1, and such medicinal products could theoretically adversely influence the clearance of drug2",True,mechanism
DDI-DrugBank.d75.s12.e0,DDI-DrugBank.d75.s12.e1,drug1 demonstrates some limited inhibitory activity towards CYP1A2 which may present a theoretical potential for interaction with other coadministered medicinal products sharing that clearance mechanism e.g. drug2,True,mechanism
DDI-DrugBank.d75.s14.e0,DDI-DrugBank.d75.s14.e1,"The effects of medicinal products with similar properties such as inotropes drug1, drug2, drug0, drug0 and drug0 may be exacerbated by drug0",False, 
DDI-DrugBank.d75.s14.e0,DDI-DrugBank.d75.s14.e2,"The effects of medicinal products with similar properties such as inotropes drug1, drug0, drug2, drug0 and drug0 may be exacerbated by drug0",False, 
DDI-DrugBank.d75.s14.e0,DDI-DrugBank.d75.s14.e5,"The effects of medicinal products with similar properties such as inotropes drug1, drug0, drug0, drug0 and drug0 may be exacerbated by drug2",True,effect
DDI-DrugBank.d75.s14.e1,DDI-DrugBank.d75.s14.e5,"The effects of medicinal products with similar properties such as inotropes drug0, drug1, drug0, drug0 and drug0 may be exacerbated by drug2",True,effect
DDI-DrugBank.d75.s14.e2,DDI-DrugBank.d75.s14.e5,"The effects of medicinal products with similar properties such as inotropes drug0, drug0, drug1, drug0 and drug0 may be exacerbated by drug2",True,effect
DDI-DrugBank.d75.s14.e3,DDI-DrugBank.d75.s14.e5,"The effects of medicinal products with similar properties such as inotropes drug0, drug0, drug0, drug1 and drug0 may be exacerbated by drug2",True,effect
DDI-DrugBank.d75.s14.e4,DDI-DrugBank.d75.s14.e5,"The effects of medicinal products with similar properties such as inotropes drug0, drug0, drug0, drug0 and drug1 may be exacerbated by drug2",True,effect
DDI-DrugBank.d75.s15.e0,DDI-DrugBank.d75.s15.e1,"There is a single case report, which suggests that drug1 may interfere with drug2",True,mechanism
DDI-DrugBank.d364.s0.e0,DDI-DrugBank.d364.s0.e1,"Because drug1 is metabolized by a variety of hepatic CYP drug-metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of drug2",False, 
DDI-DrugBank.d364.s2.e0,DDI-DrugBank.d364.s2.e1,"In a pharmacokinetic study, 40 healthy female subjects received drug1 in escalating doses from 50 to 200 mg per day for 16 days, with coadministration of drug2",False, 
DDI-DrugBank.d364.s3.e0,DDI-DrugBank.d364.s3.e1,drug1 increased mean drug2,True,mechanism
DDI-DrugBank.d364.s4.e0,DDI-DrugBank.d364.s4.e1,Concomitant administration of drug1 and drug2,True,advise
DDI-DrugBank.d364.s5.e0,DDI-DrugBank.d364.s5.e1,"Concomitant administration of drug1 and moderate CYP1A2 inhibitors, including drug2 and drug0",True,advise
DDI-DrugBank.d364.s5.e0,DDI-DrugBank.d364.s5.e2,"Concomitant administration of drug1 and moderate CYP1A2 inhibitors, including drug0 and drug2",True,advise
DDI-DrugBank.d364.s5.e1,DDI-DrugBank.d364.s5.e2,"Concomitant administration of drug0 and moderate CYP1A2 inhibitors, including drug1 and drug2",False, 
DDI-DrugBank.d364.s7.e0,DDI-DrugBank.d364.s7.e1,"In a pharmacokinetic study, 38 healthy female subjects received drug1 200 mg twice daily for 7 days, with coadministration of drug2",False, 
DDI-DrugBank.d364.s8.e0,DDI-DrugBank.d364.s8.e1,drug1 increased mean drug2,True,mechanism
DDI-DrugBank.d364.s9.e0,DDI-DrugBank.d364.s9.e1,Caution should be used when drug1 and drug2,True,advise
DDI-DrugBank.d364.s10.e0,DDI-DrugBank.d364.s10.e1,"Coadministration of drug1 and strong CYP3A4 inhibitors, such as drug2, drug0, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d364.s10.e0,DDI-DrugBank.d364.s10.e2,"Coadministration of drug1 and strong CYP3A4 inhibitors, such as drug0, drug2, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d364.s10.e0,DDI-DrugBank.d364.s10.e3,"Coadministration of drug1 and strong CYP3A4 inhibitors, such as drug0, drug0, drug2, drug0, and drug0",True,advise
DDI-DrugBank.d364.s10.e0,DDI-DrugBank.d364.s10.e4,"Coadministration of drug1 and strong CYP3A4 inhibitors, such as drug0, drug0, drug0, drug2, and drug0",True,advise
DDI-DrugBank.d364.s10.e0,DDI-DrugBank.d364.s10.e5,"Coadministration of drug1 and strong CYP3A4 inhibitors, such as drug0, drug0, drug0, drug0, and drug2",True,advise
DDI-DrugBank.d364.s10.e1,DDI-DrugBank.d364.s10.e2,"Coadministration of drug0 and strong CYP3A4 inhibitors, such as drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d364.s10.e1,DDI-DrugBank.d364.s10.e3,"Coadministration of drug0 and strong CYP3A4 inhibitors, such as drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d364.s15.e0,DDI-DrugBank.d364.s15.e1,"Although not studied with drug1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug2, drug0, and drug0",True,effect
DDI-DrugBank.d364.s15.e0,DDI-DrugBank.d364.s15.e2,"Although not studied with drug1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug0, drug2, and drug0",True,effect
DDI-DrugBank.d364.s15.e0,DDI-DrugBank.d364.s15.e3,"Although not studied with drug1, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug0, drug0, and drug2",True,effect
DDI-DrugBank.d364.s15.e1,DDI-DrugBank.d364.s15.e2,"Although not studied with drug0, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug1, drug2, and drug0",False, 
DDI-DrugBank.d364.s15.e1,DDI-DrugBank.d364.s15.e3,"Although not studied with drug0, inhibition of N-acetyltransferase may have clinically relevant consequences for drugs such as drug1, drug0, and drug2",False, 
DDI-DrugBank.d364.s17.e0,DDI-DrugBank.d364.s17.e1,Another study showed that drug1 had no clinically significant effect on plasma concentrations of the oral drug2 drug0 and drug0,False, 
DDI-DrugBank.d364.s17.e0,DDI-DrugBank.d364.s17.e2,Another study showed that drug1 had no clinically significant effect on plasma concentrations of the oral drug0 drug2 and drug0,False, 
DDI-DrugBank.d364.s18.e0,DDI-DrugBank.d364.s18.e1,A clinical interaction study was also conducted with drug1 and the CYP3A4 substrate drug2,False, 
DDI-DrugBank.d179.s1.e0,DDI-DrugBank.d179.s1.e1,"drug1 may interact with any of the following: - drug2 (e.g., drug0",True,int
DDI-DrugBank.d179.s1.e0,DDI-DrugBank.d179.s1.e2,"drug1 may interact with any of the following: - drug0 (e.g., drug2",True,int
DDI-DrugBank.d179.s1.e1,DDI-DrugBank.d179.s1.e2,"drug0 may interact with any of the following: - drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s2.e0,DDI-DrugBank.d179.s2.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s3.e0,DDI-DrugBank.d179.s3.e1,"- drug1 (drug2 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0",False, 
DDI-DrugBank.d179.s3.e0,DDI-DrugBank.d179.s3.e2,"- drug1 (drug0 [e.g., drug2], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0",False, 
DDI-DrugBank.d179.s6.e0,DDI-DrugBank.d179.s6.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s7.e0,DDI-DrugBank.d179.s7.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s8.e0,DDI-DrugBank.d179.s8.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s9.e0,DDI-DrugBank.d179.s9.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s10.e0,DDI-DrugBank.d179.s10.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s11.e0,DDI-DrugBank.d179.s11.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s12.e0,DDI-DrugBank.d179.s12.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s14.e0,DDI-DrugBank.d179.s14.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s16.e0,DDI-DrugBank.d179.s16.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s17.e0,DDI-DrugBank.d179.s17.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s18.e0,DDI-DrugBank.d179.s18.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s19.e0,DDI-DrugBank.d179.s19.e1,- Oral drug1 (birth control pills) containing drug2,False, 
DDI-DrugBank.d179.s21.e0,DDI-DrugBank.d179.s21.e1,"- drug1 (drug2 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0",False, 
DDI-DrugBank.d179.s21.e0,DDI-DrugBank.d179.s21.e2,"- drug1 (drug0 [e.g., drug2], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0], drug0 [e.g., drug0",False, 
DDI-DrugBank.d179.s22.e0,DDI-DrugBank.d179.s22.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s23.e0,DDI-DrugBank.d179.s23.e1,"- drug1 (e.g., drug2) Use of drug0",False, 
DDI-DrugBank.d179.s23.e0,DDI-DrugBank.d179.s23.e2,"- drug1 (e.g., drug0) Use of drug2",False, 
DDI-DrugBank.d179.s24.e0,DDI-DrugBank.d179.s24.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s26.e0,DDI-DrugBank.d179.s26.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s27.e0,DDI-DrugBank.d179.s27.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s29.e0,DDI-DrugBank.d179.s29.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s30.e0,DDI-DrugBank.d179.s30.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s31.e0,DDI-DrugBank.d179.s31.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s32.e0,DDI-DrugBank.d179.s32.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s33.e0,DDI-DrugBank.d179.s33.e1,"- drug1 (e.g., drug2, drug0) Use of drug0",False, 
DDI-DrugBank.d179.s33.e0,DDI-DrugBank.d179.s33.e2,"- drug1 (e.g., drug0, drug2) Use of drug0",False, 
DDI-DrugBank.d179.s34.e0,DDI-DrugBank.d179.s34.e1,- drug1 (drug2,False, 
DDI-DrugBank.d179.s35.e0,DDI-DrugBank.d179.s35.e1,"- drug1 (e.g., drug2",False, 
DDI-DrugBank.d179.s36.e0,DDI-DrugBank.d179.s36.e1,"- drug1 (e.g., drug2) Use of drug0",False, 
DDI-DrugBank.d179.s36.e0,DDI-DrugBank.d179.s36.e2,"- drug1 (e.g., drug0) Use of drug2",False, 
DDI-DrugBank.d179.s37.e0,DDI-DrugBank.d179.s37.e1,"- drug1, oral (diabetes medicine you take by mouth) Use of oral drug2 with drug0 may increase the chance of side effects affecting the blood and/or the side effects or oral drug0",False, 
DDI-DrugBank.d179.s37.e0,DDI-DrugBank.d179.s37.e2,"- drug1, oral (diabetes medicine you take by mouth) Use of oral drug0 with drug2 may increase the chance of side effects affecting the blood and/or the side effects or oral drug0",False, 
DDI-DrugBank.d179.s37.e1,DDI-DrugBank.d179.s37.e2,"- drug0, oral (diabetes medicine you take by mouth) Use of oral drug1 with drug2 may increase the chance of side effects affecting the blood and/or the side effects or oral drug0",True,effect
DDI-DrugBank.d179.s38.e0,DDI-DrugBank.d179.s38.e1,"- drug1 (e.g., drug2) Use of drug0 with drug0 may increase the chance of side effects affecting the liver and/or the side effects of drug0",False, 
DDI-DrugBank.d179.s38.e0,DDI-DrugBank.d179.s38.e2,"- drug1 (e.g., drug0) Use of drug2 with drug0 may increase the chance of side effects affecting the liver and/or the side effects of drug0",False, 
DDI-DrugBank.d179.s38.e2,DDI-DrugBank.d179.s38.e3,"- drug0 (e.g., drug0) Use of drug1 with drug2 may increase the chance of side effects affecting the liver and/or the side effects of drug0",True,effect
DDI-DrugBank.d179.s39.e0,DDI-DrugBank.d179.s39.e1,"- drug1 (e.g., drug2) Use of drug0 with drug0",False, 
DDI-DrugBank.d179.s39.e0,DDI-DrugBank.d179.s39.e2,"- drug1 (e.g., drug0) Use of drug2 with drug0",False, 
DDI-DrugBank.d179.s39.e2,DDI-DrugBank.d179.s39.e3,"- drug0 (e.g., drug0) Use of drug1 with drug2",True,effect
DDI-DrugBank.d179.s40.e0,DDI-DrugBank.d179.s40.e1,"- drug1 (e.g., drug2) Use of drug0 with drug0 may increase the chance of side effects affecting the liver and/or the side effects of drug0",False, 
DDI-DrugBank.d179.s40.e0,DDI-DrugBank.d179.s40.e2,"- drug1 (e.g., drug0) Use of drug2 with drug0 may increase the chance of side effects affecting the liver and/or the side effects of drug0",False, 
DDI-DrugBank.d179.s40.e2,DDI-DrugBank.d179.s40.e3,"- drug0 (e.g., drug0) Use of drug1 with drug2 may increase the chance of side effects affecting the liver and/or the side effects of drug0",True,effect
DDI-DrugBank.d303.s0.e0,DDI-DrugBank.d303.s0.e1,"drug1: In healthy subjects given single 500 mg doses of drug2 and drug0, plasma drug0 mean cmax and AUC increased by an average of 34% and 24%, respectively, and drug0",False, 
DDI-DrugBank.d303.s0.e0,DDI-DrugBank.d303.s0.e2,"drug1: In healthy subjects given single 500 mg doses of drug0 and drug2, plasma drug0 mean cmax and AUC increased by an average of 34% and 24%, respectively, and drug0",False, 
DDI-DrugBank.d303.s0.e1,DDI-DrugBank.d303.s0.e2,"drug0: In healthy subjects given single 500 mg doses of drug1 and drug2, plasma drug0 mean cmax and AUC increased by an average of 34% and 24%, respectively, and drug0",True,mechanism
DDI-DrugBank.d303.s1.e0,DDI-DrugBank.d303.s1.e1,No information is available about the interaction of drug1 and drug2,False, 
DDI-DrugBank.d303.s2.e0,DDI-DrugBank.d303.s2.e1,"Although not observed in this study, adverse effects could potentially arise from co-administration of drug1 and drug2",True,mechanism
DDI-DrugBank.d303.s3.e0,DDI-DrugBank.d303.s3.e1,"Accordingly, careful patient monitoring and dose adjustment of drug1 is recommended in patients concomitantly taking drug2 and drug0",False, 
DDI-DrugBank.d303.s3.e0,DDI-DrugBank.d303.s3.e2,"Accordingly, careful patient monitoring and dose adjustment of drug1 is recommended in patients concomitantly taking drug0 and drug2",False, 
DDI-DrugBank.d303.s3.e1,DDI-DrugBank.d303.s3.e2,"Accordingly, careful patient monitoring and dose adjustment of drug0 is recommended in patients concomitantly taking drug1 and drug2",True,advise
DDI-DrugBank.d303.s4.e0,DDI-DrugBank.d303.s4.e1,"drug1: As with other drug2, the renal excretion of drug0 is inhibited by drug0",False, 
DDI-DrugBank.d303.s4.e0,DDI-DrugBank.d303.s4.e2,"drug1: As with other drug0, the renal excretion of drug2 is inhibited by drug0",False, 
DDI-DrugBank.d303.s4.e2,DDI-DrugBank.d303.s4.e3,"drug0: As with other drug0, the renal excretion of drug1 is inhibited by drug2",True,mechanism
DDI-DrugBank.d563.s0.e0,DDI-DrugBank.d563.s0.e1,Special consideration should be given to the administration of drug1 in patients receiving drug2,True,advise
DDI-DrugBank.d144.s0.e0,DDI-DrugBank.d144.s0.e1,Concomitant oral administration of drug1 (a known inhibitor of CYP3A4 activity in the liver and in the intestinal mucosa) caused an eight-fold increase of the systemic exposure to oral drug2,True,mechanism
DDI-DrugBank.d144.s1.e0,DDI-DrugBank.d144.s1.e1,"If treatment with inhibitors of CYP3A4 activity (such as drug1, drug2, drug0, drug0, drug0, drug0, etc.) is indicated, reduction of the drug0",False, 
DDI-DrugBank.d144.s1.e0,DDI-DrugBank.d144.s1.e2,"If treatment with inhibitors of CYP3A4 activity (such as drug1, drug0, drug2, drug0, drug0, drug0, etc.) is indicated, reduction of the drug0",False, 
DDI-DrugBank.d144.s1.e0,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug1, drug0, drug0, drug0, drug0, drug0, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d144.s1.e1,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug0, drug1, drug0, drug0, drug0, drug0, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d144.s1.e2,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug0, drug0, drug1, drug0, drug0, drug0, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d144.s1.e3,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug0, drug0, drug0, drug1, drug0, drug0, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d144.s1.e4,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug0, drug0, drug0, drug0, drug1, drug0, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d144.s1.e5,DDI-DrugBank.d144.s1.e6,"If treatment with inhibitors of CYP3A4 activity (such as drug0, drug0, drug0, drug0, drug0, drug1, etc.) is indicated, reduction of the drug2",True,advise
DDI-DrugBank.d261.s0.e0,DDI-DrugBank.d261.s0.e1,"drug1, a drug2, may antagonize the bactericidal effect of drug0",False, 
DDI-DrugBank.d261.s0.e0,DDI-DrugBank.d261.s0.e2,"drug1, a drug0, may antagonize the bactericidal effect of drug2",True,effect
DDI-DrugBank.d261.s0.e1,DDI-DrugBank.d261.s0.e2,"drug0, a drug1, may antagonize the bactericidal effect of drug2",False, 
DDI-DrugBank.d357.s0.e0,DDI-DrugBank.d357.s0.e1,"drug1: Based on reports of profound hypotension and loss of consciousness when drug2 was administered with drug0, the concomitant use of drug0 with drugs of the drug0 (including, for example, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d357.s0.e0,DDI-DrugBank.d357.s0.e2,"drug1: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug2, the concomitant use of drug0 with drugs of the drug0 (including, for example, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d357.s0.e1,DDI-DrugBank.d357.s0.e2,"drug0: Based on reports of profound hypotension and loss of consciousness when drug1 was administered with drug2, the concomitant use of drug0 with drugs of the drug0 (including, for example, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e4,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug2 (including, for example, drug0, drug0, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e5,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug0 (including, for example, drug2, drug0, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e6,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug0 (including, for example, drug0, drug2, drug0, drug0, and drug0",True,advise
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e7,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug0 (including, for example, drug0, drug0, drug2, drug0, and drug0",True,advise
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e8,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug0 (including, for example, drug0, drug0, drug0, drug2, and drug0",True,advise
DDI-DrugBank.d357.s0.e3,DDI-DrugBank.d357.s0.e9,"drug0: Based on reports of profound hypotension and loss of consciousness when drug0 was administered with drug0, the concomitant use of drug1 with drugs of the drug0 (including, for example, drug0, drug0, drug0, drug0, and drug2",True,advise
DDI-DrugBank.d357.s1.e0,DDI-DrugBank.d357.s1.e1,drug1s and drug2: The following adverse events were experienced more commonly in patients receiving concomitant drug0 or drug0,False, 
DDI-DrugBank.d357.s1.e0,DDI-DrugBank.d357.s1.e2,drug1s and drug0: The following adverse events were experienced more commonly in patients receiving concomitant drug2 or drug0,False, 
DDI-DrugBank.d357.s1.e2,DDI-DrugBank.d357.s1.e3,drug0s and drug0: The following adverse events were experienced more commonly in patients receiving concomitant drug1 or drug2,True,effect
DDI-DrugBank.d357.s3.e0,DDI-DrugBank.d357.s3.e1,"drug1: Since drug2 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug0",False, 
DDI-DrugBank.d357.s3.e0,DDI-DrugBank.d357.s3.e2,"drug1: Since drug0 is a drug2, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug0, may diminish the effectiveness of drug0",False, 
DDI-DrugBank.d357.s3.e3,DDI-DrugBank.d357.s3.e8,"drug0: Since drug0 is a drug0, it is possible that drug1, such as the drug0 (drug0, drug0, drug0) or drug2, may diminish the effectiveness of drug0",True,effect
DDI-DrugBank.d357.s3.e5,DDI-DrugBank.d357.s3.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug1, drug0, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d357.s3.e6,DDI-DrugBank.d357.s3.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug1, drug0) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d357.s3.e7,DDI-DrugBank.d357.s3.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug1) or drug0, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d357.s3.e8,DDI-DrugBank.d357.s3.e9,"drug0: Since drug0 is a drug0, it is possible that drug0, such as the drug0 (drug0, drug0, drug0) or drug1, may diminish the effectiveness of drug2",True,effect
DDI-DrugBank.d357.s4.e0,DDI-DrugBank.d357.s4.e1,"Patients with major psychotic disorders, treated with drug1, should be treated with drug2",True,advise
DDI-DrugBank.d186.s0.e0,DDI-DrugBank.d186.s0.e1,"An encephalopathic syndrome (characterized by weakness, lethargy, fever, tremulousness and confusion, extrapyramidal symptoms, leukocytosis, elevated serum enzymes, BUN, and FBS) followed by irreversible brain damage has occurred in a few patients treated with drug1 plus drug2",True,effect
DDI-DrugBank.d186.s1.e0,DDI-DrugBank.d186.s1.e1,A causal relationship between these events and the concomitant administration of drug1 and drug2,False, 
DDI-DrugBank.d186.s3.e0,DDI-DrugBank.d186.s3.e1,"As with other drug1, it should be noted that drug2 may be capable of potentiating drug0 such as drug0, drug0, and drug0",False, 
DDI-DrugBank.d186.s3.e0,DDI-DrugBank.d186.s3.e2,"As with other drug1, it should be noted that drug0 may be capable of potentiating drug2 such as drug0, drug0, and drug0",True,effect
DDI-DrugBank.d186.s3.e0,DDI-DrugBank.d186.s3.e3,"As with other drug1, it should be noted that drug0 may be capable of potentiating drug0 such as drug2, drug0, and drug0",True,effect
DDI-DrugBank.d186.s3.e0,DDI-DrugBank.d186.s3.e4,"As with other drug1, it should be noted that drug0 may be capable of potentiating drug0 such as drug0, drug2, and drug0",True,effect
DDI-DrugBank.d186.s3.e0,DDI-DrugBank.d186.s3.e5,"As with other drug1, it should be noted that drug0 may be capable of potentiating drug0 such as drug0, drug0, and drug2",True,effect
DDI-DrugBank.d186.s3.e1,DDI-DrugBank.d186.s3.e2,"As with other drug0, it should be noted that drug1 may be capable of potentiating drug2 such as drug0, drug0, and drug0",True,effect
DDI-DrugBank.d186.s3.e1,DDI-DrugBank.d186.s3.e3,"As with other drug0, it should be noted that drug1 may be capable of potentiating drug0 such as drug2, drug0, and drug0",True,effect
DDI-DrugBank.d186.s3.e1,DDI-DrugBank.d186.s3.e4,"As with other drug0, it should be noted that drug1 may be capable of potentiating drug0 such as drug0, drug2, and drug0",True,effect
DDI-DrugBank.d186.s3.e1,DDI-DrugBank.d186.s3.e5,"As with other drug0, it should be noted that drug1 may be capable of potentiating drug0 such as drug0, drug0, and drug2",True,effect
DDI-DrugBank.d186.s3.e2,DDI-DrugBank.d186.s3.e3,"As with other drug0, it should be noted that drug0 may be capable of potentiating drug1 such as drug2, drug0, and drug0",False, 
DDI-DrugBank.d186.s4.e0,DDI-DrugBank.d186.s4.e1,"In a study of 12 schizophrenic patients coadministered oral drug1 and drug2, plasma drug0",True,mechanism
DDI-DrugBank.d186.s4.e0,DDI-DrugBank.d186.s4.e2,"In a study of 12 schizophrenic patients coadministered oral drug1 and drug0, plasma drug2",False, 
DDI-DrugBank.d186.s4.e1,DDI-DrugBank.d186.s4.e2,"In a study of 12 schizophrenic patients coadministered oral drug0 and drug1, plasma drug2",False, 
DDI-DrugBank.d186.s5.e0,DDI-DrugBank.d186.s5.e1,"In 5 other schizophrenic patients treated with oral drug1 and drug2, discontinuation of drug0 produced a mean 3.3-fold increase in drug0",False, 
DDI-DrugBank.d186.s5.e0,DDI-DrugBank.d186.s5.e2,"In 5 other schizophrenic patients treated with oral drug1 and drug0, discontinuation of drug2 produced a mean 3.3-fold increase in drug0",False, 
DDI-DrugBank.d186.s5.e2,DDI-DrugBank.d186.s5.e3,"In 5 other schizophrenic patients treated with oral drug0 and drug0, discontinuation of drug1 produced a mean 3.3-fold increase in drug2",True,mechanism
DDI-DrugBank.d186.s6.e0,DDI-DrugBank.d186.s6.e1,"Thus, careful monitoring of clinical status is warranted when drug1 is administered or discontinued in drug2",True,advise
DDI-DrugBank.d536.s1.e0,DDI-DrugBank.d536.s1.e1,"These drugs include the drug1 and other drug2, drug0, drug0, drug0, drug0, oral drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d536.s1.e0,DDI-DrugBank.d536.s1.e2,"These drugs include the drug1 and other drug0, drug2, drug0, drug0, drug0, oral drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d536.s3.e0,DDI-DrugBank.d536.s3.e1,When such drugs are withdrawn from patients receiving drug1 in combination with drug2 or drug0,False, 
DDI-DrugBank.d536.s3.e0,DDI-DrugBank.d536.s3.e2,When such drugs are withdrawn from patients receiving drug1 in combination with drug0 or drug2,False, 
DDI-DrugBank.d536.s4.e0,DDI-DrugBank.d536.s4.e1,"drug1 (e. g., drug2) and drug0 containing carbohydrate-splitting enzymes (e. g., drug0, drug0) may reduce the effect of drug0",False, 
DDI-DrugBank.d536.s4.e0,DDI-DrugBank.d536.s4.e2,"drug1 (e. g., drug0) and drug2 containing carbohydrate-splitting enzymes (e. g., drug0, drug0) may reduce the effect of drug0",False, 
DDI-DrugBank.d536.s4.e0,DDI-DrugBank.d536.s4.e5,"drug1 (e. g., drug0) and drug0 containing carbohydrate-splitting enzymes (e. g., drug0, drug0) may reduce the effect of drug2",True,mechanism
DDI-DrugBank.d536.s4.e1,DDI-DrugBank.d536.s4.e5,"drug0 (e. g., drug1) and drug0 containing carbohydrate-splitting enzymes (e. g., drug0, drug0) may reduce the effect of drug2",True,mechanism
DDI-DrugBank.d536.s4.e3,DDI-DrugBank.d536.s4.e5,"drug0 (e. g., drug0) and drug0 containing carbohydrate-splitting enzymes (e. g., drug1, drug0) may reduce the effect of drug2",True,mechanism
DDI-DrugBank.d536.s4.e4,DDI-DrugBank.d536.s4.e5,"drug0 (e. g., drug0) and drug0 containing carbohydrate-splitting enzymes (e. g., drug0, drug1) may reduce the effect of drug2",True,mechanism
DDI-DrugBank.d536.s5.e0,DDI-DrugBank.d536.s5.e1,"drug1 has been shown to change the bioavailabillty drug2 when they are co-administered, which may require drug0",True,mechanism
DDI-DrugBank.d536.s5.e0,DDI-DrugBank.d536.s5.e2,"drug1 has been shown to change the bioavailabillty drug0 when they are co-administered, which may require drug2",False, 
DDI-DrugBank.d536.s5.e1,DDI-DrugBank.d536.s5.e2,"drug0 has been shown to change the bioavailabillty drug1 when they are co-administered, which may require drug2",False, 
DDI-DrugBank.d536.s6.e0,DDI-DrugBank.d536.s6.e1,"Studies in healthy volunteers have shown that drug1 has no effect on either the pharmacokinetics or pharmacodynamics of drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d536.s6.e0,DDI-DrugBank.d536.s6.e2,"Studies in healthy volunteers have shown that drug1 has no effect on either the pharmacokinetics or pharmacodynamics of drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d536.s7.e0,DDI-DrugBank.d536.s7.e1,drug1 did not interfere with the absorption or disposition of the drug2 drug0,False, 
DDI-DrugBank.d536.s7.e0,DDI-DrugBank.d536.s7.e2,drug1 did not interfere with the absorption or disposition of the drug0 drug2,False, 
DDI-DrugBank.d536.s8.e0,DDI-DrugBank.d536.s8.e1,"drug1 may affect drug2 bioavailabillty and may require dose adjustment of drug0 by 16% (90% confidence interval: 8-23%), decrease mean C max drug0 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of drug0",False, 
DDI-DrugBank.d536.s8.e0,DDI-DrugBank.d536.s8.e2,"drug1 may affect drug0 bioavailabillty and may require dose adjustment of drug2 by 16% (90% confidence interval: 8-23%), decrease mean C max drug0 by 26% (90% confidence interval: 16-34%) and decrease mean trough concentrations of drug0",False, 
DDI-DrugBank.d536.s9.e0,DDI-DrugBank.d536.s9.e1,The amount of drug1 absorbed while taking drug2,False, 
DDI-DrugBank.d536.s10.e0,DDI-DrugBank.d536.s10.e1,"However, the peak plasma level of drug1 was reduced by approximately 20% when taking drug2 due to a slight delay in the absorption of drug0",True,mechanism
DDI-DrugBank.d536.s10.e0,DDI-DrugBank.d536.s10.e2,"However, the peak plasma level of drug1 was reduced by approximately 20% when taking drug0 due to a slight delay in the absorption of drug2",False, 
DDI-DrugBank.d536.s10.e1,DDI-DrugBank.d536.s10.e2,"However, the peak plasma level of drug0 was reduced by approximately 20% when taking drug1 due to a slight delay in the absorption of drug2",True,mechanism
DDI-DrugBank.d536.s11.e0,DDI-DrugBank.d536.s11.e1,There is little if any clinically significant interaction between drug1 and drug2,False, 
DDI-DrugBank.d200.s0.e0,DDI-DrugBank.d200.s0.e1,Co-administration of drug1 with drug2,True,mechanism
DDI-DrugBank.d543.s0.e0,DDI-DrugBank.d543.s0.e1,"The following agents may increase certain actions or side effects of drug1. drug2 drug0 of class (e.g. drug0), drug0 drug0 (e.g. drug0), drug0",False, 
DDI-DrugBank.d543.s0.e0,DDI-DrugBank.d543.s0.e2,"The following agents may increase certain actions or side effects of drug1. drug0 drug2 of class (e.g. drug0), drug0 drug0 (e.g. drug0), drug0",False, 
DDI-DrugBank.d543.s1.e0,DDI-DrugBank.d543.s1.e1,"drug1, drug2 (e.g., drug0), drug0 and drug0, drug0, drug0",False, 
DDI-DrugBank.d543.s1.e0,DDI-DrugBank.d543.s1.e2,"drug1, drug0 (e.g., drug2), drug0 and drug0, drug0, drug0",False, 
DDI-DrugBank.d543.s2.e0,DDI-DrugBank.d543.s2.e1,drug1 antagonize the effects of drug2,False, 
DDI-DrugBank.d543.s4.e0,DDI-DrugBank.d543.s4.e1,"drug1 may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of drug2",True,mechanism
DDI-DrugBank.d543.s6.e0,DDI-DrugBank.d543.s6.e1,"drug1 may antagonize the effects of the drugs that alter gastrointestinal motility, such as drug2",True,mechanism
DDI-DrugBank.d543.s7.e0,DDI-DrugBank.d543.s7.e1,Because drug1 may interfere with the absorption of drug2,True,mechanism
DDI-DrugBank.d399.s0.e0,DDI-DrugBank.d399.s0.e1,Preliminary data which suggest that drug1 may inhibit the anti-inflammatory activity of drug2,True,effect
DDI-DrugBank.d399.s1.e0,DDI-DrugBank.d399.s1.e1,If leprosy-associated inflammatory reactions develop in patients being treated with drug1 and drug2,True,advise
DDI-DrugBank.d397.s0.e0,DDI-DrugBank.d397.s0.e1,drug1 use in patients who are receiving high doses of drug2 may be associated with an increase in serum drug0 levels and potential drug0,True,effect
DDI-DrugBank.d397.s0.e0,DDI-DrugBank.d397.s0.e2,drug1 use in patients who are receiving high doses of drug0 may be associated with an increase in serum drug2 levels and potential drug0,False, 
DDI-DrugBank.d397.s0.e0,DDI-DrugBank.d397.s0.e3,drug1 use in patients who are receiving high doses of drug0 may be associated with an increase in serum drug0 levels and potential drug2,False, 
DDI-DrugBank.d397.s1.e0,DDI-DrugBank.d397.s1.e1,"In case of drug1 toxicity and/or elevated serum drug2 levels, the dose of drug0 should be reduced while the patient is receiving concomitant drug0",False, 
DDI-DrugBank.d397.s1.e0,DDI-DrugBank.d397.s1.e2,"In case of drug1 toxicity and/or elevated serum drug0 levels, the dose of drug2 should be reduced while the patient is receiving concomitant drug0",False, 
DDI-DrugBank.d397.s1.e2,DDI-DrugBank.d397.s1.e3,"In case of drug0 toxicity and/or elevated serum drug0 levels, the dose of drug1 should be reduced while the patient is receiving concomitant drug2",True,advise
DDI-DrugBank.d397.s2.e0,DDI-DrugBank.d397.s2.e1,Concomitant administration of drug1 and drug2 has been reported to result in elevated drug0,True,mechanism
DDI-DrugBank.d397.s2.e0,DDI-DrugBank.d397.s2.e2,Concomitant administration of drug1 and drug0 has been reported to result in elevated drug2,False, 
DDI-DrugBank.d397.s2.e1,DDI-DrugBank.d397.s2.e2,Concomitant administration of drug0 and drug1 has been reported to result in elevated drug2,False, 
DDI-DrugBank.d397.s3.e0,DDI-DrugBank.d397.s3.e1,There have been reports of increased anticoagulant effects when drug1 and oral drug2,True,effect
DDI-DrugBank.d397.s5.e0,DDI-DrugBank.d397.s5.e1,Concurrent use of drug1 and drug2 or drug0,True,effect
DDI-DrugBank.d397.s5.e0,DDI-DrugBank.d397.s5.e2,Concurrent use of drug1 and drug0 or drug2,True,effect
DDI-DrugBank.d397.s5.e1,DDI-DrugBank.d397.s5.e2,Concurrent use of drug0 and drug1 or drug2,False, 
DDI-DrugBank.d397.s6.e0,DDI-DrugBank.d397.s6.e1,drug1 has been reported to decrease the clearance of drug2 and drug0 and thus may increase the pharmacologic effect of these drug0,True,mechanism
DDI-DrugBank.d397.s6.e0,DDI-DrugBank.d397.s6.e2,drug1 has been reported to decrease the clearance of drug0 and drug2 and thus may increase the pharmacologic effect of these drug0,True,mechanism
DDI-DrugBank.d397.s6.e0,DDI-DrugBank.d397.s6.e3,drug1 has been reported to decrease the clearance of drug0 and drug0 and thus may increase the pharmacologic effect of these drug2,True,effect
DDI-DrugBank.d397.s6.e1,DDI-DrugBank.d397.s6.e2,drug0 has been reported to decrease the clearance of drug1 and drug2 and thus may increase the pharmacologic effect of these drug0,False, 
DDI-DrugBank.d397.s6.e1,DDI-DrugBank.d397.s6.e3,drug0 has been reported to decrease the clearance of drug1 and drug0 and thus may increase the pharmacologic effect of these drug2,False, 
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e1,"There have been reports of interactions of drug1 with drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e2,"There have been reports of interactions of drug1 with drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e3,"There have been reports of interactions of drug1 with drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e4,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e5,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e6,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e7,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e8,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e9,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e10,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e11,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e12,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,int
DDI-DrugBank.d397.s8.e0,DDI-DrugBank.d397.s8.e13,"There have been reports of interactions of drug1 with drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,int
DDI-DrugBank.d397.s8.e1,DDI-DrugBank.d397.s8.e2,"There have been reports of interactions of drug0 with drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d397.s8.e1,DDI-DrugBank.d397.s8.e3,"There have been reports of interactions of drug0 with drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d397.s10.e0,DDI-DrugBank.d397.s10.e1,drug1 has been reported to significantly alter the metabolism of nonsedating drug2 drug0 and drug0,False, 
DDI-DrugBank.d397.s10.e0,DDI-DrugBank.d397.s10.e2,drug1 has been reported to significantly alter the metabolism of nonsedating drug0 drug2 and drug0,True,mechanism
DDI-DrugBank.d397.s10.e0,DDI-DrugBank.d397.s10.e3,drug1 has been reported to significantly alter the metabolism of nonsedating drug0 drug0 and drug2,True,mechanism
DDI-DrugBank.d397.s10.e1,DDI-DrugBank.d397.s10.e2,drug0 has been reported to significantly alter the metabolism of nonsedating drug1 drug2 and drug0,False, 
DDI-DrugBank.d397.s12.e0,DDI-DrugBank.d397.s12.e1,"In addition, deaths have been reported rarely with concomitant administration of drug1 and drug2",True,effect
DDI-DrugBank.d397.s13.e0,DDI-DrugBank.d397.s13.e1,"There have been postmarketing reports of drug interactions when drug1 is coadministered with drug2, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of drug0 by drug0",True,effect
DDI-DrugBank.d397.s13.e0,DDI-DrugBank.d397.s13.e2,"There have been postmarketing reports of drug interactions when drug1 is coadministered with drug0, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of drug2 by drug0",False, 
DDI-DrugBank.d397.s13.e0,DDI-DrugBank.d397.s13.e3,"There have been postmarketing reports of drug interactions when drug1 is coadministered with drug0, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of drug0 by drug2",False, 
DDI-DrugBank.d397.s13.e2,DDI-DrugBank.d397.s13.e3,"There have been postmarketing reports of drug interactions when drug0 is coadministered with drug0, resulting in QT prolongation, cardiac arrythmias, ventricular tachycardia, ventricular fibrulation, and torsades de pointes, most like due to inhibition of hepatic metabolism of drug1 by drug2",True,mechanism
DDI-DrugBank.d397.s15.e0,DDI-DrugBank.d397.s15.e1,Patients receiving concomitant drug1 and drug2,True,advise
DDI-DrugBank.d516.s0.e0,DDI-DrugBank.d516.s0.e1,"drug1: In three pharmacokinetic studies including 46 normal, healthy subjects, drug2 clearance and concentration were not significantly altered by the addition of drug0",False, 
DDI-DrugBank.d516.s0.e0,DDI-DrugBank.d516.s0.e2,"drug1: In three pharmacokinetic studies including 46 normal, healthy subjects, drug0 clearance and concentration were not significantly altered by the addition of drug2",False, 
DDI-DrugBank.d516.s1.e0,DDI-DrugBank.d516.s1.e1,"In clinical studies where patients were on chronic drug1 therapy, drug2 had no measurable effect on the mean distribution of drug0 concentrations or the mean estimates of drug0",False, 
DDI-DrugBank.d516.s1.e0,DDI-DrugBank.d516.s1.e2,"In clinical studies where patients were on chronic drug1 therapy, drug0 had no measurable effect on the mean distribution of drug2 concentrations or the mean estimates of drug0",False, 
DDI-DrugBank.d516.s3.e0,DDI-DrugBank.d516.s3.e1,"drug1 and drug2: drug0 and drug0 containing drug0 or drug0, as well as formulations containing divalent and trivalent cations such as drug0  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug0",False, 
DDI-DrugBank.d516.s3.e0,DDI-DrugBank.d516.s3.e2,"drug1 and drug0: drug2 and drug0 containing drug0 or drug0, as well as formulations containing divalent and trivalent cations such as drug0  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug0",False, 
DDI-DrugBank.d516.s3.e2,DDI-DrugBank.d516.s3.e8,"drug0 and drug0: drug1 and drug0 containing drug0 or drug0, as well as formulations containing divalent and trivalent cations such as drug0  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug2",True,mechanism
DDI-DrugBank.d516.s3.e4,DDI-DrugBank.d516.s3.e8,"drug0 and drug0: drug0 and drug0 containing drug1 or drug0, as well as formulations containing divalent and trivalent cations such as drug0  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug2",True,mechanism
DDI-DrugBank.d516.s3.e5,DDI-DrugBank.d516.s3.e8,"drug0 and drug0: drug0 and drug0 containing drug0 or drug1, as well as formulations containing divalent and trivalent cations such as drug0  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug2",True,mechanism
DDI-DrugBank.d516.s3.e6,DDI-DrugBank.d516.s3.e8,"drug0 and drug0: drug0 and drug0 containing drug0 or drug0, as well as formulations containing divalent and trivalent cations such as drug1  (drug0), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug2",True,mechanism
DDI-DrugBank.d516.s3.e7,DDI-DrugBank.d516.s3.e8,"drug0 and drug0: drug0 and drug0 containing drug0 or drug0, as well as formulations containing divalent and trivalent cations such as drug0  (drug1), chewable/buffered tablets or the pediatric powder for oral solution can form chelation complexes with drug2",True,mechanism
DDI-DrugBank.d516.s4.e0,DDI-DrugBank.d516.s4.e1,drug1 administered 2 hours before drug2,True,mechanism
DDI-DrugBank.d516.s5.e0,DDI-DrugBank.d516.s5.e1,"drug1- and drug2-containing drug0, administered concomitantly with drug0, significantly decreased the bioavailability (48%) of drug0",False, 
DDI-DrugBank.d516.s5.e0,DDI-DrugBank.d516.s5.e2,"drug1- and drug0-containing drug2, administered concomitantly with drug0, significantly decreased the bioavailability (48%) of drug0",False, 
DDI-DrugBank.d516.s5.e0,DDI-DrugBank.d516.s5.e3,"drug1- and drug0-containing drug0, administered concomitantly with drug2, significantly decreased the bioavailability (48%) of drug0",True,mechanism
DDI-DrugBank.d516.s5.e1,DDI-DrugBank.d516.s5.e3,"drug0- and drug1-containing drug0, administered concomitantly with drug2, significantly decreased the bioavailability (48%) of drug0",True,mechanism
DDI-DrugBank.d516.s5.e2,DDI-DrugBank.d516.s5.e3,"drug0- and drug0-containing drug1, administered concomitantly with drug2, significantly decreased the bioavailability (48%) of drug0",True,mechanism
DDI-DrugBank.d516.s6.e0,DDI-DrugBank.d516.s6.e1,Separating the doses of drug1 and drug2,True,mechanism
DDI-DrugBank.d516.s7.e0,DDI-DrugBank.d516.s7.e1,"therefore, administration of these agents should precede drug1 dosing by 4 hours or follow drug2",False, 
DDI-DrugBank.d516.s8.e0,DDI-DrugBank.d516.s8.e1,"drug1: Two hundred mg of drug2 (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of drug0",False, 
DDI-DrugBank.d516.s8.e0,DDI-DrugBank.d516.s8.e2,"drug1: Two hundred mg of drug0 (equivalent to 1 to 3 cups of American coffee) was administered to 16 normal, healthy volunteers who had achieved steady-state blood concentrations of drug2",False, 
DDI-DrugBank.d516.s9.e0,DDI-DrugBank.d516.s9.e1,"This did not result in any statistically or clinically relevant changes in the pharmacokinetic parameters of either drug1 or its major metabolite, drug2",False, 
DDI-DrugBank.d516.s11.e0,DDI-DrugBank.d516.s11.e1,"Other drug1 have demonstrated moderate to marked interference with the metabolism of drug2, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of drug0",True,mechanism
DDI-DrugBank.d516.s11.e0,DDI-DrugBank.d516.s11.e2,"Other drug1 have demonstrated moderate to marked interference with the metabolism of drug0, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of drug2",False, 
DDI-DrugBank.d516.s11.e1,DDI-DrugBank.d516.s11.e2,"Other drug0 have demonstrated moderate to marked interference with the metabolism of drug1, resulting in a reduced clearance, a prolongation of plasma half-life, and an increase in symptoms that accompany high levels of drug2",False, 
DDI-DrugBank.d516.s12.e0,DDI-DrugBank.d516.s12.e1,drug1: drug2 has been demonstrated to interfere with the elimination of other drug0,False, 
DDI-DrugBank.d516.s12.e0,DDI-DrugBank.d516.s12.e2,drug1: drug0 has been demonstrated to interfere with the elimination of other drug2,False, 
DDI-DrugBank.d516.s12.e1,DDI-DrugBank.d516.s12.e2,drug0: drug1 has been demonstrated to interfere with the elimination of other drug2,True,mechanism
DDI-DrugBank.d516.s14.e0,DDI-DrugBank.d516.s14.e1,The interaction between drug1 and drug2,False, 
DDI-DrugBank.d516.s15.e0,DDI-DrugBank.d516.s15.e1,drug1: Elevated serum levels of drug2 have been reported with concomitant use of drug0 with other members of the drug0,False, 
DDI-DrugBank.d516.s15.e0,DDI-DrugBank.d516.s15.e2,drug1: Elevated serum levels of drug0 have been reported with concomitant use of drug2 with other members of the drug0,False, 
DDI-DrugBank.d516.s15.e2,DDI-DrugBank.d516.s15.e3,drug0: Elevated serum levels of drug0 have been reported with concomitant use of drug1 with other members of the drug2,True,mechanism
DDI-DrugBank.d516.s16.e0,DDI-DrugBank.d516.s16.e1,Interaction between drug1 and drug2,False, 
DDI-DrugBank.d516.s17.e0,DDI-DrugBank.d516.s17.e1,"drug1: No clinically significant changes in drug2 pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of drug0 400 mg was given after multiple doses of drug0",False, 
DDI-DrugBank.d516.s17.e0,DDI-DrugBank.d516.s17.e2,"drug1: No clinically significant changes in drug0 pharmacokinetics (AUC, C max , or T max ) were observed when a single dose of drug2 400 mg was given after multiple doses of drug0",False, 
DDI-DrugBank.d516.s19.e0,DDI-DrugBank.d516.s19.e1,"drug1: No significant differences were observed in mean drug2 AUC, C max , C min or T max (although C max increased by 11%) when extended drug0 capsules (100 mg tid) were coadministered with drug0",False, 
DDI-DrugBank.d516.s19.e0,DDI-DrugBank.d516.s19.e2,"drug1: No significant differences were observed in mean drug0 AUC, C max , C min or T max (although C max increased by 11%) when extended drug2 capsules (100 mg tid) were coadministered with drug0",False, 
DDI-DrugBank.d516.s20.e0,DDI-DrugBank.d516.s20.e1,drug1 is unlikely to have a significant effect on drug2,False, 
DDI-DrugBank.d516.s21.e0,DDI-DrugBank.d516.s21.e1,drug1: drug2,False, 
DDI-DrugBank.d516.s23.e0,DDI-DrugBank.d516.s23.e1,"drug1: No clinically significant changes occurred in heart rate or corrected QT intervals, or in drug2 metabolite or drug0 pharmacokinetics, during concurrent administration of drug0 and drug0",False, 
DDI-DrugBank.d516.s23.e0,DDI-DrugBank.d516.s23.e2,"drug1: No clinically significant changes occurred in heart rate or corrected QT intervals, or in drug0 metabolite or drug2 pharmacokinetics, during concurrent administration of drug0 and drug0",False, 
DDI-DrugBank.d516.s24.e0,DDI-DrugBank.d516.s24.e1,"drug1: drug2 may enhance the effects of the oral drug0, drug0",False, 
DDI-DrugBank.d516.s24.e0,DDI-DrugBank.d516.s24.e2,"drug1: drug0 may enhance the effects of the oral drug2, drug0",False, 
DDI-DrugBank.d516.s24.e1,DDI-DrugBank.d516.s24.e2,"drug0: drug1 may enhance the effects of the oral drug2, drug0",True,effect
DDI-DrugBank.d516.s24.e1,DDI-DrugBank.d516.s24.e3,"drug0: drug1 may enhance the effects of the oral drug0, drug2",True,effect
DDI-DrugBank.d516.s26.e0,DDI-DrugBank.d516.s26.e1,"However, no clinically or statistically significant differences in prothrombin time ratio or drug1 enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both drug2 and drug0",False, 
DDI-DrugBank.d516.s26.e0,DDI-DrugBank.d516.s26.e2,"However, no clinically or statistically significant differences in prothrombin time ratio or drug1 enantiomer pharmacokinetics were observed in a small study of 7 healthy males who received both drug0 and drug2",False, 
DDI-DrugBank.d474.s1.e0,DDI-DrugBank.d474.s1.e1,"These agents include medications such as: drug1, drug2 including drug0, sali-cylates, drug0 (including drug0), drug0, or drug0",False, 
DDI-DrugBank.d474.s1.e0,DDI-DrugBank.d474.s1.e2,"These agents include medications such as: drug1, drug0 including drug2, sali-cylates, drug0 (including drug0), drug0, or drug0",False, 
DDI-DrugBank.d71.s3.e0,DDI-DrugBank.d71.s3.e1,There is no information regarding the effect on drug1 pharmacokinetics of higher doses of drug2/drug0,False, 
DDI-DrugBank.d71.s3.e0,DDI-DrugBank.d71.s3.e2,There is no information regarding the effect on drug1 pharmacokinetics of higher doses of drug0/drug2,False, 
DDI-DrugBank.d71.s5.e0,DDI-DrugBank.d71.s5.e1,drug1 and drug2,True,effect
DDI-DrugBank.d71.s6.e0,DDI-DrugBank.d71.s6.e1,"Therefore, use of drug1 in combination with drug2",True,advise
DDI-DrugBank.d234.s0.e0,DDI-DrugBank.d234.s0.e1,Interaction with drug1 other than drug2,False, 
DDI-DrugBank.d234.s1.e0,DDI-DrugBank.d234.s1.e1,"however, no deleterious interactions were seen when drug1 was administered after drug2, inhalational drug0, drug0",False, 
DDI-DrugBank.d234.s1.e0,DDI-DrugBank.d234.s1.e2,"however, no deleterious interactions were seen when drug1 was administered after drug0, inhalational drug2, drug0",False, 
DDI-DrugBank.d234.s2.e0,DDI-DrugBank.d234.s2.e1,Particular caution is necessary when using drug1 in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially drug2) may emerge with the reversal of the drug0 effect by drug0,True,effect
DDI-DrugBank.d234.s2.e0,DDI-DrugBank.d234.s2.e2,Particular caution is necessary when using drug1 in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially drug0) may emerge with the reversal of the drug2 effect by drug0,False, 
DDI-DrugBank.d234.s2.e0,DDI-DrugBank.d234.s2.e3,Particular caution is necessary when using drug1 in cases of mixed drug overdosage since the toxic effects (such as convulsions and cardiac dysrhythmias) of other drugs taken in overdose (especially drug0) may emerge with the reversal of the drug0 effect by drug2,False, 
DDI-DrugBank.d234.s4.e0,DDI-DrugBank.d234.s4.e1,"Although drug1 exerts a slight intrinsic anticonvulsant effect, its abrupt suppression of the protective effect of a drug2",True,effect
DDI-DrugBank.d234.s5.e0,DDI-DrugBank.d234.s5.e1,drug1 blocks the central effects of drug2,True,effect
DDI-DrugBank.d234.s6.e0,DDI-DrugBank.d234.s6.e1,"The effects of nonbenzodiazepine agonists at benzodiazepine receptors, such as drug1, triazolopyridazines and others, are also blocked by drug2",True,effect
DDI-DrugBank.d234.s7.e0,DDI-DrugBank.d234.s7.e1,The pharmacokinetics of drug1 are unaltered in the presence of drug2,False, 
DDI-DrugBank.d234.s8.e0,DDI-DrugBank.d234.s8.e1,There is no pharmacokinetic interaction between drug1 and drug2,False, 
DDI-DrugBank.d234.s9.e0,DDI-DrugBank.d234.s9.e1,Use in Ambulatory Patients The effects of drug1 may wear off before a drug2,False, 
DDI-DrugBank.d234.s11.e0,DDI-DrugBank.d234.s11.e1,An adequate period of observation must be provided for any patient in whom either drug1 (such as drug2) or large doses of drug0 (such as  10 mg of drug0,False, 
DDI-DrugBank.d234.s11.e0,DDI-DrugBank.d234.s11.e2,An adequate period of observation must be provided for any patient in whom either drug1 (such as drug0) or large doses of drug2 (such as  10 mg of drug0,False, 
DDI-DrugBank.d234.s12.e0,DDI-DrugBank.d234.s12.e1,"Because of the increased risk of adverse reactions in patients who have been taking drug1 on a regular basis, it is particularly important that physicians query patients or their guardians carefully about drug2, drug0 and drug0 use as part of the history prior to any procedure in which the use of drug0",False, 
DDI-DrugBank.d234.s12.e0,DDI-DrugBank.d234.s12.e2,"Because of the increased risk of adverse reactions in patients who have been taking drug1 on a regular basis, it is particularly important that physicians query patients or their guardians carefully about drug0, drug2 and drug0 use as part of the history prior to any procedure in which the use of drug0",False, 
DDI-DrugBank.d113.s0.e0,DDI-DrugBank.d113.s0.e1,drug1: drug2 enhances the effect of drug0,True,effect
DDI-DrugBank.d113.s0.e0,DDI-DrugBank.d113.s0.e2,drug1: drug0 enhances the effect of drug2,False, 
DDI-DrugBank.d113.s0.e1,DDI-DrugBank.d113.s0.e2,drug0: drug1 enhances the effect of drug2,False, 
DDI-DrugBank.d113.s1.e0,DDI-DrugBank.d113.s1.e1,"Therefore, when drug1 is given to a patient receiving drug2, the dosage of drug0",True,advise
DDI-DrugBank.d113.s1.e0,DDI-DrugBank.d113.s1.e2,"Therefore, when drug1 is given to a patient receiving drug0, the dosage of drug2",False, 
DDI-DrugBank.d113.s1.e1,DDI-DrugBank.d113.s1.e2,"Therefore, when drug0 is given to a patient receiving drug1, the dosage of drug2",False, 
DDI-DrugBank.d113.s2.e0,DDI-DrugBank.d113.s2.e1,drug1: Concurrent administration of drug2 may lower drug0,False, 
DDI-DrugBank.d113.s2.e0,DDI-DrugBank.d113.s2.e2,drug1: Concurrent administration of drug0 may lower drug2,False, 
DDI-DrugBank.d113.s2.e1,DDI-DrugBank.d113.s2.e2,drug0: Concurrent administration of drug1 may lower drug2,True,mechanism
DDI-DrugBank.d113.s3.e0,DDI-DrugBank.d113.s3.e1,"The urinary excretion of drug1 is unaffected by drug2, indicating no change in drug0",False, 
DDI-DrugBank.d113.s3.e0,DDI-DrugBank.d113.s3.e2,"The urinary excretion of drug1 is unaffected by drug0, indicating no change in drug2",False, 
DDI-DrugBank.d113.s4.e0,DDI-DrugBank.d113.s4.e1,drug1 does not affect serum drug2,False, 
DDI-DrugBank.d113.s6.e0,DDI-DrugBank.d113.s6.e1,drug1: The concurrent administration of drug2 does not affect the bioavailability of drug0,False, 
DDI-DrugBank.d113.s6.e0,DDI-DrugBank.d113.s6.e2,drug1: The concurrent administration of drug0 does not affect the bioavailability of drug2,False, 
DDI-DrugBank.d113.s7.e0,DDI-DrugBank.d113.s7.e1,drug1: Concomitant administration of drug2 and drug0s does not interfere with absorption of drug0,False, 
DDI-DrugBank.d113.s7.e0,DDI-DrugBank.d113.s7.e2,drug1: Concomitant administration of drug0 and drug2s does not interfere with absorption of drug0,False, 
DDI-DrugBank.d561.s0.e0,DDI-DrugBank.d561.s0.e1,"drug1: Patients on drug2, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug0",False, 
DDI-DrugBank.d561.s0.e0,DDI-DrugBank.d561.s0.e2,"drug1: Patients on drug0, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2",False, 
DDI-DrugBank.d561.s0.e1,DDI-DrugBank.d561.s0.e2,"drug0: Patients on drug1, especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2",True,effect
DDI-DrugBank.d561.s1.e0,DDI-DrugBank.d561.s1.e1,The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug2 or increasing the salt intake prior to initiation of treatment with drug0,False, 
DDI-DrugBank.d561.s1.e0,DDI-DrugBank.d561.s1.e2,The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug0 or increasing the salt intake prior to initiation of treatment with drug2,False, 
DDI-DrugBank.d561.s1.e1,DDI-DrugBank.d561.s1.e2,The possibility of hypotensive effects with drug0 can be minimized by either discontinuing the drug1 or increasing the salt intake prior to initiation of treatment with drug2,True,advise
DDI-DrugBank.d561.s3.e0,DDI-DrugBank.d561.s3.e1,drug1 Supplements and drug2 Lotensin can attenuate potassium loss caused by drug0,False, 
DDI-DrugBank.d561.s3.e0,DDI-DrugBank.d561.s3.e2,drug1 Supplements and drug0 Lotensin can attenuate potassium loss caused by drug2,False, 
DDI-DrugBank.d561.s3.e1,DDI-DrugBank.d561.s3.e2,drug0 Supplements and drug1 Lotensin can attenuate potassium loss caused by drug2,True,effect
DDI-DrugBank.d561.s4.e0,DDI-DrugBank.d561.s4.e1,"drug1 (drug2, drug0, drug0, and others) or drug0",False, 
DDI-DrugBank.d561.s4.e0,DDI-DrugBank.d561.s4.e2,"drug1 (drug0, drug2, drug0, and others) or drug0",False, 
DDI-DrugBank.d561.s6.e0,DDI-DrugBank.d561.s6.e1,Oral drug1 Interaction studies with drug2 and drug0 failed to identify any clinically important effects on the serum concentrations or clinical effects of these drug0,False, 
DDI-DrugBank.d561.s6.e0,DDI-DrugBank.d561.s6.e2,Oral drug1 Interaction studies with drug0 and drug2 failed to identify any clinically important effects on the serum concentrations or clinical effects of these drug0,False, 
DDI-DrugBank.d561.s7.e0,DDI-DrugBank.d561.s7.e1,drug1: Increased serum drug2 levels and symptoms of drug0 toxicity have been reported in patients receiving drug0 during therapy with drug0,False, 
DDI-DrugBank.d561.s7.e0,DDI-DrugBank.d561.s7.e2,drug1: Increased serum drug0 levels and symptoms of drug2 toxicity have been reported in patients receiving drug0 during therapy with drug0,False, 
DDI-DrugBank.d561.s7.e3,DDI-DrugBank.d561.s7.e4,drug0: Increased serum drug0 levels and symptoms of drug0 toxicity have been reported in patients receiving drug1 during therapy with drug2,True,mechanism
DDI-DrugBank.d561.s9.e0,DDI-DrugBank.d561.s9.e1,"If a drug1 is also used, the risk of drug2",True,effect
DDI-DrugBank.d561.s10.e0,DDI-DrugBank.d561.s10.e1,"Other No clinically important pharmacokinetic interactions occurred when drug1 was administered concomitantly with drug2, drug0, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d561.s10.e0,DDI-DrugBank.d561.s10.e2,"Other No clinically important pharmacokinetic interactions occurred when drug1 was administered concomitantly with drug0, drug2, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d561.s11.e0,DDI-DrugBank.d561.s11.e1,"drug1 has been used concomitantly with drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d561.s11.e0,DDI-DrugBank.d561.s11.e2,"drug1 has been used concomitantly with drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d561.s12.e0,DDI-DrugBank.d561.s12.e1,"drug1, like other drug2, has had less than additive effects with drug0",False, 
DDI-DrugBank.d561.s12.e0,DDI-DrugBank.d561.s12.e2,"drug1, like other drug0, has had less than additive effects with drug2",True,effect
DDI-DrugBank.d561.s12.e1,DDI-DrugBank.d561.s12.e2,"drug0, like other drug1, has had less than additive effects with drug2",True,effect
DDI-DrugBank.d132.s0.e0,DDI-DrugBank.d132.s0.e1,"Oral drug1: In some normal volunteers, the concomitant administration of drug2 and drug0, drug0, or drug0",False, 
DDI-DrugBank.d132.s0.e0,DDI-DrugBank.d132.s0.e2,"Oral drug1: In some normal volunteers, the concomitant administration of drug0 and drug2, drug0, or drug0",False, 
DDI-DrugBank.d132.s0.e1,DDI-DrugBank.d132.s0.e2,"Oral drug0: In some normal volunteers, the concomitant administration of drug1 and drug2, drug0, or drug0",True,effect
DDI-DrugBank.d132.s0.e1,DDI-DrugBank.d132.s0.e3,"Oral drug0: In some normal volunteers, the concomitant administration of drug1 and drug0, drug2, or drug0",True,effect
DDI-DrugBank.d132.s0.e1,DDI-DrugBank.d132.s0.e4,"Oral drug0: In some normal volunteers, the concomitant administration of drug1 and drug0, drug0, or drug2",True,effect
DDI-DrugBank.d132.s1.e0,DDI-DrugBank.d132.s1.e1,This may occur because drug1 competitively displaces drug2,True,mechanism
DDI-DrugBank.d132.s2.e0,DDI-DrugBank.d132.s2.e1,"Accordingly, when drug1 is administered with oral drug2",True,advise
DDI-DrugBank.d132.s4.e0,DDI-DrugBank.d132.s4.e1,"drug1: In diabetic patients receiving drug2 and drug0, no significant effects were seen on drug0",False, 
DDI-DrugBank.d132.s4.e0,DDI-DrugBank.d132.s4.e2,"drug1: In diabetic patients receiving drug0 and drug2, no significant effects were seen on drug0",False, 
DDI-DrugBank.d132.s5.e0,DDI-DrugBank.d132.s5.e1,"drug1: In normal volunteers, concomitant administration of drug2 and drug0 resulted in significantly increased plasma levels of drug0",False, 
DDI-DrugBank.d132.s5.e0,DDI-DrugBank.d132.s5.e2,"drug1: In normal volunteers, concomitant administration of drug0 and drug2 resulted in significantly increased plasma levels of drug0",False, 
DDI-DrugBank.d132.s5.e1,DDI-DrugBank.d132.s5.e2,"drug0: In normal volunteers, concomitant administration of drug1 and drug2 resulted in significantly increased plasma levels of drug0",True,mechanism
DDI-DrugBank.d132.s6.e0,DDI-DrugBank.d132.s6.e1,drug1 decreased the hyperuricemic effect of drug2,True,effect
DDI-DrugBank.d132.s7.e0,DDI-DrugBank.d132.s7.e1,"drug1: In normal volunteers, the concomitant administration of drug2 and drug0 had no effect on the diuretic activity of drug0",False, 
DDI-DrugBank.d132.s7.e0,DDI-DrugBank.d132.s7.e2,"drug1: In normal volunteers, the concomitant administration of drug0 and drug2 had no effect on the diuretic activity of drug0",False, 
DDI-DrugBank.d132.s8.e0,DDI-DrugBank.d132.s8.e1,drug1 decreased the hyperuricemic effect of drug2,True,effect
DDI-DrugBank.d132.s9.e0,DDI-DrugBank.d132.s9.e1,drug1: Concomitant administration of drug2 may reduce plasma levels of drug0,False, 
DDI-DrugBank.d132.s9.e0,DDI-DrugBank.d132.s9.e2,drug1: Concomitant administration of drug0 may reduce plasma levels of drug2,False, 
DDI-DrugBank.d132.s9.e1,DDI-DrugBank.d132.s9.e2,drug0: Concomitant administration of drug1 may reduce plasma levels of drug2,True,mechanism
DDI-DrugBank.d132.s10.e0,DDI-DrugBank.d132.s10.e1,"This effect is small with occasional doses of drug1, but may be clinically significant when drug2",False, 
DDI-DrugBank.d132.s11.e0,DDI-DrugBank.d132.s11.e1,"drug1: In normal volunteers, concomitant administration of drug2 and drug0 resulted in an approximate 50% increase in plasma levels of drug0",False, 
DDI-DrugBank.d132.s11.e0,DDI-DrugBank.d132.s11.e2,"drug1: In normal volunteers, concomitant administration of drug0 and drug2 resulted in an approximate 50% increase in plasma levels of drug0",False, 
DDI-DrugBank.d132.s11.e1,DDI-DrugBank.d132.s11.e2,"drug0: In normal volunteers, concomitant administration of drug1 and drug2 resulted in an approximate 50% increase in plasma levels of drug0",True,mechanism
DDI-DrugBank.d132.s12.e0,DDI-DrugBank.d132.s12.e1,drug1 had no effect on plasma levels of drug2,False, 
DDI-DrugBank.d132.s13.e0,DDI-DrugBank.d132.s13.e1,"Since drug1 in high doses has been associated with hepatotoxicity, concomitant administration of drug2 and drug0",False, 
DDI-DrugBank.d132.s13.e0,DDI-DrugBank.d132.s13.e2,"Since drug1 in high doses has been associated with hepatotoxicity, concomitant administration of drug0 and drug2",False, 
DDI-DrugBank.d132.s13.e1,DDI-DrugBank.d132.s13.e2,"Since drug0 in high doses has been associated with hepatotoxicity, concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d132.s14.e0,DDI-DrugBank.d132.s14.e1,"Concomitant administration of drug1 and drug2 in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of drug0/drug0",True,effect
DDI-DrugBank.d132.s14.e0,DDI-DrugBank.d132.s14.e2,"Concomitant administration of drug1 and drug0 in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of drug2/drug0",False, 
DDI-DrugBank.d132.s14.e0,DDI-DrugBank.d132.s14.e3,"Concomitant administration of drug1 and drug0 in dogs, but not in rats, at approximately 2 times the recommended maximum human therapeutic dose of each (40 to 52 mg/kg/day of drug0/drug2",False, 
DDI-DrugBank.d132.s16.e0,DDI-DrugBank.d132.s16.e1,drug1: Caution should be used if drug2 is administered concomitantly with drug0,False, 
DDI-DrugBank.d132.s16.e0,DDI-DrugBank.d132.s16.e2,drug1: Caution should be used if drug0 is administered concomitantly with drug2,False, 
DDI-DrugBank.d132.s16.e1,DDI-DrugBank.d132.s16.e2,drug0: Caution should be used if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d132.s17.e0,DDI-DrugBank.d132.s17.e1,drug1 have been reported to decrease the tubular secretion of drug2,True,mechanism
DDI-DrugBank.d132.s18.e0,DDI-DrugBank.d132.s18.e1,drug1: Administration of drug2 concomitantly with drug0 has been associated with an increase in drug0,False, 
DDI-DrugBank.d132.s18.e0,DDI-DrugBank.d132.s18.e2,drug1: Administration of drug0 concomitantly with drug2 has been associated with an increase in drug0,False, 
DDI-DrugBank.d132.s18.e1,DDI-DrugBank.d132.s18.e2,drug0: Administration of drug1 concomitantly with drug2 has been associated with an increase in drug0,True,mechanism
DDI-DrugBank.d132.s19.e0,DDI-DrugBank.d132.s19.e1,drug1 should be used with caution in patients taking drug2,True,advise
DDI-DrugBank.d132.s20.e0,DDI-DrugBank.d132.s20.e1,drug1: The administration of drug2 to normal volunteers receiving drug0 decreased the renal clearance and significantly increased the plasma levels of drug0,False, 
DDI-DrugBank.d132.s20.e0,DDI-DrugBank.d132.s20.e2,drug1: The administration of drug0 to normal volunteers receiving drug2 decreased the renal clearance and significantly increased the plasma levels of drug0,False, 
DDI-DrugBank.d132.s20.e1,DDI-DrugBank.d132.s20.e2,drug0: The administration of drug1 to normal volunteers receiving drug2 decreased the renal clearance and significantly increased the plasma levels of drug0,True,mechanism
DDI-DrugBank.d132.s21.e0,DDI-DrugBank.d132.s21.e1,In some patients the combined use of drug1 and drug2,True,effect
DDI-DrugBank.d132.s22.e0,DDI-DrugBank.d132.s22.e1,"Therefore, drug1 and drug2",True,advise
DDI-DrugBank.d132.s23.e0,DDI-DrugBank.d132.s23.e1,The concomitant use of drug1 tablets and other drug2,True,effect
DDI-DrugBank.d132.s25.e0,DDI-DrugBank.d132.s25.e1,"drug1: In normal volunteers, a small decrease in drug2 levels was observed when multiple doses of drug0 and drug0",False, 
DDI-DrugBank.d132.s25.e0,DDI-DrugBank.d132.s25.e2,"drug1: In normal volunteers, a small decrease in drug0 levels was observed when multiple doses of drug2 and drug0",False, 
DDI-DrugBank.d132.s25.e2,DDI-DrugBank.d132.s25.e3,"drug0: In normal volunteers, a small decrease in drug0 levels was observed when multiple doses of drug1 and drug2",True,mechanism
DDI-DrugBank.d132.s26.e0,DDI-DrugBank.d132.s26.e1,drug1: The concomitant administration of drug2 and drug0,False, 
DDI-DrugBank.d132.s26.e0,DDI-DrugBank.d132.s26.e2,drug1: The concomitant administration of drug0 and drug2,False, 
DDI-DrugBank.d132.s26.e1,DDI-DrugBank.d132.s26.e2,drug0: The concomitant administration of drug1 and drug2,True,mechanism
DDI-DrugBank.d132.s27.e0,DDI-DrugBank.d132.s27.e1,"drug1: The concomitant administration of drug2 and drug0 in normal volunteers had no effect on the plasma levels of drug0, but significantly decreased the urinary excretion of drug0",False, 
DDI-DrugBank.d132.s27.e0,DDI-DrugBank.d132.s27.e2,"drug1: The concomitant administration of drug0 and drug2 in normal volunteers had no effect on the plasma levels of drug0, but significantly decreased the urinary excretion of drug0",False, 
DDI-DrugBank.d132.s27.e1,DDI-DrugBank.d132.s27.e2,"drug0: The concomitant administration of drug1 and drug2 in normal volunteers had no effect on the plasma levels of drug0, but significantly decreased the urinary excretion of drug0",True,mechanism
DDI-DrugBank.d132.s28.e0,DDI-DrugBank.d132.s28.e1,drug1 had no effect on plasma levels of drug2,False, 
DDI-DrugBank.d116.s0.e0,DDI-DrugBank.d116.s0.e1,Careful observation is required when drug1 is administered concurrently with drug2,True,advise
DDI-DrugBank.d362.s2.e0,DDI-DrugBank.d362.s2.e1,In vitro studies demonstrated that the plasma protein binding of drug1 was not affected by drug2 or drug0,False, 
DDI-DrugBank.d362.s2.e0,DDI-DrugBank.d362.s2.e2,In vitro studies demonstrated that the plasma protein binding of drug1 was not affected by drug0 or drug2,False, 
DDI-DrugBank.d362.s3.e0,DDI-DrugBank.d362.s3.e1,"In a drug interaction study, co-administration of orally inhaled drug1 and oral drug2, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either drug0 or drug0",False, 
DDI-DrugBank.d362.s3.e0,DDI-DrugBank.d362.s3.e2,"In a drug interaction study, co-administration of orally inhaled drug1 and oral drug0, an inhibitor of cytochrome P450 3A4, had no effect on the pharmacokinetics of either drug2 or drug0",False, 
DDI-DrugBank.d362.s4.e0,DDI-DrugBank.d362.s4.e1,"In another drug interaction study, co-administration of orally inhaled drug1 and oral drug2, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of drug0 by approximately 3.6-fold at steady state, while levels of drug0",True,mechanism
DDI-DrugBank.d362.s4.e0,DDI-DrugBank.d362.s4.e2,"In another drug interaction study, co-administration of orally inhaled drug1 and oral drug0, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of drug2 by approximately 3.6-fold at steady state, while levels of drug0",False, 
DDI-DrugBank.d362.s4.e0,DDI-DrugBank.d362.s4.e3,"In another drug interaction study, co-administration of orally inhaled drug1 and oral drug0, a potent inhibitor of cytochrome P450 3A4, increased the exposure (AUC) of drug0 by approximately 3.6-fold at steady state, while levels of drug2",False, 
DDI-DrugBank.d362.s5.e0,DDI-DrugBank.d362.s5.e1,"Therefore, drug1 should be administered with caution with intranasal drug2",True,advise
DDI-DrugBank.d258.s0.e0,DDI-DrugBank.d258.s0.e1,"drug1 (10 mg once daily) has been coadministered with therapeutic doses of drug2, drug0, and drug0",False, 
DDI-DrugBank.d258.s0.e0,DDI-DrugBank.d258.s0.e2,"drug1 (10 mg once daily) has been coadministered with therapeutic doses of drug0, drug2, and drug0",False, 
DDI-DrugBank.d258.s1.e0,DDI-DrugBank.d258.s1.e1,"Although increased plasma concentrations (AUC 0-24 hrs) of drug1 and/or drug2 were observed following coadministration of drug0 with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of drug0",False, 
DDI-DrugBank.d258.s1.e0,DDI-DrugBank.d258.s1.e2,"Although increased plasma concentrations (AUC 0-24 hrs) of drug1 and/or drug0 were observed following coadministration of drug2 with each of these drugs in normal volunteers (n = 24 in each study), there were no clinically relevant changes in the safety profile of drug0",False, 
DDI-DrugBank.d258.s3.e0,DDI-DrugBank.d258.s3.e1,No effects on plasma concentrations of drug1 or drug2,False, 
DDI-DrugBank.d258.s4.e0,DDI-DrugBank.d258.s4.e1,Plasma concentrations (AUC 0-24 hrs) of drug1 decreased 15% with coadministration of drug2 relative to that observed with drug0,True,mechanism
DDI-DrugBank.d258.s4.e0,DDI-DrugBank.d258.s4.e2,Plasma concentrations (AUC 0-24 hrs) of drug1 decreased 15% with coadministration of drug0 relative to that observed with drug2,False, 
DDI-DrugBank.d258.s4.e1,DDI-DrugBank.d258.s4.e2,Plasma concentrations (AUC 0-24 hrs) of drug0 decreased 15% with coadministration of drug1 relative to that observed with drug2,False, 
DDI-DrugBank.d258.s7.e0,DDI-DrugBank.d258.s7.e1,TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of drug1 and drug2 After 10 Days of Coadministration (drug0,False, 
DDI-DrugBank.d258.s7.e0,DDI-DrugBank.d258.s7.e2,TABLE 1 Effects on Plasma Concentrations (AUC 0-24 hrs) of drug1 and drug0 After 10 Days of Coadministration (drug2,False, 
DDI-DrugBank.d258.s8.e0,DDI-DrugBank.d258.s8.e1,drug1 drug2,False, 
DDI-DrugBank.d258.s12.e0,DDI-DrugBank.d258.s12.e1,There does not appear to be an increase in adverse events in subjects who received oral drug1 and drug2,False, 
DDI-DrugBank.d492.s0.e0,DDI-DrugBank.d492.s0.e1,drug1 prolong and intensify the anticholinergic effects of drug2,True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e1,"drug1 may have additive effects with drug2 and other drug0, e.g., drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e2,"drug1 may have additive effects with drug0 and other drug2, e.g., drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e3,"drug1 may have additive effects with drug0 and other drug0, e.g., drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e4,"drug1 may have additive effects with drug0 and other drug0, e.g., drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e5,"drug1 may have additive effects with drug0 and other drug0, e.g., drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d492.s1.e0,DDI-DrugBank.d492.s1.e6,"drug1 may have additive effects with drug0 and other drug0, e.g., drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d492.s1.e1,DDI-DrugBank.d492.s1.e2,"drug0 may have additive effects with drug1 and other drug2, e.g., drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d492.s1.e1,DDI-DrugBank.d492.s1.e3,"drug0 may have additive effects with drug1 and other drug0, e.g., drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d350.s3.e0,DDI-DrugBank.d350.s3.e1,"Clinical studies in healthy volunteers show that the pharmacokinetics of drug1 are not altered by drug2, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d350.s3.e0,DDI-DrugBank.d350.s3.e2,"Clinical studies in healthy volunteers show that the pharmacokinetics of drug1 are not altered by drug0, drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d350.s4.e0,DDI-DrugBank.d350.s4.e1,"drug1 has no effect on the pharmacokinetics of drug2, drug0",False, 
DDI-DrugBank.d350.s4.e0,DDI-DrugBank.d350.s4.e2,"drug1 has no effect on the pharmacokinetics of drug0, drug2",False, 
DDI-DrugBank.d350.s5.e0,DDI-DrugBank.d350.s5.e1,"drug1 reduced the blood AUC0-12 of drug2 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when drug0 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of drug0 70 mg daily, as compared to results from a control period in which drug0",True,mechanism
DDI-DrugBank.d350.s5.e0,DDI-DrugBank.d350.s5.e2,"drug1 reduced the blood AUC0-12 of drug0 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when drug2 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of drug0 70 mg daily, as compared to results from a control period in which drug0",False, 
DDI-DrugBank.d350.s5.e0,DDI-DrugBank.d350.s5.e3,"drug1 reduced the blood AUC0-12 of drug0 by approximately 20%, peak blood concentration (Cmax) by 16%, and 12-hour blood concentration (C12hr) by 26% in healthy subjects when drug0 (2 doses of 0.1 mg/kg 12 hours apart) was administered on the 10th day of drug2 70 mg daily, as compared to results from a control period in which drug0",False, 
DDI-DrugBank.d350.s6.e0,DDI-DrugBank.d350.s6.e1,"For patients receiving both therapies, standard monitoring of drug1 blood concentrations and appropriate drug2",False, 
DDI-DrugBank.d350.s7.e0,DDI-DrugBank.d350.s7.e1,"In two clinical studies, drug1 (one 4 mg/kg dose or two 3 mg/kg doses) increased the AUC of drug2",True,mechanism
DDI-DrugBank.d350.s8.e0,DDI-DrugBank.d350.s8.e1,drug1 did not increase the plasma levels of drug2,False, 
DDI-DrugBank.d350.s9.e0,DDI-DrugBank.d350.s9.e1,There were transient increases in liver ALT and AST when drug1 and drug2,True,effect
DDI-DrugBank.d350.s10.e0,DDI-DrugBank.d350.s10.e1,A drug-drug interaction study with drug1 in healthy volunteers has shown a 30% decrease in drug2,True,mechanism
DDI-DrugBank.d350.s11.e0,DDI-DrugBank.d350.s11.e1,Patients on drug1 should receive 70 mg of drug2,True,advise
DDI-DrugBank.d350.s12.e0,DDI-DrugBank.d350.s12.e1,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug1, drug2, drug0, drug0, or drug0) with drug0 may result in clinically meaningful reductions in drug0",False, 
DDI-DrugBank.d350.s12.e0,DDI-DrugBank.d350.s12.e2,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug1, drug0, drug2, drug0, or drug0) with drug0 may result in clinically meaningful reductions in drug0",False, 
DDI-DrugBank.d350.s12.e0,DDI-DrugBank.d350.s12.e5,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug1, drug0, drug0, drug0, or drug0) with drug2 may result in clinically meaningful reductions in drug0",True,mechanism
DDI-DrugBank.d350.s12.e1,DDI-DrugBank.d350.s12.e5,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug0, drug1, drug0, drug0, or drug0) with drug2 may result in clinically meaningful reductions in drug0",True,mechanism
DDI-DrugBank.d350.s12.e2,DDI-DrugBank.d350.s12.e5,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug0, drug0, drug1, drug0, or drug0) with drug2 may result in clinically meaningful reductions in drug0",True,mechanism
DDI-DrugBank.d350.s12.e3,DDI-DrugBank.d350.s12.e5,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug0, drug0, drug0, drug1, or drug0) with drug2 may result in clinically meaningful reductions in drug0",True,mechanism
DDI-DrugBank.d350.s12.e4,DDI-DrugBank.d350.s12.e5,"In addition, results from regression analyses of patient pharmacokinetic data suggest that co-administration of other inducers of drug clearance (drug0, drug0, drug0, drug0, or drug1) with drug2 may result in clinically meaningful reductions in drug0",True,mechanism
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e1,"When drug1 is co-administered with inducers of drug clearance, such as drug2, drug0, drug0, drug0, or drug0, use of a daily dose of 70 mg of drug0",True,advise
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e2,"When drug1 is co-administered with inducers of drug clearance, such as drug0, drug2, drug0, drug0, or drug0, use of a daily dose of 70 mg of drug0",True,advise
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e3,"When drug1 is co-administered with inducers of drug clearance, such as drug0, drug0, drug2, drug0, or drug0, use of a daily dose of 70 mg of drug0",True,advise
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e4,"When drug1 is co-administered with inducers of drug clearance, such as drug0, drug0, drug0, drug2, or drug0, use of a daily dose of 70 mg of drug0",True,advise
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e5,"When drug1 is co-administered with inducers of drug clearance, such as drug0, drug0, drug0, drug0, or drug2, use of a daily dose of 70 mg of drug0",True,advise
DDI-DrugBank.d350.s14.e0,DDI-DrugBank.d350.s14.e6,"When drug1 is co-administered with inducers of drug clearance, such as drug0, drug0, drug0, drug0, or drug0, use of a daily dose of 70 mg of drug2",False, 
DDI-DrugBank.d350.s14.e1,DDI-DrugBank.d350.s14.e2,"When drug0 is co-administered with inducers of drug clearance, such as drug1, drug2, drug0, drug0, or drug0, use of a daily dose of 70 mg of drug0",False, 
DDI-DrugBank.d69.s0.e0,DDI-DrugBank.d69.s0.e1,Use of drug1 in a patient who has previously received drug2,True,effect
DDI-DrugBank.d69.s1.e0,DDI-DrugBank.d69.s1.e1,drug1 should not be used in patients who have previously received the recommended maximum cumulative doses of drug2 or drug0,True,advise
DDI-DrugBank.d69.s1.e0,DDI-DrugBank.d69.s1.e2,drug1 should not be used in patients who have previously received the recommended maximum cumulative doses of drug0 or drug2,False, 
DDI-DrugBank.d69.s1.e1,DDI-DrugBank.d69.s1.e2,drug0 should not be used in patients who have previously received the recommended maximum cumulative doses of drug1 or drug2,False, 
DDI-DrugBank.d69.s2.e0,DDI-DrugBank.d69.s2.e1,drug1 used concurrently with drug2,True,effect
DDI-DrugBank.d205.s0.e0,DDI-DrugBank.d205.s0.e1,"Since drug1 (drug2) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg, drug0 may elevate drug0 serum levels and drug0 has been reported to both increase and decrease drug0",False, 
DDI-DrugBank.d205.s0.e0,DDI-DrugBank.d205.s0.e2,"Since drug1 (drug0) may interact with concurrently administered drug2, periodic serum level determinations of these drugs may be necessary (eg, drug0 may elevate drug0 serum levels and drug0 has been reported to both increase and decrease drug0",True,int
DDI-DrugBank.d205.s0.e0,DDI-DrugBank.d205.s0.e3,"Since drug1 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg, drug2 may elevate drug0 serum levels and drug0 has been reported to both increase and decrease drug0",False, 
DDI-DrugBank.d205.s0.e1,DDI-DrugBank.d205.s0.e2,"Since drug0 (drug1) may interact with concurrently administered drug2, periodic serum level determinations of these drugs may be necessary (eg, drug0 may elevate drug0 serum levels and drug0 has been reported to both increase and decrease drug0",True,int
DDI-DrugBank.d205.s0.e3,DDI-DrugBank.d205.s0.e4,"Since drug0 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg, drug1 may elevate drug2 serum levels and drug0 has been reported to both increase and decrease drug0",True,mechanism
DDI-DrugBank.d205.s0.e5,DDI-DrugBank.d205.s0.e6,"Since drug0 (drug0) may interact with concurrently administered drug0, periodic serum level determinations of these drugs may be necessary (eg, drug0 may elevate drug0 serum levels and drug1 has been reported to both increase and decrease drug2",True,mechanism
DDI-DrugBank.d190.s1.e0,DDI-DrugBank.d190.s1.e1,"However, since there is an increased risk of bleeding with drug1, caution should be employed when drug2",False, 
DDI-DrugBank.d190.s2.e0,DDI-DrugBank.d190.s2.e1,"Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose drug1 (drug2 up to 15,000 units/day) or prophylactic doses of drug0",False, 
DDI-DrugBank.d190.s2.e0,DDI-DrugBank.d190.s2.e2,"Approximately 2/3 of the patients in the Phase 3 study received either prophylactic low dose drug1 (drug0 up to 15,000 units/day) or prophylactic doses of drug2",False, 
DDI-DrugBank.d190.s3.e0,DDI-DrugBank.d190.s3.e1,"Concomitant use of prophylactic low dose drug1 did not appear to affect safety, however, its effects on the efficacy of drug2",False, 
DDI-DrugBank.d190.s4.e0,DDI-DrugBank.d190.s4.e1,"Drug/Laboratory Test Interaction Because drug1 may affect the APTT assay, drug2",False, 
DDI-DrugBank.d276.s0.e0,DDI-DrugBank.d276.s0.e1,"drug1 containing drug2, when administered concomitantly with drug0",False, 
DDI-DrugBank.d276.s0.e0,DDI-DrugBank.d276.s0.e2,"drug1 containing drug0, when administered concomitantly with drug2",False, 
DDI-DrugBank.d276.s0.e1,DDI-DrugBank.d276.s0.e2,"drug0 containing drug1, when administered concomitantly with drug2",True,mechanism
DDI-DrugBank.d276.s1.e0,DDI-DrugBank.d276.s1.e1,The mechanism for this interaction probably is adsorption of drug1 onto the surface of drug2,True,mechanism
DDI-DrugBank.d276.s2.e0,DDI-DrugBank.d276.s2.e1,"drug1, such as drug2 and drug0, can inhibit renal tubular secretion of drug0",False, 
DDI-DrugBank.d276.s2.e0,DDI-DrugBank.d276.s2.e2,"drug1, such as drug0 and drug2, can inhibit renal tubular secretion of drug0",False, 
DDI-DrugBank.d276.s2.e0,DDI-DrugBank.d276.s2.e3,"drug1, such as drug0 and drug0, can inhibit renal tubular secretion of drug2",True,mechanism
DDI-DrugBank.d276.s2.e1,DDI-DrugBank.d276.s2.e3,"drug0, such as drug1 and drug0, can inhibit renal tubular secretion of drug2",True,mechanism
DDI-DrugBank.d276.s2.e2,DDI-DrugBank.d276.s2.e3,"drug0, such as drug0 and drug1, can inhibit renal tubular secretion of drug2",True,mechanism
DDI-DrugBank.d276.s3.e0,DDI-DrugBank.d276.s3.e1,"The resulting increase in drug1 serum levels may increase toxicity, and the decreased urinary levels could lessen its efficacy as a urinary tract drug2",False, 
DDI-DrugBank.d542.s0.e0,DDI-DrugBank.d542.s0.e1,Interactions for drug1 (drug2): drug0 Therapy: drug0 may potentiate the effects of drug0,False, 
DDI-DrugBank.d542.s0.e0,DDI-DrugBank.d542.s0.e2,Interactions for drug1 (drug0): drug2 Therapy: drug0 may potentiate the effects of drug0,False, 
DDI-DrugBank.d542.s0.e3,DDI-DrugBank.d542.s0.e4,Interactions for drug0 (drug0): drug0 Therapy: drug1 may potentiate the effects of drug2,True,effect
DDI-DrugBank.d542.s1.e0,DDI-DrugBank.d542.s1.e1,drug1: Concomitant drug2 may decrease the metabolic clearance of drug0,False, 
DDI-DrugBank.d542.s1.e0,DDI-DrugBank.d542.s1.e2,drug1: Concomitant drug0 may decrease the metabolic clearance of drug2,False, 
DDI-DrugBank.d542.s1.e1,DDI-DrugBank.d542.s1.e2,drug0: Concomitant drug1 may decrease the metabolic clearance of drug2,True,mechanism
DDI-DrugBank.d365.s0.e0,DDI-DrugBank.d365.s0.e1,drug1 - drug2 was observed to enhance (in tissue culture) the effect of drug0,False, 
DDI-DrugBank.d365.s0.e0,DDI-DrugBank.d365.s0.e2,drug1 - drug0 was observed to enhance (in tissue culture) the effect of drug2,False, 
DDI-DrugBank.d365.s0.e1,DDI-DrugBank.d365.s0.e2,drug0 - drug1 was observed to enhance (in tissue culture) the effect of drug2,True,effect
DDI-DrugBank.d365.s1.e0,DDI-DrugBank.d365.s1.e1,"drug1 and drug2 - Although not reported, drug0, via its metabolism to histamine, might decrease the efficacy of drug0 and drug0",False, 
DDI-DrugBank.d365.s1.e0,DDI-DrugBank.d365.s1.e2,"drug1 and drug0 - Although not reported, drug2, via its metabolism to histamine, might decrease the efficacy of drug0 and drug0",False, 
DDI-DrugBank.d365.s1.e2,DDI-DrugBank.d365.s1.e3,"drug0 and drug0 - Although not reported, drug1, via its metabolism to histamine, might decrease the efficacy of drug2 and drug0",True,effect
DDI-DrugBank.d365.s1.e2,DDI-DrugBank.d365.s1.e4,"drug0 and drug0 - Although not reported, drug1, via its metabolism to histamine, might decrease the efficacy of drug0 and drug2",True,effect
DDI-DrugBank.d549.s0.e0,DDI-DrugBank.d549.s0.e1,"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous drug1 and either drug2, drug0, or drug0",False, 
DDI-DrugBank.d549.s0.e0,DDI-DrugBank.d549.s0.e2,"In studies in normal volunteers, there was no pharmacodynamic interaction between intravenous drug1 and either drug0, drug2, or drug0",False, 
DDI-DrugBank.d549.s1.e0,DDI-DrugBank.d549.s1.e1,"However, drug1 has the potential to increase the hypotensive effect of drug2 and drug0",True,effect
DDI-DrugBank.d549.s1.e0,DDI-DrugBank.d549.s1.e2,"However, drug1 has the potential to increase the hypotensive effect of drug0 and drug2",True,effect
DDI-DrugBank.d549.s1.e1,DDI-DrugBank.d549.s1.e2,"However, drug0 has the potential to increase the hypotensive effect of drug1 and drug2",False, 
DDI-DrugBank.d549.s2.e0,DDI-DrugBank.d549.s2.e1,"Since drug1 inhibits platelet function, there is a potential for increased risk of bleeding, particularly in patients maintained on drug2",True,effect
DDI-DrugBank.d549.s3.e0,DDI-DrugBank.d549.s3.e1,"During clinical trials, drug1 was used concurrently with drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d549.s3.e0,DDI-DrugBank.d549.s3.e2,"During clinical trials, drug1 was used concurrently with drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d549.s4.e0,DDI-DrugBank.d549.s4.e1,Intravenous infusion of drug1 had no effect on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d549.s5.e0,DDI-DrugBank.d549.s5.e1,drug1 did not alter the clearance (pharmacokinetics) of drug2,False, 
DDI-DrugBank.d507.s0.e0,DDI-DrugBank.d507.s0.e1,The potential for increased sedation when drug1 is given with other drug2,True,effect
DDI-DrugBank.d507.s1.e0,DDI-DrugBank.d507.s1.e1,The administration of drug1 concomitantly with known microsomal enzyme inducer (drug2 or drug0,True,mechanism
DDI-DrugBank.d507.s1.e0,DDI-DrugBank.d507.s1.e2,The administration of drug1 concomitantly with known microsomal enzyme inducer (drug0 or drug2,True,mechanism
DDI-DrugBank.d507.s1.e1,DDI-DrugBank.d507.s1.e2,The administration of drug0 concomitantly with known microsomal enzyme inducer (drug1 or drug2,False, 
DDI-DrugBank.d507.s4.e0,DDI-DrugBank.d507.s4.e1,drug1 decrease the hypotensive effect of drug2,True,effect
DDI-DrugBank.d507.s5.e0,DDI-DrugBank.d507.s5.e1,"drug1 (drug2,porpranolol,drug0) may exacerbate rebound hypertension when drug0",False, 
DDI-DrugBank.d507.s5.e0,DDI-DrugBank.d507.s5.e2,"drug1 (drug0,porpranolol,drug2) may exacerbate rebound hypertension when drug0",False, 
DDI-DrugBank.d507.s5.e0,DDI-DrugBank.d507.s5.e3,"drug1 (drug0,porpranolol,drug0) may exacerbate rebound hypertension when drug2",True,effect
DDI-DrugBank.d507.s5.e1,DDI-DrugBank.d507.s5.e3,"drug0 (drug1,porpranolol,drug0) may exacerbate rebound hypertension when drug2",True,effect
DDI-DrugBank.d507.s5.e2,DDI-DrugBank.d507.s5.e3,"drug0 (drug0,porpranolol,drug1) may exacerbate rebound hypertension when drug2",True,effect
DDI-DrugBank.d507.s7.e0,DDI-DrugBank.d507.s7.e1,The gradual withdrawal of drug1 or a drug2,False, 
DDI-DrugBank.d507.s8.e0,DDI-DrugBank.d507.s8.e1,drug1: Ten patients who were stabilized on oral drug2 were given drug0,False, 
DDI-DrugBank.d507.s8.e0,DDI-DrugBank.d507.s8.e2,drug1: Ten patients who were stabilized on oral drug0 were given drug2,False, 
DDI-DrugBank.d507.s10.e0,DDI-DrugBank.d507.s10.e1,"In several well-controlled studies, drug1 was administered together with drug2",False, 
DDI-DrugBank.d507.s12.e0,DDI-DrugBank.d507.s12.e1,"The principal drugs given (number of patients in parentheses) were: drug1 (115), drug2 and drug0 (103), drug0 (52), oral drug0 (45), cough and cold preparations (45), drug0 (38), drug0 (29), drug0 (24), oral drug0 (18), drug0 (13), drug0 (10), and drug0",False, 
DDI-DrugBank.d507.s12.e0,DDI-DrugBank.d507.s12.e2,"The principal drugs given (number of patients in parentheses) were: drug1 (115), drug0 and drug2 (103), drug0 (52), oral drug0 (45), cough and cold preparations (45), drug0 (38), drug0 (29), drug0 (24), oral drug0 (18), drug0 (13), drug0 (10), and drug0",False, 
DDI-DrugBank.d417.s0.e0,DDI-DrugBank.d417.s0.e1,drug1 should not be administered concomitantly with potent drug2 such as drug0 and drug0,True,advise
DDI-DrugBank.d417.s0.e0,DDI-DrugBank.d417.s0.e2,drug1 should not be administered concomitantly with potent drug0 such as drug2 and drug0,True,advise
DDI-DrugBank.d417.s0.e0,DDI-DrugBank.d417.s0.e3,drug1 should not be administered concomitantly with potent drug0 such as drug0 and drug2,True,advise
DDI-DrugBank.d417.s0.e1,DDI-DrugBank.d417.s0.e2,drug0 should not be administered concomitantly with potent drug1 such as drug2 and drug0,False, 
DDI-DrugBank.d417.s0.e1,DDI-DrugBank.d417.s0.e3,drug0 should not be administered concomitantly with potent drug1 such as drug0 and drug2,False, 
DDI-DrugBank.d112.s0.e0,DDI-DrugBank.d112.s0.e1,Concurrent use with drug1 or other drugs significantly eliminated by active renal tubular secretion may result in increased plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d112.s1.e0,DDI-DrugBank.d112.s1.e1,The conversion of drug1 to drug2,False, 
DDI-DrugBank.d270.s9.e0,DDI-DrugBank.d270.s9.e1,The in vitro interaction between drug1 and the drug2 drug0,False, 
DDI-DrugBank.d270.s9.e0,DDI-DrugBank.d270.s9.e2,The in vitro interaction between drug1 and the drug0 drug2,True,int
DDI-DrugBank.d270.s9.e1,DDI-DrugBank.d270.s9.e2,The in vitro interaction between drug0 and the drug1 drug2,False, 
DDI-DrugBank.d270.s11.e0,DDI-DrugBank.d270.s11.e1,When drug1 is co-administered with drug2,True,advise
DDI-DrugBank.d270.s18.e0,DDI-DrugBank.d270.s18.e1,drug1 exposure was significantly decreased by drug2,True,mechanism
DDI-DrugBank.d270.s20.e0,DDI-DrugBank.d270.s20.e1,"Alternatives to drug1,such as drug2",False, 
DDI-DrugBank.d270.s24.e0,DDI-DrugBank.d270.s24.e1,drug1 and drug2,False, 
DDI-DrugBank.d270.s25.e0,DDI-DrugBank.d270.s25.e1,drug1 drug2,False, 
DDI-DrugBank.d270.s26.e0,DDI-DrugBank.d270.s26.e1,Oral drug1 and other hormonalmethods of birth control should not be usedas the sole method of contraception inwomen taking drug2,True,advise
DDI-DrugBank.d270.s36.e0,DDI-DrugBank.d270.s36.e1,drug1 and drug2 should not beadministered concomitantly becausedecreases in drug0,True,advise
DDI-DrugBank.d270.s36.e0,DDI-DrugBank.d270.s36.e2,drug1 and drug0 should not beadministered concomitantly becausedecreases in drug2,False, 
DDI-DrugBank.d270.s36.e1,DDI-DrugBank.d270.s36.e2,drug0 and drug1 should not beadministered concomitantly becausedecreases in drug2,False, 
DDI-DrugBank.d270.s37.e0,DDI-DrugBank.d270.s37.e1,drug1/drug2,False, 
DDI-DrugBank.d270.s39.e0,DDI-DrugBank.d270.s39.e1,A dose increase of drug1/drug2 to 533/133 mg twice daily with food isrecommended in combination with drug0,False, 
DDI-DrugBank.d270.s39.e0,DDI-DrugBank.d270.s39.e2,A dose increase of drug1/drug0 to 533/133 mg twice daily with food isrecommended in combination with drug2,True,advise
DDI-DrugBank.d270.s39.e1,DDI-DrugBank.d270.s39.e2,A dose increase of drug0/drug1 to 533/133 mg twice daily with food isrecommended in combination with drug2,True,advise
DDI-DrugBank.d270.s42.e0,DDI-DrugBank.d270.s42.e1,drug1 levels may be decreased; increased dosages may be required to prevent symptoms of drug2 withdrawal. drug0 maintained patients beginning drug0 therapy should be monitored forevidence of withdrawal and drug0,False, 
DDI-DrugBank.d270.s42.e0,DDI-DrugBank.d270.s42.e2,drug1 levels may be decreased; increased dosages may be required to prevent symptoms of drug0 withdrawal. drug2 maintained patients beginning drug0 therapy should be monitored forevidence of withdrawal and drug0,False, 
DDI-DrugBank.d270.s42.e2,DDI-DrugBank.d270.s42.e3,drug0 levels may be decreased; increased dosages may be required to prevent symptoms of drug0 withdrawal. drug1 maintained patients beginning drug2 therapy should be monitored forevidence of withdrawal and drug0,True,advise
DDI-DrugBank.d270.s45.e0,DDI-DrugBank.d270.s45.e1,The appropriate dose for drug1 incombination with drug2,False, 
DDI-DrugBank.d270.s53.e0,DDI-DrugBank.d270.s53.e1,drug1 and drug2 should not beadministered concomitantly becausedecreases in drug0,True,advise
DDI-DrugBank.d270.s53.e0,DDI-DrugBank.d270.s53.e2,drug1 and drug0 should not beadministered concomitantly becausedecreases in drug2,False, 
DDI-DrugBank.d270.s53.e1,DDI-DrugBank.d270.s53.e2,drug0 and drug1 should not beadministered concomitantly becausedecreases in drug2,False, 
DDI-DrugBank.d270.s54.e0,DDI-DrugBank.d270.s54.e1,Physicians needing to treatpatients co-infected with tuberculosis andusing a drug1 containing regimen mayuse drug2,False, 
DDI-DrugBank.d270.s58.e0,DDI-DrugBank.d270.s58.e1,"aBased on reports of narcotic withdrawal syndrome in patients treated with drug1 and drug2 concurrently, and evidence of decreased plasma concentrations of drug0",True,effect
DDI-DrugBank.d270.s58.e0,DDI-DrugBank.d270.s58.e2,"aBased on reports of narcotic withdrawal syndrome in patients treated with drug1 and drug0 concurrently, and evidence of decreased plasma concentrations of drug2",False, 
DDI-DrugBank.d270.s58.e1,DDI-DrugBank.d270.s58.e2,"aBased on reports of narcotic withdrawal syndrome in patients treated with drug0 and drug1 concurrently, and evidence of decreased plasma concentrations of drug2",False, 
DDI-DrugBank.d270.s63.e0,DDI-DrugBank.d270.s63.e1,"drug1, drug2, drug0",False, 
DDI-DrugBank.d270.s63.e0,DDI-DrugBank.d270.s63.e2,"drug1, drug0, drug2",False, 
DDI-DrugBank.d270.s65.e0,DDI-DrugBank.d270.s65.e1,"drug1, drug2, drug0",False, 
DDI-DrugBank.d270.s65.e0,DDI-DrugBank.d270.s65.e2,"drug1, drug0, drug2",False, 
DDI-DrugBank.d270.s69.e0,DDI-DrugBank.d270.s69.e1,"drug1, drug2, drug0",False, 
DDI-DrugBank.d270.s69.e0,DDI-DrugBank.d270.s69.e2,"drug1, drug0, drug2",False, 
DDI-DrugBank.d270.s75.e0,DDI-DrugBank.d270.s75.e1,"drug1, drug2, drug0",False, 
DDI-DrugBank.d270.s75.e0,DDI-DrugBank.d270.s75.e2,"drug1, drug0, drug2",False, 
DDI-DrugBank.d393.s0.e0,DDI-DrugBank.d393.s0.e1,"Pharmacokinetic interaction studies with drug1 in adults were conducted with drug2, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d393.s0.e0,DDI-DrugBank.d393.s0.e2,"Pharmacokinetic interaction studies with drug1 in adults were conducted with drug0, drug2, drug0, drug0 and drug0",False, 
DDI-DrugBank.d393.s2.e0,DDI-DrugBank.d393.s2.e1,"In a multiple dose study of drug1 (400 mg once daily for 3 days) and drug2 (20 mg once daily for 3 days), a 16% decrease in the clearance of drug0",True,mechanism
DDI-DrugBank.d393.s2.e0,DDI-DrugBank.d393.s2.e2,"In a multiple dose study of drug1 (400 mg once daily for 3 days) and drug0 (20 mg once daily for 3 days), a 16% decrease in the clearance of drug2",False, 
DDI-DrugBank.d393.s2.e1,DDI-DrugBank.d393.s2.e2,"In a multiple dose study of drug0 (400 mg once daily for 3 days) and drug1 (20 mg once daily for 3 days), a 16% decrease in the clearance of drug2",False, 
DDI-DrugBank.d393.s3.e0,DDI-DrugBank.d393.s3.e1,The disposition of drug1 was not altered by concomitant drug2,False, 
DDI-DrugBank.d393.s4.e0,DDI-DrugBank.d393.s4.e1,"Drug-Drug Interactions: No clinically significant drug interactions have been found with drug1 at a low dose, drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d393.s4.e0,DDI-DrugBank.d393.s4.e2,"Drug-Drug Interactions: No clinically significant drug interactions have been found with drug1 at a low dose, drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d393.s5.e0,DDI-DrugBank.d393.s5.e1,There was a small decrease in the clearance of drug1 caused by a 400-mg dose of drug2,True,mechanism
DDI-DrugBank.d10.s1.e0,DDI-DrugBank.d10.s1.e1,"Although studies designed to examine drug interactions have not been done, it was noted that drug1 or drug2 treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving drug0",False, 
DDI-DrugBank.d10.s1.e0,DDI-DrugBank.d10.s1.e2,"Although studies designed to examine drug interactions have not been done, it was noted that drug1 or drug0 treatment of relapses for periods of up to 28 days has been administered to patients (N=180) receiving drug2",False, 
DDI-DrugBank.d10.s2.e0,DDI-DrugBank.d10.s2.e1,drug1 administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of drug2 elimination.14 The effect of alternate-day administration of 0.25 mg of drug0,True,mechanism
DDI-DrugBank.d10.s2.e0,DDI-DrugBank.d10.s2.e2,drug1 administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of drug0 elimination.14 The effect of alternate-day administration of 0.25 mg of drug2,False, 
DDI-DrugBank.d10.s2.e1,DDI-DrugBank.d10.s2.e2,drug0 administration to three cancer patients over a dose range of 0.025 mg to 2.2 mg led to a dose-dependent inhibition of drug1 elimination.14 The effect of alternate-day administration of 0.25 mg of drug2,False, 
DDI-DrugBank.d45.s0.e0,DDI-DrugBank.d45.s0.e1,Concurrent administration of drug1 (another TNF -blocking agent) and drug2 (an drug0,True,effect
DDI-DrugBank.d45.s0.e0,DDI-DrugBank.d45.s0.e2,Concurrent administration of drug1 (another TNF -blocking agent) and drug0 (an drug2,False, 
DDI-DrugBank.d45.s0.e1,DDI-DrugBank.d45.s0.e2,Concurrent administration of drug0 (another TNF -blocking agent) and drug1 (an drug2,False, 
DDI-DrugBank.d45.s1.e0,DDI-DrugBank.d45.s1.e1,Other drug1 (including drug2) used in combination with drug0,False, 
DDI-DrugBank.d45.s1.e0,DDI-DrugBank.d45.s1.e2,Other drug1 (including drug0) used in combination with drug2,True,effect
DDI-DrugBank.d45.s1.e1,DDI-DrugBank.d45.s1.e2,Other drug0 (including drug1) used in combination with drug2,True,effect
DDI-DrugBank.d45.s4.e0,DDI-DrugBank.d45.s4.e1,"In rheumatoid arthritis, concomitant medications besides drug1 were drug2, drug0, drug0 and/or drug0",False, 
DDI-DrugBank.d45.s4.e0,DDI-DrugBank.d45.s4.e2,"In rheumatoid arthritis, concomitant medications besides drug1 were drug0, drug2, drug0 and/or drug0",False, 
DDI-DrugBank.d45.s5.e0,DDI-DrugBank.d45.s5.e1,"Concomitant Crohn s disease medications were drug1, drug2, drug0, drug0/drug0",False, 
DDI-DrugBank.d45.s5.e0,DDI-DrugBank.d45.s5.e2,"Concomitant Crohn s disease medications were drug1, drug0, drug2, drug0/drug0",False, 
DDI-DrugBank.d45.s6.e0,DDI-DrugBank.d45.s6.e1,"In psoriatic arthritis clinical trials, concomitant medications included drug1 in approximately half of the patients as well as drug2, drug0 and drug0",False, 
DDI-DrugBank.d45.s6.e0,DDI-DrugBank.d45.s6.e2,"In psoriatic arthritis clinical trials, concomitant medications included drug1 in approximately half of the patients as well as drug0, drug2 and drug0",False, 
DDI-DrugBank.d45.s7.e0,DDI-DrugBank.d45.s7.e1,Patients with Crohn s disease who received drug1 tended to experience fewer infusion reactions compared to patients on no drug2,False, 
DDI-DrugBank.d45.s8.e0,DDI-DrugBank.d45.s8.e1,"Serum drug1 concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including drug2, drug0 (drug0 or drug0",False, 
DDI-DrugBank.d45.s8.e0,DDI-DrugBank.d45.s8.e2,"Serum drug1 concentrations appeared to be unaffected by baseline use of medications for the treatment of Crohn s disease including drug0, drug2 (drug0 or drug0",False, 
DDI-DrugBank.d53.s0.e0,DDI-DrugBank.d53.s0.e1,Co-administration of drug1 at steady-state with a single dose of drug2,False, 
DDI-DrugBank.d53.s1.e0,DDI-DrugBank.d53.s1.e1,Co-administration of drug1 at steady-state with a single dose of drug2 (2 x 600 mg tablets) results in increased drug0,True,effect
DDI-DrugBank.d53.s1.e0,DDI-DrugBank.d53.s1.e2,Co-administration of drug1 at steady-state with a single dose of drug0 (2 x 600 mg tablets) results in increased drug2,False, 
DDI-DrugBank.d53.s1.e1,DDI-DrugBank.d53.s1.e2,Co-administration of drug0 at steady-state with a single dose of drug1 (2 x 600 mg tablets) results in increased drug2,False, 
DDI-DrugBank.d53.s2.e0,DDI-DrugBank.d53.s2.e1,"Although a dose adjustment of drug1 is not recommended when administered in combination with drug2, close monitoring for known side effects of drug0",True,advise
DDI-DrugBank.d53.s2.e0,DDI-DrugBank.d53.s2.e2,"Although a dose adjustment of drug1 is not recommended when administered in combination with drug0, close monitoring for known side effects of drug2",False, 
DDI-DrugBank.d53.s2.e1,DDI-DrugBank.d53.s2.e2,"Although a dose adjustment of drug0 is not recommended when administered in combination with drug1, close monitoring for known side effects of drug2",False, 
DDI-DrugBank.d53.s3.e0,DDI-DrugBank.d53.s3.e1,drug1 did not affect the prothrombin time response to a single dose of drug2,False, 
DDI-DrugBank.d53.s4.e0,DDI-DrugBank.d53.s4.e1,"However, prudent medical practice dictates careful monitoring of prothrombin time in all patients treated with drug1 and drug2",True,advise
DDI-DrugBank.d53.s5.e0,DDI-DrugBank.d53.s5.e1,Concurrent use of drug1 and drug2,True,effect
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e1,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e2,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e3,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e4,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e5,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e6,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e7,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e8,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e9,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e10,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e11,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2 (intravenous and oral), drug0, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e12,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug2, drug0/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e13,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug2/drug0 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e14,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug2 or drug0",True,mechanism
DDI-DrugBank.d53.s7.e0,DDI-DrugBank.d53.s7.e15,"When used in therapeutic doses, drug1 had a modest effect on the pharmacokinetics of drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug2",True,mechanism
DDI-DrugBank.d53.s7.e1,DDI-DrugBank.d53.s7.e2,"When used in therapeutic doses, drug0 had a modest effect on the pharmacokinetics of drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",False, 
DDI-DrugBank.d53.s7.e1,DDI-DrugBank.d53.s7.e3,"When used in therapeutic doses, drug0 had a modest effect on the pharmacokinetics of drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 (intravenous and oral), drug0, drug0/drug0 or drug0",False, 
DDI-DrugBank.d53.s8.e0,DDI-DrugBank.d53.s8.e1,Co-administration with drug1 or drug2 had a modest effect on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d53.s8.e0,DDI-DrugBank.d53.s8.e2,Co-administration with drug1 or drug0 had a modest effect on the pharmacokinetics of drug2,True,mechanism
DDI-DrugBank.d53.s8.e1,DDI-DrugBank.d53.s8.e2,Co-administration with drug0 or drug1 had a modest effect on the pharmacokinetics of drug2,True,mechanism
DDI-DrugBank.d53.s13.e0,DDI-DrugBank.d53.s13.e1,"Until further data are developed regarding drug interactions when drug1 and these drugs are used concomitantly, careful monitoring of patients is advised: drug2 elevated drug0",False, 
DDI-DrugBank.d53.s13.e0,DDI-DrugBank.d53.s13.e2,"Until further data are developed regarding drug interactions when drug1 and these drugs are used concomitantly, careful monitoring of patients is advised: drug0 elevated drug2",False, 
DDI-DrugBank.d53.s14.e0,DDI-DrugBank.d53.s14.e1,drug1 or drug2,False, 
DDI-DrugBank.d53.s15.e0,DDI-DrugBank.d53.s15.e1,"drug1, drug2 and drug0",False, 
DDI-DrugBank.d53.s15.e0,DDI-DrugBank.d53.s15.e2,"drug1, drug0 and drug2",False, 
DDI-DrugBank.d162.s1.e0,DDI-DrugBank.d162.s1.e1,"drug1, drug2, or drug0",False, 
DDI-DrugBank.d162.s1.e0,DDI-DrugBank.d162.s1.e2,"drug1, drug0, or drug2",False, 
DDI-DrugBank.d162.s2.e0,DDI-DrugBank.d162.s2.e1,drug1: (oral agents and drug2) - dosage adjustment of the drug0,False, 
DDI-DrugBank.d162.s2.e0,DDI-DrugBank.d162.s2.e2,drug1: (oral agents and drug0) - dosage adjustment of the drug2,False, 
DDI-DrugBank.d162.s4.e0,DDI-DrugBank.d162.s4.e1,drug1 and drug2 drug0: Absorption of drug0 is impaired in the presence of drug0,False, 
DDI-DrugBank.d162.s4.e0,DDI-DrugBank.d162.s4.e2,drug1 and drug0 drug2: Absorption of drug0 is impaired in the presence of drug0,False, 
DDI-DrugBank.d162.s4.e3,DDI-DrugBank.d162.s4.e4,drug0 and drug0 drug0: Absorption of drug1 is impaired in the presence of drug2,True,mechanism
DDI-DrugBank.d162.s5.e0,DDI-DrugBank.d162.s5.e1,Single doses of either drug1 or drug2 drug0 bind the drug0,False, 
DDI-DrugBank.d162.s5.e0,DDI-DrugBank.d162.s5.e2,Single doses of either drug1 or drug0 drug2 bind the drug0,False, 
DDI-DrugBank.d162.s5.e0,DDI-DrugBank.d162.s5.e3,Single doses of either drug1 or drug0 drug0 bind the drug2,True,mechanism
DDI-DrugBank.d162.s5.e1,DDI-DrugBank.d162.s5.e3,Single doses of either drug0 or drug1 drug0 bind the drug2,True,mechanism
DDI-DrugBank.d162.s6.e0,DDI-DrugBank.d162.s6.e1,"drug1, drug2",False, 
DDI-DrugBank.d162.s8.e0,DDI-DrugBank.d162.s8.e1,"drug1, nondepolarizing (e.g., drug2): possible increased responsiveness to the drug0",False, 
DDI-DrugBank.d162.s8.e0,DDI-DrugBank.d162.s8.e2,"drug1, nondepolarizing (e.g., drug0): possible increased responsiveness to the drug2",False, 
DDI-DrugBank.d162.s9.e0,DDI-DrugBank.d162.s9.e1,drug1: generally should not be given with drug2,True,advise
DDI-DrugBank.d162.s10.e0,DDI-DrugBank.d162.s10.e1,drug1 reduce the renal clearance of drug2 and add a high risk of drug0,True,mechanism
DDI-DrugBank.d162.s10.e0,DDI-DrugBank.d162.s10.e2,drug1 reduce the renal clearance of drug0 and add a high risk of drug2,True,effect
DDI-DrugBank.d162.s10.e1,DDI-DrugBank.d162.s10.e2,drug0 reduce the renal clearance of drug1 and add a high risk of drug2,False, 
DDI-DrugBank.d162.s11.e0,DDI-DrugBank.d162.s11.e1,Refer to the package insert for drug1 preparations before use of such preparations with drug2,True,advise
DDI-DrugBank.d162.s12.e0,DDI-DrugBank.d162.s12.e1,"drug1: In some patients, the administration of a drug2 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug0",False, 
DDI-DrugBank.d162.s12.e0,DDI-DrugBank.d162.s12.e2,"drug1: In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",False, 
DDI-DrugBank.d162.s12.e1,DDI-DrugBank.d162.s12.e2,"drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",True,effect
DDI-DrugBank.d162.s12.e1,DDI-DrugBank.d162.s12.e3,"drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2 and drug0",True,effect
DDI-DrugBank.d162.s12.e1,DDI-DrugBank.d162.s12.e4,"drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug2",True,effect
DDI-DrugBank.d162.s13.e0,DDI-DrugBank.d162.s13.e1,"Therefore, when drug1 and drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",True,advise
DDI-DrugBank.d162.s13.e0,DDI-DrugBank.d162.s13.e2,"Therefore, when drug1 and drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d162.s13.e1,DDI-DrugBank.d162.s13.e2,"Therefore, when drug0 and drug1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d483.s1.e0,DDI-DrugBank.d483.s1.e1,If drug1 and an drug2,True,effect
DDI-DrugBank.d483.s4.e0,DDI-DrugBank.d483.s4.e1,"As with other drug1, high concentrations of drug2",False, 
DDI-DrugBank.d96.s0.e0,DDI-DrugBank.d96.s0.e1,drug1 may decrease drug2 response to drug0,False, 
DDI-DrugBank.d96.s0.e0,DDI-DrugBank.d96.s0.e2,drug1 may decrease drug0 response to drug2,True,effect
DDI-DrugBank.d96.s0.e1,DDI-DrugBank.d96.s0.e2,drug0 may decrease drug1 response to drug2,False, 
DDI-DrugBank.d197.s1.e0,DDI-DrugBank.d197.s1.e1,"drug1/drug2/drug0/drug0: Co-administration of drug0 with drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d197.s1.e0,DDI-DrugBank.d197.s1.e2,"drug1/drug0/drug2/drug0: Co-administration of drug0 with drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d197.s1.e4,DDI-DrugBank.d197.s1.e5,"drug0/drug0/drug0/drug0: Co-administration of drug1 with drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d197.s1.e4,DDI-DrugBank.d197.s1.e6,"drug0/drug0/drug0/drug0: Co-administration of drug1 with drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d197.s1.e4,DDI-DrugBank.d197.s1.e7,"drug0/drug0/drug0/drug0: Co-administration of drug1 with drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d197.s1.e4,DDI-DrugBank.d197.s1.e8,"drug0/drug0/drug0/drug0: Co-administration of drug1 with drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d197.s2.e0,DDI-DrugBank.d197.s2.e1,"Specific studies have confirmed these effects with drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d197.s2.e0,DDI-DrugBank.d197.s2.e2,"Specific studies have confirmed these effects with drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d197.s3.e0,DDI-DrugBank.d197.s3.e1,"No pharmacokinetic interactions between drug1 and drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d197.s3.e0,DDI-DrugBank.d197.s3.e2,"No pharmacokinetic interactions between drug1 and drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d197.s4.e0,DDI-DrugBank.d197.s4.e1,"However, due to possible pharmacodynamic interactions, when co-administered with drug1, a reduction in dosage of drug2 on the concomitant drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d197.s4.e0,DDI-DrugBank.d197.s4.e2,"However, due to possible pharmacodynamic interactions, when co-administered with drug1, a reduction in dosage of drug0 on the concomitant drug2, drug0, drug0 or drug0",False, 
DDI-DrugBank.d197.s4.e1,DDI-DrugBank.d197.s4.e2,"However, due to possible pharmacodynamic interactions, when co-administered with drug0, a reduction in dosage of drug1 on the concomitant drug2, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d197.s4.e1,DDI-DrugBank.d197.s4.e3,"However, due to possible pharmacodynamic interactions, when co-administered with drug0, a reduction in dosage of drug1 on the concomitant drug0, drug2, drug0 or drug0",True,advise
DDI-DrugBank.d197.s4.e1,DDI-DrugBank.d197.s4.e4,"However, due to possible pharmacodynamic interactions, when co-administered with drug0, a reduction in dosage of drug1 on the concomitant drug0, drug0, drug2 or drug0",True,advise
DDI-DrugBank.d197.s4.e1,DDI-DrugBank.d197.s4.e5,"However, due to possible pharmacodynamic interactions, when co-administered with drug0, a reduction in dosage of drug1 on the concomitant drug0, drug0, drug0 or drug2",True,advise
DDI-DrugBank.d197.s5.e0,DDI-DrugBank.d197.s5.e1,"drug1: In one study of 10 healthy volunteers, administration of drug2 for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with drug0",False, 
DDI-DrugBank.d197.s5.e0,DDI-DrugBank.d197.s5.e2,"drug1: In one study of 10 healthy volunteers, administration of drug0 for 45 minutes at a plasma concentration of 1 (one) ng/mL resulted in no clinically meaningful increases in the magnitude or neuromuscular blockade associated with drug2",False, 
DDI-DrugBank.d389.s0.e0,DDI-DrugBank.d389.s0.e1,"drug1 may enhance the effects of drug2, drug0, drug0, and other drug0",True,effect
DDI-DrugBank.d389.s0.e0,DDI-DrugBank.d389.s0.e2,"drug1 may enhance the effects of drug0, drug2, drug0, and other drug0",True,effect
DDI-DrugBank.d389.s0.e0,DDI-DrugBank.d389.s0.e3,"drug1 may enhance the effects of drug0, drug0, drug2, and other drug0",True,effect
DDI-DrugBank.d389.s0.e0,DDI-DrugBank.d389.s0.e4,"drug1 may enhance the effects of drug0, drug0, drug0, and other drug2",True,effect
DDI-DrugBank.d389.s0.e1,DDI-DrugBank.d389.s0.e2,"drug0 may enhance the effects of drug1, drug2, drug0, and other drug0",False, 
DDI-DrugBank.d389.s0.e1,DDI-DrugBank.d389.s0.e3,"drug0 may enhance the effects of drug1, drug0, drug2, and other drug0",False, 
DDI-DrugBank.d389.s1.e0,DDI-DrugBank.d389.s1.e1,drug1 prolong and intensify the anticholinergic effects of drug2,True,effect
DDI-DrugBank.d389.s2.e0,DDI-DrugBank.d389.s2.e1,"drug1 may reduce the antihypertensive effects of drug2, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d389.s2.e0,DDI-DrugBank.d389.s2.e2,"drug1 may reduce the antihypertensive effects of drug0, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d389.s2.e0,DDI-DrugBank.d389.s2.e3,"drug1 may reduce the antihypertensive effects of drug0, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d389.s2.e0,DDI-DrugBank.d389.s2.e4,"drug1 may reduce the antihypertensive effects of drug0, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d389.s2.e1,DDI-DrugBank.d389.s2.e2,"drug0 may reduce the antihypertensive effects of drug1, drug2, drug0 and drug0",False, 
DDI-DrugBank.d389.s2.e1,DDI-DrugBank.d389.s2.e3,"drug0 may reduce the antihypertensive effects of drug1, drug0, drug2 and drug0",False, 
DDI-DrugBank.d389.s3.e0,DDI-DrugBank.d389.s3.e1,Effects of drug1 are increased with drug2 and drug0,True,effect
DDI-DrugBank.d389.s3.e0,DDI-DrugBank.d389.s3.e2,Effects of drug1 are increased with drug0 and drug2,True,effect
DDI-DrugBank.d389.s3.e1,DDI-DrugBank.d389.s3.e2,Effects of drug0 are increased with drug1 and drug2,False, 
DDI-DrugBank.d470.s1.e0,DDI-DrugBank.d470.s1.e1,Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval (e.g. certain drug2 or drug0) or lead to electrolyte abnormalities (such as drug0 or drug0,True,advise
DDI-DrugBank.d470.s1.e0,DDI-DrugBank.d470.s1.e2,Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval (e.g. certain drug0 or drug2) or lead to electrolyte abnormalities (such as drug0 or drug0,True,advise
DDI-DrugBank.d470.s1.e0,DDI-DrugBank.d470.s1.e3,Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval (e.g. certain drug0 or drug0) or lead to electrolyte abnormalities (such as drug2 or drug0,True,advise
DDI-DrugBank.d470.s1.e0,DDI-DrugBank.d470.s1.e4,Caution is advised when drug1 is coadministered with other medications that can prolong the QT interval (e.g. certain drug0 or drug0) or lead to electrolyte abnormalities (such as drug0 or drug2,True,advise
DDI-DrugBank.d470.s1.e1,DDI-DrugBank.d470.s1.e2,Caution is advised when drug0 is coadministered with other medications that can prolong the QT interval (e.g. certain drug1 or drug2) or lead to electrolyte abnormalities (such as drug0 or drug0,False, 
DDI-DrugBank.d470.s1.e1,DDI-DrugBank.d470.s1.e3,Caution is advised when drug0 is coadministered with other medications that can prolong the QT interval (e.g. certain drug1 or drug0) or lead to electrolyte abnormalities (such as drug2 or drug0,False, 
DDI-DrugBank.d298.s0.e0,DDI-DrugBank.d298.s0.e1,drug1 may interfere with the anti-glaucoma action of drug2 or drug0,True,effect
DDI-DrugBank.d298.s0.e0,DDI-DrugBank.d298.s0.e2,drug1 may interfere with the anti-glaucoma action of drug0 or drug2,True,effect
DDI-DrugBank.d298.s0.e1,DDI-DrugBank.d298.s0.e2,drug0 may interfere with the anti-glaucoma action of drug1 or drug2,False, 
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e1,"drug1 may interact with drug2, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e2,"drug1 may interact with drug0, drug2s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e3,"drug1 may interact with drug0, drug0s, drug2 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e4,"drug1 may interact with drug0, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug2, drug0, drug0 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e5,"drug1 may interact with drug0, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug2, drug0 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e6,"drug1 may interact with drug0, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug2 like drug0 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e7,"drug1 may interact with drug0, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug2 or drug0",True,int
DDI-DrugBank.d208.s0.e0,DDI-DrugBank.d208.s0.e8,"drug1 may interact with drug0, drug0s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug2",True,int
DDI-DrugBank.d208.s0.e1,DDI-DrugBank.d208.s0.e2,"drug0 may interact with drug1, drug2s, drug0 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug0",False, 
DDI-DrugBank.d208.s0.e1,DDI-DrugBank.d208.s0.e3,"drug0 may interact with drug1, drug0s, drug2 (allergy, cold, and sinus medicines), diabetic drugs, drug0, drug0, drug0 like drug0 or drug0",False, 
DDI-DrugBank.d548.s0.e0,DDI-DrugBank.d548.s0.e1,Potential for Other Drugs to Affect drug1: Both CYP1A2 and CYP2D6 are responsible for drug2,False, 
DDI-DrugBank.d548.s1.e0,DDI-DrugBank.d548.s1.e1,"Inhibitors of CYP1A2: Concomitant use of drug1 with drug2, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of drug0",True,mechanism
DDI-DrugBank.d548.s1.e0,DDI-DrugBank.d548.s1.e2,"Inhibitors of CYP1A2: Concomitant use of drug1 with drug0, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of drug2",False, 
DDI-DrugBank.d548.s1.e1,DDI-DrugBank.d548.s1.e2,"Inhibitors of CYP1A2: Concomitant use of drug0 with drug1, an inhibitor of CYP1A2, results in approximately a 6-fold increase in AUC and about a 2.5-fold increase in Cmax of drug2",False, 
DDI-DrugBank.d548.s3.e0,DDI-DrugBank.d548.s3.e1,"Inhibitors of CYP2D6: Because CYP2D6 is involved in drug1 metabolism, concomitant use of drug2 with potent inhibitors of CYP2D6 may result in higher concentrations of drug0",False, 
DDI-DrugBank.d548.s3.e0,DDI-DrugBank.d548.s3.e2,"Inhibitors of CYP2D6: Because CYP2D6 is involved in drug1 metabolism, concomitant use of drug0 with potent inhibitors of CYP2D6 may result in higher concentrations of drug2",False, 
DDI-DrugBank.d548.s4.e0,DDI-DrugBank.d548.s4.e1,"drug1 (20 mg QD) increased the concentration of drug2 (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of drug0",True,mechanism
DDI-DrugBank.d548.s4.e0,DDI-DrugBank.d548.s4.e2,"drug1 (20 mg QD) increased the concentration of drug0 (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of drug2",False, 
DDI-DrugBank.d548.s4.e1,DDI-DrugBank.d548.s4.e2,"drug0 (20 mg QD) increased the concentration of drug1 (40 mg QD) by about 60%, and greater degrees of inhibition are expected with higher doses of drug2",False, 
DDI-DrugBank.d548.s5.e0,DDI-DrugBank.d548.s5.e1,"Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., drug1, drug2",False, 
DDI-DrugBank.d548.s6.e0,DDI-DrugBank.d548.s6.e1,Potential for drug1 to Affect Other Drugs: Drugs Metabolized by CYP1A2: In vitro drug interaction studies demonstrate that drug2,False, 
DDI-DrugBank.d548.s8.e0,DDI-DrugBank.d548.s8.e1,"When drug1 was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of drug2, a CYP2D6 substrate, the AUC of drug0",True,mechanism
DDI-DrugBank.d548.s8.e0,DDI-DrugBank.d548.s8.e2,"When drug1 was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of drug0, a CYP2D6 substrate, the AUC of drug2",False, 
DDI-DrugBank.d548.s8.e1,DDI-DrugBank.d548.s8.e2,"When drug0 was administered (at a dose of 60 mg BID) in conjunction with a single 50-mg dose of drug1, a CYP2D6 substrate, the AUC of drug2",False, 
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e1,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug2 (drug0 [drug0], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e2,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug2 [drug0], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e3,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug2], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e4,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug2, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e5,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug2, and drug0), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e6,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug0, and drug2), drug0 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e7,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug0, and drug0), drug2 and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e8,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug0, and drug0), drug0 and drug2 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e9,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug2, drug0",True,advise
DDI-DrugBank.d548.s9.e0,DDI-DrugBank.d548.s9.e10,"Therefore, co-administration of drug1 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug0 (drug0 [drug0], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug2",True,advise
DDI-DrugBank.d548.s9.e1,DDI-DrugBank.d548.s9.e2,"Therefore, co-administration of drug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug1 (drug2 [drug0], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d548.s9.e1,DDI-DrugBank.d548.s9.e3,"Therefore, co-administration of drug0 with other drugs that are extensively metabolized by this isozyme and which have a narrow therapeutic index, including certain drug1 (drug0 [drug2], such as drug0, drug0, and drug0), drug0 and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d548.s10.e0,DDI-DrugBank.d548.s10.e1,Plasma drug1 concentrations may need to be monitored and the dose of the drug2 may need to be reduced if a drug0 is co-administered with drug0,False, 
DDI-DrugBank.d548.s10.e0,DDI-DrugBank.d548.s10.e2,Plasma drug1 concentrations may need to be monitored and the dose of the drug0 may need to be reduced if a drug2 is co-administered with drug0,False, 
DDI-DrugBank.d548.s10.e2,DDI-DrugBank.d548.s10.e3,Plasma drug0 concentrations may need to be monitored and the dose of the drug0 may need to be reduced if a drug1 is co-administered with drug2,True,advise
DDI-DrugBank.d548.s11.e0,DDI-DrugBank.d548.s11.e1,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of drug1, drug2 and drug0",False, 
DDI-DrugBank.d548.s11.e0,DDI-DrugBank.d548.s11.e2,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of drug1, drug0 and drug2",False, 
DDI-DrugBank.d548.s11.e1,DDI-DrugBank.d548.s11.e2,"Because of the risk of serious ventricular arrhythmias and sudden death potentially associated with elevated plasma levels of drug0, drug1 and drug2",True,advise
DDI-DrugBank.d548.s13.e0,DDI-DrugBank.d548.s13.e1,"drug1 May Have a Clinically Important Interaction with the Following Other Drugs: drug2: When drug0 and drug0 were administered several hours apart so that peak concentrations of each would coincide, drug0 did not increase the impairment of mental and motor skills caused by drug0",False, 
DDI-DrugBank.d548.s13.e0,DDI-DrugBank.d548.s13.e2,"drug1 May Have a Clinically Important Interaction with the Following Other Drugs: drug0: When drug2 and drug0 were administered several hours apart so that peak concentrations of each would coincide, drug0 did not increase the impairment of mental and motor skills caused by drug0",False, 
DDI-DrugBank.d548.s14.e0,DDI-DrugBank.d548.s14.e1,"In the drug1 clinical trials database, three drug2",False, 
DDI-DrugBank.d548.s21.e0,DDI-DrugBank.d548.s21.e1,"However, co-administration of drug1 with drug2- and drug0-containing drug0 (51 mEq) or drug0 with drug0, had no significant effect on the rate or extent of drug0",False, 
DDI-DrugBank.d548.s21.e0,DDI-DrugBank.d548.s21.e2,"However, co-administration of drug1 with drug0- and drug2-containing drug0 (51 mEq) or drug0 with drug0, had no significant effect on the rate or extent of drug0",False, 
DDI-DrugBank.d548.s22.e0,DDI-DrugBank.d548.s22.e1,It is unknown whether the concomitant administration of drug1 affects drug2,False, 
DDI-DrugBank.d428.s1.e0,DDI-DrugBank.d428.s1.e1,"Concomitant use of drug1 with other cardioactive compounds that could cause heart failure (e.g., drug2",True,advise
DDI-DrugBank.d428.s10.e0,DDI-DrugBank.d428.s10.e1,drug1 increased the AUC of drug2,True,mechanism
DDI-DrugBank.d428.s11.e0,DDI-DrugBank.d428.s11.e1,drug1 treatment should be stopped during treatment with drug2,True,advise
DDI-DrugBank.d295.s0.e0,DDI-DrugBank.d295.s0.e1,"Since drug1 is primarily eliminated by the kidneys, coadministration of drug2 with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either drug0",False, 
DDI-DrugBank.d295.s0.e0,DDI-DrugBank.d295.s0.e2,"Since drug1 is primarily eliminated by the kidneys, coadministration of drug0 with drugs that reduce renal function or compete for active tubular secretion may increase serum concentrations of either drug2",False, 
DDI-DrugBank.d295.s1.e0,DDI-DrugBank.d295.s1.e1,"Coadministration of drug1 with drug2, drug0,or drug0",False, 
DDI-DrugBank.d295.s1.e0,DDI-DrugBank.d295.s1.e2,"Coadministration of drug1 with drug0, drug2,or drug0",False, 
DDI-DrugBank.d295.s2.e0,DDI-DrugBank.d295.s2.e1,"The effects of coadministration of drug1 with other drugs that are renally eliminated or are known to affect renal function have not been evaluated, and patients should be monitored closely for adverse events when drug2",False, 
DDI-DrugBank.d311.s0.e0,DDI-DrugBank.d311.s0.e1,Taking a drug1 while you are taking or within 2 weeks of taking drug2,True,effect
DDI-DrugBank.d468.s0.e0,DDI-DrugBank.d468.s0.e1,"drug1: In controlled clinical studies, drug2 have been frequently administered concomitantly with drug0",False, 
DDI-DrugBank.d468.s0.e0,DDI-DrugBank.d468.s0.e2,"drug1: In controlled clinical studies, drug0 have been frequently administered concomitantly with drug2",False, 
DDI-DrugBank.d468.s2.e0,DDI-DrugBank.d468.s2.e1,drug1: drug2 increases drug0,False, 
DDI-DrugBank.d468.s2.e0,DDI-DrugBank.d468.s2.e2,drug1: drug0 increases drug2,False, 
DDI-DrugBank.d468.s2.e1,DDI-DrugBank.d468.s2.e2,drug0: drug1 increases drug2,True,mechanism
DDI-DrugBank.d468.s4.e0,DDI-DrugBank.d468.s4.e1,drug1: Some drug2 may increase the concentration of drug0,False, 
DDI-DrugBank.d468.s4.e0,DDI-DrugBank.d468.s4.e2,drug1: Some drug0 may increase the concentration of drug2,False, 
DDI-DrugBank.d468.s4.e1,DDI-DrugBank.d468.s4.e2,drug0: Some drug1 may increase the concentration of drug2,True,mechanism
DDI-DrugBank.d468.s5.e0,DDI-DrugBank.d468.s5.e1,"drug1 usually does not alter the plasma levels of drug2, however, serum drug0 levels should be evaluated after concomitant therapy with drug0",False, 
DDI-DrugBank.d468.s5.e0,DDI-DrugBank.d468.s5.e2,"drug1 usually does not alter the plasma levels of drug0, however, serum drug2 levels should be evaluated after concomitant therapy with drug0",False, 
DDI-DrugBank.d468.s5.e2,DDI-DrugBank.d468.s5.e3,"drug0 usually does not alter the plasma levels of drug0, however, serum drug1 levels should be evaluated after concomitant therapy with drug2",True,advise
DDI-DrugBank.d468.s6.e0,DDI-DrugBank.d468.s6.e1,drug1 * Coadministration of drug2 had no effect on drug0,False, 
DDI-DrugBank.d468.s6.e0,DDI-DrugBank.d468.s6.e2,drug1 * Coadministration of drug0 had no effect on drug2,False, 
DDI-DrugBank.d468.s8.e0,DDI-DrugBank.d468.s8.e1,drug1: Concomitant administration of drug2 and drug0,False, 
DDI-DrugBank.d468.s8.e0,DDI-DrugBank.d468.s8.e2,drug1: Concomitant administration of drug0 and drug2,False, 
DDI-DrugBank.d468.s9.e0,DDI-DrugBank.d468.s9.e1,"Plasma concentrations of drug1 should therefore be closely monitored, and its dosage reduced accordingly, in patients treated with drug2",True,advise
DDI-DrugBank.d468.s10.e0,DDI-DrugBank.d468.s10.e1,"When therapeutic concentrations of drug1, drug2, drug0, drug0, drug0, or drug0 were added to human plasma (in vitro), the plasma protein binding of drug0",False, 
DDI-DrugBank.d468.s10.e0,DDI-DrugBank.d468.s10.e2,"When therapeutic concentrations of drug1, drug0, drug2, drug0, drug0, or drug0 were added to human plasma (in vitro), the plasma protein binding of drug0",False, 
DDI-DrugBank.d263.s0.e0,DDI-DrugBank.d263.s0.e1,drug1: There is no significant pharmacokinetic interaction between drug2 and drug0,False, 
DDI-DrugBank.d263.s0.e0,DDI-DrugBank.d263.s0.e2,drug1: There is no significant pharmacokinetic interaction between drug0 and drug2,False, 
DDI-DrugBank.d263.s1.e0,DDI-DrugBank.d263.s1.e1,drug1 also has no significant effect on the intracellular phosphorylation of drug2,True,effect
DDI-DrugBank.d263.s2.e0,DDI-DrugBank.d263.s2.e1,In the same study it was shown that drug1 and drug2 had no significant effect on the intracellular phosphorylation of drug0,False, 
DDI-DrugBank.d263.s2.e0,DDI-DrugBank.d263.s2.e2,In the same study it was shown that drug1 and drug0 had no significant effect on the intracellular phosphorylation of drug2,False, 
DDI-DrugBank.d263.s3.e0,DDI-DrugBank.d263.s3.e1,"drug1: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that drug2 significantly inhibited drug0",False, 
DDI-DrugBank.d263.s3.e0,DDI-DrugBank.d263.s3.e2,"drug1: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that drug0 significantly inhibited drug2",False, 
DDI-DrugBank.d263.s3.e1,DDI-DrugBank.d263.s3.e2,"drug0: In vitro studies in peripheral blood mononuclear cells, U937 and Molt-4 cells revealed that drug1 significantly inhibited drug2",True,effect
DDI-DrugBank.d263.s5.e0,DDI-DrugBank.d263.s5.e1,drug1 inhibited drug2,True,effect
DDI-DrugBank.d263.s6.e0,DDI-DrugBank.d263.s6.e1,"however, it is considered to be unlikely that this decrease of phosphorylated drug1 concentration is of clinical significance, as drug2 is a more efficient substrate for deoxycytidine kinase than drug0",False, 
DDI-DrugBank.d263.s6.e0,DDI-DrugBank.d263.s6.e2,"however, it is considered to be unlikely that this decrease of phosphorylated drug1 concentration is of clinical significance, as drug0 is a more efficient substrate for deoxycytidine kinase than drug2",False, 
DDI-DrugBank.d263.s7.e0,DDI-DrugBank.d263.s7.e1,"These in vitro studies suggest that concomitant administration of drug1 and drug2 in humans may result in sub-therapeutic concentrations of active phosphorylated drug0, which may lead to a decreased drug0 effect of drug0",True,effect
DDI-DrugBank.d263.s7.e0,DDI-DrugBank.d263.s7.e2,"These in vitro studies suggest that concomitant administration of drug1 and drug0 in humans may result in sub-therapeutic concentrations of active phosphorylated drug2, which may lead to a decreased drug0 effect of drug0",False, 
DDI-DrugBank.d263.s7.e0,DDI-DrugBank.d263.s7.e3,"These in vitro studies suggest that concomitant administration of drug1 and drug0 in humans may result in sub-therapeutic concentrations of active phosphorylated drug0, which may lead to a decreased drug2 effect of drug0",False, 
DDI-DrugBank.d263.s9.e0,DDI-DrugBank.d263.s9.e1,Concomitant use of drug1 and drug2,True,advise
DDI-DrugBank.d263.s10.e0,DDI-DrugBank.d263.s10.e1,"drug1: The combination of drug2, drug0, and drug0",False, 
DDI-DrugBank.d263.s10.e0,DDI-DrugBank.d263.s10.e2,"drug1: The combination of drug0, drug2, and drug0",False, 
DDI-DrugBank.d263.s13.e0,DDI-DrugBank.d263.s13.e1,"Drugs that have been associated with peripheral neuropathy include drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d263.s13.e0,DDI-DrugBank.d263.s13.e2,"Drugs that have been associated with peripheral neuropathy include drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d263.s14.e0,DDI-DrugBank.d263.s14.e1,Concomitant use of drug1 with drug2,True,advise
DDI-DrugBank.d263.s15.e0,DDI-DrugBank.d263.s15.e1,Intravenous drug1: Treatment with drug2,False, 
DDI-DrugBank.d263.s16.e0,DDI-DrugBank.d263.s16.e1,Death due to fulminant pancreatitis possibly related to intravenous drug1 and drug2,True,effect
DDI-DrugBank.d263.s17.e0,DDI-DrugBank.d263.s17.e1,"If intravenous drug1 is required to treat Pneumocystis carinii pneumonia, treatment with drug2",True,advise
DDI-DrugBank.d263.s18.e0,DDI-DrugBank.d263.s18.e1,"drug1, drug2, and drug0: Drugs such as drug0, drug0, and drug0 may increase the risk of developing peripheral neuropathy or other drug0-associated adverse events by interfering with the renal clearance of drug0",False, 
DDI-DrugBank.d263.s18.e0,DDI-DrugBank.d263.s18.e2,"drug1, drug0, and drug2: Drugs such as drug0, drug0, and drug0 may increase the risk of developing peripheral neuropathy or other drug0-associated adverse events by interfering with the renal clearance of drug0",False, 
DDI-DrugBank.d263.s18.e3,DDI-DrugBank.d263.s18.e6,"drug0, drug0, and drug0: Drugs such as drug1, drug0, and drug0 may increase the risk of developing peripheral neuropathy or other drug2-associated adverse events by interfering with the renal clearance of drug0",True,effect
DDI-DrugBank.d263.s18.e3,DDI-DrugBank.d263.s18.e7,"drug0, drug0, and drug0: Drugs such as drug1, drug0, and drug0 may increase the risk of developing peripheral neuropathy or other drug0-associated adverse events by interfering with the renal clearance of drug2",True,mechanism
DDI-DrugBank.d263.s18.e4,DDI-DrugBank.d263.s18.e6,"drug0, drug0, and drug0: Drugs such as drug0, drug1, and drug0 may increase the risk of developing peripheral neuropathy or other drug2-associated adverse events by interfering with the renal clearance of drug0",True,effect
DDI-DrugBank.d263.s18.e4,DDI-DrugBank.d263.s18.e7,"drug0, drug0, and drug0: Drugs such as drug0, drug1, and drug0 may increase the risk of developing peripheral neuropathy or other drug0-associated adverse events by interfering with the renal clearance of drug2",True,mechanism
DDI-DrugBank.d263.s18.e5,DDI-DrugBank.d263.s18.e6,"drug0, drug0, and drug0: Drugs such as drug0, drug0, and drug1 may increase the risk of developing peripheral neuropathy or other drug2-associated adverse events by interfering with the renal clearance of drug0",True,effect
DDI-DrugBank.d263.s18.e5,DDI-DrugBank.d263.s18.e7,"drug0, drug0, and drug0: Drugs such as drug0, drug0, and drug1 may increase the risk of developing peripheral neuropathy or other drug0-associated adverse events by interfering with the renal clearance of drug2",True,mechanism
DDI-DrugBank.d263.s20.e0,DDI-DrugBank.d263.s20.e1,"drug1 or drug2: Concomitant administration of drug0 or drug0 decreases the elimination of drug0, most likely by inhibition of renal tubular secretion of drug0",False, 
DDI-DrugBank.d263.s20.e0,DDI-DrugBank.d263.s20.e2,"drug1 or drug0: Concomitant administration of drug2 or drug0 decreases the elimination of drug0, most likely by inhibition of renal tubular secretion of drug0",False, 
DDI-DrugBank.d263.s20.e2,DDI-DrugBank.d263.s20.e4,"drug0 or drug0: Concomitant administration of drug1 or drug0 decreases the elimination of drug2, most likely by inhibition of renal tubular secretion of drug0",True,mechanism
DDI-DrugBank.d263.s20.e3,DDI-DrugBank.d263.s20.e4,"drug0 or drug0: Concomitant administration of drug0 or drug1 decreases the elimination of drug2, most likely by inhibition of renal tubular secretion of drug0",True,mechanism
DDI-DrugBank.d263.s21.e0,DDI-DrugBank.d263.s21.e1,Patients receiving these drugs in combination with drug1 should be monitored for signs of toxicity and the dose of drug2,False, 
DDI-DrugBank.d263.s22.e0,DDI-DrugBank.d263.s22.e1,drug1/drug2-containing drug0: Absorption of drug0 is moderately reduced (approximately 25%) when coadministered with drug0/drug0-containing drug0,False, 
DDI-DrugBank.d263.s22.e0,DDI-DrugBank.d263.s22.e2,drug1/drug0-containing drug2: Absorption of drug0 is moderately reduced (approximately 25%) when coadministered with drug0/drug0-containing drug0,False, 
DDI-DrugBank.d263.s23.e0,DDI-DrugBank.d263.s23.e1,"The clinical significance of this reduction is not known, hence drug1 is not recommended to be ingested simultaneously with drug2/drug0-containing drug0",True,advise
DDI-DrugBank.d263.s23.e0,DDI-DrugBank.d263.s23.e2,"The clinical significance of this reduction is not known, hence drug1 is not recommended to be ingested simultaneously with drug0/drug2-containing drug0",True,advise
DDI-DrugBank.d263.s23.e0,DDI-DrugBank.d263.s23.e3,"The clinical significance of this reduction is not known, hence drug1 is not recommended to be ingested simultaneously with drug0/drug0-containing drug2",True,advise
DDI-DrugBank.d263.s23.e1,DDI-DrugBank.d263.s23.e2,"The clinical significance of this reduction is not known, hence drug0 is not recommended to be ingested simultaneously with drug1/drug2-containing drug0",False, 
DDI-DrugBank.d263.s23.e1,DDI-DrugBank.d263.s23.e3,"The clinical significance of this reduction is not known, hence drug0 is not recommended to be ingested simultaneously with drug1/drug0-containing drug2",False, 
DDI-DrugBank.d263.s24.e0,DDI-DrugBank.d263.s24.e1,drug1: Bioavailability is mildly reduced (approximately 10%) when drug2 and drug0,False, 
DDI-DrugBank.d263.s24.e0,DDI-DrugBank.d263.s24.e2,drug1: Bioavailability is mildly reduced (approximately 10%) when drug0 and drug2,False, 
DDI-DrugBank.d263.s24.e1,DDI-DrugBank.d263.s24.e2,drug0: Bioavailability is mildly reduced (approximately 10%) when drug1 and drug2,True,mechanism
DDI-DrugBank.d263.s25.e0,DDI-DrugBank.d263.s25.e1,drug1: drug2 caused a decrease in drug0,False, 
DDI-DrugBank.d263.s25.e0,DDI-DrugBank.d263.s25.e2,drug1: drug0 caused a decrease in drug2,False, 
DDI-DrugBank.d263.s25.e1,DDI-DrugBank.d263.s25.e2,drug0: drug1 caused a decrease in drug2,True,effect
DDI-DrugBank.d449.s0.e0,DDI-DrugBank.d449.s0.e1,Co-administration with drug1 such as drug2 or drug0,False, 
DDI-DrugBank.d449.s0.e0,DDI-DrugBank.d449.s0.e2,Co-administration with drug1 such as drug0 or drug2,False, 
DDI-DrugBank.d449.s1.e0,DDI-DrugBank.d449.s1.e1,"drug1, drug2, drug0 (consider drug0",False, 
DDI-DrugBank.d449.s1.e0,DDI-DrugBank.d449.s1.e2,"drug1, drug0, drug2 (consider drug0",False, 
DDI-DrugBank.d449.s1.e0,DDI-DrugBank.d449.s1.e3,"drug1, drug0, drug0 (consider drug2",True,advise
DDI-DrugBank.d449.s1.e1,DDI-DrugBank.d449.s1.e3,"drug0, drug1, drug0 (consider drug2",True,advise
DDI-DrugBank.d449.s1.e2,DDI-DrugBank.d449.s1.e3,"drug0, drug0, drug1 (consider drug2",True,advise
DDI-DrugBank.d449.s2.e0,DDI-DrugBank.d449.s2.e1,"drug1, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d449.s2.e0,DDI-DrugBank.d449.s2.e2,"drug1, drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d340.s1.e0,DDI-DrugBank.d340.s1.e1,"Coadministration of drug1 and drugs primarily metabolized by CYP3A (e.g., drug2",False, 
DDI-DrugBank.d340.s3.e0,DDI-DrugBank.d340.s3.e1,Coadministration of drug1 and drugs that induce CYP3A may decrease drug2,False, 
DDI-DrugBank.d340.s4.e0,DDI-DrugBank.d340.s4.e1,Coadministration of drug1 and drugs that inhibit CYP3A may increase drug2,False, 
DDI-DrugBank.d340.s5.e0,DDI-DrugBank.d340.s5.e1,"Based on known metabolic profiles, clinically significant drug interactions are not expected between drug1 and drug2, drug0/drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d340.s5.e0,DDI-DrugBank.d340.s5.e2,"Based on known metabolic profiles, clinically significant drug interactions are not expected between drug1 and drug0, drug2/drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e1,"Drugs That Should Not Be Coadministered With drug1 drug2: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e2,"Drugs That Should Not Be Coadministered With drug1 drug0: drug2, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e3,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug2 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e4,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug2: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e5,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug2, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e6,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug2 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e7,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug2 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e8,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug2: drug0 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e9,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug2 drug0 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e10,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug2 drug0, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e11,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug2, drug0 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e12,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug2 GI motility agents: drug0",True,advise
DDI-DrugBank.d340.s6.e0,DDI-DrugBank.d340.s6.e13,"Drugs That Should Not Be Coadministered With drug1 drug0: drug0, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug2",True,advise
DDI-DrugBank.d340.s6.e1,DDI-DrugBank.d340.s6.e2,"Drugs That Should Not Be Coadministered With drug0 drug1: drug2, drug0 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",False, 
DDI-DrugBank.d340.s6.e1,DDI-DrugBank.d340.s6.e3,"Drugs That Should Not Be Coadministered With drug0 drug1: drug0, drug2 drug0: drug0, drug0 Antimigraine: drug0 drug0: drug0 drug0 drug0, drug0 GI motility agents: drug0",False, 
DDI-DrugBank.d340.s7.e0,DDI-DrugBank.d340.s7.e1,Drugs Which Require a Dose Reduction When Coadminstered With drug1 drug2: drug0,True,advise
DDI-DrugBank.d340.s7.e0,DDI-DrugBank.d340.s7.e2,Drugs Which Require a Dose Reduction When Coadminstered With drug1 drug0: drug2,True,advise
DDI-DrugBank.d340.s7.e1,DDI-DrugBank.d340.s7.e2,Drugs Which Require a Dose Reduction When Coadminstered With drug0 drug1: drug2,False, 
DDI-DrugBank.d340.s8.e0,DDI-DrugBank.d340.s8.e1,* This table is not all inclusive ** drug1 may not be effective due to decreased drug2,False, 
DDI-DrugBank.d340.s10.e0,DDI-DrugBank.d340.s10.e1,drug1: Administration of drug2 with drug0 resulted in the appearance of unchanged drug0,False, 
DDI-DrugBank.d340.s10.e0,DDI-DrugBank.d340.s10.e2,drug1: Administration of drug0 with drug2 resulted in the appearance of unchanged drug0,False, 
DDI-DrugBank.d340.s11.e0,DDI-DrugBank.d340.s11.e1,"therefore, drug1 should not be administered concurrently with drug2",True,advise
DDI-DrugBank.d340.s12.e0,DDI-DrugBank.d340.s12.e1,"Because a similar interaction is likely, drug1 should also not be administered concurrently with drug2",True,advise
DDI-DrugBank.d340.s14.e0,DDI-DrugBank.d340.s14.e1,drug1: Coadministration of drug2 with drug0 resulted in an 83% increase in drug0 plasma AUC and a 51% increase in drug0,False, 
DDI-DrugBank.d340.s14.e0,DDI-DrugBank.d340.s14.e2,drug1: Coadministration of drug0 with drug2 resulted in an 83% increase in drug0 plasma AUC and a 51% increase in drug0,False, 
DDI-DrugBank.d340.s14.e1,DDI-DrugBank.d340.s14.e2,drug0: Coadministration of drug1 with drug2 resulted in an 83% increase in drug0 plasma AUC and a 51% increase in drug0,True,mechanism
DDI-DrugBank.d340.s16.e0,DDI-DrugBank.d340.s16.e1,drug1: Coadministration of drug2 with drug0 resulted in a 152% increase in drug0 plasma AUC and very little change in drug0,False, 
DDI-DrugBank.d340.s16.e0,DDI-DrugBank.d340.s16.e2,drug1: Coadministration of drug0 with drug2 resulted in a 152% increase in drug0 plasma AUC and very little change in drug0,False, 
DDI-DrugBank.d340.s16.e1,DDI-DrugBank.d340.s16.e2,drug0: Coadministration of drug1 with drug2 resulted in a 152% increase in drug0 plasma AUC and very little change in drug0,True,mechanism
DDI-DrugBank.d340.s18.e0,DDI-DrugBank.d340.s18.e1,drug1: Coadministration of drug2 (using an experimental soft-gelatin capsule formulation of drug0 1200mg) with drug0 resulted in an 18% increase in drug0 plasma AUC and a 4-fold increase in drug0,False, 
DDI-DrugBank.d340.s18.e0,DDI-DrugBank.d340.s18.e2,drug1: Coadministration of drug0 (using an experimental soft-gelatin capsule formulation of drug2 1200mg) with drug0 resulted in an 18% increase in drug0 plasma AUC and a 4-fold increase in drug0,False, 
DDI-DrugBank.d340.s18.e1,DDI-DrugBank.d340.s18.e3,drug0: Coadministration of drug1 (using an experimental soft-gelatin capsule formulation of drug0 1200mg) with drug2 resulted in an 18% increase in drug0 plasma AUC and a 4-fold increase in drug0,True,mechanism
DDI-DrugBank.d340.s22.e0,DDI-DrugBank.d340.s22.e1,drug1: Coadministration of drug2 with drug0 resulted in a 35% increase in drug0,False, 
DDI-DrugBank.d340.s22.e0,DDI-DrugBank.d340.s22.e2,drug1: Coadministration of drug0 with drug2 resulted in a 35% increase in drug0,False, 
DDI-DrugBank.d340.s22.e1,DDI-DrugBank.d340.s22.e2,drug0: Coadministration of drug1 with drug2 resulted in a 35% increase in drug0,True,mechanism
DDI-DrugBank.d340.s23.e0,DDI-DrugBank.d340.s23.e1,This change was not considered clinically significant and no dose adjustment is needed when drug1 and drug2,False, 
DDI-DrugBank.d340.s25.e0,DDI-DrugBank.d340.s25.e1,drug1: It is recommended that drug2,False, 
DDI-DrugBank.d340.s26.e0,DDI-DrugBank.d340.s26.e1,"therefore, drug1 should be administered (with food) one hour after or more than two hours before drug2",True,advise
DDI-DrugBank.d340.s27.e0,DDI-DrugBank.d340.s27.e1,A dose adjustment is not needed when drug1 is administered with drug2,True,advise
DDI-DrugBank.d340.s28.e0,DDI-DrugBank.d340.s28.e1,Little or no change in the pharmacokinetics of either drug was observed when drug1 was coadministered with drug2 or drug0,False, 
DDI-DrugBank.d340.s28.e0,DDI-DrugBank.d340.s28.e2,Little or no change in the pharmacokinetics of either drug was observed when drug1 was coadministered with drug0 or drug2,False, 
DDI-DrugBank.d340.s30.e0,DDI-DrugBank.d340.s30.e1,drug1: Coadministration of drug2 and drug0 resulted in a 32% decrease in drug0 plasma AUC and a 207% increase in drug0,False, 
DDI-DrugBank.d340.s30.e0,DDI-DrugBank.d340.s30.e2,drug1: Coadministration of drug0 and drug2 resulted in a 32% decrease in drug0 plasma AUC and a 207% increase in drug0,False, 
DDI-DrugBank.d340.s30.e1,DDI-DrugBank.d340.s30.e2,drug0: Coadministration of drug1 and drug2 resulted in a 32% decrease in drug0 plasma AUC and a 207% increase in drug0,True,mechanism
DDI-DrugBank.d340.s31.e0,DDI-DrugBank.d340.s31.e1,It is recommended that the dose of drug1 be reduced to one-half the usual dose when administered with drug2,True,advise
DDI-DrugBank.d340.s32.e0,DDI-DrugBank.d340.s32.e1,drug1: Coadministration of drug2 and drug0 resulted in an 82% decrease in drug0,False, 
DDI-DrugBank.d340.s32.e0,DDI-DrugBank.d340.s32.e2,drug1: Coadministration of drug0 and drug2 resulted in an 82% decrease in drug0,False, 
DDI-DrugBank.d340.s32.e1,DDI-DrugBank.d340.s32.e2,drug0: Coadministration of drug1 and drug2 resulted in an 82% decrease in drug0,True,mechanism
DDI-DrugBank.d340.s33.e0,DDI-DrugBank.d340.s33.e1,drug1 and drug2,True,advise
DDI-DrugBank.d340.s35.e0,DDI-DrugBank.d340.s35.e1,drug1 and drug2: Coadministration of drug0 with drug0 resulted in a 47% decrease in drug0 and an 18% decrease in drug0,False, 
DDI-DrugBank.d340.s35.e0,DDI-DrugBank.d340.s35.e2,drug1 and drug0: Coadministration of drug2 with drug0 resulted in a 47% decrease in drug0 and an 18% decrease in drug0,False, 
DDI-DrugBank.d340.s35.e2,DDI-DrugBank.d340.s35.e3,drug0 and drug0: Coadministration of drug1 with drug2 resulted in a 47% decrease in drug0 and an 18% decrease in drug0,True,mechanism
DDI-DrugBank.d35.s0.e0,DDI-DrugBank.d35.s0.e1,Interactions may occur between drug1 supplements and drug2 and other drug0 and herbs such as garlic (Allium sativum) and drug0 (drug0,True,int
DDI-DrugBank.d35.s0.e0,DDI-DrugBank.d35.s0.e2,Interactions may occur between drug1 supplements and drug0 and other drug2 and herbs such as garlic (Allium sativum) and drug0 (drug0,True,int
DDI-DrugBank.d35.s0.e0,DDI-DrugBank.d35.s0.e3,Interactions may occur between drug1 supplements and drug0 and other drug0 and herbs such as garlic (Allium sativum) and drug2 (drug0,True,int
DDI-DrugBank.d35.s0.e0,DDI-DrugBank.d35.s0.e4,Interactions may occur between drug1 supplements and drug0 and other drug0 and herbs such as garlic (Allium sativum) and drug0 (drug2,True,int
DDI-DrugBank.d35.s0.e1,DDI-DrugBank.d35.s0.e2,Interactions may occur between drug0 supplements and drug1 and other drug2 and herbs such as garlic (Allium sativum) and drug0 (drug0,False, 
DDI-DrugBank.d35.s0.e1,DDI-DrugBank.d35.s0.e3,Interactions may occur between drug0 supplements and drug1 and other drug0 and herbs such as garlic (Allium sativum) and drug2 (drug0,False, 
DDI-DrugBank.d448.s0.e0,DDI-DrugBank.d448.s0.e1,drug1 prolong and intensify the effects of drug2,True,effect
DDI-DrugBank.d448.s1.e0,DDI-DrugBank.d448.s1.e1,"Concomitant use of drug1 with drug2, drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d448.s1.e0,DDI-DrugBank.d448.s1.e2,"Concomitant use of drug1 with drug0, drug2, drug0, or other drug0",True,effect
DDI-DrugBank.d448.s1.e0,DDI-DrugBank.d448.s1.e3,"Concomitant use of drug1 with drug0, drug0, drug2, or other drug0",True,effect
DDI-DrugBank.d448.s1.e0,DDI-DrugBank.d448.s1.e4,"Concomitant use of drug1 with drug0, drug0, drug0, or other drug2",True,effect
DDI-DrugBank.d448.s1.e1,DDI-DrugBank.d448.s1.e2,"Concomitant use of drug0 with drug1, drug2, drug0, or other drug0",False, 
DDI-DrugBank.d448.s1.e1,DDI-DrugBank.d448.s1.e3,"Concomitant use of drug0 with drug1, drug0, drug2, or other drug0",False, 
DDI-DrugBank.d448.s2.e0,DDI-DrugBank.d448.s2.e1,When drug1 are given to patients receiving drug2,True,effect
DDI-DrugBank.d448.s3.e0,DDI-DrugBank.d448.s3.e1,"The antihypertensive effects of drug1, drug2, drug0, and drug0 may be reduced by drug0",False, 
DDI-DrugBank.d448.s3.e0,DDI-DrugBank.d448.s3.e2,"The antihypertensive effects of drug1, drug0, drug2, and drug0 may be reduced by drug0",False, 
DDI-DrugBank.d448.s3.e0,DDI-DrugBank.d448.s3.e4,"The antihypertensive effects of drug1, drug0, drug0, and drug0 may be reduced by drug2",True,effect
DDI-DrugBank.d448.s3.e1,DDI-DrugBank.d448.s3.e4,"The antihypertensive effects of drug0, drug1, drug0, and drug0 may be reduced by drug2",True,effect
DDI-DrugBank.d448.s3.e2,DDI-DrugBank.d448.s3.e4,"The antihypertensive effects of drug0, drug0, drug1, and drug0 may be reduced by drug2",True,effect
DDI-DrugBank.d448.s3.e3,DDI-DrugBank.d448.s3.e4,"The antihypertensive effects of drug0, drug0, drug0, and drug1 may be reduced by drug2",True,effect
DDI-DrugBank.d448.s4.e0,DDI-DrugBank.d448.s4.e1,drug1 may also interact with drug2,True,int
DDI-DrugBank.d448.s5.e0,DDI-DrugBank.d448.s5.e1,Increased ectopic pacemaker activity can occur when drug1 is used concomitantly with drug2,True,effect
DDI-DrugBank.d448.s6.e0,DDI-DrugBank.d448.s6.e1,"drug1 increase the rate of absorption of drug2, while drug0",True,mechanism
DDI-DrugBank.d448.s6.e0,DDI-DrugBank.d448.s6.e2,"drug1 increase the rate of absorption of drug0, while drug2",False, 
DDI-DrugBank.d448.s6.e1,DDI-DrugBank.d448.s6.e2,"drug0 increase the rate of absorption of drug1, while drug2",True,mechanism
DDI-DrugBank.d98.s0.e0,DDI-DrugBank.d98.s0.e1,"Interactions for drug1 (drug2, drug0, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d98.s0.e0,DDI-DrugBank.d98.s0.e2,"Interactions for drug1 (drug0, drug2, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d98.s0.e6,DDI-DrugBank.d98.s0.e7,"Interactions for drug0 (drug0, drug0, drug0, and drug0): drug0: drug1 has been reported to reduce intestinal absorption of drug2",True,mechanism
DDI-DrugBank.d98.s2.e0,DDI-DrugBank.d98.s2.e1,"drug1/drug2: The coadministration of drug0 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d98.s2.e0,DDI-DrugBank.d98.s2.e2,"drug1/drug0: The coadministration of drug2 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d98.s2.e2,DDI-DrugBank.d98.s2.e5,"drug0/drug0: The coadministration of drug1 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug2",True,mechanism
DDI-DrugBank.d98.s2.e3,DDI-DrugBank.d98.s2.e5,"drug0/drug0: The coadministration of drug0 or drug1 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug2",True,mechanism
DDI-DrugBank.d98.s3.e0,DDI-DrugBank.d98.s3.e1,"Since blood level of drug1/ergocalcitriol will be reduced, higher doses of drug2",False, 
DDI-DrugBank.d98.s4.e0,DDI-DrugBank.d98.s4.e1,drug1: drug2,False, 
DDI-DrugBank.d98.s5.e0,DDI-DrugBank.d98.s5.e1,Some reports have shown that the concomitant administration of drug1 with drug2,True,effect
DDI-DrugBank.d98.s7.e0,DDI-DrugBank.d98.s7.e1,drug1: drug2 dosage must be determined with care in patients undergoing treatment with drug0,False, 
DDI-DrugBank.d98.s7.e0,DDI-DrugBank.d98.s7.e2,drug1: drug0 dosage must be determined with care in patients undergoing treatment with drug2,False, 
DDI-DrugBank.d98.s7.e1,DDI-DrugBank.d98.s7.e2,drug0: drug1 dosage must be determined with care in patients undergoing treatment with drug2,True,advise
DDI-DrugBank.d98.s8.e0,DDI-DrugBank.d98.s8.e1,drug1: drug2 may inhibit both synthetic and catabolic enzymes of drug0,False, 
DDI-DrugBank.d98.s8.e0,DDI-DrugBank.d98.s8.e2,drug1: drug0 may inhibit both synthetic and catabolic enzymes of drug2,False, 
DDI-DrugBank.d98.s8.e1,DDI-DrugBank.d98.s8.e2,drug0: drug1 may inhibit both synthetic and catabolic enzymes of drug2,True,mechanism
DDI-DrugBank.d98.s10.e0,DDI-DrugBank.d98.s10.e1,"However, in vivo drug interaction studies of drug1 with drug2",False, 
DDI-DrugBank.d98.s11.e0,DDI-DrugBank.d98.s11.e1,"drug1: A relationship of functional antagonism exists between drug2, which promote calcium absorption, and drug0",False, 
DDI-DrugBank.d98.s11.e0,DDI-DrugBank.d98.s11.e2,"drug1: A relationship of functional antagonism exists between drug0, which promote calcium absorption, and drug2",False, 
DDI-DrugBank.d98.s11.e1,DDI-DrugBank.d98.s11.e2,"drug0: A relationship of functional antagonism exists between drug1, which promote calcium absorption, and drug2",True,mechanism
DDI-DrugBank.d98.s13.e0,DDI-DrugBank.d98.s13.e1,drug1: The coadministration of any of the drug2,False, 
DDI-DrugBank.d98.s14.e0,DDI-DrugBank.d98.s14.e1,drug1 Supplements: Uncontrolled intake of additional drug2,False, 
DDI-DrugBank.d98.s15.e0,DDI-DrugBank.d98.s15.e1,"drug1: drug2-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d98.s15.e0,DDI-DrugBank.d98.s15.e2,"drug1: drug0-containing preparations (eg, drug2) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d98.s15.e1,DDI-DrugBank.d98.s15.e3,"drug0: drug1-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,advise
DDI-DrugBank.d98.s15.e2,DDI-DrugBank.d98.s15.e3,"drug0: drug0-containing preparations (eg, drug1) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,advise
DDI-DrugBank.d3.s1.e0,DDI-DrugBank.d3.s1.e1,"drug1, drug2, drug0, and drug0 The in vitro binding of drug0 to plasma proteins is only slightly reduced by drug0 (99.5% control vs 99.3%) when drug0",False, 
DDI-DrugBank.d3.s1.e0,DDI-DrugBank.d3.s1.e2,"drug1, drug0, drug2, and drug0 The in vitro binding of drug0 to plasma proteins is only slightly reduced by drug0 (99.5% control vs 99.3%) when drug0",False, 
DDI-DrugBank.d3.s1.e4,DDI-DrugBank.d3.s1.e5,"drug0, drug0, drug0, and drug0 The in vitro binding of drug1 to plasma proteins is only slightly reduced by drug2 (99.5% control vs 99.3%) when drug0",True,mechanism
DDI-DrugBank.d3.s2.e0,DDI-DrugBank.d3.s2.e1,drug1 does not alter drug2,False, 
DDI-DrugBank.d3.s3.e0,DDI-DrugBank.d3.s3.e1,"In vitro studies indicate that, at therapeutic concentrations of drug1 (300 m g/mL), the binding of drug2 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound drug0",True,mechanism
DDI-DrugBank.d3.s3.e0,DDI-DrugBank.d3.s3.e2,"In vitro studies indicate that, at therapeutic concentrations of drug1 (300 m g/mL), the binding of drug0 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound drug2",False, 
DDI-DrugBank.d3.s3.e1,DDI-DrugBank.d3.s3.e2,"In vitro studies indicate that, at therapeutic concentrations of drug0 (300 m g/mL), the binding of drug1 was reduced from approximately 99.2% to 97.5%, representing a potential twofold increase in unbound drug2",False, 
DDI-DrugBank.d3.s4.e0,DDI-DrugBank.d3.s4.e1,"Therapeutic concentrations of drug1, drug2, drug0, drug0, drug0, drug0, drug0 andtolbutamide did not alter drug0",False, 
DDI-DrugBank.d3.s4.e0,DDI-DrugBank.d3.s4.e2,"Therapeutic concentrations of drug1, drug0, drug2, drug0, drug0, drug0, drug0 andtolbutamide did not alter drug0",False, 
DDI-DrugBank.d3.s5.e0,DDI-DrugBank.d3.s5.e1,"In a study involving 12 adult volunteers, TORADOLORAL was coadministered with a single dose of 25 mg drug1, causing no significant changes in pharmacokinetics or pharmacodynamics of drug2",False, 
DDI-DrugBank.d3.s6.e0,DDI-DrugBank.d3.s6.e1,"In another study, TORADOLIV/IM was given with two doses of 5000 U of drug1 to 11 healthy volunteers, resulting in a mean template bleeding time of 6.4 minutes (3.2 to 11.4 min) compared to a mean of 6.0 minutes (3.4 to 7.5 min) for drug2",False, 
DDI-DrugBank.d3.s7.e0,DDI-DrugBank.d3.s7.e1,"Although these results do not indicate a significant interaction between drug1 and drug2 or drug0, the administration of drug0 to patients taking drug0",False, 
DDI-DrugBank.d3.s7.e0,DDI-DrugBank.d3.s7.e2,"Although these results do not indicate a significant interaction between drug1 and drug0 or drug2, the administration of drug0 to patients taking drug0",False, 
DDI-DrugBank.d3.s7.e3,DDI-DrugBank.d3.s7.e4,"Although these results do not indicate a significant interaction between drug0 and drug0 or drug0, the administration of drug1 to patients taking drug2",True,advise
DDI-DrugBank.d3.s8.e0,DDI-DrugBank.d3.s8.e1,drug1: drug2 IV/IM reduced the drug0 response to drug0,False, 
DDI-DrugBank.d3.s8.e0,DDI-DrugBank.d3.s8.e2,drug1: drug0 IV/IM reduced the drug2 response to drug0,False, 
DDI-DrugBank.d3.s8.e1,DDI-DrugBank.d3.s8.e3,drug0: drug1 IV/IM reduced the drug0 response to drug2,True,effect
DDI-DrugBank.d3.s9.e0,DDI-DrugBank.d3.s9.e1,drug1: Concomitant administration of drug2 ORAL and drug0 resulted in decreased clearance of drug0 and significant increases in drug0,False, 
DDI-DrugBank.d3.s9.e0,DDI-DrugBank.d3.s9.e2,drug1: Concomitant administration of drug0 ORAL and drug2 resulted in decreased clearance of drug0 and significant increases in drug0,False, 
DDI-DrugBank.d3.s9.e1,DDI-DrugBank.d3.s9.e2,drug0: Concomitant administration of drug1 ORAL and drug2 resulted in decreased clearance of drug0 and significant increases in drug0,True,mechanism
DDI-DrugBank.d3.s10.e0,DDI-DrugBank.d3.s10.e1,"Therefore, concomitant use of drug1 and drug2",True,advise
DDI-DrugBank.d3.s11.e0,DDI-DrugBank.d3.s11.e1,"drug1: Inhibition of renal drug2 clearance, leading to an increase in plasma drug0",False, 
DDI-DrugBank.d3.s11.e0,DDI-DrugBank.d3.s11.e2,"drug1: Inhibition of renal drug0 clearance, leading to an increase in plasma drug2",False, 
DDI-DrugBank.d3.s12.e0,DDI-DrugBank.d3.s12.e1,"The effect of drug1 on plasma drug2 has not been studied, but cases of increased drug0 plasma levels during drug0",False, 
DDI-DrugBank.d3.s12.e0,DDI-DrugBank.d3.s12.e2,"The effect of drug1 on plasma drug0 has not been studied, but cases of increased drug2 plasma levels during drug0",False, 
DDI-DrugBank.d3.s12.e2,DDI-DrugBank.d3.s12.e3,"The effect of drug0 on plasma drug0 has not been studied, but cases of increased drug1 plasma levels during drug2",True,mechanism
DDI-DrugBank.d3.s13.e0,DDI-DrugBank.d3.s13.e1,"drug1: Concomitant administration of drug2 and some drug0 has been reported to reduce the clearance of drug0, enhancing the toxicity of drug0",False, 
DDI-DrugBank.d3.s13.e0,DDI-DrugBank.d3.s13.e2,"drug1: Concomitant administration of drug0 and some drug2 has been reported to reduce the clearance of drug0, enhancing the toxicity of drug0",False, 
DDI-DrugBank.d3.s13.e1,DDI-DrugBank.d3.s13.e2,"drug0: Concomitant administration of drug1 and some drug2 has been reported to reduce the clearance of drug0, enhancing the toxicity of drug0",True,mechanism
DDI-DrugBank.d3.s14.e0,DDI-DrugBank.d3.s14.e1,The effect of drug1 on drug2,False, 
DDI-DrugBank.d3.s15.e0,DDI-DrugBank.d3.s15.e1,drug1: In postmarketing experience there have been reports of a possible interaction between TORADOLIV/IM and drug2,False, 
DDI-DrugBank.d3.s16.e0,DDI-DrugBank.d3.s16.e1,The concurrent use of drug1 with drug2,False, 
DDI-DrugBank.d3.s17.e0,DDI-DrugBank.d3.s17.e1,drug1: Concomitant use of drug2,False, 
DDI-DrugBank.d3.s18.e0,DDI-DrugBank.d3.s18.e1,"drug1: Sporadic cases of seizures have been reported during concomitant use of drug2 and drug0 (drug0, drug0",False, 
DDI-DrugBank.d3.s18.e0,DDI-DrugBank.d3.s18.e2,"drug1: Sporadic cases of seizures have been reported during concomitant use of drug0 and drug2 (drug0, drug0",False, 
DDI-DrugBank.d3.s18.e1,DDI-DrugBank.d3.s18.e2,"drug0: Sporadic cases of seizures have been reported during concomitant use of drug1 and drug2 (drug0, drug0",True,effect
DDI-DrugBank.d3.s18.e1,DDI-DrugBank.d3.s18.e3,"drug0: Sporadic cases of seizures have been reported during concomitant use of drug1 and drug0 (drug2, drug0",True,effect
DDI-DrugBank.d3.s18.e1,DDI-DrugBank.d3.s18.e4,"drug0: Sporadic cases of seizures have been reported during concomitant use of drug1 and drug0 (drug0, drug2",True,effect
DDI-DrugBank.d3.s19.e0,DDI-DrugBank.d3.s19.e1,"drug1: Hallucinations have been reported when drug2 was used in patients taking drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d3.s19.e0,DDI-DrugBank.d3.s19.e2,"drug1: Hallucinations have been reported when drug0 was used in patients taking drug2 (drug0, drug0, drug0",False, 
DDI-DrugBank.d3.s19.e1,DDI-DrugBank.d3.s19.e2,"drug0: Hallucinations have been reported when drug1 was used in patients taking drug2 (drug0, drug0, drug0",True,effect
DDI-DrugBank.d3.s19.e1,DDI-DrugBank.d3.s19.e3,"drug0: Hallucinations have been reported when drug1 was used in patients taking drug0 (drug2, drug0, drug0",True,effect
DDI-DrugBank.d3.s19.e1,DDI-DrugBank.d3.s19.e4,"drug0: Hallucinations have been reported when drug1 was used in patients taking drug0 (drug0, drug2, drug0",True,effect
DDI-DrugBank.d3.s19.e1,DDI-DrugBank.d3.s19.e5,"drug0: Hallucinations have been reported when drug1 was used in patients taking drug0 (drug0, drug0, drug2",True,effect
DDI-DrugBank.d3.s20.e0,DDI-DrugBank.d3.s20.e1,drug1: TORADOLIV/IM has been administered concurrently with drug2,False, 
DDI-DrugBank.d3.s21.e0,DDI-DrugBank.d3.s21.e1,Do not mix drug1 and drug2,False, 
DDI-DrugBank.d4.s0.e0,DDI-DrugBank.d4.s0.e1,"Synergism between drug1 (e.g., drug2), drug0, and other drug0",False, 
DDI-DrugBank.d4.s0.e0,DDI-DrugBank.d4.s0.e2,"Synergism between drug1 (e.g., drug0), drug2, and other drug0",False, 
DDI-DrugBank.d4.s0.e0,DDI-DrugBank.d4.s0.e3,"Synergism between drug1 (e.g., drug0), drug0, and other drug2",True,effect
DDI-DrugBank.d4.s0.e1,DDI-DrugBank.d4.s0.e3,"Synergism between drug0 (e.g., drug1), drug0, and other drug2",True,effect
DDI-DrugBank.d4.s0.e2,DDI-DrugBank.d4.s0.e3,"Synergism between drug0 (e.g., drug0), drug1, and other drug2",True,effect
DDI-DrugBank.d4.s2.e0,DDI-DrugBank.d4.s2.e1,"Concurrent administration of drug1 and drug2, which competes for tubular secretion, has been shown to increase the plasma half-life of drug0",True,mechanism
DDI-DrugBank.d4.s2.e0,DDI-DrugBank.d4.s2.e2,"Concurrent administration of drug1 and drug0, which competes for tubular secretion, has been shown to increase the plasma half-life of drug2",False, 
DDI-DrugBank.d4.s2.e1,DDI-DrugBank.d4.s2.e2,"Concurrent administration of drug0 and drug1, which competes for tubular secretion, has been shown to increase the plasma half-life of drug2",False, 
DDI-DrugBank.d387.s0.e0,DDI-DrugBank.d387.s0.e1,"Potential drug interactions for drug1 include, increased sedation if drug2 is combined with other drug0",False, 
DDI-DrugBank.d387.s0.e0,DDI-DrugBank.d387.s0.e2,"Potential drug interactions for drug1 include, increased sedation if drug0 is combined with other drug2",False, 
DDI-DrugBank.d387.s0.e1,DDI-DrugBank.d387.s0.e2,"Potential drug interactions for drug0 include, increased sedation if drug1 is combined with other drug2",True,effect
DDI-DrugBank.d387.s1.e0,DDI-DrugBank.d387.s1.e1,drug1 may partially counteract the anticoagulation effects of drug2 or drug0,True,effect
DDI-DrugBank.d387.s1.e0,DDI-DrugBank.d387.s1.e2,drug1 may partially counteract the anticoagulation effects of drug0 or drug2,True,effect
DDI-DrugBank.d387.s1.e1,DDI-DrugBank.d387.s1.e2,drug0 may partially counteract the anticoagulation effects of drug1 or drug2,False, 
DDI-DrugBank.d387.s2.e0,DDI-DrugBank.d387.s2.e1,drug1 may enhance the effects of drug2,True,effect
DDI-DrugBank.d213.s0.e0,DDI-DrugBank.d213.s0.e1,"drug1 or drug2 excess may decrease the effect of drug0, and an drug0 deficiency can increase the effect of drug0",False, 
DDI-DrugBank.d213.s0.e0,DDI-DrugBank.d213.s0.e2,"drug1 or drug0 excess may decrease the effect of drug2, and an drug0 deficiency can increase the effect of drug0",True,effect
DDI-DrugBank.d213.s0.e0,DDI-DrugBank.d213.s0.e3,"drug1 or drug0 excess may decrease the effect of drug0, and an drug2 deficiency can increase the effect of drug0",False, 
DDI-DrugBank.d213.s0.e3,DDI-DrugBank.d213.s0.e4,"drug0 or drug0 excess may decrease the effect of drug0, and an drug1 deficiency can increase the effect of drug2",True,effect
DDI-DrugBank.d213.s1.e0,DDI-DrugBank.d213.s1.e1,Serum concentration of drug1 and drug2 may increase when patients take drug0,False, 
DDI-DrugBank.d213.s1.e0,DDI-DrugBank.d213.s1.e2,Serum concentration of drug1 and drug0 may increase when patients take drug2,True,mechanism
DDI-DrugBank.d213.s1.e1,DDI-DrugBank.d213.s1.e2,Serum concentration of drug0 and drug1 may increase when patients take drug2,True,mechanism
DDI-DrugBank.d213.s3.e0,DDI-DrugBank.d213.s3.e1,"drug1 may decrease thyroidal uptake of drug2, a rebound in uptake may occur up to 5 days after sudden withdrawal of drug0",True,effect
DDI-DrugBank.d213.s3.e0,DDI-DrugBank.d213.s3.e2,"drug1 may decrease thyroidal uptake of drug0, a rebound in uptake may occur up to 5 days after sudden withdrawal of drug2",False, 
DDI-DrugBank.d213.s3.e1,DDI-DrugBank.d213.s3.e2,"drug0 may decrease thyroidal uptake of drug1, a rebound in uptake may occur up to 5 days after sudden withdrawal of drug2",False, 
DDI-DrugBank.d204.s0.e0,DDI-DrugBank.d204.s0.e1,"When administered concurrently, the following drugs may interact with drug1: drug2, general: exaggeration of the hypotension induced by general drug0",True,int
DDI-DrugBank.d204.s0.e0,DDI-DrugBank.d204.s0.e2,"When administered concurrently, the following drugs may interact with drug1: drug0, general: exaggeration of the hypotension induced by general drug2",False, 
DDI-DrugBank.d204.s0.e1,DDI-DrugBank.d204.s0.e2,"When administered concurrently, the following drugs may interact with drug0: drug1, general: exaggeration of the hypotension induced by general drug2",False, 
DDI-DrugBank.d204.s1.e0,DDI-DrugBank.d204.s1.e1,drug1 (oral agents and drug2,False, 
DDI-DrugBank.d231.s0.e0,DDI-DrugBank.d231.s0.e1,drug1 may increase the ototoxic potential of drug2,True,effect
DDI-DrugBank.d231.s2.e0,DDI-DrugBank.d231.s2.e1,drug1 should not be used concomitantly with drug2,True,advise
DDI-DrugBank.d231.s3.e0,DDI-DrugBank.d231.s3.e1,"Patients receiving high doses of drug1 concomitantly with drug2, as in rheumatic disease, may experience drug0",True,effect
DDI-DrugBank.d231.s3.e0,DDI-DrugBank.d231.s3.e2,"Patients receiving high doses of drug1 concomitantly with drug0, as in rheumatic disease, may experience drug2",False, 
DDI-DrugBank.d231.s3.e1,DDI-DrugBank.d231.s3.e2,"Patients receiving high doses of drug0 concomitantly with drug1, as in rheumatic disease, may experience drug2",False, 
DDI-DrugBank.d231.s4.e0,DDI-DrugBank.d231.s4.e1,drug1 has a tendency to antagonize the skeletal muscle relaxing effect of drug2 and may potentiate the action of drug0,True,effect
DDI-DrugBank.d231.s4.e0,DDI-DrugBank.d231.s4.e2,drug1 has a tendency to antagonize the skeletal muscle relaxing effect of drug0 and may potentiate the action of drug2,True,effect
DDI-DrugBank.d231.s4.e1,DDI-DrugBank.d231.s4.e2,drug0 has a tendency to antagonize the skeletal muscle relaxing effect of drug1 and may potentiate the action of drug2,False, 
DDI-DrugBank.d231.s5.e0,DDI-DrugBank.d231.s5.e1,drug1 generally should not be given with drug2 because they reduce drug0s renal clearance and add a high risk of drug0,True,advise
DDI-DrugBank.d231.s5.e0,DDI-DrugBank.d231.s5.e2,drug1 generally should not be given with drug0 because they reduce drug2s renal clearance and add a high risk of drug0,False, 
DDI-DrugBank.d231.s5.e0,DDI-DrugBank.d231.s5.e3,drug1 generally should not be given with drug0 because they reduce drug0s renal clearance and add a high risk of drug2,False, 
DDI-DrugBank.d231.s6.e0,DDI-DrugBank.d231.s6.e1,drug1 may add to or potentiate the therapeutic effect of other drug2,True,effect
DDI-DrugBank.d231.s7.e0,DDI-DrugBank.d231.s7.e1,Potentiation occurs with drug1 or drug2,False, 
DDI-DrugBank.d231.s8.e0,DDI-DrugBank.d231.s8.e1,drug1 may decrease arterial responsiveness to drug2,True,effect
DDI-DrugBank.d231.s10.e0,DDI-DrugBank.d231.s10.e1,Tablets Simultaneous administration of drug1 and drug2 tablets may reduce the natriuretic and antihypertensive effects of drug0,True,effect
DDI-DrugBank.d231.s10.e0,DDI-DrugBank.d231.s10.e2,Tablets Simultaneous administration of drug1 and drug0 tablets may reduce the natriuretic and antihypertensive effects of drug2,False, 
DDI-DrugBank.d231.s10.e1,DDI-DrugBank.d231.s10.e2,Tablets Simultaneous administration of drug0 and drug1 tablets may reduce the natriuretic and antihypertensive effects of drug2,False, 
DDI-DrugBank.d231.s12.e0,DDI-DrugBank.d231.s12.e1,The intake of drug1 and drug2,True,advise
DDI-DrugBank.d231.s13.e0,DDI-DrugBank.d231.s13.e1,"Tablets, Injection, and Oral Solution One study in six subjects demonstrated that the combination of drug1 and drug2",True,effect
DDI-DrugBank.d231.s14.e0,DDI-DrugBank.d231.s14.e1,"There are case reports of patients who developed increased BUN, serum creatinine and serum potassium levels, and weight gain when drug1 was used in conjunction with drug2",True,effect
DDI-DrugBank.d231.s15.e0,DDI-DrugBank.d231.s15.e1,Literature reports indicate that coadministration of drug1 may reduce the natriuretic and antihypertensive effects of drug2,True,effect
DDI-DrugBank.d231.s17.e0,DDI-DrugBank.d231.s17.e1,Patients receiving both drug1 and drug2 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of drug0,True,advise
DDI-DrugBank.d231.s17.e0,DDI-DrugBank.d231.s17.e2,Patients receiving both drug1 and drug0 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of drug2,False, 
DDI-DrugBank.d231.s17.e1,DDI-DrugBank.d231.s17.e2,Patients receiving both drug0 and drug1 should be observed closely to determine if the desired diuretic and/or antihypertensive effect of drug2,False, 
DDI-DrugBank.d511.s0.e0,DDI-DrugBank.d511.s0.e1,A possible drug interaction of drug1 and intravenous drug2,True,int
DDI-DrugBank.d511.s1.e0,DDI-DrugBank.d511.s1.e1,Concomitant treatment of four patients in the United Kingdom with drug1 and intravenous drug2,True,effect
DDI-DrugBank.d511.s4.e0,DDI-DrugBank.d511.s4.e1,"Because of drug1s tendency to cause renal impairment, the use of drug2 should be avoided in combination with potentially nephrotoxic drugs such as drug0, drug0 and intravenous drug0",False, 
DDI-DrugBank.d511.s4.e0,DDI-DrugBank.d511.s4.e2,"Because of drug1s tendency to cause renal impairment, the use of drug0 should be avoided in combination with potentially nephrotoxic drugs such as drug2, drug0 and intravenous drug0",False, 
DDI-DrugBank.d511.s4.e1,DDI-DrugBank.d511.s4.e2,"Because of drug0s tendency to cause renal impairment, the use of drug1 should be avoided in combination with potentially nephrotoxic drugs such as drug2, drug0 and intravenous drug0",True,advise
DDI-DrugBank.d511.s4.e1,DDI-DrugBank.d511.s4.e3,"Because of drug0s tendency to cause renal impairment, the use of drug1 should be avoided in combination with potentially nephrotoxic drugs such as drug0, drug2 and intravenous drug0",True,advise
DDI-DrugBank.d511.s4.e1,DDI-DrugBank.d511.s4.e4,"Because of drug0s tendency to cause renal impairment, the use of drug1 should be avoided in combination with potentially nephrotoxic drugs such as drug0, drug0 and intravenous drug2",True,advise
DDI-DrugBank.d511.s6.e0,DDI-DrugBank.d511.s6.e1,drug1: The pharmacokinetics of drug2 and drug0,False, 
DDI-DrugBank.d511.s6.e0,DDI-DrugBank.d511.s6.e2,drug1: The pharmacokinetics of drug0 and drug2,False, 
DDI-DrugBank.d206.s0.e0,DDI-DrugBank.d206.s0.e1,Results of preliminary studies in humans and rats suggest that nonabsorbable drug1 given concurrently with drug2 may inhibit the desired drug0,True,mechanism
DDI-DrugBank.d206.s0.e0,DDI-DrugBank.d206.s0.e2,Results of preliminary studies in humans and rats suggest that nonabsorbable drug1 given concurrently with drug0 may inhibit the desired drug2,False, 
DDI-DrugBank.d206.s0.e1,DDI-DrugBank.d206.s0.e2,Results of preliminary studies in humans and rats suggest that nonabsorbable drug0 given concurrently with drug1 may inhibit the desired drug2,False, 
DDI-DrugBank.d44.s1.e0,DDI-DrugBank.d44.s1.e1,drug1 should not be used with other drug2,True,advise
DDI-DrugBank.d44.s2.e0,DDI-DrugBank.d44.s2.e1,"drug1, drug2 and drug0 should not be administered during drug0",False, 
DDI-DrugBank.d44.s2.e0,DDI-DrugBank.d44.s2.e2,"drug1, drug0 and drug2 should not be administered during drug0",False, 
DDI-DrugBank.d44.s2.e0,DDI-DrugBank.d44.s2.e3,"drug1, drug0 and drug0 should not be administered during drug2",True,advise
DDI-DrugBank.d44.s2.e1,DDI-DrugBank.d44.s2.e3,"drug0, drug1 and drug0 should not be administered during drug2",True,advise
DDI-DrugBank.d44.s2.e2,DDI-DrugBank.d44.s2.e3,"drug0, drug0 and drug1 should not be administered during drug2",True,advise
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e1,"In patients receiving nonselective drug1 (drug2) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e2,"In patients receiving nonselective drug1 (drug0) (e.g., drug2) in combination with drug0 (e.g., drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e3,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug2 (e.g., drug0, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e4,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug0 (e.g., drug2, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e5,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug0 (e.g., drug0, drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e6,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e7,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d423.s0.e0,DDI-DrugBank.d423.s0.e8,"In patients receiving nonselective drug1 (drug0) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e3,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug2 (e.g., drug0, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e4,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug0 (e.g., drug2, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e5,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug0 (e.g., drug0, drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e6,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e7,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d423.s0.e1,DDI-DrugBank.d423.s0.e8,"In patients receiving nonselective drug0 (drug1) (e.g., drug0) in combination with drug0 (e.g., drug0, drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e3,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug2 (e.g., drug0, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e4,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug0 (e.g., drug2, drug0, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e5,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug0 (e.g., drug0, drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e6,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug0 (e.g., drug0, drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e7,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug0 (e.g., drug0, drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d423.s0.e2,DDI-DrugBank.d423.s0.e8,"In patients receiving nonselective drug0 (drug0) (e.g., drug1) in combination with drug0 (e.g., drug0, drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d423.s1.e0,DDI-DrugBank.d423.s1.e1,"Because drug1 is a serotonin releaser and reuptake inhibitor, drug2 should not be used concomitantly with a drug0",False, 
DDI-DrugBank.d423.s1.e0,DDI-DrugBank.d423.s1.e2,"Because drug1 is a serotonin releaser and reuptake inhibitor, drug0 should not be used concomitantly with a drug2",False, 
DDI-DrugBank.d423.s1.e1,DDI-DrugBank.d423.s1.e2,"Because drug0 is a serotonin releaser and reuptake inhibitor, drug1 should not be used concomitantly with a drug2",True,advise
DDI-DrugBank.d423.s2.e0,DDI-DrugBank.d423.s2.e1,At least 14 days should elapse between discontinuation of a drug1 and initiation of treatment with drug2,True,advise
DDI-DrugBank.d423.s3.e0,DDI-DrugBank.d423.s3.e1,At least 3 weeks should elapse between discontinuation of drug1 and initiation of treatment with a drug2,True,advise
DDI-DrugBank.d423.s4.e0,DDI-DrugBank.d423.s4.e1,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug1 (drug2) and agents for migraine therapy, such as drug0 (drug0) and drug0",False, 
DDI-DrugBank.d423.s4.e0,DDI-DrugBank.d423.s4.e2,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug1 (drug0) and agents for migraine therapy, such as drug2 (drug0) and drug0",True,effect
DDI-DrugBank.d423.s4.e0,DDI-DrugBank.d423.s4.e3,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug1 (drug0) and agents for migraine therapy, such as drug0 (drug2) and drug0",True,effect
DDI-DrugBank.d423.s4.e0,DDI-DrugBank.d423.s4.e4,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug1 (drug0) and agents for migraine therapy, such as drug0 (drug0) and drug2",True,effect
DDI-DrugBank.d423.s4.e1,DDI-DrugBank.d423.s4.e2,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug0 (drug1) and agents for migraine therapy, such as drug2 (drug0) and drug0",True,effect
DDI-DrugBank.d423.s4.e1,DDI-DrugBank.d423.s4.e3,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug0 (drug1) and agents for migraine therapy, such as drug0 (drug2) and drug0",True,effect
DDI-DrugBank.d423.s4.e1,DDI-DrugBank.d423.s4.e4,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug0 (drug1) and agents for migraine therapy, such as drug0 (drug0) and drug2",True,effect
DDI-DrugBank.d423.s4.e2,DDI-DrugBank.d423.s4.e3,"A rare, but serious, constellation of symptoms, termed serotonin syndrome, has been reported with the concomitant use of drug0 (drug0) and agents for migraine therapy, such as drug1 (drug2) and drug0",False, 
DDI-DrugBank.d423.s6.e0,DDI-DrugBank.d423.s6.e1,drug1 should not be administered with other drug2,True,advise
DDI-DrugBank.d39.s0.e0,DDI-DrugBank.d39.s0.e1,"Persons taking most drug1, drug2 and drug0 invalidate drug0 and drug0",False, 
DDI-DrugBank.d39.s0.e0,DDI-DrugBank.d39.s0.e2,"Persons taking most drug1, drug0 and drug2 invalidate drug0 and drug0",False, 
DDI-DrugBank.d39.s1.e0,DDI-DrugBank.d39.s1.e1,drug1 drug2 and heavy drug0 intake for longer than 2 weeks may produce malabsorption of drug0,False, 
DDI-DrugBank.d39.s1.e0,DDI-DrugBank.d39.s1.e2,drug1 drug0 and heavy drug2 intake for longer than 2 weeks may produce malabsorption of drug0,False, 
DDI-DrugBank.d39.s1.e0,DDI-DrugBank.d39.s1.e3,drug1 drug0 and heavy drug0 intake for longer than 2 weeks may produce malabsorption of drug2,True,mechanism
DDI-DrugBank.d39.s1.e1,DDI-DrugBank.d39.s1.e3,drug0 drug1 and heavy drug0 intake for longer than 2 weeks may produce malabsorption of drug2,True,mechanism
DDI-DrugBank.d39.s1.e2,DDI-DrugBank.d39.s1.e3,drug0 drug0 and heavy drug1 intake for longer than 2 weeks may produce malabsorption of drug2,True,mechanism
DDI-DrugBank.d336.s0.e0,DDI-DrugBank.d336.s0.e1,"Although clinical studies have not established a cause and effect relationship, physicians should be aware that variable effects an blood coagulation have been reported very rarely in patients receiving oral drug1 and drug2",True,effect
DDI-DrugBank.d336.s1.e0,DDI-DrugBank.d336.s1.e1,The concomitant use of drug1 or other drug2,False, 
DDI-DrugBank.d18.s0.e0,DDI-DrugBank.d18.s0.e1,"Tablets: The drug1, including drug2, produce CNS-depressant effects when administered with such medications as drug0 or drug0",False, 
DDI-DrugBank.d18.s0.e0,DDI-DrugBank.d18.s0.e2,"Tablets: The drug1, including drug0, produce CNS-depressant effects when administered with such medications as drug2 or drug0",True,effect
DDI-DrugBank.d18.s0.e0,DDI-DrugBank.d18.s0.e3,"Tablets: The drug1, including drug0, produce CNS-depressant effects when administered with such medications as drug0 or drug2",True,effect
DDI-DrugBank.d18.s0.e1,DDI-DrugBank.d18.s0.e2,"Tablets: The drug0, including drug1, produce CNS-depressant effects when administered with such medications as drug2 or drug0",True,effect
DDI-DrugBank.d18.s0.e1,DDI-DrugBank.d18.s0.e3,"Tablets: The drug0, including drug1, produce CNS-depressant effects when administered with such medications as drug0 or drug2",True,effect
DDI-DrugBank.d18.s0.e2,DDI-DrugBank.d18.s0.e3,"Tablets: The drug0, including drug0, produce CNS-depressant effects when administered with such medications as drug1 or drug2",False, 
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e1,"Injection: drug1 injection, like other injectable drug2, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",False, 
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e2,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug2, drug0, drug0, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e3,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug2, drug0, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e4,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug0, drug2, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e5,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug2, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e6,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug0, and other drug2.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e0,DDI-DrugBank.d18.s1.e7,"Injection: drug1 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug0, and other drug0.When drug2 is used concomitantly with injectable drug0",False, 
DDI-DrugBank.d18.s1.e1,DDI-DrugBank.d18.s1.e2,"Injection: drug0 injection, like other injectable drug1, produces depression of the central nervous system when administered with drug2, drug0, drug0, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e1,DDI-DrugBank.d18.s1.e3,"Injection: drug0 injection, like other injectable drug1, produces depression of the central nervous system when administered with drug0, drug2, drug0, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e1,DDI-DrugBank.d18.s1.e4,"Injection: drug0 injection, like other injectable drug1, produces depression of the central nervous system when administered with drug0, drug0, drug2, drug0, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e1,DDI-DrugBank.d18.s1.e5,"Injection: drug0 injection, like other injectable drug1, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug2, and other drug0.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e1,DDI-DrugBank.d18.s1.e6,"Injection: drug0 injection, like other injectable drug1, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug0, and other drug2.When drug0 is used concomitantly with injectable drug0",True,effect
DDI-DrugBank.d18.s1.e7,DDI-DrugBank.d18.s1.e8,"Injection: drug0 injection, like other injectable drug0, produces depression of the central nervous system when administered with drug0, drug0, drug0, drug0, and other drug0.When drug1 is used concomitantly with injectable drug2",True,effect
DDI-DrugBank.d291.s0.e0,DDI-DrugBank.d291.s0.e1,When drug1 or drug2 is used at the same time as other medicines or substances the following interactions must be taken into account: - drug0 and drug0 may enhance the action of drug0,False, 
DDI-DrugBank.d291.s0.e0,DDI-DrugBank.d291.s0.e2,When drug1 or drug0 is used at the same time as other medicines or substances the following interactions must be taken into account: - drug2 and drug0 may enhance the action of drug0,False, 
DDI-DrugBank.d291.s0.e2,DDI-DrugBank.d291.s0.e4,When drug0 or drug0 is used at the same time as other medicines or substances the following interactions must be taken into account: - drug1 and drug0 may enhance the action of drug2,True,effect
DDI-DrugBank.d291.s0.e3,DDI-DrugBank.d291.s0.e4,When drug0 or drug0 is used at the same time as other medicines or substances the following interactions must be taken into account: - drug0 and drug1 may enhance the action of drug2,True,effect
DDI-DrugBank.d291.s1.e0,DDI-DrugBank.d291.s1.e1,"For this reason, the dose of the drug1 should be reduced by 30 - 50% at the start of treatment with drug2 or drug0",True,advise
DDI-DrugBank.d291.s1.e0,DDI-DrugBank.d291.s1.e2,"For this reason, the dose of the drug1 should be reduced by 30 - 50% at the start of treatment with drug0 or drug2",True,advise
DDI-DrugBank.d291.s1.e1,DDI-DrugBank.d291.s1.e2,"For this reason, the dose of the drug0 should be reduced by 30 - 50% at the start of treatment with drug1 or drug2",False, 
DDI-DrugBank.d291.s3.e0,DDI-DrugBank.d291.s3.e1,- The action of drug1 and drug2 may be enhanced by drug0 or drug0,False, 
DDI-DrugBank.d291.s3.e0,DDI-DrugBank.d291.s3.e2,- The action of drug1 and drug0 may be enhanced by drug2 or drug0,True,effect
DDI-DrugBank.d291.s3.e0,DDI-DrugBank.d291.s3.e3,- The action of drug1 and drug0 may be enhanced by drug0 or drug2,True,effect
DDI-DrugBank.d291.s3.e1,DDI-DrugBank.d291.s3.e2,- The action of drug0 and drug1 may be enhanced by drug2 or drug0,True,effect
DDI-DrugBank.d291.s3.e1,DDI-DrugBank.d291.s3.e3,- The action of drug0 and drug1 may be enhanced by drug0 or drug2,True,effect
DDI-DrugBank.d291.s3.e2,DDI-DrugBank.d291.s3.e3,- The action of drug0 and drug0 may be enhanced by drug1 or drug2,False, 
DDI-DrugBank.d291.s6.e0,DDI-DrugBank.d291.s6.e1,"- In isolated cases, a pronounced though reversible, impairment of renal function (accompanied by a corresponding increase in the serum creatinine level) has been reported in organ transplant patients receiving drug1 therapy and concomitant drug2",True,effect
DDI-DrugBank.d291.s9.e0,DDI-DrugBank.d291.s9.e1,"- When drug1 or drug2 is used concurrently with drug0 (e.g. drug0), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug0 or drug0",False, 
DDI-DrugBank.d291.s9.e0,DDI-DrugBank.d291.s9.e2,"- When drug1 or drug0 is used concurrently with drug2 (e.g. drug0), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug0 or drug0",True,advise
DDI-DrugBank.d291.s9.e0,DDI-DrugBank.d291.s9.e3,"- When drug1 or drug0 is used concurrently with drug0 (e.g. drug2), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug0 or drug0",True,advise
DDI-DrugBank.d291.s9.e0,DDI-DrugBank.d291.s9.e4,"- When drug1 or drug0 is used concurrently with drug0 (e.g. drug0), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug2 or drug0",False, 
DDI-DrugBank.d291.s9.e1,DDI-DrugBank.d291.s9.e2,"- When drug0 or drug1 is used concurrently with drug2 (e.g. drug0), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug0 or drug0",True,advise
DDI-DrugBank.d291.s9.e1,DDI-DrugBank.d291.s9.e3,"- When drug0 or drug1 is used concurrently with drug0 (e.g. drug2), an interval of at least 2 hours should be maintained between the two medicines, since the absorption of drug0 or drug0",True,advise
DDI-DrugBank.d291.s11.e0,DDI-DrugBank.d291.s11.e1,- drug1 or drug2 (with hepatotoxic potential) must not be administered together with drug0 or drug0,False, 
DDI-DrugBank.d291.s11.e0,DDI-DrugBank.d291.s11.e2,- drug1 or drug0 (with hepatotoxic potential) must not be administered together with drug2 or drug0,True,advise
DDI-DrugBank.d291.s11.e0,DDI-DrugBank.d291.s11.e3,- drug1 or drug0 (with hepatotoxic potential) must not be administered together with drug0 or drug2,True,advise
DDI-DrugBank.d291.s11.e1,DDI-DrugBank.d291.s11.e2,- drug0 or drug1 (with hepatotoxic potential) must not be administered together with drug2 or drug0,True,advise
DDI-DrugBank.d291.s11.e1,DDI-DrugBank.d291.s11.e3,- drug0 or drug1 (with hepatotoxic potential) must not be administered together with drug0 or drug2,True,advise
DDI-DrugBank.d291.s11.e2,DDI-DrugBank.d291.s11.e3,- drug0 or drug0 (with hepatotoxic potential) must not be administered together with drug1 or drug2,False, 
DDI-DrugBank.d556.s0.e0,DDI-DrugBank.d556.s0.e1,Increased nephrotoxicity has been reported following concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d556.s1.e0,DDI-DrugBank.d556.s1.e1,"Drug/Laboratory Test Interactions As with drug1, high concentrations of drug2",False, 
DDI-DrugBank.d459.s0.e0,DDI-DrugBank.d459.s0.e1,"The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug2, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d459.s0.e0,DDI-DrugBank.d459.s0.e2,"The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug0, drug2, drug0, drug0, drug0",True,advise
DDI-DrugBank.d459.s0.e0,DDI-DrugBank.d459.s0.e3,"The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug0, drug0, drug2, drug0, drug0",True,advise
DDI-DrugBank.d459.s0.e0,DDI-DrugBank.d459.s0.e4,"The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug2, drug0",True,advise
DDI-DrugBank.d459.s0.e0,DDI-DrugBank.d459.s0.e5,"The daily dose of drug1 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug0, drug2",True,advise
DDI-DrugBank.d459.s0.e1,DDI-DrugBank.d459.s0.e2,"The daily dose of drug0 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug1, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d459.s0.e1,DDI-DrugBank.d459.s0.e3,"The daily dose of drug0 should not exceed 7.5 mg when coadministered with potent CYP3A4 inhibitors (e.g., drug1, drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d459.s1.e0,DDI-DrugBank.d459.s1.e1,"Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as drug2, drug0 and drug0",True,advise
DDI-DrugBank.d459.s1.e0,DDI-DrugBank.d459.s1.e2,"Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as drug0, drug2 and drug0",True,advise
DDI-DrugBank.d459.s1.e0,DDI-DrugBank.d459.s1.e3,"Caution should be taken when drug1 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as drug0, drug0 and drug2",True,advise
DDI-DrugBank.d459.s1.e1,DDI-DrugBank.d459.s1.e2,"Caution should be taken when drug0 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as drug1, drug2 and drug0",False, 
DDI-DrugBank.d459.s1.e1,DDI-DrugBank.d459.s1.e3,"Caution should be taken when drug0 is used concomitantly with medications that are predominantly metabolized by CYP2D6 and which have a narrow therapeutic window, such as drug1, drug0 and drug2",False, 
DDI-DrugBank.d459.s2.e0,DDI-DrugBank.d459.s2.e1,The concomitant use of drug1 with other drug2,True,effect
DDI-DrugBank.d237.s1.e0,DDI-DrugBank.d237.s1.e1,"In some cases where serious ventricular arrhythmias, QT prolongation, and torsades de pointes have occurred when drug1 was taken in conjunction with one of the cytochrome P450 3A4 inhibitors, elevated blood drug2",False, 
DDI-DrugBank.d237.s2.e0,DDI-DrugBank.d237.s2.e1,"drug1: In vitro and/or in vivo data show that drug2, drug0, and drug0 markedly inhibit the metabolism of drug0, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s2.e0,DDI-DrugBank.d237.s2.e2,"drug1: In vitro and/or in vivo data show that drug0, drug2, and drug0 markedly inhibit the metabolism of drug0, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s2.e1,DDI-DrugBank.d237.s2.e4,"drug0: In vitro and/or in vivo data show that drug1, drug0, and drug0 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s2.e2,DDI-DrugBank.d237.s2.e4,"drug0: In vitro and/or in vivo data show that drug0, drug1, and drug0 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s2.e3,DDI-DrugBank.d237.s2.e4,"drug0: In vitro and/or in vivo data show that drug0, drug0, and drug1 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s3.e0,DDI-DrugBank.d237.s3.e1,"drug1: Concurrent administration of certain drug2, such as drug0 and drug0, would be expected to compromise the beneficial effects of drug0",False, 
DDI-DrugBank.d237.s3.e0,DDI-DrugBank.d237.s3.e2,"drug1: Concurrent administration of certain drug0, such as drug2 and drug0, would be expected to compromise the beneficial effects of drug0",False, 
DDI-DrugBank.d237.s3.e1,DDI-DrugBank.d237.s3.e4,"drug0: Concurrent administration of certain drug1, such as drug0 and drug0, would be expected to compromise the beneficial effects of drug2",True,effect
DDI-DrugBank.d237.s3.e2,DDI-DrugBank.d237.s3.e4,"drug0: Concurrent administration of certain drug0, such as drug1 and drug0, would be expected to compromise the beneficial effects of drug2",True,effect
DDI-DrugBank.d237.s3.e3,DDI-DrugBank.d237.s3.e4,"drug0: Concurrent administration of certain drug0, such as drug0 and drug1, would be expected to compromise the beneficial effects of drug2",True,effect
DDI-DrugBank.d237.s4.e0,DDI-DrugBank.d237.s4.e1,drug1 (Oral): In patients receiving oral drug2,False, 
DDI-DrugBank.d237.s5.e0,DDI-DrugBank.d237.s5.e1,"It is advisable to check coagulation time within the first few days after the start and discontinuation of drug1 therapy, with an appropriate adjustment of the drug2",True,advise
DDI-DrugBank.d237.s6.e0,DDI-DrugBank.d237.s6.e1,"drug1: In vitro data indicate that drug2 inhibits the metabolism of drug0, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s6.e0,DDI-DrugBank.d237.s6.e2,"drug1: In vitro data indicate that drug0 inhibits the metabolism of drug2, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s6.e1,DDI-DrugBank.d237.s6.e2,"drug0: In vitro data indicate that drug1 inhibits the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s7.e0,DDI-DrugBank.d237.s7.e1,"drug1: In vitro and/or in vivo data indicate that drug2, drug0, and oral drug0 markedly inhibit the metabolism of drug0, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s7.e0,DDI-DrugBank.d237.s7.e2,"drug1: In vitro and/or in vivo data indicate that drug0, drug2, and oral drug0 markedly inhibit the metabolism of drug0, which can result in an increase in plasma drug0",False, 
DDI-DrugBank.d237.s7.e1,DDI-DrugBank.d237.s7.e4,"drug0: In vitro and/or in vivo data indicate that drug1, drug0, and oral drug0 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s7.e2,DDI-DrugBank.d237.s7.e4,"drug0: In vitro and/or in vivo data indicate that drug0, drug1, and oral drug0 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s7.e3,DDI-DrugBank.d237.s7.e4,"drug0: In vitro and/or in vivo data indicate that drug0, drug0, and oral drug1 markedly inhibit the metabolism of drug2, which can result in an increase in plasma drug0",True,mechanism
DDI-DrugBank.d237.s8.e0,DDI-DrugBank.d237.s8.e1,"Human pharmacokinetic data indicate that oral drug1 markedly inhibits the metabolism of drug2, resulting in a mean eight-fold increase in AUC of drug0",True,mechanism
DDI-DrugBank.d237.s8.e0,DDI-DrugBank.d237.s8.e2,"Human pharmacokinetic data indicate that oral drug1 markedly inhibits the metabolism of drug0, resulting in a mean eight-fold increase in AUC of drug2",False, 
DDI-DrugBank.d237.s8.e1,DDI-DrugBank.d237.s8.e2,"Human pharmacokinetic data indicate that oral drug0 markedly inhibits the metabolism of drug1, resulting in a mean eight-fold increase in AUC of drug2",False, 
DDI-DrugBank.d237.s9.e0,DDI-DrugBank.d237.s9.e1,A study in 14 normal male and female volunteers suggests that coadministration of drug1 and drug2,True,effect
DDI-DrugBank.d237.s10.e0,DDI-DrugBank.d237.s10.e1,"drug1: drug2 coadministration leads to an increased peak plasma concentration and AUC of drug0, there is no effect on drug0 absorption when it is coadministered with drug0",False, 
DDI-DrugBank.d237.s10.e0,DDI-DrugBank.d237.s10.e2,"drug1: drug0 coadministration leads to an increased peak plasma concentration and AUC of drug2, there is no effect on drug0 absorption when it is coadministered with drug0",False, 
DDI-DrugBank.d237.s10.e1,DDI-DrugBank.d237.s10.e2,"drug0: drug1 coadministration leads to an increased peak plasma concentration and AUC of drug2, there is no effect on drug0 absorption when it is coadministered with drug0",True,mechanism
DDI-DrugBank.d237.s11.e0,DDI-DrugBank.d237.s11.e1,The gastrointestinal absorption of drug1 and drug2 is accelerated when they are coadministered with drug0,False, 
DDI-DrugBank.d237.s11.e0,DDI-DrugBank.d237.s11.e2,The gastrointestinal absorption of drug1 and drug0 is accelerated when they are coadministered with drug2,True,mechanism
DDI-DrugBank.d237.s11.e1,DDI-DrugBank.d237.s11.e2,The gastrointestinal absorption of drug0 and drug1 is accelerated when they are coadministered with drug2,True,mechanism
DDI-DrugBank.d237.s12.e0,DDI-DrugBank.d237.s12.e1,drug1: In vitro data indicate that drug2 and drug0 markedly inhibit the metabolism of drug0 which can result in an increase in plasma drug0,False, 
DDI-DrugBank.d237.s12.e0,DDI-DrugBank.d237.s12.e2,drug1: In vitro data indicate that drug0 and drug2 markedly inhibit the metabolism of drug0 which can result in an increase in plasma drug0,False, 
DDI-DrugBank.d237.s12.e1,DDI-DrugBank.d237.s12.e3,drug0: In vitro data indicate that drug1 and drug0 markedly inhibit the metabolism of drug2 which can result in an increase in plasma drug0,True,mechanism
DDI-DrugBank.d237.s12.e2,DDI-DrugBank.d237.s12.e3,drug0: In vitro data indicate that drug0 and drug1 markedly inhibit the metabolism of drug2 which can result in an increase in plasma drug0,True,mechanism
DDI-DrugBank.d237.s13.e0,DDI-DrugBank.d237.s13.e1,Other: Coadministration of grapefruit juice with drug1 increases the bioavailability of drug2,False, 
DDI-DrugBank.d237.s14.e0,DDI-DrugBank.d237.s14.e1,"drug1 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug2, including those of Class IA (such as drug0 and drug0) and Class III (such as drug0",True,advise
DDI-DrugBank.d237.s14.e0,DDI-DrugBank.d237.s14.e2,"drug1 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug0, including those of Class IA (such as drug2 and drug0) and Class III (such as drug0",True,advise
DDI-DrugBank.d237.s14.e0,DDI-DrugBank.d237.s14.e3,"drug1 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug0, including those of Class IA (such as drug0 and drug2) and Class III (such as drug0",True,advise
DDI-DrugBank.d237.s14.e0,DDI-DrugBank.d237.s14.e4,"drug1 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug0, including those of Class IA (such as drug0 and drug0) and Class III (such as drug2",True,advise
DDI-DrugBank.d237.s14.e1,DDI-DrugBank.d237.s14.e2,"drug0 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug1, including those of Class IA (such as drug2 and drug0) and Class III (such as drug0",False, 
DDI-DrugBank.d237.s14.e1,DDI-DrugBank.d237.s14.e3,"drug0 should not be used concomitantly with other drugs known to prolong the QT interval: certain drug1, including those of Class IA (such as drug0 and drug2) and Class III (such as drug0",False, 
DDI-DrugBank.d237.s15.e0,DDI-DrugBank.d237.s15.e1,drug1 (such as drug2,False, 
DDI-DrugBank.d237.s16.e0,DDI-DrugBank.d237.s16.e1,certain drug1 (such as drug2,False, 
DDI-DrugBank.d237.s17.e0,DDI-DrugBank.d237.s17.e1,certain drug1 (such as drug2,False, 
DDI-DrugBank.d237.s18.e0,DDI-DrugBank.d237.s18.e1,"drug1, drug2, drug0, and drug0",False, 
DDI-DrugBank.d237.s18.e0,DDI-DrugBank.d237.s18.e2,"drug1, drug0, drug2, and drug0",False, 
DDI-DrugBank.d287.s0.e0,DDI-DrugBank.d287.s0.e1,drug1 should be administered with caution to patients taking drug2,True,advise
DDI-DrugBank.d502.s0.e0,DDI-DrugBank.d502.s0.e1,drug1 should be used with caution in patients who are receiving a drug2,True,advise
DDI-DrugBank.d502.s1.e0,DDI-DrugBank.d502.s1.e1,Close observation of the patient is recommended when a drug1 is administered to patients receiving catecholamine-depleting drugs such as drug2,True,advise
DDI-DrugBank.d85.s0.e0,DDI-DrugBank.d85.s0.e1,The use of drug1 in patients who are receiving drug2,True,effect
DDI-DrugBank.d85.s5.e0,DDI-DrugBank.d85.s5.e1,"Similarly, patients receiving the drug and a drug1, drug2 or drug0",False, 
DDI-DrugBank.d85.s5.e0,DDI-DrugBank.d85.s5.e2,"Similarly, patients receiving the drug and a drug1, drug0 or drug2",False, 
DDI-DrugBank.d85.s6.e0,DDI-DrugBank.d85.s6.e1,Concomitant administration of drug1 and drug2 is not recommended because drug0 is displaced from its binding sites during the concomitant administration of drug0,True,advise
DDI-DrugBank.d85.s6.e0,DDI-DrugBank.d85.s6.e2,Concomitant administration of drug1 and drug0 is not recommended because drug2 is displaced from its binding sites during the concomitant administration of drug0,False, 
DDI-DrugBank.d85.s6.e0,DDI-DrugBank.d85.s6.e3,Concomitant administration of drug1 and drug0 is not recommended because drug0 is displaced from its binding sites during the concomitant administration of drug2,False, 
DDI-DrugBank.d85.s6.e2,DDI-DrugBank.d85.s6.e3,Concomitant administration of drug0 and drug0 is not recommended because drug1 is displaced from its binding sites during the concomitant administration of drug2,True,advise
DDI-DrugBank.d85.s8.e0,DDI-DrugBank.d85.s8.e1,Inhibition of renal drug1 clearance leading to increases in plasma drug2,False, 
DDI-DrugBank.d85.s9.e0,DDI-DrugBank.d85.s9.e1,drug1 and other drug2 can reduce the antihypertensive effect of drug0 and other drug0,False, 
DDI-DrugBank.d85.s9.e0,DDI-DrugBank.d85.s9.e2,drug1 and other drug0 can reduce the antihypertensive effect of drug2 and other drug0,True,effect
DDI-DrugBank.d85.s9.e0,DDI-DrugBank.d85.s9.e3,drug1 and other drug0 can reduce the antihypertensive effect of drug0 and other drug2,True,effect
DDI-DrugBank.d85.s9.e1,DDI-DrugBank.d85.s9.e2,drug0 and other drug1 can reduce the antihypertensive effect of drug2 and other drug0,True,effect
DDI-DrugBank.d85.s9.e1,DDI-DrugBank.d85.s9.e3,drug0 and other drug1 can reduce the antihypertensive effect of drug0 and other drug2,True,effect
DDI-DrugBank.d85.s9.e2,DDI-DrugBank.d85.s9.e3,drug0 and other drug0 can reduce the antihypertensive effect of drug1 and other drug2,False, 
DDI-DrugBank.d85.s10.e0,DDI-DrugBank.d85.s10.e1,drug1 given concurrently increases drug2,True,mechanism
DDI-DrugBank.d85.s11.e0,DDI-DrugBank.d85.s11.e1,Caution should be used if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d85.s12.e0,DDI-DrugBank.d85.s12.e1,"drug1, drug2 and other drug0 have been reported to reduce the tubular secretion of drug0 in an animal model, possibly increasing the toxicity of drug0",False, 
DDI-DrugBank.d85.s12.e0,DDI-DrugBank.d85.s12.e2,"drug1, drug0 and other drug2 have been reported to reduce the tubular secretion of drug0 in an animal model, possibly increasing the toxicity of drug0",False, 
DDI-DrugBank.d85.s12.e0,DDI-DrugBank.d85.s12.e3,"drug1, drug0 and other drug0 have been reported to reduce the tubular secretion of drug2 in an animal model, possibly increasing the toxicity of drug0",True,mechanism
DDI-DrugBank.d85.s12.e1,DDI-DrugBank.d85.s12.e3,"drug0, drug1 and other drug0 have been reported to reduce the tubular secretion of drug2 in an animal model, possibly increasing the toxicity of drug0",True,mechanism
DDI-DrugBank.d85.s12.e2,DDI-DrugBank.d85.s12.e3,"drug0, drug0 and other drug1 have been reported to reduce the tubular secretion of drug2 in an animal model, possibly increasing the toxicity of drug0",True,mechanism
DDI-DrugBank.d250.s0.e0,DDI-DrugBank.d250.s0.e1,Certain other drug1 (drug2 and drug0,False, 
DDI-DrugBank.d250.s0.e0,DDI-DrugBank.d250.s0.e2,Certain other drug1 (drug0 and drug2,False, 
DDI-DrugBank.d250.s2.e0,DDI-DrugBank.d250.s2.e1,"drug1 (eg, drug2) and other drugs, including ether, drug0, drug0, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug0",False, 
DDI-DrugBank.d250.s2.e0,DDI-DrugBank.d250.s2.e2,"drug1 (eg, drug0) and other drugs, including ether, drug2, drug0, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug0",False, 
DDI-DrugBank.d250.s2.e0,DDI-DrugBank.d250.s2.e6,"drug1 (eg, drug0) and other drugs, including ether, drug0, drug0, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s2.e1,DDI-DrugBank.d250.s2.e6,"drug0 (eg, drug1) and other drugs, including ether, drug0, drug0, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s2.e2,DDI-DrugBank.d250.s2.e6,"drug0 (eg, drug0) and other drugs, including ether, drug1, drug0, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s2.e3,DDI-DrugBank.d250.s2.e6,"drug0 (eg, drug0) and other drugs, including ether, drug0, drug1, drug0 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s2.e4,DDI-DrugBank.d250.s2.e6,"drug0 (eg, drug0) and other drugs, including ether, drug0, drug0, drug1 and drug0, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s2.e5,DDI-DrugBank.d250.s2.e6,"drug0 (eg, drug0) and other drugs, including ether, drug0, drug0, drug0 and drug1, potentiate the neuromuscular blocking effect and should be used with extreme caution in patients being treated with drug2",True,effect
DDI-DrugBank.d250.s3.e0,DDI-DrugBank.d250.s3.e1,drug1 may enhance the nephrotoxicity of drug2,True,effect
DDI-DrugBank.d250.s4.e0,DDI-DrugBank.d250.s4.e1,The concomitant use of drug1 and drug2,True,advise
DDI-DrugBank.d545.s0.e0,DDI-DrugBank.d545.s0.e1,drug1 (drug2) blood levels may be increased and prolonged by concurrent administration of drug0,False, 
DDI-DrugBank.d545.s0.e0,DDI-DrugBank.d545.s0.e2,drug1 (drug0) blood levels may be increased and prolonged by concurrent administration of drug2,True,mechanism
DDI-DrugBank.d545.s0.e1,DDI-DrugBank.d545.s0.e2,drug0 (drug1) blood levels may be increased and prolonged by concurrent administration of drug2,True,mechanism
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e1,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e2,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug2 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e3,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e4,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e5,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e6,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e7,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e8,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d225.s0.e0,DDI-DrugBank.d225.s0.e9,"Immediate and Extended Release Tablets The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0, some drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d225.s0.e1,DDI-DrugBank.d225.s0.e2,"Immediate and Extended Release Tablets The hypoglycemic action of drug0 may be potentiated by certain drugs including drug1, some drug2 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d225.s0.e1,DDI-DrugBank.d225.s0.e3,"Immediate and Extended Release Tablets The hypoglycemic action of drug0 may be potentiated by certain drugs including drug1, some drug0 and other drugs that are highly protein bound, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d225.s3.e0,DDI-DrugBank.d225.s3.e1,In vitro binding studies with human serum proteins indicate that drug1 binds differently than drug2 and does not interact with drug0 or drug0,False, 
DDI-DrugBank.d225.s3.e0,DDI-DrugBank.d225.s3.e2,In vitro binding studies with human serum proteins indicate that drug1 binds differently than drug0 and does not interact with drug2 or drug0,False, 
DDI-DrugBank.d225.s6.e0,DDI-DrugBank.d225.s6.e1,"These drugs include the drug1 and other drug2, drug0, drug0, drug0, drug0, oral drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d225.s6.e0,DDI-DrugBank.d225.s6.e2,"These drugs include the drug1 and other drug0, drug2, drug0, drug0, drug0, oral drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d225.s9.e0,DDI-DrugBank.d225.s9.e1,A potential interaction between oral drug1 and oral drug2,True,int
DDI-DrugBank.d225.s11.e0,DDI-DrugBank.d225.s11.e1,The effect of concomitant administration of drug1 and drug2,True,int
DDI-DrugBank.d225.s12.e0,DDI-DrugBank.d225.s12.e1,All subjects received drug1 alone and following treatment with 100 mg of drug2,False, 
DDI-DrugBank.d225.s13.e0,DDI-DrugBank.d225.s13.e1,The mean percentage increase in the drug1 AUC after drug2,True,mechanism
DDI-DrugBank.d73.s0.e0,DDI-DrugBank.d73.s0.e1,"Catecholamine-depleting drugs (eg, drug1) may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d73.s2.e0,DDI-DrugBank.d73.s2.e1,drug1 may also have an additive effect when given with drug2,True,effect
DDI-DrugBank.d73.s3.e0,DDI-DrugBank.d73.s3.e1,drug1 may exacerbate the rebound hypertension which can follow the withdrawal of drug2,True,effect
DDI-DrugBank.d73.s4.e0,DDI-DrugBank.d73.s4.e1,"If the two drugs are coadministered, the drug1 should be withdrawn several days before the gradual withdrawal of drug2",True,advise
DDI-DrugBank.d73.s5.e0,DDI-DrugBank.d73.s5.e1,"If replacing drug1 by drug2 therapy, the introduction of drug0 should be delayed for several days after drug0",False, 
DDI-DrugBank.d73.s5.e0,DDI-DrugBank.d73.s5.e2,"If replacing drug1 by drug0 therapy, the introduction of drug2 should be delayed for several days after drug0",False, 
DDI-DrugBank.d73.s5.e2,DDI-DrugBank.d73.s5.e3,"If replacing drug0 by drug0 therapy, the introduction of drug1 should be delayed for several days after drug2",True,advise
DDI-DrugBank.d73.s6.e0,DDI-DrugBank.d73.s6.e1,"Concomitant use of prostaglandin synthase inhibiting drugs, eg, drug1, may decrease the hypotensive effects of drug2",True,effect
DDI-DrugBank.d73.s7.e0,DDI-DrugBank.d73.s7.e1,Information on concurrent usage of drug1 and drug2,False, 
DDI-DrugBank.d73.s8.e0,DDI-DrugBank.d73.s8.e1,"Data from several studies, ie, TIMI-II, ISIS-2, currently do not suggest any clinical interaction between drug1 and drug2",False, 
DDI-DrugBank.d425.s1.e0,DDI-DrugBank.d425.s1.e1,"Medications can interfere with folate utilization, including: drug1 (such as drug2, and drug0) drug0 (sometimes prescribed to control blood sugar in type 2 diabetes) drug0 (used to control inflammation associated with Crohns disease and ulcerative colitis) drug0 (a drug0) drug0 There has been concern about the interaction between drug0 and drug0",False, 
DDI-DrugBank.d425.s1.e0,DDI-DrugBank.d425.s1.e2,"Medications can interfere with folate utilization, including: drug1 (such as drug0, and drug2) drug0 (sometimes prescribed to control blood sugar in type 2 diabetes) drug0 (used to control inflammation associated with Crohns disease and ulcerative colitis) drug0 (a drug0) drug0 There has been concern about the interaction between drug0 and drug0",False, 
DDI-DrugBank.d425.s1.e8,DDI-DrugBank.d425.s1.e9,"Medications can interfere with folate utilization, including: drug0 (such as drug0, and drug0) drug0 (sometimes prescribed to control blood sugar in type 2 diabetes) drug0 (used to control inflammation associated with Crohns disease and ulcerative colitis) drug0 (a drug0) drug0 There has been concern about the interaction between drug1 and drug2",True,int
DDI-DrugBank.d425.s5.e0,DDI-DrugBank.d425.s5.e1,"Therefore, intake of supplemental drug1 should not exceed 1000 micrograms ( g, sometimes mcg) per day to prevent drug2",False, 
DDI-DrugBank.d425.s6.e0,DDI-DrugBank.d425.s6.e1,It is important for older adults to be aware of the relationship between drug1 and drug2,False, 
DDI-DrugBank.d121.s0.e0,DDI-DrugBank.d121.s0.e1,Nephrotoxicity has been reported following concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d121.s1.e0,DDI-DrugBank.d121.s1.e1,Concomitant administration of drug1 doubled the AUC for drug2,True,mechanism
DDI-DrugBank.d121.s2.e0,DDI-DrugBank.d121.s2.e1,The bioavailability of the capsule formulation of drug1 was not affected when administered 5 minutes following an drug2,False, 
DDI-DrugBank.d55.s0.e0,DDI-DrugBank.d55.s0.e1,drug1 injection and drug2,True,advise
DDI-DrugBank.d55.s2.e0,DDI-DrugBank.d55.s2.e1,"drug1 should be used with caution, if at all, when potent inhalational drug2 such as drug0 are employed because of potential to sensitize the myocardium to effects of drug0",True,advise
DDI-DrugBank.d55.s2.e0,DDI-DrugBank.d55.s2.e2,"drug1 should be used with caution, if at all, when potent inhalational drug0 such as drug2 are employed because of potential to sensitize the myocardium to effects of drug0",True,advise
DDI-DrugBank.d55.s2.e0,DDI-DrugBank.d55.s2.e3,"drug1 should be used with caution, if at all, when potent inhalational drug0 such as drug0 are employed because of potential to sensitize the myocardium to effects of drug2",False, 
DDI-DrugBank.d55.s2.e1,DDI-DrugBank.d55.s2.e2,"drug0 should be used with caution, if at all, when potent inhalational drug1 such as drug2 are employed because of potential to sensitize the myocardium to effects of drug0",False, 
DDI-DrugBank.d181.s0.e0,DDI-DrugBank.d181.s0.e1,drug1 or other drug2 (concurrent use with drug0,False, 
DDI-DrugBank.d181.s0.e0,DDI-DrugBank.d181.s0.e2,drug1 or other drug0 (concurrent use with drug2,True,effect
DDI-DrugBank.d181.s0.e1,DDI-DrugBank.d181.s0.e2,drug0 or other drug1 (concurrent use with drug2,True,effect
DDI-DrugBank.d271.s0.e0,DDI-DrugBank.d271.s0.e1,"Physiological changes resulting from smoking cessation, with or without drug1 replacement, may alter the pharmacokinetics of certain concomitant medications, such as drug2 and drug0",False, 
DDI-DrugBank.d271.s0.e0,DDI-DrugBank.d271.s0.e2,"Physiological changes resulting from smoking cessation, with or without drug1 replacement, may alter the pharmacokinetics of certain concomitant medications, such as drug0 and drug2",False, 
DDI-DrugBank.d504.s0.e0,DDI-DrugBank.d504.s0.e1,"There have been rare reports of significant respiratory depression, stupor and/or hypotension with the concomitant use of drug1 and drug2",True,effect
DDI-DrugBank.d478.s1.e0,DDI-DrugBank.d478.s1.e1,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug2 (like drug0 or drug0) and drug0",False, 
DDI-DrugBank.d478.s1.e0,DDI-DrugBank.d478.s1.e2,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug0 (like drug2 or drug0) and drug0",False, 
DDI-DrugBank.d478.s1.e0,DDI-DrugBank.d478.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug0 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d478.s1.e1,DDI-DrugBank.d478.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug1 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d478.s1.e2,DDI-DrugBank.d478.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug0 (like drug1 or drug0) and drug2",True,advise
DDI-DrugBank.d478.s1.e3,DDI-DrugBank.d478.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug0 (like drug0 or drug1) and drug2",True,advise
DDI-DrugBank.d478.s2.e0,DDI-DrugBank.d478.s2.e1,The administration of drug1 with other drug2,False, 
DDI-DrugBank.d478.s3.e0,DDI-DrugBank.d478.s3.e1,"Because their vasospastic effects may be additive, coadministration of drug1 and other drug2",True,advise
DDI-DrugBank.d478.s4.e0,DDI-DrugBank.d478.s4.e1,"drug1 (drug2) (e.g., drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d478.s4.e0,DDI-DrugBank.d478.s4.e2,"drug1 (drug0) (e.g., drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d478.s5.e0,DDI-DrugBank.d478.s5.e1,If concomitant treatment with drug1 and an drug2,True,advise
DDI-DrugBank.d129.s2.e0,DDI-DrugBank.d129.s2.e1,Concurrent administration of drug1 and drug2 may result in elevated serum levels of drug0,True,mechanism
DDI-DrugBank.d129.s2.e0,DDI-DrugBank.d129.s2.e2,Concurrent administration of drug1 and drug0 may result in elevated serum levels of drug2,False, 
DDI-DrugBank.d129.s2.e1,DDI-DrugBank.d129.s2.e2,Concurrent administration of drug0 and drug1 may result in elevated serum levels of drug2,False, 
DDI-DrugBank.d129.s3.e0,DDI-DrugBank.d129.s3.e1,"In diabetic patients, the metabolic effects of drug1 may decrease blood glucose and therefore, drug2",True,effect
DDI-DrugBank.d503.s0.e0,DDI-DrugBank.d503.s0.e1,drug1 may increase the plasma-level of concomitantly given drug2,True,mechanism
DDI-DrugBank.d503.s1.e0,DDI-DrugBank.d503.s1.e1,"In order to avoid drug1 intoxication, drug2",False, 
DDI-DrugBank.d503.s2.e0,DDI-DrugBank.d503.s2.e1,"If drug1 is given concomitantly with drug2, the drug0 dose should be reduced (by approx. 50%), because drug0 amplifies the therapeutic actions and side-effects of drug0",True,advise
DDI-DrugBank.d503.s2.e0,DDI-DrugBank.d503.s2.e2,"If drug1 is given concomitantly with drug0, the drug2 dose should be reduced (by approx. 50%), because drug0 amplifies the therapeutic actions and side-effects of drug0",False, 
DDI-DrugBank.d503.s2.e0,DDI-DrugBank.d503.s2.e3,"If drug1 is given concomitantly with drug0, the drug0 dose should be reduced (by approx. 50%), because drug2 amplifies the therapeutic actions and side-effects of drug0",False, 
DDI-DrugBank.d503.s2.e3,DDI-DrugBank.d503.s2.e4,"If drug0 is given concomitantly with drug0, the drug0 dose should be reduced (by approx. 50%), because drug1 amplifies the therapeutic actions and side-effects of drug2",True,effect
DDI-DrugBank.d503.s3.e0,DDI-DrugBank.d503.s3.e1,Avoid the concomitant use of drug1 and drug2 (drug0,True,advise
DDI-DrugBank.d503.s3.e0,DDI-DrugBank.d503.s3.e2,Avoid the concomitant use of drug1 and drug0 (drug2,True,advise
DDI-DrugBank.d503.s3.e1,DDI-DrugBank.d503.s3.e2,Avoid the concomitant use of drug0 and drug1 (drug2,False, 
DDI-DrugBank.d503.s5.e0,DDI-DrugBank.d503.s5.e1,"Consider additive sedative effects and confusional states to emerge, if drug1 is given with drug2 or drug0",True,effect
DDI-DrugBank.d503.s5.e0,DDI-DrugBank.d503.s5.e2,"Consider additive sedative effects and confusional states to emerge, if drug1 is given with drug0 or drug2",True,effect
DDI-DrugBank.d503.s5.e1,DDI-DrugBank.d503.s5.e2,"Consider additive sedative effects and confusional states to emerge, if drug0 is given with drug1 or drug2",False, 
DDI-DrugBank.d503.s7.e0,DDI-DrugBank.d503.s7.e1,Exert particular caution in combining drug1 with other drug2 (drug0 and drug0,True,advise
DDI-DrugBank.d503.s7.e0,DDI-DrugBank.d503.s7.e2,Exert particular caution in combining drug1 with other drug0 (drug2 and drug0,True,advise
DDI-DrugBank.d503.s7.e0,DDI-DrugBank.d503.s7.e3,Exert particular caution in combining drug1 with other drug0 (drug0 and drug2,True,advise
DDI-DrugBank.d503.s7.e1,DDI-DrugBank.d503.s7.e2,Exert particular caution in combining drug0 with other drug1 (drug2 and drug0,False, 
DDI-DrugBank.d503.s7.e1,DDI-DrugBank.d503.s7.e3,Exert particular caution in combining drug0 with other drug1 (drug0 and drug2,False, 
DDI-DrugBank.d409.s0.e0,DDI-DrugBank.d409.s0.e1,"Because the drug1 have been shown to depress plasma prothrombin activity, patients who are on drug2 therapy may require downward adjustment of their drug0",True,advise
DDI-DrugBank.d409.s0.e0,DDI-DrugBank.d409.s0.e2,"Because the drug1 have been shown to depress plasma prothrombin activity, patients who are on drug0 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d409.s0.e1,DDI-DrugBank.d409.s0.e2,"Because the drug0 have been shown to depress plasma prothrombin activity, patients who are on drug1 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d409.s1.e0,DDI-DrugBank.d409.s1.e1,"Since bacteriostatic drugs, such as the drug1 of drug2, may interfere with the bactericidal action of drug0",False, 
DDI-DrugBank.d409.s1.e0,DDI-DrugBank.d409.s1.e2,"Since bacteriostatic drugs, such as the drug1 of drug0, may interfere with the bactericidal action of drug2",True,effect
DDI-DrugBank.d409.s1.e1,DDI-DrugBank.d409.s1.e2,"Since bacteriostatic drugs, such as the drug0 of drug1, may interfere with the bactericidal action of drug2",False, 
DDI-DrugBank.d409.s2.e0,DDI-DrugBank.d409.s2.e1,Concurrent use of drug1 with oral drug2 may render oral drug0,True,effect
DDI-DrugBank.d409.s2.e0,DDI-DrugBank.d409.s2.e2,Concurrent use of drug1 with oral drug0 may render oral drug2,False, 
DDI-DrugBank.d409.s2.e1,DDI-DrugBank.d409.s2.e2,Concurrent use of drug0 with oral drug1 may render oral drug2,False, 
DDI-DrugBank.d235.s2.e0,DDI-DrugBank.d235.s2.e1,"Increased toxicity (CNS depression): drug1, drug2, drug0, drug0",False, 
DDI-DrugBank.d235.s2.e0,DDI-DrugBank.d235.s2.e2,"Increased toxicity (CNS depression): drug1, drug0, drug2, drug0",False, 
DDI-DrugBank.d235.s4.e0,DDI-DrugBank.d235.s4.e1,"Example inhibitors include drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d235.s4.e0,DDI-DrugBank.d235.s4.e2,"Example inhibitors include drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d70.s11.e0,DDI-DrugBank.d70.s11.e1,"The potential effects of drug1 on the fertility of male animals were not studied but in a 6-month toxicology study, male rats treated with intramuscular doses of 15 mg/kg/30 days, 10 mg/rat/30 days, or 10 mg/rat/15 days drug2",False, 
DDI-DrugBank.d195.s2.e0,DDI-DrugBank.d195.s2.e1,drug1 did not alter the pharmacokinetics of drug2,False, 
DDI-DrugBank.d195.s3.e0,DDI-DrugBank.d195.s3.e1,"Although there have been no formal interaction studies other than with drug1, based on these in vivo and in vitro studies, it is unlikely that co-administration of a 1 mg dose of drug2",False, 
DDI-DrugBank.d195.s4.e0,DDI-DrugBank.d195.s4.e1,An interaction study with drug1 showed no clinically significant effect of drug2 on drug0,False, 
DDI-DrugBank.d195.s4.e0,DDI-DrugBank.d195.s4.e2,An interaction study with drug1 showed no clinically significant effect of drug0 on drug2,False, 
DDI-DrugBank.d195.s5.e0,DDI-DrugBank.d195.s5.e1,"At a median follow-up of 33 months, the combination of drug1 and drug2 did not demonstrate any efficacy benefit when compared with drug0",False, 
DDI-DrugBank.d195.s5.e0,DDI-DrugBank.d195.s5.e2,"At a median follow-up of 33 months, the combination of drug1 and drug0 did not demonstrate any efficacy benefit when compared with drug2",False, 
DDI-DrugBank.d195.s7.e0,DDI-DrugBank.d195.s7.e1,"Based on clinical and pharmacokinetic results from the ATAC trial, drug1 should not be administered with drug2",True,advise
DDI-DrugBank.d195.s8.e0,DDI-DrugBank.d195.s8.e1,Co-administration of drug1 and drug2 resulted in a reduction of drug0 plasma levels by 27% compared with those achieved with drug0,True,mechanism
DDI-DrugBank.d195.s8.e0,DDI-DrugBank.d195.s8.e2,Co-administration of drug1 and drug0 resulted in a reduction of drug2 plasma levels by 27% compared with those achieved with drug0,False, 
DDI-DrugBank.d195.s8.e0,DDI-DrugBank.d195.s8.e3,Co-administration of drug1 and drug0 resulted in a reduction of drug0 plasma levels by 27% compared with those achieved with drug2,False, 
DDI-DrugBank.d195.s9.e0,DDI-DrugBank.d195.s9.e1,drug1-containing therapies should not be used with drug2,True,advise
DDI-DrugBank.d169.s0.e0,DDI-DrugBank.d169.s0.e1,Results from human in vitro metabolism studies and nonclinical studies show that drug1  (drug2) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that drug0,False, 
DDI-DrugBank.d169.s0.e0,DDI-DrugBank.d169.s0.e2,Results from human in vitro metabolism studies and nonclinical studies show that drug1  (drug0) is neither metabolized by nor inhibits or induces the cytochrome P450 pathway suggesting that drug2,False, 
DDI-DrugBank.d169.s1.e0,DDI-DrugBank.d169.s1.e1,Co-administration of multiple doses of 10 mg of drug1 had no effect on the single dose pharmacokinetics of drug2 and drug0,False, 
DDI-DrugBank.d169.s1.e0,DDI-DrugBank.d169.s1.e2,Co-administration of multiple doses of 10 mg of drug1 had no effect on the single dose pharmacokinetics of drug0 and drug2,False, 
DDI-DrugBank.d169.s2.e0,DDI-DrugBank.d169.s2.e1,Co-administration of single 25-mg dose drug1 had no effect on the pharmacokinetics of total drug2,False, 
DDI-DrugBank.d169.s3.e0,DDI-DrugBank.d169.s3.e1,"Expected changes in laboratory assessments of PT and INR were observed after drug1 administration, but these changes were not affected by concomitant drug2",False, 
DDI-DrugBank.d199.s0.e0,DDI-DrugBank.d199.s0.e1,"drug1: When coadministered with drug2, drug0, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of drug0",False, 
DDI-DrugBank.d199.s0.e0,DDI-DrugBank.d199.s0.e2,"drug1: When coadministered with drug0, drug2, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of drug0",False, 
DDI-DrugBank.d199.s0.e1,DDI-DrugBank.d199.s0.e2,"drug0: When coadministered with drug1, drug2, a drug which increases gastrointestinal motility, lowers the serum concentration and urinary excretion of drug0",True,mechanism
DDI-DrugBank.d199.s2.e0,DDI-DrugBank.d199.s2.e1,drug1: drug2 does not affect the pharmacokinetics of drug0 when coadministered with drug0,False, 
DDI-DrugBank.d199.s2.e0,DDI-DrugBank.d199.s2.e2,drug1: drug0 does not affect the pharmacokinetics of drug2 when coadministered with drug0,False, 
DDI-DrugBank.d99.s2.e0,DDI-DrugBank.d99.s2.e1,Poor metabolizers have higher than expected plasma concentrations of drug1 (drug2,False, 
DDI-DrugBank.d99.s7.e0,DDI-DrugBank.d99.s7.e1,"drug1) and many that are substrates for P450 2D6 (many other drug2, drug0, and the drug0 drug0 and drug0",False, 
DDI-DrugBank.d99.s7.e0,DDI-DrugBank.d99.s7.e2,"drug1) and many that are substrates for P450 2D6 (many other drug0, drug2, and the drug0 drug0 and drug0",False, 
DDI-DrugBank.d99.s8.e0,DDI-DrugBank.d99.s8.e1,"While all the selective drug1 (drug2), e.g., drug0, drug0, and drug0",False, 
DDI-DrugBank.d99.s8.e0,DDI-DrugBank.d99.s8.e2,"While all the selective drug1 (drug0), e.g., drug2, drug0, and drug0",False, 
DDI-DrugBank.d99.s9.e0,DDI-DrugBank.d99.s9.e1,The extent to which drug1-drug2 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drug0,True,effect
DDI-DrugBank.d99.s9.e0,DDI-DrugBank.d99.s9.e2,The extent to which drug1-drug0 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drug2,False, 
DDI-DrugBank.d99.s9.e1,DDI-DrugBank.d99.s9.e2,The extent to which drug0-drug1 interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the drug2,False, 
DDI-DrugBank.d99.s10.e0,DDI-DrugBank.d99.s10.e1,"Nevertheless, caution is indicated in the coadministration of drug1 with any of the drug2",True,advise
DDI-DrugBank.d99.s12.e0,DDI-DrugBank.d99.s12.e1,Concomitant use of drug1 with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the drug2,False, 
DDI-DrugBank.d99.s14.e0,DDI-DrugBank.d99.s14.e1,It is desirable to monitor drug1 plasma levels whenever a drug2,False, 
DDI-DrugBank.d99.s15.e0,DDI-DrugBank.d99.s15.e1,drug1: drug2,False, 
DDI-DrugBank.d99.s17.e0,DDI-DrugBank.d99.s17.e1,"drug1, drug2 and other drug0",False, 
DDI-DrugBank.d99.s17.e0,DDI-DrugBank.d99.s17.e2,"drug1, drug0 and other drug2",False, 
DDI-DrugBank.d99.s18.e0,DDI-DrugBank.d99.s18.e1,"and drug1 When drug2 is given with drug0 agents or drug0 drugs, including drug0 combined with local drug0",False, 
DDI-DrugBank.d99.s18.e0,DDI-DrugBank.d99.s18.e2,"and drug1 When drug0 is given with drug2 agents or drug0 drugs, including drug0 combined with local drug0",False, 
DDI-DrugBank.d99.s19.e0,DDI-DrugBank.d99.s19.e1,Hyperpyrexia has been reported when drug1 is administered with drug2 agents or with drug0,True,effect
DDI-DrugBank.d99.s19.e0,DDI-DrugBank.d99.s19.e2,Hyperpyrexia has been reported when drug1 is administered with drug0 agents or with drug2,False, 
DDI-DrugBank.d99.s19.e1,DDI-DrugBank.d99.s19.e2,Hyperpyrexia has been reported when drug0 is administered with drug1 agents or with drug2,False, 
DDI-DrugBank.d99.s20.e0,DDI-DrugBank.d99.s20.e1,Paralytic ileus may occur in patients taking drug1 in combination with drug2,True,effect
DDI-DrugBank.d99.s21.e0,DDI-DrugBank.d99.s21.e1,"drug1 is reported to reduce hepatic metabolism of certain drug2, thereby delaying elimination and increasing steady-state concentrations of these drug0",True,mechanism
DDI-DrugBank.d99.s21.e0,DDI-DrugBank.d99.s21.e2,"drug1 is reported to reduce hepatic metabolism of certain drug0, thereby delaying elimination and increasing steady-state concentrations of these drug2",False, 
DDI-DrugBank.d99.s21.e1,DDI-DrugBank.d99.s21.e2,"drug0 is reported to reduce hepatic metabolism of certain drug1, thereby delaying elimination and increasing steady-state concentrations of these drug2",False, 
DDI-DrugBank.d99.s22.e0,DDI-DrugBank.d99.s22.e1,Clinically significant effects have been reported with the drug1 when used concomitantly with drug2,True,effect
DDI-DrugBank.d99.s23.e0,DDI-DrugBank.d99.s23.e1,"Increases in plasma levels of drug1, and in the frequency and severity of side effects, particularly drug2, have been reported when drug0 was added to the drug0",False, 
DDI-DrugBank.d99.s23.e0,DDI-DrugBank.d99.s23.e2,"Increases in plasma levels of drug1, and in the frequency and severity of side effects, particularly drug0, have been reported when drug2 was added to the drug0",True,mechanism
DDI-DrugBank.d99.s23.e0,DDI-DrugBank.d99.s23.e3,"Increases in plasma levels of drug1, and in the frequency and severity of side effects, particularly drug0, have been reported when drug0 was added to the drug2",False, 
DDI-DrugBank.d99.s24.e0,DDI-DrugBank.d99.s24.e1,Discontinuation of drug1 in well-controlled patients receiving drug2 and drug0 may decrease the plasma levels and efficacy of the drug0,False, 
DDI-DrugBank.d99.s24.e0,DDI-DrugBank.d99.s24.e2,Discontinuation of drug1 in well-controlled patients receiving drug0 and drug2 may decrease the plasma levels and efficacy of the drug0,False, 
DDI-DrugBank.d99.s24.e1,DDI-DrugBank.d99.s24.e2,Discontinuation of drug0 in well-controlled patients receiving drug1 and drug2 may decrease the plasma levels and efficacy of the drug0,True,mechanism
DDI-DrugBank.d99.s26.e0,DDI-DrugBank.d99.s26.e1,Transient delirium has been reported in patients who were treated with one gram of drug1 and 75 - 150 mg of drug2,True,effect
DDI-DrugBank.d249.s0.e0,DDI-DrugBank.d249.s0.e1,drug1: Concomitant administration of drug2 and drug0 is not recommended because drug0 is displaced from its binding sites during the concomitant administration of drug0,False, 
DDI-DrugBank.d249.s0.e0,DDI-DrugBank.d249.s0.e2,drug1: Concomitant administration of drug0 and drug2 is not recommended because drug0 is displaced from its binding sites during the concomitant administration of drug0,False, 
DDI-DrugBank.d249.s0.e1,DDI-DrugBank.d249.s0.e2,drug0: Concomitant administration of drug1 and drug2 is not recommended because drug0 is displaced from its binding sites during the concomitant administration of drug0,True,advise
DDI-DrugBank.d249.s0.e3,DDI-DrugBank.d249.s0.e4,drug0: Concomitant administration of drug0 and drug0 is not recommended because drug1 is displaced from its binding sites during the concomitant administration of drug2,True,mechanism
DDI-DrugBank.d249.s1.e0,DDI-DrugBank.d249.s1.e1,"drug1: While studies have not shown drug2 to interact with drug0, caution should be exercised, nonetheless, since interactions have been seen with other drug0",False, 
DDI-DrugBank.d249.s1.e0,DDI-DrugBank.d249.s1.e2,"drug1: While studies have not shown drug0 to interact with drug2, caution should be exercised, nonetheless, since interactions have been seen with other drug0",False, 
DDI-DrugBank.d249.s1.e1,DDI-DrugBank.d249.s1.e3,"drug0: While studies have not shown drug1 to interact with drug0, caution should be exercised, nonetheless, since interactions have been seen with other drug2",True,advise
DDI-DrugBank.d249.s2.e0,DDI-DrugBank.d249.s2.e1,"Because prostaglandins play an important role in hemostasis, and drug1 affect platelet function as well, concurrent therapy with all drug2, including drug0, and drug0 requires close monitoring of patients to be certain that no change in their drug0",False, 
DDI-DrugBank.d249.s2.e0,DDI-DrugBank.d249.s2.e2,"Because prostaglandins play an important role in hemostasis, and drug1 affect platelet function as well, concurrent therapy with all drug0, including drug2, and drug0 requires close monitoring of patients to be certain that no change in their drug0",False, 
DDI-DrugBank.d249.s2.e1,DDI-DrugBank.d249.s2.e3,"Because prostaglandins play an important role in hemostasis, and drug0 affect platelet function as well, concurrent therapy with all drug1, including drug0, and drug2 requires close monitoring of patients to be certain that no change in their drug0",True,advise
DDI-DrugBank.d249.s2.e2,DDI-DrugBank.d249.s2.e3,"Because prostaglandins play an important role in hemostasis, and drug0 affect platelet function as well, concurrent therapy with all drug0, including drug1, and drug2 requires close monitoring of patients to be certain that no change in their drug0",True,advise
DDI-DrugBank.d249.s3.e0,DDI-DrugBank.d249.s3.e1,"drug1, drug2, drug0: drug0, like other drug0",False, 
DDI-DrugBank.d249.s3.e0,DDI-DrugBank.d249.s3.e2,"drug1, drug0, drug2: drug0, like other drug0",False, 
DDI-DrugBank.d249.s4.e0,DDI-DrugBank.d249.s4.e1,Ingestion of drug1 may increase serum concentrations of drug2 and drug0 and increase drug0,True,mechanism
DDI-DrugBank.d249.s4.e0,DDI-DrugBank.d249.s4.e2,Ingestion of drug1 may increase serum concentrations of drug0 and drug2 and increase drug0,True,mechanism
DDI-DrugBank.d249.s4.e0,DDI-DrugBank.d249.s4.e3,Ingestion of drug1 may increase serum concentrations of drug0 and drug0 and increase drug2,True,effect
DDI-DrugBank.d249.s4.e1,DDI-DrugBank.d249.s4.e2,Ingestion of drug0 may increase serum concentrations of drug1 and drug2 and increase drug0,False, 
DDI-DrugBank.d249.s4.e1,DDI-DrugBank.d249.s4.e3,Ingestion of drug0 may increase serum concentrations of drug1 and drug0 and increase drug2,False, 
DDI-DrugBank.d249.s5.e0,DDI-DrugBank.d249.s5.e1,"Patients who begin taking drug1 or who increase their drug2 dose or any other drug0 while taking drug0, drug0, or drug0",False, 
DDI-DrugBank.d249.s5.e0,DDI-DrugBank.d249.s5.e2,"Patients who begin taking drug1 or who increase their drug0 dose or any other drug2 while taking drug0, drug0, or drug0",False, 
DDI-DrugBank.d249.s5.e0,DDI-DrugBank.d249.s5.e3,"Patients who begin taking drug1 or who increase their drug0 dose or any other drug0 while taking drug2, drug0, or drug0",True,effect
DDI-DrugBank.d249.s5.e0,DDI-DrugBank.d249.s5.e4,"Patients who begin taking drug1 or who increase their drug0 dose or any other drug0 while taking drug0, drug2, or drug0",True,effect
DDI-DrugBank.d249.s5.e0,DDI-DrugBank.d249.s5.e5,"Patients who begin taking drug1 or who increase their drug0 dose or any other drug0 while taking drug0, drug0, or drug2",True,effect
DDI-DrugBank.d249.s5.e2,DDI-DrugBank.d249.s5.e3,"Patients who begin taking drug0 or who increase their drug0 dose or any other drug1 while taking drug2, drug0, or drug0",True,effect
DDI-DrugBank.d249.s5.e2,DDI-DrugBank.d249.s5.e4,"Patients who begin taking drug0 or who increase their drug0 dose or any other drug1 while taking drug0, drug2, or drug0",True,effect
DDI-DrugBank.d249.s5.e2,DDI-DrugBank.d249.s5.e5,"Patients who begin taking drug0 or who increase their drug0 dose or any other drug1 while taking drug0, drug0, or drug2",True,effect
DDI-DrugBank.d249.s8.e0,DDI-DrugBank.d249.s8.e1,drug1: drug2 decreases drug0 renal clearance and increases drug0,False, 
DDI-DrugBank.d249.s8.e0,DDI-DrugBank.d249.s8.e2,drug1: drug0 decreases drug2 renal clearance and increases drug0,False, 
DDI-DrugBank.d249.s8.e1,DDI-DrugBank.d249.s8.e2,drug0: drug1 decreases drug2 renal clearance and increases drug0,True,mechanism
DDI-DrugBank.d249.s8.e1,DDI-DrugBank.d249.s8.e3,drug0: drug1 decreases drug0 renal clearance and increases drug2,True,mechanism
DDI-DrugBank.d249.s9.e0,DDI-DrugBank.d249.s9.e1,"In patients taking drug1 and drug2 concomitantly, drug0",True,effect
DDI-DrugBank.d249.s9.e0,DDI-DrugBank.d249.s9.e2,"In patients taking drug1 and drug0 concomitantly, drug2",False, 
DDI-DrugBank.d249.s9.e1,DDI-DrugBank.d249.s9.e2,"In patients taking drug0 and drug1 concomitantly, drug2",False, 
DDI-DrugBank.d249.s10.e0,DDI-DrugBank.d249.s10.e1,Oral drug1: drug2 does not alter glucose metabolism in normal subjects nor does it alter the effects of oral drug0,False, 
DDI-DrugBank.d249.s10.e0,DDI-DrugBank.d249.s10.e2,Oral drug1: drug0 does not alter glucose metabolism in normal subjects nor does it alter the effects of oral drug2,False, 
DDI-DrugBank.d249.s11.e0,DDI-DrugBank.d249.s11.e1,"There are rare reports, however, from marketing experiences, of changes in effects of drug1 or oral drug2 in the presence of drug0",False, 
DDI-DrugBank.d249.s11.e0,DDI-DrugBank.d249.s11.e2,"There are rare reports, however, from marketing experiences, of changes in effects of drug1 or oral drug0 in the presence of drug2",True,effect
DDI-DrugBank.d249.s11.e1,DDI-DrugBank.d249.s11.e2,"There are rare reports, however, from marketing experiences, of changes in effects of drug0 or oral drug1 in the presence of drug2",True,effect
DDI-DrugBank.d249.s13.e0,DDI-DrugBank.d249.s13.e1,"A direct causal relationship has not been established, but physicians should consider the possibility that drug1 may alter a diabetic patient s response to drug2 or oral drug0",True,effect
DDI-DrugBank.d249.s13.e0,DDI-DrugBank.d249.s13.e2,"A direct causal relationship has not been established, but physicians should consider the possibility that drug1 may alter a diabetic patient s response to drug0 or oral drug2",True,effect
DDI-DrugBank.d249.s13.e1,DDI-DrugBank.d249.s13.e2,"A direct causal relationship has not been established, but physicians should consider the possibility that drug0 may alter a diabetic patient s response to drug1 or oral drug2",False, 
DDI-DrugBank.d249.s14.e0,DDI-DrugBank.d249.s14.e1,drug1: drug2 and other drug0 can inhibit the activity of drug0,False, 
DDI-DrugBank.d249.s14.e0,DDI-DrugBank.d249.s14.e2,drug1: drug0 and other drug2 can inhibit the activity of drug0,False, 
DDI-DrugBank.d249.s14.e1,DDI-DrugBank.d249.s14.e3,drug0: drug1 and other drug0 can inhibit the activity of drug2,True,effect
DDI-DrugBank.d249.s14.e2,DDI-DrugBank.d249.s14.e3,drug0: drug0 and other drug1 can inhibit the activity of drug2,True,effect
DDI-DrugBank.d249.s16.e0,DDI-DrugBank.d249.s16.e1,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of drug1, drug2, drug0, drug0, drug0, drug0, or drug0 did not significantly affect the peak levels and AUC values of drug0",False, 
DDI-DrugBank.d249.s16.e0,DDI-DrugBank.d249.s16.e2,"Other Drugs: In small groups of patients (7-10/interaction study), the concomitant administration of drug1, drug0, drug2, drug0, drug0, drug0, or drug0 did not significantly affect the peak levels and AUC values of drug0",False, 
DDI-DrugBank.d249.s17.e0,DDI-DrugBank.d249.s17.e1,drug1 toxicity has been reported to have occurred in a patient on chronic drug2 treatment following the initiation of drug0,False, 
DDI-DrugBank.d249.s17.e0,DDI-DrugBank.d249.s17.e2,drug1 toxicity has been reported to have occurred in a patient on chronic drug0 treatment following the initiation of drug2,False, 
DDI-DrugBank.d249.s17.e1,DDI-DrugBank.d249.s17.e2,drug0 toxicity has been reported to have occurred in a patient on chronic drug1 treatment following the initiation of drug2,True,effect
DDI-DrugBank.d249.s18.e0,DDI-DrugBank.d249.s18.e1,"Protein Binding In vitro, drug1 interferes minimally or not at all with the protein binding of drug2 (20% decrease in binding), drug0, drug0 (10% decrease in binding), or drug0",True,mechanism
DDI-DrugBank.d249.s18.e0,DDI-DrugBank.d249.s18.e2,"Protein Binding In vitro, drug1 interferes minimally or not at all with the protein binding of drug0 (20% decrease in binding), drug2, drug0 (10% decrease in binding), or drug0",True,mechanism
DDI-DrugBank.d249.s18.e0,DDI-DrugBank.d249.s18.e3,"Protein Binding In vitro, drug1 interferes minimally or not at all with the protein binding of drug0 (20% decrease in binding), drug0, drug2 (10% decrease in binding), or drug0",True,mechanism
DDI-DrugBank.d249.s18.e0,DDI-DrugBank.d249.s18.e4,"Protein Binding In vitro, drug1 interferes minimally or not at all with the protein binding of drug0 (20% decrease in binding), drug0, drug0 (10% decrease in binding), or drug2",True,mechanism
DDI-DrugBank.d249.s18.e1,DDI-DrugBank.d249.s18.e2,"Protein Binding In vitro, drug0 interferes minimally or not at all with the protein binding of drug1 (20% decrease in binding), drug2, drug0 (10% decrease in binding), or drug0",False, 
DDI-DrugBank.d249.s18.e1,DDI-DrugBank.d249.s18.e3,"Protein Binding In vitro, drug0 interferes minimally or not at all with the protein binding of drug1 (20% decrease in binding), drug0, drug2 (10% decrease in binding), or drug0",False, 
DDI-DrugBank.d249.s19.e0,DDI-DrugBank.d249.s19.e1,"drug1, drug2, drug0, drug0, drug0, drug0, drug0, and drug0 have no influence in vitro on the protein binding of drug0",False, 
DDI-DrugBank.d249.s19.e0,DDI-DrugBank.d249.s19.e2,"drug1, drug0, drug2, drug0, drug0, drug0, drug0, and drug0 have no influence in vitro on the protein binding of drug0",False, 
DDI-DrugBank.d413.s2.e0,DDI-DrugBank.d413.s2.e1,drug1/drug2: drug0 inhibits the enzymatic oxidation of drug0 and drug0 to drug0,False, 
DDI-DrugBank.d413.s2.e0,DDI-DrugBank.d413.s2.e2,drug1/drug0: drug2 inhibits the enzymatic oxidation of drug0 and drug0 to drug0,False, 
DDI-DrugBank.d413.s2.e2,DDI-DrugBank.d413.s2.e3,drug0/drug0: drug1 inhibits the enzymatic oxidation of drug2 and drug0 to drug0,True,mechanism
DDI-DrugBank.d413.s2.e2,DDI-DrugBank.d413.s2.e4,drug0/drug0: drug1 inhibits the enzymatic oxidation of drug0 and drug2 to drug0,True,mechanism
DDI-DrugBank.d413.s4.e0,DDI-DrugBank.d413.s4.e1,"In patients receiving drug1 (drug2) or drug0 (drug0), the concomitant administration of 300-600 mg of drug0 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug0 or drug0",False, 
DDI-DrugBank.d413.s4.e0,DDI-DrugBank.d413.s4.e2,"In patients receiving drug1 (drug0) or drug2 (drug0), the concomitant administration of 300-600 mg of drug0 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug0 or drug0",False, 
DDI-DrugBank.d413.s4.e4,DDI-DrugBank.d413.s4.e5,"In patients receiving drug0 (drug0) or drug0 (drug0), the concomitant administration of 300-600 mg of drug1 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug2 or drug0",True,advise
DDI-DrugBank.d413.s4.e4,DDI-DrugBank.d413.s4.e6,"In patients receiving drug0 (drug0) or drug0 (drug0), the concomitant administration of 300-600 mg of drug1 per day will require a reduction in dose to approximately one-third to one-fourth of the usual dose of drug0 or drug2",True,advise
DDI-DrugBank.d413.s5.e0,DDI-DrugBank.d413.s5.e1,Subsequent adjustment of doses of drug1 or drug2,False, 
DDI-DrugBank.d413.s6.e0,DDI-DrugBank.d413.s6.e1,"drug1: It has been reported that drug2 prolongs the half-life of the drug0, drug0",False, 
DDI-DrugBank.d413.s6.e0,DDI-DrugBank.d413.s6.e2,"drug1: It has been reported that drug0 prolongs the half-life of the drug2, drug0",False, 
DDI-DrugBank.d413.s6.e1,DDI-DrugBank.d413.s6.e3,"drug0: It has been reported that drug1 prolongs the half-life of the drug0, drug2",True,mechanism
DDI-DrugBank.d413.s7.e0,DDI-DrugBank.d413.s7.e1,The clinical basis of this drug interaction has not been established but should be noted when drug1 is given to patients already on drug2,False, 
DDI-DrugBank.d413.s9.e0,DDI-DrugBank.d413.s9.e1,"drug1: Since the excretion of drug2 is similar to that of urate, drug0, which increase the excretion of urate, are also likely to increase the excretion of drug0",False, 
DDI-DrugBank.d413.s9.e0,DDI-DrugBank.d413.s9.e2,"drug1: Since the excretion of drug0 is similar to that of urate, drug2, which increase the excretion of urate, are also likely to increase the excretion of drug0",False, 
DDI-DrugBank.d413.s9.e2,DDI-DrugBank.d413.s9.e3,"drug0: Since the excretion of drug0 is similar to that of urate, drug1, which increase the excretion of urate, are also likely to increase the excretion of drug2",True,mechanism
DDI-DrugBank.d413.s10.e0,DDI-DrugBank.d413.s10.e1,The concomitant administration of drug1 and drug2 has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with drug0,True,mechanism
DDI-DrugBank.d413.s10.e0,DDI-DrugBank.d413.s10.e2,The concomitant administration of drug1 and drug0 has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with drug2,False, 
DDI-DrugBank.d413.s10.e1,DDI-DrugBank.d413.s10.e2,The concomitant administration of drug0 and drug1 has been associated with a decrease in the excretion of oxypurines (hypoxanthine and xanthine) and an increase in urinary uric acid excretion compared with that observed with drug2,False, 
DDI-DrugBank.d413.s11.e0,DDI-DrugBank.d413.s11.e1,Although clinical evidence to date has not demonstrated renal precipitation of oxypurines in patients either on drug1 alone or in combination with drug2,False, 
DDI-DrugBank.d413.s12.e0,DDI-DrugBank.d413.s12.e1,drug1: The reports that the concomitant use of drug2 and drug0 may contribute to the enhancement of drug0,False, 
DDI-DrugBank.d413.s12.e0,DDI-DrugBank.d413.s12.e2,drug1: The reports that the concomitant use of drug0 and drug2 may contribute to the enhancement of drug0,False, 
DDI-DrugBank.d413.s12.e1,DDI-DrugBank.d413.s12.e2,drug0: The reports that the concomitant use of drug1 and drug2 may contribute to the enhancement of drug0,True,effect
DDI-DrugBank.d413.s15.e0,DDI-DrugBank.d413.s15.e1,"Although a causal mechanism and a cause-and-effect relationship have not been established, current evidence suggests that renal function should be monitored in patients on drug1 and drug2",True,advise
DDI-DrugBank.d413.s16.e0,DDI-DrugBank.d413.s16.e1,drug1/drug2: An increase in the frequency of skin rash has been reported among patients receiving drug0 or drug0 concurrently with drug0,False, 
DDI-DrugBank.d413.s16.e0,DDI-DrugBank.d413.s16.e2,drug1/drug0: An increase in the frequency of skin rash has been reported among patients receiving drug2 or drug0 concurrently with drug0,False, 
DDI-DrugBank.d413.s16.e2,DDI-DrugBank.d413.s16.e4,drug0/drug0: An increase in the frequency of skin rash has been reported among patients receiving drug1 or drug0 concurrently with drug2,True,effect
DDI-DrugBank.d413.s16.e3,DDI-DrugBank.d413.s16.e4,drug0/drug0: An increase in the frequency of skin rash has been reported among patients receiving drug0 or drug1 concurrently with drug2,True,effect
DDI-DrugBank.d413.s18.e0,DDI-DrugBank.d413.s18.e1,"drug1: Enhanced bone marrow suppression by drug2 and other drug0 has been reported among patients with neoplastic disease, except leukemia, in the presence of drug0",False, 
DDI-DrugBank.d413.s18.e0,DDI-DrugBank.d413.s18.e2,"drug1: Enhanced bone marrow suppression by drug0 and other drug2 has been reported among patients with neoplastic disease, except leukemia, in the presence of drug0",False, 
DDI-DrugBank.d413.s18.e1,DDI-DrugBank.d413.s18.e3,"drug0: Enhanced bone marrow suppression by drug1 and other drug0 has been reported among patients with neoplastic disease, except leukemia, in the presence of drug2",True,effect
DDI-DrugBank.d413.s18.e2,DDI-DrugBank.d413.s18.e3,"drug0: Enhanced bone marrow suppression by drug0 and other drug1 has been reported among patients with neoplastic disease, except leukemia, in the presence of drug2",True,effect
DDI-DrugBank.d413.s19.e0,DDI-DrugBank.d413.s19.e1,"However, in a well-controlled study of patients with lymphoma on combination therapy, drug1 did not increase the marrow toxicity of patients treated with drug2, drug0, drug0, drug0 and/or drug0",False, 
DDI-DrugBank.d413.s19.e0,DDI-DrugBank.d413.s19.e2,"However, in a well-controlled study of patients with lymphoma on combination therapy, drug1 did not increase the marrow toxicity of patients treated with drug0, drug2, drug0, drug0 and/or drug0",False, 
DDI-DrugBank.d413.s20.e0,DDI-DrugBank.d413.s20.e1,"drug1: drug2s plasma half-life may be prolonged by drug0, since drug0 and drug0",False, 
DDI-DrugBank.d413.s20.e0,DDI-DrugBank.d413.s20.e2,"drug1: drug0s plasma half-life may be prolonged by drug2, since drug0 and drug0",False, 
DDI-DrugBank.d413.s20.e1,DDI-DrugBank.d413.s20.e2,"drug0: drug1s plasma half-life may be prolonged by drug2, since drug0 and drug0",True,mechanism
DDI-DrugBank.d413.s20.e3,DDI-DrugBank.d413.s20.e4,"drug0: drug0s plasma half-life may be prolonged by drug0, since drug1 and drug2",True,mechanism
DDI-DrugBank.d413.s21.e0,DDI-DrugBank.d413.s21.e1,The risk of hypoglycemia secondary to this mechanism may be increased if drug1 and drug2,True,effect
DDI-DrugBank.d413.s22.e0,DDI-DrugBank.d413.s22.e1,drug1: Reports indicate that drug2 levels may be increased during concomitant treatment with drug0,False, 
DDI-DrugBank.d413.s22.e0,DDI-DrugBank.d413.s22.e2,drug1: Reports indicate that drug0 levels may be increased during concomitant treatment with drug2,False, 
DDI-DrugBank.d413.s22.e1,DDI-DrugBank.d413.s22.e2,drug0: Reports indicate that drug1 levels may be increased during concomitant treatment with drug2,True,mechanism
DDI-DrugBank.d413.s23.e0,DDI-DrugBank.d413.s23.e1,Monitoring of drug1 levels and possible adjustment of drug2,False, 
DDI-DrugBank.d541.s0.e0,DDI-DrugBank.d541.s0.e1,"May interact with the following: drug1 (these medicines may make your condition worse and prevent the drug2 from working properly) and drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d541.s0.e0,DDI-DrugBank.d541.s0.e2,"May interact with the following: drug1 (these medicines may make your condition worse and prevent the drug0 from working properly) and drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d475.s0.e0,DDI-DrugBank.d475.s0.e1,"No interactions have been observed between drug1 and drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d475.s0.e0,DDI-DrugBank.d475.s0.e2,"No interactions have been observed between drug1 and drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d475.s3.e0,DDI-DrugBank.d475.s3.e1,"In patients given very high doses (3900 mg) of drug1 daily, increases in serum drug2 levels were seen when drug0",False, 
DDI-DrugBank.d475.s3.e0,DDI-DrugBank.d475.s3.e2,"In patients given very high doses (3900 mg) of drug1 daily, increases in serum drug0 levels were seen when drug2",True,mechanism
DDI-DrugBank.d475.s3.e1,DDI-DrugBank.d475.s3.e2,"In patients given very high doses (3900 mg) of drug0 daily, increases in serum drug1 levels were seen when drug2",False, 
DDI-DrugBank.d168.s0.e0,DDI-DrugBank.d168.s0.e1,"This drug may interact with drug1 or other drug2 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d168.s0.e0,DDI-DrugBank.d168.s0.e2,"This drug may interact with drug1 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug2), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d130.s0.e0,DDI-DrugBank.d130.s0.e1,drug1 has been shown to have neuromuscular blocking properties that may enhance the action of other drug2,True,effect
DDI-DrugBank.d130.s2.e0,DDI-DrugBank.d130.s2.e1,Antagonism between drug1 and drug2,True,effect
DDI-DrugBank.d315.s0.e0,DDI-DrugBank.d315.s0.e1,"drug1: Coadministration of drug2, a P-glycoprotein substrate, with oral drug0 resulted in a reduction in clearance and an increase in drug0",False, 
DDI-DrugBank.d315.s0.e0,DDI-DrugBank.d315.s0.e2,"drug1: Coadministration of drug0, a P-glycoprotein substrate, with oral drug2 resulted in a reduction in clearance and an increase in drug0",False, 
DDI-DrugBank.d315.s0.e1,DDI-DrugBank.d315.s0.e2,"drug0: Coadministration of drug1, a P-glycoprotein substrate, with oral drug2 resulted in a reduction in clearance and an increase in drug0",True,mechanism
DDI-DrugBank.d315.s1.e0,DDI-DrugBank.d315.s1.e1,"Therefore, if drug1 is administered with drug2, the clinician should be alert to the possibility of increases in drug0",True,mechanism
DDI-DrugBank.d315.s1.e0,DDI-DrugBank.d315.s1.e2,"Therefore, if drug1 is administered with drug0, the clinician should be alert to the possibility of increases in drug2",False, 
DDI-DrugBank.d315.s1.e1,DDI-DrugBank.d315.s1.e2,"Therefore, if drug0 is administered with drug1, the clinician should be alert to the possibility of increases in drug2",False, 
DDI-DrugBank.d526.s1.e0,DDI-DrugBank.d526.s1.e1,"drug1 or drug2 (drug0 and related drugs, drug0 and drug0",False, 
DDI-DrugBank.d526.s1.e0,DDI-DrugBank.d526.s1.e2,"drug1 or drug0 (drug2 and related drugs, drug0 and drug0",False, 
DDI-DrugBank.d526.s4.e0,DDI-DrugBank.d526.s4.e1,drug1 enhanced possibility of arrhythmias or drug2,False, 
DDI-DrugBank.d526.s9.e0,DDI-DrugBank.d526.s9.e1,drug1 (oral agents and drug2,False, 
DDI-DrugBank.d526.s14.e0,DDI-DrugBank.d526.s14.e1,Rarely drug1 toxicity may occur in patients who discontinue drug2 after concurrent high-dose drug0,False, 
DDI-DrugBank.d526.s14.e0,DDI-DrugBank.d526.s14.e2,Rarely drug1 toxicity may occur in patients who discontinue drug0 after concurrent high-dose drug2,False, 
DDI-DrugBank.d526.s14.e1,DDI-DrugBank.d526.s14.e2,Rarely drug0 toxicity may occur in patients who discontinue drug1 after concurrent high-dose drug2,True,effect
DDI-DrugBank.d526.s15.e0,DDI-DrugBank.d526.s15.e1,Monitor drug1 levels or the therapeutic effect for which drug2,False, 
DDI-DrugBank.d526.s17.e0,DDI-DrugBank.d526.s17.e1,"drug1, drug2, or drug0 increased metabolic clearance of drug0",False, 
DDI-DrugBank.d526.s17.e0,DDI-DrugBank.d526.s17.e2,"drug1, drug0, or drug2 increased metabolic clearance of drug0",False, 
DDI-DrugBank.d526.s17.e0,DDI-DrugBank.d526.s17.e3,"drug1, drug0, or drug0 increased metabolic clearance of drug2",True,mechanism
DDI-DrugBank.d526.s17.e1,DDI-DrugBank.d526.s17.e3,"drug0, drug1, or drug0 increased metabolic clearance of drug2",True,mechanism
DDI-DrugBank.d526.s17.e2,DDI-DrugBank.d526.s17.e3,"drug0, drug0, or drug1 increased metabolic clearance of drug2",True,mechanism
DDI-DrugBank.d526.s18.e0,DDI-DrugBank.d526.s18.e1,Observe the patient for possible diminished effect of drug1 and increase the drug2,False, 
DDI-DrugBank.d526.s19.e0,DDI-DrugBank.d526.s19.e1,"drug1 (particularly C-17 alkylated drug2 such as drug0, drug0, drug0",False, 
DDI-DrugBank.d526.s19.e0,DDI-DrugBank.d526.s19.e2,"drug1 (particularly C-17 alkylated drug0 such as drug2, drug0, drug0",False, 
DDI-DrugBank.d526.s24.e0,DDI-DrugBank.d526.s24.e1,"When drug1 therapy is initiated, a reduction in drug2 dosage may be required, and increased amounts may be required when drug0",False, 
DDI-DrugBank.d526.s24.e0,DDI-DrugBank.d526.s24.e2,"When drug1 therapy is initiated, a reduction in drug0 dosage may be required, and increased amounts may be required when drug2",False, 
DDI-DrugBank.d77.s2.e0,DDI-DrugBank.d77.s2.e1,"Avoid the use of preparations such as drug1 and local drug2 which contain any drug0 (e.g., drug0, drug0), since it has been reported that drug0",False, 
DDI-DrugBank.d77.s2.e0,DDI-DrugBank.d77.s2.e2,"Avoid the use of preparations such as drug1 and local drug0 which contain any drug2 (e.g., drug0, drug0), since it has been reported that drug0",False, 
DDI-DrugBank.d77.s2.e0,DDI-DrugBank.d77.s2.e5,"Avoid the use of preparations such as drug1 and local drug0 which contain any drug0 (e.g., drug0, drug0), since it has been reported that drug2",True,advise
DDI-DrugBank.d77.s2.e1,DDI-DrugBank.d77.s2.e5,"Avoid the use of preparations such as drug0 and local drug1 which contain any drug0 (e.g., drug0, drug0), since it has been reported that drug2",True,advise
DDI-DrugBank.d77.s2.e2,DDI-DrugBank.d77.s2.e5,"Avoid the use of preparations such as drug0 and local drug0 which contain any drug1 (e.g., drug0, drug0), since it has been reported that drug2",True,advise
DDI-DrugBank.d77.s2.e3,DDI-DrugBank.d77.s2.e5,"Avoid the use of preparations such as drug0 and local drug0 which contain any drug0 (e.g., drug1, drug0), since it has been reported that drug2",True,advise
DDI-DrugBank.d77.s2.e4,DDI-DrugBank.d77.s2.e5,"Avoid the use of preparations such as drug0 and local drug0 which contain any drug0 (e.g., drug0, drug1), since it has been reported that drug2",True,advise
DDI-DrugBank.d77.s4.e0,DDI-DrugBank.d77.s4.e1,drug1 may potentiate the effects of drug2,True,effect
DDI-DrugBank.d77.s5.e0,DDI-DrugBank.d77.s5.e1,"The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug2, drug0) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug0, drug0), and adjustment of the dosage of drug0",True,mechanism
DDI-DrugBank.d77.s5.e0,DDI-DrugBank.d77.s5.e2,"The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug0, drug2) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug0, drug0), and adjustment of the dosage of drug0",True,mechanism
DDI-DrugBank.d77.s5.e0,DDI-DrugBank.d77.s5.e3,"The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug0, drug0) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug2, drug0), and adjustment of the dosage of drug0",True,mechanism
DDI-DrugBank.d77.s5.e0,DDI-DrugBank.d77.s5.e4,"The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug0, drug0) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug0, drug2), and adjustment of the dosage of drug0",True,mechanism
DDI-DrugBank.d77.s5.e0,DDI-DrugBank.d77.s5.e5,"The plasma concentration of drug1 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug0, drug0) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug0, drug0), and adjustment of the dosage of drug2",False, 
DDI-DrugBank.d77.s5.e1,DDI-DrugBank.d77.s5.e2,"The plasma concentration of drug0 may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., drug1, drug2) and decrease by concomitant administration of hepatic enzyme inducers (e.g., drug0, drug0), and adjustment of the dosage of drug0",False, 
DDI-DrugBank.d77.s8.e0,DDI-DrugBank.d77.s8.e1,Poor metabolizers have higher than expected plasma concentrations of drug1 (drug2,False, 
DDI-DrugBank.d77.s14.e0,DDI-DrugBank.d77.s14.e1,"drug1) and many that are substrates for P450 2D6 (many other drug2, drug0, and the drug0 drug0 and drug0",False, 
DDI-DrugBank.d77.s14.e0,DDI-DrugBank.d77.s14.e2,"drug1) and many that are substrates for P450 2D6 (many other drug0, drug2, and the drug0 drug0 and drug0",False, 
DDI-DrugBank.d77.s15.e0,DDI-DrugBank.d77.s15.e1,"While all the drug1 (drug2), e. g., drug0, drug0, and drug0",False, 
DDI-DrugBank.d77.s15.e0,DDI-DrugBank.d77.s15.e2,"While all the drug1 (drug0), e. g., drug2, drug0, and drug0",False, 
DDI-DrugBank.d77.s16.e0,DDI-DrugBank.d77.s16.e1,"The extent to which drug1-drug2 interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the drug0",True,int
DDI-DrugBank.d77.s16.e0,DDI-DrugBank.d77.s16.e2,"The extent to which drug1-drug0 interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the drug2",False, 
DDI-DrugBank.d77.s16.e1,DDI-DrugBank.d77.s16.e2,"The extent to which drug0-drug1 interactions may pose clinical problems will depend on the degree of inhibition, and the pharmacokinetics of the drug2",False, 
DDI-DrugBank.d77.s19.e0,DDI-DrugBank.d77.s19.e1,Concomitant use of drug1 with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the drug2,False, 
DDI-DrugBank.d77.s21.e0,DDI-DrugBank.d77.s21.e1,It is desirable to monitor drug1 plasma levels whenever a drug2,False, 
DDI-DrugBank.d394.s0.e0,DDI-DrugBank.d394.s0.e1,"The hypotensive effect of drug1 is augmented by that of most other drug2, including drug0, negative inotropic agents, and inhaled drug0",True,effect
DDI-DrugBank.d394.s0.e0,DDI-DrugBank.d394.s0.e2,"The hypotensive effect of drug1 is augmented by that of most other drug0, including drug2, negative inotropic agents, and inhaled drug0",True,effect
DDI-DrugBank.d394.s0.e0,DDI-DrugBank.d394.s0.e3,"The hypotensive effect of drug1 is augmented by that of most other drug0, including drug0, negative inotropic agents, and inhaled drug2",True,effect
DDI-DrugBank.d394.s0.e1,DDI-DrugBank.d394.s0.e2,"The hypotensive effect of drug0 is augmented by that of most other drug1, including drug2, negative inotropic agents, and inhaled drug0",False, 
DDI-DrugBank.d394.s0.e1,DDI-DrugBank.d394.s0.e3,"The hypotensive effect of drug0 is augmented by that of most other drug1, including drug0, negative inotropic agents, and inhaled drug2",False, 
DDI-DrugBank.d480.s4.e0,DDI-DrugBank.d480.s4.e1,"Given the primary CNS effects of drug1, caution is advised in using it concomitantly with other CNS-active drugs or drug2",True,effect
DDI-DrugBank.d480.s7.e0,DDI-DrugBank.d480.s7.e1,similar events have been reported in patients taking other drug1 or even drug2,False, 
DDI-DrugBank.d480.s8.e0,DDI-DrugBank.d480.s8.e1,"Although it has not been established that there is an interaction between drug1 and drug2 or other drug0, caution is advised when drug0 is initiated in patients taking a drug0 or any other drug0",False, 
DDI-DrugBank.d480.s8.e0,DDI-DrugBank.d480.s8.e2,"Although it has not been established that there is an interaction between drug1 and drug0 or other drug2, caution is advised when drug0 is initiated in patients taking a drug0 or any other drug0",False, 
DDI-DrugBank.d480.s8.e3,DDI-DrugBank.d480.s8.e4,"Although it has not been established that there is an interaction between drug0 and drug0 or other drug0, caution is advised when drug1 is initiated in patients taking a drug2 or any other drug0",True,advise
DDI-DrugBank.d480.s8.e3,DDI-DrugBank.d480.s8.e5,"Although it has not been established that there is an interaction between drug0 and drug0 or other drug0, caution is advised when drug1 is initiated in patients taking a drug0 or any other drug2",True,advise
DDI-DrugBank.d480.s9.e0,DDI-DrugBank.d480.s9.e1,drug1 may potentiate the hypotensive effects of drug2 and the anticholinergic effects of drug0,True,effect
DDI-DrugBank.d480.s9.e0,DDI-DrugBank.d480.s9.e2,drug1 may potentiate the hypotensive effects of drug0 and the anticholinergic effects of drug2,True,effect
DDI-DrugBank.d480.s9.e1,DDI-DrugBank.d480.s9.e2,drug0 may potentiate the hypotensive effects of drug1 and the anticholinergic effects of drug2,False, 
DDI-DrugBank.d480.s10.e0,DDI-DrugBank.d480.s10.e1,The administration of drug1 should be avoided in the treatment of drug induced hypotension because of a possible reverse drug2,False, 
DDI-DrugBank.d480.s15.e0,DDI-DrugBank.d480.s15.e1,"drug1, drug2, and drug0 may decrease drug0 plasma levels, resulting in a decrease in effectiveness of a previously effective drug0",False, 
DDI-DrugBank.d480.s15.e0,DDI-DrugBank.d480.s15.e2,"drug1, drug0, and drug2 may decrease drug0 plasma levels, resulting in a decrease in effectiveness of a previously effective drug0",False, 
DDI-DrugBank.d480.s15.e0,DDI-DrugBank.d480.s15.e3,"drug1, drug0, and drug0 may decrease drug2 plasma levels, resulting in a decrease in effectiveness of a previously effective drug0",True,mechanism
DDI-DrugBank.d480.s15.e1,DDI-DrugBank.d480.s15.e3,"drug0, drug1, and drug0 may decrease drug2 plasma levels, resulting in a decrease in effectiveness of a previously effective drug0",True,mechanism
DDI-DrugBank.d480.s15.e2,DDI-DrugBank.d480.s15.e3,"drug0, drug0, and drug1 may decrease drug2 plasma levels, resulting in a decrease in effectiveness of a previously effective drug0",True,mechanism
DDI-DrugBank.d480.s17.e0,DDI-DrugBank.d480.s17.e1,"drug1, drug2, and drug0 may increase plasma levels of drug0",False, 
DDI-DrugBank.d480.s17.e0,DDI-DrugBank.d480.s17.e2,"drug1, drug0, and drug2 may increase plasma levels of drug0",False, 
DDI-DrugBank.d480.s17.e0,DDI-DrugBank.d480.s17.e3,"drug1, drug0, and drug0 may increase plasma levels of drug2",True,mechanism
DDI-DrugBank.d480.s17.e1,DDI-DrugBank.d480.s17.e3,"drug0, drug1, and drug0 may increase plasma levels of drug2",True,mechanism
DDI-DrugBank.d480.s17.e2,DDI-DrugBank.d480.s17.e3,"drug0, drug0, and drug1 may increase plasma levels of drug2",True,mechanism
DDI-DrugBank.d480.s18.e0,DDI-DrugBank.d480.s18.e1,"Although concomitant use of drug1 and drug2 is not recommended, it should be noted that discontinuation of concomitant drug0 administration may result in an increase in drug0",True,advise
DDI-DrugBank.d480.s18.e0,DDI-DrugBank.d480.s18.e2,"Although concomitant use of drug1 and drug0 is not recommended, it should be noted that discontinuation of concomitant drug2 administration may result in an increase in drug0",False, 
DDI-DrugBank.d480.s18.e0,DDI-DrugBank.d480.s18.e3,"Although concomitant use of drug1 and drug0 is not recommended, it should be noted that discontinuation of concomitant drug0 administration may result in an increase in drug2",False, 
DDI-DrugBank.d480.s18.e2,DDI-DrugBank.d480.s18.e3,"Although concomitant use of drug0 and drug0 is not recommended, it should be noted that discontinuation of concomitant drug1 administration may result in an increase in drug2",True,mechanism
DDI-DrugBank.d480.s19.e0,DDI-DrugBank.d480.s19.e1,"In a study of schizophrenic patients who received drug1 under steady state conditions, drug2 or drug0",False, 
DDI-DrugBank.d480.s19.e0,DDI-DrugBank.d480.s19.e2,"In a study of schizophrenic patients who received drug1 under steady state conditions, drug0 or drug2",False, 
DDI-DrugBank.d480.s20.e0,DDI-DrugBank.d480.s20.e1,"After 14 days of co-administration, mean trough concentrations of drug1 and its metabolites, drug2 and drug0, were elevated with drug0",False, 
DDI-DrugBank.d480.s20.e0,DDI-DrugBank.d480.s20.e2,"After 14 days of co-administration, mean trough concentrations of drug1 and its metabolites, drug0 and drug2, were elevated with drug0",False, 
DDI-DrugBank.d480.s21.e0,DDI-DrugBank.d480.s21.e1,drug1 produced only minor changes in the levels of drug2,True,mechanism
DDI-DrugBank.d480.s22.e0,DDI-DrugBank.d480.s22.e1,"However, other published reports describe modest elevations (less than two-fold) of drug1 and metabolite concentrations when drug2 was taken with drug0, drug0, and drug0",False, 
DDI-DrugBank.d480.s22.e0,DDI-DrugBank.d480.s22.e2,"However, other published reports describe modest elevations (less than two-fold) of drug1 and metabolite concentrations when drug0 was taken with drug2, drug0, and drug0",False, 
DDI-DrugBank.d480.s22.e1,DDI-DrugBank.d480.s22.e2,"However, other published reports describe modest elevations (less than two-fold) of drug0 and metabolite concentrations when drug1 was taken with drug2, drug0, and drug0",True,mechanism
DDI-DrugBank.d480.s22.e1,DDI-DrugBank.d480.s22.e3,"However, other published reports describe modest elevations (less than two-fold) of drug0 and metabolite concentrations when drug1 was taken with drug0, drug2, and drug0",True,mechanism
DDI-DrugBank.d480.s22.e1,DDI-DrugBank.d480.s22.e4,"However, other published reports describe modest elevations (less than two-fold) of drug0 and metabolite concentrations when drug1 was taken with drug0, drug0, and drug2",True,mechanism
DDI-DrugBank.d480.s23.e0,DDI-DrugBank.d480.s23.e1,"Therefore, such combined treatment should be approached with caution and patients should be monitored closely when drug1 is combined with these drugs, particularly with drug2",True,advise
DDI-DrugBank.d480.s26.e0,DDI-DrugBank.d480.s26.e1,"Such individuals are referred to as poor metabolizers of drugs such as drug1, drug2, the drug0, and drug0",False, 
DDI-DrugBank.d480.s26.e0,DDI-DrugBank.d480.s26.e2,"Such individuals are referred to as poor metabolizers of drugs such as drug1, drug0, the drug2, and drug0",False, 
DDI-DrugBank.d480.s28.e0,DDI-DrugBank.d480.s28.e1,"In addition, certain drugs that are metabolized by this isozyme, including many drug1 (drug2, drug0",False, 
DDI-DrugBank.d480.s28.e0,DDI-DrugBank.d480.s28.e2,"In addition, certain drugs that are metabolized by this isozyme, including many drug1 (drug0, drug2",False, 
DDI-DrugBank.d480.s29.e0,DDI-DrugBank.d480.s29.e1,Concomitant use of drug1 with other drugs metabolized by cytochrome P450 2D6 may require lower doses than usually prescribed for either drug2,False, 
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e1,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug2, drug0, drug0, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e2,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug2, drug0, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e3,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug2, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e4,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug0, and drug2 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e5,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug0, and drug0 (e.g., drug2, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e6,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug0, and drug0 (e.g., drug0, drug2 and drug0), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e7,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug0, and drug0 (e.g., drug0, drug0 and drug2), or that inhibit this enzyme (e.g., drug0",True,advise
DDI-DrugBank.d480.s30.e0,DDI-DrugBank.d480.s30.e8,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isozyme, including drug0, drug0, drug0, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug2",True,advise
DDI-DrugBank.d480.s30.e1,DDI-DrugBank.d480.s30.e2,"Therefore, co-administration of drug0 with other drugs that are metabolized by this isozyme, including drug1, drug2, drug0, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",False, 
DDI-DrugBank.d480.s30.e1,DDI-DrugBank.d480.s30.e3,"Therefore, co-administration of drug0 with other drugs that are metabolized by this isozyme, including drug1, drug0, drug2, and drug0 (e.g., drug0, drug0 and drug0), or that inhibit this enzyme (e.g., drug0",False, 
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e1,"Concurrent use of drug1 with drug2 (e.g., drug0, drug0, drug0, and drug0) may result in increased drug0",True,effect
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e2,"Concurrent use of drug1 with drug0 (e.g., drug2, drug0, drug0, and drug0) may result in increased drug0",True,effect
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e3,"Concurrent use of drug1 with drug0 (e.g., drug0, drug2, drug0, and drug0) may result in increased drug0",True,effect
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e4,"Concurrent use of drug1 with drug0 (e.g., drug0, drug0, drug2, and drug0) may result in increased drug0",True,effect
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e5,"Concurrent use of drug1 with drug0 (e.g., drug0, drug0, drug0, and drug2) may result in increased drug0",True,effect
DDI-DrugBank.d246.s0.e0,DDI-DrugBank.d246.s0.e6,"Concurrent use of drug1 with drug0 (e.g., drug0, drug0, drug0, and drug0) may result in increased drug2",False, 
DDI-DrugBank.d246.s0.e1,DDI-DrugBank.d246.s0.e2,"Concurrent use of drug0 with drug1 (e.g., drug2, drug0, drug0, and drug0) may result in increased drug0",False, 
DDI-DrugBank.d246.s1.e0,DDI-DrugBank.d246.s1.e1,"When used concurrently with such drugs, the dose of drug1 should be the smallest effective dose and the frequency of dosing reduced as much as possible when administered concomitantly with drugs that potentiate the action of drug2",False, 
DDI-DrugBank.d246.s2.e0,DDI-DrugBank.d246.s2.e1,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of drug1 administered as drug2 were not affected by the coadministration of a single 6-mg subcutaneous dose of drug0",False, 
DDI-DrugBank.d246.s2.e0,DDI-DrugBank.d246.s2.e2,"In healthy volunteers, the pharmacokinetics of a 1-mg dose of drug1 administered as drug0 were not affected by the coadministration of a single 6-mg subcutaneous dose of drug2",False, 
DDI-DrugBank.d246.s3.e0,DDI-DrugBank.d246.s3.e1,"However, in another study in healthy volunteers, the pharmacokinetics of drug1 were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of drug2 was administered 1 minute after a 20-mg dose of drug0",False, 
DDI-DrugBank.d246.s3.e0,DDI-DrugBank.d246.s3.e2,"However, in another study in healthy volunteers, the pharmacokinetics of drug1 were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of drug0 was administered 1 minute after a 20-mg dose of drug2",False, 
DDI-DrugBank.d246.s3.e1,DDI-DrugBank.d246.s3.e2,"However, in another study in healthy volunteers, the pharmacokinetics of drug0 were significantly altered (29% decrease in AUC and 38% decrease in Cmax) when a 1-mg dose of drug1 was administered 1 minute after a 20-mg dose of drug2",True,mechanism
DDI-DrugBank.d246.s5.e0,DDI-DrugBank.d246.s5.e1,"When the drug1 was administered 30 minutes after the drug2 nasal spray, the AUC of drug0",True,mechanism
DDI-DrugBank.d246.s5.e0,DDI-DrugBank.d246.s5.e2,"When the drug1 was administered 30 minutes after the drug0 nasal spray, the AUC of drug2",False, 
DDI-DrugBank.d246.s5.e1,DDI-DrugBank.d246.s5.e2,"When the drug0 was administered 30 minutes after the drug1 nasal spray, the AUC of drug2",False, 
DDI-DrugBank.d246.s6.e0,DDI-DrugBank.d246.s6.e1,In neither case were the pharmacokinetics of drug1 affected by coadministration with drug2,False, 
DDI-DrugBank.d246.s7.e0,DDI-DrugBank.d246.s7.e1,These results suggest that the analgesic effect of drug1 may be diminished when it is administered shortly after drug2,True,effect
DDI-DrugBank.d246.s8.e0,DDI-DrugBank.d246.s8.e1,The safety of using drug1 and drug2 (drug0,False, 
DDI-DrugBank.d246.s8.e0,DDI-DrugBank.d246.s8.e2,The safety of using drug1 and drug0 (drug2,False, 
DDI-DrugBank.d246.s10.e0,DDI-DrugBank.d246.s10.e1,The pharmacokinetics of a 1-mg dose of drug1 administered as drug2 were not affected by the coadministration of drug0,False, 
DDI-DrugBank.d246.s10.e0,DDI-DrugBank.d246.s10.e2,The pharmacokinetics of a 1-mg dose of drug1 administered as drug0 were not affected by the coadministration of drug2,False, 
DDI-DrugBank.d246.s11.e0,DDI-DrugBank.d246.s11.e1,"Conversely, the administration of drug1 (1 mg drug2 QID) did not alter the pharmacokinetics of a 300-mg dose of drug0",False, 
DDI-DrugBank.d246.s11.e0,DDI-DrugBank.d246.s11.e2,"Conversely, the administration of drug1 (1 mg drug0 QID) did not alter the pharmacokinetics of a 300-mg dose of drug2",False, 
DDI-DrugBank.d246.s12.e0,DDI-DrugBank.d246.s12.e1,It is not known if the effects of drug1 are altered by concomitant medications that affect hepatic metabolism of drugs (drug2,True,advise
DDI-DrugBank.d246.s13.e0,DDI-DrugBank.d246.s13.e1,The fraction of drug1 absorbed is unaffected by the concomitant administration of a drug2 (drug0,False, 
DDI-DrugBank.d246.s13.e0,DDI-DrugBank.d246.s13.e2,The fraction of drug1 absorbed is unaffected by the concomitant administration of a drug0 (drug2,False, 
DDI-DrugBank.d246.s14.e0,DDI-DrugBank.d246.s14.e1,"Therefore, a slower onset can be anticipated if drug1 is administered concomitantly with, or immediately following, a drug2",True,effect
DDI-DrugBank.d246.s15.e0,DDI-DrugBank.d246.s15.e1,No information is available about the use of drug1 concurrently with drug2,False, 
DDI-DrugBank.d89.s3.e0,DDI-DrugBank.d89.s3.e1,"Based on adult data, lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug2 elimination (e.g., drug0 and drug0) and higher drug0 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug0 and drug0",False, 
DDI-DrugBank.d89.s3.e0,DDI-DrugBank.d89.s3.e2,"Based on adult data, lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug0 elimination (e.g., drug2 and drug0) and higher drug0 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug0 and drug0",True,advise
DDI-DrugBank.d89.s3.e0,DDI-DrugBank.d89.s3.e3,"Based on adult data, lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug0 elimination (e.g., drug0 and drug2) and higher drug0 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug0 and drug0",True,advise
DDI-DrugBank.d89.s3.e0,DDI-DrugBank.d89.s3.e4,"Based on adult data, lower doses of drug1 may be needed following coadministration of drugs which are reported to decrease drug0 elimination (e.g., drug0 and drug0) and higher drug2 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug0 and drug0",False, 
DDI-DrugBank.d89.s3.e4,DDI-DrugBank.d89.s3.e6,"Based on adult data, lower doses of drug0 may be needed following coadministration of drugs which are reported to decrease drug0 elimination (e.g., drug0 and drug0) and higher drug1 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug2 and drug0",True,advise
DDI-DrugBank.d89.s3.e4,DDI-DrugBank.d89.s3.e7,"Based on adult data, lower doses of drug0 may be needed following coadministration of drugs which are reported to decrease drug0 elimination (e.g., drug0 and drug0) and higher drug1 doses may be needed following coadministration of drugs that increase drug0 elimination (e.g., drug0 and drug2",True,advise
DDI-DrugBank.d89.s4.e0,DDI-DrugBank.d89.s4.e1,drug1 administered concurrently with drug2,True,effect
DDI-DrugBank.d89.s6.e0,DDI-DrugBank.d89.s6.e1,Interconversion between drug1 and drug2,False, 
DDI-DrugBank.d528.s0.e0,DDI-DrugBank.d528.s0.e1,drug1 and drug2 - drug0 may decrease hepatic toxicity in those with drug0 overdosage or in those taking drug0,False, 
DDI-DrugBank.d528.s0.e0,DDI-DrugBank.d528.s0.e2,drug1 and drug0 - drug2 may decrease hepatic toxicity in those with drug0 overdosage or in those taking drug0,False, 
DDI-DrugBank.d528.s0.e2,DDI-DrugBank.d528.s0.e3,drug0 and drug0 - drug1 may decrease hepatic toxicity in those with drug2 overdosage or in those taking drug0,True,effect
DDI-DrugBank.d528.s0.e2,DDI-DrugBank.d528.s0.e4,drug0 and drug0 - drug1 may decrease hepatic toxicity in those with drug0 overdosage or in those taking drug2,True,effect
DDI-DrugBank.d528.s2.e0,DDI-DrugBank.d528.s2.e1,drug1 - drug2 may protect against the ototoxic effects of drug0,False, 
DDI-DrugBank.d528.s2.e0,DDI-DrugBank.d528.s2.e2,drug1 - drug0 may protect against the ototoxic effects of drug2,False, 
DDI-DrugBank.d528.s2.e1,DDI-DrugBank.d528.s2.e2,drug0 - drug1 may protect against the ototoxic effects of drug2,True,effect
DDI-DrugBank.d325.s0.e0,DDI-DrugBank.d325.s0.e1,"Because drug1 is metabolized by monoamine oxidase (MAO), inhibition of this enzyme prolongs and potentiates the effect of drug2",False, 
DDI-DrugBank.d325.s1.e0,DDI-DrugBank.d325.s1.e1,Patients who have been treated with drug1 within two to three weeks prior to the administration of drug2 should receive initial doses of drug0,True,advise
DDI-DrugBank.d325.s1.e0,DDI-DrugBank.d325.s1.e2,Patients who have been treated with drug1 within two to three weeks prior to the administration of drug0 should receive initial doses of drug2,False, 
DDI-DrugBank.d325.s1.e1,DDI-DrugBank.d325.s1.e2,Patients who have been treated with drug0 within two to three weeks prior to the administration of drug1 should receive initial doses of drug2,False, 
DDI-DrugBank.d325.s2.e0,DDI-DrugBank.d325.s2.e1,Concurrent administration of low-dose drug1 and drug2,True,effect
DDI-DrugBank.d325.s4.e0,DDI-DrugBank.d325.s4.e1,"Cardiac effects of drug1 are antagonized by drug2, such as drug0 and drug0",True,effect
DDI-DrugBank.d325.s4.e0,DDI-DrugBank.d325.s4.e2,"Cardiac effects of drug1 are antagonized by drug0, such as drug2 and drug0",True,effect
DDI-DrugBank.d325.s4.e0,DDI-DrugBank.d325.s4.e3,"Cardiac effects of drug1 are antagonized by drug0, such as drug0 and drug2",True,effect
DDI-DrugBank.d325.s4.e1,DDI-DrugBank.d325.s4.e2,"Cardiac effects of drug0 are antagonized by drug1, such as drug2 and drug0",False, 
DDI-DrugBank.d325.s4.e1,DDI-DrugBank.d325.s4.e3,"Cardiac effects of drug0 are antagonized by drug1, such as drug0 and drug2",False, 
DDI-DrugBank.d325.s5.e0,DDI-DrugBank.d325.s5.e1,The peripheral vasoconstriction caused by high doses of drug1 is antagonized by drug2,True,effect
DDI-DrugBank.d325.s6.e0,DDI-DrugBank.d325.s6.e1,drug1-induced renal and mesenteric vasodilation is not antagonized by either drug2 or drug0,False, 
DDI-DrugBank.d325.s6.e0,DDI-DrugBank.d325.s6.e2,drug1-induced renal and mesenteric vasodilation is not antagonized by either drug0 or drug2,False, 
DDI-DrugBank.d325.s7.e0,DDI-DrugBank.d325.s7.e1,drug1 (such as drug2) and drug0 can suppress the drug0,False, 
DDI-DrugBank.d325.s7.e0,DDI-DrugBank.d325.s7.e2,drug1 (such as drug0) and drug2 can suppress the drug0,False, 
DDI-DrugBank.d325.s7.e0,DDI-DrugBank.d325.s7.e3,drug1 (such as drug0) and drug0 can suppress the drug2,True,effect
DDI-DrugBank.d325.s7.e1,DDI-DrugBank.d325.s7.e3,drug0 (such as drug1) and drug0 can suppress the drug2,True,effect
DDI-DrugBank.d325.s7.e2,DDI-DrugBank.d325.s7.e3,drug0 (such as drug0) and drug1 can suppress the drug2,True,effect
DDI-DrugBank.d325.s8.e0,DDI-DrugBank.d325.s8.e1,"drug1 or drug2 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug0, such as drug0",False, 
DDI-DrugBank.d325.s8.e0,DDI-DrugBank.d325.s8.e2,"drug1 or drug0 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug2, such as drug0",True,effect
DDI-DrugBank.d325.s8.e0,DDI-DrugBank.d325.s8.e3,"drug1 or drug0 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug0, such as drug2",True,effect
DDI-DrugBank.d325.s8.e1,DDI-DrugBank.d325.s8.e2,"drug0 or drug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug2, such as drug0",True,effect
DDI-DrugBank.d325.s8.e1,DDI-DrugBank.d325.s8.e3,"drug0 or drug1 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug0, such as drug2",True,effect
DDI-DrugBank.d325.s8.e2,DDI-DrugBank.d325.s8.e3,"drug0 or drug0 increase cardiac autonomic irritability and may sensitize the myocardium to the action of certain intravenously administered drug1, such as drug2",False, 
DDI-DrugBank.d325.s10.e0,DDI-DrugBank.d325.s10.e1,"Therefore, EXTREME CAUTION should be exercised when administering drug1 to patients receiving drug2 or drug0",True,advise
DDI-DrugBank.d325.s10.e0,DDI-DrugBank.d325.s10.e2,"Therefore, EXTREME CAUTION should be exercised when administering drug1 to patients receiving drug0 or drug2",True,advise
DDI-DrugBank.d325.s10.e1,DDI-DrugBank.d325.s10.e2,"Therefore, EXTREME CAUTION should be exercised when administering drug0 to patients receiving drug1 or drug2",False, 
DDI-DrugBank.d325.s11.e0,DDI-DrugBank.d325.s11.e1,It has been reported that results of studies in animals indicate that drug1-induced ventricular arrhythmias during anesthesia can be reversed by drug2,True,effect
DDI-DrugBank.d325.s12.e0,DDI-DrugBank.d325.s12.e1,"The concomitant use of drug1s, vasoconstricting agents (such as drug2) and some drug0",False, 
DDI-DrugBank.d325.s12.e0,DDI-DrugBank.d325.s12.e2,"The concomitant use of drug1s, vasoconstricting agents (such as drug0) and some drug2",True,effect
DDI-DrugBank.d325.s12.e1,DDI-DrugBank.d325.s12.e2,"The concomitant use of drug0s, vasoconstricting agents (such as drug1) and some drug2",True,effect
DDI-DrugBank.d325.s13.e0,DDI-DrugBank.d325.s13.e1,Administration of drug1 to patients receiving drug2,True,effect
DDI-DrugBank.d325.s14.e0,DDI-DrugBank.d325.s14.e1,"It is suggested that in patients receiving drug1, alternatives to drug2 should be used if drug0",True,advise
DDI-DrugBank.d325.s14.e0,DDI-DrugBank.d325.s14.e2,"It is suggested that in patients receiving drug1, alternatives to drug0 should be used if drug2",False, 
DDI-DrugBank.d325.s14.e1,DDI-DrugBank.d325.s14.e2,"It is suggested that in patients receiving drug0, alternatives to drug1 should be used if drug2",False, 
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e1,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug2 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e2,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug2, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e3,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug2, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e4,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug2, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e5,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug2, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e6,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug2, drug0, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e7,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug2, drug0, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e8,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug2, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e9,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug0, drug2, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e10,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e11,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d257.s0.e0,DDI-DrugBank.d257.s0.e12,"Interactions with Other CNS Agents: Concurrent use of drug1 with all drug0 (eg, drug0, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d257.s0.e1,DDI-DrugBank.d257.s0.e2,"Interactions with Other CNS Agents: Concurrent use of drug0 with all drug1 (eg, drug2, drug0, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d257.s0.e1,DDI-DrugBank.d257.s0.e3,"Interactions with Other CNS Agents: Concurrent use of drug0 with all drug1 (eg, drug0, drug2, drug0, other drug0, general drug0, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d257.s3.e0,DDI-DrugBank.d257.s3.e1,"Although no interaction between drug1 and drug2 has been observed, it is not recommended for use with drug0",False, 
DDI-DrugBank.d257.s3.e0,DDI-DrugBank.d257.s3.e2,"Although no interaction between drug1 and drug0 has been observed, it is not recommended for use with drug2",False, 
DDI-DrugBank.d257.s3.e1,DDI-DrugBank.d257.s3.e2,"Although no interaction between drug0 and drug1 has been observed, it is not recommended for use with drug2",True,advise
DDI-DrugBank.d257.s4.e0,DDI-DrugBank.d257.s4.e1,"Most cases of serious or fatal adverse events involving drug1 reported to the manufacturer or the FDA have involved either the administration of large initial doses or too frequent doses of the drug to nonopioid tolerant patients, or the simultaneous administration of drug2",False, 
DDI-DrugBank.d257.s6.e0,DDI-DrugBank.d257.s6.e1,"Interactions with drug1: drug2 (eg, drug0, drug0, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug0",False, 
DDI-DrugBank.d257.s6.e0,DDI-DrugBank.d257.s6.e2,"Interactions with drug1: drug0 (eg, drug2, drug0, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug0",False, 
DDI-DrugBank.d257.s6.e1,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug1 (eg, drug0, drug0, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e2,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug1, drug0, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e3,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug0, drug1, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e4,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug0, drug0, drug1, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e5,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug0, drug0, drug0, drug1 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e6,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug0, drug0, drug0, drug0 and drug1) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug0 such as drug2",True,advise
DDI-DrugBank.d257.s6.e7,DDI-DrugBank.d257.s6.e8,"Interactions with drug0: drug0 (eg, drug0, drug0, drug0, drug0 and drug0) should NOT be administered to a patient who has received or is receiving a course of therapy with a drug1 such as drug2",True,advise
DDI-DrugBank.d257.s7.e0,DDI-DrugBank.d257.s7.e1,"In drug1-dependent patients, drug2",False, 
DDI-DrugBank.d26.s0.e0,DDI-DrugBank.d26.s0.e1,"Patients receiving other drug1s, general drug2, drug0, drug0, drug0, drug0 or other drug0 (including drug0) concomitantly with drug0",False, 
DDI-DrugBank.d26.s0.e0,DDI-DrugBank.d26.s0.e2,"Patients receiving other drug1s, general drug0, drug2, drug0, drug0, drug0 or other drug0 (including drug0) concomitantly with drug0",False, 
DDI-DrugBank.d26.s0.e0,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug1s, general drug0, drug0, drug0, drug0, drug0 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e1,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug1, drug0, drug0, drug0, drug0 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e2,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug1, drug0, drug0, drug0 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e3,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug0, drug1, drug0, drug0 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e4,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug0, drug0, drug1, drug0 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e5,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug0, drug0, drug0, drug1 or other drug0 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e6,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug0, drug0, drug0, drug0 or other drug1 (including drug0) concomitantly with drug2",True,effect
DDI-DrugBank.d26.s0.e7,DDI-DrugBank.d26.s0.e8,"Patients receiving other drug0s, general drug0, drug0, drug0, drug0, drug0 or other drug0 (including drug1) concomitantly with drug2",True,effect
DDI-DrugBank.d567.s5.e0,DDI-DrugBank.d567.s5.e1,drug1 drug2 drug0 drug0 drug0 drug0 drug0 drug0,False, 
DDI-DrugBank.d567.s5.e0,DDI-DrugBank.d567.s5.e2,drug1 drug0 drug2 drug0 drug0 drug0 drug0 drug0,False, 
DDI-DrugBank.d567.s9.e0,DDI-DrugBank.d567.s9.e1,drug1 Other drug2 drug0 (drug0,False, 
DDI-DrugBank.d567.s9.e0,DDI-DrugBank.d567.s9.e2,drug1 Other drug0 drug2 (drug0,False, 
DDI-DrugBank.d567.s11.e0,DDI-DrugBank.d567.s11.e1,drug1: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of drug2 particularly with higher doses of drug0,False, 
DDI-DrugBank.d567.s11.e0,DDI-DrugBank.d567.s11.e2,drug1: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of drug0 particularly with higher doses of drug2,False, 
DDI-DrugBank.d567.s11.e1,DDI-DrugBank.d567.s11.e2,drug0: The risk of myopathy/rhabdomyolysis is increased by concomitant administration of drug1 particularly with higher doses of drug2,True,effect
DDI-DrugBank.d567.s12.e0,DDI-DrugBank.d567.s12.e1,drug1 or drug2: The risk of myopathy/rhabdomyolysis is increased when either drug0 or drug0 is used concomitantly with a closely related member of the drug0,False, 
DDI-DrugBank.d567.s12.e0,DDI-DrugBank.d567.s12.e2,drug1 or drug0: The risk of myopathy/rhabdomyolysis is increased when either drug2 or drug0 is used concomitantly with a closely related member of the drug0,False, 
DDI-DrugBank.d567.s12.e2,DDI-DrugBank.d567.s12.e4,drug0 or drug0: The risk of myopathy/rhabdomyolysis is increased when either drug1 or drug0 is used concomitantly with a closely related member of the drug2,True,effect
DDI-DrugBank.d567.s12.e3,DDI-DrugBank.d567.s12.e4,drug0 or drug0: The risk of myopathy/rhabdomyolysis is increased when either drug0 or drug1 is used concomitantly with a closely related member of the drug2,True,effect
DDI-DrugBank.d567.s13.e0,DDI-DrugBank.d567.s13.e1,drug1s: In a small clinical trial in which drug2 was administered to drug0,False, 
DDI-DrugBank.d567.s13.e0,DDI-DrugBank.d567.s13.e2,drug1s: In a small clinical trial in which drug0 was administered to drug2,False, 
DDI-DrugBank.d567.s14.e0,DDI-DrugBank.d567.s14.e1,"However, another drug1 has been found to produce a less than two-second increase in prothrombin time in healthy volunteers receiving low doses of drug2",True,effect
DDI-DrugBank.d567.s15.e0,DDI-DrugBank.d567.s15.e1,"Also, bleeding and/or increased prothrombin time have been reported in a few patients taking drug1s concomitantly with drug2",True,effect
DDI-DrugBank.d567.s16.e0,DDI-DrugBank.d567.s16.e1,"It is recommended that in patients taking drug1, prothrombin time be determined before starting drug2",True,advise
DDI-DrugBank.d567.s19.e0,DDI-DrugBank.d567.s19.e1,drug1 therapy has not been associated with bleeding or with changes in prothrombin time in patients not taking drug2,False, 
DDI-DrugBank.d567.s20.e0,DDI-DrugBank.d567.s20.e1,"drug1: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of drug2 and drug0",False, 
DDI-DrugBank.d567.s20.e0,DDI-DrugBank.d567.s20.e2,"drug1: In normal volunteers, there was no clinically significant pharmacokinetic or pharmacodynamic interaction with concomitant administration of single doses of drug0 and drug2",False, 
DDI-DrugBank.d567.s21.e0,DDI-DrugBank.d567.s21.e1,"drug1: In patients with hypercholesterolemia, concomitant administration of drug2 and drug0 resulted in no effect on drug0",False, 
DDI-DrugBank.d567.s21.e0,DDI-DrugBank.d567.s21.e2,"drug1: In patients with hypercholesterolemia, concomitant administration of drug0 and drug2 resulted in no effect on drug0",False, 
DDI-DrugBank.d567.s22.e0,DDI-DrugBank.d567.s22.e1,"Oral drug1: In pharmacokinetic studies of drug2 in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with drug0 or with drug0",False, 
DDI-DrugBank.d567.s22.e0,DDI-DrugBank.d567.s22.e2,"Oral drug1: In pharmacokinetic studies of drug0 in hypercholesterolemic noninsulin dependent diabetic patients, there was no drug interaction with drug2 or with drug0",False, 
DDI-DrugBank.d305.s1.e0,DDI-DrugBank.d305.s1.e1,"However, neither drug1 nor drug2 appears to affect drug0",False, 
DDI-DrugBank.d305.s1.e0,DDI-DrugBank.d305.s1.e2,"However, neither drug1 nor drug0 appears to affect drug2",False, 
DDI-DrugBank.d305.s2.e0,DDI-DrugBank.d305.s2.e1,"Binding to plasma protein is not significantly altered by drug1, drug2, or drug0",False, 
DDI-DrugBank.d305.s2.e0,DDI-DrugBank.d305.s2.e2,"Binding to plasma protein is not significantly altered by drug1, drug0, or drug2",False, 
DDI-DrugBank.d305.s3.e0,DDI-DrugBank.d305.s3.e1,Binding to plasma proteins is reduced by drug1 and clotibrate and increased by drug2,False, 
DDI-DrugBank.d305.s5.e0,DDI-DrugBank.d305.s5.e1,The combination of therapeutic doses of intravenous drug1 and drug2 in drug0,False, 
DDI-DrugBank.d305.s5.e0,DDI-DrugBank.d305.s5.e2,The combination of therapeutic doses of intravenous drug1 and drug0 in drug2,False, 
DDI-DrugBank.d305.s6.e0,DDI-DrugBank.d305.s6.e1,"It is recommended that the combination of intravenous drug1 and drug2, such as drug0",True,advise
DDI-DrugBank.d305.s6.e0,DDI-DrugBank.d305.s6.e2,"It is recommended that the combination of intravenous drug1 and drug0, such as drug2",True,advise
DDI-DrugBank.d305.s6.e1,DDI-DrugBank.d305.s6.e2,"It is recommended that the combination of intravenous drug0 and drug1, such as drug2",False, 
DDI-DrugBank.d305.s7.e0,DDI-DrugBank.d305.s7.e1,Administration of drug1 may potentiate drug2,True,effect
DDI-DrugBank.d86.s0.e0,DDI-DrugBank.d86.s0.e1,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 (eg, drug2), an drug0 (eg, drug0), and/or a drug0 (eg, drug0",False, 
DDI-DrugBank.d86.s0.e0,DDI-DrugBank.d86.s0.e2,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 (eg, drug0), an drug2 (eg, drug0), and/or a drug0 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e0,DDI-DrugBank.d86.s0.e3,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 (eg, drug0), an drug0 (eg, drug2), and/or a drug0 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e0,DDI-DrugBank.d86.s0.e4,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 (eg, drug0), an drug0 (eg, drug0), and/or a drug2 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e0,DDI-DrugBank.d86.s0.e5,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug1 (eg, drug0), an drug0 (eg, drug0), and/or a drug0 (eg, drug2",True,effect
DDI-DrugBank.d86.s0.e1,DDI-DrugBank.d86.s0.e2,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug1), an drug2 (eg, drug0), and/or a drug0 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e1,DDI-DrugBank.d86.s0.e3,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug1), an drug0 (eg, drug2), and/or a drug0 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e1,DDI-DrugBank.d86.s0.e4,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug1), an drug0 (eg, drug0), and/or a drug2 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e1,DDI-DrugBank.d86.s0.e5,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug1), an drug0 (eg, drug0), and/or a drug0 (eg, drug2",True,effect
DDI-DrugBank.d86.s0.e2,DDI-DrugBank.d86.s0.e3,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug0), an drug1 (eg, drug2), and/or a drug0 (eg, drug0",False, 
DDI-DrugBank.d86.s0.e2,DDI-DrugBank.d86.s0.e4,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug0), an drug1 (eg, drug0), and/or a drug2 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e2,DDI-DrugBank.d86.s0.e5,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug0), an drug1 (eg, drug0), and/or a drug0 (eg, drug2",True,effect
DDI-DrugBank.d86.s0.e3,DDI-DrugBank.d86.s0.e4,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug0), an drug0 (eg, drug1), and/or a drug2 (eg, drug0",True,effect
DDI-DrugBank.d86.s0.e3,DDI-DrugBank.d86.s0.e5,"The concurrent use of two or more drugs with anticholinergic activity--such as an drug0 (eg, drug0), an drug0 (eg, drug1), and/or a drug0 (eg, drug2",True,effect
DDI-DrugBank.d86.s1.e0,DDI-DrugBank.d86.s1.e1,"Interactions may also occur with the following: drug1/drug2, drugs used to treat an overactive thyroid, drug0 (e.g., drug0), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 pain medication (e.g., drug0), drugs used to aid sleep, drowsiness-causing drug0 (e.g., drug0",False, 
DDI-DrugBank.d86.s1.e0,DDI-DrugBank.d86.s1.e2,"Interactions may also occur with the following: drug1/drug0, drugs used to treat an overactive thyroid, drug2 (e.g., drug0), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 pain medication (e.g., drug0), drugs used to aid sleep, drowsiness-causing drug0 (e.g., drug0",False, 
DDI-DrugBank.d135.s0.e0,DDI-DrugBank.d135.s0.e1,Effects of drug1 on Drug Metabolizing Enzymes and Drug Transport Systems drug2,False, 
DDI-DrugBank.d135.s5.e0,DDI-DrugBank.d135.s5.e1,"Drugs that Inhibit or Induce Cytochrome P450 3A4 Enzymes drug1 undergoes extensive metabolism by CYP3A4, and concomitant administration of strong inhibitors or inducers of CYP3A4 alter drug2",False, 
DDI-DrugBank.d135.s7.e0,DDI-DrugBank.d135.s7.e1,"drug1: In healthy subjects receiving drug2, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to drug0",False, 
DDI-DrugBank.d135.s7.e0,DDI-DrugBank.d135.s7.e2,"drug1: In healthy subjects receiving drug0, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to drug2",False, 
DDI-DrugBank.d135.s7.e1,DDI-DrugBank.d135.s7.e2,"drug0: In healthy subjects receiving drug1, a CYP3A4 inhibitor, at 200 mg twice daily for 7 days, systemic exposure (AUC) to drug2",True,mechanism
DDI-DrugBank.d135.s8.e0,DDI-DrugBank.d135.s8.e1,"drug1: In healthy subjects receiving the CYP3A4 inducer, drug2, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to drug0",False, 
DDI-DrugBank.d135.s8.e0,DDI-DrugBank.d135.s8.e2,"drug1: In healthy subjects receiving the CYP3A4 inducer, drug0, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to drug2",False, 
DDI-DrugBank.d135.s8.e1,DDI-DrugBank.d135.s8.e2,"drug0: In healthy subjects receiving the CYP3A4 inducer, drug1, at 100 mg twice daily for 3 days and 200 mg twice daily for 17 days, systemic exposure (AUC) to drug2",True,mechanism
DDI-DrugBank.d135.s10.e0,DDI-DrugBank.d135.s10.e1,"If drug1 is administered with drugs that inhibit Pgp, increased concentrations of drug2",False, 
DDI-DrugBank.d135.s11.e0,DDI-DrugBank.d135.s11.e1,"Other Chemotherapy Agents In a separate study, concomitant administration of drug1 with drug2 did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of drug0",False, 
DDI-DrugBank.d135.s11.e0,DDI-DrugBank.d135.s11.e2,"Other Chemotherapy Agents In a separate study, concomitant administration of drug1 with drug0 did not meaningfully alter the pharmacokinetics of either agent (or the metabolites of drug2",False, 
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e1,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug2 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e2,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e3,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e4,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug0, drug2, drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e5,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e6,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e7,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d178.s0.e0,DDI-DrugBank.d178.s0.e8,"The hypoglycemic action of drug1 may be potentiated by certain drugs including drug0 and other drugs that are highly protein bound, drug0, drug0, drug0, drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d178.s0.e1,DDI-DrugBank.d178.s0.e2,"The hypoglycemic action of drug0 may be potentiated by certain drugs including drug1 and other drugs that are highly protein bound, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d178.s0.e1,DDI-DrugBank.d178.s0.e3,"The hypoglycemic action of drug0 may be potentiated by certain drugs including drug1 and other drugs that are highly protein bound, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d178.s4.e0,DDI-DrugBank.d178.s4.e1,"These drugs include the drug1 and other drug2, drug0, phe-nothiazines, drug0, drug0, oral drug0, drug0, drug0, sympathomimet-ics, drug0, and drug0",False, 
DDI-DrugBank.d178.s4.e0,DDI-DrugBank.d178.s4.e2,"These drugs include the drug1 and other drug0, drug2, phe-nothiazines, drug0, drug0, oral drug0, drug0, drug0, sympathomimet-ics, drug0, and drug0",False, 
DDI-DrugBank.d178.s7.e0,DDI-DrugBank.d178.s7.e1,"A possible interaction between drug1 and drug2, a drug0, has been reported, resulting in a potentiation of the hypoglycemic action of drug0",True,int
DDI-DrugBank.d178.s7.e0,DDI-DrugBank.d178.s7.e2,"A possible interaction between drug1 and drug0, a drug2, has been reported, resulting in a potentiation of the hypoglycemic action of drug0",False, 
DDI-DrugBank.d178.s7.e0,DDI-DrugBank.d178.s7.e3,"A possible interaction between drug1 and drug0, a drug0, has been reported, resulting in a potentiation of the hypoglycemic action of drug2",False, 
DDI-DrugBank.d178.s9.e0,DDI-DrugBank.d178.s9.e1,A potential interaction between oral drug1 and oral drug2,True,effect
DDI-DrugBank.d178.s11.e0,DDI-DrugBank.d178.s11.e1,"drug1: In a single-dose interaction study in NIDDM subjects, decreases in drug2",False, 
DDI-DrugBank.d178.s13.e0,DDI-DrugBank.d178.s13.e1,Coadministration of gly-buride and drug1 did not result in any changes in either drug2,False, 
DDI-DrugBank.d254.s0.e0,DDI-DrugBank.d254.s0.e1,"Other drug1 (e.g. drug2, drug0, drug0 and general drug0) have additive or potentiating effects with drug0",False, 
DDI-DrugBank.d254.s0.e0,DDI-DrugBank.d254.s0.e2,"Other drug1 (e.g. drug0, drug2, drug0 and general drug0) have additive or potentiating effects with drug0",False, 
DDI-DrugBank.d254.s0.e0,DDI-DrugBank.d254.s0.e5,"Other drug1 (e.g. drug0, drug0, drug0 and general drug0) have additive or potentiating effects with drug2",True,effect
DDI-DrugBank.d254.s0.e1,DDI-DrugBank.d254.s0.e5,"Other drug0 (e.g. drug1, drug0, drug0 and general drug0) have additive or potentiating effects with drug2",True,effect
DDI-DrugBank.d254.s0.e2,DDI-DrugBank.d254.s0.e5,"Other drug0 (e.g. drug0, drug1, drug0 and general drug0) have additive or potentiating effects with drug2",True,effect
DDI-DrugBank.d254.s0.e3,DDI-DrugBank.d254.s0.e5,"Other drug0 (e.g. drug0, drug0, drug1 and general drug0) have additive or potentiating effects with drug2",True,effect
DDI-DrugBank.d254.s0.e4,DDI-DrugBank.d254.s0.e5,"Other drug0 (e.g. drug0, drug0, drug0 and general drug1) have additive or potentiating effects with drug2",True,effect
DDI-DrugBank.d254.s2.e0,DDI-DrugBank.d254.s2.e1,"Following the administration of drug1, the dose of other drug2",True,advise
DDI-DrugBank.d547.s0.e0,DDI-DrugBank.d547.s0.e1,"No significant drug interactions have been reported in studies of drug1 given with other drugs such as drug2, drug0, drug0, drug0, drug0, and oral drug0 in healthy volunteers, or given with drug0",False, 
DDI-DrugBank.d547.s0.e0,DDI-DrugBank.d547.s0.e2,"No significant drug interactions have been reported in studies of drug1 given with other drugs such as drug0, drug2, drug0, drug0, drug0, and oral drug0 in healthy volunteers, or given with drug0",False, 
DDI-DrugBank.d547.s2.e0,DDI-DrugBank.d547.s2.e1,"drug1 Reversible increases in serum drug2 concentrations and toxicity have been reported during concomitant administration of drug0 with drug0, and with some drug0",False, 
DDI-DrugBank.d547.s2.e0,DDI-DrugBank.d547.s2.e2,"drug1 Reversible increases in serum drug0 concentrations and toxicity have been reported during concomitant administration of drug2 with drug0, and with some drug0",False, 
DDI-DrugBank.d547.s2.e2,DDI-DrugBank.d547.s2.e3,"drug0 Reversible increases in serum drug0 concentrations and toxicity have been reported during concomitant administration of drug1 with drug2, and with some drug0",True,mechanism
DDI-DrugBank.d547.s2.e2,DDI-DrugBank.d547.s2.e4,"drug0 Reversible increases in serum drug0 concentrations and toxicity have been reported during concomitant administration of drug1 with drug0, and with some drug2",True,mechanism
DDI-DrugBank.d547.s3.e0,DDI-DrugBank.d547.s3.e1,"An increase in serum drug1 concentration has been reported during concomitant administration of drug2 with drug0, so careful monitoring of serum drug0",False, 
DDI-DrugBank.d547.s3.e0,DDI-DrugBank.d547.s3.e2,"An increase in serum drug1 concentration has been reported during concomitant administration of drug0 with drug2, so careful monitoring of serum drug0",False, 
DDI-DrugBank.d547.s3.e1,DDI-DrugBank.d547.s3.e2,"An increase in serum drug0 concentration has been reported during concomitant administration of drug1 with drug2, so careful monitoring of serum drug0",True,mechanism
DDI-DrugBank.d149.s0.e0,DDI-DrugBank.d149.s0.e1,Possible drug interactions of drug1 with drug2 or with other drug0,True,int
DDI-DrugBank.d149.s0.e0,DDI-DrugBank.d149.s0.e2,Possible drug interactions of drug1 with drug0 or with other drug2,True,int
DDI-DrugBank.d149.s0.e1,DDI-DrugBank.d149.s0.e2,Possible drug interactions of drug0 with drug1 or with other drug2,False, 
DDI-DrugBank.d396.s0.e0,DDI-DrugBank.d396.s0.e1,"Patients receiving other drug1, drug2, drug0, or other drug0 (including drug0) concomitantly with drug0 and drug0",False, 
DDI-DrugBank.d396.s0.e0,DDI-DrugBank.d396.s0.e2,"Patients receiving other drug1, drug0, drug2, or other drug0 (including drug0) concomitantly with drug0 and drug0",False, 
DDI-DrugBank.d396.s0.e0,DDI-DrugBank.d396.s0.e5,"Patients receiving other drug1, drug0, drug0, or other drug0 (including drug0) concomitantly with drug2 and drug0",True,effect
DDI-DrugBank.d396.s0.e1,DDI-DrugBank.d396.s0.e5,"Patients receiving other drug0, drug1, drug0, or other drug0 (including drug0) concomitantly with drug2 and drug0",True,effect
DDI-DrugBank.d396.s0.e2,DDI-DrugBank.d396.s0.e5,"Patients receiving other drug0, drug0, drug1, or other drug0 (including drug0) concomitantly with drug2 and drug0",True,effect
DDI-DrugBank.d396.s0.e3,DDI-DrugBank.d396.s0.e5,"Patients receiving other drug0, drug0, drug0, or other drug1 (including drug0) concomitantly with drug2 and drug0",True,effect
DDI-DrugBank.d396.s0.e4,DDI-DrugBank.d396.s0.e5,"Patients receiving other drug0, drug0, drug0, or other drug0 (including drug1) concomitantly with drug2 and drug0",True,effect
DDI-DrugBank.d396.s2.e0,DDI-DrugBank.d396.s2.e1,The use of drug1 or drug2 with drug0 preparations may increase the effect of either the drug0 or drug0,False, 
DDI-DrugBank.d396.s2.e0,DDI-DrugBank.d396.s2.e2,The use of drug1 or drug0 with drug2 preparations may increase the effect of either the drug0 or drug0,True,effect
DDI-DrugBank.d396.s2.e0,DDI-DrugBank.d396.s2.e3,The use of drug1 or drug0 with drug0 preparations may increase the effect of either the drug2 or drug0,False, 
DDI-DrugBank.d396.s2.e1,DDI-DrugBank.d396.s2.e2,The use of drug0 or drug1 with drug2 preparations may increase the effect of either the drug0 or drug0,True,effect
DDI-DrugBank.d396.s3.e0,DDI-DrugBank.d396.s3.e1,The concurrent use of drug1 with drug2,True,effect
DDI-DrugBank.d454.s0.e0,DDI-DrugBank.d454.s0.e1,"- drug1 may enhance the CNS depressive effects of drug2, drug0 and other drug0",True,effect
DDI-DrugBank.d454.s0.e0,DDI-DrugBank.d454.s0.e2,"- drug1 may enhance the CNS depressive effects of drug0, drug2 and other drug0",True,effect
DDI-DrugBank.d454.s0.e0,DDI-DrugBank.d454.s0.e3,"- drug1 may enhance the CNS depressive effects of drug0, drug0 and other drug2",True,effect
DDI-DrugBank.d454.s0.e1,DDI-DrugBank.d454.s0.e2,"- drug0 may enhance the CNS depressive effects of drug1, drug2 and other drug0",False, 
DDI-DrugBank.d454.s0.e1,DDI-DrugBank.d454.s0.e3,"- drug0 may enhance the CNS depressive effects of drug1, drug0 and other drug2",False, 
DDI-DrugBank.d454.s2.e0,DDI-DrugBank.d454.s2.e1,- drug1 may enhance the effects of drug2,True,effect
DDI-DrugBank.d454.s4.e0,DDI-DrugBank.d454.s4.e1,- Concomitant use of drug1 may reduce the efficacy of drug2,True,effect
DDI-DrugBank.d180.s0.e0,DDI-DrugBank.d180.s0.e1,drug1 toxicity may be aggravated by the initial release of norepinephrine caused by drug2,True,effect
DDI-DrugBank.d180.s1.e0,DDI-DrugBank.d180.s1.e1,The pressor effects of drug1 such as drug2 or drug0 are enhanced by drug0,False, 
DDI-DrugBank.d180.s1.e0,DDI-DrugBank.d180.s1.e2,The pressor effects of drug1 such as drug0 or drug2 are enhanced by drug0,False, 
DDI-DrugBank.d180.s1.e0,DDI-DrugBank.d180.s1.e3,The pressor effects of drug1 such as drug0 or drug0 are enhanced by drug2,True,effect
DDI-DrugBank.d180.s1.e1,DDI-DrugBank.d180.s1.e3,The pressor effects of drug0 such as drug1 or drug0 are enhanced by drug2,True,effect
DDI-DrugBank.d180.s1.e2,DDI-DrugBank.d180.s1.e3,The pressor effects of drug0 such as drug0 or drug1 are enhanced by drug2,True,effect
DDI-DrugBank.d180.s3.e0,DDI-DrugBank.d180.s3.e1,Although there is little published information on concomitant administration of drug1 and drug2,False, 
DDI-DrugBank.d262.s0.e0,DDI-DrugBank.d262.s0.e1,The concomitant use of drug1 or other drug2,False, 
DDI-DrugBank.d30.s0.e0,DDI-DrugBank.d30.s0.e1,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with drug1, drug2, drug0, drug0 and drug0",False, 
DDI-DrugBank.d30.s0.e0,DDI-DrugBank.d30.s0.e2,"No significant drug-drug pharmacokinetic interactions have been found in interaction studies with drug1, drug0, drug2, drug0 and drug0",False, 
DDI-DrugBank.d30.s1.e0,DDI-DrugBank.d30.s1.e1,"drug1, an inducer of drug metabolism, decreased the concentrations of drug2",True,mechanism
DDI-DrugBank.d30.s3.e0,DDI-DrugBank.d30.s3.e1,"drug1 did not affect the conversion of drug2 to the active metabolite after intravenous administration of drug0, and drug0",False, 
DDI-DrugBank.d30.s3.e0,DDI-DrugBank.d30.s3.e2,"drug1 did not affect the conversion of drug0 to the active metabolite after intravenous administration of drug2, and drug0",False, 
DDI-DrugBank.d30.s4.e0,DDI-DrugBank.d30.s4.e1,"drug1, an inhibitor of P450 2C9, decreased active metabolite concentration and increased drug2",True,mechanism
DDI-DrugBank.d30.s8.e0,DDI-DrugBank.d30.s8.e1,"As with other drugs that block angiotensin II or its effects, concomitant use of drug1 (e.g., drug2, drug0, drug0), drug0",False, 
DDI-DrugBank.d30.s8.e0,DDI-DrugBank.d30.s8.e2,"As with other drugs that block angiotensin II or its effects, concomitant use of drug1 (e.g., drug0, drug2, drug0), drug0",False, 
DDI-DrugBank.d30.s9.e0,DDI-DrugBank.d30.s9.e1,"As with other drug1, the antihypertensive effect of drug2 may be blunted by the drug0 drug0",False, 
DDI-DrugBank.d30.s9.e0,DDI-DrugBank.d30.s9.e2,"As with other drug1, the antihypertensive effect of drug0 may be blunted by the drug2 drug0",False, 
DDI-DrugBank.d30.s9.e1,DDI-DrugBank.d30.s9.e3,"As with other drug0, the antihypertensive effect of drug1 may be blunted by the drug0 drug2",True,effect
DDI-DrugBank.d117.s0.e0,DDI-DrugBank.d117.s0.e1,Concomitant use with drug1s may result in the reduced absorption of drug2,False, 
DDI-DrugBank.d335.s1.e0,DDI-DrugBank.d335.s1.e1,"Animal experience indicates that drug1 prolongs the sleeping time after drug2 or after drug0, increases the inhibitory effects of drug0",True,effect
DDI-DrugBank.d335.s1.e0,DDI-DrugBank.d335.s1.e2,"Animal experience indicates that drug1 prolongs the sleeping time after drug0 or after drug2, increases the inhibitory effects of drug0",True,effect
DDI-DrugBank.d335.s1.e0,DDI-DrugBank.d335.s1.e3,"Animal experience indicates that drug1 prolongs the sleeping time after drug0 or after drug0, increases the inhibitory effects of drug2",True,effect
DDI-DrugBank.d335.s1.e1,DDI-DrugBank.d335.s1.e2,"Animal experience indicates that drug0 prolongs the sleeping time after drug1 or after drug2, increases the inhibitory effects of drug0",False, 
DDI-DrugBank.d335.s1.e1,DDI-DrugBank.d335.s1.e3,"Animal experience indicates that drug0 prolongs the sleeping time after drug1 or after drug0, increases the inhibitory effects of drug2",False, 
DDI-DrugBank.d335.s3.e0,DDI-DrugBank.d335.s3.e1,"The actions of the drug1 may be potentiated by drug2, drug0, drug0, drug0 or other drug0",True,effect
DDI-DrugBank.d335.s3.e0,DDI-DrugBank.d335.s3.e2,"The actions of the drug1 may be potentiated by drug0, drug2, drug0, drug0 or other drug0",True,effect
DDI-DrugBank.d335.s3.e0,DDI-DrugBank.d335.s3.e3,"The actions of the drug1 may be potentiated by drug0, drug0, drug2, drug0 or other drug0",True,effect
DDI-DrugBank.d335.s3.e0,DDI-DrugBank.d335.s3.e4,"The actions of the drug1 may be potentiated by drug0, drug0, drug0, drug2 or other drug0",True,effect
DDI-DrugBank.d335.s3.e0,DDI-DrugBank.d335.s3.e5,"The actions of the drug1 may be potentiated by drug0, drug0, drug0, drug0 or other drug2",True,effect
DDI-DrugBank.d335.s3.e1,DDI-DrugBank.d335.s3.e2,"The actions of the drug0 may be potentiated by drug1, drug2, drug0, drug0 or other drug0",False, 
DDI-DrugBank.d335.s3.e1,DDI-DrugBank.d335.s3.e3,"The actions of the drug0 may be potentiated by drug1, drug0, drug2, drug0 or other drug0",False, 
DDI-DrugBank.d335.s5.e0,DDI-DrugBank.d335.s5.e1,"In bioavailability studies with normal subjects, the concurrent administration of drug1 at therapeutic levels did not significantly influence the bioavailability of drug2",False, 
DDI-DrugBank.d82.s0.e0,DDI-DrugBank.d82.s0.e1,"In normal volunteers receiving drug1, the administration of drug2 decreased the renal clearance and significantly increased the plasma levels of drug0",False, 
DDI-DrugBank.d82.s0.e0,DDI-DrugBank.d82.s0.e2,"In normal volunteers receiving drug1, the administration of drug0 decreased the renal clearance and significantly increased the plasma levels of drug2",False, 
DDI-DrugBank.d82.s0.e1,DDI-DrugBank.d82.s0.e2,"In normal volunteers receiving drug0, the administration of drug1 decreased the renal clearance and significantly increased the plasma levels of drug2",True,mechanism
DDI-DrugBank.d82.s1.e0,DDI-DrugBank.d82.s1.e1,"In some patients, combined use of drug1 and drug2",True,effect
DDI-DrugBank.d82.s2.e0,DDI-DrugBank.d82.s2.e1,"Therefore, drug1 and drug2",True,advise
DDI-DrugBank.d82.s3.e0,DDI-DrugBank.d82.s3.e1,"In a study in normal volunteers, it was found that chronic concurrent administration of 3.6 g of drug1 per day decreases drug2",True,mechanism
DDI-DrugBank.d82.s4.e0,DDI-DrugBank.d82.s4.e1,The concomitant use of drug1 with other drug2,True,advise
DDI-DrugBank.d82.s5.e0,DDI-DrugBank.d82.s5.e1,Clinical studies have shown that drug1 does not influence the hypoprothrombinemia produced by drug2,False, 
DDI-DrugBank.d82.s6.e0,DDI-DrugBank.d82.s6.e1,"However, when any additional drug, including drug1, is added to the treatment of patients on drug2",True,advise
DDI-DrugBank.d82.s7.e0,DDI-DrugBank.d82.s7.e1,"In post-marketing experience, bleeding has been reported in patients on concomitant treatment with drug1 and drug2",True,effect
DDI-DrugBank.d82.s8.e0,DDI-DrugBank.d82.s8.e1,Caution should be exercised when drug1 and drug2,True,advise
DDI-DrugBank.d82.s9.e0,DDI-DrugBank.d82.s9.e1,"When drug1 is given to patients receiving drug2, the plasma levels of drug0",True,mechanism
DDI-DrugBank.d82.s9.e0,DDI-DrugBank.d82.s9.e2,"When drug1 is given to patients receiving drug0, the plasma levels of drug2",False, 
DDI-DrugBank.d82.s9.e1,DDI-DrugBank.d82.s9.e2,"When drug0 is given to patients receiving drug1, the plasma levels of drug2",False, 
DDI-DrugBank.d82.s12.e0,DDI-DrugBank.d82.s12.e1,Caution should be used if drug1 is administered simultaneously with drug2,True,advise
DDI-DrugBank.d82.s13.e0,DDI-DrugBank.d82.s13.e1,drug1 has been reported to decrease the tubular secretion of drug2,True,mechanism
DDI-DrugBank.d82.s14.e0,DDI-DrugBank.d82.s14.e1,Administration of drug1 concomitantly with drug2 has been associated with an increase in drug0,True,effect
DDI-DrugBank.d82.s14.e0,DDI-DrugBank.d82.s14.e2,Administration of drug1 concomitantly with drug0 has been associated with an increase in drug2,False, 
DDI-DrugBank.d82.s14.e1,DDI-DrugBank.d82.s14.e2,Administration of drug0 concomitantly with drug1 has been associated with an increase in drug2,False, 
DDI-DrugBank.d82.s15.e0,DDI-DrugBank.d82.s15.e1,drug1 should be used with caution in patients taking drug2,True,advise
DDI-DrugBank.d82.s16.e0,DDI-DrugBank.d82.s16.e1,Capsules drug1 50 mg t.i.d. produced a clinically relevant elevation of plasma drug2 and reduction in renal drug0 clearance in psychiatric patients and normal subjects with steady state plasma drug0,True,mechanism
DDI-DrugBank.d82.s16.e0,DDI-DrugBank.d82.s16.e2,Capsules drug1 50 mg t.i.d. produced a clinically relevant elevation of plasma drug0 and reduction in renal drug2 clearance in psychiatric patients and normal subjects with steady state plasma drug0,False, 
DDI-DrugBank.d82.s16.e0,DDI-DrugBank.d82.s16.e3,Capsules drug1 50 mg t.i.d. produced a clinically relevant elevation of plasma drug0 and reduction in renal drug0 clearance in psychiatric patients and normal subjects with steady state plasma drug2,False, 
DDI-DrugBank.d82.s18.e0,DDI-DrugBank.d82.s18.e1,"As a consequence, when drug1 and drug2 are given concomitantly, the patient should be carefully observed for signs of drug0",True,advise
DDI-DrugBank.d82.s18.e0,DDI-DrugBank.d82.s18.e2,"As a consequence, when drug1 and drug0 are given concomitantly, the patient should be carefully observed for signs of drug2",False, 
DDI-DrugBank.d82.s18.e1,DDI-DrugBank.d82.s18.e2,"As a consequence, when drug0 and drug1 are given concomitantly, the patient should be carefully observed for signs of drug2",False, 
DDI-DrugBank.d82.s21.e0,DDI-DrugBank.d82.s21.e1,drug1 given concomitantly with drug2 has been reported to increase the serum concentration and prolong the half-life of drug0,True,mechanism
DDI-DrugBank.d82.s21.e0,DDI-DrugBank.d82.s21.e2,drug1 given concomitantly with drug0 has been reported to increase the serum concentration and prolong the half-life of drug2,False, 
DDI-DrugBank.d82.s21.e1,DDI-DrugBank.d82.s21.e2,drug0 given concomitantly with drug1 has been reported to increase the serum concentration and prolong the half-life of drug2,False, 
DDI-DrugBank.d82.s22.e0,DDI-DrugBank.d82.s22.e1,"Therefore, when drug1 and drug2 are used concomitantly, serum drug0",True,advise
DDI-DrugBank.d82.s22.e0,DDI-DrugBank.d82.s22.e2,"Therefore, when drug1 and drug0 are used concomitantly, serum drug2",False, 
DDI-DrugBank.d82.s22.e1,DDI-DrugBank.d82.s22.e2,"Therefore, when drug0 and drug1 are used concomitantly, serum drug2",False, 
DDI-DrugBank.d82.s23.e0,DDI-DrugBank.d82.s23.e1,"In some patients, the administration of drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d82.s23.e0,DDI-DrugBank.d82.s23.e2,"In some patients, the administration of drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d82.s23.e0,DDI-DrugBank.d82.s23.e3,"In some patients, the administration of drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d82.s23.e1,DDI-DrugBank.d82.s23.e2,"In some patients, the administration of drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug2, and drug0",False, 
DDI-DrugBank.d82.s23.e1,DDI-DrugBank.d82.s23.e3,"In some patients, the administration of drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug0, and drug2",False, 
DDI-DrugBank.d82.s24.e0,DDI-DrugBank.d82.s24.e1,"Therefore, when drug1 and drug2",False, 
DDI-DrugBank.d82.s25.e0,DDI-DrugBank.d82.s25.e1,"(drug1) drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",False, 
DDI-DrugBank.d82.s25.e0,DDI-DrugBank.d82.s25.e2,"(drug1) drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d82.s26.e0,DDI-DrugBank.d82.s26.e1,"drug1 reduces basal plasma renin activity (PRA), as well as those elevations of PRA induced by drug2",False, 
DDI-DrugBank.d82.s28.e0,DDI-DrugBank.d82.s28.e1,It has been reported that the addition of drug1 to a maintenance schedule of drug2,True,effect
DDI-DrugBank.d82.s29.e0,DDI-DrugBank.d82.s29.e1,drug1 and drug2,True,advise
DDI-DrugBank.d82.s30.e0,DDI-DrugBank.d82.s30.e1,drug1 and drug2,False, 
DDI-DrugBank.d82.s31.e0,DDI-DrugBank.d82.s31.e1,The potential effects of drug1 and drug2,True,effect
DDI-DrugBank.d82.s32.e0,DDI-DrugBank.d82.s32.e1,"Most of the above effects concerning drug1 have been attributed, at least in part, to mechanisms involving inhibition of prostaglandin synthesis by drug2",True,effect
DDI-DrugBank.d82.s33.e0,DDI-DrugBank.d82.s33.e1,Blunting of the antihypertensive effect of drug1 by drug2 including drug0,True,effect
DDI-DrugBank.d82.s33.e0,DDI-DrugBank.d82.s33.e2,Blunting of the antihypertensive effect of drug1 by drug0 including drug2,True,effect
DDI-DrugBank.d82.s33.e1,DDI-DrugBank.d82.s33.e2,Blunting of the antihypertensive effect of drug0 by drug1 including drug2,False, 
DDI-DrugBank.d82.s35.e0,DDI-DrugBank.d82.s35.e1,drug1 can reduce the antihypertensive effects of drug2 and drug0,True,effect
DDI-DrugBank.d82.s35.e0,DDI-DrugBank.d82.s35.e2,drug1 can reduce the antihypertensive effects of drug0 and drug2,True,effect
DDI-DrugBank.d82.s35.e1,DDI-DrugBank.d82.s35.e2,drug0 can reduce the antihypertensive effects of drug1 and drug2,False, 
DDI-DrugBank.d242.s1.e0,DDI-DrugBank.d242.s1.e1,"However, the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug2, interfere with the metabolism of drug0, and enhance the effects of the oral drug0 drug0 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug0",True,mechanism
DDI-DrugBank.d242.s1.e0,DDI-DrugBank.d242.s1.e2,"However, the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug0, interfere with the metabolism of drug2, and enhance the effects of the oral drug0 drug0 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug0",True,mechanism
DDI-DrugBank.d242.s1.e0,DDI-DrugBank.d242.s1.e3,"However, the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug0, interfere with the metabolism of drug0, and enhance the effects of the oral drug2 drug0 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug0",False, 
DDI-DrugBank.d242.s1.e0,DDI-DrugBank.d242.s1.e4,"However, the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug0, interfere with the metabolism of drug0, and enhance the effects of the oral drug0 drug2 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug0",True,effect
DDI-DrugBank.d242.s1.e0,DDI-DrugBank.d242.s1.e5,"However, the systemic administration of some drug1 has been shown to elevate plasma concentrations of drug0, interfere with the metabolism of drug0, and enhance the effects of the oral drug0 drug0 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug2",True,effect
DDI-DrugBank.d242.s1.e1,DDI-DrugBank.d242.s1.e2,"However, the systemic administration of some drug0 has been shown to elevate plasma concentrations of drug1, interfere with the metabolism of drug2, and enhance the effects of the oral drug0 drug0 and its derivatives, and has been associated with transient elevations in serum creatinine in patients receiving systemic drug0",False, 
DDI-DrugBank.d183.s1.e0,DDI-DrugBank.d183.s1.e1,"drug1 has been administered with drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d183.s1.e0,DDI-DrugBank.d183.s1.e2,"drug1 has been administered with drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d183.s2.e0,DDI-DrugBank.d183.s2.e1,"Although there are no study data to evaluate the possibility, drug1, including drug2 and drug0, may have an additive effect with drug0",False, 
DDI-DrugBank.d183.s2.e0,DDI-DrugBank.d183.s2.e2,"Although there are no study data to evaluate the possibility, drug1, including drug0 and drug2, may have an additive effect with drug0",False, 
DDI-DrugBank.d183.s2.e0,DDI-DrugBank.d183.s2.e3,"Although there are no study data to evaluate the possibility, drug1, including drug0 and drug0, may have an additive effect with drug2",True,effect
DDI-DrugBank.d183.s2.e1,DDI-DrugBank.d183.s2.e3,"Although there are no study data to evaluate the possibility, drug0, including drug1 and drug0, may have an additive effect with drug2",True,effect
DDI-DrugBank.d183.s2.e2,DDI-DrugBank.d183.s2.e3,"Although there are no study data to evaluate the possibility, drug0, including drug0 and drug1, may have an additive effect with drug2",True,effect
DDI-DrugBank.d288.s0.e0,DDI-DrugBank.d288.s0.e1,"In a Phase I trial using escalating doses of drug1 (110-200 mg/m2) and drug2 (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when drug0 was given after drug0 than with the alternate sequence (ie, drug0 before drug0",False, 
DDI-DrugBank.d288.s0.e0,DDI-DrugBank.d288.s0.e2,"In a Phase I trial using escalating doses of drug1 (110-200 mg/m2) and drug0 (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when drug2 was given after drug0 than with the alternate sequence (ie, drug0 before drug0",False, 
DDI-DrugBank.d288.s0.e2,DDI-DrugBank.d288.s0.e3,"In a Phase I trial using escalating doses of drug0 (110-200 mg/m2) and drug0 (50 or 75 mg/m2) given as sequential infusions, myelosuppression was more profound when drug1 was given after drug2 than with the alternate sequence (ie, drug0 before drug0",True,effect
DDI-DrugBank.d288.s1.e0,DDI-DrugBank.d288.s1.e1,Pharmacokinetic data from these patients demonstrated a decrease in drug1 clearance of approximately 33% when drug2 was administered following drug0,False, 
DDI-DrugBank.d288.s1.e0,DDI-DrugBank.d288.s1.e2,Pharmacokinetic data from these patients demonstrated a decrease in drug1 clearance of approximately 33% when drug0 was administered following drug2,False, 
DDI-DrugBank.d288.s1.e1,DDI-DrugBank.d288.s1.e2,Pharmacokinetic data from these patients demonstrated a decrease in drug0 clearance of approximately 33% when drug1 was administered following drug2,True,mechanism
DDI-DrugBank.d288.s4.e0,DDI-DrugBank.d288.s4.e1,"Potential interactions between drug1, a substrate of CYP3A4, and drug2 (drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d288.s4.e0,DDI-DrugBank.d288.s4.e2,"Potential interactions between drug1, a substrate of CYP3A4, and drug0 (drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d288.s5.e0,DDI-DrugBank.d288.s5.e1,Reports in the literature suggest that plasma levels of drug1 (and its active metabolite drug2) may be increased when drug0 and drug0,False, 
DDI-DrugBank.d288.s5.e0,DDI-DrugBank.d288.s5.e2,Reports in the literature suggest that plasma levels of drug1 (and its active metabolite drug0) may be increased when drug2 and drug0,False, 
DDI-DrugBank.d288.s5.e2,DDI-DrugBank.d288.s5.e3,Reports in the literature suggest that plasma levels of drug0 (and its active metabolite drug0) may be increased when drug1 and drug2,True,mechanism
DDI-DrugBank.d288.s11.e0,DDI-DrugBank.d288.s11.e1,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, drug1 for injection concentrate and drug2 for injection concentrate) should not be treated with drug0",False, 
DDI-DrugBank.d288.s11.e0,DDI-DrugBank.d288.s11.e2,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, drug1 for injection concentrate and drug0 for injection concentrate) should not be treated with drug2",True,advise
DDI-DrugBank.d288.s11.e1,DDI-DrugBank.d288.s11.e2,"Hypersensitivity Reactions: Patients with a history of severe hypersensitivity reactions to products containing Cremophor  EL (eg, drug0 for injection concentrate and drug1 for injection concentrate) should not be treated with drug2",True,advise
DDI-DrugBank.d288.s12.e0,DDI-DrugBank.d288.s12.e1,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with drug1 should be premedicated with drug2 (such as drug0), diphen-hydramine and drug0 (such as drug0 or drug0",False, 
DDI-DrugBank.d288.s12.e0,DDI-DrugBank.d288.s12.e2,"In order to avoid the occurrence of severe hypersensitivity reactions, all patients treated with drug1 should be premedicated with drug0 (such as drug2), diphen-hydramine and drug0 (such as drug0 or drug0",False, 
DDI-DrugBank.d288.s14.e0,DDI-DrugBank.d288.s14.e1,"However, severe reactions, such as hypotension requiring treatment, dyspnea requiring drug1, angioedema, or generalized urticaria require immediate discontinuation of drug2",False, 
DDI-DrugBank.d562.s0.e0,DDI-DrugBank.d562.s0.e1,Elevated plasma levels of drug1 have been reported with concomitant use of some drug2,True,mechanism
DDI-DrugBank.d562.s1.e0,DDI-DrugBank.d562.s1.e1,There have been reports of drug1-related side-effects in patients on concomitant drug2-drug0,False, 
DDI-DrugBank.d562.s1.e0,DDI-DrugBank.d562.s1.e2,There have been reports of drug1-related side-effects in patients on concomitant drug0-drug2,False, 
DDI-DrugBank.d562.s1.e1,DDI-DrugBank.d562.s1.e2,There have been reports of drug0-related side-effects in patients on concomitant drug1-drug2,True,effect
DDI-DrugBank.d562.s2.e0,DDI-DrugBank.d562.s2.e1,"Therefore, monitoring of drug1 plasma levels should be considered and dosage of drug2",False, 
DDI-DrugBank.d562.s3.e0,DDI-DrugBank.d562.s3.e1,drug1 have also been shown to interfere with the metabolism of drug2,True,mechanism
DDI-DrugBank.d562.s5.e0,DDI-DrugBank.d562.s5.e1,"Although this interaction has not been reported with drug1, caution should be exercised when drug2 is given concomitantly with drug0",False, 
DDI-DrugBank.d562.s5.e0,DDI-DrugBank.d562.s5.e2,"Although this interaction has not been reported with drug1, caution should be exercised when drug0 is given concomitantly with drug2",False, 
DDI-DrugBank.d562.s5.e1,DDI-DrugBank.d562.s5.e2,"Although this interaction has not been reported with drug0, caution should be exercised when drug1 is given concomitantly with drug2",True,advise
DDI-DrugBank.d562.s6.e0,DDI-DrugBank.d562.s6.e1,drug1 or drug2 substantially interfere with the absorption of some drug0,False, 
DDI-DrugBank.d562.s6.e0,DDI-DrugBank.d562.s6.e2,drug1 or drug0 substantially interfere with the absorption of some drug2,True,mechanism
DDI-DrugBank.d562.s6.e1,DDI-DrugBank.d562.s6.e2,drug0 or drug1 substantially interfere with the absorption of some drug2,True,mechanism
DDI-DrugBank.d562.s7.e0,DDI-DrugBank.d562.s7.e1,"Also, concomitant administration of drug1 with products containing drug2, drug0 containing drug0, or drug0 (drug0",True,mechanism
DDI-DrugBank.d562.s7.e0,DDI-DrugBank.d562.s7.e2,"Also, concomitant administration of drug1 with products containing drug0, drug2 containing drug0, or drug0 (drug0",False, 
DDI-DrugBank.d562.s7.e0,DDI-DrugBank.d562.s7.e3,"Also, concomitant administration of drug1 with products containing drug0, drug0 containing drug2, or drug0 (drug0",True,mechanism
DDI-DrugBank.d562.s7.e0,DDI-DrugBank.d562.s7.e4,"Also, concomitant administration of drug1 with products containing drug0, drug0 containing drug0, or drug2 (drug0",True,mechanism
DDI-DrugBank.d562.s7.e0,DDI-DrugBank.d562.s7.e5,"Also, concomitant administration of drug1 with products containing drug0, drug0 containing drug0, or drug0 (drug2",True,mechanism
DDI-DrugBank.d562.s7.e1,DDI-DrugBank.d562.s7.e2,"Also, concomitant administration of drug0 with products containing drug1, drug2 containing drug0, or drug0 (drug0",False, 
DDI-DrugBank.d562.s8.e0,DDI-DrugBank.d562.s8.e1,"drug1, including drug2, may enhance the effects of oral drug0, such as drug0",False, 
DDI-DrugBank.d562.s8.e0,DDI-DrugBank.d562.s8.e2,"drug1, including drug0, may enhance the effects of oral drug2, such as drug0",True,effect
DDI-DrugBank.d562.s8.e0,DDI-DrugBank.d562.s8.e3,"drug1, including drug0, may enhance the effects of oral drug0, such as drug2",True,effect
DDI-DrugBank.d562.s8.e1,DDI-DrugBank.d562.s8.e2,"drug0, including drug1, may enhance the effects of oral drug2, such as drug0",True,effect
DDI-DrugBank.d562.s8.e1,DDI-DrugBank.d562.s8.e3,"drug0, including drug1, may enhance the effects of oral drug0, such as drug2",True,effect
DDI-DrugBank.d562.s8.e2,DDI-DrugBank.d562.s8.e3,"drug0, including drug0, may enhance the effects of oral drug1, such as drug2",False, 
DDI-DrugBank.d562.s10.e0,DDI-DrugBank.d562.s10.e1,Seizures have been reported in patients taking another drug1 and the drug2 drug0,True,effect
DDI-DrugBank.d562.s10.e0,DDI-DrugBank.d562.s10.e2,Seizures have been reported in patients taking another drug1 and the drug0 drug2,True,effect
DDI-DrugBank.d562.s10.e1,DDI-DrugBank.d562.s10.e2,Seizures have been reported in patients taking another drug0 and the drug1 drug2,False, 
DDI-DrugBank.d562.s13.e0,DDI-DrugBank.d562.s13.e1,Physicians are provided this information to increase awareness of the potential for serious interactions when drug1 and certain drug2,True,advise
DDI-DrugBank.d562.s14.e0,DDI-DrugBank.d562.s14.e1,Elevated drug1 serum levels have been reported with the concomitant use of drug2 and drug0,False, 
DDI-DrugBank.d562.s14.e0,DDI-DrugBank.d562.s14.e2,Elevated drug1 serum levels have been reported with the concomitant use of drug0 and drug2,False, 
DDI-DrugBank.d562.s14.e1,DDI-DrugBank.d562.s14.e2,Elevated drug0 serum levels have been reported with the concomitant use of drug1 and drug2,True,mechanism
DDI-DrugBank.d189.s0.e0,DDI-DrugBank.d189.s0.e1,"No Important Interactions To Date drug1 does not have clinically important pharmacokinetic interactions with drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d189.s0.e0,DDI-DrugBank.d189.s0.e2,"No Important Interactions To Date drug1 does not have clinically important pharmacokinetic interactions with drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d118.s0.e0,DDI-DrugBank.d118.s0.e1,In vitro studies have shown that precipitation occurs when eye drops containing drug1 are mixed with drug2,False, 
DDI-DrugBank.d500.s0.e0,DDI-DrugBank.d500.s0.e1,"Because drug1 have been shown to depress plasma prothrombin activity, patients who are on drug2 therapy may require downward adjustment of their drug0",True,advise
DDI-DrugBank.d500.s0.e0,DDI-DrugBank.d500.s0.e2,"Because drug1 have been shown to depress plasma prothrombin activity, patients who are on drug0 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d500.s0.e1,DDI-DrugBank.d500.s0.e2,"Because drug0 have been shown to depress plasma prothrombin activity, patients who are on drug1 therapy may require downward adjustment of their drug2",False, 
DDI-DrugBank.d500.s1.e0,DDI-DrugBank.d500.s1.e1,"Since bacteriostatic drugs may interfere with the bactericidal action of drug1, it is advisable to avoid giving drug2 in conjunction with drug0",False, 
DDI-DrugBank.d500.s1.e0,DDI-DrugBank.d500.s1.e2,"Since bacteriostatic drugs may interfere with the bactericidal action of drug1, it is advisable to avoid giving drug0 in conjunction with drug2",False, 
DDI-DrugBank.d500.s1.e1,DDI-DrugBank.d500.s1.e2,"Since bacteriostatic drugs may interfere with the bactericidal action of drug0, it is advisable to avoid giving drug1 in conjunction with drug2",True,advise
DDI-DrugBank.d500.s2.e0,DDI-DrugBank.d500.s2.e1,"Absorption of drug1 is impaired by drug2 containing drug0, drug0, or drug0, and drug0",False, 
DDI-DrugBank.d500.s2.e0,DDI-DrugBank.d500.s2.e2,"Absorption of drug1 is impaired by drug0 containing drug2, drug0, or drug0, and drug0",True,mechanism
DDI-DrugBank.d500.s2.e0,DDI-DrugBank.d500.s2.e3,"Absorption of drug1 is impaired by drug0 containing drug0, drug2, or drug0, and drug0",True,mechanism
DDI-DrugBank.d500.s2.e0,DDI-DrugBank.d500.s2.e4,"Absorption of drug1 is impaired by drug0 containing drug0, drug0, or drug2, and drug0",True,mechanism
DDI-DrugBank.d500.s2.e0,DDI-DrugBank.d500.s2.e5,"Absorption of drug1 is impaired by drug0 containing drug0, drug0, or drug0, and drug2",True,mechanism
DDI-DrugBank.d500.s2.e1,DDI-DrugBank.d500.s2.e2,"Absorption of drug0 is impaired by drug1 containing drug2, drug0, or drug0, and drug0",False, 
DDI-DrugBank.d500.s3.e0,DDI-DrugBank.d500.s3.e1,Absorption of drug1 is impaired by drug2,True,mechanism
DDI-DrugBank.d500.s4.e0,DDI-DrugBank.d500.s4.e1,"drug1, drug2, and drug0 decrease the half-life of drug0",False, 
DDI-DrugBank.d500.s4.e0,DDI-DrugBank.d500.s4.e2,"drug1, drug0, and drug2 decrease the half-life of drug0",False, 
DDI-DrugBank.d500.s4.e0,DDI-DrugBank.d500.s4.e3,"drug1, drug0, and drug0 decrease the half-life of drug2",True,mechanism
DDI-DrugBank.d500.s4.e1,DDI-DrugBank.d500.s4.e3,"drug0, drug1, and drug0 decrease the half-life of drug2",True,mechanism
DDI-DrugBank.d500.s4.e2,DDI-DrugBank.d500.s4.e3,"drug0, drug0, and drug1 decrease the half-life of drug2",True,mechanism
DDI-DrugBank.d500.s5.e0,DDI-DrugBank.d500.s5.e1,The concurrent use of drug1 and drug2 (drug0,True,effect
DDI-DrugBank.d500.s5.e0,DDI-DrugBank.d500.s5.e2,The concurrent use of drug1 and drug0 (drug2,True,effect
DDI-DrugBank.d500.s5.e1,DDI-DrugBank.d500.s5.e2,The concurrent use of drug0 and drug1 (drug2,False, 
DDI-DrugBank.d500.s6.e0,DDI-DrugBank.d500.s6.e1,Concurrent use of drug1 may render oral drug2,True,effect
DDI-DrugBank.d79.s0.e0,DDI-DrugBank.d79.s0.e1,"The absorption of drug1 may be affected by the simultaneous administration of indigestion remedies, drug2 or drug0",True,mechanism
DDI-DrugBank.d79.s0.e0,DDI-DrugBank.d79.s0.e2,"The absorption of drug1 may be affected by the simultaneous administration of indigestion remedies, drug0 or drug2",True,mechanism
DDI-DrugBank.d79.s0.e1,DDI-DrugBank.d79.s0.e2,"The absorption of drug0 may be affected by the simultaneous administration of indigestion remedies, drug1 or drug2",False, 
DDI-DrugBank.d79.s1.e0,DDI-DrugBank.d79.s1.e1,Oral drug1 may be less effective while you are taking drug2,True,effect
DDI-DrugBank.d152.s0.e0,DDI-DrugBank.d152.s0.e1,Certain endocrine and liver function tests may be affected by drug1-containing oral drug2,False, 
DDI-DrugBank.d80.s0.e0,DDI-DrugBank.d80.s0.e1,Potential drug interactions between drug1 (drug2,False, 
DDI-DrugBank.d191.s1.e0,DDI-DrugBank.d191.s1.e1,drug1 enhance the renal toxicity of drug2 in animals. 7 drug0 interferes with the action of drug0 preparations by chelating the drug0,True,effect
DDI-DrugBank.d191.s1.e0,DDI-DrugBank.d191.s1.e2,drug1 enhance the renal toxicity of drug0 in animals. 7 drug2 interferes with the action of drug0 preparations by chelating the drug0,False, 
DDI-DrugBank.d191.s1.e0,DDI-DrugBank.d191.s1.e3,drug1 enhance the renal toxicity of drug0 in animals. 7 drug0 interferes with the action of drug2 preparations by chelating the drug0,False, 
DDI-DrugBank.d191.s1.e2,DDI-DrugBank.d191.s1.e3,drug0 enhance the renal toxicity of drug0 in animals. 7 drug1 interferes with the action of drug2 preparations by chelating the drug0,True,mechanism
DDI-DrugBank.d110.s0.e0,DDI-DrugBank.d110.s0.e1,"The administration of local drug1 containing drug2 or drug0 to patients receiving drug0, drug0 or drug0",False, 
DDI-DrugBank.d110.s0.e0,DDI-DrugBank.d110.s0.e2,"The administration of local drug1 containing drug0 or drug2 to patients receiving drug0, drug0 or drug0",False, 
DDI-DrugBank.d110.s0.e0,DDI-DrugBank.d110.s0.e4,"The administration of local drug1 containing drug0 or drug0 to patients receiving drug0, drug2 or drug0",True,effect
DDI-DrugBank.d110.s0.e0,DDI-DrugBank.d110.s0.e5,"The administration of local drug1 containing drug0 or drug0 to patients receiving drug0, drug0 or drug2",True,effect
DDI-DrugBank.d110.s0.e1,DDI-DrugBank.d110.s0.e3,"The administration of local drug0 containing drug1 or drug0 to patients receiving drug2, drug0 or drug0",True,effect
DDI-DrugBank.d110.s0.e1,DDI-DrugBank.d110.s0.e4,"The administration of local drug0 containing drug1 or drug0 to patients receiving drug0, drug2 or drug0",True,effect
DDI-DrugBank.d110.s0.e1,DDI-DrugBank.d110.s0.e5,"The administration of local drug0 containing drug1 or drug0 to patients receiving drug0, drug0 or drug2",True,effect
DDI-DrugBank.d110.s0.e2,DDI-DrugBank.d110.s0.e3,"The administration of local drug0 containing drug0 or drug1 to patients receiving drug2, drug0 or drug0",True,effect
DDI-DrugBank.d110.s0.e2,DDI-DrugBank.d110.s0.e4,"The administration of local drug0 containing drug0 or drug1 to patients receiving drug0, drug2 or drug0",True,effect
DDI-DrugBank.d110.s0.e2,DDI-DrugBank.d110.s0.e5,"The administration of local drug0 containing drug0 or drug1 to patients receiving drug0, drug0 or drug2",True,effect
DDI-DrugBank.d110.s3.e0,DDI-DrugBank.d110.s3.e1,Concurrent administration of drug1 (for the treatment of hypotension related to obstetric blocks) and drug2,True,effect
DDI-DrugBank.d110.s5.e0,DDI-DrugBank.d110.s5.e1,"Therefore, drug1 should not be used in any condition in which a drug2",True,advise
DDI-DrugBank.d368.s0.e0,DDI-DrugBank.d368.s0.e1,drug1 modifies drug2 metabolism with increased serum levels of drug0,True,mechanism
DDI-DrugBank.d368.s0.e0,DDI-DrugBank.d368.s0.e2,drug1 modifies drug0 metabolism with increased serum levels of drug2,True,mechanism
DDI-DrugBank.d368.s0.e1,DDI-DrugBank.d368.s0.e2,drug0 modifies drug1 metabolism with increased serum levels of drug2,False, 
DDI-DrugBank.d368.s3.e0,DDI-DrugBank.d368.s3.e1,"By decreasing the gastrointestinal absorption of drug1, drug2 may decrease serum concentrations of drug0",False, 
DDI-DrugBank.d368.s3.e0,DDI-DrugBank.d368.s3.e2,"By decreasing the gastrointestinal absorption of drug1, drug0 may decrease serum concentrations of drug2",False, 
DDI-DrugBank.d368.s3.e1,DDI-DrugBank.d368.s3.e2,"By decreasing the gastrointestinal absorption of drug0, drug1 may decrease serum concentrations of drug2",True,mechanism
DDI-DrugBank.d368.s4.e0,DDI-DrugBank.d368.s4.e1,"Caution is advised when beginning, discontinuing, or changing the dose of drug1 in patients receiving drug2",True,advise
DDI-DrugBank.d368.s6.e0,DDI-DrugBank.d368.s6.e1,drug1 may increase the effects of other drug2,True,effect
DDI-DrugBank.d368.s9.e0,DDI-DrugBank.d368.s9.e1,drug1 decreases urinary excretion of drug2,True,mechanism
DDI-DrugBank.d368.s10.e0,DDI-DrugBank.d368.s10.e1,drug1 reduces urinary excretion of drug2,True,mechanism
DDI-DrugBank.d368.s11.e0,DDI-DrugBank.d368.s11.e1,drug1 may prevent the urinary antiseptic effect of drug2,True,effect
DDI-DrugBank.d368.s12.e0,DDI-DrugBank.d368.s12.e1,drug1 increases drug2 excretion and the drug0,True,mechanism
DDI-DrugBank.d368.s12.e0,DDI-DrugBank.d368.s12.e2,drug1 increases drug0 excretion and the drug2,False, 
DDI-DrugBank.d368.s12.e1,DDI-DrugBank.d368.s12.e2,drug0 increases drug1 excretion and the drug2,False, 
DDI-DrugBank.d368.s13.e0,DDI-DrugBank.d368.s13.e1,drug1 and drug2,True,effect
DDI-DrugBank.d368.s14.e0,DDI-DrugBank.d368.s14.e1,drug1 may elevate drug2,True,mechanism
DDI-DrugBank.d289.s6.e0,DDI-DrugBank.d289.s6.e1,"drug1, Including Oral, Injectable, Transdermal, and Implantable drug2: An interaction study demonstrated that co-administration of drug0 and the oral drug0 drug0 produced average decreases of drug0 and drug0",False, 
DDI-DrugBank.d289.s6.e0,DDI-DrugBank.d289.s6.e2,"drug1, Including Oral, Injectable, Transdermal, and Implantable drug0: An interaction study demonstrated that co-administration of drug2 and the oral drug0 drug0 produced average decreases of drug0 and drug0",False, 
DDI-DrugBank.d289.s6.e2,DDI-DrugBank.d289.s6.e4,"drug0, Including Oral, Injectable, Transdermal, and Implantable drug0: An interaction study demonstrated that co-administration of drug1 and the oral drug0 drug2 produced average decreases of drug0 and drug0",True,mechanism
DDI-DrugBank.d289.s8.e0,DDI-DrugBank.d289.s8.e1,"Therefore, drug1, including oral, injectable, transdermal, and implantable forms, may not be reliable when drug2",True,effect
DDI-DrugBank.d289.s10.e0,DDI-DrugBank.d289.s10.e1,"Specific interaction studies have demonstrated the following: drug1: During the first day of concomitant administration, trough concentrations of drug2",False, 
DDI-DrugBank.d289.s11.e0,DDI-DrugBank.d289.s11.e1,Steady-state drug1 plasma concentrations were 3- to 4-fold higher than in the absence of drug2,True,mechanism
DDI-DrugBank.d289.s12.e0,DDI-DrugBank.d289.s12.e1,The concomitant administration of drug1 and drug2,True,advise
DDI-DrugBank.d289.s13.e0,DDI-DrugBank.d289.s13.e1,Co-administration of drug1 decreased the plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d289.s14.e0,DDI-DrugBank.d289.s14.e1,drug1: Co-administration of drug2 and drug0,False, 
DDI-DrugBank.d289.s14.e0,DDI-DrugBank.d289.s14.e2,drug1: Co-administration of drug0 and drug2,False, 
DDI-DrugBank.d289.s15.e0,DDI-DrugBank.d289.s15.e1,Co-administration of drug1 and drug2 resulted in markedly increased plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d289.s15.e0,DDI-DrugBank.d289.s15.e2,Co-administration of drug1 and drug0 resulted in markedly increased plasma concentrations of drug2,False, 
DDI-DrugBank.d289.s15.e1,DDI-DrugBank.d289.s15.e2,Co-administration of drug0 and drug1 resulted in markedly increased plasma concentrations of drug2,False, 
DDI-DrugBank.d289.s16.e0,DDI-DrugBank.d289.s16.e1,Caution should be exercised if drug1 and drug2,True,advise
DDI-DrugBank.d289.s17.e0,DDI-DrugBank.d289.s17.e1,drug1: An increased risk of elevated liver aminotransferases was observed in patients receiving concomitant therapy with drug2,False, 
DDI-DrugBank.d289.s18.e0,DDI-DrugBank.d289.s18.e1,"Therefore, the concomitant administration of drug1 and drug2 is contraindicated, and alternative drug0",True,advise
DDI-DrugBank.d289.s18.e0,DDI-DrugBank.d289.s18.e2,"Therefore, the concomitant administration of drug1 and drug0 is contraindicated, and alternative drug2",False, 
DDI-DrugBank.d289.s18.e1,DDI-DrugBank.d289.s18.e2,"Therefore, the concomitant administration of drug0 and drug1 is contraindicated, and alternative drug2",False, 
DDI-DrugBank.d289.s19.e0,DDI-DrugBank.d289.s19.e1,Co-administration of drug1 decreased the plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d289.s21.e0,DDI-DrugBank.d289.s21.e1,drug1 is also expected to reduce plasma concentrations of other oral drug2,True,mechanism
DDI-DrugBank.d289.s23.e0,DDI-DrugBank.d289.s23.e1,"drug1: Co-administration of drug2 125 mg b.i.d. and drug0, a potent CYP3A4 inhibitor, increased the plasma concentrations of drug0",False, 
DDI-DrugBank.d289.s23.e0,DDI-DrugBank.d289.s23.e2,"drug1: Co-administration of drug0 125 mg b.i.d. and drug2, a potent CYP3A4 inhibitor, increased the plasma concentrations of drug0",False, 
DDI-DrugBank.d289.s23.e1,DDI-DrugBank.d289.s23.e2,"drug0: Co-administration of drug1 125 mg b.i.d. and drug2, a potent CYP3A4 inhibitor, increased the plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d289.s24.e0,DDI-DrugBank.d289.s24.e1,"No dose adjustment of drug1 is necessary, but increased effects of drug2",False, 
DDI-DrugBank.d289.s25.e0,DDI-DrugBank.d289.s25.e1,drug1 and Other drug2: Co-administration of drug0 decreased the plasma concentrations of drug0,False, 
DDI-DrugBank.d289.s25.e0,DDI-DrugBank.d289.s25.e2,drug1 and Other drug0: Co-administration of drug2 decreased the plasma concentrations of drug0,False, 
DDI-DrugBank.d289.s25.e2,DDI-DrugBank.d289.s25.e3,drug0 and Other drug0: Co-administration of drug1 decreased the plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d289.s27.e0,DDI-DrugBank.d289.s27.e1,"drug1 is also expected to reduce plasma concentrations of other drug2 that have significant metabolism by CYP3A4, such as drug0 and drug0",True,mechanism
DDI-DrugBank.d289.s27.e0,DDI-DrugBank.d289.s27.e2,"drug1 is also expected to reduce plasma concentrations of other drug0 that have significant metabolism by CYP3A4, such as drug2 and drug0",True,mechanism
DDI-DrugBank.d289.s27.e0,DDI-DrugBank.d289.s27.e3,"drug1 is also expected to reduce plasma concentrations of other drug0 that have significant metabolism by CYP3A4, such as drug0 and drug2",True,mechanism
DDI-DrugBank.d289.s27.e1,DDI-DrugBank.d289.s27.e2,"drug0 is also expected to reduce plasma concentrations of other drug1 that have significant metabolism by CYP3A4, such as drug2 and drug0",False, 
DDI-DrugBank.d289.s27.e1,DDI-DrugBank.d289.s27.e3,"drug0 is also expected to reduce plasma concentrations of other drug1 that have significant metabolism by CYP3A4, such as drug0 and drug2",False, 
DDI-DrugBank.d289.s29.e0,DDI-DrugBank.d289.s29.e1,Patients using CYP3A4 metabolized drug1 should have cholesterol levels monitored after drug2 is initiated to see whether the drug0,True,advise
DDI-DrugBank.d289.s29.e0,DDI-DrugBank.d289.s29.e2,Patients using CYP3A4 metabolized drug1 should have cholesterol levels monitored after drug0 is initiated to see whether the drug2,False, 
DDI-DrugBank.d289.s29.e1,DDI-DrugBank.d289.s29.e2,Patients using CYP3A4 metabolized drug0 should have cholesterol levels monitored after drug1 is initiated to see whether the drug2,False, 
DDI-DrugBank.d289.s30.e0,DDI-DrugBank.d289.s30.e1,drug1: Co-administration of drug2 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug0 (a CYP2C9 substrate) and drug0,False, 
DDI-DrugBank.d289.s30.e0,DDI-DrugBank.d289.s30.e2,drug1: Co-administration of drug0 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug2 (a CYP2C9 substrate) and drug0,False, 
DDI-DrugBank.d289.s30.e1,DDI-DrugBank.d289.s30.e2,drug0: Co-administration of drug1 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug2 (a CYP2C9 substrate) and drug0,True,mechanism
DDI-DrugBank.d289.s30.e1,DDI-DrugBank.d289.s30.e3,drug0: Co-administration of drug1 500 mg b.i.d. for 6 days decreased the plasma concentrations of both drug0 (a CYP2C9 substrate) and drug2,True,mechanism
DDI-DrugBank.d289.s31.e0,DDI-DrugBank.d289.s31.e1,"Clinical experience with concomitant administration of drug1 and drug2 in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or drug0 dose (baseline vs. end of the clinical studies), and the need to change the drug0 dose during the trials due to changes in INR or due to adverse events was similar among drug0",False, 
DDI-DrugBank.d289.s31.e0,DDI-DrugBank.d289.s31.e2,"Clinical experience with concomitant administration of drug1 and drug0 in patients with pulmonary arterial hypertension did not show clinically relevant changes in INR or drug2 dose (baseline vs. end of the clinical studies), and the need to change the drug0 dose during the trials due to changes in INR or due to adverse events was similar among drug0",False, 
DDI-DrugBank.d289.s32.e0,DDI-DrugBank.d289.s32.e1,"drug1, drug2 and drug0: drug0 has no significant pharmacokinetic interactions with drug0 and drug0, and drug0 has no significant effect on plasma levels of drug0",False, 
DDI-DrugBank.d289.s32.e0,DDI-DrugBank.d289.s32.e2,"drug1, drug0 and drug2: drug0 has no significant pharmacokinetic interactions with drug0 and drug0, and drug0 has no significant effect on plasma levels of drug0",False, 
DDI-DrugBank.d232.s0.e0,DDI-DrugBank.d232.s0.e1,"After multiple dosing, drug1 (drug2  30 mcg IM once weekly) reduced drug0",False, 
DDI-DrugBank.d232.s0.e0,DDI-DrugBank.d232.s0.e2,"After multiple dosing, drug1 (drug0  30 mcg IM once weekly) reduced drug2",True,mechanism
DDI-DrugBank.d232.s0.e1,DDI-DrugBank.d232.s0.e2,"After multiple dosing, drug0 (drug1  30 mcg IM once weekly) reduced drug2",True,mechanism
DDI-DrugBank.d232.s1.e0,DDI-DrugBank.d232.s1.e1,The similarity of the drug1 -associated adverse event profile between Study 1 (without co-administered drug2 ) and Study 2 (with co-administered drug0 ) indicates that this alteration in clearance does not necessitate reduction of the drug0,False, 
DDI-DrugBank.d232.s1.e0,DDI-DrugBank.d232.s1.e2,The similarity of the drug1 -associated adverse event profile between Study 1 (without co-administered drug0 ) and Study 2 (with co-administered drug2 ) indicates that this alteration in clearance does not necessitate reduction of the drug0,False, 
DDI-DrugBank.d232.s2.e0,DDI-DrugBank.d232.s2.e1,Results of studies in multiple sclerosis patients taking drug1  and concomitant drug2 (drug0  30 mcg IM once weekly) or drug0 were inconclusive with regard to the need for dose adjustment of the drug0 or drug0,False, 
DDI-DrugBank.d232.s2.e0,DDI-DrugBank.d232.s2.e2,Results of studies in multiple sclerosis patients taking drug1  and concomitant drug0 (drug2  30 mcg IM once weekly) or drug0 were inconclusive with regard to the need for dose adjustment of the drug0 or drug0,False, 
DDI-DrugBank.d202.s0.e0,DDI-DrugBank.d202.s0.e1,Steady-state serum concentrations of drug1 are reported to fluctuate significantly when drug2,True,mechanism
DDI-DrugBank.d202.s1.e0,DDI-DrugBank.d202.s1.e1,"Serious anticholinergic symptoms (severe dry mouth, urinary retention, blurred vision) have been associated with elevations in the serum levels of drug1 when drug2",True,effect
DDI-DrugBank.d202.s2.e0,DDI-DrugBank.d202.s2.e1,"In addition, higher-than expected steady-state serum concentrations of drug1 have been observed when therapy is initiated in patients already taking drug2",True,mechanism
DDI-DrugBank.d202.s3.e0,DDI-DrugBank.d202.s3.e1,"In well-controlled patients undergoing concurrent therapy with drug1, a decrease in the steady-state serum concentrations of drug2",True,mechanism
DDI-DrugBank.d202.s4.e0,DDI-DrugBank.d202.s4.e1,The therapeutic efficacy of drug1 may be compromised in these patients when drug2,True,effect
DDI-DrugBank.d202.s6.e0,DDI-DrugBank.d202.s6.e1,"There have been greater than 2-fold increases in previously stable plasma levels of other drug1, including drug2, when drug0",False, 
DDI-DrugBank.d202.s6.e0,DDI-DrugBank.d202.s6.e2,"There have been greater than 2-fold increases in previously stable plasma levels of other drug1, including drug0, when drug2",True,mechanism
DDI-DrugBank.d202.s6.e1,DDI-DrugBank.d202.s6.e2,"There have been greater than 2-fold increases in previously stable plasma levels of other drug0, including drug1, when drug2",True,mechanism
DDI-DrugBank.d202.s7.e0,DDI-DrugBank.d202.s7.e1,"drug1 and its active metabolite, norfluoxe-tine, have long half-lives (4 to 16 days for drug2",False, 
DDI-DrugBank.d202.s8.e0,DDI-DrugBank.d202.s8.e1,Administration of drug1 during therapy with a drug2,True,effect
DDI-DrugBank.d202.s9.e0,DDI-DrugBank.d202.s9.e1,Close supervision and careful adjustment of the dosage are required when drug1 is used with other drug2 or drug0,True,advise
DDI-DrugBank.d202.s9.e0,DDI-DrugBank.d202.s9.e2,Close supervision and careful adjustment of the dosage are required when drug1 is used with other drug0 or drug2,True,advise
DDI-DrugBank.d202.s9.e1,DDI-DrugBank.d202.s9.e2,Close supervision and careful adjustment of the dosage are required when drug0 is used with other drug1 or drug2,False, 
DDI-DrugBank.d202.s12.e0,DDI-DrugBank.d202.s12.e1,"Such individuals are referred to as  poor metabolizers  of drugs such as drug1, drug2, and the drug0",False, 
DDI-DrugBank.d202.s12.e0,DDI-DrugBank.d202.s12.e2,"Such individuals are referred to as  poor metabolizers  of drugs such as drug1, drug0, and the drug2",False, 
DDI-DrugBank.d202.s14.e0,DDI-DrugBank.d202.s14.e1,"In addition, certain drugs that are metabolized by this isoenzyme, including many drug1 (drug2, drug0",False, 
DDI-DrugBank.d202.s14.e0,DDI-DrugBank.d202.s14.e2,"In addition, certain drugs that are metabolized by this isoenzyme, including many drug1 (drug0, drug2",False, 
DDI-DrugBank.d202.s15.e0,DDI-DrugBank.d202.s15.e1,Concomitant use of drug1 with other drugs metabolized by cytochrome P450IID6 may require lower doses than usually prescribed for either the drug2,False, 
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e1,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug2, drug0, drug0, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e2,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug2, drug0, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e3,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug2, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e4,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug0, and drug2 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e5,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug0, and drug0 (eg, drug2, drug0, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e6,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug0, and drug0 (eg, drug0, drug2, and drug0), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e7,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug0, and drug0 (eg, drug0, drug0, and drug2), or that inhibit this enzyme (eg, drug0",True,advise
DDI-DrugBank.d202.s16.e0,DDI-DrugBank.d202.s16.e8,"Therefore, co-administration of drug1 with other drugs that are metabolized by this isoenzyme, including other drug0, drug0, drug0, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug2",True,advise
DDI-DrugBank.d202.s16.e1,DDI-DrugBank.d202.s16.e2,"Therefore, co-administration of drug0 with other drugs that are metabolized by this isoenzyme, including other drug1, drug2, drug0, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",False, 
DDI-DrugBank.d202.s16.e1,DDI-DrugBank.d202.s16.e3,"Therefore, co-administration of drug0 with other drugs that are metabolized by this isoenzyme, including other drug1, drug0, drug2, and drug0 (eg, drug0, drug0, and drug0), or that inhibit this enzyme (eg, drug0",False, 
DDI-DrugBank.d312.s1.e0,DDI-DrugBank.d312.s1.e1,"In Study 1, patients with colorectal cancer were given drug1/drug2/drug0 (bolus-IFL) with or without drug0",False, 
DDI-DrugBank.d312.s1.e0,DDI-DrugBank.d312.s1.e2,"In Study 1, patients with colorectal cancer were given drug1/drug0/drug2 (bolus-IFL) with or without drug0",False, 
DDI-DrugBank.d312.s2.e0,DDI-DrugBank.d312.s2.e1,drug1 concentrations were similar in patients receiving bolus-IFL alone and in combination with drug2,False, 
DDI-DrugBank.d312.s3.e0,DDI-DrugBank.d312.s3.e1,"The concentrations of drug1, the active metabolite of drug2, were on average 33% higher in patients receiving bolus-IFL in combination with drug0",False, 
DDI-DrugBank.d312.s3.e0,DDI-DrugBank.d312.s3.e2,"The concentrations of drug1, the active metabolite of drug0, were on average 33% higher in patients receiving bolus-IFL in combination with drug2",False, 
DDI-DrugBank.d312.s5.e0,DDI-DrugBank.d312.s5.e1,"Due to high inter-patient variability and limited sampling, the extent of the increase in drug1 levels in patients receiving concurrent drug2 and drug0",False, 
DDI-DrugBank.d312.s5.e0,DDI-DrugBank.d312.s5.e2,"Due to high inter-patient variability and limited sampling, the extent of the increase in drug1 levels in patients receiving concurrent drug0 and drug2",False, 
DDI-DrugBank.d220.s1.e0,DDI-DrugBank.d220.s1.e1,"There is one report of cardiopulmonary arrest, with full recovery, in a patient who was taking a drug1 (drug2",False, 
DDI-DrugBank.d220.s4.e0,DDI-DrugBank.d220.s4.e1,"Because of the danger of a potentially fatal prolongation of the QTc interval, drug1 must not be given simultaneously with or subsequent to drug2",True,advise
DDI-DrugBank.d220.s5.e0,DDI-DrugBank.d220.s5.e1,"Concomitant administration of drug1 and other related compounds (eg, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d220.s5.e0,DDI-DrugBank.d220.s5.e2,"Concomitant administration of drug1 and other related compounds (eg, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d220.s5.e0,DDI-DrugBank.d220.s5.e3,"Concomitant administration of drug1 and other related compounds (eg, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d220.s5.e1,DDI-DrugBank.d220.s5.e2,"Concomitant administration of drug0 and other related compounds (eg, drug1, drug2 and drug0",False, 
DDI-DrugBank.d220.s5.e1,DDI-DrugBank.d220.s5.e3,"Concomitant administration of drug0 and other related compounds (eg, drug1, drug0 and drug2",False, 
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e1,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug2 or drug0, drug0, drug0 or drug0, drug0 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e2,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug2, drug0, drug0 or drug0, drug0 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e3,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug0, drug2, drug0 or drug0, drug0 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e4,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug0, drug0, drug2 or drug0, drug0 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e5,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug0, drug0, drug0 or drug2, drug0 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e6,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug0, drug0, drug0 or drug0, drug2 and drug0",True,effect
DDI-DrugBank.d220.s9.e0,DDI-DrugBank.d220.s9.e7,"This appears to be the only clinically relevant interaction of this kind with drug1, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug0 or drug0, drug0, drug0 or drug0, drug0 and drug2",True,effect
DDI-DrugBank.d220.s9.e1,DDI-DrugBank.d220.s9.e2,"This appears to be the only clinically relevant interaction of this kind with drug0, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug1 or drug2, drug0, drug0 or drug0, drug0 and drug0",False, 
DDI-DrugBank.d220.s9.e1,DDI-DrugBank.d220.s9.e3,"This appears to be the only clinically relevant interaction of this kind with drug0, although theoretically, coadministration of other drugs known to alter cardiac conduction (eg, drug1 or drug0, drug2, drug0 or drug0, drug0 and drug0",False, 
DDI-DrugBank.d220.s11.e0,DDI-DrugBank.d220.s11.e1,"In patients taking an drug1 (eg, drug2, drug0, drug0 or drug0), the concomitant use of drug0 may reduce seizure control by lowering the plasma levels of the drug0",False, 
DDI-DrugBank.d220.s11.e0,DDI-DrugBank.d220.s11.e2,"In patients taking an drug1 (eg, drug0, drug2, drug0 or drug0), the concomitant use of drug0 may reduce seizure control by lowering the plasma levels of the drug0",False, 
DDI-DrugBank.d220.s11.e0,DDI-DrugBank.d220.s11.e5,"In patients taking an drug1 (eg, drug0, drug0, drug0 or drug0), the concomitant use of drug2 may reduce seizure control by lowering the plasma levels of the drug0",True,effect
DDI-DrugBank.d220.s11.e1,DDI-DrugBank.d220.s11.e5,"In patients taking an drug0 (eg, drug1, drug0, drug0 or drug0), the concomitant use of drug2 may reduce seizure control by lowering the plasma levels of the drug0",True,effect
DDI-DrugBank.d220.s11.e2,DDI-DrugBank.d220.s11.e5,"In patients taking an drug0 (eg, drug0, drug1, drug0 or drug0), the concomitant use of drug2 may reduce seizure control by lowering the plasma levels of the drug0",True,effect
DDI-DrugBank.d220.s11.e3,DDI-DrugBank.d220.s11.e5,"In patients taking an drug0 (eg, drug0, drug0, drug1 or drug0), the concomitant use of drug2 may reduce seizure control by lowering the plasma levels of the drug0",True,effect
DDI-DrugBank.d220.s11.e4,DDI-DrugBank.d220.s11.e5,"In patients taking an drug0 (eg, drug0, drug0, drug0 or drug1), the concomitant use of drug2 may reduce seizure control by lowering the plasma levels of the drug0",True,effect
DDI-DrugBank.d220.s13.e0,DDI-DrugBank.d220.s13.e1,When drug1 is taken concurrently with oral drug2,True,effect
DDI-DrugBank.d220.s16.e0,DDI-DrugBank.d220.s16.e1,"Nevertheless, the effects of drug1 on travelers receiving comedication, particularly diabetics or patients using drug2",True,advise
DDI-DrugBank.d220.s17.e0,DDI-DrugBank.d220.s17.e1,"In clinical trials, the concomitant administration of drug1 and drug2",False, 
DDI-DrugBank.d326.s0.e0,DDI-DrugBank.d326.s0.e1,drug1 - Taking drug2 and a drug0,False, 
DDI-DrugBank.d326.s0.e0,DDI-DrugBank.d326.s0.e2,drug1 - Taking drug0 and a drug2,False, 
DDI-DrugBank.d326.s0.e1,DDI-DrugBank.d326.s0.e2,drug0 - Taking drug1 and a drug2,True,effect
DDI-DrugBank.d326.s1.e0,DDI-DrugBank.d326.s1.e1,"drug1 (e.g., drug2) - Taking drug0 and drug0 together may decrease the effects of drug0",False, 
DDI-DrugBank.d326.s1.e0,DDI-DrugBank.d326.s1.e2,"drug1 (e.g., drug0) - Taking drug2 and drug0 together may decrease the effects of drug0",False, 
DDI-DrugBank.d326.s1.e2,DDI-DrugBank.d326.s1.e3,"drug0 (e.g., drug0) - Taking drug1 and drug2 together may decrease the effects of drug0",True,effect
DDI-DrugBank.d244.s0.e0,DDI-DrugBank.d244.s0.e1,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: drug1 (e.g., drug2, drug0), drug0, drug0, drug0 drugs (e.g., drug0), drug0, drug0",False, 
DDI-DrugBank.d244.s0.e0,DDI-DrugBank.d244.s0.e2,"Before using this medication, tell your doctor or pharmacist of all prescription and nonprescription products you may use, especially of: drug1 (e.g., drug0, drug2), drug0, drug0, drug0 drugs (e.g., drug0), drug0, drug0",False, 
DDI-DrugBank.d233.s0.e0,DDI-DrugBank.d233.s0.e1,Use with drug1: The principal pathway for detoxification of drug2 is inhibited by drug0,False, 
DDI-DrugBank.d233.s0.e0,DDI-DrugBank.d233.s0.e2,Use with drug1: The principal pathway for detoxification of drug0 is inhibited by drug2,False, 
DDI-DrugBank.d233.s0.e1,DDI-DrugBank.d233.s0.e2,Use with drug0: The principal pathway for detoxification of drug1 is inhibited by drug2,True,mechanism
DDI-DrugBank.d233.s1.e0,DDI-DrugBank.d233.s1.e1,Patients receiving drug1 and drug2 concomitantly should have a dose reduction of drug0,True,advise
DDI-DrugBank.d233.s1.e0,DDI-DrugBank.d233.s1.e2,Patients receiving drug1 and drug0 concomitantly should have a dose reduction of drug2,False, 
DDI-DrugBank.d233.s1.e1,DDI-DrugBank.d233.s1.e2,Patients receiving drug0 and drug1 concomitantly should have a dose reduction of drug2,False, 
DDI-DrugBank.d233.s3.e0,DDI-DrugBank.d233.s3.e1,Use with drug1: The use of drug2 to control hypertension in patients on drug0,False, 
DDI-DrugBank.d233.s3.e0,DDI-DrugBank.d233.s3.e2,Use with drug1: The use of drug0 to control hypertension in patients on drug2,False, 
DDI-DrugBank.d233.s3.e1,DDI-DrugBank.d233.s3.e2,Use with drug0: The use of drug1 to control hypertension in patients on drug2,True,effect
DDI-DrugBank.d455.s4.e0,DDI-DrugBank.d455.s4.e1,"In vitro studies have shown no binding displacement between drug1 and other highly bound drugs, such as drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d455.s4.e0,DDI-DrugBank.d455.s4.e2,"In vitro studies have shown no binding displacement between drug1 and other highly bound drugs, such as drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d455.s6.e0,DDI-DrugBank.d455.s6.e1,Treatment with drug1 coadministered with drug2/drug0,False, 
DDI-DrugBank.d455.s6.e0,DDI-DrugBank.d455.s6.e2,Treatment with drug1 coadministered with drug0/drug2,False, 
DDI-DrugBank.d455.s7.e0,DDI-DrugBank.d455.s7.e1,No interaction was noted with the drug1 drug2 in two multiple-dose interaction studies when drug0 was coadministered with a drug0/drug0,False, 
DDI-DrugBank.d455.s7.e0,DDI-DrugBank.d455.s7.e2,No interaction was noted with the drug1 drug0 in two multiple-dose interaction studies when drug2 was coadministered with a drug0/drug0,False, 
DDI-DrugBank.d455.s8.e0,DDI-DrugBank.d455.s8.e1,More than 600 Parkinsons disease patients in clinical trials have used drug1 in combination with drug2 and drug0/drug0,False, 
DDI-DrugBank.d455.s8.e0,DDI-DrugBank.d455.s8.e2,More than 600 Parkinsons disease patients in clinical trials have used drug1 in combination with drug0 and drug2/drug0,False, 
DDI-DrugBank.d455.s9.e0,DDI-DrugBank.d455.s9.e1,"As most drug1 excretion is via the bile, caution should be exercised when drugs known to interfere with biliary excretion, glucuronidation, and intestinal beta-glucuronidase are given concurrently with drug2",False, 
DDI-DrugBank.d455.s10.e0,DDI-DrugBank.d455.s10.e1,"These include drug1, drug2, and some drug0 (e.g. drug0, rifamipicin, drug0 and drug0",False, 
DDI-DrugBank.d455.s10.e0,DDI-DrugBank.d455.s10.e2,"These include drug1, drug0, and some drug2 (e.g. drug0, rifamipicin, drug0 and drug0",False, 
DDI-DrugBank.d455.s11.e0,DDI-DrugBank.d455.s11.e1,No interaction with the drug1 drug2 was shown in a single-dose study with drug0 without coadministered drug0/drug0,False, 
DDI-DrugBank.d455.s11.e0,DDI-DrugBank.d455.s11.e2,No interaction with the drug1 drug0 was shown in a single-dose study with drug2 without coadministered drug0/drug0,False, 
DDI-DrugBank.d381.s0.e0,DDI-DrugBank.d381.s0.e1,drug1  (drug2) has been reported to produce ANTABUSE-like side effects when given concomitantly with drug0,False, 
DDI-DrugBank.d381.s0.e0,DDI-DrugBank.d381.s0.e2,drug1  (drug0) has been reported to produce ANTABUSE-like side effects when given concomitantly with drug2,True,effect
DDI-DrugBank.d381.s0.e1,DDI-DrugBank.d381.s0.e2,drug0  (drug1) has been reported to produce ANTABUSE-like side effects when given concomitantly with drug2,True,effect
DDI-DrugBank.d381.s2.e0,DDI-DrugBank.d381.s2.e1,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drug1 and drug2, it is suggested that the prothrombin time be monitored carefully, and the dose of drug0 or other drug0",True,advise
DDI-DrugBank.d381.s2.e0,DDI-DrugBank.d381.s2.e2,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drug1 and drug0, it is suggested that the prothrombin time be monitored carefully, and the dose of drug2 or other drug0",False, 
DDI-DrugBank.d381.s2.e0,DDI-DrugBank.d381.s2.e3,"Because of reports of prolongation of the prothrombin time beyond the therapeutic range in patients taking concurrent drug1 and drug0, it is suggested that the prothrombin time be monitored carefully, and the dose of drug0 or other drug2",False, 
DDI-DrugBank.d141.s0.e0,DDI-DrugBank.d141.s0.e1,"drug1, drug2, drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d141.s0.e0,DDI-DrugBank.d141.s0.e2,"drug1, drug0, drug2 (drug0, drug0, drug0",False, 
DDI-DrugBank.d141.s1.e0,DDI-DrugBank.d141.s1.e1,drug1 (drug2): drug0 plasma concentrations were not affected by co-administration of drug0,False, 
DDI-DrugBank.d141.s1.e0,DDI-DrugBank.d141.s1.e2,drug1 (drug0): drug2 plasma concentrations were not affected by co-administration of drug0,False, 
DDI-DrugBank.d141.s2.e0,DDI-DrugBank.d141.s2.e1,drug1: drug2 plasma concentrations were not affected by co-administration of drug0,False, 
DDI-DrugBank.d141.s2.e0,DDI-DrugBank.d141.s2.e2,drug1: drug0 plasma concentrations were not affected by co-administration of drug2,False, 
DDI-DrugBank.d141.s3.e0,DDI-DrugBank.d141.s3.e1,drug1: The influence of the bile-acidsequestering agent drug2 on the pharmacokinetits of drug0,False, 
DDI-DrugBank.d141.s3.e0,DDI-DrugBank.d141.s3.e2,drug1: The influence of the bile-acidsequestering agent drug0 on the pharmacokinetits of drug2,False, 
DDI-DrugBank.d141.s4.e0,DDI-DrugBank.d141.s4.e1,"In the first study, concomitant administration of 0.2 mg drug1 and 12 g drug2 resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing drug0",True,mechanism
DDI-DrugBank.d141.s4.e0,DDI-DrugBank.d141.s4.e2,"In the first study, concomitant administration of 0.2 mg drug1 and 12 g drug0 resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing drug2",False, 
DDI-DrugBank.d141.s4.e1,DDI-DrugBank.d141.s4.e2,"In the first study, concomitant administration of 0.2 mg drug0 and 12 g drug1 resulted in decreases of more than 22% for AUC and 40% for Cmax when compared to dosing drug2",False, 
DDI-DrugBank.d141.s5.e0,DDI-DrugBank.d141.s5.e1,"However, in the second study, administration of 12 g drug1 1 hour before the evening meal and 0.3 mg drug2 approximately 4 hours after the same evening meal resulted in a decrease in the drug0 AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing drug0",True,mechanism
DDI-DrugBank.d141.s5.e0,DDI-DrugBank.d141.s5.e2,"However, in the second study, administration of 12 g drug1 1 hour before the evening meal and 0.3 mg drug0 approximately 4 hours after the same evening meal resulted in a decrease in the drug2 AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing drug0",False, 
DDI-DrugBank.d141.s5.e0,DDI-DrugBank.d141.s5.e3,"However, in the second study, administration of 12 g drug1 1 hour before the evening meal and 0.3 mg drug0 approximately 4 hours after the same evening meal resulted in a decrease in the drug0 AUC of less than 8%, and a decrease in Cmax of about 30% when compared to dosing drug2",False, 
DDI-DrugBank.d141.s6.e0,DDI-DrugBank.d141.s6.e1,"Therefore, it would be expected that a dosing schedule of drug1 given at bedtime and drug2 given before the evening meal would not result in a significant decrease in the clinical effect of drug0",False, 
DDI-DrugBank.d141.s6.e0,DDI-DrugBank.d141.s6.e2,"Therefore, it would be expected that a dosing schedule of drug1 given at bedtime and drug0 given before the evening meal would not result in a significant decrease in the clinical effect of drug2",False, 
DDI-DrugBank.d141.s7.e0,DDI-DrugBank.d141.s7.e1,drug1: Plasma drug2 levels and drug0 clearance at steady-state were not affected by co-administration of 0.2 mg drug0,False, 
DDI-DrugBank.d141.s7.e0,DDI-DrugBank.d141.s7.e2,drug1: Plasma drug0 levels and drug2 clearance at steady-state were not affected by co-administration of 0.2 mg drug0,False, 
DDI-DrugBank.d141.s8.e0,DDI-DrugBank.d141.s8.e1,drug1 plasma concentrations were also not affected by co-administration of drug2,False, 
DDI-DrugBank.d141.s9.e0,DDI-DrugBank.d141.s9.e1,drug1: Co- administration of drug2 and drug0 to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of drug0,False, 
DDI-DrugBank.d141.s9.e0,DDI-DrugBank.d141.s9.e2,drug1: Co- administration of drug0 and drug2 to healthy volunteers did not result in any changes in prothrombin time or clotting factor VII when compared to co-administration of drug0,False, 
DDI-DrugBank.d141.s10.e0,DDI-DrugBank.d141.s10.e1,The AUC and Cmax of both the (R) and (S) isomers of drug1 were unaffected by concurrent dosing of 0.3 mg drug2,False, 
DDI-DrugBank.d141.s11.e0,DDI-DrugBank.d141.s11.e1,Co-administration of drug1 and drug2 did not alter the pharmacokinetics of drug0,False, 
DDI-DrugBank.d141.s11.e0,DDI-DrugBank.d141.s11.e2,Co-administration of drug1 and drug0 did not alter the pharmacokinetics of drug2,False, 
DDI-DrugBank.d141.s12.e0,DDI-DrugBank.d141.s12.e1,"drug1: In hypercholesterolemic patients, steady-state drug2 AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of drug0",False, 
DDI-DrugBank.d141.s12.e0,DDI-DrugBank.d141.s12.e2,"drug1: In hypercholesterolemic patients, steady-state drug0 AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of drug2",False, 
DDI-DrugBank.d141.s12.e1,DDI-DrugBank.d141.s12.e2,"drug0: In hypercholesterolemic patients, steady-state drug1 AUC and Cmax increased approximately 50% and 24% respectively after 10 days with co-administration of drug2",True,mechanism
DDI-DrugBank.d141.s13.e0,DDI-DrugBank.d141.s13.e1,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, drug1 was used concomitantly with drug2, drug0, drug0, drug0, and drug0 (drug0",False, 
DDI-DrugBank.d141.s13.e0,DDI-DrugBank.d141.s13.e2,"OTHER CONCOMITANT THERAPY: Although specific interaction studies were not performed, in clinical studies, drug1 was used concomitantly with drug0, drug2, drug0, drug0, and drug0 (drug0",False, 
DDI-DrugBank.d28.s1.e0,DDI-DrugBank.d28.s1.e1,"Results from existing clinical trials suggest no significant interactions between drug1  and other therapies commonly used in MS patients, including the concurrent use of drug2",False, 
DDI-DrugBank.d28.s2.e0,DDI-DrugBank.d28.s2.e1,drug1  has not been formally evaluated in combination with drug2,False, 
DDI-DrugBank.d28.s3.e0,DDI-DrugBank.d28.s3.e1,"However, 10 patients who switched from therapy with drug1 to drug2",False, 
DDI-DrugBank.d48.s0.e0,DDI-DrugBank.d48.s0.e1,Drugs that may increase drug1 plasma concentrations CYP3A4 Inhibitors: drug2,False, 
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e1,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e2,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e3,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e4,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e5,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e6,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e7,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e8,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e9,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e10,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e11,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2) may increase exposure to drug0",True,mechanism
DDI-DrugBank.d48.s1.e0,DDI-DrugBank.d48.s1.e12,"Concomitant use of drug1 and drugs that inhibit CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug2",False, 
DDI-DrugBank.d48.s1.e1,DDI-DrugBank.d48.s1.e2,"Concomitant use of drug0 and drugs that inhibit CYP3A4 (eg, drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0) may increase exposure to drug0",False, 
DDI-DrugBank.d48.s2.e0,DDI-DrugBank.d48.s2.e1,"In patients receiving treatment with drug1, close monitoring for toxicity and a drug2",False, 
DDI-DrugBank.d48.s3.e0,DDI-DrugBank.d48.s3.e1,Drugs that may decrease drug1 plasma concentrations CYP3A4 Inducers: Drugs that induce CYP3A4 activity may decrease drug2,False, 
DDI-DrugBank.d48.s4.e0,DDI-DrugBank.d48.s4.e1,"In patients in whom CYP3A4 inducers (eg, drug1, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d48.s4.e0,DDI-DrugBank.d48.s4.e2,"In patients in whom CYP3A4 inducers (eg, drug1, drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d48.s5.e0,DDI-DrugBank.d48.s5.e1,"If drug1 must be administered with a CYP3A4 inducer, a dose increase in drug2",False, 
DDI-DrugBank.d48.s8.e0,DDI-DrugBank.d48.s8.e1,drug1: Nonclinical data demonstrate that the solubility of drug2,False, 
DDI-DrugBank.d48.s9.e0,DDI-DrugBank.d48.s9.e1,Simultaneous administration of drug1 with drug2,True,advise
DDI-DrugBank.d48.s10.e0,DDI-DrugBank.d48.s10.e1,"If drug1 therapy is needed, the antacid dose should be administered at least 2 hours prior to or 2 hours after the dose of drug2",True,advise
DDI-DrugBank.d48.s11.e0,DDI-DrugBank.d48.s11.e1,"drug1/drug2: Long-term suppression of gastric acid secretion by drug0 or drug0 (eg, drug0 and drug0) is likely to reduce drug0",False, 
DDI-DrugBank.d48.s11.e0,DDI-DrugBank.d48.s11.e2,"drug1/drug0: Long-term suppression of gastric acid secretion by drug2 or drug0 (eg, drug0 and drug0) is likely to reduce drug0",False, 
DDI-DrugBank.d48.s11.e2,DDI-DrugBank.d48.s11.e6,"drug0/drug0: Long-term suppression of gastric acid secretion by drug1 or drug0 (eg, drug0 and drug0) is likely to reduce drug2",True,effect
DDI-DrugBank.d48.s11.e3,DDI-DrugBank.d48.s11.e6,"drug0/drug0: Long-term suppression of gastric acid secretion by drug0 or drug1 (eg, drug0 and drug0) is likely to reduce drug2",True,effect
DDI-DrugBank.d48.s11.e4,DDI-DrugBank.d48.s11.e6,"drug0/drug0: Long-term suppression of gastric acid secretion by drug0 or drug0 (eg, drug1 and drug0) is likely to reduce drug2",True,effect
DDI-DrugBank.d48.s11.e5,DDI-DrugBank.d48.s11.e6,"drug0/drug0: Long-term suppression of gastric acid secretion by drug0 or drug0 (eg, drug0 and drug1) is likely to reduce drug2",True,effect
DDI-DrugBank.d48.s12.e0,DDI-DrugBank.d48.s12.e1,The concomitant use of drug1 or drug2 with drug0,False, 
DDI-DrugBank.d48.s12.e0,DDI-DrugBank.d48.s12.e2,The concomitant use of drug1 or drug0 with drug2,True,advise
DDI-DrugBank.d48.s12.e1,DDI-DrugBank.d48.s12.e2,The concomitant use of drug0 or drug1 with drug2,True,advise
DDI-DrugBank.d48.s13.e0,DDI-DrugBank.d48.s13.e1,The use of drug1 should be considered in place of drug2 or drug0 in patients receiving drug0,False, 
DDI-DrugBank.d48.s13.e0,DDI-DrugBank.d48.s13.e2,The use of drug1 should be considered in place of drug0 or drug2 in patients receiving drug0,False, 
DDI-DrugBank.d48.s13.e1,DDI-DrugBank.d48.s13.e3,The use of drug0 should be considered in place of drug1 or drug0 in patients receiving drug2,True,advise
DDI-DrugBank.d48.s13.e2,DDI-DrugBank.d48.s13.e3,The use of drug0 should be considered in place of drug0 or drug1 in patients receiving drug2,True,advise
DDI-DrugBank.d48.s14.e0,DDI-DrugBank.d48.s14.e1,Drugs that may have their plasma concentration altered by drug1 CYP3A4 Substrates: drug2,False, 
DDI-DrugBank.d48.s15.e0,DDI-DrugBank.d48.s15.e1,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug0",False, 
DDI-DrugBank.d48.s15.e0,DDI-DrugBank.d48.s15.e2,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug0",False, 
DDI-DrugBank.d48.s15.e0,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e1,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e2,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e3,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e4,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e5,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e6,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e7,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e8,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e9,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, or drug0 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e10,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug1 (drug0, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e11,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug1, drug0) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d48.s15.e12,DDI-DrugBank.d48.s15.e13,"Therefore, CYP3A4 substrates known to have a narrow therapeutic index such as drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0 (drug0, drug1) should be administered with caution in patients receiving drug2",True,advise
DDI-DrugBank.d106.s0.e0,DDI-DrugBank.d106.s0.e1,A 30 to 45% increase in AUC and Cmax of drug1 was observed with concomitant administration of drug2,True,mechanism
DDI-DrugBank.d106.s1.e0,DDI-DrugBank.d106.s1.e1,drug1 150 mg twice daily did not interact significantly with drug2,False, 
DDI-DrugBank.d106.s3.e0,DDI-DrugBank.d106.s3.e1,Coadministration of drug1 with 40 mg drug2 tablets in epileptic patients lowered the drug0,True,mechanism
DDI-DrugBank.d106.s3.e0,DDI-DrugBank.d106.s3.e2,Coadministration of drug1 with 40 mg drug0 tablets in epileptic patients lowered the drug2,False, 
DDI-DrugBank.d106.s3.e1,DDI-DrugBank.d106.s3.e2,Coadministration of drug0 with 40 mg drug1 tablets in epileptic patients lowered the drug2,False, 
DDI-DrugBank.d106.s4.e0,DDI-DrugBank.d106.s4.e1,Coadministration of drug1 with drug2 or any known CYP3A4 inducer should be avoided and alternative drug0,True,advise
DDI-DrugBank.d106.s4.e0,DDI-DrugBank.d106.s4.e2,Coadministration of drug1 with drug0 or any known CYP3A4 inducer should be avoided and alternative drug2,False, 
DDI-DrugBank.d106.s4.e1,DDI-DrugBank.d106.s4.e2,Coadministration of drug0 with drug1 or any known CYP3A4 inducer should be avoided and alternative drug2,False, 
DDI-DrugBank.d106.s5.e0,DDI-DrugBank.d106.s5.e1,"Pharmacokinetic interactions between drug1 and drug2 (drug0, drug0",False, 
DDI-DrugBank.d106.s5.e0,DDI-DrugBank.d106.s5.e2,"Pharmacokinetic interactions between drug1 and drug0 (drug2, drug0",False, 
DDI-DrugBank.d106.s6.e0,DDI-DrugBank.d106.s6.e1,drug1 attenuated the heart rate increase following administration of immediate release drug2,True,effect
DDI-DrugBank.d106.s7.e0,DDI-DrugBank.d106.s7.e1,The blood pressure effect of drug1 tended to be greater in patients on drug2 than in patients on no other drug0,True,effect
DDI-DrugBank.d106.s7.e0,DDI-DrugBank.d106.s7.e2,The blood pressure effect of drug1 tended to be greater in patients on drug0 than in patients on no other drug2,False, 
DDI-DrugBank.d106.s7.e1,DDI-DrugBank.d106.s7.e2,The blood pressure effect of drug0 tended to be greater in patients on drug1 than in patients on no other drug2,False, 
DDI-DrugBank.d106.s8.e0,DDI-DrugBank.d106.s8.e1,drug1 at 648 mg bid decreased the bioavailability (AUC) of drug2,True,mechanism
DDI-DrugBank.d106.s9.e0,DDI-DrugBank.d106.s9.e1,"The immediate release, but not the coat-core formulation of drug1 increased plasma drug2",True,mechanism
DDI-DrugBank.d106.s11.e0,DDI-DrugBank.d106.s11.e1,No significant interactions were found between drug1 and drug2 or drug0,False, 
DDI-DrugBank.d106.s11.e0,DDI-DrugBank.d106.s11.e2,No significant interactions were found between drug1 and drug0 or drug2,False, 
DDI-DrugBank.d354.s1.e0,DDI-DrugBank.d354.s1.e1,"Therefore, caution should be used when administering drug1 concurrently with other highly plasma protein-bound drugs with narrow therapeutic indices, as competition for binding sites may occur (e.g., drug2",True,mechanism
DDI-DrugBank.d554.s0.e0,DDI-DrugBank.d554.s0.e1,"Certain drug1, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d554.s0.e0,DDI-DrugBank.d554.s0.e2,"Certain drug1, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d229.s0.e0,DDI-DrugBank.d229.s0.e1,Drug Interaction During Pregnancy: drug1 and drug2,False, 
DDI-DrugBank.d229.s3.e0,DDI-DrugBank.d229.s3.e1,The addition of 540 mg/kg/day of drug1 (approximately 340 times the maximum recommended daily inhalation dose in adults on a mg/m2 basis) to 2.7 mg/kg/day of drug2,True,effect
DDI-DrugBank.d440.s0.e0,DDI-DrugBank.d440.s0.e1,drug1 Supplements/drug2,False, 
DDI-DrugBank.d440.s1.e0,DDI-DrugBank.d440.s1.e1,"Products containing drug1 and other multivalent cations (such as drug2, drug0, drug0) are likely to interfere with absorption of drug0",False, 
DDI-DrugBank.d440.s1.e0,DDI-DrugBank.d440.s1.e2,"Products containing drug1 and other multivalent cations (such as drug0, drug2, drug0) are likely to interfere with absorption of drug0",False, 
DDI-DrugBank.d440.s1.e0,DDI-DrugBank.d440.s1.e4,"Products containing drug1 and other multivalent cations (such as drug0, drug0, drug0) are likely to interfere with absorption of drug2",True,mechanism
DDI-DrugBank.d440.s1.e1,DDI-DrugBank.d440.s1.e4,"Products containing drug0 and other multivalent cations (such as drug1, drug0, drug0) are likely to interfere with absorption of drug2",True,mechanism
DDI-DrugBank.d440.s1.e2,DDI-DrugBank.d440.s1.e4,"Products containing drug0 and other multivalent cations (such as drug0, drug1, drug0) are likely to interfere with absorption of drug2",True,mechanism
DDI-DrugBank.d440.s1.e3,DDI-DrugBank.d440.s1.e4,"Products containing drug0 and other multivalent cations (such as drug0, drug0, drug1) are likely to interfere with absorption of drug2",True,mechanism
DDI-DrugBank.d440.s2.e0,DDI-DrugBank.d440.s2.e1,"drug1 should be taken at least 60 minutes before any oral medications containing multivalent cations (including drug2, supplements or drug0",True,advise
DDI-DrugBank.d440.s2.e0,DDI-DrugBank.d440.s2.e2,"drug1 should be taken at least 60 minutes before any oral medications containing multivalent cations (including drug0, supplements or drug2",True,advise
DDI-DrugBank.d440.s2.e1,DDI-DrugBank.d440.s2.e2,"drug0 should be taken at least 60 minutes before any oral medications containing multivalent cations (including drug1, supplements or drug2",False, 
DDI-DrugBank.d440.s3.e0,DDI-DrugBank.d440.s3.e1,drug1 and drug2 (drug0,False, 
DDI-DrugBank.d440.s3.e0,DDI-DrugBank.d440.s3.e2,drug1 and drug0 (drug2,False, 
DDI-DrugBank.d440.s4.e0,DDI-DrugBank.d440.s4.e1,"Of over 3500 patients enrolled in the drug1 osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily drug2 and drug0",False, 
DDI-DrugBank.d440.s4.e0,DDI-DrugBank.d440.s4.e2,"Of over 3500 patients enrolled in the drug1 osteoporosis Treatment and Prevention Studies, 15% used anti-peptic agents (primarily drug0 and drug2",False, 
DDI-DrugBank.d440.s7.e0,DDI-DrugBank.d440.s7.e1,"Among these patients, the incidence of upper gastrointestinal adverse experiences in the patients treated with drug1 150 mg once monthly was similar to that in patients treated with drug2",False, 
DDI-DrugBank.d440.s8.e0,DDI-DrugBank.d440.s8.e1,drug1/drug2s (drug0,False, 
DDI-DrugBank.d440.s8.e0,DDI-DrugBank.d440.s8.e2,drug1/drug0s (drug2,False, 
DDI-DrugBank.d440.s9.e0,DDI-DrugBank.d440.s9.e1,"In the large, placebo-controlled osteoporosis Treatment Study, drug1 and drug2",False, 
DDI-DrugBank.d440.s10.e0,DDI-DrugBank.d440.s10.e1,"Among drug1 or drug2 users, the incidence of upper gastrointestinal adverse events in patients treated with drug0",False, 
DDI-DrugBank.d440.s10.e0,DDI-DrugBank.d440.s10.e2,"Among drug1 or drug0 users, the incidence of upper gastrointestinal adverse events in patients treated with drug2",False, 
DDI-DrugBank.d440.s11.e0,DDI-DrugBank.d440.s11.e1,"Similarly, in the 1-year monthly comparison study, drug1 and drug2",False, 
DDI-DrugBank.d440.s12.e0,DDI-DrugBank.d440.s12.e1,The incidence of upper gastrointestinal events in patients concomitantly taking drug1 or drug2 was similar in patients taking drug0,False, 
DDI-DrugBank.d440.s12.e0,DDI-DrugBank.d440.s12.e2,The incidence of upper gastrointestinal events in patients concomitantly taking drug1 or drug0 was similar in patients taking drug2,False, 
DDI-DrugBank.d440.s13.e0,DDI-DrugBank.d440.s13.e1,"However, since drug1, drug2, and drug0 are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of drug0 or drug0 with drug0",False, 
DDI-DrugBank.d440.s13.e0,DDI-DrugBank.d440.s13.e2,"However, since drug1, drug0, and drug2 are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of drug0 or drug0 with drug0",False, 
DDI-DrugBank.d440.s13.e3,DDI-DrugBank.d440.s13.e5,"However, since drug0, drug0, and drug0 are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of drug1 or drug0 with drug2",True,advise
DDI-DrugBank.d440.s13.e4,DDI-DrugBank.d440.s13.e5,"However, since drug0, drug0, and drug0 are all associated with gastrointestinal irritation, caution should be exercised in the concomitant use of drug0 or drug1 with drug2",True,advise
DDI-DrugBank.d460.s1.e0,DDI-DrugBank.d460.s1.e1,drug1 is a potential inhibitor of the CYP2C9 isoenzyme in vivo as indicated by its ability to inhibit the in vitro metabolism of drug2,True,mechanism
DDI-DrugBank.d460.s3.e0,DDI-DrugBank.d460.s3.e1,"drug1: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg drug2 three times a day before meals for 1 day in combination with drug0",False, 
DDI-DrugBank.d460.s3.e0,DDI-DrugBank.d460.s3.e2,"drug1: In a randomized, multiple-dose crossover study, patients with Type 2 diabetes were administered 120 mg drug0 three times a day before meals for 1 day in combination with drug2",False, 
DDI-DrugBank.d460.s5.e0,DDI-DrugBank.d460.s5.e1,drug1: When drug2 120 mg three times daily before meals was administered in combination with drug0,False, 
DDI-DrugBank.d460.s5.e0,DDI-DrugBank.d460.s5.e2,drug1: When drug0 120 mg three times daily before meals was administered in combination with drug2,False, 
DDI-DrugBank.d460.s6.e0,DDI-DrugBank.d460.s6.e1,drug1: When drug2 120 mg before meals was administered in combination with a single 1-mg dose of drug0,False, 
DDI-DrugBank.d460.s6.e0,DDI-DrugBank.d460.s6.e2,drug1: When drug0 120 mg before meals was administered in combination with a single 1-mg dose of drug2,False, 
DDI-DrugBank.d460.s7.e0,DDI-DrugBank.d460.s7.e1,drug1: When healthy subjects were administered drug2 120 mg three times daily before meals for four days in combination with a single dose of drug0,False, 
DDI-DrugBank.d460.s7.e0,DDI-DrugBank.d460.s7.e2,drug1: When healthy subjects were administered drug0 120 mg three times daily before meals for four days in combination with a single dose of drug2,False, 
DDI-DrugBank.d460.s9.e0,DDI-DrugBank.d460.s9.e1,drug1: Administration of morning and lunch doses of drug2 120 mg in combination with a single 75-mg dose of drug0,False, 
DDI-DrugBank.d460.s9.e0,DDI-DrugBank.d460.s9.e2,drug1: Administration of morning and lunch doses of drug0 120 mg in combination with a single 75-mg dose of drug2,False, 
DDI-DrugBank.d460.s11.e0,DDI-DrugBank.d460.s11.e1,"In vitro displacement studies with highly protein-bound drugs such as drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0 showed no influence on the extent of drug0",False, 
DDI-DrugBank.d460.s11.e0,DDI-DrugBank.d460.s11.e2,"In vitro displacement studies with highly protein-bound drugs such as drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0 showed no influence on the extent of drug0",False, 
DDI-DrugBank.d460.s12.e0,DDI-DrugBank.d460.s12.e1,"Similarly, drug1 had no influence on the serum protein binding of drug2, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d460.s12.e0,DDI-DrugBank.d460.s12.e2,"Similarly, drug1 had no influence on the serum protein binding of drug0, drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d460.s14.e0,DDI-DrugBank.d460.s14.e1,"Certain drugs, including drug1 (drug2), drug0, drug0, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug0",False, 
DDI-DrugBank.d460.s14.e0,DDI-DrugBank.d460.s14.e2,"Certain drugs, including drug1 (drug0), drug2, drug0, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug0",False, 
DDI-DrugBank.d460.s14.e0,DDI-DrugBank.d460.s14.e5,"Certain drugs, including drug1 (drug0), drug0, drug0, and drug0 may potentiate the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s14.e0,DDI-DrugBank.d460.s14.e6,"Certain drugs, including drug1 (drug0), drug0, drug0, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s14.e1,DDI-DrugBank.d460.s14.e5,"Certain drugs, including drug0 (drug1), drug0, drug0, and drug0 may potentiate the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s14.e1,DDI-DrugBank.d460.s14.e6,"Certain drugs, including drug0 (drug1), drug0, drug0, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s14.e2,DDI-DrugBank.d460.s14.e5,"Certain drugs, including drug0 (drug0), drug1, drug0, and drug0 may potentiate the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s14.e2,DDI-DrugBank.d460.s14.e6,"Certain drugs, including drug0 (drug0), drug1, drug0, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s14.e3,DDI-DrugBank.d460.s14.e5,"Certain drugs, including drug0 (drug0), drug0, drug1, and drug0 may potentiate the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s14.e3,DDI-DrugBank.d460.s14.e6,"Certain drugs, including drug0 (drug0), drug0, drug1, and drug0 may potentiate the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s14.e4,DDI-DrugBank.d460.s14.e5,"Certain drugs, including drug0 (drug0), drug0, drug0, and drug1 may potentiate the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s14.e4,DDI-DrugBank.d460.s14.e6,"Certain drugs, including drug0 (drug0), drug0, drug0, and drug1 may potentiate the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s15.e0,DDI-DrugBank.d460.s15.e1,"Certain drugs including drug1, drug2, drug0, and drug0 may reduce the hypoglycemic action of drug0 and other oral drug0",False, 
DDI-DrugBank.d460.s15.e0,DDI-DrugBank.d460.s15.e2,"Certain drugs including drug1, drug0, drug2, and drug0 may reduce the hypoglycemic action of drug0 and other oral drug0",False, 
DDI-DrugBank.d460.s15.e0,DDI-DrugBank.d460.s15.e4,"Certain drugs including drug1, drug0, drug0, and drug0 may reduce the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s15.e0,DDI-DrugBank.d460.s15.e5,"Certain drugs including drug1, drug0, drug0, and drug0 may reduce the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s15.e1,DDI-DrugBank.d460.s15.e4,"Certain drugs including drug0, drug1, drug0, and drug0 may reduce the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s15.e1,DDI-DrugBank.d460.s15.e5,"Certain drugs including drug0, drug1, drug0, and drug0 may reduce the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s15.e2,DDI-DrugBank.d460.s15.e4,"Certain drugs including drug0, drug0, drug1, and drug0 may reduce the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s15.e2,DDI-DrugBank.d460.s15.e5,"Certain drugs including drug0, drug0, drug1, and drug0 may reduce the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d460.s15.e3,DDI-DrugBank.d460.s15.e4,"Certain drugs including drug0, drug0, drug0, and drug1 may reduce the hypoglycemic action of drug2 and other oral drug0",True,effect
DDI-DrugBank.d460.s15.e3,DDI-DrugBank.d460.s15.e5,"Certain drugs including drug0, drug0, drug0, and drug1 may reduce the hypoglycemic action of drug0 and other oral drug2",True,effect
DDI-DrugBank.d373.s0.e0,DDI-DrugBank.d373.s0.e1,drug1: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of drug2 and drug0,False, 
DDI-DrugBank.d373.s0.e0,DDI-DrugBank.d373.s0.e2,drug1: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of drug0 and drug2,False, 
DDI-DrugBank.d373.s0.e1,DDI-DrugBank.d373.s0.e2,drug0: Experience in over 1400 patients in a non-comparative clinical trial has shown that concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d373.s1.e0,DDI-DrugBank.d373.s1.e1,Long Acting drug1: drug2 may be safely co-administered with drug0,False, 
DDI-DrugBank.d373.s1.e0,DDI-DrugBank.d373.s1.e2,Long Acting drug1: drug0 may be safely co-administered with drug2,False, 
DDI-DrugBank.d373.s2.e0,DDI-DrugBank.d373.s2.e1,"drug1: Immediate Release Capsules: Since there have been isolated reports of patients with elevated drug2 levels, and there is a possible interaction between drug0 and drug0, it is recommended that drug0 levels be monitored when initiating, adjusting, and discontinuing drug0",False, 
DDI-DrugBank.d373.s2.e0,DDI-DrugBank.d373.s2.e2,"drug1: Immediate Release Capsules: Since there have been isolated reports of patients with elevated drug0 levels, and there is a possible interaction between drug2 and drug0, it is recommended that drug0 levels be monitored when initiating, adjusting, and discontinuing drug0",False, 
DDI-DrugBank.d373.s2.e2,DDI-DrugBank.d373.s2.e3,"drug0: Immediate Release Capsules: Since there have been isolated reports of patients with elevated drug0 levels, and there is a possible interaction between drug1 and drug2, it is recommended that drug0 levels be monitored when initiating, adjusting, and discontinuing drug0",True,int
DDI-DrugBank.d373.s2.e4,DDI-DrugBank.d373.s2.e5,"drug0: Immediate Release Capsules: Since there have been isolated reports of patients with elevated drug0 levels, and there is a possible interaction between drug0 and drug0, it is recommended that drug1 levels be monitored when initiating, adjusting, and discontinuing drug2",True,advise
DDI-DrugBank.d373.s3.e0,DDI-DrugBank.d373.s3.e1,Extended Release Tablets: Administration of drug1 with drug2 increased drug0,False, 
DDI-DrugBank.d373.s3.e0,DDI-DrugBank.d373.s3.e2,Extended Release Tablets: Administration of drug1 with drug0 increased drug2,False, 
DDI-DrugBank.d373.s3.e1,DDI-DrugBank.d373.s3.e2,Extended Release Tablets: Administration of drug0 with drug1 increased drug2,True,mechanism
DDI-DrugBank.d373.s7.e0,DDI-DrugBank.d373.s7.e1,"Since there have been isolated reports of patients with elevated drug1 levels, it is recommended that drug2 levels be monitored when initiating, adjusting, and discontinuing drug0",False, 
DDI-DrugBank.d373.s7.e0,DDI-DrugBank.d373.s7.e2,"Since there have been isolated reports of patients with elevated drug1 levels, it is recommended that drug0 levels be monitored when initiating, adjusting, and discontinuing drug2",False, 
DDI-DrugBank.d373.s7.e1,DDI-DrugBank.d373.s7.e2,"Since there have been isolated reports of patients with elevated drug0 levels, it is recommended that drug1 levels be monitored when initiating, adjusting, and discontinuing drug2",True,advise
DDI-DrugBank.d373.s8.e0,DDI-DrugBank.d373.s8.e1,drug1: Immediate Release Capsules: There have been rare reports of an interaction between drug2 and drug0 (with a decreased plasma level of drug0,False, 
DDI-DrugBank.d373.s8.e0,DDI-DrugBank.d373.s8.e2,drug1: Immediate Release Capsules: There have been rare reports of an interaction between drug0 and drug2 (with a decreased plasma level of drug0,False, 
DDI-DrugBank.d373.s8.e1,DDI-DrugBank.d373.s8.e2,drug0: Immediate Release Capsules: There have been rare reports of an interaction between drug1 and drug2 (with a decreased plasma level of drug0,True,mechanism
DDI-DrugBank.d373.s9.e0,DDI-DrugBank.d373.s9.e1,drug1: There have been rare reports of increased prothrombin time in patients taking drug2 to whom drug0,False, 
DDI-DrugBank.d373.s9.e0,DDI-DrugBank.d373.s9.e2,drug1: There have been rare reports of increased prothrombin time in patients taking drug0 to whom drug2,False, 
DDI-DrugBank.d373.s9.e1,DDI-DrugBank.d373.s9.e2,drug0: There have been rare reports of increased prothrombin time in patients taking drug1 to whom drug2,True,effect
DDI-DrugBank.d373.s11.e0,DDI-DrugBank.d373.s11.e1,drug1: A study in 6 healthy volunteers has shown a significant increase in peak drug2 plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of drug0 at 1000 mg per day and drug0,False, 
DDI-DrugBank.d373.s11.e0,DDI-DrugBank.d373.s11.e2,drug1: A study in 6 healthy volunteers has shown a significant increase in peak drug0 plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of drug2 at 1000 mg per day and drug0,False, 
DDI-DrugBank.d373.s11.e2,DDI-DrugBank.d373.s11.e3,drug0: A study in 6 healthy volunteers has shown a significant increase in peak drug0 plasma levels (80%) and area-under-the-curve (74%) after a 1 week course of drug1 at 1000 mg per day and drug2,True,mechanism
DDI-DrugBank.d373.s13.e0,DDI-DrugBank.d373.s13.e1,"The effect may be mediated by the known inhibition of drug1 on hepatic cytochrome P-450, the enzyme system probably responsible for the first-pass metabolism of drug2",False, 
DDI-DrugBank.d373.s14.e0,DDI-DrugBank.d373.s14.e1,If drug1 therapy is initiated in a patient currently receiving drug2,True,advise
DDI-DrugBank.d203.s2.e0,DDI-DrugBank.d203.s2.e1,"Compounds tested in man include drug1, drug2, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d203.s2.e0,DDI-DrugBank.d203.s2.e2,"Compounds tested in man include drug1, drug0, drug2, drug0, drug0 and drug0",False, 
DDI-DrugBank.d505.s0.e0,DDI-DrugBank.d505.s0.e1,No pharmacokinetic drug-drug interaction studies were conducted with drug1  (drug2,False, 
DDI-DrugBank.d505.s2.e0,DDI-DrugBank.d505.s2.e1,drug1: drug2 has been reported to increase the plasma levels and cardiovascular effects of drug0,False, 
DDI-DrugBank.d505.s2.e0,DDI-DrugBank.d505.s2.e2,drug1: drug0 has been reported to increase the plasma levels and cardiovascular effects of drug2,False, 
DDI-DrugBank.d505.s2.e1,DDI-DrugBank.d505.s2.e2,drug0: drug1 has been reported to increase the plasma levels and cardiovascular effects of drug2,True,mechanism
DDI-DrugBank.d505.s4.e0,DDI-DrugBank.d505.s4.e1,drug1: drug2 may counteract the anticholinesterase effect of drug0,False, 
DDI-DrugBank.d505.s4.e0,DDI-DrugBank.d505.s4.e2,drug1: drug0 may counteract the anticholinesterase effect of drug2,False, 
DDI-DrugBank.d505.s4.e1,DDI-DrugBank.d505.s4.e2,drug0: drug1 may counteract the anticholinesterase effect of drug2,True,effect
DDI-DrugBank.d434.s1.e0,DDI-DrugBank.d434.s1.e1,Use in Conjunction with Other drug1: The addition of drug2  to drug0 (drug0) affects the steady-state plasma concentrations of drug0,False, 
DDI-DrugBank.d434.s1.e0,DDI-DrugBank.d434.s1.e2,Use in Conjunction with Other drug1: The addition of drug0  to drug2 (drug0) affects the steady-state plasma concentrations of drug0,False, 
DDI-DrugBank.d434.s1.e1,DDI-DrugBank.d434.s1.e2,Use in Conjunction with Other drug0: The addition of drug1  to drug2 (drug0) affects the steady-state plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d434.s1.e1,DDI-DrugBank.d434.s1.e3,Use in Conjunction with Other drug0: The addition of drug1  to drug0 (drug2) affects the steady-state plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d434.s2.e0,DDI-DrugBank.d434.s2.e1,The net effect of these interactions is summarized in the following table: drug1 drug2 drug0,False, 
DDI-DrugBank.d434.s2.e0,DDI-DrugBank.d434.s2.e2,The net effect of these interactions is summarized in the following table: drug1 drug0 drug2,False, 
DDI-DrugBank.d434.s6.e0,DDI-DrugBank.d434.s6.e1,drug1 (drug2,False, 
DDI-DrugBank.d434.s11.e0,DDI-DrugBank.d434.s11.e1,Specific Effects of drug1  on Other drug2 drug0: drug0  causes an increase in steady-state drug0,False, 
DDI-DrugBank.d434.s11.e0,DDI-DrugBank.d434.s11.e2,Specific Effects of drug1  on Other drug0 drug2: drug0  causes an increase in steady-state drug0,False, 
DDI-DrugBank.d434.s11.e3,DDI-DrugBank.d434.s11.e4,Specific Effects of drug0  on Other drug0 drug0: drug1  causes an increase in steady-state drug2,True,mechanism
DDI-DrugBank.d434.s12.e0,DDI-DrugBank.d434.s12.e1,"In 10 otherwise healthy subjects with epilepsy ingesting drug1, the steadystate trough (Cmin) drug2",False, 
DDI-DrugBank.d434.s14.e0,DDI-DrugBank.d434.s14.e1,Increasing the drug1 dose to 1800 mg/day in six of these subjects increased the steady-state drug2,True,mechanism
DDI-DrugBank.d434.s15.e0,DDI-DrugBank.d434.s15.e1,"In order to maintain drug1 levels, limit adverse experiences, and achieve the drug2 dose of 3600 mg/day, a drug0",False, 
DDI-DrugBank.d434.s15.e0,DDI-DrugBank.d434.s15.e2,"In order to maintain drug1 levels, limit adverse experiences, and achieve the drug0 dose of 3600 mg/day, a drug2",False, 
DDI-DrugBank.d434.s15.e1,DDI-DrugBank.d434.s15.e2,"In order to maintain drug0 levels, limit adverse experiences, and achieve the drug1 dose of 3600 mg/day, a drug2",True,advise
DDI-DrugBank.d434.s16.e0,DDI-DrugBank.d434.s16.e1,"In a controlled clinical trial, a 20% reduction of the drug1 dose at the initiation of drug2  therapy resulted in drug0 levels comparable to those prior to drug0",False, 
DDI-DrugBank.d434.s16.e0,DDI-DrugBank.d434.s16.e2,"In a controlled clinical trial, a 20% reduction of the drug1 dose at the initiation of drug0  therapy resulted in drug2 levels comparable to those prior to drug0",False, 
DDI-DrugBank.d434.s17.e0,DDI-DrugBank.d434.s17.e1,drug1: drug2  causes a decrease in the steady-state drug0 plasma concentrations and an increase in the steady-state drug0,False, 
DDI-DrugBank.d434.s17.e0,DDI-DrugBank.d434.s17.e2,drug1: drug0  causes a decrease in the steady-state drug2 plasma concentrations and an increase in the steady-state drug0,False, 
DDI-DrugBank.d434.s17.e1,DDI-DrugBank.d434.s17.e2,drug0: drug1  causes a decrease in the steady-state drug2 plasma concentrations and an increase in the steady-state drug0,True,mechanism
DDI-DrugBank.d434.s18.e0,DDI-DrugBank.d434.s18.e1,"In nine otherwise healthy subjects with epilepsy ingesting drug1, the steady-state trough (Cmin) drug2",False, 
DDI-DrugBank.d434.s19.e0,DDI-DrugBank.d434.s19.e1,The drug1 steady-state Cmin decreased 31% to 5 1 micrograms/mL when drug2,True,mechanism
DDI-DrugBank.d434.s20.e0,DDI-DrugBank.d434.s20.e1,drug1 steady-state Cmin concentrations increased 57% from 1.0 0.3 to 1.6 0.4 micrograms/mL with the addition of drug2,False, 
DDI-DrugBank.d434.s21.e0,DDI-DrugBank.d434.s21.e1,"In clinical trials, similar changes in drug1 and drug2",False, 
DDI-DrugBank.d434.s22.e0,DDI-DrugBank.d434.s22.e1,drug1: drug2  causes an increase in steady-state drug0,False, 
DDI-DrugBank.d434.s22.e0,DDI-DrugBank.d434.s22.e2,drug1: drug0  causes an increase in steady-state drug2,False, 
DDI-DrugBank.d434.s22.e1,DDI-DrugBank.d434.s22.e2,drug0: drug1  causes an increase in steady-state drug2,True,mechanism
DDI-DrugBank.d434.s23.e0,DDI-DrugBank.d434.s23.e1,"In four subjects with epilepsy ingesting drug1, the steady-state trough (Cmin) drug2",False, 
DDI-DrugBank.d434.s25.e0,DDI-DrugBank.d434.s25.e1,Increasing the drug1 dose to 2400 mg/day increased the steadystate drug2,True,mechanism
DDI-DrugBank.d434.s26.e0,DDI-DrugBank.d434.s26.e1,"Corresponding values for free drug1 Cmin concentrations were 7 3, 9 4, and 11 6 micrograms/mL for 0, 1200, and 2400 mg/day drug2",False, 
DDI-DrugBank.d434.s27.e0,DDI-DrugBank.d434.s27.e1,"The ratios of the AUCs of unbound drug1 to the AUCs of the total drug2 were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of drug0",False, 
DDI-DrugBank.d434.s27.e0,DDI-DrugBank.d434.s27.e2,"The ratios of the AUCs of unbound drug1 to the AUCs of the total drug0 were 11.1 %, 13.0%, and 11.5%, with coadministration of 0, 1200, and 2400 mg/day of drug2",False, 
DDI-DrugBank.d434.s28.e0,DDI-DrugBank.d434.s28.e1,"drug1: Coadministration of drug2 with drug0 causes an increase in drug0 plasma concentrations, In 12 otherwise healthy male volunteers ingesting drug0, the steady-state trough (Cmin) drug0",False, 
DDI-DrugBank.d434.s28.e0,DDI-DrugBank.d434.s28.e2,"drug1: Coadministration of drug0 with drug2 causes an increase in drug0 plasma concentrations, In 12 otherwise healthy male volunteers ingesting drug0, the steady-state trough (Cmin) drug0",False, 
DDI-DrugBank.d434.s28.e1,DDI-DrugBank.d434.s28.e2,"drug0: Coadministration of drug1 with drug2 causes an increase in drug0 plasma concentrations, In 12 otherwise healthy male volunteers ingesting drug0, the steady-state trough (Cmin) drug0",True,mechanism
DDI-DrugBank.d434.s30.e0,DDI-DrugBank.d434.s30.e1,"Effects of Other drug1 on drug2  drug0: drug0 causes an approximate doubling of the clearance of drug0  (drug0) at steady state and, therefore, the addition of drug0 causes an approximate 45% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",False, 
DDI-DrugBank.d434.s30.e0,DDI-DrugBank.d434.s30.e2,"Effects of Other drug1 on drug0  drug2: drug0 causes an approximate doubling of the clearance of drug0  (drug0) at steady state and, therefore, the addition of drug0 causes an approximate 45% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",False, 
DDI-DrugBank.d434.s30.e3,DDI-DrugBank.d434.s30.e4,"Effects of Other drug0 on drug0  drug0: drug1 causes an approximate doubling of the clearance of drug2  (drug0) at steady state and, therefore, the addition of drug0 causes an approximate 45% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",True,mechanism
DDI-DrugBank.d434.s30.e3,DDI-DrugBank.d434.s30.e5,"Effects of Other drug0 on drug0  drug0: drug1 causes an approximate doubling of the clearance of drug0  (drug2) at steady state and, therefore, the addition of drug0 causes an approximate 45% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",True,mechanism
DDI-DrugBank.d434.s30.e6,DDI-DrugBank.d434.s30.e7,"Effects of Other drug0 on drug0  drug0: drug0 causes an approximate doubling of the clearance of drug0  (drug0) at steady state and, therefore, the addition of drug1 causes an approximate 45% decrease in the steady-state trough concentrations of drug2  as compared to the same dose of drug0",True,mechanism
DDI-DrugBank.d434.s31.e0,DDI-DrugBank.d434.s31.e1,"drug1: drug2 causes an approximate 50% increase in the clearance of drug0  at steady state and, therefore, the addition of drug0 results in an approximate 40% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",False, 
DDI-DrugBank.d434.s31.e0,DDI-DrugBank.d434.s31.e2,"drug1: drug0 causes an approximate 50% increase in the clearance of drug2  at steady state and, therefore, the addition of drug0 results in an approximate 40% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",False, 
DDI-DrugBank.d434.s31.e1,DDI-DrugBank.d434.s31.e2,"drug0: drug1 causes an approximate 50% increase in the clearance of drug2  at steady state and, therefore, the addition of drug0 results in an approximate 40% decrease in the steady-state trough concentrations of drug0  as compared to the same dose of drug0",True,mechanism
DDI-DrugBank.d434.s31.e3,DDI-DrugBank.d434.s31.e4,"drug0: drug0 causes an approximate 50% increase in the clearance of drug0  at steady state and, therefore, the addition of drug1 results in an approximate 40% decrease in the steady-state trough concentrations of drug2  as compared to the same dose of drug0",True,mechanism
DDI-DrugBank.d434.s32.e0,DDI-DrugBank.d434.s32.e1,"drug1: Available data suggest that there is no significant effect of drug2 on the clearance of drug0  at steady state, Therefore, the addition of drug0 is not expected to cause a clinically important effect on drug0  (drug0",False, 
DDI-DrugBank.d434.s32.e0,DDI-DrugBank.d434.s32.e2,"drug1: Available data suggest that there is no significant effect of drug0 on the clearance of drug2  at steady state, Therefore, the addition of drug0 is not expected to cause a clinically important effect on drug0  (drug0",False, 
DDI-DrugBank.d434.s33.e0,DDI-DrugBank.d434.s33.e1,drug1: It appears that drug2 may reduce plasma drug0,False, 
DDI-DrugBank.d434.s33.e0,DDI-DrugBank.d434.s33.e2,drug1: It appears that drug0 may reduce plasma drug2,False, 
DDI-DrugBank.d434.s33.e1,DDI-DrugBank.d434.s33.e2,drug0: It appears that drug1 may reduce plasma drug2,True,mechanism
DDI-DrugBank.d434.s34.e0,DDI-DrugBank.d434.s34.e1,Steady-state plasma drug1 concentrations were found to be 29% lower than the mean concentrations of a group of newly diagnosed subjects with epilepsy also receiving 2400 mg of drug2,False, 
DDI-DrugBank.d434.s35.e0,DDI-DrugBank.d434.s35.e1,Effects of drug1 on drug2  The rate and extent of absorption of a 2400 mg dose of drug0  as monotherapy given as tablets was not affected when coadministered with drug0,False, 
DDI-DrugBank.d434.s35.e0,DDI-DrugBank.d434.s35.e2,Effects of drug1 on drug0  The rate and extent of absorption of a 2400 mg dose of drug2  as monotherapy given as tablets was not affected when coadministered with drug0,False, 
DDI-DrugBank.d434.s36.e0,DDI-DrugBank.d434.s36.e1,"Effects of drug1 on drug2  The coadministration of drug0 (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at drug0",False, 
DDI-DrugBank.d434.s36.e0,DDI-DrugBank.d434.s36.e2,"Effects of drug1 on drug0  The coadministration of drug2 (1000 mg/day) for 10 days did not alter the pharmacokinetic parameters of Cmax, Cmin, AUC, CI/kg or tmax at drug0",False, 
DDI-DrugBank.d434.s37.e0,DDI-DrugBank.d434.s37.e1,"Effects of drug1  on Low-Dose drug2 A group of 24 nonsmoking, healthy white female volunteers established on an oral drug0 regimen containing 30 mg drug0 and 75 mg drug0 for at least 3 months received 2400 mg/day of drug0 from midcycle (day 15) to midcycle (day 14) of two consecutive oral drug0",False, 
DDI-DrugBank.d434.s37.e0,DDI-DrugBank.d434.s37.e2,"Effects of drug1  on Low-Dose drug0 A group of 24 nonsmoking, healthy white female volunteers established on an oral drug2 regimen containing 30 mg drug0 and 75 mg drug0 for at least 3 months received 2400 mg/day of drug0 from midcycle (day 15) to midcycle (day 14) of two consecutive oral drug0",False, 
DDI-DrugBank.d434.s38.e0,DDI-DrugBank.d434.s38.e1,"drug1 treatment resulted in a 42% decrease in the drug2 AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of drug0",True,mechanism
DDI-DrugBank.d434.s38.e0,DDI-DrugBank.d434.s38.e2,"drug1 treatment resulted in a 42% decrease in the drug0 AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of drug2",False, 
DDI-DrugBank.d434.s38.e1,DDI-DrugBank.d434.s38.e2,"drug0 treatment resulted in a 42% decrease in the drug1 AUC 0-24, but no clinically relevant effect was observed on the pharmacokinetic parameters of drug2",False, 
DDI-DrugBank.d551.s1.e0,DDI-DrugBank.d551.s1.e1,"drug1  was found to have no significant effect on the bioavailability of drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d551.s1.e0,DDI-DrugBank.d551.s1.e2,"drug1  was found to have no significant effect on the bioavailability of drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d551.s2.e0,DDI-DrugBank.d551.s2.e1,drug1  decreased the Cmax and AUC of sustained-release drug2 (drug0,True,mechanism
DDI-DrugBank.d551.s2.e0,DDI-DrugBank.d551.s2.e2,drug1  decreased the Cmax and AUC of sustained-release drug0 (drug2,True,mechanism
DDI-DrugBank.d551.s2.e1,DDI-DrugBank.d551.s2.e2,drug0  decreased the Cmax and AUC of sustained-release drug1 (drug2,False, 
DDI-DrugBank.d551.s4.e0,DDI-DrugBank.d551.s4.e1,"In clinical studies, coadministration of drug1  with drug2, drug0, or drug0 did not interfere with the lipid-lowering activity of the drug0",False, 
DDI-DrugBank.d551.s4.e0,DDI-DrugBank.d551.s4.e2,"In clinical studies, coadministration of drug1  with drug0, drug2, or drug0 did not interfere with the lipid-lowering activity of the drug0",False, 
DDI-DrugBank.d297.s1.e0,DDI-DrugBank.d297.s1.e1,"Population pharmacokinetic analyses revealed that drug1, drug2, drug0, and drug0 did not influence drug0",False, 
DDI-DrugBank.d297.s1.e0,DDI-DrugBank.d297.s1.e2,"Population pharmacokinetic analyses revealed that drug1, drug0, drug2, and drug0 did not influence drug0",False, 
DDI-DrugBank.d297.s2.e0,DDI-DrugBank.d297.s2.e1,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with drug1: drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d297.s2.e0,DDI-DrugBank.d297.s2.e2,"The majority of patients in RA clinical studies received one or more of the following concomitant medications with drug1: drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d297.s3.e0,DDI-DrugBank.d297.s3.e1,Concurrent administration of a drug1 with drug2 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the drug0,True,effect
DDI-DrugBank.d297.s3.e0,DDI-DrugBank.d297.s3.e2,Concurrent administration of a drug1 with drug0 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the drug2,False, 
DDI-DrugBank.d297.s3.e1,DDI-DrugBank.d297.s3.e2,Concurrent administration of a drug0 with drug1 has been associated with an increased risk of serious infections and no significant additional efficacy over use of the drug2,False, 
DDI-DrugBank.d297.s4.e0,DDI-DrugBank.d297.s4.e1,Concurrent therapy with drug1 and drug2,True,advise
DDI-DrugBank.d297.s5.e0,DDI-DrugBank.d297.s5.e1,There is insufficient experience to assess the safety and efficacy of drug1 administered concurrently with drug2,True,advise
DDI-DrugBank.d13.s0.e0,DDI-DrugBank.d13.s0.e1,"Drug Interactions: drug1 may interact with some drugs, like drug2 (drug0): drug0 could theoretically affect drug0 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug0 increases the effect of drug0",True,int
DDI-DrugBank.d13.s0.e0,DDI-DrugBank.d13.s0.e2,"Drug Interactions: drug1 may interact with some drugs, like drug0 (drug2): drug0 could theoretically affect drug0 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug0 increases the effect of drug0",True,int
DDI-DrugBank.d13.s0.e0,DDI-DrugBank.d13.s0.e3,"Drug Interactions: drug1 may interact with some drugs, like drug0 (drug0): drug2 could theoretically affect drug0 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug0 increases the effect of drug0",False, 
DDI-DrugBank.d13.s0.e0,DDI-DrugBank.d13.s0.e4,"Drug Interactions: drug1 may interact with some drugs, like drug0 (drug0): drug0 could theoretically affect drug2 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug0 increases the effect of drug0",False, 
DDI-DrugBank.d13.s0.e3,DDI-DrugBank.d13.s0.e4,"Drug Interactions: drug0 may interact with some drugs, like drug0 (drug0): drug1 could theoretically affect drug2 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug0 increases the effect of drug0",True,effect
DDI-DrugBank.d13.s0.e7,DDI-DrugBank.d13.s0.e8,"Drug Interactions: drug0 may interact with some drugs, like drug0 (drug0): drug0 could theoretically affect drug0 pharmacodynamics - drug0 - Eproxindine - drug0: drug1 and drug2 cause additive CNS depression - drug0: drug0 increases the effect of drug0",True,effect
DDI-DrugBank.d13.s0.e10,DDI-DrugBank.d13.s0.e11,"Drug Interactions: drug0 may interact with some drugs, like drug0 (drug0): drug0 could theoretically affect drug0 pharmacodynamics - drug0 - Eproxindine - drug0: drug0 and drug0 cause additive CNS depression - drug0: drug1 increases the effect of drug2",True,effect
DDI-DrugBank.d193.s0.e0,DDI-DrugBank.d193.s0.e1,A drug interaction study was performed in which drug1 was administered in combination with drug2,False, 
DDI-DrugBank.d193.s1.e0,DDI-DrugBank.d193.s1.e1,There was no evidence of any pharmacokinetic interactions between drug1 and drug2,False, 
DDI-DrugBank.d143.s0.e0,DDI-DrugBank.d143.s0.e1,drug1 is metabolized to drug2,False, 
DDI-DrugBank.d143.s7.e0,DDI-DrugBank.d143.s7.e1,"In view of the long and variable half-life of drug1, potential for drug interactions exists not only with concomitant medication but also with drugs administered after discontinuation of drug2",False, 
DDI-DrugBank.d143.s8.e0,DDI-DrugBank.d143.s8.e1,"Since drug1 is a substrate for CYP3A4 and CYP2C8, drugs/substances that inhibit these isoenzymes may decrease the metabolism and increase serum concentration of drug2",False, 
DDI-DrugBank.d143.s9.e0,DDI-DrugBank.d143.s9.e1,Reported examples include the following: drug1: drug2,False, 
DDI-DrugBank.d143.s10.e0,DDI-DrugBank.d143.s10.e1,A case report of one patient taking drug1 200 mg and drug2 800 mg three times a day resulted in increases in drug0,True,mechanism
DDI-DrugBank.d143.s10.e0,DDI-DrugBank.d143.s10.e2,A case report of one patient taking drug1 200 mg and drug0 800 mg three times a day resulted in increases in drug2,False, 
DDI-DrugBank.d143.s10.e1,DDI-DrugBank.d143.s10.e2,A case report of one patient taking drug0 200 mg and drug1 800 mg three times a day resulted in increases in drug2,False, 
DDI-DrugBank.d143.s13.e0,DDI-DrugBank.d143.s13.e1,Monitoring for drug1 toxicity and serial measurement of drug2 serum concentration during concomitant drug0,False, 
DDI-DrugBank.d143.s13.e0,DDI-DrugBank.d143.s13.e2,Monitoring for drug1 toxicity and serial measurement of drug0 serum concentration during concomitant drug2,False, 
DDI-DrugBank.d143.s13.e1,DDI-DrugBank.d143.s13.e2,Monitoring for drug0 toxicity and serial measurement of drug1 serum concentration during concomitant drug2,True,advise
DDI-DrugBank.d143.s14.e0,DDI-DrugBank.d143.s14.e1,drug1: drug2 inhibits CYP3A4 and can increase serum drug0,True,mechanism
DDI-DrugBank.d143.s14.e0,DDI-DrugBank.d143.s14.e2,drug1: drug0 inhibits CYP3A4 and can increase serum drug2,False, 
DDI-DrugBank.d143.s14.e1,DDI-DrugBank.d143.s14.e2,drug0: drug1 inhibits CYP3A4 and can increase serum drug2,False, 
DDI-DrugBank.d143.s15.e0,DDI-DrugBank.d143.s15.e1,"Other substances: Grapefruit juice given to healthy volunteers increased drug1 AUC by 50% and Cmax by 84%, resulting in increased plasma levels of drug2",False, 
DDI-DrugBank.d143.s17.e0,DDI-DrugBank.d143.s17.e1,This information should be considered when changing from intravenous drug1 to oral drug2,False, 
DDI-DrugBank.d143.s18.e0,DDI-DrugBank.d143.s18.e1,"drug1 may suppress certain CYP450 enzymes, including drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d143.s18.e0,DDI-DrugBank.d143.s18.e2,"drug1 may suppress certain CYP450 enzymes, including drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d143.s20.e0,DDI-DrugBank.d143.s20.e1,"Reported examples of this interaction include the following: drug1s: drug2 (drug0 substrate) administered in combination with oral drug0 has been reported to produce persistently elevated plasma concentrations of drug0 resulting in elevated creatinine, despite reduction in dose of drug0",False, 
DDI-DrugBank.d143.s20.e0,DDI-DrugBank.d143.s20.e2,"Reported examples of this interaction include the following: drug1s: drug0 (drug2 substrate) administered in combination with oral drug0 has been reported to produce persistently elevated plasma concentrations of drug0 resulting in elevated creatinine, despite reduction in dose of drug0",False, 
DDI-DrugBank.d143.s21.e0,DDI-DrugBank.d143.s21.e1,drug1: drug2 (drug0 substrate) in combination with drug0,False, 
DDI-DrugBank.d143.s21.e0,DDI-DrugBank.d143.s21.e2,drug1: drug0 (drug2 substrate) in combination with drug0,False, 
DDI-DrugBank.d143.s22.e0,DDI-DrugBank.d143.s22.e1,"Cardiovasculars: drug1: In patients receiving drug2 therapy, administration of oral drug0 regularly results in an increase in serum drug0",False, 
DDI-DrugBank.d143.s22.e0,DDI-DrugBank.d143.s22.e2,"Cardiovasculars: drug1: In patients receiving drug0 therapy, administration of oral drug2 regularly results in an increase in serum drug0",False, 
DDI-DrugBank.d143.s23.e0,DDI-DrugBank.d143.s23.e1,drug1 taken concomitantly with drug2 increases the serum drug0,False, 
DDI-DrugBank.d143.s23.e0,DDI-DrugBank.d143.s23.e2,drug1 taken concomitantly with drug0 increases the serum drug2,False, 
DDI-DrugBank.d143.s24.e0,DDI-DrugBank.d143.s24.e1,"On administration of oral drug1, the need for drug2",True,advise
DDI-DrugBank.d143.s27.e0,DDI-DrugBank.d143.s27.e1,"drug1: Other drug2 drugs, such as drug0, drug0, drug0, and drug0, have been used concurrently with drug0",False, 
DDI-DrugBank.d143.s27.e0,DDI-DrugBank.d143.s27.e2,"drug1: Other drug0 drugs, such as drug2, drug0, drug0, and drug0, have been used concurrently with drug0",False, 
DDI-DrugBank.d143.s28.e0,DDI-DrugBank.d143.s28.e1,"There have been case reports of increased steady-state levels of drug1, drug2, and drug0 during concomitant therapy with drug0",False, 
DDI-DrugBank.d143.s28.e0,DDI-DrugBank.d143.s28.e2,"There have been case reports of increased steady-state levels of drug1, drug0, and drug2 during concomitant therapy with drug0",False, 
DDI-DrugBank.d143.s30.e0,DDI-DrugBank.d143.s30.e1,drug1 taken concomitantly with drug2 increases drug0,False, 
DDI-DrugBank.d143.s30.e0,DDI-DrugBank.d143.s30.e2,drug1 taken concomitantly with drug0 increases drug2,False, 
DDI-DrugBank.d143.s31.e0,DDI-DrugBank.d143.s31.e1,drug1 taken concomitantly with drug2 for less than seven days increases plasma concentrations of drug0 and n-acetyl drug0,False, 
DDI-DrugBank.d143.s31.e0,DDI-DrugBank.d143.s31.e2,drug1 taken concomitantly with drug0 for less than seven days increases plasma concentrations of drug2 and n-acetyl drug0,False, 
DDI-DrugBank.d143.s32.e0,DDI-DrugBank.d143.s32.e1,drug1 and procainamide doses should be reduced by one-third when either is administered with drug2,False, 
DDI-DrugBank.d143.s33.e0,DDI-DrugBank.d143.s33.e1,Plasma levels of drug1 have been reported to increase in the presence of oral drug2,False, 
DDI-DrugBank.d143.s34.e0,DDI-DrugBank.d143.s34.e1,"because of this, the dosage of drug1 should be adjusted when these drug2",False, 
DDI-DrugBank.d143.s36.e0,DDI-DrugBank.d143.s36.e1,Combination of drug1 with other drug2 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to drug0,False, 
DDI-DrugBank.d143.s36.e0,DDI-DrugBank.d143.s36.e2,Combination of drug1 with other drug0 therapy should be reserved for patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent or incompletely responsive to drug2,False, 
DDI-DrugBank.d143.s37.e0,DDI-DrugBank.d143.s37.e1,"During transfer to oral drug1, the dose levels of previously administered agents should be reduced by 30 to 50% several days after the addition of oral drug2",False, 
DDI-DrugBank.d143.s38.e0,DDI-DrugBank.d143.s38.e1,The continued need for the other drug1 agent should be reviewed after the effects of drug2,False, 
DDI-DrugBank.d143.s40.e0,DDI-DrugBank.d143.s40.e1,In drug1-treated patients who require additional drug2,False, 
DDI-DrugBank.d143.s41.e0,DDI-DrugBank.d143.s41.e1,"drug1: drug2 should be used with caution in patients receiving  -drug0 blocking agents (e.g., drug0, a drug0 inhibitor) or drug0 antagonists (e.g., drug0, a drug0 substrate, and drug0, a drug0",False, 
DDI-DrugBank.d143.s41.e0,DDI-DrugBank.d143.s41.e2,"drug1: drug0 should be used with caution in patients receiving  -drug2 blocking agents (e.g., drug0, a drug0 inhibitor) or drug0 antagonists (e.g., drug0, a drug0 substrate, and drug0, a drug0",False, 
DDI-DrugBank.d143.s43.e0,DDI-DrugBank.d143.s43.e1,drug1: Potentiation of drug2-type (drug0 and drug0 substrate) drug0 response is almost always seen in patients receiving drug0,False, 
DDI-DrugBank.d143.s43.e0,DDI-DrugBank.d143.s43.e2,drug1: Potentiation of drug0-type (drug2 and drug0 substrate) drug0 response is almost always seen in patients receiving drug0,False, 
DDI-DrugBank.d143.s44.e0,DDI-DrugBank.d143.s44.e1,"Since the concomitant administration of drug1 with drug2 increases the prothrombin time by 100% after 3 to 4 days, the dose of the drug0",False, 
DDI-DrugBank.d143.s44.e0,DDI-DrugBank.d143.s44.e2,"Since the concomitant administration of drug1 with drug0 increases the prothrombin time by 100% after 3 to 4 days, the dose of the drug2",False, 
DDI-DrugBank.d143.s45.e0,DDI-DrugBank.d143.s45.e1,Some drug1/substances are known to accelerate the metabolism of drug2 by stimulating the synthesis of drug0,False, 
DDI-DrugBank.d143.s45.e0,DDI-DrugBank.d143.s45.e2,Some drug1/substances are known to accelerate the metabolism of drug0 by stimulating the synthesis of drug2,False, 
DDI-DrugBank.d143.s47.e0,DDI-DrugBank.d143.s47.e1,Reported examples of this interaction include the following: drug1: drug2 is a potent inducer of drug0,False, 
DDI-DrugBank.d143.s47.e0,DDI-DrugBank.d143.s47.e2,Reported examples of this interaction include the following: drug1: drug0 is a potent inducer of drug2,False, 
DDI-DrugBank.d143.s48.e0,DDI-DrugBank.d143.s48.e1,Administration of drug1 concomitantly with oral drug2 has been shown to result in decreases in serum concentrations of drug0 and drug0,False, 
DDI-DrugBank.d143.s48.e0,DDI-DrugBank.d143.s48.e2,Administration of drug1 concomitantly with oral drug0 has been shown to result in decreases in serum concentrations of drug2 and drug0,False, 
DDI-DrugBank.d143.s50.e0,DDI-DrugBank.d143.s50.e1,"Since drug1 is a substrate for drug2, there is the potential that the use of St. John s Wort in patients receiving drug0 could result in reduced drug0",False, 
DDI-DrugBank.d143.s50.e0,DDI-DrugBank.d143.s50.e2,"Since drug1 is a substrate for drug0, there is the potential that the use of St. John s Wort in patients receiving drug2 could result in reduced drug0",False, 
DDI-DrugBank.d143.s51.e0,DDI-DrugBank.d143.s51.e1,Other reported interactions with drug1: drug2 (drug0 substrate) in combination with drug0,False, 
DDI-DrugBank.d143.s51.e0,DDI-DrugBank.d143.s51.e2,Other reported interactions with drug1: drug0 (drug2 substrate) in combination with drug0,False, 
DDI-DrugBank.d143.s52.e0,DDI-DrugBank.d143.s52.e1,Sinus bradycardia has been reported with oral drug1 in combination with drug2 (drug0 substrate) given for local drug0,False, 
DDI-DrugBank.d143.s52.e0,DDI-DrugBank.d143.s52.e2,Sinus bradycardia has been reported with oral drug1 in combination with drug0 (drug2 substrate) given for local drug0,False, 
DDI-DrugBank.d143.s53.e0,DDI-DrugBank.d143.s53.e1,"Seizure, associated with increased drug1 concentrations, has been reported with concomitant administration of intravenous drug2",False, 
DDI-DrugBank.d143.s54.e0,DDI-DrugBank.d143.s54.e1,drug1 is a substrate for both drug2 and drug0,False, 
DDI-DrugBank.d143.s54.e0,DDI-DrugBank.d143.s54.e2,drug1 is a substrate for both drug0 and drug2,False, 
DDI-DrugBank.d143.s55.e0,DDI-DrugBank.d143.s55.e1,drug1 inhibits drug2,False, 
DDI-DrugBank.d143.s56.e0,DDI-DrugBank.d143.s56.e1,drug1 increases enterohepatic elimination of drug2 and may reduce its serum levels and drug0,False, 
DDI-DrugBank.d143.s56.e0,DDI-DrugBank.d143.s56.e2,drug1 increases enterohepatic elimination of drug0 and may reduce its serum levels and drug2,False, 
DDI-DrugBank.d143.s58.e0,DDI-DrugBank.d143.s58.e1,"drug1, drug2",False, 
DDI-DrugBank.d143.s59.e0,DDI-DrugBank.d143.s59.e1,"There have been reports of QTc prolongation, with or without TdP, in patients taking drug1 when drug2, drug0",False, 
DDI-DrugBank.d143.s59.e0,DDI-DrugBank.d143.s59.e2,"There have been reports of QTc prolongation, with or without TdP, in patients taking drug1 when drug0, drug2",False, 
DDI-DrugBank.d143.s60.e0,DDI-DrugBank.d143.s60.e1,"Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with drug1, drug2, and drug0",False, 
DDI-DrugBank.d143.s60.e0,DDI-DrugBank.d143.s60.e2,"Hemodynamic and electrophysiologic interactions have also been observed after concomitant administration with drug1, drug0, and drug2",False, 
DDI-DrugBank.d143.s62.e0,DDI-DrugBank.d143.s62.e1,"In addition to the interactions noted above, chronic (  2 weeks) oral drug1 administration impairs metabolism of drug2, drug0, and drug0",False, 
DDI-DrugBank.d143.s62.e0,DDI-DrugBank.d143.s62.e2,"In addition to the interactions noted above, chronic (  2 weeks) oral drug1 administration impairs metabolism of drug0, drug2, and drug0",False, 
DDI-DrugBank.d0.s0.e0,DDI-DrugBank.d0.s0.e1,The concomitant intake of drug1 and drug2 does not affect the pharmacokinetics of either drug0 or drug0,False, 
DDI-DrugBank.d0.s0.e0,DDI-DrugBank.d0.s0.e2,The concomitant intake of drug1 and drug0 does not affect the pharmacokinetics of either drug2 or drug0,False, 
DDI-DrugBank.d0.s1.e0,DDI-DrugBank.d0.s1.e1,Pharmacokinetic studies indicate that administration of drug1 or drug2 does not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d0.s1.e0,DDI-DrugBank.d0.s1.e2,Pharmacokinetic studies indicate that administration of drug1 or drug0 does not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d0.s2.e0,DDI-DrugBank.d0.s2.e1,Co-administration of drug1 with drug2 produced a 25% increase in AUC and a 33% increase in the Cmax of drug0,True,mechanism
DDI-DrugBank.d0.s2.e0,DDI-DrugBank.d0.s2.e2,Co-administration of drug1 with drug0 produced a 25% increase in AUC and a 33% increase in the Cmax of drug2,False, 
DDI-DrugBank.d0.s2.e1,DDI-DrugBank.d0.s2.e2,Co-administration of drug0 with drug1 produced a 25% increase in AUC and a 33% increase in the Cmax of drug2,False, 
DDI-DrugBank.d0.s4.e0,DDI-DrugBank.d0.s4.e1,The pharmacokinetics of drug1 and its major metabolite drug2 were unaffected following co-administration with drug0,False, 
DDI-DrugBank.d0.s4.e0,DDI-DrugBank.d0.s4.e2,The pharmacokinetics of drug1 and its major metabolite drug0 were unaffected following co-administration with drug2,False, 
DDI-DrugBank.d0.s5.e0,DDI-DrugBank.d0.s5.e1,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with drug1 concomitantly with drug2, drug0 and drug0 (including drug0), or drug0",False, 
DDI-DrugBank.d0.s5.e0,DDI-DrugBank.d0.s5.e2,"Other concomitant therapies: In clinical trials, the safety profile in subjects treated with drug1 concomitantly with drug0, drug2 and drug0 (including drug0), or drug0",False, 
DDI-DrugBank.d0.s6.e0,DDI-DrugBank.d0.s6.e1,Patients taking drug1 concomitantly with drug2,True,effect
DDI-DrugBank.d360.s1.e0,DDI-DrugBank.d360.s1.e1,"A similar association, though less marked, has been suggested with drug1, drug2, drug0, drug0, drug0, drug0, and possibly with drug0 and drug0",False, 
DDI-DrugBank.d360.s1.e0,DDI-DrugBank.d360.s1.e2,"A similar association, though less marked, has been suggested with drug1, drug0, drug2, drug0, drug0, drug0, and possibly with drug0 and drug0",False, 
DDI-DrugBank.d360.s2.e0,DDI-DrugBank.d360.s2.e1,A possible interaction has been suggested with drug1 and the herbal supplement St. Johns Wort based on some reports of oral drug2,False, 
DDI-DrugBank.d139.s0.e0,DDI-DrugBank.d139.s0.e1,drug1-drug2 may sterilize the bowel and decrease the drug0,False, 
DDI-DrugBank.d139.s0.e0,DDI-DrugBank.d139.s0.e2,drug1-drug0 may sterilize the bowel and decrease the drug2,False, 
DDI-DrugBank.d139.s1.e0,DDI-DrugBank.d139.s1.e1,"drug1-drug2 containing side chains of N-methylthiotetrazole (drug0, drug0, drug0, drug0, drug0) or methylthiadiazole (drug0",False, 
DDI-DrugBank.d139.s1.e0,DDI-DrugBank.d139.s1.e2,"drug1-drug0 containing side chains of N-methylthiotetrazole (drug2, drug0, drug0, drug0, drug0) or methylthiadiazole (drug0",False, 
DDI-DrugBank.d139.s3.e0,DDI-DrugBank.d139.s3.e1,drug1-Concomitant intake of drug2 and drug0 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s3.e0,DDI-DrugBank.d139.s3.e2,drug1-Concomitant intake of drug0 and drug2 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s3.e1,DDI-DrugBank.d139.s3.e2,drug0-Concomitant intake of drug1 and drug2 may reduce the absorption of drug0,True,mechanism
DDI-DrugBank.d139.s4.e0,DDI-DrugBank.d139.s4.e1,drug1-Concomitant intake of drug2 and drug0 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s4.e0,DDI-DrugBank.d139.s4.e2,drug1-Concomitant intake of drug0 and drug2 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s4.e1,DDI-DrugBank.d139.s4.e2,drug0-Concomitant intake of drug1 and drug2 may reduce the absorption of drug0,True,mechanism
DDI-DrugBank.d139.s5.e0,DDI-DrugBank.d139.s5.e1,drug1-Concomitant intake of drug2 and drug0 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s5.e0,DDI-DrugBank.d139.s5.e2,drug1-Concomitant intake of drug0 and drug2 may reduce the absorption of drug0,False, 
DDI-DrugBank.d139.s5.e1,DDI-DrugBank.d139.s5.e2,drug0-Concomitant intake of drug1 and drug2 may reduce the absorption of drug0,True,mechanism
DDI-DrugBank.d139.s6.e0,DDI-DrugBank.d139.s6.e1,drug1-drug2 may decrease the absorption of drug0,False, 
DDI-DrugBank.d139.s6.e0,DDI-DrugBank.d139.s6.e2,drug1-drug0 may decrease the absorption of drug2,False, 
DDI-DrugBank.d139.s6.e1,DDI-DrugBank.d139.s6.e2,drug0-drug1 may decrease the absorption of drug2,True,mechanism
DDI-DrugBank.d139.s7.e0,DDI-DrugBank.d139.s7.e1,drug1-drug2,False, 
DDI-DrugBank.d139.s8.e0,DDI-DrugBank.d139.s8.e1,drug1-drug2 can antagonize the effect of drug0,False, 
DDI-DrugBank.d139.s8.e0,DDI-DrugBank.d139.s8.e2,drug1-drug0 can antagonize the effect of drug2,False, 
DDI-DrugBank.d139.s8.e1,DDI-DrugBank.d139.s8.e2,drug0-drug1 can antagonize the effect of drug2,True,effect
DDI-DrugBank.d329.s0.e0,DDI-DrugBank.d329.s0.e1,"When drug1 is co-administered with drug2 (500 mg p.o. every 6 hours), drug0 competes for active tubular secretion and reduces the renal clearance of drug0",False, 
DDI-DrugBank.d329.s0.e0,DDI-DrugBank.d329.s0.e2,"When drug1 is co-administered with drug0 (500 mg p.o. every 6 hours), drug2 competes for active tubular secretion and reduces the renal clearance of drug0",False, 
DDI-DrugBank.d329.s0.e2,DDI-DrugBank.d329.s0.e3,"When drug0 is co-administered with drug0 (500 mg p.o. every 6 hours), drug1 competes for active tubular secretion and reduces the renal clearance of drug2",True,mechanism
DDI-DrugBank.d329.s1.e0,DDI-DrugBank.d329.s1.e1,"Based on total drug1 concentrations, drug2",True,mechanism
DDI-DrugBank.d329.s3.e0,DDI-DrugBank.d329.s3.e1,"Because of the small effect on half-life, the coadministration with drug1 to extend the half-life of drug2",True,advise
DDI-DrugBank.d329.s4.e0,DDI-DrugBank.d329.s4.e1,In vitro studies indicate that drug1 does not inhibit P-glycoprotein-mediated transport of drug2 or drug0 and that drug0,False, 
DDI-DrugBank.d329.s4.e0,DDI-DrugBank.d329.s4.e2,In vitro studies indicate that drug1 does not inhibit P-glycoprotein-mediated transport of drug0 or drug2 and that drug0,False, 
DDI-DrugBank.d2.s0.e0,DDI-DrugBank.d2.s0.e1,drug1 may augment the activity of other drug2,True,effect
DDI-DrugBank.d277.s0.e0,DDI-DrugBank.d277.s0.e1,"In evaluating the potential for interactions among co-administered antiepilepsy drugs (drug1), whether or not an drug2",False, 
DDI-DrugBank.d277.s1.e0,DDI-DrugBank.d277.s1.e1,"drug1, drug2 and drug0",False, 
DDI-DrugBank.d277.s1.e0,DDI-DrugBank.d277.s1.e2,"drug1, drug0 and drug2",False, 
DDI-DrugBank.d277.s2.e0,DDI-DrugBank.d277.s2.e1,drug1 and drug2,False, 
DDI-DrugBank.d277.s3.e0,DDI-DrugBank.d277.s3.e1,drug1 is considered to be a non-enzyme inducing drug2,False, 
DDI-DrugBank.d277.s5.e0,DDI-DrugBank.d277.s5.e1,Effects of drug1 on other Antiepilepsy Drugs (drug2) : drug0: drug0 had no effect on the steady-state plasma concentrations of drug0,False, 
DDI-DrugBank.d277.s5.e0,DDI-DrugBank.d277.s5.e2,Effects of drug1 on other Antiepilepsy Drugs (drug0) : drug2: drug0 had no effect on the steady-state plasma concentrations of drug0,False, 
DDI-DrugBank.d277.s6.e0,DDI-DrugBank.d277.s6.e1,drug1: drug2 had no effect on the steady-state plasma concentrations of drug0,False, 
DDI-DrugBank.d277.s6.e0,DDI-DrugBank.d277.s6.e2,drug1: drug0 had no effect on the steady-state plasma concentrations of drug2,False, 
DDI-DrugBank.d277.s7.e0,DDI-DrugBank.d277.s7.e1,drug1: drug2 causes a slight decrease (about 10%) in steady-state drug0,False, 
DDI-DrugBank.d277.s7.e0,DDI-DrugBank.d277.s7.e2,drug1: drug0 causes a slight decrease (about 10%) in steady-state drug2,False, 
DDI-DrugBank.d277.s7.e1,DDI-DrugBank.d277.s7.e2,drug0: drug1 causes a slight decrease (about 10%) in steady-state drug2,True,mechanism
DDI-DrugBank.d277.s8.e0,DDI-DrugBank.d277.s8.e1,drug1 or drug2 : No formal pharmacokinetic studies have been performed examining the addition of drug0 to regimens containing drug0 or drug0,False, 
DDI-DrugBank.d277.s8.e0,DDI-DrugBank.d277.s8.e2,drug1 or drug0 : No formal pharmacokinetic studies have been performed examining the addition of drug2 to regimens containing drug0 or drug0,False, 
DDI-DrugBank.d277.s9.e0,DDI-DrugBank.d277.s9.e1,The addition of drug1 in a limited number of patients in three well-controlled studies caused no systematic changes in drug2 or drug0,False, 
DDI-DrugBank.d277.s9.e0,DDI-DrugBank.d277.s9.e2,The addition of drug1 in a limited number of patients in three well-controlled studies caused no systematic changes in drug0 or drug2,False, 
DDI-DrugBank.d277.s10.e0,DDI-DrugBank.d277.s10.e1,Effects of other Antiepilepsy Drugs (drug1) on drug2 : drug0: Population pharmacokinetic analyses indicate that drug0 clearance is 60% greater in patients taking drug0 with or without other enzyme- inducing drug0,False, 
DDI-DrugBank.d277.s10.e0,DDI-DrugBank.d277.s10.e2,Effects of other Antiepilepsy Drugs (drug1) on drug0 : drug2: Population pharmacokinetic analyses indicate that drug0 clearance is 60% greater in patients taking drug0 with or without other enzyme- inducing drug0,False, 
DDI-DrugBank.d277.s10.e3,DDI-DrugBank.d277.s10.e4,Effects of other Antiepilepsy Drugs (drug0) on drug0 : drug0: Population pharmacokinetic analyses indicate that drug1 clearance is 60% greater in patients taking drug2 with or without other enzyme- inducing drug0,True,mechanism
DDI-DrugBank.d277.s11.e0,DDI-DrugBank.d277.s11.e1,drug1: Population pharmacokinetic analyses indicate that drug2 clearance is 60% greater in patients taking drug0 with or without other enzyme- inducing drug0,False, 
DDI-DrugBank.d277.s11.e0,DDI-DrugBank.d277.s11.e2,drug1: Population pharmacokinetic analyses indicate that drug0 clearance is 60% greater in patients taking drug2 with or without other enzyme- inducing drug0,False, 
DDI-DrugBank.d277.s11.e1,DDI-DrugBank.d277.s11.e2,drug0: Population pharmacokinetic analyses indicate that drug1 clearance is 60% greater in patients taking drug2 with or without other enzyme- inducing drug0,True,mechanism
DDI-DrugBank.d277.s12.e0,DDI-DrugBank.d277.s12.e1,drug1 (drug2): Population pharmacokinetic analyses indicate that drug0 clearance is 60% greater in patients taking drug0 (drug0) with or without other enzyme-inducing drug0,False, 
DDI-DrugBank.d277.s12.e0,DDI-DrugBank.d277.s12.e2,drug1 (drug0): Population pharmacokinetic analyses indicate that drug2 clearance is 60% greater in patients taking drug0 (drug0) with or without other enzyme-inducing drug0,False, 
DDI-DrugBank.d277.s12.e2,DDI-DrugBank.d277.s12.e3,drug0 (drug0): Population pharmacokinetic analyses indicate that drug1 clearance is 60% greater in patients taking drug2 (drug0) with or without other enzyme-inducing drug0,True,mechanism
DDI-DrugBank.d277.s12.e2,DDI-DrugBank.d277.s12.e4,drug0 (drug0): Population pharmacokinetic analyses indicate that drug1 clearance is 60% greater in patients taking drug0 (drug2) with or without other enzyme-inducing drug0,True,mechanism
DDI-DrugBank.d277.s13.e0,DDI-DrugBank.d277.s13.e1,"drug1: The addition of drug2 to patients taking drug0 chronically had no effect on drug0 pharmacokinetics, but drug0 significantly decreased drug0",False, 
DDI-DrugBank.d277.s13.e0,DDI-DrugBank.d277.s13.e2,"drug1: The addition of drug0 to patients taking drug2 chronically had no effect on drug0 pharmacokinetics, but drug0 significantly decreased drug0",False, 
DDI-DrugBank.d277.s13.e4,DDI-DrugBank.d277.s13.e5,"drug0: The addition of drug0 to patients taking drug0 chronically had no effect on drug0 pharmacokinetics, but drug1 significantly decreased drug2",True,mechanism
DDI-DrugBank.d277.s15.e0,DDI-DrugBank.d277.s15.e1,Interaction of drug1 with Other Drugs : drug2 : Co-administration of drug0 (800 mg/day) to patients taking drug0 chronically had no effect on drug0,False, 
DDI-DrugBank.d277.s15.e0,DDI-DrugBank.d277.s15.e2,Interaction of drug1 with Other Drugs : drug0 : Co-administration of drug2 (800 mg/day) to patients taking drug0 chronically had no effect on drug0,False, 
DDI-DrugBank.d277.s16.e0,DDI-DrugBank.d277.s16.e1,drug1: A single 10 mg dose of drug2 did not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d277.s16.e0,DDI-DrugBank.d277.s16.e2,drug1: A single 10 mg dose of drug0 did not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d277.s17.e0,DDI-DrugBank.d277.s17.e1,drug1: No significant differences were observed in the steady-state pharmacokinetics of drug2 or drug0 with the addition of drug0,False, 
DDI-DrugBank.d277.s17.e0,DDI-DrugBank.d277.s17.e2,drug1: No significant differences were observed in the steady-state pharmacokinetics of drug0 or drug2 with the addition of drug0,False, 
DDI-DrugBank.d277.s19.e0,DDI-DrugBank.d277.s19.e1,drug1: Concomitant administration of drug2 did not affect the steady-state pharmacokinetics of drug0 or the mean daily trough serum level of drug0,False, 
DDI-DrugBank.d277.s19.e0,DDI-DrugBank.d277.s19.e2,drug1: Concomitant administration of drug0 did not affect the steady-state pharmacokinetics of drug2 or the mean daily trough serum level of drug0,False, 
DDI-DrugBank.d277.s20.e0,DDI-DrugBank.d277.s20.e1,drug1 or drug2: No significant differences were observed in the pharmacokinetics of drug0 (0.125 mg) and drug0,False, 
DDI-DrugBank.d277.s20.e0,DDI-DrugBank.d277.s20.e2,drug1 or drug0: No significant differences were observed in the pharmacokinetics of drug2 (0.125 mg) and drug0,False, 
DDI-DrugBank.d277.s21.e0,DDI-DrugBank.d277.s21.e1,The pharmacokinetics of drug1 were not affected by multiple-dose administration of drug2,False, 
DDI-DrugBank.d277.s22.e0,DDI-DrugBank.d277.s22.e1,drug1 has shown no clinically important potentiation of the pharmacodynamic effects of triazo lam or drug2,False, 
DDI-DrugBank.d277.s23.e0,DDI-DrugBank.d277.s23.e1,"Because of the possible additive effects of drugs that may depress the nervous system, drug1 or drug2 should be used cautiously in combination with drug0",False, 
DDI-DrugBank.d277.s23.e0,DDI-DrugBank.d277.s23.e2,"Because of the possible additive effects of drugs that may depress the nervous system, drug1 or drug0 should be used cautiously in combination with drug2",True,advise
DDI-DrugBank.d277.s23.e1,DDI-DrugBank.d277.s23.e2,"Because of the possible additive effects of drugs that may depress the nervous system, drug0 or drug1 should be used cautiously in combination with drug2",True,advise
DDI-DrugBank.d277.s24.e0,DDI-DrugBank.d277.s24.e1,Oral drug1: Multiple dose administration of drug2 (8 mg/day monotherapy) did not alter the pharmacokinetics of oral drug0,False, 
DDI-DrugBank.d277.s24.e0,DDI-DrugBank.d277.s24.e2,Oral drug1: Multiple dose administration of drug0 (8 mg/day monotherapy) did not alter the pharmacokinetics of oral drug2,False, 
DDI-DrugBank.d277.s25.e0,DDI-DrugBank.d277.s25.e1,drug1 : drug2 pharmacokinetics were not significantly different before and after drug0,False, 
DDI-DrugBank.d277.s25.e0,DDI-DrugBank.d277.s25.e2,drug1 : drug0 pharmacokinetics were not significantly different before and after drug2,False, 
DDI-DrugBank.d277.s26.e0,DDI-DrugBank.d277.s26.e1,This indicates that drug1 does not cause induction or inhibition of the hepatic microsomal enzyme systems responsible for the metabolism of drug2,False, 
DDI-DrugBank.d277.s27.e0,DDI-DrugBank.d277.s27.e1,Interaction of drug1 with Highly Protein Bound Drugs: In vitro data showed that drug2,False, 
DDI-DrugBank.d458.s3.e0,DDI-DrugBank.d458.s3.e1,"The following drug interactions have been identified involving drug1 Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: drug2 tablets inhibit the metabolism of drug0, resulting in an increased plasma concentration of drug0",False, 
DDI-DrugBank.d458.s3.e0,DDI-DrugBank.d458.s3.e2,"The following drug interactions have been identified involving drug1 Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: drug0 tablets inhibit the metabolism of drug2, resulting in an increased plasma concentration of drug0",False, 
DDI-DrugBank.d458.s3.e1,DDI-DrugBank.d458.s3.e2,"The following drug interactions have been identified involving drug0 Tablets and other drugs metabolized by the cytochrome P450 3A4 enzyme system: drug1 tablets inhibit the metabolism of drug2, resulting in an increased plasma concentration of drug0",True,mechanism
DDI-DrugBank.d458.s5.e0,DDI-DrugBank.d458.s5.e1,"Pharmacokinetic data indicate that oral drug1 inhibits the metabolism of drug2, resulting in elevated plasma levels of drug0 and its active metabolite drug0",True,effect
DDI-DrugBank.d458.s5.e0,DDI-DrugBank.d458.s5.e2,"Pharmacokinetic data indicate that oral drug1 inhibits the metabolism of drug0, resulting in elevated plasma levels of drug2 and its active metabolite drug0",False, 
DDI-DrugBank.d458.s5.e0,DDI-DrugBank.d458.s5.e3,"Pharmacokinetic data indicate that oral drug1 inhibits the metabolism of drug0, resulting in elevated plasma levels of drug0 and its active metabolite drug2",False, 
DDI-DrugBank.d458.s6.e0,DDI-DrugBank.d458.s6.e1,Coadministration of drug1 with drug2,True,advise
DDI-DrugBank.d458.s7.e0,DDI-DrugBank.d458.s7.e1,Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug2 resulting in a mean eight-fold increase in AUC of drug0,True,mechanism
DDI-DrugBank.d458.s7.e0,DDI-DrugBank.d458.s7.e2,Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug0 resulting in a mean eight-fold increase in AUC of drug2,False, 
DDI-DrugBank.d458.s7.e1,DDI-DrugBank.d458.s7.e2,Human pharmacokinetics data indicate that oral drug0 potently inhibits the metabolism of drug1 resulting in a mean eight-fold increase in AUC of drug2,False, 
DDI-DrugBank.d458.s8.e0,DDI-DrugBank.d458.s8.e1,Data suggest that coadministration of oral drug1 and drug2,True,effect
DDI-DrugBank.d458.s9.e0,DDI-DrugBank.d458.s9.e1,Therefore concomitant administration of drug1 tablets with drug2,True,advise
DDI-DrugBank.d458.s10.e0,DDI-DrugBank.d458.s10.e1,"drug1 tablets may alter the metabolism of drug2, drug0, and drug0",True,mechanism
DDI-DrugBank.d458.s10.e0,DDI-DrugBank.d458.s10.e2,"drug1 tablets may alter the metabolism of drug0, drug2, and drug0",True,mechanism
DDI-DrugBank.d458.s10.e0,DDI-DrugBank.d458.s10.e3,"drug1 tablets may alter the metabolism of drug0, drug0, and drug2",True,mechanism
DDI-DrugBank.d458.s10.e1,DDI-DrugBank.d458.s10.e2,"drug0 tablets may alter the metabolism of drug1, drug2, and drug0",False, 
DDI-DrugBank.d458.s10.e1,DDI-DrugBank.d458.s10.e3,"drug0 tablets may alter the metabolism of drug1, drug0, and drug2",False, 
DDI-DrugBank.d458.s11.e0,DDI-DrugBank.d458.s11.e1,"Dosage adjustment may be required if drug1, drug2, or drug0 are given concomitantly with drug0",False, 
DDI-DrugBank.d458.s11.e0,DDI-DrugBank.d458.s11.e2,"Dosage adjustment may be required if drug1, drug0, or drug2 are given concomitantly with drug0",False, 
DDI-DrugBank.d458.s12.e0,DDI-DrugBank.d458.s12.e1,Coadministration of drug1  Tablets with drug2 or drug0,True,mechanism
DDI-DrugBank.d458.s12.e0,DDI-DrugBank.d458.s12.e2,Coadministration of drug1  Tablets with drug0 or drug2,True,mechanism
DDI-DrugBank.d458.s12.e1,DDI-DrugBank.d458.s12.e2,Coadministration of drug0  Tablets with drug1 or drug2,False, 
DDI-DrugBank.d458.s18.e0,DDI-DrugBank.d458.s18.e1,"It is, therefore, advisable to monitor drug1 concentrations in patients receiving drug2",True,advise
DDI-DrugBank.d458.s19.e0,DDI-DrugBank.d458.s19.e1,"When taken orally , drug1 like drug2 may enhance the anticoagulant effect of drug0",False, 
DDI-DrugBank.d458.s19.e0,DDI-DrugBank.d458.s19.e2,"When taken orally , drug1 like drug0 may enhance the anticoagulant effect of drug2",True,effect
DDI-DrugBank.d458.s19.e1,DDI-DrugBank.d458.s19.e2,"When taken orally , drug0 like drug1 may enhance the anticoagulant effect of drug2",True,effect
DDI-DrugBank.d458.s20.e0,DDI-DrugBank.d458.s20.e1,In simultaneous treatment with drug1 and drug2,True,advise
DDI-DrugBank.d458.s21.e0,DDI-DrugBank.d458.s21.e1,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral drug1 (an drug2) and oral drug0, such a potential interaction involving the latter agents when used concomitantly with drug0 tablets (an drug0",False, 
DDI-DrugBank.d458.s21.e0,DDI-DrugBank.d458.s21.e2,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral drug1 (an drug0) and oral drug2, such a potential interaction involving the latter agents when used concomitantly with drug0 tablets (an drug0",True,effect
DDI-DrugBank.d458.s21.e0,DDI-DrugBank.d458.s21.e3,"Because severe hypoglycemia has been reported in patients concomitantly receiving oral drug1 (an drug0) and oral drug0, such a potential interaction involving the latter agents when used concomitantly with drug2 tablets (an drug0",False, 
DDI-DrugBank.d458.s22.e0,DDI-DrugBank.d458.s22.e1,Concomitant administration of drug1 tablets with drug2,True,mechanism
DDI-DrugBank.d458.s23.e0,DDI-DrugBank.d458.s23.e1,It is suggested to monitor both drug1 and drug2,True,advise
DDI-DrugBank.d458.s24.e0,DDI-DrugBank.d458.s24.e1,Concomitant administration of drug1 with drug2,True,mechanism
DDI-DrugBank.d458.s25.e0,DDI-DrugBank.d458.s25.e1,drug1 (drug2) is also reported to affect drug0,False, 
DDI-DrugBank.d458.s25.e0,DDI-DrugBank.d458.s25.e2,drug1 (drug0) is also reported to affect drug2,True,mechanism
DDI-DrugBank.d458.s25.e1,DDI-DrugBank.d458.s25.e2,drug0 (drug1) is also reported to affect drug2,True,mechanism
DDI-DrugBank.d458.s27.e0,DDI-DrugBank.d458.s27.e1,"After the coadministration of 200 mg oral drug1 twice daily and one 20 mg dose of drug2 to 11 subjects, the AUC and Cmax of drug0",True,mechanism
DDI-DrugBank.d458.s27.e0,DDI-DrugBank.d458.s27.e2,"After the coadministration of 200 mg oral drug1 twice daily and one 20 mg dose of drug0 to 11 subjects, the AUC and Cmax of drug2",False, 
DDI-DrugBank.d458.s27.e1,DDI-DrugBank.d458.s27.e2,"After the coadministration of 200 mg oral drug0 twice daily and one 20 mg dose of drug1 to 11 subjects, the AUC and Cmax of drug2",False, 
DDI-DrugBank.d458.s30.e0,DDI-DrugBank.d458.s30.e1,"Also, there were no clinically significant differences in adverse events when drug1 was administered with or without drug2",False, 
DDI-DrugBank.d127.s2.e0,DDI-DrugBank.d127.s2.e1,drug1  may interact with drugs known to interact with the conventional formulation of drug2,False, 
DDI-DrugBank.d224.s0.e0,DDI-DrugBank.d224.s0.e1,drug1 should not be used in patients receiving drug2,True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e1,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug2 (drug0, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e2,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug0 (drug2, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e3,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug0 (drug0, drug2, drug0, drug0, drug0",True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e4,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug2, drug0, drug0",True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e5,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug0, drug2, drug0",True,advise
DDI-DrugBank.d224.s1.e0,DDI-DrugBank.d224.s1.e6,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug1 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug0, drug0, drug2",True,advise
DDI-DrugBank.d224.s1.e1,DDI-DrugBank.d224.s1.e2,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug0 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug1 (drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d224.s1.e1,DDI-DrugBank.d224.s1.e3,"Although no specific drug interactions with topical glaucoma drugs or systemic medications were identified in clinical studies of drug0 0.5% Ophthalmic Solution, the possibility of an additive or potentiating effect with drug1 (drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d224.s2.e0,DDI-DrugBank.d224.s2.e1,drug1 have been reported to blunt the hypotensive effect of systemic drug2,True,effect
DDI-DrugBank.d224.s6.e0,DDI-DrugBank.d224.s6.e1,An additive hypotensive effect has been reported with the combination of systemic drug1 and drug2,True,effect
DDI-DrugBank.d224.s8.e0,DDI-DrugBank.d224.s8.e1,"Since drug1 may reduce pulse and blood pressure, caution in using drugs such as drug2 (ophthalmic and systemic), drug0, and drug0",True,advise
DDI-DrugBank.d224.s8.e0,DDI-DrugBank.d224.s8.e2,"Since drug1 may reduce pulse and blood pressure, caution in using drugs such as drug0 (ophthalmic and systemic), drug2, and drug0",True,advise
DDI-DrugBank.d224.s8.e0,DDI-DrugBank.d224.s8.e3,"Since drug1 may reduce pulse and blood pressure, caution in using drugs such as drug0 (ophthalmic and systemic), drug0, and drug2",True,advise
DDI-DrugBank.d224.s8.e1,DDI-DrugBank.d224.s8.e2,"Since drug0 may reduce pulse and blood pressure, caution in using drugs such as drug1 (ophthalmic and systemic), drug2, and drug0",False, 
DDI-DrugBank.d224.s8.e1,DDI-DrugBank.d224.s8.e3,"Since drug0 may reduce pulse and blood pressure, caution in using drugs such as drug1 (ophthalmic and systemic), drug0, and drug2",False, 
DDI-DrugBank.d170.s0.e0,DDI-DrugBank.d170.s0.e1,"Agents Affecting Cytochrome P450 3A4 Isoenzyme System drug1 is metabolized mainly via the human cytochrome P450 3A4 isoenzyme system (CYP3A4), therefore potential interactions may occur when drug2",False, 
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e1,"The concomitant use of transdermal drug1 with drug2 or other potent 3A4 inhibitors such as drug0, drug0, drug0, drug0, drug0, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e2,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug2, drug0, drug0, drug0, drug0, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e3,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug0, drug2, drug0, drug0, drug0, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e4,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug0, drug0, drug2, drug0, drug0, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e5,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug0, drug0, drug0, drug2, drug0, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e6,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug0, drug0, drug0, drug0, drug2, and nefazadone may result in an increase in drug0",True,mechanism
DDI-DrugBank.d170.s2.e0,DDI-DrugBank.d170.s2.e7,"The concomitant use of transdermal drug1 with drug0 or other potent 3A4 inhibitors such as drug0, drug0, drug0, drug0, drug0, and nefazadone may result in an increase in drug2",False, 
DDI-DrugBank.d170.s2.e1,DDI-DrugBank.d170.s2.e2,"The concomitant use of transdermal drug0 with drug1 or other potent 3A4 inhibitors such as drug2, drug0, drug0, drug0, drug0, and nefazadone may result in an increase in drug0",False, 
DDI-DrugBank.d170.s3.e0,DDI-DrugBank.d170.s3.e1,The concomitant use of other CYP3A4 inhibitors such as drug1 and drug2 with transdermal drug0 may also result in an increase in drug0,False, 
DDI-DrugBank.d170.s3.e0,DDI-DrugBank.d170.s3.e2,The concomitant use of other CYP3A4 inhibitors such as drug1 and drug0 with transdermal drug2 may also result in an increase in drug0,True,mechanism
DDI-DrugBank.d170.s3.e0,DDI-DrugBank.d170.s3.e3,The concomitant use of other CYP3A4 inhibitors such as drug1 and drug0 with transdermal drug0 may also result in an increase in drug2,False, 
DDI-DrugBank.d170.s3.e1,DDI-DrugBank.d170.s3.e2,The concomitant use of other CYP3A4 inhibitors such as drug0 and drug1 with transdermal drug2 may also result in an increase in drug0,True,mechanism
DDI-DrugBank.d170.s5.e0,DDI-DrugBank.d170.s5.e1,"drug1: The concomitant use of drug2  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d170.s5.e0,DDI-DrugBank.d170.s5.e2,"drug1: The concomitant use of drug0  (drug2 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e3,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug2, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e4,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug2, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e5,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug2, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e6,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug2, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e7,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug2 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e8,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug2), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e9,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e10,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e11,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d170.s5.e1,DDI-DrugBank.d170.s5.e12,"drug0: The concomitant use of drug1  (drug0 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e3,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug2, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e4,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug2, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e5,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug2, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e6,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug2, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e7,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug2 (e.g., drug0), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e8,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug2), general drug0, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e9,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug2, drug0, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e10,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug2, drug0, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e11,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug2, and drug0",True,effect
DDI-DrugBank.d170.s5.e2,DDI-DrugBank.d170.s5.e12,"drug0: The concomitant use of drug0  (drug1 transdermal system) with other drug0, including but not limited to other drug0, drug0, drug0, drug0 (e.g., drug0), general drug0, drug0, drug0, and drug2",True,effect
DDI-DrugBank.d170.s7.e0,DDI-DrugBank.d170.s7.e1,drug1: drug2  is not recommended for use in patients who have received drug0 within 14 days because severe and unpredictable potentiation by drug0 has been reported with drug0,False, 
DDI-DrugBank.d170.s7.e0,DDI-DrugBank.d170.s7.e2,drug1: drug0  is not recommended for use in patients who have received drug2 within 14 days because severe and unpredictable potentiation by drug0 has been reported with drug0,False, 
DDI-DrugBank.d170.s7.e1,DDI-DrugBank.d170.s7.e2,drug0: drug1  is not recommended for use in patients who have received drug2 within 14 days because severe and unpredictable potentiation by drug0 has been reported with drug0,True,advise
DDI-DrugBank.d170.s7.e3,DDI-DrugBank.d170.s7.e4,drug0: drug0  is not recommended for use in patients who have received drug0 within 14 days because severe and unpredictable potentiation by drug1 has been reported with drug2,True,advise
DDI-DrugBank.d21.s0.e0,DDI-DrugBank.d21.s0.e1,Tissue culture and animal studies indicate that drug1 can diminish or abolish the effect of drug2 on malignant cells.14 This effect on drug0,True,effect
DDI-DrugBank.d21.s0.e0,DDI-DrugBank.d21.s0.e2,Tissue culture and animal studies indicate that drug1 can diminish or abolish the effect of drug0 on malignant cells.14 This effect on drug2,False, 
DDI-DrugBank.d21.s0.e1,DDI-DrugBank.d21.s0.e2,Tissue culture and animal studies indicate that drug0 can diminish or abolish the effect of drug1 on malignant cells.14 This effect on drug2,False, 
DDI-DrugBank.d21.s1.e0,DDI-DrugBank.d21.s1.e1,"These results would seem to dictate against the clinical use of drug1 with drug2, or during the period following drug0",True,advise
DDI-DrugBank.d21.s1.e0,DDI-DrugBank.d21.s1.e2,"These results would seem to dictate against the clinical use of drug1 with drug0, or during the period following drug2",False, 
DDI-DrugBank.d21.s1.e1,DDI-DrugBank.d21.s1.e2,"These results would seem to dictate against the clinical use of drug0 with drug1, or during the period following drug2",False, 
DDI-DrugBank.d16.s2.e0,DDI-DrugBank.d16.s2.e1,"Since drug1 may raise the serum uric acid level, dosage adjustment of drug2",True,effect
DDI-DrugBank.d405.s0.e0,DDI-DrugBank.d405.s0.e1,drug1 and drug2,False, 
DDI-DrugBank.d405.s1.e0,DDI-DrugBank.d405.s1.e1,"Other depressasnts such as drug1, drug2, and drug0 may enhance CNS depression when administered with drug0",False, 
DDI-DrugBank.d405.s1.e0,DDI-DrugBank.d405.s1.e2,"Other depressasnts such as drug1, drug0, and drug2 may enhance CNS depression when administered with drug0",False, 
DDI-DrugBank.d405.s1.e0,DDI-DrugBank.d405.s1.e3,"Other depressasnts such as drug1, drug0, and drug0 may enhance CNS depression when administered with drug2",True,effect
DDI-DrugBank.d405.s1.e1,DDI-DrugBank.d405.s1.e3,"Other depressasnts such as drug0, drug1, and drug0 may enhance CNS depression when administered with drug2",True,effect
DDI-DrugBank.d405.s1.e2,DDI-DrugBank.d405.s1.e3,"Other depressasnts such as drug0, drug0, and drug1 may enhance CNS depression when administered with drug2",True,effect
DDI-DrugBank.d321.s0.e0,DDI-DrugBank.d321.s0.e1,drug1: Steady-state trough concentrations of drug2 were about 56% higher when 8 mg drug0 was coadministered with each dose of drug0,False, 
DDI-DrugBank.d321.s0.e0,DDI-DrugBank.d321.s0.e2,drug1: Steady-state trough concentrations of drug0 were about 56% higher when 8 mg drug2 was coadministered with each dose of drug0,False, 
DDI-DrugBank.d321.s0.e2,DDI-DrugBank.d321.s0.e3,drug0: Steady-state trough concentrations of drug0 were about 56% higher when 8 mg drug1 was coadministered with each dose of drug2,True,mechanism
DDI-DrugBank.d321.s1.e0,DDI-DrugBank.d321.s1.e1,"drug1: In the fed state, drug2 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of drug0 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given drug0",False, 
DDI-DrugBank.d321.s1.e0,DDI-DrugBank.d321.s1.e2,"drug1: In the fed state, drug0 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of drug2 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given drug0",False, 
DDI-DrugBank.d321.s1.e1,DDI-DrugBank.d321.s1.e2,"drug0: In the fed state, drug1 (40 mg/kg) increased mean maximum plasma concentration and area under the curve of drug2 by about 50% in healthy subjects (n=10) compared with a separate group of subjects (n=6) given drug0",True,mechanism
DDI-DrugBank.d321.s3.e0,DDI-DrugBank.d321.s3.e1,The pharmacokinetics of drug1 were unchanged following coadministration with drug2,False, 
DDI-DrugBank.d321.s4.e0,DDI-DrugBank.d321.s4.e1,drug1: drug2 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with drug0 (10 mg/kg/day) (n=7) compared with drug0,False, 
DDI-DrugBank.d321.s4.e0,DDI-DrugBank.d321.s4.e2,drug1: drug0 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with drug2 (10 mg/kg/day) (n=7) compared with drug0,False, 
DDI-DrugBank.d321.s4.e1,DDI-DrugBank.d321.s4.e2,drug0: drug1 concentrations in bile and cystic fluid were increased (about 2-fold) in hydatid cyst patients treated with drug2 (10 mg/kg/day) (n=7) compared with drug0,True,mechanism
DDI-DrugBank.d321.s6.e0,DDI-DrugBank.d321.s6.e1,drug1: The pharmacokinetics of drug2 (drug0 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of drug0,False, 
DDI-DrugBank.d321.s6.e0,DDI-DrugBank.d321.s6.e2,drug1: The pharmacokinetics of drug0 (drug2 5.8 mg/kg infused over 20 minutes) were unchanged following a single oral dose of drug0,False, 
DDI-DrugBank.d367.s1.e0,DDI-DrugBank.d367.s1.e1,"In vitro data in human plasma indicate that drug1 has no effect on protein binding of drug2, drug0, drug0 or drug0",False, 
DDI-DrugBank.d367.s1.e0,DDI-DrugBank.d367.s1.e2,"In vitro data in human plasma indicate that drug1 has no effect on protein binding of drug0, drug2, drug0 or drug0",False, 
DDI-DrugBank.d367.s3.e0,DDI-DrugBank.d367.s3.e1,"drug1 has been administered without any evidence of an adverse drug interaction to patients receiving drug2, drug0s, and drug0",False, 
DDI-DrugBank.d367.s3.e0,DDI-DrugBank.d367.s3.e2,"drug1 has been administered without any evidence of an adverse drug interaction to patients receiving drug0, drug2s, and drug0",False, 
DDI-DrugBank.d367.s4.e0,DDI-DrugBank.d367.s4.e1,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of drug1 on day 1 of a four-day regimen of oral drug2 (400 mg twice daily) resulted in a 10% increase in mean AUC of drug0 (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of drug0",True,mechanism
DDI-DrugBank.d367.s4.e0,DDI-DrugBank.d367.s4.e2,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of drug1 on day 1 of a four-day regimen of oral drug0 (400 mg twice daily) resulted in a 10% increase in mean AUC of drug2 (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of drug0",False, 
DDI-DrugBank.d367.s4.e0,DDI-DrugBank.d367.s4.e3,"In a placebo-controlled trial in normal volunteers, the administration of a single 1 mg dose of drug1 on day 1 of a four-day regimen of oral drug0 (400 mg twice daily) resulted in a 10% increase in mean AUC of drug0 (p=0.006), and a slight but not statistically significant increase in mean Cmax and mean half-life of drug2",False, 
DDI-DrugBank.d367.s9.e0,DDI-DrugBank.d367.s9.e1,"drug1/drug2 (e.g., drug0, drug0, drug0 and drug0 combinations, drug0, drug0",False, 
DDI-DrugBank.d367.s9.e0,DDI-DrugBank.d367.s9.e2,"drug1/drug0 (e.g., drug2, drug0, drug0 and drug0 combinations, drug0, drug0",False, 
DDI-DrugBank.d367.s11.e0,DDI-DrugBank.d367.s11.e1,"drug1 (e.g., drug2, drug0 and drug0, drug0",False, 
DDI-DrugBank.d367.s11.e0,DDI-DrugBank.d367.s11.e2,"drug1 (e.g., drug0, drug2 and drug0, drug0",False, 
DDI-DrugBank.d367.s13.e0,DDI-DrugBank.d367.s13.e1,"drug1 (e.g., drug2",False, 
DDI-DrugBank.d367.s15.e0,DDI-DrugBank.d367.s15.e1,"Cardiovascular agents (e.g., drug1, drug2, drug0",False, 
DDI-DrugBank.d367.s15.e0,DDI-DrugBank.d367.s15.e2,"Cardiovascular agents (e.g., drug1, drug0, drug2",False, 
DDI-DrugBank.d367.s23.e0,DDI-DrugBank.d367.s23.e1,"drug1 and drug2 (e.g., drug0",False, 
DDI-DrugBank.d367.s23.e0,DDI-DrugBank.d367.s23.e2,"drug1 and drug0 (e.g., drug2",False, 
DDI-DrugBank.d212.s2.e0,DDI-DrugBank.d212.s2.e1,"In addition, drug1 does not affect the in vitro glucuronidation of drug2",False, 
DDI-DrugBank.d212.s5.e0,DDI-DrugBank.d212.s5.e1,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (drug1, drug2, oral drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d212.s5.e0,DDI-DrugBank.d212.s5.e2,"Potential pharmacokinetic interactions were assessed in clinical pharmacokinetic studies (drug1, drug0, oral drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d212.s6.e0,DDI-DrugBank.d212.s6.e1,Drug-Drug Interactions Between drug1  And Other drug2 (drug0) drug0 drug0  (3000 mg daily) had no effect on the pharmacokinetic disposition of drug0,False, 
DDI-DrugBank.d212.s6.e0,DDI-DrugBank.d212.s6.e2,Drug-Drug Interactions Between drug1  And Other drug0 (drug2) drug0 drug0  (3000 mg daily) had no effect on the pharmacokinetic disposition of drug0,False, 
DDI-DrugBank.d212.s7.e0,DDI-DrugBank.d212.s7.e1,Pharmacokinetics of drug1 were also not affected by drug2,False, 
DDI-DrugBank.d212.s8.e0,DDI-DrugBank.d212.s8.e1,drug1 drug2  (1500 mg twice daily) did not alter the pharmacokinetics of drug0,False, 
DDI-DrugBank.d212.s8.e0,DDI-DrugBank.d212.s8.e2,drug1 drug0  (1500 mg twice daily) did not alter the pharmacokinetics of drug2,False, 
DDI-DrugBank.d212.s9.e0,DDI-DrugBank.d212.s9.e1,drug1 500 mg twice daily did not modify the rate or extent of drug2,False, 
DDI-DrugBank.d212.s11.e0,DDI-DrugBank.d212.s11.e1,"Potential drug interactions between drug1  and other drug2 (drug0, drug0, drug0, drug0, drug0, drug0 and drug0) were also assessed by evaluating the serum concentrations of drug0 and these drug0",False, 
DDI-DrugBank.d212.s11.e0,DDI-DrugBank.d212.s11.e2,"Potential drug interactions between drug1  and other drug0 (drug2, drug0, drug0, drug0, drug0, drug0 and drug0) were also assessed by evaluating the serum concentrations of drug0 and these drug0",False, 
DDI-DrugBank.d212.s12.e0,DDI-DrugBank.d212.s12.e1,These data indicate that drug1 does not influence the plasma concentration of other drug2 and that these drug0 do not influence the pharmacokinetics of drug0,False, 
DDI-DrugBank.d212.s12.e0,DDI-DrugBank.d212.s12.e2,These data indicate that drug1 does not influence the plasma concentration of other drug0 and that these drug2 do not influence the pharmacokinetics of drug0,False, 
DDI-DrugBank.d212.s13.e0,DDI-DrugBank.d212.s13.e1,Effect of drug1 in Pediatric Patients There was about a 22% increase of apparent total body clearance of drug2 when it was co-administered with enzyme-inducing drug0,False, 
DDI-DrugBank.d212.s13.e0,DDI-DrugBank.d212.s13.e2,Effect of drug1 in Pediatric Patients There was about a 22% increase of apparent total body clearance of drug0 when it was co-administered with enzyme-inducing drug2,False, 
DDI-DrugBank.d212.s13.e1,DDI-DrugBank.d212.s13.e2,Effect of drug0 in Pediatric Patients There was about a 22% increase of apparent total body clearance of drug1 when it was co-administered with enzyme-inducing drug2,True,mechanism
DDI-DrugBank.d212.s14.e0,DDI-DrugBank.d212.s14.e1,"Dose adjustment is not recommended.drug1 had no effect on plasma concentrations of drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d212.s14.e0,DDI-DrugBank.d212.s14.e2,"Dose adjustment is not recommended.drug1 had no effect on plasma concentrations of drug0, drug2, drug0, or drug0",False, 
DDI-DrugBank.d212.s15.e0,DDI-DrugBank.d212.s15.e1,Other Drug Interactions Oral drug1 drug2  (500 mg twice daily) did not influence the pharmacokinetics of an oral drug0 containing 0.03 mg drug0 and 0.15 mg drug0,False, 
DDI-DrugBank.d212.s15.e0,DDI-DrugBank.d212.s15.e2,Other Drug Interactions Oral drug1 drug0  (500 mg twice daily) did not influence the pharmacokinetics of an oral drug2 containing 0.03 mg drug0 and 0.15 mg drug0,False, 
DDI-DrugBank.d212.s16.e0,DDI-DrugBank.d212.s16.e1,Coadministration of this oral drug1 did not influence the pharmacokinetics of drug2,False, 
DDI-DrugBank.d212.s17.e0,DDI-DrugBank.d212.s17.e1,drug1 drug2  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of drug0,False, 
DDI-DrugBank.d212.s17.e0,DDI-DrugBank.d212.s17.e2,drug1 drug0  (1000 mg twice daily) did not influence the pharmacokinetics and pharmacodynamics (ECG) of drug2,False, 
DDI-DrugBank.d212.s18.e0,DDI-DrugBank.d212.s18.e1,Coadministration of drug1 did not influence the pharmacokinetics of drug2,False, 
DDI-DrugBank.d212.s19.e0,DDI-DrugBank.d212.s19.e1,drug1 drug2  (1000 mg twice daily) did not influence the pharmacokinetics of drug0 and drug0,False, 
DDI-DrugBank.d212.s19.e0,DDI-DrugBank.d212.s19.e2,drug1 drug0  (1000 mg twice daily) did not influence the pharmacokinetics of drug2 and drug0,False, 
DDI-DrugBank.d212.s21.e0,DDI-DrugBank.d212.s21.e1,Coadministration of drug1 did not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d212.s22.e0,DDI-DrugBank.d212.s22.e1,"drug1: drug2, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of drug0",False, 
DDI-DrugBank.d212.s22.e0,DDI-DrugBank.d212.s22.e2,"drug1: drug0, a renal tubular secretion blocking agent, administered at a dose of 500 mg four times a day, did not change the pharmacokinetics of drug2",False, 
DDI-DrugBank.d212.s25.e0,DDI-DrugBank.d212.s25.e1,The effect of drug1  on drug2,False, 
DDI-DrugBank.d114.s1.e0,DDI-DrugBank.d114.s1.e1,"Therefore, interactions could occur following concomitant administration of drug1 (e.g., drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d114.s1.e0,DDI-DrugBank.d114.s1.e2,"Therefore, interactions could occur following concomitant administration of drug1 (e.g., drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d114.s2.e0,DDI-DrugBank.d114.s2.e1,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug1, drug2), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug0) effects with drug0",False, 
DDI-DrugBank.d114.s2.e0,DDI-DrugBank.d114.s2.e2,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug1, drug0), myelotoxic (e.g., drug2 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug0) effects with drug0",False, 
DDI-DrugBank.d114.s2.e0,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug1, drug0), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug0) effects with drug2",True,effect
DDI-DrugBank.d114.s2.e1,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug0, drug1), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug0) effects with drug2",True,effect
DDI-DrugBank.d114.s2.e2,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug0, drug0), myelotoxic (e.g., drug1 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug0) effects with drug2",True,effect
DDI-DrugBank.d114.s2.e3,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug0, drug0), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug1) or hepatotoxic (e.g., drug0, drug0) effects with drug2",True,effect
DDI-DrugBank.d114.s2.e4,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug0, drug0), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug1, drug0) effects with drug2",True,effect
DDI-DrugBank.d114.s2.e5,DDI-DrugBank.d114.s2.e6,"Concurrent administration of drugs possessing nephrotoxic (e.g., drug0, drug0), myelotoxic (e.g., drug0 chemotherapy), cardiotoxic (e.g., drug0) or hepatotoxic (e.g., drug0, drug1) effects with drug2",True,effect
DDI-DrugBank.d114.s3.e0,DDI-DrugBank.d114.s3.e1,The safety and efficacy of drug1 in combination with any drug2,False, 
DDI-DrugBank.d114.s5.e0,DDI-DrugBank.d114.s5.e1,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug2, specifically, drug0, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d114.s5.e0,DDI-DrugBank.d114.s5.e2,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug0, specifically, drug2, drug0, drug0 and drug0",True,effect
DDI-DrugBank.d114.s5.e0,DDI-DrugBank.d114.s5.e3,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug0, specifically, drug0, drug2, drug0 and drug0",True,effect
DDI-DrugBank.d114.s5.e0,DDI-DrugBank.d114.s5.e4,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug0, specifically, drug0, drug0, drug2 and drug0",True,effect
DDI-DrugBank.d114.s5.e0,DDI-DrugBank.d114.s5.e5,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug1 and drug0, specifically, drug0, drug0, drug0 and drug2",True,effect
DDI-DrugBank.d114.s5.e1,DDI-DrugBank.d114.s5.e2,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug0 and drug1, specifically, drug2, drug0, drug0 and drug0",False, 
DDI-DrugBank.d114.s5.e1,DDI-DrugBank.d114.s5.e3,"Hypersensitivity reactions have been reported in patients receiving combination regimens containing sequential high dose drug0 and drug1, specifically, drug0, drug2, drug0 and drug0",False, 
DDI-DrugBank.d114.s8.e0,DDI-DrugBank.d114.s8.e1,"Myocardial injury, including myocardial infarction, myocarditis, ventricular hypokinesia, and severe rhabdomyolysis appear to be increased in patients receiving drug1 and drug2",True,effect
DDI-DrugBank.d114.s9.e0,DDI-DrugBank.d114.s9.e1,Exacerbation or the initial presentation of a number of autoimmune and inflammatory disorders has been observed following concurrent use of drug1 and drug2,True,effect
DDI-DrugBank.d114.s10.e0,DDI-DrugBank.d114.s10.e1,"Although drug1 have been shown to reduce drug2-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with drug0 may reduce the antitumor effectiveness of drug0 and thus should be avoided. 12 drug0 and other drug0 may potentiate the hypotension seen with drug0",True,effect
DDI-DrugBank.d114.s10.e0,DDI-DrugBank.d114.s10.e2,"Although drug1 have been shown to reduce drug0-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with drug2 may reduce the antitumor effectiveness of drug0 and thus should be avoided. 12 drug0 and other drug0 may potentiate the hypotension seen with drug0",False, 
DDI-DrugBank.d114.s10.e0,DDI-DrugBank.d114.s10.e3,"Although drug1 have been shown to reduce drug0-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with drug0 may reduce the antitumor effectiveness of drug2 and thus should be avoided. 12 drug0 and other drug0 may potentiate the hypotension seen with drug0",False, 
DDI-DrugBank.d114.s10.e4,DDI-DrugBank.d114.s10.e6,"Although drug0 have been shown to reduce drug0-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with drug0 may reduce the antitumor effectiveness of drug0 and thus should be avoided. 12 drug1 and other drug0 may potentiate the hypotension seen with drug2",True,effect
DDI-DrugBank.d114.s10.e5,DDI-DrugBank.d114.s10.e6,"Although drug0 have been shown to reduce drug0-induced side effects including fever, renal insufficiency, hyperbilirubinemia, confusion, and dyspnea, concomitant administration of these agents with drug0 may reduce the antitumor effectiveness of drug0 and thus should be avoided. 12 drug0 and other drug1 may potentiate the hypotension seen with drug2",True,effect
DDI-DrugBank.d114.s11.e0,DDI-DrugBank.d114.s11.e1,Delayed Adverse Reactions to drug1: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various drug2 containing regimens who were subsequently administered drug0,False, 
DDI-DrugBank.d114.s11.e0,DDI-DrugBank.d114.s11.e2,Delayed Adverse Reactions to drug1: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various drug0 containing regimens who were subsequently administered drug2,False, 
DDI-DrugBank.d114.s11.e1,DDI-DrugBank.d114.s11.e2,Delayed Adverse Reactions to drug0: A review of the literature revealed that 12.6% (range 11-28%) of 501 patients treated with various drug1 containing regimens who were subsequently administered drug2,True,effect
DDI-DrugBank.d571.s4.e0,DDI-DrugBank.d571.s4.e1,Patients on oral drug1 receiving drug2 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drug0,True,advise
DDI-DrugBank.d571.s4.e0,DDI-DrugBank.d571.s4.e2,Patients on oral drug1 receiving drug0 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drug2,False, 
DDI-DrugBank.d571.s4.e1,DDI-DrugBank.d571.s4.e2,Patients on oral drug0 receiving drug1 treatment may require close monitoring of their blood glucose levels and adjustment of the dose of their drug2,False, 
DDI-DrugBank.d376.s0.e0,DDI-DrugBank.d376.s0.e1,"May interact with addictive medications, especially drug1 with habituating potential (prolonged concurrent use may increase the risk of habituation), drug2 or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or drug0",False, 
DDI-DrugBank.d376.s0.e0,DDI-DrugBank.d376.s0.e2,"May interact with addictive medications, especially drug1 with habituating potential (prolonged concurrent use may increase the risk of habituation), drug0 or CNS depression producing medications (concurrent use may increase the CNS depressant effects of either these medications or drug2",False, 
DDI-DrugBank.d29.s3.e0,DDI-DrugBank.d29.s3.e1,"Drug interaction studies have shown that drug1 does not have any clinically significant interactions with drug2, drug0, drug0, drug0 or drug0",False, 
DDI-DrugBank.d29.s3.e0,DDI-DrugBank.d29.s3.e2,"Drug interaction studies have shown that drug1 does not have any clinically significant interactions with drug0, drug2, drug0, drug0 or drug0",False, 
DDI-DrugBank.d29.s4.e0,DDI-DrugBank.d29.s4.e1,Post-marketing reports of changes in prothrombin measures have been received among patients on concomitant drug1 and drug2,False, 
DDI-DrugBank.d29.s6.e0,DDI-DrugBank.d29.s6.e1,Patients treated with drug1 and drug2,True,effect
DDI-DrugBank.d29.s7.e0,DDI-DrugBank.d29.s7.e1,"drug1 may potentially interfere with CYP2C19, the major drug2",False, 
DDI-DrugBank.d29.s8.e0,DDI-DrugBank.d29.s8.e1,"Coadministration of drug1 30 mg and drug2, a CYP2C19 substrate, resulted in a 45% decrease in clearance of drug0",True,mechanism
DDI-DrugBank.d29.s8.e0,DDI-DrugBank.d29.s8.e2,"Coadministration of drug1 30 mg and drug0, a CYP2C19 substrate, resulted in a 45% decrease in clearance of drug2",False, 
DDI-DrugBank.d29.s8.e1,DDI-DrugBank.d29.s8.e2,"Coadministration of drug0 30 mg and drug1, a CYP2C19 substrate, resulted in a 45% decrease in clearance of drug2",False, 
DDI-DrugBank.d29.s12.e0,DDI-DrugBank.d29.s12.e1,"Therefore, drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, drug2, drug0 salts and drug0",True,mechanism
DDI-DrugBank.d29.s12.e0,DDI-DrugBank.d29.s12.e2,"Therefore, drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, drug0, drug2 salts and drug0",True,mechanism
DDI-DrugBank.d29.s12.e0,DDI-DrugBank.d29.s12.e3,"Therefore, drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, drug0, drug0 salts and drug2",True,mechanism
DDI-DrugBank.d29.s12.e1,DDI-DrugBank.d29.s12.e2,"Therefore, drug0 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, drug1, drug2 salts and drug0",False, 
DDI-DrugBank.d29.s12.e1,DDI-DrugBank.d29.s12.e3,"Therefore, drug0 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (eg, drug1, drug0 salts and drug2",False, 
DDI-DrugBank.d29.s13.e0,DDI-DrugBank.d29.s13.e1,"Coadministration of oral drug1, drug2, drug0, or drug0 did not seem to change the pharmacokinetic profile of drug0",False, 
DDI-DrugBank.d29.s13.e0,DDI-DrugBank.d29.s13.e2,"Coadministration of oral drug1, drug0, drug2, or drug0 did not seem to change the pharmacokinetic profile of drug0",False, 
DDI-DrugBank.d29.s14.e0,DDI-DrugBank.d29.s14.e1,Concomitant administration of drug1 with drug2,True,advise
DDI-DrugBank.d150.s0.e0,DDI-DrugBank.d150.s0.e1,drug1 may have life-threatening interactions with drug2,True,int
DDI-DrugBank.d150.s1.e0,DDI-DrugBank.d150.s1.e1,"drug1 may enhance the effects of drug2, drug0, and other drug0",True,effect
DDI-DrugBank.d150.s1.e0,DDI-DrugBank.d150.s1.e2,"drug1 may enhance the effects of drug0, drug2, and other drug0",True,effect
DDI-DrugBank.d150.s1.e0,DDI-DrugBank.d150.s1.e3,"drug1 may enhance the effects of drug0, drug0, and other drug2",True,effect
DDI-DrugBank.d150.s1.e1,DDI-DrugBank.d150.s1.e2,"drug0 may enhance the effects of drug1, drug2, and other drug0",False, 
DDI-DrugBank.d150.s1.e1,DDI-DrugBank.d150.s1.e3,"drug0 may enhance the effects of drug1, drug0, and other drug2",False, 
DDI-DrugBank.d150.s2.e0,DDI-DrugBank.d150.s2.e1,drug1 may block the antihypertensive action of drug2,True,effect
DDI-DrugBank.d150.s3.e0,DDI-DrugBank.d150.s3.e1,drug1 may enhance the seizure risk in patients taking drug2,True,effect
DDI-DrugBank.d239.s2.e0,DDI-DrugBank.d239.s2.e1,"The co-administration of drug1 with IV drug2 such as drug0, drug0, drug0, or IV drug0 has not been evaluated (these drugs were not co-administered with drug0",False, 
DDI-DrugBank.d239.s2.e0,DDI-DrugBank.d239.s2.e2,"The co-administration of drug1 with IV drug0 such as drug2, drug0, drug0, or IV drug0 has not been evaluated (these drugs were not co-administered with drug0",False, 
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e1,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug2 (drug0, drug0, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e2,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug0 (drug2, drug0, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e3,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug0 (drug0, drug2, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e4,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug2, drug0, or drug0",True,advise
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e5,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug0, drug2, or drug0",True,advise
DDI-DrugBank.d138.s0.e0,DDI-DrugBank.d138.s0.e6,"Although specific drug interaction studies have not been conducted with drug1, the possibility of an additive or potentiating effect with drug0 (drug0, drug0, drug0, drug0, or drug2",True,advise
DDI-DrugBank.d138.s0.e1,DDI-DrugBank.d138.s0.e2,"Although specific drug interaction studies have not been conducted with drug0, the possibility of an additive or potentiating effect with drug1 (drug2, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d138.s0.e1,DDI-DrugBank.d138.s0.e3,"Although specific drug interaction studies have not been conducted with drug0, the possibility of an additive or potentiating effect with drug1 (drug0, drug2, drug0, drug0, or drug0",False, 
DDI-DrugBank.d138.s2.e0,DDI-DrugBank.d138.s2.e1,"Caution in using concomitant drugs such as drug1 (ophthalmic and systemic), drug2 and/or drug0",False, 
DDI-DrugBank.d138.s2.e0,DDI-DrugBank.d138.s2.e2,"Caution in using concomitant drugs such as drug1 (ophthalmic and systemic), drug0 and/or drug2",False, 
DDI-DrugBank.d138.s3.e0,DDI-DrugBank.d138.s3.e1,drug1 have been reported to blunt the hypotensive effect of systemic drug2.It is not known whether the concurrent use of these agents with drug0,True,effect
DDI-DrugBank.d138.s3.e0,DDI-DrugBank.d138.s3.e2,drug1 have been reported to blunt the hypotensive effect of systemic drug0.It is not known whether the concurrent use of these agents with drug2,False, 
DDI-DrugBank.d138.s3.e1,DDI-DrugBank.d138.s3.e2,drug0 have been reported to blunt the hypotensive effect of systemic drug1.It is not known whether the concurrent use of these agents with drug2,False, 
DDI-DrugBank.d226.s0.e0,DDI-DrugBank.d226.s0.e1,"Intravenous drug1 (drug2) has been effectively administered in the presence of other cardioactive drugs, such as drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d226.s0.e0,DDI-DrugBank.d226.s0.e2,"Intravenous drug1 (drug0) has been effectively administered in the presence of other cardioactive drugs, such as drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d226.s1.e0,DDI-DrugBank.d226.s1.e1,drug1 and drug2 use may be rarely associated with ventricular fibrillation when combined with drug0,False, 
DDI-DrugBank.d226.s1.e0,DDI-DrugBank.d226.s1.e2,drug1 and drug0 use may be rarely associated with ventricular fibrillation when combined with drug2,True,effect
DDI-DrugBank.d226.s1.e1,DDI-DrugBank.d226.s1.e2,drug0 and drug1 use may be rarely associated with ventricular fibrillation when combined with drug2,True,effect
DDI-DrugBank.d226.s3.e0,DDI-DrugBank.d226.s3.e1,The use of drug1 in patients receiving drug2,True,effect
DDI-DrugBank.d226.s4.e0,DDI-DrugBank.d226.s4.e1,The effects of drug1 are antagonized by drug2 such as drug0 and drug0,True,effect
DDI-DrugBank.d226.s4.e0,DDI-DrugBank.d226.s4.e2,The effects of drug1 are antagonized by drug0 such as drug2 and drug0,True,effect
DDI-DrugBank.d226.s4.e0,DDI-DrugBank.d226.s4.e3,The effects of drug1 are antagonized by drug0 such as drug0 and drug2,True,effect
DDI-DrugBank.d226.s4.e1,DDI-DrugBank.d226.s4.e2,The effects of drug0 are antagonized by drug1 such as drug2 and drug0,False, 
DDI-DrugBank.d226.s4.e1,DDI-DrugBank.d226.s4.e3,The effects of drug0 are antagonized by drug1 such as drug0 and drug2,False, 
DDI-DrugBank.d226.s5.e0,DDI-DrugBank.d226.s5.e1,"In the presence of these drug1, larger doses of drug2 may be required or drug0",True,advise
DDI-DrugBank.d226.s5.e0,DDI-DrugBank.d226.s5.e2,"In the presence of these drug1, larger doses of drug0 may be required or drug2",True,advise
DDI-DrugBank.d226.s5.e1,DDI-DrugBank.d226.s5.e2,"In the presence of these drug0, larger doses of drug1 may be required or drug2",False, 
DDI-DrugBank.d226.s6.e0,DDI-DrugBank.d226.s6.e1,drug1 effects are potentiated by drug2,True,effect
DDI-DrugBank.d226.s7.e0,DDI-DrugBank.d226.s7.e1,"Thus, smaller doses of drug1 may be effective in the presence of drug2",True,effect
DDI-DrugBank.d226.s9.e0,DDI-DrugBank.d226.s9.e1,"As the primary effect of drug1 is to decrease conduction through the A-V node, higher degrees of heart block may be produced in the presence of drug2",True,effect
DDI-DrugBank.d54.s0.e0,DDI-DrugBank.d54.s0.e1,Oral drug1: drug2,False, 
DDI-DrugBank.d54.s2.e0,DDI-DrugBank.d54.s2.e1,Patients stabilized on oral drug1 who are found to require drug2,True,advise
DDI-DrugBank.d54.s5.e0,DDI-DrugBank.d54.s5.e1,drug1 or Oral drug2: Initiating thyroid replacement therapy may cause increases in drug0 or oral drug0,False, 
DDI-DrugBank.d54.s5.e0,DDI-DrugBank.d54.s5.e2,drug1 or Oral drug0: Initiating thyroid replacement therapy may cause increases in drug2 or oral drug0,False, 
DDI-DrugBank.d54.s7.e0,DDI-DrugBank.d54.s7.e1,Patients receiving drug1 or oral drug2,False, 
DDI-DrugBank.d54.s8.e0,DDI-DrugBank.d54.s8.e1,"drug1: drug2 binds both drug0 and drug0 in the intestine, thus impairing absorption of these drug0",False, 
DDI-DrugBank.d54.s8.e0,DDI-DrugBank.d54.s8.e2,"drug1: drug0 binds both drug2 and drug0 in the intestine, thus impairing absorption of these drug0",False, 
DDI-DrugBank.d54.s8.e1,DDI-DrugBank.d54.s8.e2,"drug0: drug1 binds both drug2 and drug0 in the intestine, thus impairing absorption of these drug0",True,mechanism
DDI-DrugBank.d54.s8.e1,DDI-DrugBank.d54.s8.e3,"drug0: drug1 binds both drug0 and drug2 in the intestine, thus impairing absorption of these drug0",True,mechanism
DDI-DrugBank.d54.s10.e0,DDI-DrugBank.d54.s10.e1,"Therefore, 4 to 5 hours should elapse between administration of drug1 and drug2",True,advise
DDI-DrugBank.d54.s11.e0,DDI-DrugBank.d54.s11.e1,"drug1, Oral drug2: drug0",False, 
DDI-DrugBank.d54.s11.e0,DDI-DrugBank.d54.s11.e2,"drug1, Oral drug0: drug2",False, 
DDI-DrugBank.d54.s12.e0,DDI-DrugBank.d54.s12.e1,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free drug1 may be decreased when drug2 are started thus increasing drug0",True,mechanism
DDI-DrugBank.d54.s12.e0,DDI-DrugBank.d54.s12.e2,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free drug1 may be decreased when drug0 are started thus increasing drug2",False, 
DDI-DrugBank.d54.s12.e1,DDI-DrugBank.d54.s12.e2,"In a patient with a nonfunctioning thyroid gland who is receiving thyroid replacement therapy, free drug0 may be decreased when drug1 are started thus increasing drug2",False, 
DDI-DrugBank.d54.s14.e0,DDI-DrugBank.d54.s14.e1,"Therefore, patients without a functioning drug1 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug2 or drug0-containing oral drug0",True,advise
DDI-DrugBank.d54.s14.e0,DDI-DrugBank.d54.s14.e2,"Therefore, patients without a functioning drug1 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug0 or drug2-containing oral drug0",False, 
DDI-DrugBank.d54.s14.e0,DDI-DrugBank.d54.s14.e3,"Therefore, patients without a functioning drug1 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug0 or drug0-containing oral drug2",True,advise
DDI-DrugBank.d54.s14.e1,DDI-DrugBank.d54.s14.e2,"Therefore, patients without a functioning drug0 gland who are on thyroid replacement therapy may need to increase their thyroid dose if drug1 or drug2-containing oral drug0",False, 
DDI-DrugBank.d54.s15.e0,DDI-DrugBank.d54.s15.e1,drug1: Use of drug2 with drug0 and other drug0,False, 
DDI-DrugBank.d54.s15.e0,DDI-DrugBank.d54.s15.e2,drug1: Use of drug0 with drug2 and other drug0,False, 
DDI-DrugBank.d54.s15.e1,DDI-DrugBank.d54.s15.e2,drug0: Use of drug1 with drug2 and other drug0,True,effect
DDI-DrugBank.d54.s15.e1,DDI-DrugBank.d54.s15.e3,drug0: Use of drug1 with drug0 and other drug2,True,effect
DDI-DrugBank.d54.s17.e0,DDI-DrugBank.d54.s17.e1,drug1: drug2 may potentiate the toxic effects of drug0,False, 
DDI-DrugBank.d54.s17.e0,DDI-DrugBank.d54.s17.e2,drug1: drug0 may potentiate the toxic effects of drug2,False, 
DDI-DrugBank.d54.s17.e1,DDI-DrugBank.d54.s17.e2,drug0: drug1 may potentiate the toxic effects of drug2,True,effect
DDI-DrugBank.d54.s19.e0,DDI-DrugBank.d54.s19.e1,"drug1: When administered to patients on a drug2, this parenteral drug0",False, 
DDI-DrugBank.d54.s19.e0,DDI-DrugBank.d54.s19.e2,"drug1: When administered to patients on a drug0, this parenteral drug2",False, 
DDI-DrugBank.d54.s19.e1,DDI-DrugBank.d54.s19.e2,"drug0: When administered to patients on a drug1, this parenteral drug2",True,effect
DDI-DrugBank.d54.s21.e0,DDI-DrugBank.d54.s21.e1,drug1s: drug2 increases the adrenergic effect of catecholamines such as drug0 and drug0,False, 
DDI-DrugBank.d54.s21.e0,DDI-DrugBank.d54.s21.e2,drug1s: drug0 increases the adrenergic effect of catecholamines such as drug2 and drug0,False, 
DDI-DrugBank.d54.s21.e1,DDI-DrugBank.d54.s21.e2,drug0s: drug1 increases the adrenergic effect of catecholamines such as drug2 and drug0,True,effect
DDI-DrugBank.d54.s21.e1,DDI-DrugBank.d54.s21.e3,drug0s: drug1 increases the adrenergic effect of catecholamines such as drug0 and drug2,True,effect
DDI-DrugBank.d54.s24.e0,DDI-DrugBank.d54.s24.e1,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on drug1 therapy: drug2, drug0, drug0, oral drug0 containing drug0, drug0-containing preparations and the numerous preparations containing drug0",False, 
DDI-DrugBank.d54.s24.e0,DDI-DrugBank.d54.s24.e2,"Drug/Laboratory Test Interactions The following drugs or moieties are known to interfere with laboratory tests performed in patients on drug1 therapy: drug0, drug2, drug0, oral drug0 containing drug0, drug0-containing preparations and the numerous preparations containing drug0",False, 
DDI-DrugBank.d54.s27.e0,DDI-DrugBank.d54.s27.e1,Pregnancy drug1 and drug2-containing oral drug0,False, 
DDI-DrugBank.d54.s27.e0,DDI-DrugBank.d54.s27.e2,Pregnancy drug1 and drug0-containing oral drug2,False, 
DDI-DrugBank.d54.s29.e0,DDI-DrugBank.d54.s29.e1,"Decreases in TBg concentrations are observed in nephrosis, acromegaly and after drug1 or drug2",False, 
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e1,"drug1 can interact with drug2 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,effect
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e2,"drug1 can interact with drug0 or other drug2 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,effect
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e3,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug2), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e4,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug2 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,effect
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e5,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug2), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d192.s0.e0,DDI-DrugBank.d192.s0.e6,"drug1 can interact with drug0 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug2 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",True,effect
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e1,"drug1 may interact with the following medications: drug2 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e2,"drug1 may interact with the following medications: drug0 (drug2), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e3,"drug1 may interact with the following medications: drug0 (drug0), drug2 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e4,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug2 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e5,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug2, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e6,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug2 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e7,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug2, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e8,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug2, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e9,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug2, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e10,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug2, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e11,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug2, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e12,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug2), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e13,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug2 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e14,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug2, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e15,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug2, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e16,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug2), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e17,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug2 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e18,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug2), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e19,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug2 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e20,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug2), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e21,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug2 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e22,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug2, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e23,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug2), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e24,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug2 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e25,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug2, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e26,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug2, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e27,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug2, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e28,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug2, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e29,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug2, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e30,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug2, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e31,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug2), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e32,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug2 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e33,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug2, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e34,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug2, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e35,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug2), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e36,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug2, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e37,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug2 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e38,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug2), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e39,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug2 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e40,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug2), St. Johns wort, drug0, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e41,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug2, drug0 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e42,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug2 (drug0), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e43,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug2), and drug0",True,int
DDI-DrugBank.d484.s0.e0,DDI-DrugBank.d484.s0.e44,"drug1 may interact with the following medications: drug0 (drug0), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug2",True,int
DDI-DrugBank.d484.s0.e1,DDI-DrugBank.d484.s0.e2,"drug0 may interact with the following medications: drug1 (drug2), drug0 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",False, 
DDI-DrugBank.d484.s0.e1,DDI-DrugBank.d484.s0.e3,"drug0 may interact with the following medications: drug1 (drug0), drug2 such as drug0 and drug0, drug0 (drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0, drug0), HIV drugs classified as drug0 (drug0, drug0, drug0, drug0, drug0, drug0, drug0), drug0 (drug0, drug0, drug0), drug0, drug0 (drug0), drug0 (drug0), St. Johns wort, drug0, drug0 (drug0), and drug0",False, 
DDI-DrugBank.d154.s0.e0,DDI-DrugBank.d154.s0.e1,The coadministration of drug1 decreases the biologic half-life of drug2 because of an increase in metabolic clearance that results in a greater amount of drug0,True,mechanism
DDI-DrugBank.d154.s0.e0,DDI-DrugBank.d154.s0.e2,The coadministration of drug1 decreases the biologic half-life of drug0 because of an increase in metabolic clearance that results in a greater amount of drug2,False, 
DDI-DrugBank.d154.s0.e1,DDI-DrugBank.d154.s0.e2,The coadministration of drug0 decreases the biologic half-life of drug1 because of an increase in metabolic clearance that results in a greater amount of drug2,False, 
DDI-DrugBank.d154.s1.e0,DDI-DrugBank.d154.s1.e1,"Although the mechanism of interaction between drug1 and drug2 is not totally known, enzyme induction and displacement of drug0",True,mechanism
DDI-DrugBank.d154.s1.e0,DDI-DrugBank.d154.s1.e2,"Although the mechanism of interaction between drug1 and drug0 is not totally known, enzyme induction and displacement of drug2",False, 
DDI-DrugBank.d154.s1.e1,DDI-DrugBank.d154.s1.e2,"Although the mechanism of interaction between drug0 and drug1 is not totally known, enzyme induction and displacement of drug2",False, 
DDI-DrugBank.d154.s2.e0,DDI-DrugBank.d154.s2.e1,"Because drug1 has not been shown to produce any additional effect beyond that obtained with drug2 alone and because drug0 increases the rate of excretion of drug0, the concomitant use of drug0 and drug0",False, 
DDI-DrugBank.d154.s2.e0,DDI-DrugBank.d154.s2.e2,"Because drug1 has not been shown to produce any additional effect beyond that obtained with drug0 alone and because drug2 increases the rate of excretion of drug0, the concomitant use of drug0 and drug0",False, 
DDI-DrugBank.d154.s2.e2,DDI-DrugBank.d154.s2.e3,"Because drug0 has not been shown to produce any additional effect beyond that obtained with drug0 alone and because drug1 increases the rate of excretion of drug2, the concomitant use of drug0 and drug0",True,mechanism
DDI-DrugBank.d154.s2.e4,DDI-DrugBank.d154.s2.e5,"Because drug0 has not been shown to produce any additional effect beyond that obtained with drug0 alone and because drug0 increases the rate of excretion of drug0, the concomitant use of drug1 and drug2",True,advise
DDI-DrugBank.d154.s3.e0,DDI-DrugBank.d154.s3.e1,"Chronic administration of drug1, a known enzyme inducer, may be associated with a decrease in the plasma half-life of drug2",True,mechanism
DDI-DrugBank.d154.s4.e0,DDI-DrugBank.d154.s4.e1,"When drug1 is added to or withdrawn from treatment, dosage adjustment of drug2",True,advise
DDI-DrugBank.d154.s7.e0,DDI-DrugBank.d154.s7.e1,"Patients receiving drug1, drug2, or drug0",False, 
DDI-DrugBank.d154.s7.e0,DDI-DrugBank.d154.s7.e2,"Patients receiving drug1, drug0, or drug2",False, 
DDI-DrugBank.d154.s8.e0,DDI-DrugBank.d154.s8.e1,"In patients receiving drug1, the addition of drug2",True,effect
DDI-DrugBank.d154.s10.e0,DDI-DrugBank.d154.s10.e1,Patients treated with drug1 may be resistant to the effects of drug2,True,effect
DDI-DrugBank.d154.s11.e0,DDI-DrugBank.d154.s11.e1,"In patients receiving drug1 and a drug2 concomitantly, any reduction in drug0 dosage should be gradual in order to avoid the possible complications of sudden drug0",True,advise
DDI-DrugBank.d154.s11.e0,DDI-DrugBank.d154.s11.e2,"In patients receiving drug1 and a drug0 concomitantly, any reduction in drug2 dosage should be gradual in order to avoid the possible complications of sudden drug0",False, 
DDI-DrugBank.d154.s11.e0,DDI-DrugBank.d154.s11.e3,"In patients receiving drug1 and a drug0 concomitantly, any reduction in drug0 dosage should be gradual in order to avoid the possible complications of sudden drug2",False, 
DDI-DrugBank.d486.s0.e0,DDI-DrugBank.d486.s0.e1,"No drug interaction studies have been conducted for drug1, however the use of orally administered drug2 could, theoretically, interfere with the release of drug0",False, 
DDI-DrugBank.d486.s0.e0,DDI-DrugBank.d486.s0.e2,"No drug interaction studies have been conducted for drug1, however the use of orally administered drug0 could, theoretically, interfere with the release of drug2",False, 
DDI-DrugBank.d382.s4.e0,DDI-DrugBank.d382.s4.e1,drug1 has been shown to induce the metabolism of drug2 and drug0,True,mechanism
DDI-DrugBank.d382.s4.e0,DDI-DrugBank.d382.s4.e2,drug1 has been shown to induce the metabolism of drug0 and drug2,True,mechanism
DDI-DrugBank.d382.s4.e1,DDI-DrugBank.d382.s4.e2,drug0 has been shown to induce the metabolism of drug1 and drug2,False, 
DDI-DrugBank.d382.s5.e0,DDI-DrugBank.d382.s5.e1,"Coadministration of drug1 with these drugs or other drugs that are known to be metabolized by CYP2C9, such as drug2",True,mechanism
DDI-DrugBank.d382.s6.e0,DDI-DrugBank.d382.s6.e1,"drug1 is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of drug2 with drug0",False, 
DDI-DrugBank.d382.s6.e0,DDI-DrugBank.d382.s6.e2,"drug1 is unlikely to interact with drugs that are substrates for the P-glycoprotein transporter, as demonstrated by the lack of interaction of drug0 with drug2",False, 
DDI-DrugBank.d382.s7.e0,DDI-DrugBank.d382.s7.e1,"drug1: In clinical drug interaction studies, drug2 did not have clinically important effects on the pharmacokinetics of drug0 or drug0",False, 
DDI-DrugBank.d382.s7.e0,DDI-DrugBank.d382.s7.e2,"drug1: In clinical drug interaction studies, drug0 did not have clinically important effects on the pharmacokinetics of drug2 or drug0",False, 
DDI-DrugBank.d382.s9.e0,DDI-DrugBank.d382.s9.e1,"drug1: drug2: drug0, when given as a regimen of 125mg with drug0 coadministered orally as 20 mg on Day 1, and drug0 when given as 80 mg/day with drug0 coadministered orally as 8 mg on Days 2 through 5, increased the AUC of drug0",False, 
DDI-DrugBank.d382.s9.e0,DDI-DrugBank.d382.s9.e2,"drug1: drug0: drug2, when given as a regimen of 125mg with drug0 coadministered orally as 20 mg on Day 1, and drug0 when given as 80 mg/day with drug0 coadministered orally as 8 mg on Days 2 through 5, increased the AUC of drug0",False, 
DDI-DrugBank.d382.s9.e2,DDI-DrugBank.d382.s9.e3,"drug0: drug0: drug1, when given as a regimen of 125mg with drug2 coadministered orally as 20 mg on Day 1, and drug0 when given as 80 mg/day with drug0 coadministered orally as 8 mg on Days 2 through 5, increased the AUC of drug0",True,mechanism
DDI-DrugBank.d382.s9.e4,DDI-DrugBank.d382.s9.e5,"drug0: drug0: drug0, when given as a regimen of 125mg with drug0 coadministered orally as 20 mg on Day 1, and drug1 when given as 80 mg/day with drug2 coadministered orally as 8 mg on Days 2 through 5, increased the AUC of drug0",True,mechanism
DDI-DrugBank.d382.s10.e0,DDI-DrugBank.d382.s10.e1,"The oral drug1 doses should be reduced by approximately 50% when coadministered with drug2, to achieve exposures of drug0 similar to those obtained when it is given without drug0",True,advise
DDI-DrugBank.d382.s10.e0,DDI-DrugBank.d382.s10.e2,"The oral drug1 doses should be reduced by approximately 50% when coadministered with drug0, to achieve exposures of drug2 similar to those obtained when it is given without drug0",False, 
DDI-DrugBank.d382.s10.e0,DDI-DrugBank.d382.s10.e3,"The oral drug1 doses should be reduced by approximately 50% when coadministered with drug0, to achieve exposures of drug0 similar to those obtained when it is given without drug2",False, 
DDI-DrugBank.d382.s11.e0,DDI-DrugBank.d382.s11.e1,The daily dose of drug1 administered in clinical studies with drug2 reflects an approximate 50% reduction of the dose of drug0,True,mechanism
DDI-DrugBank.d382.s11.e0,DDI-DrugBank.d382.s11.e2,The daily dose of drug1 administered in clinical studies with drug0 reflects an approximate 50% reduction of the dose of drug2,False, 
DDI-DrugBank.d382.s11.e1,DDI-DrugBank.d382.s11.e2,The daily dose of drug0 administered in clinical studies with drug1 reflects an approximate 50% reduction of the dose of drug2,False, 
DDI-DrugBank.d382.s13.e0,DDI-DrugBank.d382.s13.e1,"drug1, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of drug2, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when drug0",True,mechanism
DDI-DrugBank.d382.s13.e0,DDI-DrugBank.d382.s13.e2,"drug1, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of drug0, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when drug2",False, 
DDI-DrugBank.d382.s13.e1,DDI-DrugBank.d382.s13.e2,"drug0, when given as a regimen of 125 mg on Day 1 and 80 mg/day on Days 2 and 3, increased the AUC of drug1, a CYP3A4 substrate, by 1.34-fold on Day 1 and by 2.5-fold on Day 3, when drug2",False, 
DDI-DrugBank.d382.s14.e0,DDI-DrugBank.d382.s14.e1,"The IV drug1 dose should be reduced by approximately 25%, and the oral drug2 dose should be reduced by approximately 50% when coadministered with drug0 to achieve exposures of drug0 similar to those obtained when it is given without drug0",False, 
DDI-DrugBank.d382.s14.e0,DDI-DrugBank.d382.s14.e2,"The IV drug1 dose should be reduced by approximately 25%, and the oral drug0 dose should be reduced by approximately 50% when coadministered with drug2 to achieve exposures of drug0 similar to those obtained when it is given without drug0",True,advise
DDI-DrugBank.d382.s14.e0,DDI-DrugBank.d382.s14.e3,"The IV drug1 dose should be reduced by approximately 25%, and the oral drug0 dose should be reduced by approximately 50% when coadministered with drug0 to achieve exposures of drug2 similar to those obtained when it is given without drug0",False, 
DDI-DrugBank.d382.s14.e1,DDI-DrugBank.d382.s14.e2,"The IV drug0 dose should be reduced by approximately 25%, and the oral drug1 dose should be reduced by approximately 50% when coadministered with drug2 to achieve exposures of drug0 similar to those obtained when it is given without drug0",True,advise
DDI-DrugBank.d382.s15.e0,DDI-DrugBank.d382.s15.e1,drug1: A single 125-mg dose of drug2 was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic drug0,False, 
DDI-DrugBank.d382.s15.e0,DDI-DrugBank.d382.s15.e2,drug1: A single 125-mg dose of drug0 was administered on Day 1 and 80 mg/day on Days 2 and 3 to healthy subjects who were stabilized on chronic drug2,False, 
DDI-DrugBank.d382.s16.e0,DDI-DrugBank.d382.s16.e1,"Although there was no effect of drug1 on the plasma AUC of drug2 or drug0 determined on Day 3, there was a 34% decrease in drug0 (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with drug0",False, 
DDI-DrugBank.d382.s16.e0,DDI-DrugBank.d382.s16.e2,"Although there was no effect of drug1 on the plasma AUC of drug0 or drug2 determined on Day 3, there was a 34% decrease in drug0 (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with drug0",False, 
DDI-DrugBank.d382.s16.e3,DDI-DrugBank.d382.s16.e4,"Although there was no effect of drug0 on the plasma AUC of drug0 or drug0 determined on Day 3, there was a 34% decrease in drug1 (a CYP2C9 substrate) trough concentration accompanied by a 14% decrease in the prothrombin time (reported as International Normalized Ratio or INR) 5 days after completion of dosing with drug2",True,mechanism
DDI-DrugBank.d382.s17.e0,DDI-DrugBank.d382.s17.e1,"In patients on chronic drug1 therapy, the prothrombin time (INR) should be closely monitored in the 2-week period, particularly at 7 to 10 days, following initiation of the 3-day regimen of drug2",True,advise
DDI-DrugBank.d382.s18.e0,DDI-DrugBank.d382.s18.e1,"drug1: drug2, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of drug0 (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of drug0 500 mg was admini,stered orally prior to the administration of the 3-day regimen of drug0",False, 
DDI-DrugBank.d382.s18.e0,DDI-DrugBank.d382.s18.e2,"drug1: drug0, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of drug2 (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of drug0 500 mg was admini,stered orally prior to the administration of the 3-day regimen of drug0",False, 
DDI-DrugBank.d382.s18.e3,DDI-DrugBank.d382.s18.e4,"drug0: drug0, when given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, decreased the AUC of drug0 (a CYP2C9 substrate) by 23% on Day 4, 28% on Day 8, and 15% on Day 15, when a single dose of drug1 500 mg was admini,stered orally prior to the administration of the 3-day regimen of drug2",True,mechanism
DDI-DrugBank.d382.s19.e0,DDI-DrugBank.d382.s19.e1,"Oral drug1: drug2, when given once daily for 14 days as a 100-mg capsule with an oral drug0 containing 35 mcg of drug0 and 1 mg of drug0, decreased the AUC of drug0 by 43%, and decreased the AUC of drug0",False, 
DDI-DrugBank.d382.s19.e0,DDI-DrugBank.d382.s19.e2,"Oral drug1: drug0, when given once daily for 14 days as a 100-mg capsule with an oral drug2 containing 35 mcg of drug0 and 1 mg of drug0, decreased the AUC of drug0 by 43%, and decreased the AUC of drug0",False, 
DDI-DrugBank.d382.s19.e1,DDI-DrugBank.d382.s19.e3,"Oral drug0: drug1, when given once daily for 14 days as a 100-mg capsule with an oral drug0 containing 35 mcg of drug2 and 1 mg of drug0, decreased the AUC of drug0 by 43%, and decreased the AUC of drug0",True,mechanism
DDI-DrugBank.d382.s19.e1,DDI-DrugBank.d382.s19.e4,"Oral drug0: drug1, when given once daily for 14 days as a 100-mg capsule with an oral drug0 containing 35 mcg of drug0 and 1 mg of drug2, decreased the AUC of drug0 by 43%, and decreased the AUC of drug0",True,mechanism
DDI-DrugBank.d382.s20.e0,DDI-DrugBank.d382.s20.e1,"therefore, the efficacy of oral drug1 during administration of drug2",True,effect
DDI-DrugBank.d382.s21.e0,DDI-DrugBank.d382.s21.e1,Although a 3-day regimen of drug1 given concomitantly with oral drug2,True,advise
DDI-DrugBank.d382.s22.e0,DDI-DrugBank.d382.s22.e1,"drug1: drug2 increased the AUC of drug0, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of drug0 2 mg was coadministered on Day 1 and Day 5 of a regimen of drug0",False, 
DDI-DrugBank.d382.s22.e0,DDI-DrugBank.d382.s22.e2,"drug1: drug0 increased the AUC of drug2, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of drug0 2 mg was coadministered on Day 1 and Day 5 of a regimen of drug0",False, 
DDI-DrugBank.d382.s22.e1,DDI-DrugBank.d382.s22.e2,"drug0: drug1 increased the AUC of drug2, a sensitive CYP3A4 substrate, by 2.3-fold on Day 1 and 3.3-fold on Day 5, when a single oral dose of drug0 2 mg was coadministered on Day 1 and Day 5 of a regimen of drug0",True,mechanism
DDI-DrugBank.d382.s23.e0,DDI-DrugBank.d382.s23.e1,"The potential effects of increased plasma concentrations of drug1 or other drug2 metabolized via CYP3A4 (drug0, drug0) should be considered when coadministering these agents with drug0",False, 
DDI-DrugBank.d382.s23.e0,DDI-DrugBank.d382.s23.e2,"The potential effects of increased plasma concentrations of drug1 or other drug0 metabolized via CYP3A4 (drug2, drug0) should be considered when coadministering these agents with drug0",False, 
DDI-DrugBank.d382.s23.e0,DDI-DrugBank.d382.s23.e4,"The potential effects of increased plasma concentrations of drug1 or other drug0 metabolized via CYP3A4 (drug0, drug0) should be considered when coadministering these agents with drug2",True,advise
DDI-DrugBank.d382.s23.e1,DDI-DrugBank.d382.s23.e4,"The potential effects of increased plasma concentrations of drug0 or other drug1 metabolized via CYP3A4 (drug0, drug0) should be considered when coadministering these agents with drug2",True,advise
DDI-DrugBank.d382.s23.e2,DDI-DrugBank.d382.s23.e4,"The potential effects of increased plasma concentrations of drug0 or other drug0 metabolized via CYP3A4 (drug1, drug0) should be considered when coadministering these agents with drug2",True,advise
DDI-DrugBank.d382.s23.e3,DDI-DrugBank.d382.s23.e4,"The potential effects of increased plasma concentrations of drug0 or other drug0 metabolized via CYP3A4 (drug0, drug1) should be considered when coadministering these agents with drug2",True,advise
DDI-DrugBank.d382.s24.e0,DDI-DrugBank.d382.s24.e1,"In another study with intravenous administration of drug1, drug2 was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and drug0 2 mg IV was given prior to the administration of the 3-day regimen of drug0",False, 
DDI-DrugBank.d382.s24.e0,DDI-DrugBank.d382.s24.e2,"In another study with intravenous administration of drug1, drug0 was given as 125 mg on Day 1 and 80 mg/day on Days 2 and 3, and drug2 2 mg IV was given prior to the administration of the 3-day regimen of drug0",False, 
DDI-DrugBank.d382.s25.e0,DDI-DrugBank.d382.s25.e1,drug1 increased the AUC of drug2 by 25% on Day 4 and decreased the AUC of drug0 by 19% on Day 8 relative to the dosing of drug0,True,mechanism
DDI-DrugBank.d382.s25.e0,DDI-DrugBank.d382.s25.e2,drug1 increased the AUC of drug0 by 25% on Day 4 and decreased the AUC of drug2 by 19% on Day 8 relative to the dosing of drug0,True,mechanism
DDI-DrugBank.d382.s25.e0,DDI-DrugBank.d382.s25.e3,drug1 increased the AUC of drug0 by 25% on Day 4 and decreased the AUC of drug0 by 19% on Day 8 relative to the dosing of drug2,False, 
DDI-DrugBank.d382.s25.e1,DDI-DrugBank.d382.s25.e2,drug0 increased the AUC of drug1 by 25% on Day 4 and decreased the AUC of drug2 by 19% on Day 8 relative to the dosing of drug0,False, 
DDI-DrugBank.d382.s30.e0,DDI-DrugBank.d382.s30.e1,"therefore, coadministration of drug1 with drugs that inhibit CYP3A4 activity may result in increased plasma concentrations of drug2",False, 
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e1,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e2,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug2, drug0, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e3,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug0, drug2, drug0, drug0, drug0, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e4,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug2, drug0, drug0, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e5,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug0, drug2, drug0, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e6,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug0, drug0, drug2, drug0",True,advise
DDI-DrugBank.d382.s31.e0,DDI-DrugBank.d382.s31.e7,"Consequently, concomitant administration of drug1 with strong CYP3A4 inhibitors (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug2",True,advise
DDI-DrugBank.d382.s31.e1,DDI-DrugBank.d382.s31.e2,"Consequently, concomitant administration of drug0 with strong CYP3A4 inhibitors (e.g., drug1, drug2, drug0, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d382.s31.e1,DDI-DrugBank.d382.s31.e3,"Consequently, concomitant administration of drug0 with strong CYP3A4 inhibitors (e.g., drug1, drug0, drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d382.s32.e0,DDI-DrugBank.d382.s32.e1,"Because moderate CYP3A4 inhibitors (e.g., drug1) result in 2-fold increase in plasma concentrations of drug2",True,advise
DDI-DrugBank.d382.s34.e0,DDI-DrugBank.d382.s34.e1,"therefore, coadministration of drug1 with drugs that strongly induce CYP3A4 activity (e.g., drug2, drug0, drug0) may result in reduced plasma concentrations of drug0 that may result in decreased efficacy of drug0",True,mechanism
DDI-DrugBank.d382.s34.e0,DDI-DrugBank.d382.s34.e2,"therefore, coadministration of drug1 with drugs that strongly induce CYP3A4 activity (e.g., drug0, drug2, drug0) may result in reduced plasma concentrations of drug0 that may result in decreased efficacy of drug0",False, 
DDI-DrugBank.d382.s34.e0,DDI-DrugBank.d382.s34.e3,"therefore, coadministration of drug1 with drugs that strongly induce CYP3A4 activity (e.g., drug0, drug0, drug2) may result in reduced plasma concentrations of drug0 that may result in decreased efficacy of drug0",True,mechanism
DDI-DrugBank.d382.s34.e0,DDI-DrugBank.d382.s34.e4,"therefore, coadministration of drug1 with drugs that strongly induce CYP3A4 activity (e.g., drug0, drug0, drug0) may result in reduced plasma concentrations of drug2 that may result in decreased efficacy of drug0",True,mechanism
DDI-DrugBank.d382.s34.e0,DDI-DrugBank.d382.s34.e5,"therefore, coadministration of drug1 with drugs that strongly induce CYP3A4 activity (e.g., drug0, drug0, drug0) may result in reduced plasma concentrations of drug0 that may result in decreased efficacy of drug2",False, 
DDI-DrugBank.d382.s35.e0,DDI-DrugBank.d382.s35.e1,drug1: When a single 125-mg dose of drug2,False, 
DDI-DrugBank.d382.s36.e0,DDI-DrugBank.d382.s36.e1,"drug1: When a single 125-mg dose of drug2 was administered on Day5 of a 10-day regimen of 400 mg/day of drug0, a strong CYP3A4 inhibitor, the AUC of drug0 increased approximately 5-fold and the mean terminal half-life of drug0",False, 
DDI-DrugBank.d382.s36.e0,DDI-DrugBank.d382.s36.e2,"drug1: When a single 125-mg dose of drug0 was administered on Day5 of a 10-day regimen of 400 mg/day of drug2, a strong CYP3A4 inhibitor, the AUC of drug0 increased approximately 5-fold and the mean terminal half-life of drug0",False, 
DDI-DrugBank.d382.s36.e1,DDI-DrugBank.d382.s36.e2,"drug0: When a single 125-mg dose of drug1 was administered on Day5 of a 10-day regimen of 400 mg/day of drug2, a strong CYP3A4 inhibitor, the AUC of drug0 increased approximately 5-fold and the mean terminal half-life of drug0",True,mechanism
DDI-DrugBank.d382.s38.e0,DDI-DrugBank.d382.s38.e1,"drug1: When a single 375-mg dose of drug2 was administered on Day9 of a 14-day regimen of 600 mg/day of drug0, a strong CYP3A4 inducer, the AUC of drug0",False, 
DDI-DrugBank.d382.s38.e0,DDI-DrugBank.d382.s38.e2,"drug1: When a single 375-mg dose of drug0 was administered on Day9 of a 14-day regimen of 600 mg/day of drug2, a strong CYP3A4 inducer, the AUC of drug0",False, 
DDI-DrugBank.d382.s38.e1,DDI-DrugBank.d382.s38.e2,"drug0: When a single 375-mg dose of drug1 was administered on Day9 of a 14-day regimen of 600 mg/day of drug2, a strong CYP3A4 inducer, the AUC of drug0",True,mechanism
DDI-DrugBank.d382.s39.e0,DDI-DrugBank.d382.s39.e1,Coadministration of drug1 with drugs that induce CYP3A4 activity may result in reduced plasma concentrations and decreased efficacy of drug2,False, 
DDI-DrugBank.d382.s41.e0,DDI-DrugBank.d382.s41.e1,"drug1: In patients with mild to moderate hypertension, administration of drug2 once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with drug0 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of drug0 AUC and a simultaneous 1.7-fold increase of drug0",False, 
DDI-DrugBank.d382.s41.e0,DDI-DrugBank.d382.s41.e2,"drug1: In patients with mild to moderate hypertension, administration of drug0 once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with drug2 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of drug0 AUC and a simultaneous 1.7-fold increase of drug0",False, 
DDI-DrugBank.d382.s41.e1,DDI-DrugBank.d382.s41.e2,"drug0: In patients with mild to moderate hypertension, administration of drug1 once daily, as a tablet formulation comparable to 230 mg of the capsule formulation, with drug2 120 mg 3 times daily for 5 days, resulted in a 2-fold increase of drug0 AUC and a simultaneous 1.7-fold increase of drug0",True,mechanism
DDI-DrugBank.d382.s43.e0,DDI-DrugBank.d382.s43.e1,"drug1: Coadministration of once daily doses of drug2, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with drug0 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both drug0 and drug0",False, 
DDI-DrugBank.d382.s43.e0,DDI-DrugBank.d382.s43.e2,"drug1: Coadministration of once daily doses of drug0, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with drug2 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both drug0 and drug0",False, 
DDI-DrugBank.d382.s43.e1,DDI-DrugBank.d382.s43.e2,"drug0: Coadministration of once daily doses of drug1, as a tablet formulation comparable to 85 mg or 170 mg of the capsule formulation, with drug2 20 mg once daily, resulted in a decrease in AUC by approximately 25% and Cmax, by approximately 20% of both drug0 and drug0",True,mechanism
DDI-DrugBank.d88.s0.e0,DDI-DrugBank.d88.s0.e1,drug1: The effect of an drug2- and drug0-containing drug0 (drug0)* on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d88.s0.e0,DDI-DrugBank.d88.s0.e2,drug1: The effect of an drug0- and drug2-containing drug0 (drug0)* on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d88.s1.e0,DDI-DrugBank.d88.s1.e1,There was a small increase in plasma concentrations of drug1 and one metabolite (drug2,False, 
DDI-DrugBank.d88.s2.e0,DDI-DrugBank.d88.s2.e1,"there was no effect on the 3 major metabolites (drug1, drug2 and drug0",False, 
DDI-DrugBank.d88.s2.e0,DDI-DrugBank.d88.s2.e2,"there was no effect on the 3 major metabolites (drug1, drug0 and drug2",False, 
DDI-DrugBank.d88.s3.e0,DDI-DrugBank.d88.s3.e1,drug1 Altered coagulation parameters and/or bleeding have been reported in patients taking drug2 concomitantly with drug0 such as drug0 and drug0,False, 
DDI-DrugBank.d88.s3.e0,DDI-DrugBank.d88.s3.e2,drug1 Altered coagulation parameters and/or bleeding have been reported in patients taking drug0 concomitantly with drug2 such as drug0 and drug0,False, 
DDI-DrugBank.d88.s3.e1,DDI-DrugBank.d88.s3.e2,drug0 Altered coagulation parameters and/or bleeding have been reported in patients taking drug1 concomitantly with drug2 such as drug0 and drug0,True,effect
DDI-DrugBank.d88.s3.e1,DDI-DrugBank.d88.s3.e4,drug0 Altered coagulation parameters and/or bleeding have been reported in patients taking drug1 concomitantly with drug0 such as drug0 and drug2,True,effect
DDI-DrugBank.d88.s4.e0,DDI-DrugBank.d88.s4.e1,Patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d88.s5.e0,DDI-DrugBank.d88.s5.e1,drug1: The concentration of drug2 is increased and its toxicity may be enhanced by drug0,False, 
DDI-DrugBank.d88.s5.e0,DDI-DrugBank.d88.s5.e2,drug1: The concentration of drug0 is increased and its toxicity may be enhanced by drug2,False, 
DDI-DrugBank.d88.s5.e1,DDI-DrugBank.d88.s5.e2,drug0: The concentration of drug1 is increased and its toxicity may be enhanced by drug2,True,mechanism
DDI-DrugBank.d88.s6.e0,DDI-DrugBank.d88.s6.e1,"Deaths from severe enterocolitis, diarrhea, and dehydration have been reported in elderly patients receiving weekly drug1 and drug2",True,effect
DDI-DrugBank.d404.s0.e0,DDI-DrugBank.d404.s0.e1,"Interactions for drug1 analogues (drug2, drug0, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d404.s0.e0,DDI-DrugBank.d404.s0.e2,"Interactions for drug1 analogues (drug0, drug2, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d404.s0.e6,DDI-DrugBank.d404.s0.e7,"Interactions for drug0 analogues (drug0, drug0, drug0, and drug0): drug0: drug1 has been reported to reduce intestinal absorption of drug2",True,mechanism
DDI-DrugBank.d404.s2.e0,DDI-DrugBank.d404.s2.e1,"drug1/drug2: The coadministration of drug0 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d404.s2.e0,DDI-DrugBank.d404.s2.e2,"drug1/drug0: The coadministration of drug2 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d404.s3.e0,DDI-DrugBank.d404.s3.e1,"Since blood level of drug1/ergocalcitriol will be reduced, higher doses of drug2",False, 
DDI-DrugBank.d404.s4.e0,DDI-DrugBank.d404.s4.e1,drug1: drug2,False, 
DDI-DrugBank.d404.s5.e0,DDI-DrugBank.d404.s5.e1,Some reports have shown that the concomitant administration of drug1 with drug2,True,effect
DDI-DrugBank.d404.s7.e0,DDI-DrugBank.d404.s7.e1,drug1: drug2 dosage must be determined with care in patients undergoing treatment with drug0,False, 
DDI-DrugBank.d404.s7.e0,DDI-DrugBank.d404.s7.e2,drug1: drug0 dosage must be determined with care in patients undergoing treatment with drug2,False, 
DDI-DrugBank.d404.s7.e1,DDI-DrugBank.d404.s7.e2,drug0: drug1 dosage must be determined with care in patients undergoing treatment with drug2,True,advise
DDI-DrugBank.d404.s8.e0,DDI-DrugBank.d404.s8.e1,drug1: drug2 may inhibit both synthetic and catabolic enzymes of drug0,False, 
DDI-DrugBank.d404.s8.e0,DDI-DrugBank.d404.s8.e2,drug1: drug0 may inhibit both synthetic and catabolic enzymes of drug2,False, 
DDI-DrugBank.d404.s8.e1,DDI-DrugBank.d404.s8.e2,drug0: drug1 may inhibit both synthetic and catabolic enzymes of drug2,True,mechanism
DDI-DrugBank.d404.s10.e0,DDI-DrugBank.d404.s10.e1,"However, in vivo drug interaction studies of drug1 with drug2",False, 
DDI-DrugBank.d404.s11.e0,DDI-DrugBank.d404.s11.e1,"drug1: A relationship of functional antagonism exists between drug2 analogues, which promote calcium absorption, and drug0",False, 
DDI-DrugBank.d404.s11.e0,DDI-DrugBank.d404.s11.e2,"drug1: A relationship of functional antagonism exists between drug0 analogues, which promote calcium absorption, and drug2",False, 
DDI-DrugBank.d404.s11.e1,DDI-DrugBank.d404.s11.e2,"drug0: A relationship of functional antagonism exists between drug1 analogues, which promote calcium absorption, and drug2",True,effect
DDI-DrugBank.d404.s13.e0,DDI-DrugBank.d404.s13.e1,drug1: The coadministration of any of the drug2,False, 
DDI-DrugBank.d404.s14.e0,DDI-DrugBank.d404.s14.e1,drug1 Supplements: Uncontrolled intake of additional drug2,False, 
DDI-DrugBank.d404.s15.e0,DDI-DrugBank.d404.s15.e1,"drug1: drug2-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d404.s15.e0,DDI-DrugBank.d404.s15.e2,"drug1: drug0-containing preparations (eg, drug2) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d404.s15.e1,DDI-DrugBank.d404.s15.e3,"drug0: drug1-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,effect
DDI-DrugBank.d404.s15.e2,DDI-DrugBank.d404.s15.e3,"drug0: drug0-containing preparations (eg, drug1) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,effect
DDI-DrugBank.d251.s0.e0,DDI-DrugBank.d251.s0.e1,"Antiacid, drug1, drug2, drug0, drug0, Indanavir, drug0, drug0, Phenobarbitol, drug0, drug0, drug0, Ritanovir, drug0",False, 
DDI-DrugBank.d251.s0.e0,DDI-DrugBank.d251.s0.e2,"Antiacid, drug1, drug0, drug2, drug0, Indanavir, drug0, drug0, Phenobarbitol, drug0, drug0, drug0, Ritanovir, drug0",False, 
DDI-DrugBank.d559.s0.e0,DDI-DrugBank.d559.s0.e1,The CNS effects of drug1 may be enhanced by drug2,True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e1,"drug1, drug2 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug0, or other drug0",False, 
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e2,"drug1, drug0 and drug2 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug0, or other drug0",False, 
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e3,"drug1, drug0 and drug0 may enhance the effects of: other drug2s, drug0, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e4,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug2, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e5,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug0, general drug2, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e6,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug2 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e7,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug2, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e8,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug2, or other drug0",True,effect
DDI-DrugBank.d559.s1.e0,DDI-DrugBank.d559.s1.e9,"drug1, drug0 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug0, or other drug2",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e3,"drug0, drug1 and drug0 may enhance the effects of: other drug2s, drug0, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e4,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug2, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e5,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug0, general drug2, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e6,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug2 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e7,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug2, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e8,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug2, or other drug0",True,effect
DDI-DrugBank.d559.s1.e1,DDI-DrugBank.d559.s1.e9,"drug0, drug1 and drug0 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug0, or other drug2",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e3,"drug0, drug0 and drug1 may enhance the effects of: other drug2s, drug0, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e4,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug2, general drug0, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e5,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug0, general drug2, drug0 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e6,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug0, general drug0, drug2 such as drug0, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e7,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug2, drug0, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e8,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug2, or other drug0",True,effect
DDI-DrugBank.d559.s1.e2,DDI-DrugBank.d559.s1.e9,"drug0, drug0 and drug1 may enhance the effects of: other drug0s, drug0, general drug0, drug0 such as drug0, drug0, or other drug2",True,effect
DDI-DrugBank.d281.s0.e0,DDI-DrugBank.d281.s0.e1,"drug1 may decrease renal tubular secretion of drug2 when used concurrently, resulting in increased and more prolonged drug0",True,mechanism
DDI-DrugBank.d281.s0.e0,DDI-DrugBank.d281.s0.e2,"drug1 may decrease renal tubular secretion of drug0 when used concurrently, resulting in increased and more prolonged drug2",False, 
DDI-DrugBank.d281.s0.e1,DDI-DrugBank.d281.s0.e2,"drug0 may decrease renal tubular secretion of drug1 when used concurrently, resulting in increased and more prolonged drug2",False, 
DDI-DrugBank.d52.s0.e0,DDI-DrugBank.d52.s0.e1,"Concomitant treatment with drug1 (eg, rt-PA or drug2) may: - increase the risk of bleeding complications - considerably enhance the effect of drug0",False, 
DDI-DrugBank.d52.s0.e0,DDI-DrugBank.d52.s0.e2,"Concomitant treatment with drug1 (eg, rt-PA or drug0) may: - increase the risk of bleeding complications - considerably enhance the effect of drug2",False, 
DDI-DrugBank.d52.s1.e0,DDI-DrugBank.d52.s1.e1,Concomitant treatment with drug1 (drug2,False, 
DDI-DrugBank.d296.s0.e0,DDI-DrugBank.d296.s0.e1,"drug1 has additive effects with drug2 and other drug0 (drug0, drug0, drug0",True,effect
DDI-DrugBank.d296.s0.e0,DDI-DrugBank.d296.s0.e2,"drug1 has additive effects with drug0 and other drug2 (drug0, drug0, drug0",True,effect
DDI-DrugBank.d296.s0.e0,DDI-DrugBank.d296.s0.e3,"drug1 has additive effects with drug0 and other drug0 (drug2, drug0, drug0",True,effect
DDI-DrugBank.d296.s0.e0,DDI-DrugBank.d296.s0.e4,"drug1 has additive effects with drug0 and other drug0 (drug0, drug2, drug0",True,effect
DDI-DrugBank.d296.s0.e0,DDI-DrugBank.d296.s0.e5,"drug1 has additive effects with drug0 and other drug0 (drug0, drug0, drug2",True,effect
DDI-DrugBank.d296.s0.e1,DDI-DrugBank.d296.s0.e2,"drug0 has additive effects with drug1 and other drug2 (drug0, drug0, drug0",False, 
DDI-DrugBank.d296.s0.e1,DDI-DrugBank.d296.s0.e3,"drug0 has additive effects with drug1 and other drug0 (drug2, drug0, drug0",False, 
DDI-DrugBank.d296.s1.e0,DDI-DrugBank.d296.s1.e1,drug1 prolong and intensify the anticholinergic (drying) effects of drug2,True,effect
DDI-DrugBank.d65.s0.e0,DDI-DrugBank.d65.s0.e1,drug1 preparations are incompatible with drug2,True,int
DDI-DrugBank.d95.s0.e0,DDI-DrugBank.d95.s0.e1,drug1 - drug2 may counteract the antinaturetic effect of drug0,False, 
DDI-DrugBank.d95.s0.e0,DDI-DrugBank.d95.s0.e2,drug1 - drug0 may counteract the antinaturetic effect of drug2,False, 
DDI-DrugBank.d95.s0.e1,DDI-DrugBank.d95.s0.e2,drug0 - drug1 may counteract the antinaturetic effect of drug2,True,effect
DDI-DrugBank.d95.s1.e0,DDI-DrugBank.d95.s1.e1,drug1 - drug2 may increase the absorption of drug0,False, 
DDI-DrugBank.d95.s1.e0,DDI-DrugBank.d95.s1.e2,drug1 - drug0 may increase the absorption of drug2,False, 
DDI-DrugBank.d95.s1.e1,DDI-DrugBank.d95.s1.e2,drug0 - drug1 may increase the absorption of drug2,True,mechanism
DDI-DrugBank.d95.s2.e0,DDI-DrugBank.d95.s2.e1,Organic drug1 - drug2 supplements theoretically may potentiate the effects of organic drug0,False, 
DDI-DrugBank.d95.s2.e0,DDI-DrugBank.d95.s2.e2,Organic drug1 - drug0 supplements theoretically may potentiate the effects of organic drug2,False, 
DDI-DrugBank.d95.s2.e1,DDI-DrugBank.d95.s2.e2,Organic drug0 - drug1 supplements theoretically may potentiate the effects of organic drug2,True,effect
DDI-DrugBank.d95.s3.e0,DDI-DrugBank.d95.s3.e1,"drug1 - Theoretically, drug2 supplements taken concomitantly with drug0",False, 
DDI-DrugBank.d95.s3.e0,DDI-DrugBank.d95.s3.e2,"drug1 - Theoretically, drug0 supplements taken concomitantly with drug2",False, 
DDI-DrugBank.d95.s3.e1,DDI-DrugBank.d95.s3.e2,"drug0 - Theoretically, drug1 supplements taken concomitantly with drug2",True,effect
DDI-DrugBank.d407.s1.e0,DDI-DrugBank.d407.s1.e1,An immune response to drug1 may interfere with subsequent diagnostic serum tests that utilize drug2,False, 
DDI-DrugBank.d348.s0.e0,DDI-DrugBank.d348.s0.e1,"Although the pressor activity of drug1 is very low compared to its antidiuretic activity, large doses of drug2",False, 
DDI-DrugBank.d400.s0.e0,DDI-DrugBank.d400.s0.e1,"drug1: As with other drug2, concomitant administration of drug0 and drug0",False, 
DDI-DrugBank.d400.s0.e0,DDI-DrugBank.d400.s0.e2,"drug1: As with other drug0, concomitant administration of drug2 and drug0",False, 
DDI-DrugBank.d400.s0.e1,DDI-DrugBank.d400.s0.e3,"drug0: As with other drug1, concomitant administration of drug0 and drug2",True,advise
DDI-DrugBank.d400.s0.e2,DDI-DrugBank.d400.s0.e3,"drug0: As with other drug0, concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d400.s1.e0,DDI-DrugBank.d400.s1.e1,drug1: drug2 have been reported to competitively inhibit drug0,False, 
DDI-DrugBank.d400.s1.e0,DDI-DrugBank.d400.s1.e2,drug1: drug0 have been reported to competitively inhibit drug2,False, 
DDI-DrugBank.d400.s1.e1,DDI-DrugBank.d400.s1.e2,drug0: drug1 have been reported to competitively inhibit drug2,True,mechanism
DDI-DrugBank.d400.s3.e0,DDI-DrugBank.d400.s3.e1,Caution should be used when drug1 are administered concomitantly with drug2,True,advise
DDI-DrugBank.d400.s4.e0,DDI-DrugBank.d400.s4.e1,drug1: Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d400.s4.e0,DDI-DrugBank.d400.s4.e2,drug1: Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d400.s4.e1,DDI-DrugBank.d400.s4.e2,drug0: Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d400.s5.e0,DDI-DrugBank.d400.s5.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d400.s6.e0,DDI-DrugBank.d400.s6.e1,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug2 can reduce the natriuretic effect of drug0 and drug0",False, 
DDI-DrugBank.d400.s6.e0,DDI-DrugBank.d400.s6.e2,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug0 can reduce the natriuretic effect of drug2 and drug0",False, 
DDI-DrugBank.d400.s6.e1,DDI-DrugBank.d400.s6.e2,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d400.s6.e1,DDI-DrugBank.d400.s6.e3,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d400.s8.e0,DDI-DrugBank.d400.s8.e1,During concomitant therapy of drug1 with drug2,True,advise
DDI-DrugBank.d400.s9.e0,DDI-DrugBank.d400.s9.e1,drug1: drug2 have produced an elevation of plasma drug0 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d400.s9.e0,DDI-DrugBank.d400.s9.e2,drug1: drug0 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d400.s9.e1,DDI-DrugBank.d400.s9.e2,drug0: drug1 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,True,mechanism
DDI-DrugBank.d400.s9.e1,DDI-DrugBank.d400.s9.e3,drug0: drug1 have produced an elevation of plasma drug0 levels and a reduction in renal drug2,True,mechanism
DDI-DrugBank.d400.s12.e0,DDI-DrugBank.d400.s12.e1,"Thus, when drug1 and drug2 are administered concurrently, subjects should be observed carefully for signs of drug0",True,advise
DDI-DrugBank.d400.s12.e0,DDI-DrugBank.d400.s12.e2,"Thus, when drug1 and drug0 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d400.s12.e1,DDI-DrugBank.d400.s12.e2,"Thus, when drug0 and drug1 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d400.s13.e0,DDI-DrugBank.d400.s13.e1,drug1: The effects of drug2 and drug0,False, 
DDI-DrugBank.d400.s13.e0,DDI-DrugBank.d400.s13.e2,drug1: The effects of drug0 and drug2,False, 
DDI-DrugBank.d400.s13.e1,DDI-DrugBank.d400.s13.e2,drug0: The effects of drug1 and drug2,True,effect
DDI-DrugBank.d400.s14.e0,DDI-DrugBank.d400.s14.e1,"drug1: In a single dose study (n=6), ingestion of an drug2 containing 1.7-gram of drug0 with 500-mg of drug0 increased the Cmax and AUC of drug0 by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including drug0, drug0 and drug0",False, 
DDI-DrugBank.d400.s14.e0,DDI-DrugBank.d400.s14.e2,"drug1: In a single dose study (n=6), ingestion of an drug0 containing 1.7-gram of drug2 with 500-mg of drug0 increased the Cmax and AUC of drug0 by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including drug0, drug0 and drug0",False, 
DDI-DrugBank.d400.s14.e2,DDI-DrugBank.d400.s14.e3,"drug0: In a single dose study (n=6), ingestion of an drug0 containing 1.7-gram of drug1 with 500-mg of drug2 increased the Cmax and AUC of drug0 by 125% and 36%, respectively.  A number of compounds are inhibitors of CYP2C9 including drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d299.s1.e0,DDI-DrugBank.d299.s1.e1,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug2 (like drug0 or drug0) and drug0",False, 
DDI-DrugBank.d299.s1.e0,DDI-DrugBank.d299.s1.e2,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug0 (like drug2 or drug0) and drug0",False, 
DDI-DrugBank.d299.s1.e0,DDI-DrugBank.d299.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug1-containing or drug0 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d299.s1.e1,DDI-DrugBank.d299.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug1 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d299.s1.e2,DDI-DrugBank.d299.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug0 (like drug1 or drug0) and drug2",True,advise
DDI-DrugBank.d299.s1.e3,DDI-DrugBank.d299.s1.e4,"Because there is a theoretical basis that these effects may be additive, use of drug0-containing or drug0 (like drug0 or drug1) and drug2",True,advise
DDI-DrugBank.d299.s2.e0,DDI-DrugBank.d299.s2.e1,drug1: Coadministration of drug2 resulted in a 27% decrease in drug0,False, 
DDI-DrugBank.d299.s2.e0,DDI-DrugBank.d299.s2.e2,drug1: Coadministration of drug0 resulted in a 27% decrease in drug2,False, 
DDI-DrugBank.d299.s2.e1,DDI-DrugBank.d299.s2.e2,drug0: Coadministration of drug1 resulted in a 27% decrease in drug2,True,mechanism
DDI-DrugBank.d299.s4.e0,DDI-DrugBank.d299.s4.e1,Other drug1 Concomitant use of other drug2 within 24 hours of treatment with drug0,False, 
DDI-DrugBank.d299.s4.e0,DDI-DrugBank.d299.s4.e2,Other drug1 Concomitant use of other drug0 within 24 hours of treatment with drug2,False, 
DDI-DrugBank.d299.s4.e1,DDI-DrugBank.d299.s4.e2,Other drug0 Concomitant use of other drug1 within 24 hours of treatment with drug2,True,advise
DDI-DrugBank.d299.s5.e0,DDI-DrugBank.d299.s5.e1,drug1: The pharmacokinetics of drug2 were not affected by coadministration of drug0,False, 
DDI-DrugBank.d299.s5.e0,DDI-DrugBank.d299.s5.e2,drug1: The pharmacokinetics of drug0 were not affected by coadministration of drug2,False, 
DDI-DrugBank.d299.s6.e0,DDI-DrugBank.d299.s6.e1,"drug1 (drug2): drug0 (e.g., drug0, drug0, drug0, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug0",False, 
DDI-DrugBank.d299.s6.e0,DDI-DrugBank.d299.s6.e2,"drug1 (drug0): drug2 (e.g., drug0, drug0, drug0, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug0",False, 
DDI-DrugBank.d299.s6.e2,DDI-DrugBank.d299.s6.e7,"drug0 (drug0): drug1 (e.g., drug0, drug0, drug0, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d299.s6.e3,DDI-DrugBank.d299.s6.e7,"drug0 (drug0): drug0 (e.g., drug1, drug0, drug0, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d299.s6.e4,DDI-DrugBank.d299.s6.e7,"drug0 (drug0): drug0 (e.g., drug0, drug1, drug0, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d299.s6.e5,DDI-DrugBank.d299.s6.e7,"drug0 (drug0): drug0 (e.g., drug0, drug0, drug1, drug0) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d299.s6.e6,DDI-DrugBank.d299.s6.e7,"drug0 (drug0): drug0 (e.g., drug0, drug0, drug0, drug1) have been rarely reported to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d299.s7.e0,DDI-DrugBank.d299.s7.e1,If concomitant treatment with drug1 and an drug2,True,advise
DDI-DrugBank.d299.s8.e0,DDI-DrugBank.d299.s8.e1,drug1: Coadministration of drug2 and drug0 resulted in a 24% increase in plasma concentrations of drug0,False, 
DDI-DrugBank.d299.s8.e0,DDI-DrugBank.d299.s8.e2,drug1: Coadministration of drug0 and drug2 resulted in a 24% increase in plasma concentrations of drug0,False, 
DDI-DrugBank.d299.s8.e1,DDI-DrugBank.d299.s8.e2,drug0: Coadministration of drug1 and drug2 resulted in a 24% increase in plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d299.s10.e0,DDI-DrugBank.d299.s10.e1,Coadministration of drug1 and the potent CYP3A4 inhibitor drug2 (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d299.s10.e0,DDI-DrugBank.d299.s10.e2,Coadministration of drug1 and the potent CYP3A4 inhibitor drug0 (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of drug2,False, 
DDI-DrugBank.d299.s10.e1,DDI-DrugBank.d299.s10.e2,Coadministration of drug0 and the potent CYP3A4 inhibitor drug1 (400 mg q.d. for 3 days) resulted in an approximately 60% increase in the area under the plasma concentration-time curve and maximal plasma concentrations of drug2,False, 
DDI-DrugBank.d299.s11.e0,DDI-DrugBank.d299.s11.e1,"Although the interaction between drug1 and other potent CYP3A4 inhibitors (e.g., drug2, drug0, and drug0) has not been studied, increased exposures to drug0 may be expected when drug0",False, 
DDI-DrugBank.d299.s11.e0,DDI-DrugBank.d299.s11.e2,"Although the interaction between drug1 and other potent CYP3A4 inhibitors (e.g., drug0, drug2, and drug0) has not been studied, increased exposures to drug0 may be expected when drug0",False, 
DDI-DrugBank.d299.s11.e1,DDI-DrugBank.d299.s11.e5,"Although the interaction between drug0 and other potent CYP3A4 inhibitors (e.g., drug1, drug0, and drug0) has not been studied, increased exposures to drug0 may be expected when drug2",True,advise
DDI-DrugBank.d299.s11.e2,DDI-DrugBank.d299.s11.e5,"Although the interaction between drug0 and other potent CYP3A4 inhibitors (e.g., drug0, drug1, and drug0) has not been studied, increased exposures to drug0 may be expected when drug2",True,advise
DDI-DrugBank.d299.s11.e3,DDI-DrugBank.d299.s11.e5,"Although the interaction between drug0 and other potent CYP3A4 inhibitors (e.g., drug0, drug0, and drug1) has not been studied, increased exposures to drug0 may be expected when drug2",True,advise
DDI-DrugBank.d314.s0.e0,DDI-DrugBank.d314.s0.e1,drug1: drug2 may diminish adrenal suppression by drug0,False, 
DDI-DrugBank.d314.s0.e0,DDI-DrugBank.d314.s0.e2,drug1: drug0 may diminish adrenal suppression by drug2,False, 
DDI-DrugBank.d314.s0.e1,DDI-DrugBank.d314.s0.e2,drug0: drug1 may diminish adrenal suppression by drug2,True,effect
DDI-DrugBank.d314.s1.e0,DDI-DrugBank.d314.s1.e1,"drug1 injection and potassium-depleting agents: When drug2 are administered concomitantly with potassium-depleting agents (e.g., drug0, drug0",False, 
DDI-DrugBank.d314.s1.e0,DDI-DrugBank.d314.s1.e2,"drug1 injection and potassium-depleting agents: When drug0 are administered concomitantly with potassium-depleting agents (e.g., drug2, drug0",False, 
DDI-DrugBank.d314.s1.e1,DDI-DrugBank.d314.s1.e2,"drug0 injection and potassium-depleting agents: When drug1 are administered concomitantly with potassium-depleting agents (e.g., drug2, drug0",True,advise
DDI-DrugBank.d314.s1.e1,DDI-DrugBank.d314.s1.e3,"drug0 injection and potassium-depleting agents: When drug1 are administered concomitantly with potassium-depleting agents (e.g., drug0, drug2",True,advise
DDI-DrugBank.d314.s2.e0,DDI-DrugBank.d314.s2.e1,"In addition, there have been cases reported in which concomitant use of drug1 and drug2",True,effect
DDI-DrugBank.d314.s3.e0,DDI-DrugBank.d314.s3.e1,drug1: drug2 have been reported to cause a significant decrease in drug0,False, 
DDI-DrugBank.d314.s3.e0,DDI-DrugBank.d314.s3.e2,drug1: drug0 have been reported to cause a significant decrease in drug2,False, 
DDI-DrugBank.d314.s3.e1,DDI-DrugBank.d314.s3.e2,drug0: drug1 have been reported to cause a significant decrease in drug2,True,mechanism
DDI-DrugBank.d314.s4.e0,DDI-DrugBank.d314.s4.e1,drug1: Concomitant use of drug2 and drug0,False, 
DDI-DrugBank.d314.s4.e0,DDI-DrugBank.d314.s4.e2,drug1: Concomitant use of drug0 and drug2,False, 
DDI-DrugBank.d314.s4.e1,DDI-DrugBank.d314.s4.e2,drug0: Concomitant use of drug1 and drug2,True,effect
DDI-DrugBank.d314.s5.e0,DDI-DrugBank.d314.s5.e1,"If possible, drug1 should be withdrawn at least 24 hours before initiating drug2",True,advise
DDI-DrugBank.d314.s6.e0,DDI-DrugBank.d314.s6.e1,"drug1, oral: Co-administration of drug2 and drug0 usually results in inhibition of response to drug0",False, 
DDI-DrugBank.d314.s6.e0,DDI-DrugBank.d314.s6.e2,"drug1, oral: Co-administration of drug0 and drug2 usually results in inhibition of response to drug0",False, 
DDI-DrugBank.d314.s6.e1,DDI-DrugBank.d314.s6.e2,"drug0, oral: Co-administration of drug1 and drug2 usually results in inhibition of response to drug0",True,effect
DDI-DrugBank.d314.s8.e0,DDI-DrugBank.d314.s8.e1,"drug1: Because drug2 may increase blood glucose concentrations, dosage adjustments of drug0",False, 
DDI-DrugBank.d314.s8.e0,DDI-DrugBank.d314.s8.e2,"drug1: Because drug0 may increase blood glucose concentrations, dosage adjustments of drug2",False, 
DDI-DrugBank.d314.s8.e1,DDI-DrugBank.d314.s8.e2,"drug0: Because drug1 may increase blood glucose concentrations, dosage adjustments of drug2",True,effect
DDI-DrugBank.d314.s10.e0,DDI-DrugBank.d314.s10.e1,drug1: drug2 may increase the clearance of drug0,False, 
DDI-DrugBank.d314.s10.e0,DDI-DrugBank.d314.s10.e2,drug1: drug0 may increase the clearance of drug2,False, 
DDI-DrugBank.d314.s10.e1,DDI-DrugBank.d314.s10.e2,drug0: drug1 may increase the clearance of drug2,True,mechanism
DDI-DrugBank.d314.s11.e0,DDI-DrugBank.d314.s11.e1,drug1: Increased activity of both drug2 and drug0,False, 
DDI-DrugBank.d314.s11.e0,DDI-DrugBank.d314.s11.e2,drug1: Increased activity of both drug0 and drug2,False, 
DDI-DrugBank.d314.s11.e1,DDI-DrugBank.d314.s11.e2,drug0: Increased activity of both drug1 and drug2,True,effect
DDI-DrugBank.d314.s15.e0,DDI-DrugBank.d314.s15.e1,drug1: Patients on drug2,False, 
DDI-DrugBank.d314.s16.e0,DDI-DrugBank.d314.s16.e1,"drug1: drug2 may enhance the metabolic clearance of drug0, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in drug0",False, 
DDI-DrugBank.d314.s16.e0,DDI-DrugBank.d314.s16.e2,"drug1: drug0 may enhance the metabolic clearance of drug2, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in drug0",False, 
DDI-DrugBank.d314.s16.e1,DDI-DrugBank.d314.s16.e2,"drug0: drug1 may enhance the metabolic clearance of drug2, resulting in decreased blood levels and lessened physiologic activity, thus requiring an increase in drug0",True,mechanism
DDI-DrugBank.d314.s17.e0,DDI-DrugBank.d314.s17.e1,"drug1, including oral drug2: drug0 may decrease the hepatic metabolism of certain drug0",False, 
DDI-DrugBank.d314.s17.e0,DDI-DrugBank.d314.s17.e2,"drug1, including oral drug0: drug2 may decrease the hepatic metabolism of certain drug0",False, 
DDI-DrugBank.d314.s17.e2,DDI-DrugBank.d314.s17.e3,"drug0, including oral drug0: drug1 may decrease the hepatic metabolism of certain drug2",True,mechanism
DDI-DrugBank.d314.s18.e0,DDI-DrugBank.d314.s18.e1,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug1, drug2, drug0, drug0) may enhance the metabolism of drug0 and require that the dosage of the drug0",False, 
DDI-DrugBank.d314.s18.e0,DDI-DrugBank.d314.s18.e2,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug1, drug0, drug2, drug0) may enhance the metabolism of drug0 and require that the dosage of the drug0",False, 
DDI-DrugBank.d314.s18.e0,DDI-DrugBank.d314.s18.e4,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug1, drug0, drug0, drug0) may enhance the metabolism of drug2 and require that the dosage of the drug0",True,mechanism
DDI-DrugBank.d314.s18.e1,DDI-DrugBank.d314.s18.e4,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug0, drug1, drug0, drug0) may enhance the metabolism of drug2 and require that the dosage of the drug0",True,mechanism
DDI-DrugBank.d314.s18.e2,DDI-DrugBank.d314.s18.e4,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug0, drug0, drug1, drug0) may enhance the metabolism of drug2 and require that the dosage of the drug0",True,mechanism
DDI-DrugBank.d314.s18.e3,DDI-DrugBank.d314.s18.e4,"Hepatic Enzyme Inducers, Inhibitors and Substrates: Drugs which induce cytochrome P450 3A4 (CYP 3A4) enzyme activity (e.g., drug0, drug0, drug0, drug1) may enhance the metabolism of drug2 and require that the dosage of the drug0",True,mechanism
DDI-DrugBank.d314.s19.e0,DDI-DrugBank.d314.s19.e1,"Drugs which inhibit CYP 3A4 (e.g., drug1, drug2 such as drug0) have the potential to result in increased plasma concentrations of drug0",False, 
DDI-DrugBank.d314.s19.e0,DDI-DrugBank.d314.s19.e2,"Drugs which inhibit CYP 3A4 (e.g., drug1, drug0 such as drug2) have the potential to result in increased plasma concentrations of drug0",False, 
DDI-DrugBank.d314.s19.e0,DDI-DrugBank.d314.s19.e3,"Drugs which inhibit CYP 3A4 (e.g., drug1, drug0 such as drug0) have the potential to result in increased plasma concentrations of drug2",True,mechanism
DDI-DrugBank.d314.s19.e1,DDI-DrugBank.d314.s19.e3,"Drugs which inhibit CYP 3A4 (e.g., drug0, drug1 such as drug0) have the potential to result in increased plasma concentrations of drug2",True,mechanism
DDI-DrugBank.d314.s19.e2,DDI-DrugBank.d314.s19.e3,"Drugs which inhibit CYP 3A4 (e.g., drug0, drug0 such as drug1) have the potential to result in increased plasma concentrations of drug2",True,mechanism
DDI-DrugBank.d314.s21.e0,DDI-DrugBank.d314.s21.e1,"Co-administration with other drugs that are metabolized by CYP 3A4 (e.g., drug1, drug2",False, 
DDI-DrugBank.d314.s22.e0,DDI-DrugBank.d314.s22.e1,"drug1: drug2 has been reported to decrease the metabolism of certain drug0 by up to 60%, leading to increased risk of drug0",False, 
DDI-DrugBank.d314.s22.e0,DDI-DrugBank.d314.s22.e2,"drug1: drug0 has been reported to decrease the metabolism of certain drug2 by up to 60%, leading to increased risk of drug0",False, 
DDI-DrugBank.d314.s22.e1,DDI-DrugBank.d314.s22.e2,"drug0: drug1 has been reported to decrease the metabolism of certain drug2 by up to 60%, leading to increased risk of drug0",True,mechanism
DDI-DrugBank.d314.s23.e0,DDI-DrugBank.d314.s23.e1,"In addition, drug1 alone can inhibit adrenal drug2",True,effect
DDI-DrugBank.d314.s24.e0,DDI-DrugBank.d314.s24.e1,drug1 (drug2): Concomitant use of drug0 (or other drug0) and drug0,False, 
DDI-DrugBank.d314.s24.e0,DDI-DrugBank.d314.s24.e2,drug1 (drug0): Concomitant use of drug2 (or other drug0) and drug0,False, 
DDI-DrugBank.d314.s24.e2,DDI-DrugBank.d314.s24.e4,drug0 (drug0): Concomitant use of drug1 (or other drug0) and drug2,True,effect
DDI-DrugBank.d314.s24.e3,DDI-DrugBank.d314.s24.e4,drug0 (drug0): Concomitant use of drug0 (or other drug1) and drug2,True,effect
DDI-DrugBank.d314.s25.e0,DDI-DrugBank.d314.s25.e1,drug1 should be used cautiously in conjunction with drug2,True,advise
DDI-DrugBank.d314.s26.e0,DDI-DrugBank.d314.s26.e1,The clearance of drug1 may be increased with concurrent use of drug2,True,mechanism
DDI-DrugBank.d314.s27.e0,DDI-DrugBank.d314.s27.e1,"drug1: In post-marketing experience, there have been reports of both increases and decreases in drug2 levels with drug0",False, 
DDI-DrugBank.d314.s27.e0,DDI-DrugBank.d314.s27.e2,"drug1: In post-marketing experience, there have been reports of both increases and decreases in drug0 levels with drug2",False, 
DDI-DrugBank.d314.s27.e1,DDI-DrugBank.d314.s27.e2,"drug0: In post-marketing experience, there have been reports of both increases and decreases in drug1 levels with drug2",True,mechanism
DDI-DrugBank.d314.s29.e0,DDI-DrugBank.d314.s29.e1,drug1: Co-administration with drug2,False, 
DDI-DrugBank.d314.s30.e0,DDI-DrugBank.d314.s30.e1,drug1: Patients on drug2 therapy may exhibit a diminished response to toxoids and drug0 or drug0,False, 
DDI-DrugBank.d314.s30.e0,DDI-DrugBank.d314.s30.e2,drug1: Patients on drug0 therapy may exhibit a diminished response to toxoids and drug2 or drug0,False, 
DDI-DrugBank.d314.s30.e1,DDI-DrugBank.d314.s30.e2,drug0: Patients on drug1 therapy may exhibit a diminished response to toxoids and drug2 or drug0,True,effect
DDI-DrugBank.d314.s30.e1,DDI-DrugBank.d314.s30.e3,drug0: Patients on drug1 therapy may exhibit a diminished response to toxoids and drug0 or drug2,True,effect
DDI-DrugBank.d314.s31.e0,DDI-DrugBank.d314.s31.e1,drug1 may also potentiate the replication of some organisms contained in drug2,True,effect
DDI-DrugBank.d314.s32.e0,DDI-DrugBank.d314.s32.e1,Routine administration of drug1 or toxoids should be deferred until drug2,True,advise
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e1,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug2, drug0, drug0, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e2,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug2, drug0, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e3,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug2, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e4,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug2, drug0, drug0, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e5,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug2, drug0, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e6,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug0, drug2, certain drug0, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e7,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug0, drug0, certain drug2, drug0, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e8,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug0, drug0, certain drug0, drug2, drug0 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e9,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug0, drug0, certain drug0, drug0, drug2 and drug0",True,mechanism
DDI-DrugBank.d171.s0.e0,DDI-DrugBank.d171.s0.e10,"drug1, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug0, drug0, drug0, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug2",True,mechanism
DDI-DrugBank.d171.s0.e1,DDI-DrugBank.d171.s0.e2,"drug0, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug1, drug2, drug0, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d171.s0.e1,DDI-DrugBank.d171.s0.e3,"drug0, apparently through an effect on certain microsomal enzyme systems, has been reported to reduce the hepatic metabolism of drug1, drug0, drug2, drug0, drug0, drug0, certain drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d171.s2.e0,DDI-DrugBank.d171.s2.e1,"therefore, close monitoring of prothrombin time is recommended, and adjustment of the drug1 dose may be necessary when drug2",True,advise
DDI-DrugBank.d171.s3.e0,DDI-DrugBank.d171.s3.e1,"Interaction with drug1, drug2 and drug0",False, 
DDI-DrugBank.d171.s3.e0,DDI-DrugBank.d171.s3.e2,"Interaction with drug1, drug0 and drug2",False, 
DDI-DrugBank.d171.s4.e0,DDI-DrugBank.d171.s4.e1,"However, a crossover study in healthy subjects receiving either drug1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug2 (drug0 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state drug0",True,mechanism
DDI-DrugBank.d171.s4.e0,DDI-DrugBank.d171.s4.e2,"However, a crossover study in healthy subjects receiving either drug1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug0 (drug2 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state drug0",True,mechanism
DDI-DrugBank.d171.s4.e0,DDI-DrugBank.d171.s4.e3,"However, a crossover study in healthy subjects receiving either drug1 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug0 (drug0 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state drug2",False, 
DDI-DrugBank.d171.s4.e1,DDI-DrugBank.d171.s4.e2,"However, a crossover study in healthy subjects receiving either drug0 300 mg q.i.d. or 800 mg h.s. concomitantly with a 300 mg b.i.d. dosage of drug1 (drug2 , Key Pharmaceuticals, Inc.) demonstrated less alteration in steady-state drug0",False, 
DDI-DrugBank.d491.s1.e0,DDI-DrugBank.d491.s1.e1,The duration of the period following treatment with drug1  before one should consider starting other drug2,False, 
DDI-DrugBank.d491.s16.e0,DDI-DrugBank.d491.s16.e1,"Since the effect of drug1 on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking drug2 who become pregnant into the Biogen Pregnancy Registry by calling 1-866-drug0",False, 
DDI-DrugBank.d491.s16.e0,DDI-DrugBank.d491.s16.e2,"Since the effect of drug1 on pregnancy and fetal development, including immune system development, is not known, health care providers are encouraged to enroll patients currently taking drug0 who become pregnant into the Biogen Pregnancy Registry by calling 1-866-drug2",False, 
DDI-DrugBank.d87.s1.e0,DDI-DrugBank.d87.s1.e1,drug1 has been administered to patients receiving drug2 or drug0,False, 
DDI-DrugBank.d87.s1.e0,DDI-DrugBank.d87.s1.e2,drug1 has been administered to patients receiving drug0 or drug2,False, 
DDI-DrugBank.d87.s2.e0,DDI-DrugBank.d87.s2.e1,"During administration of multiple oral doses of drug1 to healthy subjects stabilized on a maintenance dose of drug2, a 13%-19% increase in plasma drug0",True,mechanism
DDI-DrugBank.d87.s2.e0,DDI-DrugBank.d87.s2.e2,"During administration of multiple oral doses of drug1 to healthy subjects stabilized on a maintenance dose of drug0, a 13%-19% increase in plasma drug2",False, 
DDI-DrugBank.d87.s2.e1,DDI-DrugBank.d87.s2.e2,"During administration of multiple oral doses of drug0 to healthy subjects stabilized on a maintenance dose of drug1, a 13%-19% increase in plasma drug2",False, 
DDI-DrugBank.d87.s3.e0,DDI-DrugBank.d87.s3.e1,"In a study involving healthy subjects receiving drug1 and drug2 concurrently, plasma drug0 levels were increased about 20% and drug0",True,mechanism
DDI-DrugBank.d87.s3.e0,DDI-DrugBank.d87.s3.e2,"In a study involving healthy subjects receiving drug1 and drug0 concurrently, plasma drug2 levels were increased about 20% and drug0",False, 
DDI-DrugBank.d87.s3.e0,DDI-DrugBank.d87.s3.e3,"In a study involving healthy subjects receiving drug1 and drug0 concurrently, plasma drug0 levels were increased about 20% and drug2",False, 
DDI-DrugBank.d87.s4.e0,DDI-DrugBank.d87.s4.e1,"In this formal interaction study, drug1 and drug2",False, 
DDI-DrugBank.d87.s6.e0,DDI-DrugBank.d87.s6.e1,The effects of concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d87.s7.e0,DDI-DrugBank.d87.s7.e1,"In drug1 clinical trials, patients who were receiving drug2",False, 
DDI-DrugBank.d87.s8.e0,DDI-DrugBank.d87.s8.e1,"Nevertheless, the possibility of additive negative inotropic effects of drug1 and drug2",True,effect
DDI-DrugBank.d87.s12.e0,DDI-DrugBank.d87.s12.e1,drug1 has been used in a large number of patients receiving drug2,False, 
DDI-DrugBank.d87.s13.e0,DDI-DrugBank.d87.s13.e1,"Limited data in patients receiving known enzyme inducers ( drug1, drug2, drug0 ) indicate only a 30% increase in the rate of drug0",False, 
DDI-DrugBank.d87.s13.e0,DDI-DrugBank.d87.s13.e2,"Limited data in patients receiving known enzyme inducers ( drug1, drug0, drug2 ) indicate only a 30% increase in the rate of drug0",False, 
DDI-DrugBank.d87.s13.e0,DDI-DrugBank.d87.s13.e3,"Limited data in patients receiving known enzyme inducers ( drug1, drug0, drug0 ) indicate only a 30% increase in the rate of drug2",True,mechanism
DDI-DrugBank.d87.s13.e1,DDI-DrugBank.d87.s13.e3,"Limited data in patients receiving known enzyme inducers ( drug0, drug1, drug0 ) indicate only a 30% increase in the rate of drug2",True,mechanism
DDI-DrugBank.d87.s13.e2,DDI-DrugBank.d87.s13.e3,"Limited data in patients receiving known enzyme inducers ( drug0, drug0, drug1 ) indicate only a 30% increase in the rate of drug2",True,mechanism
DDI-DrugBank.d87.s14.e0,DDI-DrugBank.d87.s14.e1,"In healthy subjects receiving drug1 (1 gm daily) for one week, plasma drug2",True,mechanism
DDI-DrugBank.d87.s15.e0,DDI-DrugBank.d87.s15.e1,"When drug1 is added to drug2 therapy, plasma drug0 levels may increase two-fold or more in some patients, if drug0",True,mechanism
DDI-DrugBank.d87.s15.e0,DDI-DrugBank.d87.s15.e2,"When drug1 is added to drug0 therapy, plasma drug2 levels may increase two-fold or more in some patients, if drug0",False, 
DDI-DrugBank.d87.s15.e0,DDI-DrugBank.d87.s15.e3,"When drug1 is added to drug0 therapy, plasma drug0 levels may increase two-fold or more in some patients, if drug2",False, 
DDI-DrugBank.d87.s16.e0,DDI-DrugBank.d87.s16.e1,"Drugs that inhibit cytochrome P450IID6, such as drug1 , might increase the plasma concentrations of drug2 in patients that are on chronic drug0",True,mechanism
DDI-DrugBank.d87.s16.e0,DDI-DrugBank.d87.s16.e2,"Drugs that inhibit cytochrome P450IID6, such as drug1 , might increase the plasma concentrations of drug0 in patients that are on chronic drug2",False, 
DDI-DrugBank.d87.s16.e1,DDI-DrugBank.d87.s16.e2,"Drugs that inhibit cytochrome P450IID6, such as drug0 , might increase the plasma concentrations of drug1 in patients that are on chronic drug2",False, 
DDI-DrugBank.d87.s18.e0,DDI-DrugBank.d87.s18.e1,There has been little experience with the coadministration of drug1 and either drug2 or drug0,False, 
DDI-DrugBank.d87.s18.e0,DDI-DrugBank.d87.s18.e2,There has been little experience with the coadministration of drug1 and either drug0 or drug2,False, 
DDI-DrugBank.d87.s19.e0,DDI-DrugBank.d87.s19.e1,"Because both of these drugs have negative inotropic properties and the effects of coadministration with drug1 are unknown, neither drug2 nor drug0 should be administered concurrently with drug0",False, 
DDI-DrugBank.d87.s19.e0,DDI-DrugBank.d87.s19.e2,"Because both of these drugs have negative inotropic properties and the effects of coadministration with drug1 are unknown, neither drug0 nor drug2 should be administered concurrently with drug0",False, 
DDI-DrugBank.d87.s19.e1,DDI-DrugBank.d87.s19.e3,"Because both of these drugs have negative inotropic properties and the effects of coadministration with drug0 are unknown, neither drug1 nor drug0 should be administered concurrently with drug2",True,advise
DDI-DrugBank.d87.s19.e2,DDI-DrugBank.d87.s19.e3,"Because both of these drugs have negative inotropic properties and the effects of coadministration with drug0 are unknown, neither drug0 nor drug1 should be administered concurrently with drug2",True,advise
DDI-DrugBank.d87.s20.e0,DDI-DrugBank.d87.s20.e1,There has been too little experience with the coadministration of drug1 with drug2 or drug0,False, 
DDI-DrugBank.d87.s20.e0,DDI-DrugBank.d87.s20.e2,There has been too little experience with the coadministration of drug1 with drug0 or drug2,False, 
DDI-DrugBank.d93.s0.e0,DDI-DrugBank.d93.s0.e1,"Clinical trials have indicated that drug1 can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral drug2, drug0, enzyme supplements, drug0, oral or inhaled drug0, and drug0",False, 
DDI-DrugBank.d93.s0.e0,DDI-DrugBank.d93.s0.e2,"Clinical trials have indicated that drug1 can be effectively and safely used in conjunction with standard cystic fibrosis therapies including oral, inhaled and/or parenteral drug0, drug2, enzyme supplements, drug0, oral or inhaled drug0, and drug0",False, 
DDI-DrugBank.d564.s0.e0,DDI-DrugBank.d564.s0.e1,The administration of local drug1 containing drug2 or drug0 to patients receiving drug0 or drug0,False, 
DDI-DrugBank.d564.s0.e0,DDI-DrugBank.d564.s0.e2,The administration of local drug1 containing drug0 or drug2 to patients receiving drug0 or drug0,False, 
DDI-DrugBank.d564.s0.e1,DDI-DrugBank.d564.s0.e3,The administration of local drug0 containing drug1 or drug0 to patients receiving drug2 or drug0,True,effect
DDI-DrugBank.d564.s0.e1,DDI-DrugBank.d564.s0.e4,The administration of local drug0 containing drug1 or drug0 to patients receiving drug0 or drug2,True,effect
DDI-DrugBank.d564.s0.e2,DDI-DrugBank.d564.s0.e3,The administration of local drug0 containing drug0 or drug1 to patients receiving drug2 or drug0,True,effect
DDI-DrugBank.d564.s0.e2,DDI-DrugBank.d564.s0.e4,The administration of local drug0 containing drug0 or drug1 to patients receiving drug0 or drug2,True,effect
DDI-DrugBank.d564.s1.e0,DDI-DrugBank.d564.s1.e1,drug1 and drug2 may reduce or reverse the pressor effect of drug0,False, 
DDI-DrugBank.d564.s1.e0,DDI-DrugBank.d564.s1.e2,drug1 and drug0 may reduce or reverse the pressor effect of drug2,True,effect
DDI-DrugBank.d564.s1.e1,DDI-DrugBank.d564.s1.e2,drug0 and drug1 may reduce or reverse the pressor effect of drug2,True,effect
DDI-DrugBank.d564.s4.e0,DDI-DrugBank.d564.s4.e1,Concurrent administration of drug1 (for the treatment of hypotension related to obstetric blocks) and drug2,False, 
DDI-DrugBank.d301.s14.e0,DDI-DrugBank.d301.s14.e1,"Other binding proteins may be elevated in serum, i.e., corticosteroid binding globulin (CBG), sex hormone-binding globulin (SHBG), leading to increased total circulating drug1 and drug2",False, 
DDI-DrugBank.d356.s0.e0,DDI-DrugBank.d356.s0.e1,When drug1 HCl is administered concomitantly with an drug2,True,effect
DDI-DrugBank.d356.s2.e0,DDI-DrugBank.d356.s2.e1,drug1 generally should not be given with drug2,True,advise
DDI-DrugBank.d356.s4.e0,DDI-DrugBank.d356.s4.e1,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",True,effect
DDI-DrugBank.d356.s4.e0,DDI-DrugBank.d356.s4.e2,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2 and drug0",True,effect
DDI-DrugBank.d356.s4.e0,DDI-DrugBank.d356.s4.e3,"In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug2",True,effect
DDI-DrugBank.d356.s4.e1,DDI-DrugBank.d356.s4.e2,"In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug2 and drug0",False, 
DDI-DrugBank.d356.s4.e1,DDI-DrugBank.d356.s4.e3,"In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug0 and drug2",False, 
DDI-DrugBank.d356.s5.e0,DDI-DrugBank.d356.s5.e1,"Therefore, when drug1 and drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",True,advise
DDI-DrugBank.d356.s5.e0,DDI-DrugBank.d356.s5.e2,"Therefore, when drug1 and drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d356.s5.e1,DDI-DrugBank.d356.s5.e2,"Therefore, when drug0 and drug1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d356.s6.e0,DDI-DrugBank.d356.s6.e1,"Since drug1 and drug2, including drug0",True,effect
DDI-DrugBank.d356.s6.e0,DDI-DrugBank.d356.s6.e2,"Since drug1 and drug0, including drug2",True,effect
DDI-DrugBank.d356.s6.e1,DDI-DrugBank.d356.s6.e2,"Since drug0 and drug1, including drug2",False, 
DDI-DrugBank.d25.s0.e0,DDI-DrugBank.d25.s0.e1,drug1 may accentuate the electrolyte loss associated with drug2,True,effect
DDI-DrugBank.d219.s0.e0,DDI-DrugBank.d219.s0.e1,drug1 Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d219.s0.e0,DDI-DrugBank.d219.s0.e2,drug1 Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d219.s0.e1,DDI-DrugBank.d219.s0.e2,drug0 Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d219.s1.e0,DDI-DrugBank.d219.s1.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d219.s2.e0,DDI-DrugBank.d219.s2.e1,drug1: The concomitant administration of drug2 has no apparent effect on the extent of absorption of drug0,False, 
DDI-DrugBank.d219.s2.e0,DDI-DrugBank.d219.s2.e2,drug1: The concomitant administration of drug0 has no apparent effect on the extent of absorption of drug2,False, 
DDI-DrugBank.d219.s4.e0,DDI-DrugBank.d219.s4.e1,"drug1: When drug2 is administered with drug0, its protein binding is reduced, although the clearance of free drug0",False, 
DDI-DrugBank.d219.s4.e0,DDI-DrugBank.d219.s4.e2,"drug1: When drug0 is administered with drug2, its protein binding is reduced, although the clearance of free drug0",False, 
DDI-DrugBank.d219.s4.e1,DDI-DrugBank.d219.s4.e2,"drug0: When drug1 is administered with drug2, its protein binding is reduced, although the clearance of free drug0",True,mechanism
DDI-DrugBank.d219.s6.e0,DDI-DrugBank.d219.s6.e1,"however, as with other drug1, concomitant administration of drug2 and drug0",False, 
DDI-DrugBank.d219.s6.e0,DDI-DrugBank.d219.s6.e2,"however, as with other drug1, concomitant administration of drug0 and drug2",False, 
DDI-DrugBank.d219.s6.e1,DDI-DrugBank.d219.s6.e2,"however, as with other drug0, concomitant administration of drug1 and drug2",True,advise
DDI-DrugBank.d219.s7.e0,DDI-DrugBank.d219.s7.e1,"Cyclosporine, Digoxin, Methotrexate drug1, like other drug2, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug0, drug0, drug0",False, 
DDI-DrugBank.d219.s7.e0,DDI-DrugBank.d219.s7.e2,"Cyclosporine, Digoxin, Methotrexate drug1, like other drug0, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug2, drug0, drug0",True,mechanism
DDI-DrugBank.d219.s7.e0,DDI-DrugBank.d219.s7.e3,"Cyclosporine, Digoxin, Methotrexate drug1, like other drug0, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug0, drug2, drug0",True,mechanism
DDI-DrugBank.d219.s7.e0,DDI-DrugBank.d219.s7.e4,"Cyclosporine, Digoxin, Methotrexate drug1, like other drug0, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug0, drug0, drug2",True,mechanism
DDI-DrugBank.d219.s7.e1,DDI-DrugBank.d219.s7.e2,"Cyclosporine, Digoxin, Methotrexate drug0, like other drug1, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug2, drug0, drug0",True,mechanism
DDI-DrugBank.d219.s7.e1,DDI-DrugBank.d219.s7.e3,"Cyclosporine, Digoxin, Methotrexate drug0, like other drug1, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug0, drug2, drug0",True,mechanism
DDI-DrugBank.d219.s7.e1,DDI-DrugBank.d219.s7.e4,"Cyclosporine, Digoxin, Methotrexate drug0, like other drug1, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug0, drug0, drug2",True,mechanism
DDI-DrugBank.d219.s7.e2,DDI-DrugBank.d219.s7.e3,"Cyclosporine, Digoxin, Methotrexate drug0, like other drug0, through effects on renal prostaglandins, may cause changes in the elimination of these drugs leading to elevated serum levels of drug1, drug2, drug0",False, 
DDI-DrugBank.d219.s9.e0,DDI-DrugBank.d219.s9.e1,"Patients receiving these drugs who are given drug1, or any other drug2",False, 
DDI-DrugBank.d219.s10.e0,DDI-DrugBank.d219.s10.e1,drug1: Etodolac has no apparent pharmacokinetic interaction when administered with drug2 or drug0,False, 
DDI-DrugBank.d219.s10.e0,DDI-DrugBank.d219.s10.e2,drug1: Etodolac has no apparent pharmacokinetic interaction when administered with drug0 or drug2,False, 
DDI-DrugBank.d219.s11.e0,DDI-DrugBank.d219.s11.e1,"Nevertheless, clinical studies, as well as postmarketing observations have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d219.s11.e0,DDI-DrugBank.d219.s11.e2,"Nevertheless, clinical studies, as well as postmarketing observations have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d219.s11.e1,DDI-DrugBank.d219.s11.e2,"Nevertheless, clinical studies, as well as postmarketing observations have shown that drug0 can reduce the natriuretic effect of drug1 and drug2",False, 
DDI-DrugBank.d219.s14.e0,DDI-DrugBank.d219.s14.e1,drug1: drug2 has no apparent pharmacokinetic interaction when administered with drug0,False, 
DDI-DrugBank.d219.s14.e0,DDI-DrugBank.d219.s14.e2,drug1: drug0 has no apparent pharmacokinetic interaction when administered with drug2,False, 
DDI-DrugBank.d219.s15.e0,DDI-DrugBank.d219.s15.e1,drug1: drug2 have produced an elevation of plasma drug0 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d219.s15.e0,DDI-DrugBank.d219.s15.e2,drug1: drug0 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d219.s15.e1,DDI-DrugBank.d219.s15.e2,drug0: drug1 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,True,mechanism
DDI-DrugBank.d219.s18.e0,DDI-DrugBank.d219.s18.e1,"Thus, when drug1 and drug2 are administered concurrently, subjects should be observed carefully for signs of drug0",True,effect
DDI-DrugBank.d219.s18.e0,DDI-DrugBank.d219.s18.e2,"Thus, when drug1 and drug0 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d219.s18.e1,DDI-DrugBank.d219.s18.e2,"Thus, when drug0 and drug1 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d219.s19.e0,DDI-DrugBank.d219.s19.e1,drug1: drug2 causes increase (by about 80%) in the free fraction of drug0,False, 
DDI-DrugBank.d219.s19.e0,DDI-DrugBank.d219.s19.e2,drug1: drug0 causes increase (by about 80%) in the free fraction of drug2,False, 
DDI-DrugBank.d219.s19.e1,DDI-DrugBank.d219.s19.e2,drug0: drug1 causes increase (by about 80%) in the free fraction of drug2,True,mechanism
DDI-DrugBank.d219.s20.e0,DDI-DrugBank.d219.s20.e1,Although in vivo studies have not been done to see if drug1 clearance is changed by coadministration of drug2,True,advise
DDI-DrugBank.d219.s21.e0,DDI-DrugBank.d219.s21.e1,drug1: drug2 has no apparent pharmacokinetic interaction when administered with drug0,False, 
DDI-DrugBank.d219.s21.e0,DDI-DrugBank.d219.s21.e2,drug1: drug0 has no apparent pharmacokinetic interaction when administered with drug2,False, 
DDI-DrugBank.d219.s22.e0,DDI-DrugBank.d219.s22.e1,drug1: The effects of drug2 and drug0,False, 
DDI-DrugBank.d219.s22.e0,DDI-DrugBank.d219.s22.e2,drug1: The effects of drug0 and drug2,False, 
DDI-DrugBank.d219.s22.e1,DDI-DrugBank.d219.s22.e2,drug0: The effects of drug1 and drug2,True,effect
DDI-DrugBank.d219.s23.e0,DDI-DrugBank.d219.s23.e1,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of drug1 and drug2  (drug0 capsules and tablets) results in reduced protein binding of drug0, but there was no change in the clearance of free drug0",True,mechanism
DDI-DrugBank.d219.s23.e0,DDI-DrugBank.d219.s23.e2,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of drug1 and drug0  (drug2 capsules and tablets) results in reduced protein binding of drug0, but there was no change in the clearance of free drug0",True,mechanism
DDI-DrugBank.d219.s23.e0,DDI-DrugBank.d219.s23.e3,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of drug1 and drug0  (drug0 capsules and tablets) results in reduced protein binding of drug2, but there was no change in the clearance of free drug0",False, 
DDI-DrugBank.d219.s23.e0,DDI-DrugBank.d219.s23.e4,"Short-term pharmacokinetic studies have demonstrated that concomitant administration of drug1 and drug0  (drug0 capsules and tablets) results in reduced protein binding of drug0, but there was no change in the clearance of free drug2",False, 
DDI-DrugBank.d219.s24.e0,DDI-DrugBank.d219.s24.e1,There was no significant difference in the pharmacodynamic effect of drug1 administered alone and drug2 administered with drug0,False, 
DDI-DrugBank.d219.s24.e0,DDI-DrugBank.d219.s24.e2,There was no significant difference in the pharmacodynamic effect of drug1 administered alone and drug0 administered with drug2,False, 
DDI-DrugBank.d219.s25.e0,DDI-DrugBank.d219.s25.e1,"Thus, concomitant therapy with drug1 and drug2",False, 
DDI-DrugBank.d219.s26.e0,DDI-DrugBank.d219.s26.e1,"However, caution should be exercised because there have been a few spontaneous reports of prolonged prothrombin times, with or without bleeding, in drug1-treated patients receiving concomitant drug2",True,effect
DDI-DrugBank.d219.s27.e0,DDI-DrugBank.d219.s27.e1,Drug/Laboratory Test Interactions The urine of patients who take drug1 can give a false-positive reaction for urinary bilirubin (urobilin) due to the presence of phenolic metabolites of drug2,False, 
DDI-DrugBank.d128.s0.e0,DDI-DrugBank.d128.s0.e1,May interact with wthionamide (drug1) and drug2 (drug0,False, 
DDI-DrugBank.d128.s0.e0,DDI-DrugBank.d128.s0.e2,May interact with wthionamide (drug1) and drug0 (drug2,False, 
DDI-DrugBank.d282.s0.e0,DDI-DrugBank.d282.s0.e1,"drug1 should not be administered concurrently with D2-antagonists, such as drug2, drug0, drug0, or drug0",True,advise
DDI-DrugBank.d282.s0.e0,DDI-DrugBank.d282.s0.e2,"drug1 should not be administered concurrently with D2-antagonists, such as drug0, drug2, drug0, or drug0",True,advise
DDI-DrugBank.d282.s0.e0,DDI-DrugBank.d282.s0.e3,"drug1 should not be administered concurrently with D2-antagonists, such as drug0, drug0, drug2, or drug0",True,advise
DDI-DrugBank.d282.s0.e0,DDI-DrugBank.d282.s0.e4,"drug1 should not be administered concurrently with D2-antagonists, such as drug0, drug0, drug0, or drug2",True,advise
DDI-DrugBank.d282.s0.e1,DDI-DrugBank.d282.s0.e2,"drug0 should not be administered concurrently with D2-antagonists, such as drug1, drug2, drug0, or drug0",False, 
DDI-DrugBank.d282.s0.e1,DDI-DrugBank.d282.s0.e3,"drug0 should not be administered concurrently with D2-antagonists, such as drug1, drug0, drug2, or drug0",False, 
DDI-DrugBank.d346.s0.e0,DDI-DrugBank.d346.s0.e1,Studies to evaluate possible interactions between drug1 and drugs other than drug2,False, 
DDI-DrugBank.d346.s2.e0,DDI-DrugBank.d346.s2.e1,The safety and efficacy of concomitant use of drug1 and drug2,True,effect
DDI-DrugBank.d346.s3.e0,DDI-DrugBank.d346.s3.e1,Lethargy and somnolence have been reported following doses of drug1 and drug2,True,effect
DDI-DrugBank.d346.s4.e0,DDI-DrugBank.d346.s4.e1,"Patients taking drug1 may not benefit from drug2 containing medicines, such as cough and cold preparations, antidiarrheal preparations, and drug0",True,effect
DDI-DrugBank.d346.s4.e0,DDI-DrugBank.d346.s4.e2,"Patients taking drug1 may not benefit from drug0 containing medicines, such as cough and cold preparations, antidiarrheal preparations, and drug2",True,effect
DDI-DrugBank.d346.s4.e1,DDI-DrugBank.d346.s4.e2,"Patients taking drug0 may not benefit from drug1 containing medicines, such as cough and cold preparations, antidiarrheal preparations, and drug2",False, 
DDI-DrugBank.d346.s5.e0,DDI-DrugBank.d346.s5.e1,"In an emergency situation when opioid analgesia must be administered to a patient receiving drug1, the amount of drug2",True,effect
DDI-DrugBank.d38.s0.e0,DDI-DrugBank.d38.s0.e1,drug1 does not influence the pharmacokinetics of drug2,False, 
DDI-DrugBank.d107.s0.e0,DDI-DrugBank.d107.s0.e1,"Hypotension: Patients on Diuretic Therapy: Patients on drug1 and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2 or drug0",True,effect
DDI-DrugBank.d107.s0.e0,DDI-DrugBank.d107.s0.e2,"Hypotension: Patients on Diuretic Therapy: Patients on drug1 and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug0 or drug2",True,effect
DDI-DrugBank.d107.s0.e1,DDI-DrugBank.d107.s0.e2,"Hypotension: Patients on Diuretic Therapy: Patients on drug0 and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug1 or drug2",False, 
DDI-DrugBank.d107.s1.e0,DDI-DrugBank.d107.s1.e1,The possibility of hypotensive effects with drug1 or drug2 can be minimized by either discontinuing the drug0 or increasing the salt intake prior to initiation of treatment with drug0 or drug0,False, 
DDI-DrugBank.d107.s1.e0,DDI-DrugBank.d107.s1.e2,The possibility of hypotensive effects with drug1 or drug0 can be minimized by either discontinuing the drug2 or increasing the salt intake prior to initiation of treatment with drug0 or drug0,True,effect
DDI-DrugBank.d107.s1.e0,DDI-DrugBank.d107.s1.e3,The possibility of hypotensive effects with drug1 or drug0 can be minimized by either discontinuing the drug0 or increasing the salt intake prior to initiation of treatment with drug2 or drug0,False, 
DDI-DrugBank.d107.s1.e1,DDI-DrugBank.d107.s1.e2,The possibility of hypotensive effects with drug0 or drug1 can be minimized by either discontinuing the drug2 or increasing the salt intake prior to initiation of treatment with drug0 or drug0,True,effect
DDI-DrugBank.d107.s3.e0,DDI-DrugBank.d107.s3.e1,"Agents Causing Renin Release: The antihypertensive effect of drug1 and drug2 IV is augmented by drug0 that cause renin release (e.g., drug0",False, 
DDI-DrugBank.d107.s3.e0,DDI-DrugBank.d107.s3.e2,"Agents Causing Renin Release: The antihypertensive effect of drug1 and drug0 IV is augmented by drug2 that cause renin release (e.g., drug0",True,effect
DDI-DrugBank.d107.s3.e0,DDI-DrugBank.d107.s3.e3,"Agents Causing Renin Release: The antihypertensive effect of drug1 and drug0 IV is augmented by drug0 that cause renin release (e.g., drug2",True,effect
DDI-DrugBank.d107.s3.e1,DDI-DrugBank.d107.s3.e2,"Agents Causing Renin Release: The antihypertensive effect of drug0 and drug1 IV is augmented by drug2 that cause renin release (e.g., drug0",True,effect
DDI-DrugBank.d107.s3.e1,DDI-DrugBank.d107.s3.e3,"Agents Causing Renin Release: The antihypertensive effect of drug0 and drug1 IV is augmented by drug0 that cause renin release (e.g., drug2",True,effect
DDI-DrugBank.d107.s3.e2,DDI-DrugBank.d107.s3.e3,"Agents Causing Renin Release: The antihypertensive effect of drug0 and drug0 IV is augmented by drug1 that cause renin release (e.g., drug2",False, 
DDI-DrugBank.d107.s4.e0,DDI-DrugBank.d107.s4.e1,"drug1: In some patients with compromised renal function who are being treated with drug2, the co-administration of drug0",False, 
DDI-DrugBank.d107.s4.e0,DDI-DrugBank.d107.s4.e2,"drug1: In some patients with compromised renal function who are being treated with drug0, the co-administration of drug2",False, 
DDI-DrugBank.d107.s4.e1,DDI-DrugBank.d107.s4.e2,"drug0: In some patients with compromised renal function who are being treated with drug1, the co-administration of drug2",True,effect
DDI-DrugBank.d107.s6.e0,DDI-DrugBank.d107.s6.e1,"In a clinical pharmacology study, drug1 or drug2 was administered to hypertensive patients receiving drug0",False, 
DDI-DrugBank.d107.s6.e0,DDI-DrugBank.d107.s6.e2,"In a clinical pharmacology study, drug1 or drug0 was administered to hypertensive patients receiving drug2",False, 
DDI-DrugBank.d107.s8.e0,DDI-DrugBank.d107.s8.e1,"However, reports suggest that drug1 may diminish the antihypertensive effect of drug2",True,effect
DDI-DrugBank.d107.s9.e0,DDI-DrugBank.d107.s9.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d107.s10.e0,DDI-DrugBank.d107.s10.e1,"Other Cardiovascular Agents: drug1 and drug2 IV have been used concomitantly with drug0, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d107.s10.e0,DDI-DrugBank.d107.s10.e2,"Other Cardiovascular Agents: drug1 and drug0 IV have been used concomitantly with drug2, drug0, drug0, drug0, drug0, drug0 and drug0",False, 
DDI-DrugBank.d107.s11.e0,DDI-DrugBank.d107.s11.e1,drug1 IV has been used concomitantly with drug2,False, 
DDI-DrugBank.d107.s12.e0,DDI-DrugBank.d107.s12.e1,Agents Increasing Serum Potassium: drug1 and drug2 IV attenuate potassium loss caused by drug0,False, 
DDI-DrugBank.d107.s12.e0,DDI-DrugBank.d107.s12.e2,Agents Increasing Serum Potassium: drug1 and drug0 IV attenuate potassium loss caused by drug2,True,effect
DDI-DrugBank.d107.s12.e1,DDI-DrugBank.d107.s12.e2,Agents Increasing Serum Potassium: drug0 and drug1 IV attenuate potassium loss caused by drug2,True,effect
DDI-DrugBank.d107.s13.e0,DDI-DrugBank.d107.s13.e1,"drug1 (e.g., drug2, drug0, or drug0), drug0 supplements, or drug0",False, 
DDI-DrugBank.d107.s13.e0,DDI-DrugBank.d107.s13.e2,"drug1 (e.g., drug0, drug2, or drug0), drug0 supplements, or drug0",False, 
DDI-DrugBank.d107.s16.e0,DDI-DrugBank.d107.s16.e1,"drug1: drug2 toxicity has been reported in patients receiving drug0 concomitantly with drugs which cause elimination of sodium, including drug0",False, 
DDI-DrugBank.d107.s16.e0,DDI-DrugBank.d107.s16.e2,"drug1: drug0 toxicity has been reported in patients receiving drug2 concomitantly with drugs which cause elimination of sodium, including drug0",False, 
DDI-DrugBank.d107.s16.e2,DDI-DrugBank.d107.s16.e3,"drug0: drug0 toxicity has been reported in patients receiving drug1 concomitantly with drugs which cause elimination of sodium, including drug2",True,effect
DDI-DrugBank.d107.s17.e0,DDI-DrugBank.d107.s17.e1,It is recommended that serum drug1 levels be monitored frequently if drug2 is administered concomitantly with drug0,False, 
DDI-DrugBank.d107.s17.e0,DDI-DrugBank.d107.s17.e2,It is recommended that serum drug1 levels be monitored frequently if drug0 is administered concomitantly with drug2,False, 
DDI-DrugBank.d107.s17.e1,DDI-DrugBank.d107.s17.e2,It is recommended that serum drug0 levels be monitored frequently if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d472.s0.e0,DDI-DrugBank.d472.s0.e1,"drug1 (CNS) drugs including drug2, drug0, drug0, drug0, blood pressure medications (drug0, drug0, drug0), motion sickness medications, drug0, drug0, drug0, sleeping pills and drug0",False, 
DDI-DrugBank.d472.s0.e0,DDI-DrugBank.d472.s0.e2,"drug1 (CNS) drugs including drug0, drug2, drug0, drug0, blood pressure medications (drug0, drug0, drug0), motion sickness medications, drug0, drug0, drug0, sleeping pills and drug0",False, 
DDI-DrugBank.d5.s0.e0,DDI-DrugBank.d5.s0.e1,"Few systemic data have been collected on the metabolism of drug1 following concomitant administration with other drugs or, alternatively, the effect of concomitant administration of drug2",False, 
DDI-DrugBank.d5.s2.e0,DDI-DrugBank.d5.s2.e1,In vitro studies indicate that drug1 is primarily metabolized to drug2,False, 
DDI-DrugBank.d5.s3.e0,DDI-DrugBank.d5.s3.e1,"Therefore, the potential exists for a drug interaction between drug1 and drugs that affect the CYP2B6 isoenzyme (e.g., drug2 and drug0",True,int
DDI-DrugBank.d5.s3.e0,DDI-DrugBank.d5.s3.e2,"Therefore, the potential exists for a drug interaction between drug1 and drugs that affect the CYP2B6 isoenzyme (e.g., drug0 and drug2",True,int
DDI-DrugBank.d5.s3.e1,DDI-DrugBank.d5.s3.e2,"Therefore, the potential exists for a drug interaction between drug0 and drugs that affect the CYP2B6 isoenzyme (e.g., drug1 and drug2",False, 
DDI-DrugBank.d5.s4.e0,DDI-DrugBank.d5.s4.e1,The drug1 metabolite of drug2,False, 
DDI-DrugBank.d5.s5.e0,DDI-DrugBank.d5.s5.e1,The effects of concomitant administration of drug1 on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d5.s6.e0,DDI-DrugBank.d5.s6.e1,"Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of drug1, the pharmacokinetics of drug2 and drug0",False, 
DDI-DrugBank.d5.s6.e0,DDI-DrugBank.d5.s6.e2,"Following oral administration of two 150-mg sustained-release tablets with and without 800 mg of drug1, the pharmacokinetics of drug0 and drug2",False, 
DDI-DrugBank.d5.s7.e0,DDI-DrugBank.d5.s7.e1,"However, there were 16% and 32% increases in the AUC and Cmax, respectively, of the combined moieties of drug1 and drug2",False, 
DDI-DrugBank.d5.s8.e0,DDI-DrugBank.d5.s8.e1,"While not systematically studied, certain drugs may induce the metabolism of drug1 (e.g., drug2, drug0, drug0",True,mechanism
DDI-DrugBank.d5.s8.e0,DDI-DrugBank.d5.s8.e2,"While not systematically studied, certain drugs may induce the metabolism of drug1 (e.g., drug0, drug2, drug0",True,mechanism
DDI-DrugBank.d5.s8.e0,DDI-DrugBank.d5.s8.e3,"While not systematically studied, certain drugs may induce the metabolism of drug1 (e.g., drug0, drug0, drug2",True,mechanism
DDI-DrugBank.d5.s8.e1,DDI-DrugBank.d5.s8.e2,"While not systematically studied, certain drugs may induce the metabolism of drug0 (e.g., drug1, drug2, drug0",False, 
DDI-DrugBank.d5.s8.e1,DDI-DrugBank.d5.s8.e3,"While not systematically studied, certain drugs may induce the metabolism of drug0 (e.g., drug1, drug0, drug2",False, 
DDI-DrugBank.d5.s12.e0,DDI-DrugBank.d5.s12.e1,"Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most drug1 (SSRIs, many drug2), drug0, drug0, and drug0",False, 
DDI-DrugBank.d5.s12.e0,DDI-DrugBank.d5.s12.e2,"Drugs Metabolized by Cytochrome P450IID6 (CYP2D6): Many drugs, including most drug1 (SSRIs, many drug0), drug2, drug0, and drug0",False, 
DDI-DrugBank.d5.s13.e0,DDI-DrugBank.d5.s13.e1,"Although drug1 is not metabolized by this isoenzyme, drug2 and drug0",False, 
DDI-DrugBank.d5.s13.e0,DDI-DrugBank.d5.s13.e2,"Although drug1 is not metabolized by this isoenzyme, drug0 and drug2",False, 
DDI-DrugBank.d5.s14.e0,DDI-DrugBank.d5.s14.e1,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of drug1 given as 150 mg twice daily followed by a single dose of 50 mg drug2 increased the Cmax, AUC, and t1/2 of drug0",True,mechanism
DDI-DrugBank.d5.s14.e0,DDI-DrugBank.d5.s14.e2,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of drug1 given as 150 mg twice daily followed by a single dose of 50 mg drug0 increased the Cmax, AUC, and t1/2 of drug2",False, 
DDI-DrugBank.d5.s14.e1,DDI-DrugBank.d5.s14.e2,"In a study of 15 male subjects (ages 19 to 35 years) who were extensive metabolizers of the CYP2D6 isoenzyme, daily doses of drug0 given as 150 mg twice daily followed by a single dose of 50 mg drug1 increased the Cmax, AUC, and t1/2 of drug2",False, 
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e1,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug2 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e2,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug2, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e3,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug2, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e4,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug2, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e5,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug2, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e6,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug2, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e7,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug2), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e8,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug2 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e9,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug2, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e10,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug2, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e11,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug2), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e12,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug2 (e.g., drug0), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e13,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug2), and drug0 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e14,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug2 (e.g., drug0, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e15,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug2, drug0",True,advise
DDI-DrugBank.d5.s17.e0,DDI-DrugBank.d5.s17.e16,"Therefore, co-administration of drug1 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug0 (e.g., drug0, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug2",True,advise
DDI-DrugBank.d5.s17.e1,DDI-DrugBank.d5.s17.e2,"Therefore, co-administration of drug0 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug1 (e.g., drug2, drug0, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d5.s17.e1,DDI-DrugBank.d5.s17.e3,"Therefore, co-administration of drug0 with drugs that are metabolized by CYP2D6 isoenzyme including certain drug1 (e.g., drug0, drug2, drug0, drug0, drug0, drug0), drug0 (e.g., drug0, drug0, drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d5.s19.e0,DDI-DrugBank.d5.s19.e1,drug1: Studies in animals demonstrate that the acute toxicity of drug2 is enhanced by the drug0 drug0,False, 
DDI-DrugBank.d5.s19.e0,DDI-DrugBank.d5.s19.e2,drug1: Studies in animals demonstrate that the acute toxicity of drug0 is enhanced by the drug2 drug0,False, 
DDI-DrugBank.d5.s19.e1,DDI-DrugBank.d5.s19.e3,drug0: Studies in animals demonstrate that the acute toxicity of drug1 is enhanced by the drug0 drug2,True,effect
DDI-DrugBank.d5.s20.e0,DDI-DrugBank.d5.s20.e1,drug1 and drug2: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug0 concurrently with either drug0 or drug0,False, 
DDI-DrugBank.d5.s20.e0,DDI-DrugBank.d5.s20.e2,drug1 and drug0: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug2 concurrently with either drug0 or drug0,False, 
DDI-DrugBank.d5.s20.e2,DDI-DrugBank.d5.s20.e3,drug0 and drug0: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug1 concurrently with either drug2 or drug0,True,effect
DDI-DrugBank.d5.s20.e2,DDI-DrugBank.d5.s20.e4,drug0 and drug0: Limited clinical data suggest a higher incidence of adverse experiences in patients receiving drug1 concurrently with either drug0 or drug2,True,effect
DDI-DrugBank.d5.s21.e0,DDI-DrugBank.d5.s21.e1,Administration of drug1 Tablets to patients receiving either drug2 or drug0,True,advise
DDI-DrugBank.d5.s21.e0,DDI-DrugBank.d5.s21.e2,Administration of drug1 Tablets to patients receiving either drug0 or drug2,True,advise
DDI-DrugBank.d5.s21.e1,DDI-DrugBank.d5.s21.e2,Administration of drug0 Tablets to patients receiving either drug1 or drug2,False, 
DDI-DrugBank.d5.s22.e0,DDI-DrugBank.d5.s22.e1,"Drugs that Lower Seizure Threshold: Concurrent administration of drug1 and agents (e.g., drug2, other drug0, drug0, systemic drug0",True,advise
DDI-DrugBank.d5.s22.e0,DDI-DrugBank.d5.s22.e2,"Drugs that Lower Seizure Threshold: Concurrent administration of drug1 and agents (e.g., drug0, other drug2, drug0, systemic drug0",True,advise
DDI-DrugBank.d5.s22.e0,DDI-DrugBank.d5.s22.e3,"Drugs that Lower Seizure Threshold: Concurrent administration of drug1 and agents (e.g., drug0, other drug0, drug2, systemic drug0",True,advise
DDI-DrugBank.d5.s22.e0,DDI-DrugBank.d5.s22.e4,"Drugs that Lower Seizure Threshold: Concurrent administration of drug1 and agents (e.g., drug0, other drug0, drug0, systemic drug2",True,advise
DDI-DrugBank.d5.s22.e1,DDI-DrugBank.d5.s22.e2,"Drugs that Lower Seizure Threshold: Concurrent administration of drug0 and agents (e.g., drug1, other drug2, drug0, systemic drug0",False, 
DDI-DrugBank.d5.s22.e1,DDI-DrugBank.d5.s22.e3,"Drugs that Lower Seizure Threshold: Concurrent administration of drug0 and agents (e.g., drug1, other drug0, drug2, systemic drug0",False, 
DDI-DrugBank.d5.s25.e0,DDI-DrugBank.d5.s25.e1,"drug1: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced drug2 tolerance in patients who were drinking drug0 during treatment with drug0",False, 
DDI-DrugBank.d5.s25.e0,DDI-DrugBank.d5.s25.e2,"drug1: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced drug0 tolerance in patients who were drinking drug2 during treatment with drug0",False, 
DDI-DrugBank.d5.s25.e2,DDI-DrugBank.d5.s25.e3,"drug0: In post-marketing experience, there have been rare reports of adverse neuropsychiatric events or reduced drug0 tolerance in patients who were drinking drug1 during treatment with drug2",True,effect
DDI-DrugBank.d5.s26.e0,DDI-DrugBank.d5.s26.e1,The consumption of drug1 during treatment with drug2,True,advise
DDI-DrugBank.d328.s0.e0,DDI-DrugBank.d328.s0.e1,The drug interaction studies with drug1 were performed both with drug2,False, 
DDI-DrugBank.d328.s4.e0,DDI-DrugBank.d328.s4.e1,drug1: Concomitant administration of drug2 with drug0 may result in an increased risk of GI ulceration and complications compared to drug0,False, 
DDI-DrugBank.d328.s4.e0,DDI-DrugBank.d328.s4.e2,drug1: Concomitant administration of drug0 with drug2 may result in an increased risk of GI ulceration and complications compared to drug0,False, 
DDI-DrugBank.d328.s4.e1,DDI-DrugBank.d328.s4.e2,drug0: Concomitant administration of drug1 with drug2 may result in an increased risk of GI ulceration and complications compared to drug0,True,effect
DDI-DrugBank.d328.s5.e0,DDI-DrugBank.d328.s5.e1,Because of its lack of anti-platelet effect drug1 is not a substitute for drug2,False, 
DDI-DrugBank.d328.s6.e0,DDI-DrugBank.d328.s6.e1,"In a parallel group drug interaction study comparing the intravenous prodrug form of drug1 at 40 mg BID (n=10) vs placebo (n=9), drug2 had no effect on in vitro drug0",False, 
DDI-DrugBank.d328.s6.e0,DDI-DrugBank.d328.s6.e2,"In a parallel group drug interaction study comparing the intravenous prodrug form of drug1 at 40 mg BID (n=10) vs placebo (n=9), drug0 had no effect on in vitro drug2",False, 
DDI-DrugBank.d328.s7.e0,DDI-DrugBank.d328.s7.e1,drug1: drug2 BID did not show a significant effect on the plasma exposure or renal clearance of drug0,False, 
DDI-DrugBank.d328.s7.e0,DDI-DrugBank.d328.s7.e2,drug1: drug0 BID did not show a significant effect on the plasma exposure or renal clearance of drug2,False, 
DDI-DrugBank.d328.s8.e0,DDI-DrugBank.d328.s8.e1,drug1:Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d328.s8.e0,DDI-DrugBank.d328.s8.e2,drug1:Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d328.s8.e1,DDI-DrugBank.d328.s8.e2,drug0:Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d328.s9.e0,DDI-DrugBank.d328.s9.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d328.s10.e0,DDI-DrugBank.d328.s10.e1,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug2 can reduce the natriuretic effect of drug0 and drug0",False, 
DDI-DrugBank.d328.s10.e0,DDI-DrugBank.d328.s10.e2,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug0 can reduce the natriuretic effect of drug2 and drug0",False, 
DDI-DrugBank.d328.s10.e1,DDI-DrugBank.d328.s10.e2,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d328.s10.e1,DDI-DrugBank.d328.s10.e3,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d328.s12.e0,DDI-DrugBank.d328.s12.e1,drug1 (drug2): Steady state plasma exposure (AUC) of drug0 (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of drug0,False, 
DDI-DrugBank.d328.s12.e0,DDI-DrugBank.d328.s12.e2,drug1 (drug0): Steady state plasma exposure (AUC) of drug2 (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of drug0,False, 
DDI-DrugBank.d328.s12.e2,DDI-DrugBank.d328.s12.e3,drug0 (drug0): Steady state plasma exposure (AUC) of drug1 (40 mg BID for 12 days) was decreased by 27% when co-administered with multiple doses (300 mg QD for 12 days) of drug2,True,mechanism
DDI-DrugBank.d328.s13.e0,DDI-DrugBank.d328.s13.e1,Patients already stabilized on drug1 should be closely monitored for loss of symptom control with drug2,True,advise
DDI-DrugBank.d328.s14.e0,DDI-DrugBank.d328.s14.e1,drug1 did not have a statistically significant effect on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d328.s17.e0,DDI-DrugBank.d328.s17.e1,drug1: drug2,False, 
DDI-DrugBank.d328.s18.e0,DDI-DrugBank.d328.s18.e1,"Coadministration with drug1 (40 mg BID for 7 days) resulted in a significant increase in drug2 plasma levels suggesting that, at these doses, drug0",True,mechanism
DDI-DrugBank.d328.s18.e0,DDI-DrugBank.d328.s18.e2,"Coadministration with drug1 (40 mg BID for 7 days) resulted in a significant increase in drug0 plasma levels suggesting that, at these doses, drug2",False, 
DDI-DrugBank.d328.s18.e1,DDI-DrugBank.d328.s18.e2,"Coadministration with drug0 (40 mg BID for 7 days) resulted in a significant increase in drug1 plasma levels suggesting that, at these doses, drug2",False, 
DDI-DrugBank.d328.s19.e0,DDI-DrugBank.d328.s19.e1,Even so drug1 plasma concentrations in the presence of high doses of drug2,True,mechanism
DDI-DrugBank.d328.s20.e0,DDI-DrugBank.d328.s20.e1,drug1: drug2 40 mg BID for 7 days produced significant decreases in drug0 serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to drug0,False, 
DDI-DrugBank.d328.s20.e0,DDI-DrugBank.d328.s20.e2,drug1: drug0 40 mg BID for 7 days produced significant decreases in drug2 serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to drug0,False, 
DDI-DrugBank.d328.s20.e1,DDI-DrugBank.d328.s20.e2,drug0: drug1 40 mg BID for 7 days produced significant decreases in drug2 serum clearance (25%) and renal clearance (30%) with a 34% higher serum exposure compared to drug0,True,mechanism
DDI-DrugBank.d328.s21.e0,DDI-DrugBank.d328.s21.e1,drug1 serum concentrations should be monitored closely when initiating or changing therapy with drug2 in patients receiving drug0,False, 
DDI-DrugBank.d328.s21.e0,DDI-DrugBank.d328.s21.e2,drug1 serum concentrations should be monitored closely when initiating or changing therapy with drug0 in patients receiving drug2,False, 
DDI-DrugBank.d328.s21.e1,DDI-DrugBank.d328.s21.e2,drug0 serum concentrations should be monitored closely when initiating or changing therapy with drug1 in patients receiving drug2,True,advise
DDI-DrugBank.d328.s22.e0,DDI-DrugBank.d328.s22.e1,drug1 (450 mg BID for 7 days) had no effect on drug2,False, 
DDI-DrugBank.d328.s23.e0,DDI-DrugBank.d328.s23.e1,drug1: The effect of drug2 on the anticoagulant effect of drug0 (1 - 8 mg/day) was studied in healthy subjects by coadministration of drug0,False, 
DDI-DrugBank.d328.s23.e0,DDI-DrugBank.d328.s23.e2,drug1: The effect of drug0 on the anticoagulant effect of drug2 (1 - 8 mg/day) was studied in healthy subjects by coadministration of drug0,False, 
DDI-DrugBank.d328.s24.e0,DDI-DrugBank.d328.s24.e1,"drug1 caused a statistically significant increase in plasma exposures of drug2 and drug0 (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of drug0",True,mechanism
DDI-DrugBank.d328.s24.e0,DDI-DrugBank.d328.s24.e2,"drug1 caused a statistically significant increase in plasma exposures of drug0 and drug2 (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of drug0",True,mechanism
DDI-DrugBank.d328.s24.e0,DDI-DrugBank.d328.s24.e3,"drug1 caused a statistically significant increase in plasma exposures of drug0 and drug0 (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of drug2",True,effect
DDI-DrugBank.d328.s24.e1,DDI-DrugBank.d328.s24.e2,"drug0 caused a statistically significant increase in plasma exposures of drug1 and drug2 (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of drug0",False, 
DDI-DrugBank.d328.s24.e1,DDI-DrugBank.d328.s24.e3,"drug0 caused a statistically significant increase in plasma exposures of drug1 and drug0 (12% and 15%, respectively), and in the pharmacodynamic effects (prothrombin time, measured as INR) of drug2",False, 
DDI-DrugBank.d328.s26.e0,DDI-DrugBank.d328.s26.e1,"drug1 therapy should be monitored, particularly during the first few weeks, after initiating therapy with drug2 in patients receiving drug0",False, 
DDI-DrugBank.d328.s26.e0,DDI-DrugBank.d328.s26.e2,"drug1 therapy should be monitored, particularly during the first few weeks, after initiating therapy with drug0 in patients receiving drug2",False, 
DDI-DrugBank.d328.s26.e1,DDI-DrugBank.d328.s26.e2,"drug0 therapy should be monitored, particularly during the first few weeks, after initiating therapy with drug1 in patients receiving drug2",True,advise
DDI-DrugBank.d328.s27.e0,DDI-DrugBank.d328.s27.e1,drug1 and drug2: drug0 and drug0,False, 
DDI-DrugBank.d328.s27.e0,DDI-DrugBank.d328.s27.e2,drug1 and drug0: drug2 and drug0,False, 
DDI-DrugBank.d328.s28.e0,DDI-DrugBank.d328.s28.e1,Concomitant single dose administration of drug1 20 mg with multiple doses of drug2 and drug0 produced a significant increase in exposure of drug0,True,mechanism
DDI-DrugBank.d328.s28.e0,DDI-DrugBank.d328.s28.e2,Concomitant single dose administration of drug1 20 mg with multiple doses of drug0 and drug2 produced a significant increase in exposure of drug0,True,mechanism
DDI-DrugBank.d328.s28.e0,DDI-DrugBank.d328.s28.e3,Concomitant single dose administration of drug1 20 mg with multiple doses of drug0 and drug0 produced a significant increase in exposure of drug2,False, 
DDI-DrugBank.d328.s28.e1,DDI-DrugBank.d328.s28.e2,Concomitant single dose administration of drug0 20 mg with multiple doses of drug1 and drug2 produced a significant increase in exposure of drug0,False, 
DDI-DrugBank.d328.s29.e0,DDI-DrugBank.d328.s29.e1,Plasma exposure (AUC) to drug1 was increased 62% when coadministered with drug2 and 38% when coadministered with drug0,True,mechanism
DDI-DrugBank.d328.s29.e0,DDI-DrugBank.d328.s29.e2,Plasma exposure (AUC) to drug1 was increased 62% when coadministered with drug0 and 38% when coadministered with drug2,True,mechanism
DDI-DrugBank.d328.s29.e1,DDI-DrugBank.d328.s29.e2,Plasma exposure (AUC) to drug0 was increased 62% when coadministered with drug1 and 38% when coadministered with drug2,False, 
DDI-DrugBank.d328.s30.e0,DDI-DrugBank.d328.s30.e1,drug1: drug2,False, 
DDI-DrugBank.d328.s31.e0,DDI-DrugBank.d328.s31.e1,Coadministration of drug1 (10 mg BID for 7 days) with drug2 (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of drug0,False, 
DDI-DrugBank.d328.s31.e0,DDI-DrugBank.d328.s31.e2,Coadministration of drug1 (10 mg BID for 7 days) with drug0 (5 mg QD or 10 mg BID) did not affect the pharmacokinetics (exposure) of drug2,False, 
DDI-DrugBank.d328.s32.e0,DDI-DrugBank.d328.s32.e1,Coadministration of drug1 (40 mg BID (day 1) and 40 mg QD (days 2-7)) with drug2 (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of drug0,False, 
DDI-DrugBank.d328.s32.e0,DDI-DrugBank.d328.s32.e2,Coadministration of drug1 (40 mg BID (day 1) and 40 mg QD (days 2-7)) with drug0 (5 mg QD) did not affect either the pharmacokinetics (exposure) or the pharmacodynamics (blood glucose and insulin levels) of drug2,False, 
DDI-DrugBank.d328.s33.e0,DDI-DrugBank.d328.s33.e1,Coadministration of drug1 (40 mg BID (day 1) and 40 mg QD (days 2-7)) with drug2 (10 mg drug0 BID) resulted in 21% increase in drug0 AUC0-12 and a 16% increase in drug0,True,mechanism
DDI-DrugBank.d328.s33.e0,DDI-DrugBank.d328.s33.e2,Coadministration of drug1 (40 mg BID (day 1) and 40 mg QD (days 2-7)) with drug0 (10 mg drug2 BID) resulted in 21% increase in drug0 AUC0-12 and a 16% increase in drug0,False, 
DDI-DrugBank.d328.s33.e0,DDI-DrugBank.d328.s33.e3,Coadministration of drug1 (40 mg BID (day 1) and 40 mg QD (days 2-7)) with drug0 (10 mg drug0 BID) resulted in 21% increase in drug2 AUC0-12 and a 16% increase in drug0,False, 
DDI-DrugBank.d328.s35.e0,DDI-DrugBank.d328.s35.e1,"Because changes in glucose concentrations with drug1 coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for drug2 (5 mg QD and 10 mg BID) with drug0",False, 
DDI-DrugBank.d328.s35.e0,DDI-DrugBank.d328.s35.e2,"Because changes in glucose concentrations with drug1 coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for drug0 (5 mg QD and 10 mg BID) with drug2",False, 
DDI-DrugBank.d328.s35.e1,DDI-DrugBank.d328.s35.e2,"Because changes in glucose concentrations with drug0 coadministration were within the normal variability and individual glucose concentrations were above or near 70 mg/dL, dose adjustment for drug1 (5 mg QD and 10 mg BID) with drug2",True,advise
DDI-DrugBank.d328.s36.e0,DDI-DrugBank.d328.s36.e1,Coadministration of drug1 with doses higher than 40 mg drug2,False, 
DDI-DrugBank.d328.s37.e0,DDI-DrugBank.d328.s37.e1,drug1: drug2,False, 
DDI-DrugBank.d328.s38.e0,DDI-DrugBank.d328.s38.e1,drug1 steady state plasma concentrations (40 mg BID) were not affected significantly with multiple doses of drug2,False, 
DDI-DrugBank.d328.s39.e0,DDI-DrugBank.d328.s39.e1,Coadministration with drug1 increased exposure of drug2,True,mechanism
DDI-DrugBank.d328.s40.e0,DDI-DrugBank.d328.s40.e1,Drugs whose absorption is sensitive to pH may be negatively impacted by concomitant administration of drug1 and drug2,False, 
DDI-DrugBank.d328.s41.e0,DDI-DrugBank.d328.s41.e1,"However, because higher doses (up to 360 mg QD) of drug1 are tolerated in Zollinger-Ellison (ZE) patients, no dose adjustment for drug2",False, 
DDI-DrugBank.d328.s42.e0,DDI-DrugBank.d328.s42.e1,Coadministration of drug1 with doses higher than 40 mg QD drug2,False, 
DDI-DrugBank.d328.s43.e0,DDI-DrugBank.d328.s43.e1,"Oral drug1: drug2 (40 mg BID) did not induce the metabolism of the combination oral drug0 drug0/drug0 (1 mg /35 mcg combination, drug0",False, 
DDI-DrugBank.d328.s43.e0,DDI-DrugBank.d328.s43.e2,"Oral drug1: drug0 (40 mg BID) did not induce the metabolism of the combination oral drug2 drug0/drug0 (1 mg /35 mcg combination, drug0",False, 
DDI-DrugBank.d328.s44.e0,DDI-DrugBank.d328.s44.e1,Coadministration of drug1 and drug2 1/35  increased the exposure of drug0 and drug0,True,mechanism
DDI-DrugBank.d328.s44.e0,DDI-DrugBank.d328.s44.e2,Coadministration of drug1 and drug0 1/35  increased the exposure of drug2 and drug0,False, 
DDI-DrugBank.d328.s44.e0,DDI-DrugBank.d328.s44.e3,Coadministration of drug1 and drug0 1/35  increased the exposure of drug0 and drug2,False, 
DDI-DrugBank.d328.s46.e0,DDI-DrugBank.d328.s46.e1,These increased exposures of drug1 and drug2 should be taken into consideration when selecting an oral drug0 for women taking drug0,False, 
DDI-DrugBank.d328.s46.e0,DDI-DrugBank.d328.s46.e2,These increased exposures of drug1 and drug0 should be taken into consideration when selecting an oral drug2 for women taking drug0,False, 
DDI-DrugBank.d328.s46.e2,DDI-DrugBank.d328.s46.e3,These increased exposures of drug0 and drug0 should be taken into consideration when selecting an oral drug1 for women taking drug2,True,advise
DDI-DrugBank.d328.s47.e0,DDI-DrugBank.d328.s47.e1,drug1: drug2 (drug0,False, 
DDI-DrugBank.d328.s47.e0,DDI-DrugBank.d328.s47.e2,drug1: drug0 (drug2,False, 
DDI-DrugBank.d328.s48.e0,DDI-DrugBank.d328.s48.e1,"Plasma exposure of drug1 (10 mg BID) was increased by 28% following administration of drug2 (40 mg BID) for 12 days, while plasma exposure of drug0 (40 mg BID) was not substantially increased following administration of drug0",True,mechanism
DDI-DrugBank.d328.s48.e0,DDI-DrugBank.d328.s48.e2,"Plasma exposure of drug1 (10 mg BID) was increased by 28% following administration of drug0 (40 mg BID) for 12 days, while plasma exposure of drug2 (40 mg BID) was not substantially increased following administration of drug0",False, 
DDI-DrugBank.d328.s48.e0,DDI-DrugBank.d328.s48.e3,"Plasma exposure of drug1 (10 mg BID) was increased by 28% following administration of drug0 (40 mg BID) for 12 days, while plasma exposure of drug0 (40 mg BID) was not substantially increased following administration of drug2",False, 
DDI-DrugBank.d328.s49.e0,DDI-DrugBank.d328.s49.e1,"Although the magnitude of changes in drug1 plasma exposure when coadministered with drug2 were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of drug0",False, 
DDI-DrugBank.d328.s49.e0,DDI-DrugBank.d328.s49.e2,"Although the magnitude of changes in drug1 plasma exposure when coadministered with drug0 were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of drug2",False, 
DDI-DrugBank.d328.s49.e1,DDI-DrugBank.d328.s49.e2,"Although the magnitude of changes in drug0 plasma exposure when coadministered with drug1 were not sufficient to warrant dosage adjustments, patients may experience enhanced sedative side effects caused by increased exposure of drug2",True,effect
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e1,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug2 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e2,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug2 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e3,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug2 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e4,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug2), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e5,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug2 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e6,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug2, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e7,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug2 (drug0), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e8,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug2), drug0 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e9,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug2 (drug0), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e10,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug2), or drug0 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e11,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug2 (drug0",True,advise
DDI-DrugBank.d521.s1.e0,DDI-DrugBank.d521.s1.e12,"Before taking drug1, tell your doctor if you are taking any of the following medicines: - drug0 or another drug0 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug2",True,advise
DDI-DrugBank.d521.s1.e1,DDI-DrugBank.d521.s1.e2,"Before taking drug0, tell your doctor if you are taking any of the following medicines: - drug1 or another drug2 such as drug0 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s1.e1,DDI-DrugBank.d521.s1.e3,"Before taking drug0, tell your doctor if you are taking any of the following medicines: - drug1 or another drug0 such as drug2 (drug0), drug0 (drug0, others), drug0 (drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s2.e0,DDI-DrugBank.d521.s2.e1,"- a drug1 (drug2) such as drug0 (drug0, drug0, drug0, others), drug0 (drug0, drug0, drug0), drug0 (drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0), and drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d521.s2.e0,DDI-DrugBank.d521.s2.e2,"- a drug1 (drug0) such as drug2 (drug0, drug0, drug0, others), drug0 (drug0, drug0, drug0), drug0 (drug0, drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0), and drug0 (drug0, drug0, drug0",False, 
DDI-DrugBank.d521.s3.e0,DDI-DrugBank.d521.s3.e1,"- a sulfa-based drug such as drug1-drug2 (drug0, drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s3.e0,DDI-DrugBank.d521.s3.e2,"- a sulfa-based drug such as drug1-drug0 (drug2, drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s4.e0,DDI-DrugBank.d521.s4.e1,"- a drug1 (drug2) such as drug0 (drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s4.e0,DDI-DrugBank.d521.s4.e2,"- a drug1 (drug0) such as drug2 (drug0), drug0 (drug0), or drug0 (drug0",False, 
DDI-DrugBank.d521.s5.e0,DDI-DrugBank.d521.s5.e1,"- a drug1 such as drug2 (drug0), drug0 (drug0), drug0 (drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s5.e0,DDI-DrugBank.d521.s5.e2,"- a drug1 such as drug0 (drug2), drug0 (drug0), drug0 (drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s6.e0,DDI-DrugBank.d521.s6.e1,"- a drug1 (water pill) such as drug2 (drug0, drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s6.e0,DDI-DrugBank.d521.s6.e2,"- a drug1 (water pill) such as drug0 (drug2, drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s7.e0,DDI-DrugBank.d521.s7.e1,"- a drug1 such as drug2 (drug0, drug0, others), drug0 (drug0, others), drug0 (drug0, drug0",False, 
DDI-DrugBank.d521.s7.e0,DDI-DrugBank.d521.s7.e2,"- a drug1 such as drug0 (drug2, drug0, others), drug0 (drug0, others), drug0 (drug0, drug0",False, 
DDI-DrugBank.d521.s8.e0,DDI-DrugBank.d521.s8.e1,"- a drug1 such as drug2 (drug0), drug0 (drug0, drug0), drug0 (drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s8.e0,DDI-DrugBank.d521.s8.e2,"- a drug1 such as drug0 (drug2), drug0 (drug0, drug0), drug0 (drug0), drug0 (drug0",False, 
DDI-DrugBank.d521.s9.e0,DDI-DrugBank.d521.s9.e1,- drug1 (drug2,False, 
DDI-DrugBank.d521.s10.e0,DDI-DrugBank.d521.s10.e1,- drug1 (drug2,False, 
DDI-DrugBank.d521.s11.e0,DDI-DrugBank.d521.s11.e1,"- drug1 (drug2, drug0",False, 
DDI-DrugBank.d521.s11.e0,DDI-DrugBank.d521.s11.e2,"- drug1 (drug0, drug2",False, 
DDI-DrugBank.d166.s0.e0,DDI-DrugBank.d166.s0.e1,drug1 has been found to temporarily raise serum concentrations of drug2,True,mechanism
DDI-DrugBank.d166.s1.e0,DDI-DrugBank.d166.s1.e1,drug1 may potentiate the adverse effects of other drug2,True,effect
DDI-DrugBank.d166.s2.e0,DDI-DrugBank.d166.s2.e1,"In particular, convulsions have been reported when drug1 is administered with drug2",True,effect
DDI-DrugBank.d467.s2.e0,DDI-DrugBank.d467.s2.e1,"On the basis of the metabolism of drug1 by cytochrome P450 3A4, drug2, drug0, drug0, drug0, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug0",False, 
DDI-DrugBank.d467.s2.e0,DDI-DrugBank.d467.s2.e2,"On the basis of the metabolism of drug1 by cytochrome P450 3A4, drug0, drug2, drug0, drug0, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug0",False, 
DDI-DrugBank.d467.s2.e1,DDI-DrugBank.d467.s2.e5,"On the basis of the metabolism of drug0 by cytochrome P450 3A4, drug1, drug0, drug0, drug0, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug2",True,mechanism
DDI-DrugBank.d467.s2.e2,DDI-DrugBank.d467.s2.e5,"On the basis of the metabolism of drug0 by cytochrome P450 3A4, drug0, drug1, drug0, drug0, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug2",True,mechanism
DDI-DrugBank.d467.s2.e3,DDI-DrugBank.d467.s2.e5,"On the basis of the metabolism of drug0 by cytochrome P450 3A4, drug0, drug0, drug1, drug0, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug2",True,mechanism
DDI-DrugBank.d467.s2.e4,DDI-DrugBank.d467.s2.e5,"On the basis of the metabolism of drug0 by cytochrome P450 3A4, drug0, drug0, drug0, drug1, grapefruit juice, and other inhibitors of cytochrome P450 3A4 would be expected to lead to an increase in plasma drug2",True,mechanism
DDI-DrugBank.d467.s3.e0,DDI-DrugBank.d467.s3.e1,"Furthermore, drug1, drug2, drug0, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug0",False, 
DDI-DrugBank.d467.s3.e0,DDI-DrugBank.d467.s3.e2,"Furthermore, drug1, drug0, drug2, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug0",False, 
DDI-DrugBank.d467.s3.e0,DDI-DrugBank.d467.s3.e3,"Furthermore, drug1, drug0, drug0, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug2",True,mechanism
DDI-DrugBank.d467.s3.e1,DDI-DrugBank.d467.s3.e3,"Furthermore, drug0, drug1, drug0, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug2",True,mechanism
DDI-DrugBank.d467.s3.e2,DDI-DrugBank.d467.s3.e3,"Furthermore, drug0, drug0, drug1, and other inducers of cytochrome P450 3A4 may cause a reduction in plasma drug2",True,mechanism
DDI-DrugBank.d467.s4.e0,DDI-DrugBank.d467.s4.e1,"Concomitant administration of drug1 capsules and drug2 resulted in substantial increases in plasma concentrations of drug0, probably at least partially related to cytochrome P450 3A4 inhibition by drug0",True,mechanism
DDI-DrugBank.d467.s4.e0,DDI-DrugBank.d467.s4.e2,"Concomitant administration of drug1 capsules and drug0 resulted in substantial increases in plasma concentrations of drug2, probably at least partially related to cytochrome P450 3A4 inhibition by drug0",False, 
DDI-DrugBank.d467.s4.e0,DDI-DrugBank.d467.s4.e3,"Concomitant administration of drug1 capsules and drug0 resulted in substantial increases in plasma concentrations of drug0, probably at least partially related to cytochrome P450 3A4 inhibition by drug2",False, 
DDI-DrugBank.d467.s5.e0,DDI-DrugBank.d467.s5.e1,"Under similar conditions, drug1 concentrations were not affected by concomitant drug2",False, 
DDI-DrugBank.d467.s6.e0,DDI-DrugBank.d467.s6.e1,Concomitant administration of drug1 with drug2,True,advise
DDI-DrugBank.d532.s2.e0,DDI-DrugBank.d532.s2.e1,"These medications have included drug1, drug2, drug0, drug0, drug0, intravenous and oral drug0, drug0, and drug0",False, 
DDI-DrugBank.d532.s2.e0,DDI-DrugBank.d532.s2.e2,"These medications have included drug1, drug0, drug2, drug0, drug0, intravenous and oral drug0, drug0, and drug0",False, 
DDI-DrugBank.d532.s3.e0,DDI-DrugBank.d532.s3.e1,"drug1, other drug2, drug0, and drug0",False, 
DDI-DrugBank.d532.s3.e0,DDI-DrugBank.d532.s3.e2,"drug1, other drug0, drug2, and drug0",False, 
DDI-DrugBank.d532.s4.e0,DDI-DrugBank.d532.s4.e1,Patients with HACA titers may have allergic or hypersensitivity reactions when treated with other drug1 or drug2,False, 
DDI-DrugBank.d461.s0.e0,DDI-DrugBank.d461.s0.e1,"Additive depressant effect when used with general drug1, drug2, drug0, drug0, drug0, and other drug0",False, 
DDI-DrugBank.d461.s0.e0,DDI-DrugBank.d461.s0.e2,"Additive depressant effect when used with general drug1, drug0, drug2, drug0, drug0, and other drug0",False, 
DDI-DrugBank.d252.s0.e0,DDI-DrugBank.d252.s0.e1,"Although drug1 used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with drug2 and drug0",False, 
DDI-DrugBank.d252.s0.e0,DDI-DrugBank.d252.s0.e2,"Although drug1 used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with drug0 and drug2",False, 
DDI-DrugBank.d252.s0.e1,DDI-DrugBank.d252.s0.e2,"Although drug0 used alone has little or no effect on pupil size, mydriasis resulting from concomitant therapy with drug1 and drug2",True,effect
DDI-DrugBank.d252.s1.e0,DDI-DrugBank.d252.s1.e1,Close observation of the patient is recommended when a drug1 is administered to patients receiving catecholamine-depleting drugs such as drug2,True,advise
DDI-DrugBank.d252.s2.e0,DDI-DrugBank.d252.s2.e1,Patients receiving drug1 along with either oral or intravenous drug2,True,advise
DDI-DrugBank.d252.s4.e0,DDI-DrugBank.d252.s4.e1,The concomitant use of drug1 with drug2 and drug0,True,effect
DDI-DrugBank.d252.s4.e0,DDI-DrugBank.d252.s4.e2,The concomitant use of drug1 with drug0 and drug2,True,effect
DDI-DrugBank.d252.s4.e1,DDI-DrugBank.d252.s4.e2,The concomitant use of drug0 with drug1 and drug2,False, 
DDI-DrugBank.d252.s5.e0,DDI-DrugBank.d252.s5.e1,drug1 and drug2,True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e1,"drug1 drug2 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",False, 
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e2,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug2, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e3,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug2, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e4,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug2 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e5,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug2 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e6,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug2 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e7,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug2, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e8,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug2, thyroid and drug0 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e9,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug2 preparations, drug0 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e10,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug2 and drug0, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e11,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug2, and drug0",True,mechanism
DDI-DrugBank.d566.s0.e0,DDI-DrugBank.d566.s0.e12,"drug1 drug0 may delay or reduce the absorption of concomitant oral medication such as drug0, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug2",True,mechanism
DDI-DrugBank.d566.s0.e1,DDI-DrugBank.d566.s0.e2,"drug0 drug1 may delay or reduce the absorption of concomitant oral medication such as drug2, drug0, drug0 (acidic) or drug0 (basic), as well as drug0 drug0, drug0, thyroid and drug0 preparations, drug0 and drug0, and drug0",False, 
DDI-DrugBank.d566.s2.e0,DDI-DrugBank.d566.s2.e1,"drug1 drug2 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of drug0 drug0 could pose a hazard to health if a potentially toxic drug such as drug0 has been filtrated to a maintenance level while the patient was taking drug0 drug0",False, 
DDI-DrugBank.d566.s2.e0,DDI-DrugBank.d566.s2.e2,"drug1 drug0 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of drug2 drug0 could pose a hazard to health if a potentially toxic drug such as drug0 has been filtrated to a maintenance level while the patient was taking drug0 drug0",False, 
DDI-DrugBank.d566.s2.e2,DDI-DrugBank.d566.s2.e4,"drug0 drug0 may interfere with the pharmacokinetics of drugs that undergo enterohepatic circulation, The discontinuance of drug1 drug0 could pose a hazard to health if a potentially toxic drug such as drug2 has been filtrated to a maintenance level while the patient was taking drug0 drug0",True,mechanism
DDI-DrugBank.d566.s3.e0,DDI-DrugBank.d566.s3.e1,"Because drug1 binds bile acids, drug2 drug0 may interfere with normal fat digestion and absorption and thus may prevent absorption of drug0",False, 
DDI-DrugBank.d566.s3.e0,DDI-DrugBank.d566.s3.e2,"Because drug1 binds bile acids, drug0 drug2 may interfere with normal fat digestion and absorption and thus may prevent absorption of drug0",False, 
DDI-DrugBank.d566.s4.e0,DDI-DrugBank.d566.s4.e1,"When drug1 drug2 is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of drug0",False, 
DDI-DrugBank.d566.s4.e0,DDI-DrugBank.d566.s4.e2,"When drug1 drug0 is given for long periods of time, concomitant supplementation with water-miscible (or parenteral) forms of drug2",False, 
DDI-DrugBank.d566.s5.e0,DDI-DrugBank.d566.s5.e1,"SINCE drug1 drug2 MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER drug0 drug0",False, 
DDI-DrugBank.d566.s5.e0,DDI-DrugBank.d566.s5.e2,"SINCE drug1 drug0 MAY BIND OTHER DRUGS GIVEN CONCURRENTLY, IT IS RECOMMENDED THAT PATIENTS TAKE OTHER DRUGS AT LEAST 1 HOUR BEFORE OR 4 TO 6 HOURS AFTER drug2 drug0",False, 
DDI-DrugBank.d100.s0.e0,DDI-DrugBank.d100.s0.e1,Increased nephrotoxicity has been reported following concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d100.s1.e0,DDI-DrugBank.d100.s1.e1,"Drug/Laboratory Test Interactions drug1, including drug2",False, 
DDI-DrugBank.d509.s0.e0,DDI-DrugBank.d509.s0.e1,"Drug-Drug Interactions Given the primary CNS effects of drug1, caution should be used when drug2 is taken in combination with other drug0 and drug0",False, 
DDI-DrugBank.d509.s0.e0,DDI-DrugBank.d509.s0.e2,"Drug-Drug Interactions Given the primary CNS effects of drug1, caution should be used when drug0 is taken in combination with other drug2 and drug0",False, 
DDI-DrugBank.d509.s0.e1,DDI-DrugBank.d509.s0.e2,"Drug-Drug Interactions Given the primary CNS effects of drug0, caution should be used when drug1 is taken in combination with other drug2 and drug0",True,advise
DDI-DrugBank.d509.s0.e1,DDI-DrugBank.d509.s0.e3,"Drug-Drug Interactions Given the primary CNS effects of drug0, caution should be used when drug1 is taken in combination with other drug0 and drug2",True,advise
DDI-DrugBank.d509.s2.e0,DDI-DrugBank.d509.s2.e1,"1- adrenergic receptor antagonism, drug1 has the potential to enhance the effect of certain drug2",True,effect
DDI-DrugBank.d509.s3.e0,DDI-DrugBank.d509.s3.e1,Potential for Other Drugs to Affect drug1 drug2,False, 
DDI-DrugBank.d509.s7.e0,DDI-DrugBank.d509.s7.e1,"Agents that induce CYP3A4 (eg, drug1) could cause an increase in drug2",True,mechanism
DDI-DrugBank.d509.s8.e0,DDI-DrugBank.d509.s8.e1,"Inhibitors of CYP3A4 (eg, drug1) or CYP2D6 (eg, drug2, drug0, or drug0) can inhibit drug0",False, 
DDI-DrugBank.d509.s8.e0,DDI-DrugBank.d509.s8.e2,"Inhibitors of CYP3A4 (eg, drug1) or CYP2D6 (eg, drug0, drug2, or drug0) can inhibit drug0",False, 
DDI-DrugBank.d509.s8.e0,DDI-DrugBank.d509.s8.e4,"Inhibitors of CYP3A4 (eg, drug1) or CYP2D6 (eg, drug0, drug0, or drug0) can inhibit drug2",True,mechanism
DDI-DrugBank.d509.s8.e1,DDI-DrugBank.d509.s8.e4,"Inhibitors of CYP3A4 (eg, drug0) or CYP2D6 (eg, drug1, drug0, or drug0) can inhibit drug2",True,mechanism
DDI-DrugBank.d509.s8.e2,DDI-DrugBank.d509.s8.e4,"Inhibitors of CYP3A4 (eg, drug0) or CYP2D6 (eg, drug0, drug1, or drug0) can inhibit drug2",True,mechanism
DDI-DrugBank.d509.s8.e3,DDI-DrugBank.d509.s8.e4,"Inhibitors of CYP3A4 (eg, drug0) or CYP2D6 (eg, drug0, drug0, or drug1) can inhibit drug2",True,mechanism
DDI-DrugBank.d509.s9.e0,DDI-DrugBank.d509.s9.e1,drug1: Coadministration of drug2 (200 mg/day for 14 days) with a 15-mg single dose of drug0 increased the AUC of drug0,False, 
DDI-DrugBank.d509.s9.e0,DDI-DrugBank.d509.s9.e2,drug1: Coadministration of drug0 (200 mg/day for 14 days) with a 15-mg single dose of drug2 increased the AUC of drug0,False, 
DDI-DrugBank.d509.s9.e1,DDI-DrugBank.d509.s9.e2,drug0: Coadministration of drug1 (200 mg/day for 14 days) with a 15-mg single dose of drug2 increased the AUC of drug0,True,mechanism
DDI-DrugBank.d509.s11.e0,DDI-DrugBank.d509.s11.e1,"When concomitant administration of drug1 with drug2 occurs, drug0",True,advise
DDI-DrugBank.d509.s11.e0,DDI-DrugBank.d509.s11.e2,"When concomitant administration of drug1 with drug0 occurs, drug2",False, 
DDI-DrugBank.d509.s11.e1,DDI-DrugBank.d509.s11.e2,"When concomitant administration of drug0 with drug1 occurs, drug2",False, 
DDI-DrugBank.d509.s15.e0,DDI-DrugBank.d509.s15.e1,"drug1: Coadministration of a 10-mg single dose of drug2 with drug0 (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of drug0 by 112% but decreased the AUC of its active metabolite, drug0",False, 
DDI-DrugBank.d509.s15.e0,DDI-DrugBank.d509.s15.e2,"drug1: Coadministration of a 10-mg single dose of drug0 with drug2 (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of drug0 by 112% but decreased the AUC of its active metabolite, drug0",False, 
DDI-DrugBank.d509.s15.e1,DDI-DrugBank.d509.s15.e2,"drug0: Coadministration of a 10-mg single dose of drug1 with drug2 (166 mg/day for 13 days), a potent inhibitor of CYP2D6, increased the AUC of drug0 by 112% but decreased the AUC of its active metabolite, drug0",True,mechanism
DDI-DrugBank.d509.s16.e0,DDI-DrugBank.d509.s16.e1,drug1 dose should be reduced to one-half of its normal dose when concomitant administration of drug2 with drug0,False, 
DDI-DrugBank.d509.s16.e0,DDI-DrugBank.d509.s16.e2,drug1 dose should be reduced to one-half of its normal dose when concomitant administration of drug0 with drug2,False, 
DDI-DrugBank.d509.s16.e1,DDI-DrugBank.d509.s16.e2,drug0 dose should be reduced to one-half of its normal dose when concomitant administration of drug1 with drug2,True,advise
DDI-DrugBank.d509.s17.e0,DDI-DrugBank.d509.s17.e1,"Other significant inhibitors of CYP2D6, such as drug1 or drug2",False, 
DDI-DrugBank.d509.s19.e0,DDI-DrugBank.d509.s19.e1,"drug1: Coadministration of drug2 (200 mg BID), a potent CYP3A4 inducer, with drug0 (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both drug0 and its active metabolite, drug0",False, 
DDI-DrugBank.d509.s19.e0,DDI-DrugBank.d509.s19.e2,"drug1: Coadministration of drug0 (200 mg BID), a potent CYP3A4 inducer, with drug2 (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both drug0 and its active metabolite, drug0",False, 
DDI-DrugBank.d509.s19.e1,DDI-DrugBank.d509.s19.e2,"drug0: Coadministration of drug1 (200 mg BID), a potent CYP3A4 inducer, with drug2 (30 mg QD) resulted in an approximate 70% decrease in Cmax and AUC values of both drug0 and its active metabolite, drug0",True,mechanism
DDI-DrugBank.d509.s20.e0,DDI-DrugBank.d509.s20.e1,"When drug1 is added to drug2 therapy, drug0",True,advise
DDI-DrugBank.d509.s20.e0,DDI-DrugBank.d509.s20.e2,"When drug1 is added to drug0 therapy, drug2",False, 
DDI-DrugBank.d509.s20.e1,DDI-DrugBank.d509.s20.e2,"When drug0 is added to drug1 therapy, drug2",False, 
DDI-DrugBank.d509.s22.e0,DDI-DrugBank.d509.s22.e1,"When drug1 is withdrawn from the combination therapy, drug2",True,advise
DDI-DrugBank.d509.s23.e0,DDI-DrugBank.d509.s23.e1,"No clinically significant effect of drug1, drug2, or drug0 was seen on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d509.s23.e0,DDI-DrugBank.d509.s23.e2,"No clinically significant effect of drug1, drug0, or drug2 was seen on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d509.s24.e0,DDI-DrugBank.d509.s24.e1,Potential for drug1 to Affect Other Drugs drug2,False, 
DDI-DrugBank.d509.s25.e0,DDI-DrugBank.d509.s25.e1,"In in vivo studies, 10- to 30-mg/day doses of drug1 had no significant effect on metabolism by CYP2D6 (drug2), CYP2C9 (drug0), CYP2C19 (drug0, drug0), and CYP3A4 (drug0",False, 
DDI-DrugBank.d509.s25.e0,DDI-DrugBank.d509.s25.e2,"In in vivo studies, 10- to 30-mg/day doses of drug1 had no significant effect on metabolism by CYP2D6 (drug0), CYP2C9 (drug2), CYP2C19 (drug0, drug0), and CYP3A4 (drug0",False, 
DDI-DrugBank.d509.s26.e0,DDI-DrugBank.d509.s26.e1,"Additionally, drug1 and drug2",False, 
DDI-DrugBank.d509.s27.e0,DDI-DrugBank.d509.s27.e1,drug1: There was no significant difference between drug2 coadministered with drug0 and placebo coadministered with drug0,False, 
DDI-DrugBank.d509.s27.e0,DDI-DrugBank.d509.s27.e2,drug1: There was no significant difference between drug0 coadministered with drug2 and placebo coadministered with drug0,False, 
DDI-DrugBank.d509.s28.e0,DDI-DrugBank.d509.s28.e1,"As with most psychoactive medications, patients should be advised to avoid drug1 while taking drug2",True,advise
DDI-DrugBank.d450.s0.e0,DDI-DrugBank.d450.s0.e1,drug1 are a major contributing factor to drug2,True,effect
DDI-DrugBank.d450.s2.e0,DDI-DrugBank.d450.s2.e1,"drug1, drug2, drug0, drug0, drug0, drug0, drug0, and drug0 raise the serum drug0 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",False, 
DDI-DrugBank.d450.s2.e0,DDI-DrugBank.d450.s2.e2,"drug1, drug0, drug2, drug0, drug0, drug0, drug0, and drug0 raise the serum drug0 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",False, 
DDI-DrugBank.d450.s2.e0,DDI-DrugBank.d450.s2.e8,"drug1, drug0, drug0, drug0, drug0, drug0, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e1,DDI-DrugBank.d450.s2.e8,"drug0, drug1, drug0, drug0, drug0, drug0, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e2,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug1, drug0, drug0, drug0, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e3,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug0, drug1, drug0, drug0, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e4,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug0, drug0, drug1, drug0, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e5,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug0, drug0, drug0, drug1, drug0, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e6,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug0, drug0, drug0, drug0, drug1, and drug0 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s2.e7,DDI-DrugBank.d450.s2.e8,"drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug1 raise the serum drug2 concentration due to a reduction in clearance and/or in volume of distribution of the drug, with the implication that drug0",True,mechanism
DDI-DrugBank.d450.s3.e0,DDI-DrugBank.d450.s3.e1,"drug1 and drug2 (and possibly other drug0) and drug0 may increase drug0 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",False, 
DDI-DrugBank.d450.s3.e0,DDI-DrugBank.d450.s3.e2,"drug1 and drug0 (and possibly other drug2) and drug0 may increase drug0 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",False, 
DDI-DrugBank.d450.s3.e0,DDI-DrugBank.d450.s3.e4,"drug1 and drug0 (and possibly other drug0) and drug0 may increase drug2 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",True,mechanism
DDI-DrugBank.d450.s3.e1,DDI-DrugBank.d450.s3.e4,"drug0 and drug1 (and possibly other drug0) and drug0 may increase drug2 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",True,mechanism
DDI-DrugBank.d450.s3.e2,DDI-DrugBank.d450.s3.e4,"drug0 and drug0 (and possibly other drug1) and drug0 may increase drug2 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",True,mechanism
DDI-DrugBank.d450.s3.e3,DDI-DrugBank.d450.s3.e4,"drug0 and drug0 (and possibly other drug0) and drug1 may increase drug2 absorption in patients who inactivate drug0 by bacterial metabolism in the lower intestine, so that drug0",True,mechanism
DDI-DrugBank.d450.s5.e0,DDI-DrugBank.d450.s5.e1,"drug1 and drug2, by decreasing gut motility, may increase drug0",False, 
DDI-DrugBank.d450.s5.e0,DDI-DrugBank.d450.s5.e2,"drug1 and drug0, by decreasing gut motility, may increase drug2",True,mechanism
DDI-DrugBank.d450.s5.e1,DDI-DrugBank.d450.s5.e2,"drug0 and drug1, by decreasing gut motility, may increase drug2",True,mechanism
DDI-DrugBank.d450.s6.e0,DDI-DrugBank.d450.s6.e1,"drug1, drug2-pectin, drug0, drug0, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug0",False, 
DDI-DrugBank.d450.s6.e0,DDI-DrugBank.d450.s6.e2,"drug1, drug0-pectin, drug2, drug0, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug0",False, 
DDI-DrugBank.d450.s6.e0,DDI-DrugBank.d450.s6.e6,"drug1, drug0-pectin, drug0, drug0, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s6.e1,DDI-DrugBank.d450.s6.e6,"drug0, drug1-pectin, drug0, drug0, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s6.e2,DDI-DrugBank.d450.s6.e6,"drug0, drug0-pectin, drug1, drug0, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s6.e3,DDI-DrugBank.d450.s6.e6,"drug0, drug0-pectin, drug0, drug1, drug0, certain anticancer drugs, and drug0 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s6.e4,DDI-DrugBank.d450.s6.e6,"drug0, drug0-pectin, drug0, drug0, drug1, certain anticancer drugs, and drug0 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s6.e5,DDI-DrugBank.d450.s6.e6,"drug0, drug0-pectin, drug0, drug0, drug0, certain anticancer drugs, and drug1 may interfere with intestinal drug2",True,mechanism
DDI-DrugBank.d450.s7.e0,DDI-DrugBank.d450.s7.e1,"drug1 may decrease serum drug2 concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of drug0",True,mechanism
DDI-DrugBank.d450.s7.e0,DDI-DrugBank.d450.s7.e2,"drug1 may decrease serum drug0 concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of drug2",False, 
DDI-DrugBank.d450.s7.e1,DDI-DrugBank.d450.s7.e2,"drug0 may decrease serum drug1 concentration, especially in patients with renal dysfunction, by increasing the non-renal clearance of drug2",False, 
DDI-DrugBank.d450.s8.e0,DDI-DrugBank.d450.s8.e1,"There have been inconsistent reports regarding the effects of other drugs (e.g., drug1, drug2) on serum drug0",False, 
DDI-DrugBank.d450.s8.e0,DDI-DrugBank.d450.s8.e2,"There have been inconsistent reports regarding the effects of other drugs (e.g., drug1, drug0) on serum drug2",False, 
DDI-DrugBank.d450.s9.e0,DDI-DrugBank.d450.s9.e1,"drug1 administration to a digitalized, hypothyroid patient may increase the dose requirement of drug2",True,advise
DDI-DrugBank.d450.s10.e0,DDI-DrugBank.d450.s10.e1,Concomitant use of drug1 and drug2,True,effect
DDI-DrugBank.d450.s12.e0,DDI-DrugBank.d450.s12.e1,Although drug1 or drug2 and drug0,False, 
DDI-DrugBank.d450.s12.e0,DDI-DrugBank.d450.s12.e2,Although drug1 or drug0 and drug2,True,effect
DDI-DrugBank.d450.s12.e1,DDI-DrugBank.d450.s12.e2,Although drug0 or drug1 and drug2,True,effect
DDI-DrugBank.d450.s14.e0,DDI-DrugBank.d450.s14.e1,"Furthermore, caution should be exercised when combining drug1 with any drug that may cause a significant deterioration in renal function, since a decline in glomerular filtration or tubular secretion may impair the excretion of drug2",False, 
DDI-DrugBank.d274.s0.e0,DDI-DrugBank.d274.s0.e1,Animal studies indicate that drug1 may be ineffective if the patient has recently received a drug2,True,effect
DDI-DrugBank.d274.s2.e0,DDI-DrugBank.d274.s2.e1,Preliminary studies indicate that the concomitant use of drug1 and drug2,True,effect
DDI-DrugBank.d274.s3.e0,DDI-DrugBank.d274.s3.e1,"There was no evidence of drug interactions in clinical studies in which drug1 was administered concurrently with other drugs, including drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d274.s3.e0,DDI-DrugBank.d274.s3.e2,"There was no evidence of drug interactions in clinical studies in which drug1 was administered concurrently with other drugs, including drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d431.s1.e0,DDI-DrugBank.d431.s1.e1,"Studies have shown that drug1 does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d431.s1.e0,DDI-DrugBank.d431.s1.e2,"Studies have shown that drug1 does not have clinically significant interactions with other drugs metabolized by the cytochrome P450 system, such as drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, or drug0",False, 
DDI-DrugBank.d431.s3.e0,DDI-DrugBank.d431.s3.e1,"When drug1 was administered concomitantly with drug2 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of drug0",True,mechanism
DDI-DrugBank.d431.s3.e0,DDI-DrugBank.d431.s3.e2,"When drug1 was administered concomitantly with drug0 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of drug2",False, 
DDI-DrugBank.d431.s3.e1,DDI-DrugBank.d431.s3.e2,"When drug0 was administered concomitantly with drug1 (CYP1A2, CYP3A), a minor increase (10%) in the clearance of drug2",False, 
DDI-DrugBank.d431.s5.e0,DDI-DrugBank.d431.s5.e1,"Nonetheless, individual patients may require additional titration of their drug1 dosage when drug2",True,advise
DDI-DrugBank.d431.s6.e0,DDI-DrugBank.d431.s6.e1,drug1 has also been shown to have no clinically significant interaction with drug2,False, 
DDI-DrugBank.d431.s7.e0,DDI-DrugBank.d431.s7.e1,"In a single-dose crossover study examining drug1 30 mg and drug2 20 mg each administered alone and concomitantly with drug0 1 gram, absorption of the drug0 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with drug0",False, 
DDI-DrugBank.d431.s7.e0,DDI-DrugBank.d431.s7.e2,"In a single-dose crossover study examining drug1 30 mg and drug0 20 mg each administered alone and concomitantly with drug2 1 gram, absorption of the drug0 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with drug0",False, 
DDI-DrugBank.d431.s7.e3,DDI-DrugBank.d431.s7.e4,"In a single-dose crossover study examining drug0 30 mg and drug0 20 mg each administered alone and concomitantly with drug0 1 gram, absorption of the drug1 was delayed and their bioavailability was reduced by 17% and 16%, respectively, when administered concomitantly with drug2",True,mechanism
DDI-DrugBank.d431.s8.e0,DDI-DrugBank.d431.s8.e1,"Therefore, drug1 should be taken at least 30 minutes prior to drug2",True,advise
DDI-DrugBank.d431.s9.e0,DDI-DrugBank.d431.s9.e1,"In clinical trials, drug1 were administered concomitantly with drug2",False, 
DDI-DrugBank.d431.s12.e0,DDI-DrugBank.d431.s12.e1,"therefore, it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug2, drug0 esters, drug0 salts, drug0",True,mechanism
DDI-DrugBank.d431.s12.e0,DDI-DrugBank.d431.s12.e2,"therefore, it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug0, drug2 esters, drug0 salts, drug0",True,mechanism
DDI-DrugBank.d431.s12.e0,DDI-DrugBank.d431.s12.e3,"therefore, it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug0, drug0 esters, drug2 salts, drug0",True,mechanism
DDI-DrugBank.d431.s12.e0,DDI-DrugBank.d431.s12.e4,"therefore, it is theoretically possible that drug1 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug0, drug0 esters, drug0 salts, drug2",True,mechanism
DDI-DrugBank.d431.s12.e1,DDI-DrugBank.d431.s12.e2,"therefore, it is theoretically possible that drug0 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug1, drug2 esters, drug0 salts, drug0",False, 
DDI-DrugBank.d431.s12.e1,DDI-DrugBank.d431.s12.e3,"therefore, it is theoretically possible that drug0 may interfere with the absorption of drugs where gastric pH is an important determinant of bioavailability (e.g. drug1, drug0 esters, drug2 salts, drug0",False, 
DDI-DrugBank.d6.s2.e0,DDI-DrugBank.d6.s2.e1,"If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of drug1 than when drug2 or drug0",False, 
DDI-DrugBank.d6.s2.e0,DDI-DrugBank.d6.s2.e2,"If the usual amounts of nondepolarizing relaxants are given, the time for recovery from neuromuscular blockade will be longer in the presence of drug1 than when drug0 or drug2",False, 
DDI-DrugBank.d339.s0.e0,DDI-DrugBank.d339.s0.e1,drug1: Elevated drug2 levels have been reported in postmarketing experience when drug0,False, 
DDI-DrugBank.d339.s0.e0,DDI-DrugBank.d339.s0.e2,drug1: Elevated drug0 levels have been reported in postmarketing experience when drug2,False, 
DDI-DrugBank.d339.s0.e1,DDI-DrugBank.d339.s0.e2,drug0: Elevated drug1 levels have been reported in postmarketing experience when drug2,True,mechanism
DDI-DrugBank.d339.s2.e0,DDI-DrugBank.d339.s2.e1,"drug1 and drug2: Increased prothrombin time, with or without clinical bleeding, has been reported when drug0",False, 
DDI-DrugBank.d339.s2.e0,DDI-DrugBank.d339.s2.e2,"drug1 and drug0: Increased prothrombin time, with or without clinical bleeding, has been reported when drug2",True,effect
DDI-DrugBank.d339.s2.e1,DDI-DrugBank.d339.s2.e2,"drug0 and drug1: Increased prothrombin time, with or without clinical bleeding, has been reported when drug2",True,effect
DDI-DrugBank.d339.s3.e0,DDI-DrugBank.d339.s3.e1,Drug/Laboratory Test Interactions A false-positive reaction for ketones in the urine may occur with tests using drug1 but not with those using drug2,False, 
DDI-DrugBank.d332.s0.e0,DDI-DrugBank.d332.s0.e1,Administration of drug1 to patients who are receiving drug2 or drug0,True,effect
DDI-DrugBank.d332.s0.e0,DDI-DrugBank.d332.s0.e2,Administration of drug1 to patients who are receiving drug0 or drug2,True,effect
DDI-DrugBank.d332.s0.e1,DDI-DrugBank.d332.s0.e2,Administration of drug0 to patients who are receiving drug1 or drug2,False, 
DDI-DrugBank.d332.s1.e0,DDI-DrugBank.d332.s1.e1,"In patients who have received drug1, drug2 may temporarily mask the residual effects of drug0",False, 
DDI-DrugBank.d332.s1.e0,DDI-DrugBank.d332.s1.e2,"In patients who have received drug1, drug0 may temporarily mask the residual effects of drug2",False, 
DDI-DrugBank.d332.s1.e1,DDI-DrugBank.d332.s1.e2,"In patients who have received drug0, drug1 may temporarily mask the residual effects of drug2",True,effect
DDI-DrugBank.d103.s0.e0,DDI-DrugBank.d103.s0.e1,drug1: Aerosol drug2 of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using drug0,False, 
DDI-DrugBank.d103.s0.e0,DDI-DrugBank.d103.s0.e2,drug1: Aerosol drug0 of the short-acting adrenergic stimulant type may be used for relief of breakthrough symptoms while using drug2,False, 
DDI-DrugBank.d103.s2.e0,DDI-DrugBank.d103.s2.e1,Concomitant administration of other drug1 may potentiate the undesirable effects of drug2,True,effect
DDI-DrugBank.d103.s3.e0,DDI-DrugBank.d103.s3.e1,drug1 and drug2: drug0 should be administered with extreme caution in patients being treated with drug0 or drug0 because the action of drug0,False, 
DDI-DrugBank.d103.s3.e0,DDI-DrugBank.d103.s3.e2,drug1 and drug0: drug2 should be administered with extreme caution in patients being treated with drug0 or drug0 because the action of drug0,False, 
DDI-DrugBank.d103.s3.e2,DDI-DrugBank.d103.s3.e3,drug0 and drug0: drug1 should be administered with extreme caution in patients being treated with drug2 or drug0 because the action of drug0,True,advise
DDI-DrugBank.d103.s3.e2,DDI-DrugBank.d103.s3.e4,drug0 and drug0: drug1 should be administered with extreme caution in patients being treated with drug0 or drug2 because the action of drug0,True,advise
DDI-DrugBank.d103.s4.e0,DDI-DrugBank.d103.s4.e1,"drug1, drug2 and drug0: Concomitant treatment with drug0, drug0, or drug0 may potentiate a possible hypokalemic effect of  drug0",False, 
DDI-DrugBank.d103.s4.e0,DDI-DrugBank.d103.s4.e2,"drug1, drug0 and drug2: Concomitant treatment with drug0, drug0, or drug0 may potentiate a possible hypokalemic effect of  drug0",False, 
DDI-DrugBank.d103.s4.e3,DDI-DrugBank.d103.s4.e6,"drug0, drug0 and drug0: Concomitant treatment with drug1, drug0, or drug0 may potentiate a possible hypokalemic effect of  drug2",True,effect
DDI-DrugBank.d103.s4.e4,DDI-DrugBank.d103.s4.e6,"drug0, drug0 and drug0: Concomitant treatment with drug0, drug1, or drug0 may potentiate a possible hypokalemic effect of  drug2",True,effect
DDI-DrugBank.d103.s4.e5,DDI-DrugBank.d103.s4.e6,"drug0, drug0 and drug0: Concomitant treatment with drug0, drug0, or drug1 may potentiate a possible hypokalemic effect of  drug2",True,effect
DDI-DrugBank.d103.s8.e0,DDI-DrugBank.d103.s8.e1,"Other Drugs:Drugs such as drug1, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d103.s8.e0,DDI-DrugBank.d103.s8.e2,"Other Drugs:Drugs such as drug1, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d103.s10.e0,DDI-DrugBank.d103.s10.e1,It is important that patients understand how to use drug1  (drug2,False, 
DDI-DrugBank.d103.s15.e0,DDI-DrugBank.d103.s15.e1,"Acute symptoms should be treated with a short-acting, inhaled  drug1 such as drug2",False, 
DDI-DrugBank.d103.s20.e0,DDI-DrugBank.d103.s20.e1,drug1 should not be used as a substitute for oral or inhaled drug2,False, 
DDI-DrugBank.d103.s26.e0,DDI-DrugBank.d103.s26.e1,"Guardians of children who have been prescribed drug1 should be alerted to the general concern regarding asthma therapy compliance, especially neglect of anti-inflammatory therapy and overuse of drug2",False, 
DDI-DrugBank.d51.s0.e0,DDI-DrugBank.d51.s0.e1,"drug1 Inhalation Aerosol has been used concomitantly with other drugs, including drug2, drug0, and drug0",False, 
DDI-DrugBank.d51.s0.e0,DDI-DrugBank.d51.s0.e2,"drug1 Inhalation Aerosol has been used concomitantly with other drugs, including drug0, drug2, and drug0",False, 
DDI-DrugBank.d51.s1.e0,DDI-DrugBank.d51.s1.e1,"With the exception of drug1, there are no formal studies fully evaluating the interaction effects of drug2",False, 
DDI-DrugBank.d51.s2.e0,DDI-DrugBank.d51.s2.e1,"drug1: Although drug2 is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used drug0",False, 
DDI-DrugBank.d51.s2.e0,DDI-DrugBank.d51.s2.e2,"drug1: Although drug0 is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used drug2",False, 
DDI-DrugBank.d51.s2.e1,DDI-DrugBank.d51.s2.e2,"drug0: Although drug1 is minimally absorbed into the systemic circulation, there is some potential for an additive interaction with concomitantly used drug2",True,effect
DDI-DrugBank.d51.s3.e0,DDI-DrugBank.d51.s3.e1,Caution is therefore advised in the coadministration of drug1 Inhalation Aerosol with other drug2,True,advise
DDI-DrugBank.d438.s5.e0,DDI-DrugBank.d438.s5.e1,drug1 is not appreciably metabolized nor does it interfere with the metabolism of commonly coadministered drug2,False, 
DDI-DrugBank.d438.s7.e0,DDI-DrugBank.d438.s7.e1,"drug1: In a single (400 mg) and multiple dose (400 mg TID) study of drug2 in epileptic patients (N=8) maintained on drug0 monotherapy for at least 2 months, drug0 had no effect on the steady-state trough plasma concentrations of drug0 and drug0 had no effect on drug0",False, 
DDI-DrugBank.d438.s7.e0,DDI-DrugBank.d438.s7.e2,"drug1: In a single (400 mg) and multiple dose (400 mg TID) study of drug0 in epileptic patients (N=8) maintained on drug2 monotherapy for at least 2 months, drug0 had no effect on the steady-state trough plasma concentrations of drug0 and drug0 had no effect on drug0",False, 
DDI-DrugBank.d438.s8.e0,DDI-DrugBank.d438.s8.e1,drug1: Steady-state trough plasma drug2 and drug0 concentrations were not affected by concomitant drug0,False, 
DDI-DrugBank.d438.s8.e0,DDI-DrugBank.d438.s8.e2,drug1: Steady-state trough plasma drug0 and drug2 concentrations were not affected by concomitant drug0,False, 
DDI-DrugBank.d438.s10.e0,DDI-DrugBank.d438.s10.e1,"Likewise, drug1 pharmacokinetics were unaltered by drug2",False, 
DDI-DrugBank.d438.s11.e0,DDI-DrugBank.d438.s11.e1,drug1: The mean steady-state trough serum drug2 concentrations prior to and during concomitant drug0,False, 
DDI-DrugBank.d438.s11.e0,DDI-DrugBank.d438.s11.e2,drug1: The mean steady-state trough serum drug0 concentrations prior to and during concomitant drug2,False, 
DDI-DrugBank.d438.s12.e0,DDI-DrugBank.d438.s12.e1,N=17) were not different and neither were drug1 pharmacokinetic parameters affected by drug2,False, 
DDI-DrugBank.d438.s13.e0,DDI-DrugBank.d438.s13.e1,drug1: Estimates of steady-state pharmacokinetic parameters for drug2 or drug0,False, 
DDI-DrugBank.d438.s13.e0,DDI-DrugBank.d438.s13.e2,drug1: Estimates of steady-state pharmacokinetic parameters for drug0 or drug2,False, 
DDI-DrugBank.d438.s15.e0,DDI-DrugBank.d438.s15.e1,drug1: Coadministration (N=18) of drug2 capsules (250 mg) with drug0 (125 mg) appears to increase the amount of drug0,False, 
DDI-DrugBank.d438.s15.e0,DDI-DrugBank.d438.s15.e2,drug1: Coadministration (N=18) of drug0 capsules (250 mg) with drug2 (125 mg) appears to increase the amount of drug0,False, 
DDI-DrugBank.d438.s15.e1,DDI-DrugBank.d438.s15.e2,drug0: Coadministration (N=18) of drug1 capsules (250 mg) with drug2 (125 mg) appears to increase the amount of drug0,True,mechanism
DDI-DrugBank.d438.s16.e0,DDI-DrugBank.d438.s16.e1,drug1 had no effect on drug2,False, 
DDI-DrugBank.d438.s19.e0,DDI-DrugBank.d438.s19.e1,drug1: Coadministration of drug2,False, 
DDI-DrugBank.d438.s22.e0,DDI-DrugBank.d438.s22.e1,"Cmax and AUC values are 3% to 4% lower, respectively, after administration of 125 mg drug1  and 21% to 22% lower, respectively, after administration of 500 mg drug2",False, 
DDI-DrugBank.d438.s24.e0,DDI-DrugBank.d438.s24.e1,drug1 increases drug2,True,mechanism
DDI-DrugBank.d438.s26.e0,DDI-DrugBank.d438.s26.e1,"drug1: A literature article reported that when a 60-mg controlled-release drug2 capsule was administered 2 hours prior to a 600-mg drug0  capsule (N=12), mean drug0 AUC increased by 44% compared to drug0 administered without drug0",False, 
DDI-DrugBank.d438.s26.e0,DDI-DrugBank.d438.s26.e2,"drug1: A literature article reported that when a 60-mg controlled-release drug0 capsule was administered 2 hours prior to a 600-mg drug2  capsule (N=12), mean drug0 AUC increased by 44% compared to drug0 administered without drug0",False, 
DDI-DrugBank.d438.s26.e1,DDI-DrugBank.d438.s26.e2,"drug0: A literature article reported that when a 60-mg controlled-release drug1 capsule was administered 2 hours prior to a 600-mg drug2  capsule (N=12), mean drug0 AUC increased by 44% compared to drug0 administered without drug0",True,mechanism
DDI-DrugBank.d438.s27.e0,DDI-DrugBank.d438.s27.e1,drug1 pharmacokinetic parameter values were not affected by administration of drug2  2 hours after drug0,False, 
DDI-DrugBank.d438.s27.e0,DDI-DrugBank.d438.s27.e2,drug1 pharmacokinetic parameter values were not affected by administration of drug0  2 hours after drug2,False, 
DDI-DrugBank.d438.s29.e0,DDI-DrugBank.d438.s29.e1,drug1: In the presence of drug2 at 300 mg QID (N=12) the mean apparent oral clearance of drug0,False, 
DDI-DrugBank.d438.s29.e0,DDI-DrugBank.d438.s29.e2,drug1: In the presence of drug0 at 300 mg QID (N=12) the mean apparent oral clearance of drug2,False, 
DDI-DrugBank.d438.s29.e1,DDI-DrugBank.d438.s29.e2,drug0: In the presence of drug1 at 300 mg QID (N=12) the mean apparent oral clearance of drug2,True,mechanism
DDI-DrugBank.d438.s30.e0,DDI-DrugBank.d438.s30.e1,Thus drug1 appeared to alter the renal excretion of both drug2,True,mechanism
DDI-DrugBank.d438.s31.e0,DDI-DrugBank.d438.s31.e1,This small decrease in excretion of drug1 by drug2,True,mechanism
DDI-DrugBank.d438.s32.e0,DDI-DrugBank.d438.s32.e1,The effect of drug1 on drug2,False, 
DDI-DrugBank.d438.s33.e0,DDI-DrugBank.d438.s33.e1,"Oral drug1: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of drug2 and drug0 following administration of tablets containing 2.5 mg of drug0 and 50 mcg of drug0 were similar with and without coadministration of drug0",False, 
DDI-DrugBank.d438.s33.e0,DDI-DrugBank.d438.s33.e2,"Oral drug1: Based on AUC and half-life, multiple-dose pharmacokinetic profiles of drug0 and drug2 following administration of tablets containing 2.5 mg of drug0 and 50 mcg of drug0 were similar with and without coadministration of drug0",False, 
DDI-DrugBank.d438.s35.e0,DDI-DrugBank.d438.s35.e1,The Cmax of drug1 was 13% higher when it was coadministered with drug2,True,mechanism
DDI-DrugBank.d438.s37.e0,DDI-DrugBank.d438.s37.e1,drug1 (drug2 ): drug0 reduced the bioavailability of drug0,False, 
DDI-DrugBank.d438.s37.e0,DDI-DrugBank.d438.s37.e2,drug1 (drug0 ): drug2 reduced the bioavailability of drug0,False, 
DDI-DrugBank.d438.s37.e2,DDI-DrugBank.d438.s37.e3,drug0 (drug0 ): drug1 reduced the bioavailability of drug2,True,mechanism
DDI-DrugBank.d438.s38.e0,DDI-DrugBank.d438.s38.e1,This decrease in bioavailability was about 5% when drug1 was administered 2 hours after drug2,True,mechanism
DDI-DrugBank.d438.s39.e0,DDI-DrugBank.d438.s39.e1,It is recommended that drug1 be taken at least 2 hours following drug2,True,advise
DDI-DrugBank.d438.s40.e0,DDI-DrugBank.d438.s40.e1,Effect of drug1: drug2,False, 
DDI-DrugBank.d438.s41.e0,DDI-DrugBank.d438.s41.e1,drug1 pharmacokinetic parameters without and with drug2,False, 
DDI-DrugBank.d438.s42.e0,DDI-DrugBank.d438.s42.e1,This indicates that drug1 does not undergo renal tubular secretion by the pathway that is blocked by drug2,False, 
DDI-DrugBank.d438.s43.e0,DDI-DrugBank.d438.s43.e1,Drug/Laboratory Tests Interactions Because false positive readings were reported with the Ames N-Multistix SG dipstick test for urinary protein when drug1 was added to other drug2,False, 
DDI-DrugBank.d46.s1.e0,DDI-DrugBank.d46.s1.e1,"- drug1, drug2, or drug0",False, 
DDI-DrugBank.d46.s1.e0,DDI-DrugBank.d46.s1.e2,"- drug1, drug0, or drug2",False, 
DDI-DrugBank.d46.s3.e0,DDI-DrugBank.d46.s3.e1,- drug1: (Oral agents and drug2) Dosage adjustment of the drug0,False, 
DDI-DrugBank.d46.s3.e0,DDI-DrugBank.d46.s3.e2,- drug1: (Oral agents and drug0) Dosage adjustment of the drug2,False, 
DDI-DrugBank.d46.s7.e0,DDI-DrugBank.d46.s7.e1,- drug1 and drug2 drug0: drug0 and drug0 drug0 have the potential of binding drug0 and reducing drug0,False, 
DDI-DrugBank.d46.s7.e0,DDI-DrugBank.d46.s7.e2,- drug1 and drug0 drug2: drug0 and drug0 drug0 have the potential of binding drug0 and reducing drug0,False, 
DDI-DrugBank.d46.s7.e3,DDI-DrugBank.d46.s7.e6,- drug0 and drug0 drug0: drug1 and drug0 drug0 have the potential of binding drug2 and reducing drug0,True,mechanism
DDI-DrugBank.d46.s7.e4,DDI-DrugBank.d46.s7.e6,- drug0 and drug0 drug0: drug0 and drug1 drug0 have the potential of binding drug2 and reducing drug0,True,mechanism
DDI-DrugBank.d46.s9.e0,DDI-DrugBank.d46.s9.e1,"- drug1, drug2",False, 
DDI-DrugBank.d46.s13.e0,DDI-DrugBank.d46.s13.e1,"- drug1, nondepolarizing (e.g., drug2): Possible increased responsiveness to the drug0",False, 
DDI-DrugBank.d46.s13.e0,DDI-DrugBank.d46.s13.e2,"- drug1, nondepolarizing (e.g., drug0): Possible increased responsiveness to the drug2",False, 
DDI-DrugBank.d46.s15.e0,DDI-DrugBank.d46.s15.e1,- drug1: Generally should not be given with drug2,True,advise
DDI-DrugBank.d46.s16.e0,DDI-DrugBank.d46.s16.e1,drug1 reduce the renal clearance of drug2 and add a high risk of drug0,True,mechanism
DDI-DrugBank.d46.s16.e0,DDI-DrugBank.d46.s16.e2,drug1 reduce the renal clearance of drug0 and add a high risk of drug2,True,mechanism
DDI-DrugBank.d46.s16.e1,DDI-DrugBank.d46.s16.e2,drug0 reduce the renal clearance of drug1 and add a high risk of drug2,False, 
DDI-DrugBank.d46.s17.e0,DDI-DrugBank.d46.s17.e1,Refer to the package insert for drug1 preparations before use of such preparations with drug2,True,advise
DDI-DrugBank.d46.s19.e0,DDI-DrugBank.d46.s19.e1,"- drug1: In some patients, the administration of a drug2 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug0",False, 
DDI-DrugBank.d46.s19.e0,DDI-DrugBank.d46.s19.e2,"- drug1: In some patients, the administration of a drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",False, 
DDI-DrugBank.d46.s19.e1,DDI-DrugBank.d46.s19.e2,"- drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0 and drug0",True,effect
DDI-DrugBank.d46.s19.e1,DDI-DrugBank.d46.s19.e3,"- drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2 and drug0",True,effect
DDI-DrugBank.d46.s19.e1,DDI-DrugBank.d46.s19.e4,"- drug0: In some patients, the administration of a drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0 and drug2",True,effect
DDI-DrugBank.d46.s20.e0,DDI-DrugBank.d46.s20.e1,"Therefore, when drug1 and drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",True,advise
DDI-DrugBank.d46.s20.e0,DDI-DrugBank.d46.s20.e2,"Therefore, when drug1 and drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d46.s20.e1,DDI-DrugBank.d46.s20.e2,"Therefore, when drug0 and drug1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d81.s0.e0,DDI-DrugBank.d81.s0.e1,drug1: drug2  (drug0) has been safely coadministered with drug0,False, 
DDI-DrugBank.d81.s0.e0,DDI-DrugBank.d81.s0.e2,drug1: drug0  (drug2) has been safely coadministered with drug0,False, 
DDI-DrugBank.d81.s1.e0,DDI-DrugBank.d81.s1.e1,drug1: A study in normal healthy volunteers has shown that concomitant administration of drug2  (drug0) and drug0,False, 
DDI-DrugBank.d81.s1.e0,DDI-DrugBank.d81.s1.e2,drug1: A study in normal healthy volunteers has shown that concomitant administration of drug0  (drug2) and drug0,False, 
DDI-DrugBank.d81.s2.e0,DDI-DrugBank.d81.s2.e1,"In a study in hypertensive patients, addition of drug1 to existing drug2 therapy did not result in any unexpected adverse effects, and drug0",False, 
DDI-DrugBank.d81.s2.e0,DDI-DrugBank.d81.s2.e2,"In a study in hypertensive patients, addition of drug1 to existing drug0 therapy did not result in any unexpected adverse effects, and drug2",False, 
DDI-DrugBank.d81.s3.e0,DDI-DrugBank.d81.s3.e1,"drug1: In a single dose study in normal volunteers, coadministration of drug2 had a small effect on the rate but no effect on the extent of drug0",False, 
DDI-DrugBank.d81.s3.e0,DDI-DrugBank.d81.s3.e2,"drug1: In a single dose study in normal volunteers, coadministration of drug0 had a small effect on the rate but no effect on the extent of drug2",False, 
DDI-DrugBank.d81.s6.e0,DDI-DrugBank.d81.s6.e1,"drug1 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between drug2 given singly and in combination with drug0, and between drug0 given singly and in combination with drug0",False, 
DDI-DrugBank.d81.s6.e0,DDI-DrugBank.d81.s6.e2,"drug1 to healthy volunteers under steady-state conditions had no relevant effect on either drug s bioavailability, AUC and Cmax, differences were  20% between drug0 given singly and in combination with drug2, and between drug0 given singly and in combination with drug0",False, 
DDI-DrugBank.d81.s7.e0,DDI-DrugBank.d81.s7.e1,"drug1: In a study in healthy volunteers, a one-week course of drug2 at 400 mg b.i.d. with a single 5 mg dose of drug0 on the sixth day showed an increase in drug0",False, 
DDI-DrugBank.d81.s7.e0,DDI-DrugBank.d81.s7.e2,"drug1: In a study in healthy volunteers, a one-week course of drug0 at 400 mg b.i.d. with a single 5 mg dose of drug2 on the sixth day showed an increase in drug0",False, 
DDI-DrugBank.d81.s7.e1,DDI-DrugBank.d81.s7.e2,"drug0: In a study in healthy volunteers, a one-week course of drug1 at 400 mg b.i.d. with a single 5 mg dose of drug2 on the sixth day showed an increase in drug0",True,mechanism
DDI-DrugBank.d81.s8.e0,DDI-DrugBank.d81.s8.e1,If drug1 therapy is initiated in a patient currently receiving drug2,True,advise
DDI-DrugBank.d81.s9.e0,DDI-DrugBank.d81.s9.e1,"drug1: In a study in healthy volunteers, a six-day course of drug2 at 600 mg/day followed by a single 5 mg dose of drug0 resulted in a reduction in drug0",False, 
DDI-DrugBank.d81.s9.e0,DDI-DrugBank.d81.s9.e2,"drug1: In a study in healthy volunteers, a six-day course of drug0 at 600 mg/day followed by a single 5 mg dose of drug2 resulted in a reduction in drug0",False, 
DDI-DrugBank.d81.s9.e1,DDI-DrugBank.d81.s9.e2,"drug0: In a study in healthy volunteers, a six-day course of drug1 at 600 mg/day followed by a single 5 mg dose of drug2 resulted in a reduction in drug0",True,mechanism
DDI-DrugBank.d81.s10.e0,DDI-DrugBank.d81.s10.e1,"If drug1 therapy is required, drug2 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drug0",True,mechanism
DDI-DrugBank.d81.s10.e0,DDI-DrugBank.d81.s10.e2,"If drug1 therapy is required, drug0 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drug2",False, 
DDI-DrugBank.d81.s10.e1,DDI-DrugBank.d81.s10.e2,"If drug0 therapy is required, drug1 concentrations and therapeutic effects are likely to be markedly reduced or abolished as a consequence of increased metabolism and higher clearance of drug2",False, 
DDI-DrugBank.d81.s11.e0,DDI-DrugBank.d81.s11.e1,"drug1: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between drug2 and racemic drug0 was seen when two single oral doses of drug0 (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. drug0",False, 
DDI-DrugBank.d81.s11.e0,DDI-DrugBank.d81.s11.e2,"drug1: In a study in healthy volunteers, no clinically relevant pharmacokinetic or pharmacodynamic interaction between drug0 and racemic drug2 was seen when two single oral doses of drug0 (0.7 mg/kg body weight) were administered during 11 days of multipledose treatment with 5 mg b.i.d. drug0",False, 
DDI-DrugBank.d81.s12.e0,DDI-DrugBank.d81.s12.e1,Neither racemic drug1 nor drug2,False, 
DDI-DrugBank.d81.s13.e0,DDI-DrugBank.d81.s13.e1,"drug1: The concomitant administration of drug2  (drug0) and drug0 in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of drug0",False, 
DDI-DrugBank.d81.s13.e0,DDI-DrugBank.d81.s13.e2,"drug1: The concomitant administration of drug0  (drug2) and drug0 in a single-dose pharmacokinetic study did not affect renal, nonrenal and total body clearance of drug0",False, 
DDI-DrugBank.d81.s14.e0,DDI-DrugBank.d81.s14.e1,drug1 Anesthesia: Severe hypotension has been reported during drug2 anesthesia with concomitant use of a drug0 and a drug0,False, 
DDI-DrugBank.d81.s14.e0,DDI-DrugBank.d81.s14.e2,drug1 Anesthesia: Severe hypotension has been reported during drug0 anesthesia with concomitant use of a drug2 and a drug0,False, 
DDI-DrugBank.d81.s14.e1,DDI-DrugBank.d81.s14.e2,drug0 Anesthesia: Severe hypotension has been reported during drug1 anesthesia with concomitant use of a drug2 and a drug0,True,effect
DDI-DrugBank.d81.s14.e1,DDI-DrugBank.d81.s14.e3,drug0 Anesthesia: Severe hypotension has been reported during drug1 anesthesia with concomitant use of a drug0 and a drug2,True,effect
DDI-DrugBank.d81.s15.e0,DDI-DrugBank.d81.s15.e1,Even though such interactions have not been seen in clinical studies with drug1  (drug2,False, 
DDI-DrugBank.d124.s1.e0,DDI-DrugBank.d124.s1.e1,Several drug interaction studies have been completed with both drug1 and drug2,False, 
DDI-DrugBank.d124.s2.e0,DDI-DrugBank.d124.s2.e1,Observations from drug interaction studies with drug1 may not be predictive for drug2,False, 
DDI-DrugBank.d124.s3.e0,DDI-DrugBank.d124.s3.e1,"Because drug1 is coadministered, prescribers should also refer to the prescribing information for drug2",False, 
DDI-DrugBank.d124.s9.e0,DDI-DrugBank.d124.s9.e1,Additional drugs that are not recommended for coadministration with drug1 and drug2,False, 
DDI-DrugBank.d124.s12.e0,DDI-DrugBank.d124.s12.e1,Drugs That Should Not Be Coadministered With drug1/drug2,False, 
DDI-DrugBank.d124.s14.e0,DDI-DrugBank.d124.s14.e1,"drug1: drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d124.s14.e0,DDI-DrugBank.d124.s14.e2,"drug1: drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d124.s15.e0,DDI-DrugBank.d124.s15.e1,"drug1: drug2*, drug0",False, 
DDI-DrugBank.d124.s15.e0,DDI-DrugBank.d124.s15.e2,"drug1: drug0*, drug2",False, 
DDI-DrugBank.d124.s16.e0,DDI-DrugBank.d124.s16.e1,"drug1: drug2, drug0, drug0, drug0 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute drug0",False, 
DDI-DrugBank.d124.s16.e0,DDI-DrugBank.d124.s16.e2,"drug1: drug0, drug2, drug0, drug0 CONTRAINDICATED due to potential for serious and life-threatening reactions such as acute drug0",False, 
DDI-DrugBank.d124.s17.e0,DDI-DrugBank.d124.s17.e1,drug1: drug2 CONTRAINDICATED since the coadministration of this product with drug0 in an drug0 regimen reduces the plasma concentrations of drug0,False, 
DDI-DrugBank.d124.s17.e0,DDI-DrugBank.d124.s17.e2,drug1: drug0 CONTRAINDICATED since the coadministration of this product with drug2 in an drug0 regimen reduces the plasma concentrations of drug0,False, 
DDI-DrugBank.d124.s18.e0,DDI-DrugBank.d124.s18.e1,Garlic Capsules Garlic capsules should not be used while taking drug1 (drug2) as the sole drug0 due to the risk of decreased drug0,False, 
DDI-DrugBank.d124.s18.e0,DDI-DrugBank.d124.s18.e2,Garlic Capsules Garlic capsules should not be used while taking drug1 (drug0) as the sole drug2 due to the risk of decreased drug0,False, 
DDI-DrugBank.d124.s19.e0,DDI-DrugBank.d124.s19.e1,No data are available for the coadministration of drug1/drug2 or drug0/drug0,False, 
DDI-DrugBank.d124.s19.e0,DDI-DrugBank.d124.s19.e2,No data are available for the coadministration of drug1/drug0 or drug2/drug0,False, 
DDI-DrugBank.d124.s22.e0,DDI-DrugBank.d124.s22.e1,"drug1: drug2, drug0",False, 
DDI-DrugBank.d124.s22.e0,DDI-DrugBank.d124.s22.e2,"drug1: drug0, drug2",False, 
DDI-DrugBank.d124.s23.e0,DDI-DrugBank.d124.s23.e1,"drug1/drug2: drug0, drug0",False, 
DDI-DrugBank.d124.s23.e0,DDI-DrugBank.d124.s23.e2,"drug1/drug0: drug2, drug0",False, 
DDI-DrugBank.d124.s26.e0,DDI-DrugBank.d124.s26.e1,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug0",False, 
DDI-DrugBank.d124.s26.e0,DDI-DrugBank.d124.s26.e2,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug0",False, 
DDI-DrugBank.d124.s26.e0,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e1,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e2,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e3,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e4,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e5,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e6,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e7,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e8,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e9,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e10,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e11,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e12,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e13,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, drug0, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e14,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug1, and drug0) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s26.e15,DDI-DrugBank.d124.s26.e16,"Although specific studies have not been performed, coadministration with drugs that are mainly metabolized by CYP3A4 (eg, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug1) may have elevated plasma concentrations when coadministered with drug2",True,mechanism
DDI-DrugBank.d124.s28.e0,DDI-DrugBank.d124.s28.e1,"Since drug1 is coadministered with drug2, the drug0",True,advise
DDI-DrugBank.d124.s28.e0,DDI-DrugBank.d124.s28.e2,"Since drug1 is coadministered with drug0, the drug2",False, 
DDI-DrugBank.d124.s28.e1,DDI-DrugBank.d124.s28.e2,"Since drug0 is coadministered with drug1, the drug2",False, 
DDI-DrugBank.d124.s30.e0,DDI-DrugBank.d124.s30.e1,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug1, drug2, drug0, drug0) may result in decreased plasma levels of drug0",False, 
DDI-DrugBank.d124.s30.e0,DDI-DrugBank.d124.s30.e2,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug1, drug0, drug2, drug0) may result in decreased plasma levels of drug0",False, 
DDI-DrugBank.d124.s30.e0,DDI-DrugBank.d124.s30.e4,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug1, drug0, drug0, drug0) may result in decreased plasma levels of drug2",True,mechanism
DDI-DrugBank.d124.s30.e1,DDI-DrugBank.d124.s30.e4,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug0, drug1, drug0, drug0) may result in decreased plasma levels of drug2",True,mechanism
DDI-DrugBank.d124.s30.e2,DDI-DrugBank.d124.s30.e4,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug0, drug0, drug1, drug0) may result in decreased plasma levels of drug2",True,mechanism
DDI-DrugBank.d124.s30.e3,DDI-DrugBank.d124.s30.e4,"Coadministration with compounds that are potent inducers of CYP3A4 (eg, drug0, drug0, drug0, drug1) may result in decreased plasma levels of drug2",True,mechanism
DDI-DrugBank.d165.s0.e0,DDI-DrugBank.d165.s0.e1,"Both drug1 and its major metabolite, drug2",False, 
DDI-DrugBank.d165.s3.e0,DDI-DrugBank.d165.s3.e1,Coadministration of drug1 with drug2 has led to elevated plasma concentrations of drug0,True,mechanism
DDI-DrugBank.d165.s3.e0,DDI-DrugBank.d165.s3.e2,Coadministration of drug1 with drug0 has led to elevated plasma concentrations of drug2,False, 
DDI-DrugBank.d165.s3.e1,DDI-DrugBank.d165.s3.e2,Coadministration of drug0 with drug1 has led to elevated plasma concentrations of drug2,False, 
DDI-DrugBank.d165.s4.e0,DDI-DrugBank.d165.s4.e1,"Another oral drug1, drug2, inhibits the metabolism of drug0, resulting in elevated plasma concentrations of drug0 and its active metabolite drug0",False, 
DDI-DrugBank.d165.s4.e0,DDI-DrugBank.d165.s4.e2,"Another oral drug1, drug0, inhibits the metabolism of drug2, resulting in elevated plasma concentrations of drug0 and its active metabolite drug0",False, 
DDI-DrugBank.d165.s4.e1,DDI-DrugBank.d165.s4.e2,"Another oral drug0, drug1, inhibits the metabolism of drug2, resulting in elevated plasma concentrations of drug0 and its active metabolite drug0",True,mechanism
DDI-DrugBank.d165.s5.e0,DDI-DrugBank.d165.s5.e1,"In vitro data suggest that drug1, when compared to drug2, has a less pronounced effect on the biotransformation system responsible for the metabolism of drug0",False, 
DDI-DrugBank.d165.s5.e0,DDI-DrugBank.d165.s5.e2,"In vitro data suggest that drug1, when compared to drug0, has a less pronounced effect on the biotransformation system responsible for the metabolism of drug2",True,mechanism
DDI-DrugBank.d165.s5.e1,DDI-DrugBank.d165.s5.e2,"In vitro data suggest that drug0, when compared to drug1, has a less pronounced effect on the biotransformation system responsible for the metabolism of drug2",False, 
DDI-DrugBank.d165.s6.e0,DDI-DrugBank.d165.s6.e1,"Based on the chemical resemblance of drug1 and drug2, coadministration of drug0 with drug0",False, 
DDI-DrugBank.d165.s6.e0,DDI-DrugBank.d165.s6.e2,"Based on the chemical resemblance of drug1 and drug0, coadministration of drug2 with drug0",False, 
DDI-DrugBank.d165.s6.e2,DDI-DrugBank.d165.s6.e3,"Based on the chemical resemblance of drug0 and drug0, coadministration of drug1 with drug2",True,advise
DDI-DrugBank.d165.s7.e0,DDI-DrugBank.d165.s7.e1,Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug2 resulting in an eight-fold increase in the mean AUC of drug0,True,mechanism
DDI-DrugBank.d165.s7.e0,DDI-DrugBank.d165.s7.e2,Human pharmacokinetics data indicate that oral drug1 potently inhibits the metabolism of drug0 resulting in an eight-fold increase in the mean AUC of drug2,False, 
DDI-DrugBank.d165.s7.e1,DDI-DrugBank.d165.s7.e2,Human pharmacokinetics data indicate that oral drug0 potently inhibits the metabolism of drug1 resulting in an eight-fold increase in the mean AUC of drug2,False, 
DDI-DrugBank.d165.s8.e0,DDI-DrugBank.d165.s8.e1,Data suggest that coadministration of oral drug1 and drug2,True,effect
DDI-DrugBank.d165.s9.e0,DDI-DrugBank.d165.s9.e1,In vitro data suggest that drug1 also markedly inhibits the biotransformation system mainly responsible for the metabolism of drug2,True,mechanism
DDI-DrugBank.d165.s10.e0,DDI-DrugBank.d165.s10.e1,therefore concomitant administration of drug1 with drug2,True,advise
DDI-DrugBank.d165.s11.e0,DDI-DrugBank.d165.s11.e1,Coadministration of drug1 with oral drug2 or drug0,True,mechanism
DDI-DrugBank.d165.s11.e0,DDI-DrugBank.d165.s11.e2,Coadministration of drug1 with oral drug0 or drug2,True,mechanism
DDI-DrugBank.d165.s11.e1,DDI-DrugBank.d165.s11.e2,Coadministration of drug0 with oral drug1 or drug2,False, 
DDI-DrugBank.d165.s15.e0,DDI-DrugBank.d165.s15.e1,"Coadministration of drug1 and drug2, drug0 or drug0",True,mechanism
DDI-DrugBank.d165.s15.e0,DDI-DrugBank.d165.s15.e2,"Coadministration of drug1 and drug0, drug2 or drug0",True,mechanism
DDI-DrugBank.d165.s15.e0,DDI-DrugBank.d165.s15.e3,"Coadministration of drug1 and drug0, drug0 or drug2",True,mechanism
DDI-DrugBank.d165.s15.e1,DDI-DrugBank.d165.s15.e2,"Coadministration of drug0 and drug1, drug2 or drug0",False, 
DDI-DrugBank.d165.s15.e1,DDI-DrugBank.d165.s15.e3,"Coadministration of drug0 and drug1, drug0 or drug2",False, 
DDI-DrugBank.d165.s16.e0,DDI-DrugBank.d165.s16.e1,"drug1, drug2 and drug0 concentrations should be monitored at the initiation of drug0",False, 
DDI-DrugBank.d165.s16.e0,DDI-DrugBank.d165.s16.e2,"drug1, drug0 and drug2 concentrations should be monitored at the initiation of drug0",False, 
DDI-DrugBank.d165.s16.e0,DDI-DrugBank.d165.s16.e3,"drug1, drug0 and drug0 concentrations should be monitored at the initiation of drug2",True,advise
DDI-DrugBank.d165.s16.e1,DDI-DrugBank.d165.s16.e3,"drug0, drug1 and drug0 concentrations should be monitored at the initiation of drug2",True,advise
DDI-DrugBank.d165.s16.e2,DDI-DrugBank.d165.s16.e3,"drug0, drug0 and drug1 concentrations should be monitored at the initiation of drug2",True,advise
DDI-DrugBank.d165.s17.e0,DDI-DrugBank.d165.s17.e1,Rhabdomyolysis has been observed in patients receiving drug1 administered alone (at recommended dosages) or concomitantly with drug2 including drug0,True,effect
DDI-DrugBank.d165.s17.e0,DDI-DrugBank.d165.s17.e2,Rhabdomyolysis has been observed in patients receiving drug1 administered alone (at recommended dosages) or concomitantly with drug0 including drug2,True,effect
DDI-DrugBank.d165.s17.e1,DDI-DrugBank.d165.s17.e2,Rhabdomyolysis has been observed in patients receiving drug0 administered alone (at recommended dosages) or concomitantly with drug1 including drug2,False, 
DDI-DrugBank.d165.s18.e0,DDI-DrugBank.d165.s18.e1,"When drug1 was coadministered with drug2, drug0, or H2antagonists, reduced plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d165.s18.e0,DDI-DrugBank.d165.s18.e2,"When drug1 was coadministered with drug0, drug2, or H2antagonists, reduced plasma concentrations of drug0",True,mechanism
DDI-DrugBank.d165.s18.e0,DDI-DrugBank.d165.s18.e3,"When drug1 was coadministered with drug0, drug0, or H2antagonists, reduced plasma concentrations of drug2",False, 
DDI-DrugBank.d165.s18.e1,DDI-DrugBank.d165.s18.e2,"When drug0 was coadministered with drug1, drug2, or H2antagonists, reduced plasma concentrations of drug0",False, 
DDI-DrugBank.d165.s19.e0,DDI-DrugBank.d165.s19.e1,"The physician is advised to monitor the plasma concentrations of drug1 when any of these drugs is taken concurrently, and to increase the dose of drug2",False, 
DDI-DrugBank.d165.s20.e0,DDI-DrugBank.d165.s20.e1,"Although no studies have been conducted, concomitant administration of drug1 and drug2 may alter the metabolism of drug0",True,mechanism
DDI-DrugBank.d165.s20.e0,DDI-DrugBank.d165.s20.e2,"Although no studies have been conducted, concomitant administration of drug1 and drug0 may alter the metabolism of drug2",False, 
DDI-DrugBank.d165.s20.e1,DDI-DrugBank.d165.s20.e2,"Although no studies have been conducted, concomitant administration of drug0 and drug1 may alter the metabolism of drug2",False, 
DDI-DrugBank.d165.s21.e0,DDI-DrugBank.d165.s21.e1,"therefore, plasma concentrations of drug1 should also be monitored when it is given concurrently with drug2",True,advise
DDI-DrugBank.d165.s22.e0,DDI-DrugBank.d165.s22.e1,It has been reported that drug1 enhances the anticoagulant effect of drug2,True,effect
DDI-DrugBank.d165.s23.e0,DDI-DrugBank.d165.s23.e1,"Therefore, prothrombin time should be carefully monitored in patients receiving drug1 and drug2",True,advise
DDI-DrugBank.d165.s24.e0,DDI-DrugBank.d165.s24.e1,Plasma concentrations of drug1 are reduced when given concurrently with drug2,True,mechanism
DDI-DrugBank.d165.s25.e0,DDI-DrugBank.d165.s25.e1,drug1 plasma concentrations should be monitored when drug2 and drug0,False, 
DDI-DrugBank.d165.s25.e0,DDI-DrugBank.d165.s25.e2,drug1 plasma concentrations should be monitored when drug0 and drug2,False, 
DDI-DrugBank.d165.s25.e1,DDI-DrugBank.d165.s25.e2,drug0 plasma concentrations should be monitored when drug1 and drug2,True,advise
DDI-DrugBank.d165.s26.e0,DDI-DrugBank.d165.s26.e1,Severe hypoglycemia has been reported in patients concomitantly receiving drug1 and oral drug2,True,effect
DDI-DrugBank.d165.s27.e0,DDI-DrugBank.d165.s27.e1,Blood glucose concentrations should be carefully monitored when drug1 and oral drug2,True,advise
DDI-DrugBank.d165.s28.e0,DDI-DrugBank.d165.s28.e1,Tinnitus and decreased hearing have been reported in patients concomitantly receiving drug1 and drug2,True,effect
DDI-DrugBank.d165.s29.e0,DDI-DrugBank.d165.s29.e1,Edema has been reported in patients concomitantly receiving drug1 and drug2,True,effect
DDI-DrugBank.d165.s31.e0,DDI-DrugBank.d165.s31.e1,"The results from a study in which eight HIV-infected individuals were treated with drug1, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of drug2 were not affected during concomitant administration of drug0",False, 
DDI-DrugBank.d165.s31.e0,DDI-DrugBank.d165.s31.e2,"The results from a study in which eight HIV-infected individuals were treated with drug1, 8 +/- 0.4 mg/kg/day, showed that the pharmacokinetics of drug0 were not affected during concomitant administration of drug2",False, 
DDI-DrugBank.d109.s0.e0,DDI-DrugBank.d109.s0.e1,"drug1/drug2, drug0, Including drug0",False, 
DDI-DrugBank.d109.s0.e0,DDI-DrugBank.d109.s0.e2,"drug1/drug0, drug2, Including drug0",False, 
DDI-DrugBank.d94.s2.e0,DDI-DrugBank.d94.s2.e1,Agents that Inhibit Cytochrome P450 Isoenzymes and/or Epoxide Hydrolase drug1 is metabolized mainly by cytochrome P450 (CYP) 3A4 to the active drug2,False, 
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e1,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug2, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e2,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug2, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e3,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug2, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e4,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug2(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e5,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug2, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e6,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug2, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e7,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug2, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e8,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug2, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e9,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug2(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e10,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug2, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e11,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug2, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e12,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e13,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e14,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e15,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e16,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e17,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e18,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e19,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e20,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e21,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e22,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e23,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e24,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2(1), drug0, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e25,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug2, drug0",True,mechanism
DDI-DrugBank.d94.s4.e0,DDI-DrugBank.d94.s4.e26,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug1 are the following: drug0, drug0, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug2",True,mechanism
DDI-DrugBank.d94.s4.e1,DDI-DrugBank.d94.s4.e2,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug0 are the following: drug1, drug2, drug0, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",False, 
DDI-DrugBank.d94.s4.e1,DDI-DrugBank.d94.s4.e3,"Agents that are CYP3A4 inhibitors that have been found, or are expected, to increase plasma levels of drug0 are the following: drug1, drug0, drug2, drug0(1), drug0, drug0, drug0, drug0, drug0(1), drug0, drug0, grapefruit juice, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(1), drug0, drug0",False, 
DDI-DrugBank.d94.s5.e0,DDI-DrugBank.d94.s5.e1,"Thus, if a patient has been titrated to a stable dosage of drug1, and then begins a course of treatment with one of these CYP3A4 or epoxide hydrolase inhibitors, it is reasonable to expect that a dose reduction for drug2",False, 
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e1,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug2, drug0, drug0, drug0, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e2,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug2, drug0, drug0, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e3,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug2, drug0, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e4,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug2, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e5,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug2, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e6,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug2(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e7,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug0(2), drug2, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e8,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug0(2), drug0, drug2, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e9,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug0(2), drug0, drug0, and drug2 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",True,mechanism
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e10,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug2, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug0",False, 
DDI-DrugBank.d94.s8.e0,DDI-DrugBank.d94.s8.e11,"Agents that are CYP inducers that have been found, or are expected, to decrease plasma levels of drug1 are the following: drug0, drug0, drug0, drug0, drug0, drug0(2), drug0, drug0, and drug0 Thus, if a patient has been titrated to a stable dosage on drug0, and then begins a course of treatment with one of these CYP3A4 inducers, it is reasonable to expect that a dose increase for drug2",False, 
DDI-DrugBank.d94.s9.e0,DDI-DrugBank.d94.s9.e1,Agents with Decreased Levels in the Presence of drug1 due to Induction of Cytochrome P450 Enzymes drug2,False, 
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e1,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e2,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e3,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e4,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e5,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e6,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e7,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e8,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e9,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e10,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e11,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e12,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e13,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e14,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e15,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e16,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e17,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e18,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e19,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e20,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e21,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e22,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e23,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e24,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e25,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e26,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e27,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e28,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e29,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e30,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug2(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e31,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug2, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e32,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug2(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e33,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e34,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e35,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e36,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e37,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e38,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e39,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e40,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e41,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e42,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e43,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2(5) , drug0, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e44,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug2, and drug0",True,mechanism
DDI-DrugBank.d94.s11.e0,DDI-DrugBank.d94.s11.e45,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug1 due to induction of CYP enzymes are the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug2",True,mechanism
DDI-DrugBank.d94.s11.e1,DDI-DrugBank.d94.s11.e2,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug0 due to induction of CYP enzymes are the following: drug1, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",False, 
DDI-DrugBank.d94.s11.e1,DDI-DrugBank.d94.s11.e3,"Agents that have been found, or are expected to have decreased plasma levels in the presence of drug0 due to induction of CYP enzymes are the following: drug1, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, oral drug0(3), drug0, drug0(4), drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0(5) , drug0, and drug0",False, 
DDI-DrugBank.d94.s13.e0,DDI-DrugBank.d94.s13.e1,"Agents with Increased Levels in the Presence of drug1: drug2 increases the plasma levels of the following agents: drug0, drug0(6), and drug0 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with drug0",False, 
DDI-DrugBank.d94.s13.e0,DDI-DrugBank.d94.s13.e2,"Agents with Increased Levels in the Presence of drug1: drug0 increases the plasma levels of the following agents: drug2, drug0(6), and drug0 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with drug0",False, 
DDI-DrugBank.d94.s13.e1,DDI-DrugBank.d94.s13.e2,"Agents with Increased Levels in the Presence of drug0: drug1 increases the plasma levels of the following agents: drug2, drug0(6), and drug0 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with drug0",True,mechanism
DDI-DrugBank.d94.s13.e1,DDI-DrugBank.d94.s13.e3,"Agents with Increased Levels in the Presence of drug0: drug1 increases the plasma levels of the following agents: drug0, drug2(6), and drug0 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with drug0",True,mechanism
DDI-DrugBank.d94.s13.e1,DDI-DrugBank.d94.s13.e4,"Agents with Increased Levels in the Presence of drug0: drug1 increases the plasma levels of the following agents: drug0, drug0(6), and drug2 Thus, if a patient has been titrated to a stable dosage on one of the agents in this category, and then begins a course of the treatment with drug0",True,mechanism
DDI-DrugBank.d94.s14.e0,DDI-DrugBank.d94.s14.e1,Pharmacological/Pharmacodynamic Interactions with drug1 Concomitant administration of drug2 and drug0,False, 
DDI-DrugBank.d94.s14.e0,DDI-DrugBank.d94.s14.e2,Pharmacological/Pharmacodynamic Interactions with drug1 Concomitant administration of drug0 and drug2,False, 
DDI-DrugBank.d94.s14.e1,DDI-DrugBank.d94.s14.e2,Pharmacological/Pharmacodynamic Interactions with drug0 Concomitant administration of drug1 and drug2,True,effect
DDI-DrugBank.d94.s15.e0,DDI-DrugBank.d94.s15.e1,"Given the anticonvulsant properties of drug1, drug2 may reduce the thyroid function as has been reported with other drug0",False, 
DDI-DrugBank.d94.s15.e0,DDI-DrugBank.d94.s15.e2,"Given the anticonvulsant properties of drug1, drug0 may reduce the thyroid function as has been reported with other drug2",False, 
DDI-DrugBank.d94.s16.e0,DDI-DrugBank.d94.s16.e1,"Additionally, drug1, such as drug2 and drug0, may antagonize the activity of drug0",False, 
DDI-DrugBank.d94.s16.e0,DDI-DrugBank.d94.s16.e2,"Additionally, drug1, such as drug0 and drug2, may antagonize the activity of drug0",False, 
DDI-DrugBank.d94.s16.e0,DDI-DrugBank.d94.s16.e3,"Additionally, drug1, such as drug0 and drug0, may antagonize the activity of drug2",True,effect
DDI-DrugBank.d94.s16.e1,DDI-DrugBank.d94.s16.e3,"Additionally, drug0, such as drug1 and drug0, may antagonize the activity of drug2",True,effect
DDI-DrugBank.d94.s16.e2,DDI-DrugBank.d94.s16.e3,"Additionally, drug0, such as drug0 and drug1, may antagonize the activity of drug2",True,effect
DDI-DrugBank.d94.s18.e0,DDI-DrugBank.d94.s18.e1,"Because of its primary CNS effect, caution should be used when drug1 is taken with other drug2 and drug0",True,advise
DDI-DrugBank.d94.s18.e0,DDI-DrugBank.d94.s18.e2,"Because of its primary CNS effect, caution should be used when drug1 is taken with other drug0 and drug2",True,advise
DDI-DrugBank.d94.s18.e1,DDI-DrugBank.d94.s18.e2,"Because of its primary CNS effect, caution should be used when drug0 is taken with other drug1 and drug2",False, 
DDI-DrugBank.d347.s0.e0,DDI-DrugBank.d347.s0.e1,"Administration of repeat doses of drug1 had no effect on the repeat dose pharmacokinetics of drug2, drug0 or an drug0/levonorgestrol oral drug0",False, 
DDI-DrugBank.d347.s0.e0,DDI-DrugBank.d347.s0.e2,"Administration of repeat doses of drug1 had no effect on the repeat dose pharmacokinetics of drug0, drug2 or an drug0/levonorgestrol oral drug0",False, 
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e1,"Concomitant administration of drug1 and drug2, drug0, drug0, or an drug0/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e2,"Concomitant administration of drug1 and drug0, drug2, drug0, or an drug0/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e3,"Concomitant administration of drug1 and drug0, drug0, drug2, or an drug0/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e4,"Concomitant administration of drug1 and drug0, drug0, drug0, or an drug2/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e5,"Concomitant administration of drug1 and drug0, drug0, drug0, or an drug0/drug2 oral drug0 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e6,"Concomitant administration of drug1 and drug0, drug0, drug0, or an drug0/drug0 oral drug2 produced minor changes in the pharmacokinetics of drug0",True,mechanism
DDI-DrugBank.d347.s1.e0,DDI-DrugBank.d347.s1.e7,"Concomitant administration of drug1 and drug0, drug0, drug0, or an drug0/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug2",False, 
DDI-DrugBank.d347.s1.e1,DDI-DrugBank.d347.s1.e2,"Concomitant administration of drug0 and drug1, drug2, drug0, or an drug0/drug0 oral drug0 produced minor changes in the pharmacokinetics of drug0",False, 
DDI-DrugBank.d347.s2.e0,DDI-DrugBank.d347.s2.e1,Concomitant administration of drug1 with drug2 resulted in a 45% increase in systemic exposure to drug0,True,mechanism
DDI-DrugBank.d347.s2.e0,DDI-DrugBank.d347.s2.e2,Concomitant administration of drug1 with drug0 resulted in a 45% increase in systemic exposure to drug2,False, 
DDI-DrugBank.d347.s2.e1,DDI-DrugBank.d347.s2.e2,Concomitant administration of drug0 with drug1 resulted in a 45% increase in systemic exposure to drug2,False, 
DDI-DrugBank.d347.s3.e0,DDI-DrugBank.d347.s3.e1,drug1 had no significant effect on the anticoagulant effect of drug2 in healthy subjects on stable drug0,False, 
DDI-DrugBank.d347.s3.e0,DDI-DrugBank.d347.s3.e2,drug1 had no significant effect on the anticoagulant effect of drug0 in healthy subjects on stable drug2,False, 
DDI-DrugBank.d347.s4.e0,DDI-DrugBank.d347.s4.e1,"However, because some drug1 have been reported to enhance the anticoagulant effects of drug2 or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a drug0 is administered concomitantly with drug0",True,effect
DDI-DrugBank.d347.s4.e0,DDI-DrugBank.d347.s4.e2,"However, because some drug1 have been reported to enhance the anticoagulant effects of drug0 or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a drug2 is administered concomitantly with drug0",False, 
DDI-DrugBank.d347.s4.e0,DDI-DrugBank.d347.s4.e3,"However, because some drug1 have been reported to enhance the anticoagulant effects of drug0 or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a drug0 is administered concomitantly with drug2",False, 
DDI-DrugBank.d347.s4.e2,DDI-DrugBank.d347.s4.e3,"However, because some drug0 have been reported to enhance the anticoagulant effects of drug0 or its derivatives in patients, the prothrombin time or other suitable coagulation test should be closely monitored if a drug1 is administered concomitantly with drug2",True,advise
DDI-DrugBank.d347.s6.e0,DDI-DrugBank.d347.s6.e1,The absorption of oral drug1 is significantly reduced by the concomitant administration of an drug2 containing drug0 and drug0,False, 
DDI-DrugBank.d347.s6.e0,DDI-DrugBank.d347.s6.e2,The absorption of oral drug1 is significantly reduced by the concomitant administration of an drug0 containing drug2 and drug0,True,mechanism
DDI-DrugBank.d347.s6.e0,DDI-DrugBank.d347.s6.e3,The absorption of oral drug1 is significantly reduced by the concomitant administration of an drug0 containing drug0 and drug2,True,mechanism
DDI-DrugBank.d347.s6.e1,DDI-DrugBank.d347.s6.e2,The absorption of oral drug0 is significantly reduced by the concomitant administration of an drug1 containing drug2 and drug0,False, 
DDI-DrugBank.d347.s7.e0,DDI-DrugBank.d347.s7.e1,"drug1- and/or drug2-containing drug0, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug0",False, 
DDI-DrugBank.d347.s7.e0,DDI-DrugBank.d347.s7.e2,"drug1- and/or drug0-containing drug2, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug0",False, 
DDI-DrugBank.d347.s7.e0,DDI-DrugBank.d347.s7.e9,"drug1- and/or drug0-containing drug0, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e1,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug1-containing drug0, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e3,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug1 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e4,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug0 (drug1), drug0 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e5,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug0 (drug0), drug1 containing drug0 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e6,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug0 (drug0), drug0 containing drug1 or other metal cations, or drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e7,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug1 (drug0) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s7.e8,DDI-DrugBank.d347.s7.e9,"drug0- and/or drug0-containing drug0, products containing drug0 (drug0), drug0 containing drug0 or other metal cations, or drug0 (drug1) chewable/buffered tablets or the pediatric powder for oral solution should not be taken within 3 hours before or 2 hours after drug2",True,advise
DDI-DrugBank.d347.s8.e0,DDI-DrugBank.d347.s8.e1,drug1 should not be taken within 2 hours of drug2,True,advise
DDI-DrugBank.d552.s0.e0,DDI-DrugBank.d552.s0.e1,"drug1 should be administered with caution to patients who are taking other drug2 or drug0, including drug0, drug0 and drug0",True,advise
DDI-DrugBank.d552.s0.e0,DDI-DrugBank.d552.s0.e2,"drug1 should be administered with caution to patients who are taking other drug0 or drug2, including drug0, drug0 and drug0",True,advise
DDI-DrugBank.d552.s0.e0,DDI-DrugBank.d552.s0.e3,"drug1 should be administered with caution to patients who are taking other drug0 or drug0, including drug2, drug0 and drug0",True,advise
DDI-DrugBank.d552.s0.e0,DDI-DrugBank.d552.s0.e4,"drug1 should be administered with caution to patients who are taking other drug0 or drug0, including drug0, drug2 and drug0",True,advise
DDI-DrugBank.d552.s0.e0,DDI-DrugBank.d552.s0.e5,"drug1 should be administered with caution to patients who are taking other drug0 or drug0, including drug0, drug0 and drug2",True,advise
DDI-DrugBank.d552.s0.e1,DDI-DrugBank.d552.s0.e2,"drug0 should be administered with caution to patients who are taking other drug1 or drug2, including drug0, drug0 and drug0",False, 
DDI-DrugBank.d552.s0.e1,DDI-DrugBank.d552.s0.e3,"drug0 should be administered with caution to patients who are taking other drug1 or drug0, including drug2, drug0 and drug0",False, 
DDI-DrugBank.d552.s1.e0,DDI-DrugBank.d552.s1.e1,"drug1 has been shown to have an additive CNS depressant effect when given with either drug2, drug0, drug0 or drug0",True,effect
DDI-DrugBank.d552.s1.e0,DDI-DrugBank.d552.s1.e2,"drug1 has been shown to have an additive CNS depressant effect when given with either drug0, drug2, drug0 or drug0",True,effect
DDI-DrugBank.d552.s1.e0,DDI-DrugBank.d552.s1.e3,"drug1 has been shown to have an additive CNS depressant effect when given with either drug0, drug0, drug2 or drug0",True,effect
DDI-DrugBank.d552.s1.e0,DDI-DrugBank.d552.s1.e4,"drug1 has been shown to have an additive CNS depressant effect when given with either drug0, drug0, drug0 or drug2",True,effect
DDI-DrugBank.d552.s1.e1,DDI-DrugBank.d552.s1.e2,"drug0 has been shown to have an additive CNS depressant effect when given with either drug1, drug2, drug0 or drug0",False, 
DDI-DrugBank.d552.s1.e1,DDI-DrugBank.d552.s1.e3,"drug0 has been shown to have an additive CNS depressant effect when given with either drug1, drug0, drug2 or drug0",False, 
DDI-DrugBank.d380.s0.e0,DDI-DrugBank.d380.s0.e1,drug1 is metabolized to drug2,False, 
DDI-DrugBank.d380.s1.e0,DDI-DrugBank.d380.s1.e1,"Because CYP 3A4 inhibitors may increase plasma concentrations of drug1, patients already on CYP 3A4 inhibitors such as drug2",False, 
DDI-DrugBank.d380.s2.e0,DDI-DrugBank.d380.s2.e1,"drug1), drug2 (e.g. drug0), and drug0 (e.g. drug0, drug0 and drug0) should have their dose of drug0 or drug0",False, 
DDI-DrugBank.d380.s2.e0,DDI-DrugBank.d380.s2.e2,"drug1), drug0 (e.g. drug2), and drug0 (e.g. drug0, drug0 and drug0) should have their dose of drug0 or drug0",False, 
DDI-DrugBank.d380.s3.e0,DDI-DrugBank.d380.s3.e1,"Based on anecdotal reports, there may be an interaction between drug1 and drug2",True,int
DDI-DrugBank.d380.s4.e0,DDI-DrugBank.d380.s4.e1,There have been a number of reports in the post-marketing experience of coma and death associated with the concomitant intravenous misuse of drug1 and drug2,True,effect
DDI-DrugBank.d380.s5.e0,DDI-DrugBank.d380.s5.e1,"In many of these cases, drug1 was misused by self-injection of crushed drug2",False, 
DDI-DrugBank.d380.s6.e0,DDI-DrugBank.d380.s6.e1,drug1 and drug2 should be prescribed with caution to patients on drug0,False, 
DDI-DrugBank.d380.s6.e0,DDI-DrugBank.d380.s6.e2,drug1 and drug0 should be prescribed with caution to patients on drug2,True,advise
DDI-DrugBank.d380.s6.e1,DDI-DrugBank.d380.s6.e2,drug0 and drug1 should be prescribed with caution to patients on drug2,True,advise
DDI-DrugBank.d380.s7.e0,DDI-DrugBank.d380.s7.e1,Patients should be warned of the potential danger of the intravenous self-administration of drug1 while under treatment with drug2 or drug0,True,advise
DDI-DrugBank.d380.s7.e0,DDI-DrugBank.d380.s7.e2,Patients should be warned of the potential danger of the intravenous self-administration of drug1 while under treatment with drug0 or drug2,True,advise
DDI-DrugBank.d380.s7.e1,DDI-DrugBank.d380.s7.e2,Patients should be warned of the potential danger of the intravenous self-administration of drug0 while under treatment with drug1 or drug2,False, 
DDI-DrugBank.d443.s0.e0,DDI-DrugBank.d443.s0.e1,"drug1: drug2 may decrease the effects of drug0, drug0, and drug0",False, 
DDI-DrugBank.d443.s0.e0,DDI-DrugBank.d443.s0.e2,"drug1: drug0 may decrease the effects of drug2, drug0, and drug0",False, 
DDI-DrugBank.d443.s0.e1,DDI-DrugBank.d443.s0.e2,"drug0: drug1 may decrease the effects of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d443.s0.e1,DDI-DrugBank.d443.s0.e3,"drug0: drug1 may decrease the effects of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d443.s0.e1,DDI-DrugBank.d443.s0.e4,"drug0: drug1 may decrease the effects of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d443.s1.e0,DDI-DrugBank.d443.s1.e1,drug1: Has a synergistic effect with drug2,True,effect
DDI-DrugBank.d443.s2.e0,DDI-DrugBank.d443.s2.e1,drug1: Concomitant administration with drug2,True,effect
DDI-DrugBank.d443.s3.e0,DDI-DrugBank.d443.s3.e1,"drug1 (drug2, drug0, and possibly drug0): Concomitant administration with drug0",False, 
DDI-DrugBank.d443.s3.e0,DDI-DrugBank.d443.s3.e2,"drug1 (drug0, drug2, and possibly drug0): Concomitant administration with drug0",False, 
DDI-DrugBank.d443.s3.e0,DDI-DrugBank.d443.s3.e4,"drug1 (drug0, drug0, and possibly drug0): Concomitant administration with drug2",True,effect
DDI-DrugBank.d443.s3.e1,DDI-DrugBank.d443.s3.e4,"drug0 (drug1, drug0, and possibly drug0): Concomitant administration with drug2",True,effect
DDI-DrugBank.d443.s3.e2,DDI-DrugBank.d443.s3.e4,"drug0 (drug0, drug1, and possibly drug0): Concomitant administration with drug2",True,effect
DDI-DrugBank.d443.s3.e3,DDI-DrugBank.d443.s3.e4,"drug0 (drug0, drug0, and possibly drug1): Concomitant administration with drug2",True,effect
DDI-DrugBank.d443.s4.e0,DDI-DrugBank.d443.s4.e1,drug1 Agents: drug2 is contraindicated in patients who are hypersensitive to drug0,False, 
DDI-DrugBank.d443.s4.e0,DDI-DrugBank.d443.s4.e2,drug1 Agents: drug0 is contraindicated in patients who are hypersensitive to drug2,False, 
DDI-DrugBank.d443.s4.e1,DDI-DrugBank.d443.s4.e2,drug0 Agents: drug1 is contraindicated in patients who are hypersensitive to drug2,True,advise
DDI-DrugBank.d443.s5.e0,DDI-DrugBank.d443.s5.e1,Urinary Alkalinizers: Decrease drug1 effectiveness by increasing the rate of drug2,False, 
DDI-DrugBank.d443.s6.e0,DDI-DrugBank.d443.s6.e1,drug1: Decreases drug2,True,mechanism
DDI-DrugBank.d443.s7.e0,DDI-DrugBank.d443.s7.e1,drug1: Serum drug2 levels may be increased by drug0,False, 
DDI-DrugBank.d443.s7.e0,DDI-DrugBank.d443.s7.e2,drug1: Serum drug0 levels may be increased by drug2,False, 
DDI-DrugBank.d443.s7.e1,DDI-DrugBank.d443.s7.e2,drug0: Serum drug1 levels may be increased by drug2,True,effect
DDI-DrugBank.d443.s8.e0,DDI-DrugBank.d443.s8.e1,drug1: May decrease drug2,True,effect
DDI-DrugBank.d443.s9.e0,DDI-DrugBank.d443.s9.e1,drug1: Enteric Coated drug2 should not be given concurrently with drug0,False, 
DDI-DrugBank.d443.s9.e0,DDI-DrugBank.d443.s9.e2,drug1: Enteric Coated drug0 should not be given concurrently with drug2,False, 
DDI-DrugBank.d443.s9.e1,DDI-DrugBank.d443.s9.e2,drug0: Enteric Coated drug1 should not be given concurrently with drug2,True,advise
DDI-DrugBank.d266.s0.e0,DDI-DrugBank.d266.s0.e1,"In vitro studies have shown drug1 can displace drug2s, such as drug0",True,mechanism
DDI-DrugBank.d266.s0.e0,DDI-DrugBank.d266.s0.e2,"In vitro studies have shown drug1 can displace drug0s, such as drug2",True,mechanism
DDI-DrugBank.d266.s0.e1,DDI-DrugBank.d266.s0.e2,"In vitro studies have shown drug0 can displace drug1s, such as drug2",False, 
DDI-DrugBank.d266.s1.e0,DDI-DrugBank.d266.s1.e1,"It is recommended that if drug1 is started in patients already receiving drug2, prothrombin times should be closely monitored and adjustment of the drug0",True,advise
DDI-DrugBank.d266.s1.e0,DDI-DrugBank.d266.s1.e2,"It is recommended that if drug1 is started in patients already receiving drug0, prothrombin times should be closely monitored and adjustment of the drug2",True,advise
DDI-DrugBank.d266.s1.e1,DDI-DrugBank.d266.s1.e2,"It is recommended that if drug0 is started in patients already receiving drug1, prothrombin times should be closely monitored and adjustment of the drug2",False, 
DDI-DrugBank.d285.s1.e0,DDI-DrugBank.d285.s1.e1,"A similar association, though less marked, has been suggested with drug1, phenyl-butazone, drug2, drug0 and possibly with drug0, drug0, and drug0",False, 
DDI-DrugBank.d285.s1.e0,DDI-DrugBank.d285.s1.e2,"A similar association, though less marked, has been suggested with drug1, phenyl-butazone, drug0, drug2 and possibly with drug0, drug0, and drug0",False, 
DDI-DrugBank.d481.s0.e0,DDI-DrugBank.d481.s0.e1,"Milk, milk products, and drug1-rich foods or drugs may impair the absorption of drug2",True,mechanism
DDI-DrugBank.d517.s0.e0,DDI-DrugBank.d517.s0.e1,"drug1, a drug2, may antagonize the bactercidal effect of drug0",False, 
DDI-DrugBank.d517.s0.e0,DDI-DrugBank.d517.s0.e2,"drug1, a drug0, may antagonize the bactercidal effect of drug2",True,effect
DDI-DrugBank.d517.s0.e1,DDI-DrugBank.d517.s0.e2,"drug0, a drug1, may antagonize the bactercidal effect of drug2",False, 
DDI-DrugBank.d498.s0.e0,DDI-DrugBank.d498.s0.e1,"Certain drug1, especially drug2, drug0 and drug0",False, 
DDI-DrugBank.d498.s0.e0,DDI-DrugBank.d498.s0.e2,"Certain drug1, especially drug0, drug2 and drug0",False, 
DDI-DrugBank.d498.s1.e0,DDI-DrugBank.d498.s1.e1,"These drug1 should be used in the myasthenic patient only where definitely indicated, and then careful adjustment should be made of adjunctive drug2",True,advise
DDI-DrugBank.d498.s2.e0,DDI-DrugBank.d498.s2.e1,"Local and some general drug1, drug2",False, 
DDI-DrugBank.d148.s0.e0,DDI-DrugBank.d148.s0.e1,"drug1: Since drug2 is contraindicated in patients with drug0-induced thrombocytopenia, the co-administration of drug0 and drug0",False, 
DDI-DrugBank.d148.s0.e0,DDI-DrugBank.d148.s0.e2,"drug1: Since drug0 is contraindicated in patients with drug2-induced thrombocytopenia, the co-administration of drug0 and drug0",False, 
DDI-DrugBank.d148.s1.e0,DDI-DrugBank.d148.s1.e1,"However, if drug1 is to be initiated after cessation of drug2 therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of drug0",False, 
DDI-DrugBank.d148.s1.e0,DDI-DrugBank.d148.s1.e2,"However, if drug1 is to be initiated after cessation of drug0 therapy, allow sufficient time for heparins effect on the aPTT to decrease prior to initiation of drug2",False, 
DDI-DrugBank.d148.s2.e0,DDI-DrugBank.d148.s2.e1,"drug1/drug2: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drug0 and concomitantly administered drug0 (162.5 mg orally given 26 and 2 hours prior to initiation of drug0 1  g/kg/min. over 4 hours) or drug0 (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of drug0",False, 
DDI-DrugBank.d148.s2.e0,DDI-DrugBank.d148.s2.e2,"drug1/drug0: Pharmacokinetic or pharmacodynamic drug-drug interactions have not been demonstrated between drug2 and concomitantly administered drug0 (162.5 mg orally given 26 and 2 hours prior to initiation of drug0 1  g/kg/min. over 4 hours) or drug0 (1000 mg orally given 12, 6 and 0 hours prior to, and 6 and 12 hours subsequent to, initiation of drug0",False, 
DDI-DrugBank.d148.s3.e0,DDI-DrugBank.d148.s3.e1,Oral drug1: Pharmacokinetic drug-drug interactions between drug2 and drug0,False, 
DDI-DrugBank.d148.s3.e0,DDI-DrugBank.d148.s3.e2,Oral drug1: Pharmacokinetic drug-drug interactions between drug0 and drug2,False, 
DDI-DrugBank.d148.s4.e0,DDI-DrugBank.d148.s4.e1,"However, the concomitant use of drug1 and drug2",True,effect
DDI-DrugBank.d148.s5.e0,DDI-DrugBank.d148.s5.e1,drug1: The safety and effectiveness of drug2 with drug0,False, 
DDI-DrugBank.d148.s5.e0,DDI-DrugBank.d148.s5.e2,drug1: The safety and effectiveness of drug0 with drug2,False, 
DDI-DrugBank.d148.s6.e0,DDI-DrugBank.d148.s6.e1,"Co-administration: Concomitant use of drug1 with drug2, drug0, and other drug0",True,effect
DDI-DrugBank.d148.s6.e0,DDI-DrugBank.d148.s6.e2,"Co-administration: Concomitant use of drug1 with drug0, drug2, and other drug0",True,effect
DDI-DrugBank.d148.s6.e0,DDI-DrugBank.d148.s6.e3,"Co-administration: Concomitant use of drug1 with drug0, drug0, and other drug2",True,effect
DDI-DrugBank.d148.s6.e1,DDI-DrugBank.d148.s6.e2,"Co-administration: Concomitant use of drug0 with drug1, drug2, and other drug0",False, 
DDI-DrugBank.d148.s6.e1,DDI-DrugBank.d148.s6.e3,"Co-administration: Concomitant use of drug0 with drug1, drug0, and other drug2",False, 
DDI-DrugBank.d148.s7.e0,DDI-DrugBank.d148.s7.e1,Drug-drug interactions have not been observed between drug1 and drug2 or drug0,False, 
DDI-DrugBank.d148.s7.e0,DDI-DrugBank.d148.s7.e2,Drug-drug interactions have not been observed between drug1 and drug0 or drug2,False, 
DDI-DrugBank.d304.s0.e0,DDI-DrugBank.d304.s0.e1,"May interact with the following: drug1, drug2 (use with drug0 may prevent the drug0",False, 
DDI-DrugBank.d304.s0.e0,DDI-DrugBank.d304.s0.e2,"May interact with the following: drug1, drug0 (use with drug2 may prevent the drug0",True,effect
DDI-DrugBank.d304.s0.e0,DDI-DrugBank.d304.s0.e3,"May interact with the following: drug1, drug0 (use with drug0 may prevent the drug2",False, 
DDI-DrugBank.d304.s0.e1,DDI-DrugBank.d304.s0.e2,"May interact with the following: drug0, drug1 (use with drug2 may prevent the drug0",True,effect
DDI-DrugBank.d210.s0.e0,DDI-DrugBank.d210.s0.e1,drug1: Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d210.s0.e0,DDI-DrugBank.d210.s0.e2,drug1: Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d210.s0.e1,DDI-DrugBank.d210.s0.e2,drug0: Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d210.s1.e0,DDI-DrugBank.d210.s1.e1,"In patients with mild to moderate hypertension, administration of 25 mg daily of drug1 with the drug2 drug0, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to drug0",False, 
DDI-DrugBank.d210.s1.e0,DDI-DrugBank.d210.s1.e2,"In patients with mild to moderate hypertension, administration of 25 mg daily of drug1 with the drug0 drug2, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to drug0",True,effect
DDI-DrugBank.d210.s1.e0,DDI-DrugBank.d210.s1.e3,"In patients with mild to moderate hypertension, administration of 25 mg daily of drug1 with the drug0 drug0, 10 to 40 mg for 4 weeks, was associated with an average increase in mean arterial pressure of about 3 mm Hg compared to drug2",False, 
DDI-DrugBank.d210.s2.e0,DDI-DrugBank.d210.s2.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d210.s3.e0,DDI-DrugBank.d210.s3.e1,"drug1: Concomitant administration of low-dose drug2 with drug0 may result in an increased rate of GI ulceration or other complications, compared to use of drug0",False, 
DDI-DrugBank.d210.s3.e0,DDI-DrugBank.d210.s3.e2,"drug1: Concomitant administration of low-dose drug0 with drug2 may result in an increased rate of GI ulceration or other complications, compared to use of drug0",False, 
DDI-DrugBank.d210.s3.e1,DDI-DrugBank.d210.s3.e2,"drug0: Concomitant administration of low-dose drug1 with drug2 may result in an increased rate of GI ulceration or other complications, compared to use of drug0",True,effect
DDI-DrugBank.d210.s4.e0,DDI-DrugBank.d210.s4.e1,"In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated drug1 plus drug2 25 mg daily, as compared to those taking drug0",False, 
DDI-DrugBank.d210.s4.e0,DDI-DrugBank.d210.s4.e2,"In a 12-week endoscopy study conducted in OA patients there was no difference in the cumulative incidence of endoscopic gastroduodenal ulcers in patients taking low-dose (81 mg) enteric coated drug1 plus drug0 25 mg daily, as compared to those taking drug2",False, 
DDI-DrugBank.d210.s5.e0,DDI-DrugBank.d210.s5.e1,Patients taking low-dose drug1 plus drug2,False, 
DDI-DrugBank.d210.s6.e0,DDI-DrugBank.d210.s6.e1,"At steady state, drug1 50 mg once daily had no effect on the anti-platelet activity of low-dose (81 mg once daily) drug2",False, 
DDI-DrugBank.d210.s7.e0,DDI-DrugBank.d210.s7.e1,"Because of its lack of platelet effects, drug1 is not a substitute for drug2",False, 
DDI-DrugBank.d210.s9.e0,DDI-DrugBank.d210.s9.e1,"Prospective, long-term studies on concomitant administration of drug1 and drug2",False, 
DDI-DrugBank.d210.s10.e0,DDI-DrugBank.d210.s10.e1,drug1: Co-administration with high doses of drug2 [800 mg twice daily] increased the Cmax of drug0,False, 
DDI-DrugBank.d210.s10.e0,DDI-DrugBank.d210.s10.e2,drug1: Co-administration with high doses of drug0 [800 mg twice daily] increased the Cmax of drug2,False, 
DDI-DrugBank.d210.s10.e1,DDI-DrugBank.d210.s10.e2,drug0: Co-administration with high doses of drug1 [800 mg twice daily] increased the Cmax of drug2,True,mechanism
DDI-DrugBank.d210.s12.e0,DDI-DrugBank.d210.s12.e1,drug1: drug2 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of drug0,False, 
DDI-DrugBank.d210.s12.e0,DDI-DrugBank.d210.s12.e2,drug1: drug0 75 mg once daily for 11 days does not alter the plasma concentration profile or renal elimination of drug2,False, 
DDI-DrugBank.d210.s13.e0,DDI-DrugBank.d210.s13.e1,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug2 can reduce the natriuretic effect of drug0 and drug0",False, 
DDI-DrugBank.d210.s13.e0,DDI-DrugBank.d210.s13.e2,"drug1: Clinical studies, as well as post-marketing observations, have shown that drug0 can reduce the natriuretic effect of drug2 and drug0",False, 
DDI-DrugBank.d210.s13.e1,DDI-DrugBank.d210.s13.e2,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d210.s13.e1,DDI-DrugBank.d210.s13.e3,"drug0: Clinical studies, as well as post-marketing observations, have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d210.s15.e0,DDI-DrugBank.d210.s15.e1,drug1: drug2 400 mg daily did not have any clinically important effect on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d210.s15.e0,DDI-DrugBank.d210.s15.e2,drug1: drug0 400 mg daily did not have any clinically important effect on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d210.s16.e0,DDI-DrugBank.d210.s16.e1,drug1: drug2 have produced an elevation of plasma drug0 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d210.s16.e0,DDI-DrugBank.d210.s16.e2,drug1: drug0 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,False, 
DDI-DrugBank.d210.s16.e1,DDI-DrugBank.d210.s16.e2,drug0: drug1 have produced an elevation of plasma drug2 levels and a reduction in renal drug0,True,mechanism
DDI-DrugBank.d210.s18.e0,DDI-DrugBank.d210.s18.e1,"Thus, when drug1 and drug2 are administered concurrently, subjects should be observed carefully for signs of drug0",True,advise
DDI-DrugBank.d210.s18.e0,DDI-DrugBank.d210.s18.e2,"Thus, when drug1 and drug0 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d210.s18.e1,DDI-DrugBank.d210.s18.e2,"Thus, when drug0 and drug1 are administered concurrently, subjects should be observed carefully for signs of drug2",False, 
DDI-DrugBank.d210.s19.e0,DDI-DrugBank.d210.s19.e1,"drug1 drug2 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of drug0 as measured by AUC0-24hr in patients receiving single weekly drug0",False, 
DDI-DrugBank.d210.s19.e0,DDI-DrugBank.d210.s19.e2,"drug1 drug0 12.5, 25, and 50 mg, each dose administered once daily for 7 days, had no effect on the plasma concentration of drug2 as measured by AUC0-24hr in patients receiving single weekly drug0",False, 
DDI-DrugBank.d210.s20.e0,DDI-DrugBank.d210.s20.e1,"At higher than recommended doses, drug1 75 mg administered once daily for 10 days increased plasma concentrations by 23% as measured by AUC0-24hr in patients receiving drug2",True,mechanism
DDI-DrugBank.d210.s21.e0,DDI-DrugBank.d210.s21.e1,"At 24 hours postdose, a similar proportion of patients treated with drug1 alone (94%) and subsequently treated with drug2 co-administered with 75 mg of drug0 (88%) had drug0",False, 
DDI-DrugBank.d210.s21.e0,DDI-DrugBank.d210.s21.e2,"At 24 hours postdose, a similar proportion of patients treated with drug1 alone (94%) and subsequently treated with drug0 co-administered with 75 mg of drug2 (88%) had drug0",False, 
DDI-DrugBank.d210.s21.e1,DDI-DrugBank.d210.s21.e2,"At 24 hours postdose, a similar proportion of patients treated with drug0 alone (94%) and subsequently treated with drug1 co-administered with 75 mg of drug2 (88%) had drug0",True,mechanism
DDI-DrugBank.d210.s22.e0,DDI-DrugBank.d210.s22.e1,Standard monitoring of drug1-related toxicity should be continued if drug2 and drug0,False, 
DDI-DrugBank.d210.s22.e0,DDI-DrugBank.d210.s22.e2,Standard monitoring of drug1-related toxicity should be continued if drug0 and drug2,False, 
DDI-DrugBank.d210.s22.e1,DDI-DrugBank.d210.s22.e2,Standard monitoring of drug0-related toxicity should be continued if drug1 and drug2,True,advise
DDI-DrugBank.d210.s23.e0,DDI-DrugBank.d210.s23.e1,Oral drug1 drug2 did not have any clinically important effect on the pharmacokinetics of drug0 and drug0,False, 
DDI-DrugBank.d210.s23.e0,DDI-DrugBank.d210.s23.e2,Oral drug1 drug0 did not have any clinically important effect on the pharmacokinetics of drug2 and drug0,False, 
DDI-DrugBank.d210.s24.e0,DDI-DrugBank.d210.s24.e1,drug1/drug2: drug0 did not have any clinically important effect on the pharmacokinetics of drug0 or drug0,False, 
DDI-DrugBank.d210.s24.e0,DDI-DrugBank.d210.s24.e2,drug1/drug0: drug2 did not have any clinically important effect on the pharmacokinetics of drug0 or drug0,False, 
DDI-DrugBank.d210.s25.e0,DDI-DrugBank.d210.s25.e1,"drug1: Co-administration of drug2 with drug0 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in drug0",False, 
DDI-DrugBank.d210.s25.e0,DDI-DrugBank.d210.s25.e2,"drug1: Co-administration of drug0 with drug2 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in drug0",False, 
DDI-DrugBank.d210.s25.e1,DDI-DrugBank.d210.s25.e2,"drug0: Co-administration of drug1 with drug2 600 mg daily, a potent inducer of hepatic metabolism, produced an approximate 50% decrease in drug0",True,mechanism
DDI-DrugBank.d210.s26.e0,DDI-DrugBank.d210.s26.e1,"Therefore, a starting daily dose of 25 mg of drug1 should be considered for the treatment of osteoarthritis when drug2",False, 
DDI-DrugBank.d210.s27.e0,DDI-DrugBank.d210.s27.e1,"drug1 drug2 12.5, 25, and 50 mg administered once daily for 7 days increased plasma drug0 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of drug0",False, 
DDI-DrugBank.d210.s27.e0,DDI-DrugBank.d210.s27.e2,"drug1 drug0 12.5, 25, and 50 mg administered once daily for 7 days increased plasma drug2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of drug0",False, 
DDI-DrugBank.d210.s27.e1,DDI-DrugBank.d210.s27.e2,"drug0 drug1 12.5, 25, and 50 mg administered once daily for 7 days increased plasma drug2 concentrations (AUC(0- )) by 38 to 60% in healthy subjects administered a single 300-mg dose of drug0",True,mechanism
DDI-DrugBank.d210.s28.e0,DDI-DrugBank.d210.s28.e1,Adequate monitoring of drug1 plasma concentrations should be considered when therapy with drug2 is initiated or changed in patients receiving drug0,False, 
DDI-DrugBank.d210.s28.e0,DDI-DrugBank.d210.s28.e2,Adequate monitoring of drug1 plasma concentrations should be considered when therapy with drug0 is initiated or changed in patients receiving drug2,False, 
DDI-DrugBank.d210.s28.e1,DDI-DrugBank.d210.s28.e2,Adequate monitoring of drug0 plasma concentrations should be considered when therapy with drug1 is initiated or changed in patients receiving drug2,True,advise
DDI-DrugBank.d210.s30.e0,DDI-DrugBank.d210.s30.e1,"Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., drug1, drug2, and drug0",False, 
DDI-DrugBank.d210.s30.e0,DDI-DrugBank.d210.s30.e2,"Therefore, there is a potential for an interaction with other drugs that are metabolized by CYP 1A2 (e.g., drug1, drug0, and drug2",False, 
DDI-DrugBank.d210.s31.e0,DDI-DrugBank.d210.s31.e1,"drug1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug2 therapy in patients receiving drug0",False, 
DDI-DrugBank.d210.s31.e0,DDI-DrugBank.d210.s31.e2,"drug1: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug0 therapy in patients receiving drug2",False, 
DDI-DrugBank.d210.s31.e1,DDI-DrugBank.d210.s31.e2,"drug0: Anticoagulant activity should be monitored, particularly in the first few days after initiating or changing drug1 therapy in patients receiving drug2",True,advise
DDI-DrugBank.d210.s32.e0,DDI-DrugBank.d210.s32.e1,In single and multiple dose studies in healthy subjects receiving both drug1 and drug2,True,effect
DDI-DrugBank.d210.s33.e0,DDI-DrugBank.d210.s33.e1,"In post-marketing experience, bleeding events have been reported, predominantly in the elderly, in association with increases in prothrombin time in patients receiving drug1 concurrently with drug2",True,effect
DDI-DrugBank.d145.s0.e0,DDI-DrugBank.d145.s0.e1,Plasma levels of drug1 may become subtherapeutic during drug2,True,mechanism
DDI-DrugBank.d78.s0.e0,DDI-DrugBank.d78.s0.e1,"drug1, drug2, Metal Cations, drug0 drug0",False, 
DDI-DrugBank.d78.s0.e0,DDI-DrugBank.d78.s0.e2,"drug1, drug0, Metal Cations, drug2 drug0",False, 
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e1,"Administration of drug1 with drug2 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",False, 
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e2,"Administration of drug1 with drug0 containing drug2, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e3,"Administration of drug1 with drug0 containing drug0, drug2, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e4,"Administration of drug1 with drug0 containing drug0, drug0, or drug2, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e5,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug2, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e6,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug2, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e7,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug2 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e8,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug2 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e9,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug2, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e10,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug2 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e11,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug2) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug0",True,mechanism
DDI-DrugBank.d78.s1.e0,DDI-DrugBank.d78.s1.e12,"Administration of drug1 with drug0 containing drug0, drug0, or drug0, with drug0, with metal cations such as drug0, or with drug0 containing drug0 or drug0, or with formulations containing divalent and trivalent cations such as drug0 (drug0) chewable/buffered tablets or the pediatric powder for oral solution, may substantially interfere with the absorption of drug2",False, 
DDI-DrugBank.d78.s3.e0,DDI-DrugBank.d78.s3.e1,"drug1 drug2 drug0, like other drug0, may inhibit the metabolism of drug0 and drug0",False, 
DDI-DrugBank.d78.s3.e0,DDI-DrugBank.d78.s3.e2,"drug1 drug0 drug2, like other drug0, may inhibit the metabolism of drug0 and drug0",False, 
DDI-DrugBank.d78.s3.e2,DDI-DrugBank.d78.s3.e4,"drug0 drug0 drug1, like other drug0, may inhibit the metabolism of drug2 and drug0",True,mechanism
DDI-DrugBank.d78.s3.e2,DDI-DrugBank.d78.s3.e5,"drug0 drug0 drug1, like other drug0, may inhibit the metabolism of drug0 and drug2",True,mechanism
DDI-DrugBank.d78.s3.e3,DDI-DrugBank.d78.s3.e4,"drug0 drug0 drug0, like other drug1, may inhibit the metabolism of drug2 and drug0",True,mechanism
DDI-DrugBank.d78.s3.e3,DDI-DrugBank.d78.s3.e5,"drug0 drug0 drug0, like other drug1, may inhibit the metabolism of drug0 and drug2",True,mechanism
DDI-DrugBank.d78.s5.e0,DDI-DrugBank.d78.s5.e1,"In some patients, this may lead to reduced clearance, prolongation of plasma half-life, and enhanced effects of drug1 and drug2",False, 
DDI-DrugBank.d78.s6.e0,DDI-DrugBank.d78.s6.e1,drug1: drug2 is a competitive inhibitor of the metabolism of drug0,False, 
DDI-DrugBank.d78.s6.e0,DDI-DrugBank.d78.s6.e2,drug1: drug0 is a competitive inhibitor of the metabolism of drug2,False, 
DDI-DrugBank.d78.s6.e1,DDI-DrugBank.d78.s6.e2,drug0: drug1 is a competitive inhibitor of the metabolism of drug2,True,mechanism
DDI-DrugBank.d78.s7.e0,DDI-DrugBank.d78.s7.e1,Serum drug1 concentrations increase when drug2 is initiated in a patient maintained on drug0,False, 
DDI-DrugBank.d78.s7.e0,DDI-DrugBank.d78.s7.e2,Serum drug1 concentrations increase when drug0 is initiated in a patient maintained on drug2,False, 
DDI-DrugBank.d78.s7.e1,DDI-DrugBank.d78.s7.e2,Serum drug0 concentrations increase when drug1 is initiated in a patient maintained on drug2,True,mechanism
DDI-DrugBank.d78.s8.e0,DDI-DrugBank.d78.s8.e1,"When initiating a multi-day course of drug1 in a patient maintained on drug2, the drug0 maintenance dose should be halved for the period of concurrent use of drug0 and monitoring of serum drug0",False, 
DDI-DrugBank.d78.s8.e0,DDI-DrugBank.d78.s8.e2,"When initiating a multi-day course of drug1 in a patient maintained on drug0, the drug2 maintenance dose should be halved for the period of concurrent use of drug0 and monitoring of serum drug0",False, 
DDI-DrugBank.d78.s8.e2,DDI-DrugBank.d78.s8.e3,"When initiating a multi-day course of drug0 in a patient maintained on drug0, the drug1 maintenance dose should be halved for the period of concurrent use of drug2 and monitoring of serum drug0",True,advise
DDI-DrugBank.d78.s9.e0,DDI-DrugBank.d78.s9.e1,"drug1: In subjects receiving drug2, no significant change in clotting time was observed when drug0",False, 
DDI-DrugBank.d78.s9.e0,DDI-DrugBank.d78.s9.e2,"drug1: In subjects receiving drug0, no significant change in clotting time was observed when drug2",False, 
DDI-DrugBank.d78.s10.e0,DDI-DrugBank.d78.s10.e1,"However, because some drug1 have been reported to enhance the effects of drug2 or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a drug0 is administered with drug0",True,effect
DDI-DrugBank.d78.s10.e0,DDI-DrugBank.d78.s10.e2,"However, because some drug1 have been reported to enhance the effects of drug0 or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a drug2 is administered with drug0",False, 
DDI-DrugBank.d78.s10.e0,DDI-DrugBank.d78.s10.e3,"However, because some drug1 have been reported to enhance the effects of drug0 or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a drug0 is administered with drug2",False, 
DDI-DrugBank.d78.s10.e2,DDI-DrugBank.d78.s10.e3,"However, because some drug0 have been reported to enhance the effects of drug0 or its derivatives, prothrombin time or other suitable anticoagulation test should be monitored closely if a drug1 is administered with drug2",True,advise
DDI-DrugBank.d78.s11.e0,DDI-DrugBank.d78.s11.e1,Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of drug1 on drug2 indicates that drug0 inhibits drug0,False, 
DDI-DrugBank.d78.s11.e0,DDI-DrugBank.d78.s11.e2,Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of drug1 on drug0 indicates that drug2 inhibits drug0,False, 
DDI-DrugBank.d78.s11.e2,DDI-DrugBank.d78.s11.e3,Drugs Metabolized by Cytochrome P450 Enzymes The drug interaction study evaluating the effect of drug0 on drug0 indicates that drug1 inhibits drug2,True,mechanism
DDI-DrugBank.d78.s13.e0,DDI-DrugBank.d78.s13.e1,"substrates, in vitro data suggest similar effects of drug1 in CYP3A4 mediated metabolism and drug2",False, 
DDI-DrugBank.d78.s14.e0,DDI-DrugBank.d78.s14.e1,"In addition, other drug1 have been reported to decrease the CYP3A4-mediated metabolism of drug2",True,mechanism
DDI-DrugBank.d78.s16.e0,DDI-DrugBank.d78.s16.e1,"include drug1, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d78.s16.e0,DDI-DrugBank.d78.s16.e2,"include drug1, drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d78.s19.e0,DDI-DrugBank.d78.s19.e1,drug1 (drug2): The concomitant administration of a drug0 with a drug0,False, 
DDI-DrugBank.d78.s19.e0,DDI-DrugBank.d78.s19.e2,drug1 (drug0): The concomitant administration of a drug2 with a drug0,False, 
DDI-DrugBank.d78.s19.e2,DDI-DrugBank.d78.s19.e3,drug0 (drug0): The concomitant administration of a drug1 with a drug2,True,effect
DDI-DrugBank.d78.s20.e0,DDI-DrugBank.d78.s20.e1,"drug1: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with drug2 and an drug0",False, 
DDI-DrugBank.d78.s20.e0,DDI-DrugBank.d78.s20.e2,"drug1: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with drug0 and an drug2",False, 
DDI-DrugBank.d78.s20.e1,DDI-DrugBank.d78.s20.e2,"drug0: Disturbances of blood glucose, including hyperglycemia and hypoglycemia, have been reported in patients treated concomitantly with drug1 and an drug2",True,effect
DDI-DrugBank.d267.s0.e0,DDI-DrugBank.d267.s0.e1,Prior administration of drug1 has no clinically important effect on the neuromuscular blocking action of drug2,False, 
DDI-DrugBank.d267.s1.e0,DDI-DrugBank.d267.s1.e1,The use of drug1 before drug2 to attenuate some of the side effects of drug0,False, 
DDI-DrugBank.d267.s1.e0,DDI-DrugBank.d267.s1.e2,The use of drug1 before drug0 to attenuate some of the side effects of drug2,False, 
DDI-DrugBank.d267.s2.e0,DDI-DrugBank.d267.s2.e1,There are no clinical data on concomitant use of drug1 and other nondepolarizing drug2,False, 
DDI-DrugBank.d267.s3.e0,DDI-DrugBank.d267.s3.e1,"drug1, drug2, and drug0 decrease the ED50 of drug0",False, 
DDI-DrugBank.d267.s3.e0,DDI-DrugBank.d267.s3.e2,"drug1, drug0, and drug2 decrease the ED50 of drug0",False, 
DDI-DrugBank.d267.s3.e0,DDI-DrugBank.d267.s3.e3,"drug1, drug0, and drug0 decrease the ED50 of drug2",True,mechanism
DDI-DrugBank.d267.s3.e1,DDI-DrugBank.d267.s3.e3,"drug0, drug1, and drug0 decrease the ED50 of drug2",True,mechanism
DDI-DrugBank.d267.s3.e2,DDI-DrugBank.d267.s3.e3,"drug0, drug0, and drug1 decrease the ED50 of drug2",True,mechanism
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e1,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug2 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e2,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e3,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e4,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e5,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e6,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e7,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e8,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e9,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e10,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug2 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e11,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug2, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e12,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug2, drug0, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e13,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug2, and drug0",True,effect
DDI-DrugBank.d267.s5.e0,DDI-DrugBank.d267.s5.e14,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug2",True,effect
DDI-DrugBank.d267.s5.e1,DDI-DrugBank.d267.s5.e2,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug0 include certain drug1 (e. g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d267.s5.e1,DDI-DrugBank.d267.s5.e3,"Other drugs which may enhance the neuromuscular blocking action of nondepolarizing agents such as drug0 include certain drug1 (e. g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d267.s6.e0,DDI-DrugBank.d267.s6.e1,"As with some other drug1, the time of onset of neuromuscular block induced by drug2 is lengthened and the duration of block is shortened in patients receiving drug0 or drug0",False, 
DDI-DrugBank.d267.s6.e0,DDI-DrugBank.d267.s6.e2,"As with some other drug1, the time of onset of neuromuscular block induced by drug0 is lengthened and the duration of block is shortened in patients receiving drug2 or drug0",True,effect
DDI-DrugBank.d267.s6.e0,DDI-DrugBank.d267.s6.e3,"As with some other drug1, the time of onset of neuromuscular block induced by drug0 is lengthened and the duration of block is shortened in patients receiving drug0 or drug2",True,effect
DDI-DrugBank.d267.s6.e1,DDI-DrugBank.d267.s6.e2,"As with some other drug0, the time of onset of neuromuscular block induced by drug1 is lengthened and the duration of block is shortened in patients receiving drug2 or drug0",True,effect
DDI-DrugBank.d267.s6.e1,DDI-DrugBank.d267.s6.e3,"As with some other drug0, the time of onset of neuromuscular block induced by drug1 is lengthened and the duration of block is shortened in patients receiving drug0 or drug2",True,effect
DDI-DrugBank.d267.s6.e2,DDI-DrugBank.d267.s6.e3,"As with some other drug0, the time of onset of neuromuscular block induced by drug0 is lengthened and the duration of block is shortened in patients receiving drug1 or drug2",False, 
DDI-DrugBank.d260.s0.e0,DDI-DrugBank.d260.s0.e1,"drug1 : drug2 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",False, 
DDI-DrugBank.d260.s0.e0,DDI-DrugBank.d260.s0.e2,"drug1 : drug0 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",False, 
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e2,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e3,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e4,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e5,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e6,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e7,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e8,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e9,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e10,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e11,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e12,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2, drug0 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e13,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug2 agents, drug0, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e14,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug2, and drug0",True,mechanism
DDI-DrugBank.d260.s0.e1,DDI-DrugBank.d260.s0.e15,"drug0 : drug1 is known to interact with the metabolism or renal tubular excretion of many drugs (e.g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0 agents, drug0, and drug2",True,mechanism
DDI-DrugBank.d260.s2.e0,DDI-DrugBank.d260.s2.e1,drug1 should either be temporarily discontinued or decreased by 50% when coadministered with drug2 on the day of drug0,True,advise
DDI-DrugBank.d260.s2.e0,DDI-DrugBank.d260.s2.e2,drug1 should either be temporarily discontinued or decreased by 50% when coadministered with drug0 on the day of drug2,False, 
DDI-DrugBank.d260.s2.e1,DDI-DrugBank.d260.s2.e2,drug0 should either be temporarily discontinued or decreased by 50% when coadministered with drug1 on the day of drug2,False, 
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e1,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug2 (e.g., drug0, drug0, and drug0), drug0, drug0, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e2,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug2, drug0, and drug0), drug0, drug0, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e3,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug2, and drug0), drug0, drug0, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e4,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug2), drug0, drug0, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e5,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug0), drug2, drug0, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e6,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug0), drug0, drug2, intravenous drug0, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e7,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug0), drug0, drug0, intravenous drug2, drug0, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e8,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug0), drug0, drug0, intravenous drug0, drug2, and drug0",True,advise
DDI-DrugBank.d260.s3.e0,DDI-DrugBank.d260.s3.e9,"Nephrotoxic agents : Concomitant administration of drug1 and agents with nephrotoxic potential [e.g., intravenous drug0 (e.g., drug0, drug0, and drug0), drug0, drug0, intravenous drug0, drug0, and drug2",True,advise
DDI-DrugBank.d260.s3.e1,DDI-DrugBank.d260.s3.e2,"Nephrotoxic agents : Concomitant administration of drug0 and agents with nephrotoxic potential [e.g., intravenous drug1 (e.g., drug2, drug0, and drug0), drug0, drug0, intravenous drug0, drug0, and drug0",False, 
DDI-DrugBank.d260.s3.e1,DDI-DrugBank.d260.s3.e3,"Nephrotoxic agents : Concomitant administration of drug0 and agents with nephrotoxic potential [e.g., intravenous drug1 (e.g., drug0, drug2, and drug0), drug0, drug0, intravenous drug0, drug0, and drug0",False, 
DDI-DrugBank.d133.s0.e0,DDI-DrugBank.d133.s0.e1,"Co-administration of drug1 and drug2 or other agents interfering with neuromuscular transmission (e.g., drug0) should only be performed with caution as the effect of the drug0",True,advise
DDI-DrugBank.d133.s0.e0,DDI-DrugBank.d133.s0.e2,"Co-administration of drug1 and drug0 or other agents interfering with neuromuscular transmission (e.g., drug2) should only be performed with caution as the effect of the drug0",True,advise
DDI-DrugBank.d133.s0.e0,DDI-DrugBank.d133.s0.e3,"Co-administration of drug1 and drug0 or other agents interfering with neuromuscular transmission (e.g., drug0) should only be performed with caution as the effect of the drug2",False, 
DDI-DrugBank.d133.s0.e1,DDI-DrugBank.d133.s0.e2,"Co-administration of drug0 and drug1 or other agents interfering with neuromuscular transmission (e.g., drug2) should only be performed with caution as the effect of the drug0",False, 
DDI-DrugBank.d133.s2.e0,DDI-DrugBank.d133.s2.e1,Excessive neuromuscular weakness may be exacerbated by administration of another drug1 prior to the resolution of the effects of a previously administered drug2,True,effect
DDI-DrugBank.d477.s0.e0,DDI-DrugBank.d477.s0.e1,Hypertensive crises have resulted when drug1 have been used concomitantly within14 days following use of drug2,True,effect
DDI-DrugBank.d477.s1.e0,DDI-DrugBank.d477.s1.e1,drug1 should not be used concomitantly with other drug2,True,advise
DDI-DrugBank.d477.s2.e0,DDI-DrugBank.d477.s2.e1,drug1 may decrease the hypotensive effect of drug2,True,effect
DDI-DrugBank.d477.s3.e0,DDI-DrugBank.d477.s3.e1,drug1 may enhance the effects of drug2,True,effect
DDI-DrugBank.d477.s5.e0,DDI-DrugBank.d477.s5.e1,drug1 agents decrease blood levels and increase excretion of drug2,True,mechanism
DDI-DrugBank.d322.s0.e0,DDI-DrugBank.d322.s0.e1,"drug1, drug2, and drug0 may increase anticholinergic effect of drug0",False, 
DDI-DrugBank.d322.s0.e0,DDI-DrugBank.d322.s0.e2,"drug1, drug0, and drug2 may increase anticholinergic effect of drug0",False, 
DDI-DrugBank.d322.s0.e0,DDI-DrugBank.d322.s0.e3,"drug1, drug0, and drug0 may increase anticholinergic effect of drug2",True,effect
DDI-DrugBank.d322.s0.e1,DDI-DrugBank.d322.s0.e3,"drug0, drug1, and drug0 may increase anticholinergic effect of drug2",True,effect
DDI-DrugBank.d322.s0.e2,DDI-DrugBank.d322.s0.e3,"drug0, drug0, and drug1 may increase anticholinergic effect of drug2",True,effect
DDI-DrugBank.d322.s1.e0,DDI-DrugBank.d322.s1.e1,"drug1 may decrease the effect of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d322.s1.e0,DDI-DrugBank.d322.s1.e2,"drug1 may decrease the effect of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d322.s1.e0,DDI-DrugBank.d322.s1.e3,"drug1 may decrease the effect of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d322.s1.e1,DDI-DrugBank.d322.s1.e2,"drug0 may decrease the effect of drug1, drug2, and drug0",False, 
DDI-DrugBank.d322.s1.e1,DDI-DrugBank.d322.s1.e3,"drug0 may decrease the effect of drug1, drug0, and drug2",False, 
DDI-DrugBank.d351.s0.e0,DDI-DrugBank.d351.s0.e1,"drug1: As with other drug2, renal excretion of drug0 is inhibited by drug0 and resulted in an approximate 80% increase in the AUC for drug0",False, 
DDI-DrugBank.d351.s0.e0,DDI-DrugBank.d351.s0.e2,"drug1: As with other drug0, renal excretion of drug2 is inhibited by drug0 and resulted in an approximate 80% increase in the AUC for drug0",False, 
DDI-DrugBank.d351.s0.e1,DDI-DrugBank.d351.s0.e3,"drug0: As with other drug1, renal excretion of drug0 is inhibited by drug2 and resulted in an approximate 80% increase in the AUC for drug0",True,mechanism
DDI-DrugBank.d351.s0.e2,DDI-DrugBank.d351.s0.e3,"drug0: As with other drug0, renal excretion of drug1 is inhibited by drug2 and resulted in an approximate 80% increase in the AUC for drug0",True,mechanism
DDI-DrugBank.d123.s0.e0,DDI-DrugBank.d123.s0.e1,"Some drug1, including drug2, have also been shown to interfere with the metabolism of drug0",False, 
DDI-DrugBank.d123.s0.e0,DDI-DrugBank.d123.s0.e2,"Some drug1, including drug0, have also been shown to interfere with the metabolism of drug2",True,mechanism
DDI-DrugBank.d123.s0.e1,DDI-DrugBank.d123.s0.e2,"Some drug0, including drug1, have also been shown to interfere with the metabolism of drug2",True,mechanism
DDI-DrugBank.d123.s2.e0,DDI-DrugBank.d123.s2.e1,"Some drug1, including drug2, have been associated with transient elevations in serum creatinine in patients receiving drug0",False, 
DDI-DrugBank.d123.s2.e0,DDI-DrugBank.d123.s2.e2,"Some drug1, including drug0, have been associated with transient elevations in serum creatinine in patients receiving drug2",True,effect
DDI-DrugBank.d123.s2.e1,DDI-DrugBank.d123.s2.e2,"Some drug0, including drug1, have been associated with transient elevations in serum creatinine in patients receiving drug2",True,effect
DDI-DrugBank.d123.s3.e0,DDI-DrugBank.d123.s3.e1,drug1: The concomitant administration of drug2 with the drug0 drug0,False, 
DDI-DrugBank.d123.s3.e0,DDI-DrugBank.d123.s3.e2,drug1: The concomitant administration of drug0 with the drug2 drug0,False, 
DDI-DrugBank.d123.s3.e1,DDI-DrugBank.d123.s3.e2,drug0: The concomitant administration of drug1 with the drug2 drug0,True,effect
DDI-DrugBank.d123.s3.e1,DDI-DrugBank.d123.s3.e3,drug0: The concomitant administration of drug1 with the drug0 drug2,True,effect
DDI-DrugBank.d123.s4.e0,DDI-DrugBank.d123.s4.e1,drug1: drug2 appear to have no significant effect on the bioavailability of drug0,False, 
DDI-DrugBank.d123.s4.e0,DDI-DrugBank.d123.s4.e2,drug1: drug0 appear to have no significant effect on the bioavailability of drug2,False, 
DDI-DrugBank.d123.s5.e0,DDI-DrugBank.d123.s5.e1,"drug1 Renal tubular transport of drug2 may be inhibited by concomitant administration of drug0, potentially leading to increased plasma levels of drug0",False, 
DDI-DrugBank.d123.s5.e0,DDI-DrugBank.d123.s5.e2,"drug1 Renal tubular transport of drug0 may be inhibited by concomitant administration of drug2, potentially leading to increased plasma levels of drug0",False, 
DDI-DrugBank.d123.s5.e1,DDI-DrugBank.d123.s5.e2,"drug0 Renal tubular transport of drug1 may be inhibited by concomitant administration of drug2, potentially leading to increased plasma levels of drug0",True,mechanism
DDI-DrugBank.d123.s7.e0,DDI-DrugBank.d123.s7.e1,"Therefore, patients under drug1 therapy should be carefully monitored when concomitant drug2",True,advise
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e1,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug2, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",False, 
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e2,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug2 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e3,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug2 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e4,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug2, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e5,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug2, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e6,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug2 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e7,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug2, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e8,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug2, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e9,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug2 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e0,DDI-DrugBank.d123.s8.e10,"Multivalent Cation-Containing Products: Concurrent administration of a drug1, including drug0, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug2",False, 
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e2,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug2 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e3,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug2 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e4,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug2, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e5,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug2, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e6,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug2 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e7,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug2, drug0, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e8,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug2, or drug0 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e9,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug2 may substantially decrease the absorption of drug0",True,mechanism
DDI-DrugBank.d123.s8.e1,DDI-DrugBank.d123.s8.e10,"Multivalent Cation-Containing Products: Concurrent administration of a drug0, including drug1, with multivalent cation-containing products such as drug0 or drug0 drug0, drug0, drug0 chewable/buffered tablets or pediatric powder, or products containing drug0, drug0, or drug0 may substantially decrease the absorption of drug2",True,mechanism
DDI-DrugBank.d123.s10.e0,DDI-DrugBank.d123.s10.e1,"This time window is different than for other oral formulations of drug1, which are usually administered 2 hours before or 6 hours after drug2",True,advise
DDI-DrugBank.d123.s11.e0,DDI-DrugBank.d123.s11.e1,drug1 (but not drug2): These drugs in combination with very high doses of drug0,False, 
DDI-DrugBank.d123.s11.e0,DDI-DrugBank.d123.s11.e2,drug1 (but not drug0): These drugs in combination with very high doses of drug2,False, 
DDI-DrugBank.d123.s12.e0,DDI-DrugBank.d123.s12.e1,drug1: The rate and extent of absorption of drug2 was bioequivalent when drug0 was given alone or when drug0 was given 2 hours after drug0,False, 
DDI-DrugBank.d123.s12.e0,DDI-DrugBank.d123.s12.e2,drug1: The rate and extent of absorption of drug0 was bioequivalent when drug2 was given alone or when drug0 was given 2 hours after drug0,False, 
DDI-DrugBank.d123.s13.e0,DDI-DrugBank.d123.s13.e1,drug1 should be taken as directed and drug2,False, 
DDI-DrugBank.d123.s14.e0,DDI-DrugBank.d123.s14.e1,drug1: Altered serum levels of drug2 (increased and decreased) have been reported in patients receiving concomitant drug0,False, 
DDI-DrugBank.d123.s14.e0,DDI-DrugBank.d123.s14.e2,drug1: Altered serum levels of drug0 (increased and decreased) have been reported in patients receiving concomitant drug2,False, 
DDI-DrugBank.d123.s14.e1,DDI-DrugBank.d123.s14.e2,drug0: Altered serum levels of drug1 (increased and decreased) have been reported in patients receiving concomitant drug2,True,mechanism
DDI-DrugBank.d123.s15.e0,DDI-DrugBank.d123.s15.e1,drug1: drug2 interferes with renal tubular secretion of drug0 and produces an increase in the level of drug0,False, 
DDI-DrugBank.d123.s15.e0,DDI-DrugBank.d123.s15.e2,drug1: drug0 interferes with renal tubular secretion of drug2 and produces an increase in the level of drug0,False, 
DDI-DrugBank.d123.s15.e1,DDI-DrugBank.d123.s15.e2,drug0: drug1 interferes with renal tubular secretion of drug2 and produces an increase in the level of drug0,True,mechanism
DDI-DrugBank.d123.s15.e1,DDI-DrugBank.d123.s15.e3,drug0: drug1 interferes with renal tubular secretion of drug0 and produces an increase in the level of drug2,True,mechanism
DDI-DrugBank.d123.s16.e0,DDI-DrugBank.d123.s16.e1,"drug1: As with some other drug2, concurrent administration of drug0 with drug0 may lead to elevated serum concentrations of drug0",False, 
DDI-DrugBank.d123.s16.e0,DDI-DrugBank.d123.s16.e2,"drug1: As with some other drug0, concurrent administration of drug2 with drug0 may lead to elevated serum concentrations of drug0",False, 
DDI-DrugBank.d123.s16.e1,DDI-DrugBank.d123.s16.e3,"drug0: As with some other drug1, concurrent administration of drug0 with drug2 may lead to elevated serum concentrations of drug0",True,mechanism
DDI-DrugBank.d123.s16.e2,DDI-DrugBank.d123.s16.e3,"drug0: As with some other drug0, concurrent administration of drug1 with drug2 may lead to elevated serum concentrations of drug0",True,mechanism
DDI-DrugBank.d123.s19.e0,DDI-DrugBank.d123.s19.e1,drug1: drug2 have been reported to enhance the effects of the oral drug0 drug0,False, 
DDI-DrugBank.d123.s19.e0,DDI-DrugBank.d123.s19.e2,drug1: drug0 have been reported to enhance the effects of the oral drug2 drug0,False, 
DDI-DrugBank.d123.s19.e1,DDI-DrugBank.d123.s19.e3,drug0: drug1 have been reported to enhance the effects of the oral drug0 drug2,True,effect
DDI-DrugBank.d23.s0.e0,DDI-DrugBank.d23.s0.e1,drug1 may augment the activity of other drug2,True,effect
DDI-DrugBank.d514.s0.e0,DDI-DrugBank.d514.s0.e1,drug1 are strong drug2,False, 
DDI-DrugBank.d514.s1.e0,DDI-DrugBank.d514.s1.e1,"In combination with other drug1, drug2",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e1,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug2, including drug0, drug0 such as drug0 (drug0), and, to a rising degree, drug0",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e2,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug0, including drug2, drug0 such as drug0 (drug0), and, to a rising degree, drug0",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e3,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug0, including drug0, drug2 such as drug0 (drug0), and, to a rising degree, drug0",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e4,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug0, including drug0, drug0 such as drug2 (drug0), and, to a rising degree, drug0",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e5,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug0, including drug0, drug0 such as drug0 (drug2), and, to a rising degree, drug0",True,effect
DDI-DrugBank.d514.s2.e0,DDI-DrugBank.d514.s2.e6,"Toxicology studies of drug1-related deaths reveal frequent involvement of other drug0, including drug0, drug0 such as drug0 (drug0), and, to a rising degree, drug2",True,effect
DDI-DrugBank.d514.s2.e1,DDI-DrugBank.d514.s2.e2,"Toxicology studies of drug0-related deaths reveal frequent involvement of other drug1, including drug2, drug0 such as drug0 (drug0), and, to a rising degree, drug0",False, 
DDI-DrugBank.d514.s2.e1,DDI-DrugBank.d514.s2.e3,"Toxicology studies of drug0-related deaths reveal frequent involvement of other drug1, including drug0, drug2 such as drug0 (drug0), and, to a rising degree, drug0",False, 
DDI-DrugBank.d514.s3.e0,DDI-DrugBank.d514.s3.e1,"Ironically, drug1 are often used in the treatment of drug2",False, 
DDI-DrugBank.d514.s4.e0,DDI-DrugBank.d514.s4.e1,drug1 sometimes proves to be fatal when used in combination with drug2,True,effect
DDI-DrugBank.d342.s0.e0,DDI-DrugBank.d342.s0.e1,"This drug may interact with drug1 or other drug2 (may potentiate the CNS depressant effects of either these medications or drug0), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d342.s0.e0,DDI-DrugBank.d342.s0.e2,"This drug may interact with drug1 or other drug0 (may potentiate the CNS depressant effects of either these medications or drug2), drug0 or other medications with anticholinergic activity (anticholinergic effects may be potentiated when these medications are used concurrently with drug0), and drug0 (concurrent use with drug0 may prolong and intensify the anticholinergic and CNS depressant effects of drug0",False, 
DDI-DrugBank.d317.s4.e0,DDI-DrugBank.d317.s4.e1,"decreased levels of anti-factor Xa and drug1, decreased drug2",False, 
DDI-DrugBank.d317.s5.e0,DDI-DrugBank.d317.s5.e1,increased levels of drug1 and drug2,False, 
DDI-DrugBank.d317.s13.e0,DDI-DrugBank.d317.s13.e1,"Other binding proteins may be elevated in serum, (i.e., corticosteroid binding globulin (CBG), sex hormone binding globulin (SHBG)) leading to increased total circulating drug1 and drug2",False, 
DDI-DrugBank.d273.s0.e0,DDI-DrugBank.d273.s0.e1,Drug-Drug Interactions: The pharmacokinetic and pharmacodynamic interactions between drug1 and other drug2,False, 
DDI-DrugBank.d273.s1.e0,DDI-DrugBank.d273.s1.e1,"However, interactions may be expected, and drug1 should NOT be used in combination with other drug2",True,advise
DDI-DrugBank.d422.s0.e0,DDI-DrugBank.d422.s0.e1,"Catecholamine-depleting drugs, e.g., drug1, may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d422.s1.e0,DDI-DrugBank.d422.s1.e1,Patients treated concurrently with drug1 (drug2,False, 
DDI-DrugBank.d422.s2.e0,DDI-DrugBank.d422.s2.e1,A study of interaction between drug1 and drug2 showed that concomitant administration of drug0 and drug0 does not alter drug0,False, 
DDI-DrugBank.d422.s2.e0,DDI-DrugBank.d422.s2.e2,A study of interaction between drug1 and drug0 showed that concomitant administration of drug2 and drug0 does not alter drug0,False, 
DDI-DrugBank.d422.s3.e0,DDI-DrugBank.d422.s3.e1,drug1 concentrations were equivocally higher when given with drug2,True,mechanism
DDI-DrugBank.d422.s4.e0,DDI-DrugBank.d422.s4.e1,"When drug1 and drug2 were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in drug0",True,mechanism
DDI-DrugBank.d422.s4.e0,DDI-DrugBank.d422.s4.e2,"When drug1 and drug0 were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in drug2",False, 
DDI-DrugBank.d422.s4.e1,DDI-DrugBank.d422.s4.e2,"When drug0 and drug1 were concomitantly administered intravenously to normal volunteers, there was a 10-20% increase in drug2",False, 
DDI-DrugBank.d422.s5.e0,DDI-DrugBank.d422.s5.e1,drug1 did not affect drug2,False, 
DDI-DrugBank.d422.s6.e0,DDI-DrugBank.d422.s6.e1,"When intravenous drug1 and drug2 were concomitantly administered in normal subjects, no effect on drug0 blood levels was seen, but drug0 steady-state blood levels were increased by 46% in the presence of drug0",False, 
DDI-DrugBank.d422.s6.e0,DDI-DrugBank.d422.s6.e2,"When intravenous drug1 and drug0 were concomitantly administered in normal subjects, no effect on drug2 blood levels was seen, but drug0 steady-state blood levels were increased by 46% in the presence of drug0",False, 
DDI-DrugBank.d422.s6.e3,DDI-DrugBank.d422.s6.e4,"When intravenous drug0 and drug0 were concomitantly administered in normal subjects, no effect on drug0 blood levels was seen, but drug1 steady-state blood levels were increased by 46% in the presence of drug2",True,mechanism
DDI-DrugBank.d422.s8.e0,DDI-DrugBank.d422.s8.e1,The effect of drug1 on the duration of drug2,False, 
DDI-DrugBank.d422.s9.e0,DDI-DrugBank.d422.s9.e1,The onset of neuromuscular blockade by drug1 was unaffected by drug2,True,effect
DDI-DrugBank.d422.s10.e0,DDI-DrugBank.d422.s10.e1,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug1 should be titrated with caution in patients being treated concurrently with drug2, drug0, drug0 or drug0",True,advise
DDI-DrugBank.d422.s10.e0,DDI-DrugBank.d422.s10.e2,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug1 should be titrated with caution in patients being treated concurrently with drug0, drug2, drug0 or drug0",True,advise
DDI-DrugBank.d422.s10.e0,DDI-DrugBank.d422.s10.e3,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug1 should be titrated with caution in patients being treated concurrently with drug0, drug0, drug2 or drug0",True,advise
DDI-DrugBank.d422.s10.e0,DDI-DrugBank.d422.s10.e4,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug1 should be titrated with caution in patients being treated concurrently with drug0, drug0, drug0 or drug2",True,advise
DDI-DrugBank.d422.s10.e1,DDI-DrugBank.d422.s10.e2,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug0 should be titrated with caution in patients being treated concurrently with drug1, drug2, drug0 or drug0",False, 
DDI-DrugBank.d422.s10.e1,DDI-DrugBank.d422.s10.e3,"Although the interactions observed in these studies do not appear to be of major clinical importance, drug0 should be titrated with caution in patients being treated concurrently with drug1, drug0, drug2 or drug0",False, 
DDI-DrugBank.d422.s13.e0,DDI-DrugBank.d422.s13.e1,Caution should be exercised when considering the use of drug1 and drug2,True,advise
DDI-DrugBank.d422.s15.e0,DDI-DrugBank.d422.s15.e1,"Additionally, drug1 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug2, drug0, and drug0",True,advise
DDI-DrugBank.d422.s15.e0,DDI-DrugBank.d422.s15.e2,"Additionally, drug1 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug0, drug2, and drug0",True,advise
DDI-DrugBank.d422.s15.e0,DDI-DrugBank.d422.s15.e3,"Additionally, drug1 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug0, drug0, and drug2",True,advise
DDI-DrugBank.d422.s15.e1,DDI-DrugBank.d422.s15.e2,"Additionally, drug0 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug1, drug2, and drug0",False, 
DDI-DrugBank.d422.s15.e1,DDI-DrugBank.d422.s15.e3,"Additionally, drug0 should not be used to control supraventricular tachycardia in the presence of agents which are vasoconstrictive and inotropic such as drug1, drug0, and drug2",False, 
DDI-DrugBank.d293.s0.e0,DDI-DrugBank.d293.s0.e1,"May interact with thyroid medication (e.g., drug1), drug2-containing products, drug0, drug0 (e.g., drug0, drug0), and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d293.s0.e0,DDI-DrugBank.d293.s0.e2,"May interact with thyroid medication (e.g., drug1), drug0-containing products, drug2, drug0 (e.g., drug0, drug0), and drug0 (e.g., drug0, drug0",False, 
DDI-DrugBank.d198.s4.e0,DDI-DrugBank.d198.s4.e1,drug1 (400 mg b.i.d.) had no effect on drug2 bioavailability (AUC) and maximum concentration (Cmax) of drug0 when co-administered with 20 mg drug0,False, 
DDI-DrugBank.d198.s4.e0,DDI-DrugBank.d198.s4.e2,drug1 (400 mg b.i.d.) had no effect on drug0 bioavailability (AUC) and maximum concentration (Cmax) of drug2 when co-administered with 20 mg drug0,False, 
DDI-DrugBank.d198.s5.e0,DDI-DrugBank.d198.s5.e1,drug1 (500 mg t.i.d) produced a 4-fold increase in drug2 AUC and a 3-fold increase in Cmax when co-administered with drug0,True,mechanism
DDI-DrugBank.d198.s5.e0,DDI-DrugBank.d198.s5.e2,drug1 (500 mg t.i.d) produced a 4-fold increase in drug0 AUC and a 3-fold increase in Cmax when co-administered with drug2,False, 
DDI-DrugBank.d198.s5.e1,DDI-DrugBank.d198.s5.e2,drug0 (500 mg t.i.d) produced a 4-fold increase in drug1 AUC and a 3-fold increase in Cmax when co-administered with drug2,False, 
DDI-DrugBank.d198.s6.e0,DDI-DrugBank.d198.s6.e1,It is recommended not to exceed a single 5 mg dose of drug1 in a 24-hour period when used in combination with drug2,True,advise
DDI-DrugBank.d198.s7.e0,DDI-DrugBank.d198.s7.e1,drug1 (200 mg once daily) produced a 10-fold increase in drug2 AUC and a 4-fold increase in Cmax when co-administered with drug0,True,mechanism
DDI-DrugBank.d198.s7.e0,DDI-DrugBank.d198.s7.e2,drug1 (200 mg once daily) produced a 10-fold increase in drug0 AUC and a 4-fold increase in Cmax when co-administered with drug2,False, 
DDI-DrugBank.d198.s7.e1,DDI-DrugBank.d198.s7.e2,drug0 (200 mg once daily) produced a 10-fold increase in drug1 AUC and a 4-fold increase in Cmax when co-administered with drug2,False, 
DDI-DrugBank.d198.s8.e0,DDI-DrugBank.d198.s8.e1,A 5-mg drug1 dose should not be exceeded when used in combination with 200 mg once daily drug2,True,advise
DDI-DrugBank.d198.s9.e0,DDI-DrugBank.d198.s9.e1,"Since higher doses of drug1 (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of drug2 should not be exceeded in a 24-hour period when used in combination with drug0",False, 
DDI-DrugBank.d198.s9.e0,DDI-DrugBank.d198.s9.e2,"Since higher doses of drug1 (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of drug0 should not be exceeded in a 24-hour period when used in combination with drug2",False, 
DDI-DrugBank.d198.s9.e1,DDI-DrugBank.d198.s9.e2,"Since higher doses of drug0 (400 mg daily) may result in higher increases in Cmax and AUC, a single 2.5 mg dose of drug1 should not be exceeded in a 24-hour period when used in combination with drug2",True,advise
DDI-DrugBank.d198.s10.e0,DDI-DrugBank.d198.s10.e1,"drug1: drug2 (800 mg t.i.d.) co-administered with drug0 10 mg resulted in a 16-fold increase in drug0 AUC, a 7-fold increase in drug0 Cmax and a 2-fold increase in drug0",False, 
DDI-DrugBank.d198.s10.e0,DDI-DrugBank.d198.s10.e2,"drug1: drug0 (800 mg t.i.d.) co-administered with drug2 10 mg resulted in a 16-fold increase in drug0 AUC, a 7-fold increase in drug0 Cmax and a 2-fold increase in drug0",False, 
DDI-DrugBank.d198.s10.e1,DDI-DrugBank.d198.s10.e2,"drug0: drug1 (800 mg t.i.d.) co-administered with drug2 10 mg resulted in a 16-fold increase in drug0 AUC, a 7-fold increase in drug0 Cmax and a 2-fold increase in drug0",True,mechanism
DDI-DrugBank.d198.s11.e0,DDI-DrugBank.d198.s11.e1,It is recommended not to exceed a single 2.5 mg drug1 dose in a 24-hour period when used in combination with drug2,True,advise
DDI-DrugBank.d198.s12.e0,DDI-DrugBank.d198.s12.e1,drug1 (600 mg b.i.d.) co-administered with drug2 5 mg resulted in a 49-fold increase in drug0 AUC and a 13-fold increase in drug0,True,mechanism
DDI-DrugBank.d198.s12.e0,DDI-DrugBank.d198.s12.e2,drug1 (600 mg b.i.d.) co-administered with drug0 5 mg resulted in a 49-fold increase in drug2 AUC and a 13-fold increase in drug0,False, 
DDI-DrugBank.d198.s12.e0,DDI-DrugBank.d198.s12.e3,drug1 (600 mg b.i.d.) co-administered with drug0 5 mg resulted in a 49-fold increase in drug0 AUC and a 13-fold increase in drug2,False, 
DDI-DrugBank.d198.s13.e0,DDI-DrugBank.d198.s13.e1,The interaction is a consequence of blocking hepatic metabolism of drug1 by drug2,True,mechanism
DDI-DrugBank.d198.s14.e0,DDI-DrugBank.d198.s14.e1,drug1 significantly prolonged the half-life of drug2,True,mechanism
DDI-DrugBank.d198.s15.e0,DDI-DrugBank.d198.s15.e1,"Consequently, it is recommended not to exceed a single 2.5 mg drug1 dose in a 72-hour period when used in combination with drug2",True,advise
DDI-DrugBank.d198.s16.e0,DDI-DrugBank.d198.s16.e1,"Other Drug Interactions: No pharmacokinetic interactions were observed between drug1 and the following drugs: drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d198.s16.e0,DDI-DrugBank.d198.s16.e2,"Other Drug Interactions: No pharmacokinetic interactions were observed between drug1 and the following drugs: drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d198.s17.e0,DDI-DrugBank.d198.s17.e1,"In the drug1 study, drug2",False, 
DDI-DrugBank.d198.s22.e0,DDI-DrugBank.d198.s22.e1,"In vivo studies: drug1: The blood pressure lowering effects of sublingual drug2 (0.4 mg) taken 1 and 4 hours after drug0 and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of drug0",False, 
DDI-DrugBank.d198.s22.e0,DDI-DrugBank.d198.s22.e2,"In vivo studies: drug1: The blood pressure lowering effects of sublingual drug0 (0.4 mg) taken 1 and 4 hours after drug2 and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of drug0",False, 
DDI-DrugBank.d198.s22.e1,DDI-DrugBank.d198.s22.e2,"In vivo studies: drug0: The blood pressure lowering effects of sublingual drug1 (0.4 mg) taken 1 and 4 hours after drug2 and increases in heart rate when taken at 1, 4 and 8 hours were potentiated by a 20 mg dose of drug0",True,mechanism
DDI-DrugBank.d198.s23.e0,DDI-DrugBank.d198.s23.e1,These effects were not observed when drug1 20 mg was taken 24 hours before the drug2,False, 
DDI-DrugBank.d198.s24.e0,DDI-DrugBank.d198.s24.e1,"Potentiation of the hypotensive effects of drug1 for patients with ischemic heart disease has not been evaluated, and concomitant use of drug2 and drug0",False, 
DDI-DrugBank.d198.s24.e0,DDI-DrugBank.d198.s24.e2,"Potentiation of the hypotensive effects of drug1 for patients with ischemic heart disease has not been evaluated, and concomitant use of drug0 and drug2",False, 
DDI-DrugBank.d198.s24.e1,DDI-DrugBank.d198.s24.e2,"Potentiation of the hypotensive effects of drug0 for patients with ischemic heart disease has not been evaluated, and concomitant use of drug1 and drug2",True,advise
DDI-DrugBank.d198.s25.e0,DDI-DrugBank.d198.s25.e1,"drug1: drug2 20 mg, when co-administered with slow-release drug0 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of drug0",False, 
DDI-DrugBank.d198.s25.e0,DDI-DrugBank.d198.s25.e2,"drug1: drug0 20 mg, when co-administered with slow-release drug2 30 mg or 60 mg once daily, did not affect the relative bioavailability (AUC) or maximum concentration (Cmax) of drug0",False, 
DDI-DrugBank.d198.s26.e0,DDI-DrugBank.d198.s26.e1,drug1 did not alter the plasma levels of drug2,False, 
DDI-DrugBank.d198.s27.e0,DDI-DrugBank.d198.s27.e1,"In these patients whose hypertension was controlled with drug1, drug2",True,effect
DDI-DrugBank.d198.s28.e0,DDI-DrugBank.d198.s28.e1,drug1: When drug2 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of drug0,False, 
DDI-DrugBank.d198.s28.e0,DDI-DrugBank.d198.s28.e2,drug1: When drug0 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of drug2,False, 
DDI-DrugBank.d198.s28.e1,DDI-DrugBank.d198.s28.e2,drug0: When drug1 10 or 20 mg was given to healthy volunteers either simultaneously or 6 hours after a 10 mg dose of drug2,True,effect
DDI-DrugBank.d198.s29.e0,DDI-DrugBank.d198.s29.e1,With simultaneous dosing of drug1 10 mg and drug2,True,effect
DDI-DrugBank.d198.s30.e0,DDI-DrugBank.d198.s30.e1,With simultaneous dosing of drug1 20 mg and drug2,True,effect
DDI-DrugBank.d198.s31.e0,DDI-DrugBank.d198.s31.e1,"When drug1 dosing was separated from drug2 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of drug0",True,effect
DDI-DrugBank.d198.s31.e0,DDI-DrugBank.d198.s31.e2,"When drug1 dosing was separated from drug0 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of drug2",False, 
DDI-DrugBank.d198.s31.e1,DDI-DrugBank.d198.s31.e2,"When drug0 dosing was separated from drug1 10 mg by 6 hours, 7 of 28 subjects who received 20 mg of drug2",False, 
DDI-DrugBank.d198.s32.e0,DDI-DrugBank.d198.s32.e1,"In a similar study with drug1 in healthy volunteers, 1 of 24 subjects dosed with drug2 20 mg and drug0",False, 
DDI-DrugBank.d198.s32.e0,DDI-DrugBank.d198.s32.e2,"In a similar study with drug1 in healthy volunteers, 1 of 24 subjects dosed with drug0 20 mg and drug2",False, 
DDI-DrugBank.d198.s32.e1,DDI-DrugBank.d198.s32.e2,"In a similar study with drug0 in healthy volunteers, 1 of 24 subjects dosed with drug1 20 mg and drug2",True,effect
DDI-DrugBank.d198.s33.e0,DDI-DrugBank.d198.s33.e1,Two of 16 subjects dosed simultaneously with drug1 10 mg and drug2,True,effect
DDI-DrugBank.d198.s34.e0,DDI-DrugBank.d198.s34.e1,The administration of lower doses of drug1 with drug2,False, 
DDI-DrugBank.d198.s35.e0,DDI-DrugBank.d198.s35.e1,"Based on these data, drug1 should not be used in patients on drug2",True,advise
DDI-DrugBank.d198.s36.e0,DDI-DrugBank.d198.s36.e1,"drug1 and drug2: Upon concomitant administration of 5 mg of drug0 with 600 mg BID drug0, the Cmax and AUC of drug0",False, 
DDI-DrugBank.d198.s36.e0,DDI-DrugBank.d198.s36.e2,"drug1 and drug0: Upon concomitant administration of 5 mg of drug2 with 600 mg BID drug0, the Cmax and AUC of drug0",False, 
DDI-DrugBank.d198.s36.e2,DDI-DrugBank.d198.s36.e3,"drug0 and drug0: Upon concomitant administration of 5 mg of drug1 with 600 mg BID drug2, the Cmax and AUC of drug0",True,mechanism
DDI-DrugBank.d198.s37.e0,DDI-DrugBank.d198.s37.e1,"Upon administration of 10 mg of drug1 with 800 mg TID drug2, the Cmax and AUC of drug0",True,mechanism
DDI-DrugBank.d198.s37.e0,DDI-DrugBank.d198.s37.e2,"Upon administration of 10 mg of drug1 with 800 mg TID drug0, the Cmax and AUC of drug2",False, 
DDI-DrugBank.d198.s37.e1,DDI-DrugBank.d198.s37.e2,"Upon administration of 10 mg of drug0 with 800 mg TID drug1, the Cmax and AUC of drug2",False, 
DDI-DrugBank.d198.s38.e0,DDI-DrugBank.d198.s38.e1,drug1: drug2 (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and drug0,False, 
DDI-DrugBank.d198.s38.e0,DDI-DrugBank.d198.s38.e2,drug1: drug0 (0.5 g/kg body weight: approximately 40 mL of absolute alcohol in a 70 kg person) and drug2,False, 
DDI-DrugBank.d198.s39.e0,DDI-DrugBank.d198.s39.e1,drug1 (20 mg) did not potentiate the hypotensive effects of drug2 during the 4-hour observation period in healthy volunteers when administered with drug0,False, 
DDI-DrugBank.d198.s39.e0,DDI-DrugBank.d198.s39.e2,drug1 (20 mg) did not potentiate the hypotensive effects of drug0 during the 4-hour observation period in healthy volunteers when administered with drug2,False, 
DDI-DrugBank.d198.s40.e0,DDI-DrugBank.d198.s40.e1,drug1: drug2 (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by drug0,False, 
DDI-DrugBank.d198.s40.e0,DDI-DrugBank.d198.s40.e2,drug1: drug0 (10 mg and 20 mg) did not potentiate the increase in bleeding time caused by drug2,False, 
DDI-DrugBank.d198.s41.e0,DDI-DrugBank.d198.s41.e1,Other interactions: drug1 had no effect on the pharmacodynamics of drug2 (glucose and insulin concentrations) and drug0,False, 
DDI-DrugBank.d198.s41.e0,DDI-DrugBank.d198.s41.e2,Other interactions: drug1 had no effect on the pharmacodynamics of drug0 (glucose and insulin concentrations) and drug2,False, 
DDI-DrugBank.d334.s0.e0,DDI-DrugBank.d334.s0.e1,"Hypotension - Patients on Diuretic Therapy: Patients on drug1, and especially those in whom diuretic therapy was recently instituted, may occasionally experience an excessive reduction of blood pressure after initiation of therapy with drug2",True,effect
DDI-DrugBank.d334.s1.e0,DDI-DrugBank.d334.s1.e1,The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug2 or increasing the salt intake prior to initiation of treatment with drug0,False, 
DDI-DrugBank.d334.s1.e0,DDI-DrugBank.d334.s1.e2,The possibility of hypotensive effects with drug1 can be minimized by either discontinuing the drug0 or increasing the salt intake prior to initiation of treatment with drug2,False, 
DDI-DrugBank.d334.s1.e1,DDI-DrugBank.d334.s1.e2,The possibility of hypotensive effects with drug0 can be minimized by either discontinuing the drug1 or increasing the salt intake prior to initiation of treatment with drug2,True,effect
DDI-DrugBank.d334.s2.e0,DDI-DrugBank.d334.s2.e1,"If it is necessary to continue the drug1, initiate therapy with drug2",True,advise
DDI-DrugBank.d334.s3.e0,DDI-DrugBank.d334.s3.e1,When a drug1 is added to the therapy of a patient receiving drug2,True,effect
DDI-DrugBank.d334.s4.e0,DDI-DrugBank.d334.s4.e1,Studies with drug1 in combination with drug2 indicate that the dose of the drug0 can be reduced when it is given with a drug0,False, 
DDI-DrugBank.d334.s4.e0,DDI-DrugBank.d334.s4.e2,Studies with drug1 in combination with drug0 indicate that the dose of the drug2 can be reduced when it is given with a drug0,False, 
DDI-DrugBank.d334.s4.e2,DDI-DrugBank.d334.s4.e3,Studies with drug0 in combination with drug0 indicate that the dose of the drug1 can be reduced when it is given with a drug2,True,advise
DDI-DrugBank.d334.s5.e0,DDI-DrugBank.d334.s5.e1,"drug1: In some patients with compromised renal function who are being treated with drug2, the co-administration of drug0",False, 
DDI-DrugBank.d334.s5.e0,DDI-DrugBank.d334.s5.e2,"drug1: In some patients with compromised renal function who are being treated with drug0, the co-administration of drug2",False, 
DDI-DrugBank.d334.s5.e1,DDI-DrugBank.d334.s5.e2,"drug0: In some patients with compromised renal function who are being treated with drug1, the co-administration of drug2",True,effect
DDI-DrugBank.d334.s7.e0,DDI-DrugBank.d334.s7.e1,"Reports suggest that drug1 may diminish the antihypertensive effect of drug2, including drug0",True,effect
DDI-DrugBank.d334.s7.e0,DDI-DrugBank.d334.s7.e2,"Reports suggest that drug1 may diminish the antihypertensive effect of drug0, including drug2",True,effect
DDI-DrugBank.d334.s7.e1,DDI-DrugBank.d334.s7.e2,"Reports suggest that drug0 may diminish the antihypertensive effect of drug1, including drug2",False, 
DDI-DrugBank.d334.s8.e0,DDI-DrugBank.d334.s8.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d334.s9.e0,DDI-DrugBank.d334.s9.e1,"In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of drug1 alone were compared to drug2 given concomitantly with drug0, the use of drug0",False, 
DDI-DrugBank.d334.s9.e0,DDI-DrugBank.d334.s9.e2,"In a study in 36 patients with mild to moderate hypertension where the antihypertensive effects of drug1 alone were compared to drug0 given concomitantly with drug2, the use of drug0",False, 
DDI-DrugBank.d334.s10.e0,DDI-DrugBank.d334.s10.e1,Other Agents: drug1 has been used concomitantly with drug2 and/or drug0,False, 
DDI-DrugBank.d334.s10.e0,DDI-DrugBank.d334.s10.e2,Other Agents: drug1 has been used concomitantly with drug0 and/or drug2,False, 
DDI-DrugBank.d334.s12.e0,DDI-DrugBank.d334.s12.e1,No clinically important pharmacokinetic interactions occurred when drug1 was used concomitantly with drug2 or drug0,False, 
DDI-DrugBank.d334.s12.e0,DDI-DrugBank.d334.s12.e2,No clinically important pharmacokinetic interactions occurred when drug1 was used concomitantly with drug0 or drug2,False, 
DDI-DrugBank.d334.s14.e0,DDI-DrugBank.d334.s14.e1,Agents Increasing Serum Potassium: drug1 attenuates potassium loss caused by drug2,True,effect
DDI-DrugBank.d334.s15.e0,DDI-DrugBank.d334.s15.e1,"Use of drug1 with drug2 (e.g., drug0, drug0, or drug0), drug0",True,effect
DDI-DrugBank.d334.s15.e0,DDI-DrugBank.d334.s15.e2,"Use of drug1 with drug0 (e.g., drug2, drug0, or drug0), drug0",True,effect
DDI-DrugBank.d334.s15.e0,DDI-DrugBank.d334.s15.e3,"Use of drug1 with drug0 (e.g., drug0, drug2, or drug0), drug0",True,effect
DDI-DrugBank.d334.s15.e0,DDI-DrugBank.d334.s15.e4,"Use of drug1 with drug0 (e.g., drug0, drug0, or drug2), drug0",True,effect
DDI-DrugBank.d334.s15.e0,DDI-DrugBank.d334.s15.e5,"Use of drug1 with drug0 (e.g., drug0, drug0, or drug0), drug2",True,effect
DDI-DrugBank.d334.s15.e1,DDI-DrugBank.d334.s15.e2,"Use of drug0 with drug1 (e.g., drug2, drug0, or drug0), drug0",False, 
DDI-DrugBank.d334.s15.e1,DDI-DrugBank.d334.s15.e3,"Use of drug0 with drug1 (e.g., drug0, drug2, or drug0), drug0",False, 
DDI-DrugBank.d334.s18.e0,DDI-DrugBank.d334.s18.e1,"drug1: drug2 toxicity has been reported in patients receiving drug0 concomitantly with drugs which cause elimination of sodium, including drug0",False, 
DDI-DrugBank.d334.s18.e0,DDI-DrugBank.d334.s18.e2,"drug1: drug0 toxicity has been reported in patients receiving drug2 concomitantly with drugs which cause elimination of sodium, including drug0",False, 
DDI-DrugBank.d334.s18.e2,DDI-DrugBank.d334.s18.e3,"drug0: drug0 toxicity has been reported in patients receiving drug1 concomitantly with drugs which cause elimination of sodium, including drug2",True,effect
DDI-DrugBank.d334.s19.e0,DDI-DrugBank.d334.s19.e1,drug1 toxicity was usually reversible upon discontinuation of drug2 and the drug0,False, 
DDI-DrugBank.d334.s19.e0,DDI-DrugBank.d334.s19.e2,drug1 toxicity was usually reversible upon discontinuation of drug0 and the drug2,False, 
DDI-DrugBank.d334.s19.e1,DDI-DrugBank.d334.s19.e2,drug0 toxicity was usually reversible upon discontinuation of drug1 and the drug2,True,effect
DDI-DrugBank.d334.s20.e0,DDI-DrugBank.d334.s20.e1,It is recommended that serum drug1 levels be monitored frequently if drug2 is administered concomitantly with drug0,False, 
DDI-DrugBank.d334.s20.e0,DDI-DrugBank.d334.s20.e2,It is recommended that serum drug1 levels be monitored frequently if drug0 is administered concomitantly with drug2,False, 
DDI-DrugBank.d334.s20.e1,DDI-DrugBank.d334.s20.e2,It is recommended that serum drug0 levels be monitored frequently if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d318.s0.e0,DDI-DrugBank.d318.s0.e1,"When administered concurrently, the following drugs may interact with drug1: drug2",True,effect
DDI-DrugBank.d318.s1.e0,DDI-DrugBank.d318.s1.e1,"drug1 (e. g., drug2",False, 
DDI-DrugBank.d318.s2.e0,DDI-DrugBank.d318.s2.e1,drug1 and drug2 (drug0): may potentiate drug0,False, 
DDI-DrugBank.d318.s2.e0,DDI-DrugBank.d318.s2.e2,drug1 and drug0 (drug2): may potentiate drug0,False, 
DDI-DrugBank.d318.s2.e0,DDI-DrugBank.d318.s2.e3,drug1 and drug0 (drug0): may potentiate drug2,True,effect
DDI-DrugBank.d318.s2.e1,DDI-DrugBank.d318.s2.e3,drug0 and drug1 (drug0): may potentiate drug2,True,effect
DDI-DrugBank.d318.s2.e2,DDI-DrugBank.d318.s2.e3,drug0 and drug0 (drug1): may potentiate drug2,True,effect
DDI-DrugBank.d318.s5.e0,DDI-DrugBank.d318.s5.e1,drug1: drug2-induced hypokalemia may potentiate drug0,False, 
DDI-DrugBank.d318.s5.e0,DDI-DrugBank.d318.s5.e2,drug1: drug0-induced hypokalemia may potentiate drug2,False, 
DDI-DrugBank.d318.s5.e1,DDI-DrugBank.d318.s5.e2,drug0: drug1-induced hypokalemia may potentiate drug2,True,effect
DDI-DrugBank.d318.s7.e0,DDI-DrugBank.d318.s7.e1,"drug1: while a synergistic relationship with drug2 has been reported, concomitant use may increase the toxicity of drug0",False, 
DDI-DrugBank.d318.s7.e0,DDI-DrugBank.d318.s7.e2,"drug1: while a synergistic relationship with drug0 has been reported, concomitant use may increase the toxicity of drug2",False, 
DDI-DrugBank.d318.s7.e1,DDI-DrugBank.d318.s7.e2,"drug0: while a synergistic relationship with drug1 has been reported, concomitant use may increase the toxicity of drug2",True,effect
DDI-DrugBank.d318.s8.e0,DDI-DrugBank.d318.s8.e1,"drug1 (e. g., drug2, drug0, drug0, drug0, etc.): in vitro and animal studies with the combination of drug0 and drug0 suggest that drug0 may induce fungal resistance to drug0",False, 
DDI-DrugBank.d318.s8.e0,DDI-DrugBank.d318.s8.e2,"drug1 (e. g., drug0, drug2, drug0, drug0, etc.): in vitro and animal studies with the combination of drug0 and drug0 suggest that drug0 may induce fungal resistance to drug0",False, 
DDI-DrugBank.d318.s8.e7,DDI-DrugBank.d318.s8.e8,"drug0 (e. g., drug0, drug0, drug0, drug0, etc.): in vitro and animal studies with the combination of drug0 and drug0 suggest that drug1 may induce fungal resistance to drug2",True,effect
DDI-DrugBank.d318.s10.e0,DDI-DrugBank.d318.s10.e1,"Other nephrotoxic medications: agents such as drug1, drug2, and drug0",False, 
DDI-DrugBank.d318.s10.e0,DDI-DrugBank.d318.s10.e2,"Other nephrotoxic medications: agents such as drug1, drug0, and drug2",False, 
DDI-DrugBank.d318.s12.e0,DDI-DrugBank.d318.s12.e1,"drug1: drug2-induced hypokalemia may enhance the curariform effect of drug0 (e.g., drug0",False, 
DDI-DrugBank.d318.s12.e0,DDI-DrugBank.d318.s12.e2,"drug1: drug0-induced hypokalemia may enhance the curariform effect of drug2 (e.g., drug0",False, 
DDI-DrugBank.d318.s12.e1,DDI-DrugBank.d318.s12.e2,"drug0: drug1-induced hypokalemia may enhance the curariform effect of drug2 (e.g., drug0",True,effect
DDI-DrugBank.d318.s12.e1,DDI-DrugBank.d318.s12.e3,"drug0: drug1-induced hypokalemia may enhance the curariform effect of drug0 (e.g., drug2",True,effect
DDI-DrugBank.d318.s14.e0,DDI-DrugBank.d318.s14.e1,drug1: acute pulmonary toxicity has been reported in patients receiving intravenous drug2 and drug0,False, 
DDI-DrugBank.d318.s14.e0,DDI-DrugBank.d318.s14.e2,drug1: acute pulmonary toxicity has been reported in patients receiving intravenous drug0 and drug2,False, 
DDI-DrugBank.d318.s14.e1,DDI-DrugBank.d318.s14.e2,drug0: acute pulmonary toxicity has been reported in patients receiving intravenous drug1 and drug2,True,effect
DDI-DrugBank.d388.s0.e0,DDI-DrugBank.d388.s0.e1,"drug1, such as drug2, may have an additive effect when given with drug0",False, 
DDI-DrugBank.d388.s0.e0,DDI-DrugBank.d388.s0.e2,"drug1, such as drug0, may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d388.s0.e1,DDI-DrugBank.d388.s0.e2,"drug0, such as drug1, may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d388.s1.e0,DDI-DrugBank.d388.s1.e1,Patients treated with drug1 plus drug2,True,advise
DDI-DrugBank.d388.s2.e0,DDI-DrugBank.d388.s2.e1,Exaggerated hypertensive responses have been reported from the combined use of drug1 and drug2,True,effect
DDI-DrugBank.d388.s4.e0,DDI-DrugBank.d388.s4.e1,Blunting of the antihypertensive effect of drug1 by drug2,True,effect
DDI-DrugBank.d388.s5.e0,DDI-DrugBank.d388.s5.e1,"No significant interactions with drug1, drug2, drug0, drug0, oral drug0, drug0, or drug0",False, 
DDI-DrugBank.d388.s5.e0,DDI-DrugBank.d388.s5.e2,"No significant interactions with drug1, drug0, drug2, drug0, oral drug0, drug0, or drug0",False, 
DDI-DrugBank.d344.s0.e0,DDI-DrugBank.d344.s0.e1,Concomitant use of drug1 supplements and drug2 may increase drug0,True,mechanism
DDI-DrugBank.d344.s0.e0,DDI-DrugBank.d344.s0.e2,Concomitant use of drug1 supplements and drug0 may increase drug2,False, 
DDI-DrugBank.d344.s0.e1,DDI-DrugBank.d344.s0.e2,Concomitant use of drug0 supplements and drug1 may increase drug2,False, 
DDI-DrugBank.d353.s0.e0,DDI-DrugBank.d353.s0.e1,drug1:Clinical evidence has shown that drug2 can be formed with concurrent ingestion of drug0 and drug0,False, 
DDI-DrugBank.d353.s0.e0,DDI-DrugBank.d353.s0.e2,drug1:Clinical evidence has shown that drug0 can be formed with concurrent ingestion of drug2 and drug0,False, 
DDI-DrugBank.d353.s0.e2,DDI-DrugBank.d353.s0.e3,drug0:Clinical evidence has shown that drug0 can be formed with concurrent ingestion of drug1 and drug2,True,mechanism
DDI-DrugBank.d353.s1.e0,DDI-DrugBank.d353.s1.e1,"drug1: In a study of 7 healthy male volunteers, drug2 treatment potentiated the blood glucose lowering effect of drug0 (a drug0 similar to drug0",False, 
DDI-DrugBank.d353.s1.e0,DDI-DrugBank.d353.s1.e2,"drug1: In a study of 7 healthy male volunteers, drug0 treatment potentiated the blood glucose lowering effect of drug2 (a drug0 similar to drug0",False, 
DDI-DrugBank.d353.s1.e1,DDI-DrugBank.d353.s1.e2,"drug0: In a study of 7 healthy male volunteers, drug1 treatment potentiated the blood glucose lowering effect of drug2 (a drug0 similar to drug0",True,effect
DDI-DrugBank.d353.s2.e0,DDI-DrugBank.d353.s2.e1,Repeating the study with 6 healthy male volunteers in the absence of drug1 did not detect an effect of drug2,False, 
DDI-DrugBank.d353.s4.e0,DDI-DrugBank.d353.s4.e1,drug1: It has not been established if there is a pharmacokinetic interaction between drug2 and drug0,False, 
DDI-DrugBank.d353.s4.e0,DDI-DrugBank.d353.s4.e2,drug1: It has not been established if there is a pharmacokinetic interaction between drug0 and drug2,False, 
DDI-DrugBank.d353.s5.e0,DDI-DrugBank.d353.s5.e1,"However, it has been established that drug1 interferes with the contraceptive effect of microdosed drug2",True,effect
DDI-DrugBank.d353.s6.e0,DDI-DrugBank.d353.s6.e1,Microdosed minipill drug1 preparations are not recommended for use with drug2,True,advise
DDI-DrugBank.d353.s7.e0,DDI-DrugBank.d353.s7.e1,"It is not known whether other drug1, such as implants and injectables, are adequate methods of contraception during drug2",False, 
DDI-DrugBank.d353.s8.e0,DDI-DrugBank.d353.s8.e1,drug1: An increased risk of hepatitis has been reported to result from combined use of drug2 and drug0,False, 
DDI-DrugBank.d353.s8.e0,DDI-DrugBank.d353.s8.e2,drug1: An increased risk of hepatitis has been reported to result from combined use of drug0 and drug2,False, 
DDI-DrugBank.d353.s8.e1,DDI-DrugBank.d353.s8.e2,drug0: An increased risk of hepatitis has been reported to result from combined use of drug1 and drug2,True,effect
DDI-DrugBank.d353.s9.e0,DDI-DrugBank.d353.s9.e1,"Consequently, the combination of drug1 with drug2",True,advise
DDI-DrugBank.d353.s10.e0,DDI-DrugBank.d353.s10.e1,"drug1: If drug2 is given concurrently with drug0, the protein binding of drug0",False, 
DDI-DrugBank.d353.s10.e0,DDI-DrugBank.d353.s10.e2,"drug1: If drug0 is given concurrently with drug2, the protein binding of drug0",False, 
DDI-DrugBank.d353.s10.e1,DDI-DrugBank.d353.s10.e2,"drug0: If drug1 is given concurrently with drug2, the protein binding of drug0",True,mechanism
DDI-DrugBank.d353.s11.e0,DDI-DrugBank.d353.s11.e1,drug1: Since both drug2 and drug0,False, 
DDI-DrugBank.d353.s11.e0,DDI-DrugBank.d353.s11.e2,drug1: Since both drug0 and drug2,False, 
DDI-DrugBank.d353.s11.e1,DDI-DrugBank.d353.s11.e2,drug0: Since both drug1 and drug2,True,effect
DDI-DrugBank.d353.s12.e0,DDI-DrugBank.d353.s12.e1,drug1 and oral drug2: Concomitant administration of drug0 and/or other oral drug0 with drug0,False, 
DDI-DrugBank.d353.s12.e0,DDI-DrugBank.d353.s12.e2,drug1 and oral drug0: Concomitant administration of drug2 and/or other oral drug0 with drug0,False, 
DDI-DrugBank.d353.s12.e2,DDI-DrugBank.d353.s12.e4,drug0 and oral drug0: Concomitant administration of drug1 and/or other oral drug0 with drug2,True,advise
DDI-DrugBank.d353.s12.e3,DDI-DrugBank.d353.s12.e4,drug0 and oral drug0: Concomitant administration of drug0 and/or other oral drug1 with drug2,True,advise
DDI-DrugBank.d353.s13.e0,DDI-DrugBank.d353.s13.e1,"Other: There appears to be no pharmacokinetic interaction between drug1 and drug2, drug0, or drug0",False, 
DDI-DrugBank.d353.s13.e0,DDI-DrugBank.d353.s13.e2,"Other: There appears to be no pharmacokinetic interaction between drug1 and drug0, drug2, or drug0",False, 
DDI-DrugBank.d353.s14.e0,DDI-DrugBank.d353.s14.e1,Investigations into the effect of drug1 on the protein binding of drug2 (drug0,False, 
DDI-DrugBank.d353.s14.e0,DDI-DrugBank.d353.s14.e2,Investigations into the effect of drug1 on the protein binding of drug0 (drug2,False, 
DDI-DrugBank.d59.s0.e0,DDI-DrugBank.d59.s0.e1,The effects of drug1 may be potentiated by drug2 which inhibits the metabolism of drug0,True,mechanism
DDI-DrugBank.d59.s0.e0,DDI-DrugBank.d59.s0.e2,The effects of drug1 may be potentiated by drug0 which inhibits the metabolism of drug2,False, 
DDI-DrugBank.d59.s0.e1,DDI-DrugBank.d59.s0.e2,The effects of drug0 may be potentiated by drug1 which inhibits the metabolism of drug2,True,mechanism
DDI-DrugBank.d59.s1.e0,DDI-DrugBank.d59.s1.e1,The pressor effects of drug1 and other drug2,True,effect
DDI-DrugBank.d378.s0.e0,DDI-DrugBank.d378.s0.e1,Renal function should be monitored carefully if high doses of drug1 are to be administered with drug2 because of the increased potential of nephrotoxicity and ototoxicity of drug0,True,advise
DDI-DrugBank.d378.s0.e0,DDI-DrugBank.d378.s0.e2,Renal function should be monitored carefully if high doses of drug1 are to be administered with drug0 because of the increased potential of nephrotoxicity and ototoxicity of drug2,False, 
DDI-DrugBank.d378.s0.e1,DDI-DrugBank.d378.s0.e2,Renal function should be monitored carefully if high doses of drug0 are to be administered with drug1 because of the increased potential of nephrotoxicity and ototoxicity of drug2,False, 
DDI-DrugBank.d378.s1.e0,DDI-DrugBank.d378.s1.e1,Nephrotoxicity has been reported following concomitant administration of other drug1 with potent drug2 such as drug0,True,effect
DDI-DrugBank.d378.s1.e0,DDI-DrugBank.d378.s1.e2,Nephrotoxicity has been reported following concomitant administration of other drug1 with potent drug0 such as drug2,True,effect
DDI-DrugBank.d378.s1.e1,DDI-DrugBank.d378.s1.e2,Nephrotoxicity has been reported following concomitant administration of other drug0 with potent drug1 such as drug2,False, 
DDI-DrugBank.d67.s0.e0,DDI-DrugBank.d67.s0.e1,"In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, drug1 7.5 mg (1.5 times the daily dose) once daily was coadministered with drug2 500 mg every 8 hours or drug0",False, 
DDI-DrugBank.d67.s0.e0,DDI-DrugBank.d67.s0.e2,"In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) a nd female (n=12 in each study) volunteers, drug1 7.5 mg (1.5 times the daily dose) once daily was coadministered with drug0 500 mg every 8 hours or drug2",False, 
DDI-DrugBank.d67.s1.e0,DDI-DrugBank.d67.s1.e1,"In three separate controlled, parallel group clinical pharmacology studies, drug1 at the clinical dose of 5 mg has been coadministered with drug2 500 mg followed by 250 mg once daily for 4 days (n=18) or with drug0 20 mg once daily for 7 days after a 23 day pretreatment period with drug0 (n=18) or with drug0",False, 
DDI-DrugBank.d67.s1.e0,DDI-DrugBank.d67.s1.e2,"In three separate controlled, parallel group clinical pharmacology studies, drug1 at the clinical dose of 5 mg has been coadministered with drug0 500 mg followed by 250 mg once daily for 4 days (n=18) or with drug2 20 mg once daily for 7 days after a 23 day pretreatment period with drug0 (n=18) or with drug0",False, 
DDI-DrugBank.d67.s2.e0,DDI-DrugBank.d67.s2.e1,"Although increased plasma concentrations (C max and AUC 0-24 hrs) of drug1 and drug2 were observed , there were no clinically relevant changes in the safety profile of drug0",False, 
DDI-DrugBank.d67.s2.e0,DDI-DrugBank.d67.s2.e2,"Although increased plasma concentrations (C max and AUC 0-24 hrs) of drug1 and drug0 were observed , there were no clinically relevant changes in the safety profile of drug2",False, 
DDI-DrugBank.d67.s3.e0,DDI-DrugBank.d67.s3.e1,Table 1 Changes in drug1 and drug2,False, 
DDI-DrugBank.d67.s5.e0,DDI-DrugBank.d67.s5.e1,drug1 drug2,False, 
DDI-DrugBank.d172.s6.e0,DDI-DrugBank.d172.s6.e1,Clinical studies with drug1 have identified potentially significant interactions with drug2 and drug0,True,int
DDI-DrugBank.d172.s6.e0,DDI-DrugBank.d172.s6.e2,Clinical studies with drug1 have identified potentially significant interactions with drug0 and drug2,True,int
DDI-DrugBank.d172.s6.e1,DDI-DrugBank.d172.s6.e2,Clinical studies with drug0 have identified potentially significant interactions with drug1 and drug2,False, 
DDI-DrugBank.d172.s7.e0,DDI-DrugBank.d172.s7.e1,Experience with drug1 (drug2) suggests the potential for interactions with drug0 and drug0,False, 
DDI-DrugBank.d172.s7.e0,DDI-DrugBank.d172.s7.e2,Experience with drug1 (drug0) suggests the potential for interactions with drug2 and drug0,True,int
DDI-DrugBank.d172.s7.e0,DDI-DrugBank.d172.s7.e3,Experience with drug1 (drug0) suggests the potential for interactions with drug0 and drug2,True,int
DDI-DrugBank.d172.s7.e1,DDI-DrugBank.d172.s7.e2,Experience with drug0 (drug1) suggests the potential for interactions with drug2 and drug0,True,int
DDI-DrugBank.d172.s7.e1,DDI-DrugBank.d172.s7.e3,Experience with drug0 (drug1) suggests the potential for interactions with drug0 and drug2,True,int
DDI-DrugBank.d172.s7.e2,DDI-DrugBank.d172.s7.e3,Experience with drug0 (drug0) suggests the potential for interactions with drug1 and drug2,False, 
DDI-DrugBank.d172.s8.e0,DDI-DrugBank.d172.s8.e1,"The effects drug1 on the pharmacokinetics and/or pharmacodynamics of drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d172.s8.e0,DDI-DrugBank.d172.s8.e2,"The effects drug1 on the pharmacokinetics and/or pharmacodynamics of drug0, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d172.s9.e0,DDI-DrugBank.d172.s9.e1,drug1: Reports suggest that drug2 may diminish the antihypertensive effect of drug0,False, 
DDI-DrugBank.d172.s9.e0,DDI-DrugBank.d172.s9.e2,drug1: Reports suggest that drug0 may diminish the antihypertensive effect of drug2,False, 
DDI-DrugBank.d172.s9.e1,DDI-DrugBank.d172.s9.e2,drug0: Reports suggest that drug1 may diminish the antihypertensive effect of drug2,True,effect
DDI-DrugBank.d172.s10.e0,DDI-DrugBank.d172.s10.e1,This interaction should be given consideration in patients taking drug1 concomitantly with drug2,True,advise
DDI-DrugBank.d172.s11.e0,DDI-DrugBank.d172.s11.e1,"drug1: Clinical studies, as well as post marketing observations, have shown that drug2 can reduce the natriuretic effect of drug0 and drug0",False, 
DDI-DrugBank.d172.s11.e0,DDI-DrugBank.d172.s11.e2,"drug1: Clinical studies, as well as post marketing observations, have shown that drug0 can reduce the natriuretic effect of drug2 and drug0",False, 
DDI-DrugBank.d172.s11.e1,DDI-DrugBank.d172.s11.e2,"drug0: Clinical studies, as well as post marketing observations, have shown that drug1 can reduce the natriuretic effect of drug2 and drug0",True,effect
DDI-DrugBank.d172.s11.e1,DDI-DrugBank.d172.s11.e3,"drug0: Clinical studies, as well as post marketing observations, have shown that drug1 can reduce the natriuretic effect of drug0 and drug2",True,effect
DDI-DrugBank.d172.s13.e0,DDI-DrugBank.d172.s13.e1,drug1: drug2 can be used with low dose drug0,False, 
DDI-DrugBank.d172.s13.e0,DDI-DrugBank.d172.s13.e2,drug1: drug0 can be used with low dose drug2,False, 
DDI-DrugBank.d172.s13.e1,DDI-DrugBank.d172.s13.e2,drug0: drug1 can be used with low dose drug2,True,advise
DDI-DrugBank.d172.s14.e0,DDI-DrugBank.d172.s14.e1,"However, concomitant administration of drug1 with drug2 may result in an increased rate of GI ulceration or other complications, compared to use of drug0",True,effect
DDI-DrugBank.d172.s14.e0,DDI-DrugBank.d172.s14.e2,"However, concomitant administration of drug1 with drug0 may result in an increased rate of GI ulceration or other complications, compared to use of drug2",False, 
DDI-DrugBank.d172.s14.e1,DDI-DrugBank.d172.s14.e2,"However, concomitant administration of drug0 with drug1 may result in an increased rate of GI ulceration or other complications, compared to use of drug2",False, 
DDI-DrugBank.d172.s15.e0,DDI-DrugBank.d172.s15.e1,"Because of its lack of platelet effects, drug1 is not a substitute for drug2",False, 
DDI-DrugBank.d172.s16.e0,DDI-DrugBank.d172.s16.e1,drug1: Concomitant administration of drug2 at 200 mg QD resulted in a two-fold increase in drug0,False, 
DDI-DrugBank.d172.s16.e0,DDI-DrugBank.d172.s16.e2,drug1: Concomitant administration of drug0 at 200 mg QD resulted in a two-fold increase in drug2,False, 
DDI-DrugBank.d172.s16.e1,DDI-DrugBank.d172.s16.e2,drug0: Concomitant administration of drug1 at 200 mg QD resulted in a two-fold increase in drug2,True,mechanism
DDI-DrugBank.d172.s17.e0,DDI-DrugBank.d172.s17.e1,This increase is due to the inhibition of drug1 metabolism via P450 2C9 by drug2,True,mechanism
DDI-DrugBank.d172.s18.e0,DDI-DrugBank.d172.s18.e1,drug1 should be introduced at the lowest recommended dose in patients receiving drug2,True,advise
DDI-DrugBank.d172.s19.e0,DDI-DrugBank.d172.s19.e1,"drug1: In a study conducted in healthy subjects, mean steady-state drug2 plasma levels increased approximately 17% in subjects receiving drug0 450 mg BID with drug0 200 mg BID as compared to subjects receiving drug0",False, 
DDI-DrugBank.d172.s19.e0,DDI-DrugBank.d172.s19.e2,"drug1: In a study conducted in healthy subjects, mean steady-state drug0 plasma levels increased approximately 17% in subjects receiving drug2 450 mg BID with drug0 200 mg BID as compared to subjects receiving drug0",False, 
DDI-DrugBank.d172.s19.e2,DDI-DrugBank.d172.s19.e3,"drug0: In a study conducted in healthy subjects, mean steady-state drug0 plasma levels increased approximately 17% in subjects receiving drug1 450 mg BID with drug2 200 mg BID as compared to subjects receiving drug0",True,mechanism
DDI-DrugBank.d172.s20.e0,DDI-DrugBank.d172.s20.e1,Patients on drug1 treatment should be closely monitored when drug2,True,advise
DDI-DrugBank.d172.s21.e0,DDI-DrugBank.d172.s21.e1,"drug1: In an interaction study of rheumatoid arthritis patients taking drug2, drug0 did not have a significant effect on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d172.s21.e0,DDI-DrugBank.d172.s21.e2,"drug1: In an interaction study of rheumatoid arthritis patients taking drug0, drug2 did not have a significant effect on the pharmacokinetics of drug0",False, 
DDI-DrugBank.d172.s22.e0,DDI-DrugBank.d172.s22.e1,drug1: The effect of drug2 on the anti-coagulant effect of drug0 was studied in a group of healthy subjects receiving daily doses of 2-5 mg of drug0,False, 
DDI-DrugBank.d172.s22.e0,DDI-DrugBank.d172.s22.e2,drug1: The effect of drug0 on the anti-coagulant effect of drug2 was studied in a group of healthy subjects receiving daily doses of 2-5 mg of drug0,False, 
DDI-DrugBank.d172.s23.e0,DDI-DrugBank.d172.s23.e1,"In these subjects, drug1 did not alter the anticoagulant effect of drug2",False, 
DDI-DrugBank.d172.s24.e0,DDI-DrugBank.d172.s24.e1,"However, caution should be used when administering drug1 with drug2",True,advise
DDI-DrugBank.d108.s0.e0,DDI-DrugBank.d108.s0.e1,drug1 should be administered with caution to patients receiving drug2 (drug0,True,advise
DDI-DrugBank.d108.s0.e0,DDI-DrugBank.d108.s0.e2,drug1 should be administered with caution to patients receiving drug0 (drug2,True,advise
DDI-DrugBank.d108.s0.e1,DDI-DrugBank.d108.s0.e2,drug0 should be administered with caution to patients receiving drug1 (drug2,False, 
DDI-DrugBank.d108.s1.e0,DDI-DrugBank.d108.s1.e1,"In a single study, rats given high intraperitoneal doses of an drug1 plus drug2",True,effect
DDI-DrugBank.d108.s2.e0,DDI-DrugBank.d108.s2.e1,Concomitant use of drug1 and other drug2,True,advise
DDI-DrugBank.d108.s5.e0,DDI-DrugBank.d108.s5.e1,"The monoamine oxidase inhibitory effects of drug1 may persist for a substantial period after discontinuation of the drug, and this should be borne in mind when another drug is prescribed following drug2",False, 
DDI-DrugBank.d452.s0.e0,DDI-DrugBank.d452.s0.e1,Administration of drug1 to hypoparathyroid patients who are concurrently being treated with drug2,True,effect
DDI-DrugBank.d531.s1.e0,DDI-DrugBank.d531.s1.e1,Other compounds that are substrates of CYP3A4 may have decreased plasma concentrations when coadministered with drug1 (drug2,False, 
DDI-DrugBank.d531.s2.e0,DDI-DrugBank.d531.s2.e1,"In vitro studies have demonstrated that drug1 inhibits 2C9, 2C19, and 3A4 isozymes in the range of observed drug2",False, 
DDI-DrugBank.d531.s5.e0,DDI-DrugBank.d531.s5.e1,"Drugs which induce CYP3A4 activity (eg, drug1, drug2, drug0) would be expected to increase the clearance of drug0",False, 
DDI-DrugBank.d531.s5.e0,DDI-DrugBank.d531.s5.e2,"Drugs which induce CYP3A4 activity (eg, drug1, drug0, drug2) would be expected to increase the clearance of drug0",False, 
DDI-DrugBank.d531.s5.e0,DDI-DrugBank.d531.s5.e3,"Drugs which induce CYP3A4 activity (eg, drug1, drug0, drug0) would be expected to increase the clearance of drug2",True,mechanism
DDI-DrugBank.d531.s5.e1,DDI-DrugBank.d531.s5.e3,"Drugs which induce CYP3A4 activity (eg, drug0, drug1, drug0) would be expected to increase the clearance of drug2",True,mechanism
DDI-DrugBank.d531.s5.e2,DDI-DrugBank.d531.s5.e3,"Drugs which induce CYP3A4 activity (eg, drug0, drug0, drug1) would be expected to increase the clearance of drug2",True,mechanism
DDI-DrugBank.d531.s10.e0,DDI-DrugBank.d531.s10.e1,drug1: drug2 GI Motility Agents drug0 drug0,False, 
DDI-DrugBank.d531.s10.e0,DDI-DrugBank.d531.s10.e2,drug1: drug0 GI Motility Agents drug2 drug0,False, 
DDI-DrugBank.d531.s11.e0,DDI-DrugBank.d531.s11.e1,"drug1 drug2, drug0 drug0 ergot derivatives drug0",False, 
DDI-DrugBank.d531.s11.e0,DDI-DrugBank.d531.s11.e2,"drug1 drug0, drug2 drug0 ergot derivatives drug0",False, 
DDI-DrugBank.d531.s19.e0,DDI-DrugBank.d531.s19.e1,"When coadministered with drug1 in treatment-naive patients, the recommended dose of drug2 is 300 mg with drug0 100 mg and drug0",False, 
DDI-DrugBank.d531.s19.e0,DDI-DrugBank.d531.s19.e2,"When coadministered with drug1 in treatment-naive patients, the recommended dose of drug0 is 300 mg with drug2 100 mg and drug0",False, 
DDI-DrugBank.d531.s20.e0,DDI-DrugBank.d531.s20.e1,Dosing recommendations for drug1 and drug2,False, 
DDI-DrugBank.d531.s29.e0,DDI-DrugBank.d531.s29.e1,"In uninfected volunteers, 46% developed rash while receiving drug1 and drug2",True,effect
DDI-DrugBank.d531.s30.e0,DDI-DrugBank.d531.s30.e1,No dose adjustment of drug1 is recommended when given with drug2,False, 
DDI-DrugBank.d531.s31.e0,DDI-DrugBank.d531.s31.e1,"Alternatives to drug1, such as drug2",False, 
DDI-DrugBank.d531.s32.e0,DDI-DrugBank.d531.s32.e1,"Other drug1, such as drug2, have not been studied in combination with drug0",False, 
DDI-DrugBank.d531.s32.e0,DDI-DrugBank.d531.s32.e2,"Other drug1, such as drug0, have not been studied in combination with drug2",False, 
DDI-DrugBank.d531.s37.e0,DDI-DrugBank.d531.s37.e1,"The optimal dose of drug1, when given in combination with drug2",False, 
DDI-DrugBank.d531.s38.e0,DDI-DrugBank.d531.s38.e1,Increasing the drug1 dose to 1000 mg every 8 hours does not compensate for the increased drug2 metabolism due to drug0,False, 
DDI-DrugBank.d531.s38.e0,DDI-DrugBank.d531.s38.e2,Increasing the drug1 dose to 1000 mg every 8 hours does not compensate for the increased drug0 metabolism due to drug2,False, 
DDI-DrugBank.d531.s38.e1,DDI-DrugBank.d531.s38.e2,Increasing the drug0 dose to 1000 mg every 8 hours does not compensate for the increased drug1 metabolism due to drug2,True,mechanism
DDI-DrugBank.d531.s39.e0,DDI-DrugBank.d531.s39.e1,"When drug1 at an increased dose (1000 mg every 8 hours) was given with drug2 (600 mg once daily), the drug0 AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when drug0",True,mechanism
DDI-DrugBank.d531.s39.e0,DDI-DrugBank.d531.s39.e2,"When drug1 at an increased dose (1000 mg every 8 hours) was given with drug0 (600 mg once daily), the drug2 AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when drug0",False, 
DDI-DrugBank.d531.s39.e0,DDI-DrugBank.d531.s39.e3,"When drug1 at an increased dose (1000 mg every 8 hours) was given with drug0 (600 mg once daily), the drug0 AUC and Cmin were decreased on average by 33-46% and 39-57%, respectively, compared to when drug2",False, 
DDI-DrugBank.d531.s40.e0,DDI-DrugBank.d531.s40.e1,drug1/drug2,False, 
DDI-DrugBank.d531.s42.e0,DDI-DrugBank.d531.s42.e1,A dose increase of drug1/drug2 to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with drug0,False, 
DDI-DrugBank.d531.s42.e0,DDI-DrugBank.d531.s42.e2,A dose increase of drug1/drug0 to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with drug2,True,advise
DDI-DrugBank.d531.s42.e1,DDI-DrugBank.d531.s42.e2,A dose increase of drug0/drug1 to 533/133 mg (4 capsules or 6.5 mL) twice daily taken with food is recommended when used in combination with drug2,True,advise
DDI-DrugBank.d531.s45.e0,DDI-DrugBank.d531.s45.e1,Coadministration in HIV-infected individuals with a history of injection drug use resulted in decreased plasma levels of drug1 and signs of drug2,False, 
DDI-DrugBank.d531.s50.e0,DDI-DrugBank.d531.s50.e1,Plasma concentrations increased by drug1 (drug2,False, 
DDI-DrugBank.d531.s52.e0,DDI-DrugBank.d531.s52.e1,"Because the potential interaction of drug1 with oral drug2 has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral drug0",True,advise
DDI-DrugBank.d531.s52.e0,DDI-DrugBank.d531.s52.e2,"Because the potential interaction of drug1 with oral drug0 has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral drug2",False, 
DDI-DrugBank.d531.s52.e1,DDI-DrugBank.d531.s52.e2,"Because the potential interaction of drug0 with oral drug1 has not been fully characterized, a reliable method of barrier contraception should be used in addition to oral drug2",False, 
DDI-DrugBank.d531.s56.e0,DDI-DrugBank.d531.s56.e1,Consider doubling the drug1 dose in regimens where drug2,False, 
DDI-DrugBank.d531.s63.e0,DDI-DrugBank.d531.s63.e1,Monitoring of liver enzymes is recommended when drug1 is used in combination with drug2,True,advise
DDI-DrugBank.d531.s67.e0,DDI-DrugBank.d531.s67.e1,Should not be used as sole drug1 in combination with drug2,False, 
DDI-DrugBank.d531.s72.e0,DDI-DrugBank.d531.s72.e1,drug1: drug2,False, 
DDI-DrugBank.d531.s74.e0,DDI-DrugBank.d531.s74.e1,drug1: drug2 drug0 drug0,False, 
DDI-DrugBank.d531.s74.e0,DDI-DrugBank.d531.s74.e2,drug1: drug0 drug2 drug0,False, 
DDI-DrugBank.d531.s75.e0,DDI-DrugBank.d531.s75.e1,Potential for reduction in drug1 and/or drug2,True,mechanism
DDI-DrugBank.d531.s77.e0,DDI-DrugBank.d531.s77.e1,drug1: drug2 drug0,False, 
DDI-DrugBank.d531.s77.e0,DDI-DrugBank.d531.s77.e2,drug1: drug0 drug2,False, 
DDI-DrugBank.d531.s78.e0,DDI-DrugBank.d531.s78.e1,Drug interaction studies with drug1 and these drug2 and drug0,False, 
DDI-DrugBank.d531.s78.e0,DDI-DrugBank.d531.s78.e2,Drug interaction studies with drug1 and these drug0 and drug2,False, 
DDI-DrugBank.d531.s79.e0,DDI-DrugBank.d531.s79.e1,drug1 has the potential to decrease plasma concentrations of drug2 and drug0,True,mechanism
DDI-DrugBank.d531.s79.e0,DDI-DrugBank.d531.s79.e2,drug1 has the potential to decrease plasma concentrations of drug0 and drug2,True,mechanism
DDI-DrugBank.d531.s79.e1,DDI-DrugBank.d531.s79.e2,drug0 has the potential to decrease plasma concentrations of drug1 and drug2,False, 
DDI-DrugBank.d531.s80.e0,DDI-DrugBank.d531.s80.e1,drug1: drug2/drug0,False, 
DDI-DrugBank.d531.s80.e0,DDI-DrugBank.d531.s80.e2,drug1: drug0/drug2,False, 
DDI-DrugBank.d531.s87.e0,DDI-DrugBank.d531.s87.e1,Expected to substantially decrease plasma levels of drug1;has not been studied in combination with drug2,False, 
DDI-DrugBank.d531.s90.e0,DDI-DrugBank.d531.s90.e1,"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when drug1 (drug2) is given with the following: drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d531.s90.e0,DDI-DrugBank.d531.s90.e2,"Other Drugs: Based on the results of drug interaction studies, no dosage adjustment is recommended when drug1 (drug0) is given with the following: drug2, drug0, drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d531.s91.e0,DDI-DrugBank.d531.s91.e1,Specific drug interaction studies have not been performed with drug1 and drug2 other than drug0 and drug0,False, 
DDI-DrugBank.d531.s91.e0,DDI-DrugBank.d531.s91.e2,Specific drug interaction studies have not been performed with drug1 and drug0 other than drug2 and drug0,False, 
DDI-DrugBank.d531.s92.e0,DDI-DrugBank.d531.s92.e1,Clinically significant interactions would not be expected since the drug1 are metabolized via a different route than drug2,False, 
DDI-DrugBank.d33.s0.e0,DDI-DrugBank.d33.s0.e1,"Although the occurrence has not been reported with drug1, nephrotoxicity has been reported following concomitant administration of other drug2 and drug0",False, 
DDI-DrugBank.d33.s0.e0,DDI-DrugBank.d33.s0.e2,"Although the occurrence has not been reported with drug1, nephrotoxicity has been reported following concomitant administration of other drug0 and drug2",False, 
DDI-DrugBank.d33.s0.e1,DDI-DrugBank.d33.s0.e2,"Although the occurrence has not been reported with drug0, nephrotoxicity has been reported following concomitant administration of other drug1 and drug2",True,effect
DDI-DrugBank.d294.s0.e0,DDI-DrugBank.d294.s0.e1,Drug/LaboratoryTest Interactions drug1 may interfere with bioassay procedures for the determination of drug2,False, 
DDI-DrugBank.d187.s2.e0,DDI-DrugBank.d187.s2.e1,drug1: A report of severe drug2 toxicity was reported in a patient receiving drug0,False, 
DDI-DrugBank.d187.s2.e0,DDI-DrugBank.d187.s2.e2,drug1: A report of severe drug0 toxicity was reported in a patient receiving drug2,False, 
DDI-DrugBank.d187.s2.e1,DDI-DrugBank.d187.s2.e2,drug0: A report of severe drug1 toxicity was reported in a patient receiving drug2,True,effect
DDI-DrugBank.d187.s3.e0,DDI-DrugBank.d187.s3.e1,It is believed that the toxicity may have resulted from a previously unrecognized interaction between drug1 and drug2,True,effect
DDI-DrugBank.d187.s5.e0,DDI-DrugBank.d187.s5.e1,"Furthermore it has been proposed that drug1 resulted In induction of P-450IIE1 in the patients liver which, in turn, resulted in a greater proportion of the ingested drug2",True,mechanism
DDI-DrugBank.d187.s7.e0,DDI-DrugBank.d187.s7.e1,"drug1: drug2 is known to slow the metabolism of drug0 and increase its serum levels drug0 levels should be determined prior to concurrent administration with drug0, signs and symptoms of drug0 toxicity should be monitored closely, and appropriate dosage adjustment of the drug0",False, 
DDI-DrugBank.d187.s7.e0,DDI-DrugBank.d187.s7.e2,"drug1: drug0 is known to slow the metabolism of drug2 and increase its serum levels drug0 levels should be determined prior to concurrent administration with drug0, signs and symptoms of drug0 toxicity should be monitored closely, and appropriate dosage adjustment of the drug0",False, 
DDI-DrugBank.d187.s7.e1,DDI-DrugBank.d187.s7.e2,"drug0: drug1 is known to slow the metabolism of drug2 and increase its serum levels drug0 levels should be determined prior to concurrent administration with drug0, signs and symptoms of drug0 toxicity should be monitored closely, and appropriate dosage adjustment of the drug0",True,mechanism
DDI-DrugBank.d187.s7.e3,DDI-DrugBank.d187.s7.e4,"drug0: drug0 is known to slow the metabolism of drug0 and increase its serum levels drug1 levels should be determined prior to concurrent administration with drug2, signs and symptoms of drug0 toxicity should be monitored closely, and appropriate dosage adjustment of the drug0",True,advise
DDI-DrugBank.d187.s8.e0,DDI-DrugBank.d187.s8.e1,drug1: Potential interaction of drug2 and drug0,False, 
DDI-DrugBank.d187.s8.e0,DDI-DrugBank.d187.s8.e2,drug1: Potential interaction of drug0 and drug2,False, 
DDI-DrugBank.d187.s8.e1,DDI-DrugBank.d187.s8.e2,drug0: Potential interaction of drug1 and drug2,True,int
DDI-DrugBank.d187.s9.e0,DDI-DrugBank.d187.s9.e1,drug1: drug2 may increase serum levels of drug0,False, 
DDI-DrugBank.d187.s9.e0,DDI-DrugBank.d187.s9.e2,drug1: drug0 may increase serum levels of drug2,False, 
DDI-DrugBank.d187.s9.e1,DDI-DrugBank.d187.s9.e2,drug0: drug1 may increase serum levels of drug2,True,mechanism
DDI-DrugBank.d187.s10.e0,DDI-DrugBank.d187.s10.e1,"To avoid drug1 intoxication, appropriate adjustment of the drug2",False, 
DDI-DrugBank.d187.s11.e0,DDI-DrugBank.d187.s11.e1,"Therophylline: A recent study has shown that concomitan administration of drug1 and drug2 may cause elevated plasma levels of drug0, and in some instances a slight decrease in the elimination of drug0",True,mechanism
DDI-DrugBank.d187.s11.e0,DDI-DrugBank.d187.s11.e2,"Therophylline: A recent study has shown that concomitan administration of drug1 and drug0 may cause elevated plasma levels of drug2, and in some instances a slight decrease in the elimination of drug0",False, 
DDI-DrugBank.d187.s11.e0,DDI-DrugBank.d187.s11.e3,"Therophylline: A recent study has shown that concomitan administration of drug1 and drug0 may cause elevated plasma levels of drug0, and in some instances a slight decrease in the elimination of drug2",False, 
DDI-DrugBank.d187.s12.e0,DDI-DrugBank.d187.s12.e1,"Since the therapeutic range of drug1 is narrow drug2 serum levels should be monitored closely, and appropriate dosage adjustments of drug0",False, 
DDI-DrugBank.d187.s12.e0,DDI-DrugBank.d187.s12.e2,"Since the therapeutic range of drug1 is narrow drug0 serum levels should be monitored closely, and appropriate dosage adjustments of drug2",False, 
DDI-DrugBank.d187.s13.e0,DDI-DrugBank.d187.s13.e1,drug1: A recent case study has shown a possible increase in the plasma level of drug2 when co administered with drug0,False, 
DDI-DrugBank.d187.s13.e0,DDI-DrugBank.d187.s13.e2,drug1: A recent case study has shown a possible increase in the plasma level of drug0 when co administered with drug2,False, 
DDI-DrugBank.d187.s13.e1,DDI-DrugBank.d187.s13.e2,drug0: A recent case study has shown a possible increase in the plasma level of drug1 when co administered with drug2,True,mechanism
DDI-DrugBank.d187.s14.e0,DDI-DrugBank.d187.s14.e1,"Plasma drug1 concentration should be monitored when drug2 and drug0 are co administered, and appropriate dosage adjustments of drug0",False, 
DDI-DrugBank.d187.s14.e0,DDI-DrugBank.d187.s14.e2,"Plasma drug1 concentration should be monitored when drug0 and drug2 are co administered, and appropriate dosage adjustments of drug0",False, 
DDI-DrugBank.d187.s14.e1,DDI-DrugBank.d187.s14.e2,"Plasma drug0 concentration should be monitored when drug1 and drug2 are co administered, and appropriate dosage adjustments of drug0",True,advise
DDI-DrugBank.d60.s0.e0,DDI-DrugBank.d60.s0.e1,Administration of 0.1-mg/kg (2 x ED95) drug1 at 10% or 95% recovery following an intubating dose of drug2,True,effect
DDI-DrugBank.d60.s1.e0,DDI-DrugBank.d60.s1.e1,The time to onset of maximum block following drug1 is approximately 2 minutes faster with prior administration of drug2,True,effect
DDI-DrugBank.d60.s2.e0,DDI-DrugBank.d60.s2.e1,Prior administration of drug1 had no effect on the duration of neuromuscular block following initial or maintenance bolus doses of drug2,False, 
DDI-DrugBank.d60.s3.e0,DDI-DrugBank.d60.s3.e1,Infusion requirements of drug1 in patients administered drug2 prior to infusions of drug0 were comparable to or slightly greater than when drug0,False, 
DDI-DrugBank.d60.s3.e0,DDI-DrugBank.d60.s3.e2,Infusion requirements of drug1 in patients administered drug0 prior to infusions of drug2 were comparable to or slightly greater than when drug0,False, 
DDI-DrugBank.d60.s3.e1,DDI-DrugBank.d60.s3.e2,Infusion requirements of drug0 in patients administered drug1 prior to infusions of drug2 were comparable to or slightly greater than when drug0,True,effect
DDI-DrugBank.d60.s4.e0,DDI-DrugBank.d60.s4.e1,The use of drug1 before drug2 to attenuate some of the side effects of drug0,False, 
DDI-DrugBank.d60.s4.e0,DDI-DrugBank.d60.s4.e2,The use of drug1 before drug0 to attenuate some of the side effects of drug2,False, 
DDI-DrugBank.d60.s5.e0,DDI-DrugBank.d60.s5.e1,"Although not studied systematically in clinical trials, no drug interactions were observed when drug1, drug2, or drug0 were administered following varying degrees of recovery from single doses or infusions of drug0",False, 
DDI-DrugBank.d60.s5.e0,DDI-DrugBank.d60.s5.e2,"Although not studied systematically in clinical trials, no drug interactions were observed when drug1, drug0, or drug2 were administered following varying degrees of recovery from single doses or infusions of drug0",False, 
DDI-DrugBank.d60.s6.e0,DDI-DrugBank.d60.s6.e1,drug1 or drug2 administered with drug0/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug0 and decrease the required infusion rate of drug0,False, 
DDI-DrugBank.d60.s6.e0,DDI-DrugBank.d60.s6.e2,drug1 or drug0 administered with drug2/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug0 and decrease the required infusion rate of drug0,False, 
DDI-DrugBank.d60.s6.e0,DDI-DrugBank.d60.s6.e4,drug1 or drug0 administered with drug0/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug2 and decrease the required infusion rate of drug0,True,effect
DDI-DrugBank.d60.s6.e0,DDI-DrugBank.d60.s6.e5,drug1 or drug0 administered with drug0/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug0 and decrease the required infusion rate of drug2,True,effect
DDI-DrugBank.d60.s6.e1,DDI-DrugBank.d60.s6.e4,drug0 or drug1 administered with drug0/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug2 and decrease the required infusion rate of drug0,True,effect
DDI-DrugBank.d60.s6.e1,DDI-DrugBank.d60.s6.e5,drug0 or drug1 administered with drug0/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug0 and decrease the required infusion rate of drug2,True,effect
DDI-DrugBank.d60.s6.e2,DDI-DrugBank.d60.s6.e4,drug0 or drug0 administered with drug1/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug2 and decrease the required infusion rate of drug0,True,effect
DDI-DrugBank.d60.s6.e2,DDI-DrugBank.d60.s6.e5,drug0 or drug0 administered with drug1/drug0 to achieve 1.25 MAC [Minimum Alveolar Concentration] may prolong the clinically effective duration of action of initial and maintenance doses of drug0 and decrease the required infusion rate of drug2,True,effect
DDI-DrugBank.d60.s8.e0,DDI-DrugBank.d60.s8.e1,"Fifteen to 30 minutes of exposure to 1.25 MAC drug1 or drug2 had minimal effects on the duration of action of initial doses of drug0 and therefore, no adjustment to the initial dose should be necessary when drug0",False, 
DDI-DrugBank.d60.s8.e0,DDI-DrugBank.d60.s8.e2,"Fifteen to 30 minutes of exposure to 1.25 MAC drug1 or drug0 had minimal effects on the duration of action of initial doses of drug2 and therefore, no adjustment to the initial dose should be necessary when drug0",False, 
DDI-DrugBank.d60.s9.e0,DDI-DrugBank.d60.s9.e1,"In long surgical procedures during drug1 or drug2 anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of drug0",False, 
DDI-DrugBank.d60.s9.e0,DDI-DrugBank.d60.s9.e2,"In long surgical procedures during drug1 or drug0 anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of drug2",True,advise
DDI-DrugBank.d60.s9.e1,DDI-DrugBank.d60.s9.e2,"In long surgical procedures during drug0 or drug1 anesthesia, less frequent maintenance dosing, lower maintenance doses, or reduced infusion rates of drug2",True,advise
DDI-DrugBank.d60.s11.e0,DDI-DrugBank.d60.s11.e1,In clinical studies drug1 had no effect on the duration of action or dosing requirements for drug2,False, 
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e1,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug2 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e2,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug2 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e3,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e4,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e5,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e6,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e7,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e8,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e9,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e10,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e11,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug2 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e12,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug2, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e13,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug2, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e14,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug2, and drug0",True,effect
DDI-DrugBank.d60.s12.e0,DDI-DrugBank.d60.s12.e15,"Other drugs which may enhance the neuromuscular blocking action of drug1 such as drug0 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug2",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e2,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug2 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e3,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e4,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e5,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug2, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e6,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug2, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e7,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug2, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e8,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug2, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e9,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug2, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e10,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug2), drug0 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e11,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug2 salts, drug0, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e12,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug2, local drug0, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e13,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug2, drug0, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e14,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug2, and drug0",True,effect
DDI-DrugBank.d60.s12.e1,DDI-DrugBank.d60.s12.e15,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug1 include certain drug0 (e. g., drug0, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug2",True,effect
DDI-DrugBank.d60.s12.e2,DDI-DrugBank.d60.s12.e3,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug0 include certain drug1 (e. g., drug2, drug0, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d60.s12.e2,DDI-DrugBank.d60.s12.e4,"Other drugs which may enhance the neuromuscular blocking action of drug0 such as drug0 include certain drug1 (e. g., drug0, drug2, drug0, drug0, drug0, drug0, drug0, and drug0), drug0 salts, drug0, local drug0, drug0, and drug0",False, 
DDI-DrugBank.d60.s13.e0,DDI-DrugBank.d60.s13.e1,Resistance to the neuromuscular blocking action of drug1 has been demonstrated in patients chronically administered drug2 or drug0,True,effect
DDI-DrugBank.d60.s13.e0,DDI-DrugBank.d60.s13.e2,Resistance to the neuromuscular blocking action of drug1 has been demonstrated in patients chronically administered drug0 or drug2,True,effect
DDI-DrugBank.d60.s13.e1,DDI-DrugBank.d60.s13.e2,Resistance to the neuromuscular blocking action of drug0 has been demonstrated in patients chronically administered drug1 or drug2,False, 
DDI-DrugBank.d60.s14.e0,DDI-DrugBank.d60.s14.e1,While the effects of chronic drug1 or drug2 therapy on the action of drug0,False, 
DDI-DrugBank.d60.s14.e0,DDI-DrugBank.d60.s14.e2,While the effects of chronic drug1 or drug0 therapy on the action of drug2,True,effect
DDI-DrugBank.d60.s14.e1,DDI-DrugBank.d60.s14.e2,While the effects of chronic drug0 or drug1 therapy on the action of drug2,True,effect
DDI-DrugBank.d43.s1.e0,DDI-DrugBank.d43.s1.e1,"Neuropathy has occurred more frequently in patients with a history of neuropathy or neurotoxic drug therapy, including drug1, and these patients may be at increased risk of neuropathy during drug2",False, 
DDI-DrugBank.d43.s2.e0,DDI-DrugBank.d43.s2.e1,drug1: The AUC of drug2 was increased about 4-fold when drug0 at 300 mg/day was coadministered with a single 200-mg dose of drug0,False, 
DDI-DrugBank.d43.s2.e0,DDI-DrugBank.d43.s2.e2,drug1: The AUC of drug0 was increased about 4-fold when drug2 at 300 mg/day was coadministered with a single 200-mg dose of drug0,False, 
DDI-DrugBank.d43.s2.e2,DDI-DrugBank.d43.s2.e3,drug0: The AUC of drug0 was increased about 4-fold when drug1 at 300 mg/day was coadministered with a single 200-mg dose of drug2,True,mechanism
DDI-DrugBank.d43.s3.e0,DDI-DrugBank.d43.s3.e1,The effects of drug1 on drug2,False, 
DDI-DrugBank.d43.s4.e0,DDI-DrugBank.d43.s4.e1,drug1: Concomitant administration of drug2 containing drug0 or drug0 with drug0 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug0,False, 
DDI-DrugBank.d43.s4.e0,DDI-DrugBank.d43.s4.e2,drug1: Concomitant administration of drug0 containing drug2 or drug0 with drug0 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug0,False, 
DDI-DrugBank.d43.s4.e1,DDI-DrugBank.d43.s4.e4,drug0: Concomitant administration of drug1 containing drug0 or drug0 with drug2 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug0,True,effect
DDI-DrugBank.d43.s4.e2,DDI-DrugBank.d43.s4.e4,drug0: Concomitant administration of drug0 containing drug1 or drug0 with drug2 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug0,True,effect
DDI-DrugBank.d43.s4.e3,DDI-DrugBank.d43.s4.e4,drug0: Concomitant administration of drug0 containing drug0 or drug1 with drug2 Chewable/Dispersible Buffered Tablets or Pediatric Powder for Oral Solution may potentiate adverse events associated with the drug0,True,effect
DDI-DrugBank.d43.s5.e0,DDI-DrugBank.d43.s5.e1,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as drug1 and drug2 should be administered at least 2 hours prior to dosing with drug0,False, 
DDI-DrugBank.d43.s5.e0,DDI-DrugBank.d43.s5.e2,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as drug1 and drug0 should be administered at least 2 hours prior to dosing with drug2,True,advise
DDI-DrugBank.d43.s5.e1,DDI-DrugBank.d43.s5.e2,Drugs Whose Absorption Can Be Affected by the Level of Acidity in the Stomach: Drugs such as drug0 and drug1 should be administered at least 2 hours prior to dosing with drug2,True,advise
DDI-DrugBank.d43.s6.e0,DDI-DrugBank.d43.s6.e1,drug1: Administration of drug2 2 hours prior to or concurrent with oral drug0 was associated with a 111 (114)% increase in the steady-state AUC of drug0,False, 
DDI-DrugBank.d43.s6.e0,DDI-DrugBank.d43.s6.e2,drug1: Administration of drug0 2 hours prior to or concurrent with oral drug2 was associated with a 111 (114)% increase in the steady-state AUC of drug0,False, 
DDI-DrugBank.d43.s6.e1,DDI-DrugBank.d43.s6.e2,drug0: Administration of drug1 2 hours prior to or concurrent with oral drug2 was associated with a 111 (114)% increase in the steady-state AUC of drug0,True,mechanism
DDI-DrugBank.d43.s7.e0,DDI-DrugBank.d43.s7.e1,A 21 (17)% decrease in the steady-state AUC of drug1 was observed when drug2 was administered 2 hours prior to drug0,False, 
DDI-DrugBank.d43.s7.e0,DDI-DrugBank.d43.s7.e2,A 21 (17)% decrease in the steady-state AUC of drug1 was observed when drug0 was administered 2 hours prior to drug2,False, 
DDI-DrugBank.d43.s7.e1,DDI-DrugBank.d43.s7.e2,A 21 (17)% decrease in the steady-state AUC of drug0 was observed when drug1 was administered 2 hours prior to drug2,True,mechanism
DDI-DrugBank.d43.s8.e0,DDI-DrugBank.d43.s8.e1,"drug1s: drug2 should be administered at least 2 hours after or 6 hours before dosing with drug0 because plasma concentrations of drug0 are decreased when administered with drug0 containing drug0, drug0, or drug0",False, 
DDI-DrugBank.d43.s8.e0,DDI-DrugBank.d43.s8.e2,"drug1s: drug0 should be administered at least 2 hours after or 6 hours before dosing with drug2 because plasma concentrations of drug0 are decreased when administered with drug0 containing drug0, drug0, or drug0",False, 
DDI-DrugBank.d43.s8.e1,DDI-DrugBank.d43.s8.e2,"drug0s: drug1 should be administered at least 2 hours after or 6 hours before dosing with drug2 because plasma concentrations of drug0 are decreased when administered with drug0 containing drug0, drug0, or drug0",True,advise
DDI-DrugBank.d43.s8.e3,DDI-DrugBank.d43.s8.e5,"drug0s: drug0 should be administered at least 2 hours after or 6 hours before dosing with drug0 because plasma concentrations of drug1 are decreased when administered with drug0 containing drug2, drug0, or drug0",True,mechanism
DDI-DrugBank.d43.s8.e3,DDI-DrugBank.d43.s8.e6,"drug0s: drug0 should be administered at least 2 hours after or 6 hours before dosing with drug0 because plasma concentrations of drug1 are decreased when administered with drug0 containing drug0, drug2, or drug0",True,mechanism
DDI-DrugBank.d43.s8.e3,DDI-DrugBank.d43.s8.e7,"drug0s: drug0 should be administered at least 2 hours after or 6 hours before dosing with drug0 because plasma concentrations of drug1 are decreased when administered with drug0 containing drug0, drug0, or drug2",True,mechanism
DDI-DrugBank.d43.s9.e0,DDI-DrugBank.d43.s9.e1,"In eight HIV-infected patients, the steady-state AUC of drug1 was decreased an average of 26% (95% CI = 14%, 37%) when drug2 was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of drug0",False, 
DDI-DrugBank.d43.s9.e0,DDI-DrugBank.d43.s9.e2,"In eight HIV-infected patients, the steady-state AUC of drug1 was decreased an average of 26% (95% CI = 14%, 37%) when drug0 was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of drug2",False, 
DDI-DrugBank.d43.s9.e1,DDI-DrugBank.d43.s9.e2,"In eight HIV-infected patients, the steady-state AUC of drug0 was decreased an average of 26% (95% CI = 14%, 37%) when drug1 was administered 2 hours prior to a marketed chewable/dispersible tablet formulation of drug2",True,mechanism
DDI-DrugBank.d43.s10.e0,DDI-DrugBank.d43.s10.e1,The AUC of drug1 was decreased an average of 15-fold in 12 healthy subjects given drug2 and drug0,False, 
DDI-DrugBank.d43.s10.e0,DDI-DrugBank.d43.s10.e2,The AUC of drug1 was decreased an average of 15-fold in 12 healthy subjects given drug0 and drug2,False, 
DDI-DrugBank.d43.s10.e1,DDI-DrugBank.d43.s10.e2,The AUC of drug0 was decreased an average of 15-fold in 12 healthy subjects given drug1 and drug2,True,mechanism
DDI-DrugBank.d43.s11.e0,DDI-DrugBank.d43.s11.e1,"In a single subject given one dose of drug1 2 hours after a dose of drug2-placebo tablets, a greater than 50% reduction in the AUC of drug0",True,mechanism
DDI-DrugBank.d43.s11.e0,DDI-DrugBank.d43.s11.e2,"In a single subject given one dose of drug1 2 hours after a dose of drug0-placebo tablets, a greater than 50% reduction in the AUC of drug2",False, 
DDI-DrugBank.d43.s11.e1,DDI-DrugBank.d43.s11.e2,"In a single subject given one dose of drug0 2 hours after a dose of drug1-placebo tablets, a greater than 50% reduction in the AUC of drug2",False, 
DDI-DrugBank.d43.s12.e0,DDI-DrugBank.d43.s12.e1,"Plasma concentrations of drug1 are decreased when administered with drug2 containing drug0, drug0, or drug0",False, 
DDI-DrugBank.d43.s12.e0,DDI-DrugBank.d43.s12.e2,"Plasma concentrations of drug1 are decreased when administered with drug0 containing drug2, drug0, or drug0",True,mechanism
DDI-DrugBank.d43.s12.e0,DDI-DrugBank.d43.s12.e3,"Plasma concentrations of drug1 are decreased when administered with drug0 containing drug0, drug2, or drug0",True,mechanism
DDI-DrugBank.d43.s12.e0,DDI-DrugBank.d43.s12.e4,"Plasma concentrations of drug1 are decreased when administered with drug0 containing drug0, drug0, or drug2",True,mechanism
DDI-DrugBank.d43.s12.e1,DDI-DrugBank.d43.s12.e2,"Plasma concentrations of drug0 are decreased when administered with drug1 containing drug2, drug0, or drug0",False, 
DDI-DrugBank.d43.s13.e0,DDI-DrugBank.d43.s13.e1,The optimal dosing interval for coadministration with drug1 should be determined by consulting the appropriate drug2,False, 
DDI-DrugBank.d43.s14.e0,DDI-DrugBank.d43.s14.e1,Interactions with Other drug1: Significant decreases in the AUC of drug2 (20%) and drug0 (84%) occurred following simultaneous administration of these agents with drug0,False, 
DDI-DrugBank.d43.s14.e0,DDI-DrugBank.d43.s14.e2,Interactions with Other drug1: Significant decreases in the AUC of drug0 (20%) and drug2 (84%) occurred following simultaneous administration of these agents with drug0,False, 
DDI-DrugBank.d43.s14.e1,DDI-DrugBank.d43.s14.e3,Interactions with Other drug0: Significant decreases in the AUC of drug1 (20%) and drug0 (84%) occurred following simultaneous administration of these agents with drug2,True,mechanism
DDI-DrugBank.d43.s14.e2,DDI-DrugBank.d43.s14.e3,Interactions with Other drug0: Significant decreases in the AUC of drug0 (20%) and drug1 (84%) occurred following simultaneous administration of these agents with drug2,True,mechanism
DDI-DrugBank.d43.s15.e0,DDI-DrugBank.d43.s15.e1,"To avoid this interaction, drug1 or drug2 should be given 1 hour prior to dosing with drug0",False, 
DDI-DrugBank.d43.s15.e0,DDI-DrugBank.d43.s15.e2,"To avoid this interaction, drug1 or drug0 should be given 1 hour prior to dosing with drug2",True,advise
DDI-DrugBank.d43.s15.e1,DDI-DrugBank.d43.s15.e2,"To avoid this interaction, drug0 or drug1 should be given 1 hour prior to dosing with drug2",True,advise
DDI-DrugBank.d43.s16.e0,DDI-DrugBank.d43.s16.e1,The pharmacokinetics of drug1 are not altered to a clinically significant degree when it is administered with a light meal 1 hour after drug2,False, 
DDI-DrugBank.d493.s0.e0,DDI-DrugBank.d493.s0.e1,drug1: drug2 has been studied in rheumatoid arthritis patients taking concomitant drug0,False, 
DDI-DrugBank.d493.s0.e0,DDI-DrugBank.d493.s0.e2,drug1: drug0 has been studied in rheumatoid arthritis patients taking concomitant drug2,False, 
DDI-DrugBank.d493.s1.e0,DDI-DrugBank.d493.s1.e1,The data do not suggest the need for dose adjustment of either drug1 or drug2,False, 
DDI-DrugBank.d493.s2.e0,DDI-DrugBank.d493.s2.e1,drug1: Concurrent administration of drug2 (an drug0) and another drug0,False, 
DDI-DrugBank.d493.s2.e0,DDI-DrugBank.d493.s2.e2,drug1: Concurrent administration of drug0 (an drug2) and another drug0,False, 
DDI-DrugBank.d493.s2.e1,DDI-DrugBank.d493.s2.e3,drug0: Concurrent administration of drug1 (an drug0) and another drug2,True,effect
DDI-DrugBank.d493.s2.e2,DDI-DrugBank.d493.s2.e3,drug0: Concurrent administration of drug0 (an drug1) and another drug2,True,effect
DDI-DrugBank.d493.s3.e0,DDI-DrugBank.d493.s3.e1,The safety and efficacy of drug1 used in combination with drug2,False, 
DDI-DrugBank.d493.s4.e0,DDI-DrugBank.d493.s4.e1,"Therefore the, combination of drug1 with other drug2, including drug0",True,effect
DDI-DrugBank.d493.s4.e0,DDI-DrugBank.d493.s4.e2,"Therefore the, combination of drug1 with other drug0, including drug2",True,effect
DDI-DrugBank.d493.s4.e1,DDI-DrugBank.d493.s4.e2,"Therefore the, combination of drug0 with other drug1, including drug2",False, 
DDI-DrugBank.d216.s0.e0,DDI-DrugBank.d216.s0.e1,CNS-Active Drugs drug1 An additive effect on psychomotor performance was seen with coadministration of drug2 and drug0 0.70 g/kg for up to 4 hours after drug0,False, 
DDI-DrugBank.d216.s0.e0,DDI-DrugBank.d216.s0.e2,CNS-Active Drugs drug1 An additive effect on psychomotor performance was seen with coadministration of drug0 and drug2 0.70 g/kg for up to 4 hours after drug0,False, 
DDI-DrugBank.d216.s0.e1,DDI-DrugBank.d216.s0.e2,CNS-Active Drugs drug0 An additive effect on psychomotor performance was seen with coadministration of drug1 and drug2 0.70 g/kg for up to 4 hours after drug0,True,effect
DDI-DrugBank.d216.s1.e0,DDI-DrugBank.d216.s1.e1,drug1: Coadministration of single doses of drug2 3 mg and drug0,False, 
DDI-DrugBank.d216.s1.e0,DDI-DrugBank.d216.s1.e2,drug1: Coadministration of single doses of drug0 3 mg and drug2,False, 
DDI-DrugBank.d216.s2.e0,DDI-DrugBank.d216.s2.e1,drug1: Coadministration of single doses of drug2 3 mg and drug0,False, 
DDI-DrugBank.d216.s2.e0,DDI-DrugBank.d216.s2.e2,drug1: Coadministration of single doses of drug0 3 mg and drug2,False, 
DDI-DrugBank.d216.s3.e0,DDI-DrugBank.d216.s3.e1,drug1: Coadministration of drug2 3 mg and drug0,False, 
DDI-DrugBank.d216.s3.e0,DDI-DrugBank.d216.s3.e2,drug1: Coadministration of drug0 3 mg and drug2,False, 
DDI-DrugBank.d216.s3.e1,DDI-DrugBank.d216.s3.e2,drug0: Coadministration of drug1 3 mg and drug2,True,effect
DDI-DrugBank.d216.s6.e0,DDI-DrugBank.d216.s6.e1,Drugs That Inhibit CYP3A4 (drug1) CYP3A4 is a major metabolic pathway for elimination of drug2,False, 
DDI-DrugBank.d216.s7.e0,DDI-DrugBank.d216.s7.e1,The AUC of drug1 was increased 2.2-fold by coadministration of drug2,True,mechanism
DDI-DrugBank.d216.s9.e0,DDI-DrugBank.d216.s9.e1,"Other strong inhibitors of CYP3A4 (e.g., drug1, drug2, drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d216.s9.e0,DDI-DrugBank.d216.s9.e2,"Other strong inhibitors of CYP3A4 (e.g., drug1, drug0, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d216.s10.e0,DDI-DrugBank.d216.s10.e1,Drugs That Induce CYP3A4 (drug1) Racemic drug2 exposure was decreased 80% by concomitant useof drug0,False, 
DDI-DrugBank.d216.s10.e0,DDI-DrugBank.d216.s10.e2,Drugs That Induce CYP3A4 (drug1) Racemic drug0 exposure was decreased 80% by concomitant useof drug2,False, 
DDI-DrugBank.d216.s10.e1,DDI-DrugBank.d216.s10.e2,Drugs That Induce CYP3A4 (drug0) Racemic drug1 exposure was decreased 80% by concomitant useof drug2,True,mechanism
DDI-DrugBank.d216.s15.e0,DDI-DrugBank.d216.s15.e1,Drugs With A Narrow Therapeutic Index drug1 A single dose of drug2 3 mg did not affect the pharmacokinetics of drug0,False, 
DDI-DrugBank.d216.s15.e0,DDI-DrugBank.d216.s15.e2,Drugs With A Narrow Therapeutic Index drug1 A single dose of drug0 3 mg did not affect the pharmacokinetics of drug2,False, 
DDI-DrugBank.d216.s16.e0,DDI-DrugBank.d216.s16.e1,"drug1: drug2 3 mg administered daily for 5 days did not affect the pharmacokinetics ofdrug0- or drug0n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of drug0",False, 
DDI-DrugBank.d216.s16.e0,DDI-DrugBank.d216.s16.e2,"drug1: drug0 3 mg administered daily for 5 days did not affect the pharmacokinetics ofdrug2- or drug0n, nor were there any changes in the pharmacodynamic profile (prothrombin time) following a single 25 mg oral dose of drug0",False, 
DDI-DrugBank.d27.s0.e0,DDI-DrugBank.d27.s0.e1,"No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with drug1, drug2, drug0, and drug0",False, 
DDI-DrugBank.d27.s0.e0,DDI-DrugBank.d27.s0.e2,"No significant drug-drug pharmacokinetic (or pharmacodynamic) interactions have been found in interaction studies with drug1, drug0, drug2, and drug0",False, 
DDI-DrugBank.d27.s1.e0,DDI-DrugBank.d27.s1.e1,"In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors drug1, drug2 and drug0",False, 
DDI-DrugBank.d27.s1.e0,DDI-DrugBank.d27.s1.e2,"In vitro studies show significant inhibition of the formation of oxidized irbesartan metabolites with the known cytochrome CYP 2C9 substrates/inhibitors drug1, drug0 and drug2",False, 
DDI-DrugBank.d27.s2.e0,DDI-DrugBank.d27.s2.e1,"However, in clinical studies the consequences of concomitant drug1 on the pharmacodynamics of drug2",False, 
DDI-DrugBank.d27.s4.e0,DDI-DrugBank.d27.s4.e1,"In separate studies of patients receiving maintenance doses of drug1, drug2, or drug0, drug0 administration for 7 days had no effect on the pharmacodynamics of drug0 (prothrombin time) or pharmacokinetics of drug0",False, 
DDI-DrugBank.d27.s4.e0,DDI-DrugBank.d27.s4.e2,"In separate studies of patients receiving maintenance doses of drug1, drug0, or drug2, drug0 administration for 7 days had no effect on the pharmacodynamics of drug0 (prothrombin time) or pharmacokinetics of drug0",False, 
DDI-DrugBank.d27.s5.e0,DDI-DrugBank.d27.s5.e1,The pharmacokinetics of drug1 were not affected by coadministration of drug2 or drug0,False, 
DDI-DrugBank.d27.s5.e0,DDI-DrugBank.d27.s5.e2,The pharmacokinetics of drug1 were not affected by coadministration of drug0 or drug2,False, 
DDI-DrugBank.d17.s6.e0,DDI-DrugBank.d17.s6.e1,"drug1, other, especially drug2, or predrug0 and anesthetic agents used in surgery or drug0",False, 
DDI-DrugBank.d17.s6.e0,DDI-DrugBank.d17.s6.e2,"drug1, other, especially drug0, or predrug2 and anesthetic agents used in surgery or drug0",False, 
DDI-DrugBank.d17.s9.e0,DDI-DrugBank.d17.s9.e1,drug1 or drug2 or drug0 (drug0,False, 
DDI-DrugBank.d17.s9.e0,DDI-DrugBank.d17.s9.e2,drug1 or drug0 or drug2 (drug0,False, 
DDI-DrugBank.d17.s12.e0,DDI-DrugBank.d17.s12.e1,(Concurrent use with drug1 may enhance the possibility of drug2,True,effect
DDI-DrugBank.d17.s18.e0,DDI-DrugBank.d17.s18.e1,"for adult-onset diabetics, dosage adjustment of drug1 may be necessary during and after drug2",True,advise
DDI-DrugBank.d17.s21.e0,DDI-DrugBank.d17.s21.e1,"(Concurrent use with drug1 is not recommended, as they may provoke drug2",False, 
DDI-DrugBank.d17.s25.e0,DDI-DrugBank.d17.s25.e1,"(In some patients, the drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug2, drug0, and drug0",True,effect
DDI-DrugBank.d17.s25.e0,DDI-DrugBank.d17.s25.e2,"(In some patients, the drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug2, and drug0",True,effect
DDI-DrugBank.d17.s25.e0,DDI-DrugBank.d17.s25.e3,"(In some patients, the drug1 can reduce the diuretic, natriuretic, and antihypertensive effects of drug0, drug0, and drug2",True,effect
DDI-DrugBank.d17.s25.e1,DDI-DrugBank.d17.s25.e2,"(In some patients, the drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug2, and drug0",False, 
DDI-DrugBank.d17.s25.e1,DDI-DrugBank.d17.s25.e3,"(In some patients, the drug0 can reduce the diuretic, natriuretic, and antihypertensive effects of drug1, drug0, and drug2",False, 
DDI-DrugBank.d17.s26.e0,DDI-DrugBank.d17.s26.e1,"Therefore, when drug1 and drug2 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug0",True,advise
DDI-DrugBank.d17.s26.e0,DDI-DrugBank.d17.s26.e2,"Therefore, when drug1 and drug0 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d17.s26.e1,DDI-DrugBank.d17.s26.e2,"Therefore, when drug0 and drug1 are used concomitantly, the patient should be observed closely to determine if the desired effect of the drug2",False, 
DDI-DrugBank.d17.s28.e0,DDI-DrugBank.d17.s28.e1,(drug1 may decrease arterial responsiveness to drug2,True,effect
DDI-DrugBank.d17.s31.e0,DDI-DrugBank.d17.s31.e1,(drug1 may increase the responsiveness to drug2,True,effect
DDI-DrugBank.d337.s0.e0,DDI-DrugBank.d337.s0.e1,drug1: Concomitant administration of drug2 (6 mg/kg once every 24 hours for 5 days) and drug0,False, 
DDI-DrugBank.d337.s0.e0,DDI-DrugBank.d337.s0.e2,drug1: Concomitant administration of drug0 (6 mg/kg once every 24 hours for 5 days) and drug2,False, 
DDI-DrugBank.d337.s1.e0,DDI-DrugBank.d337.s1.e1,drug1: drug2,False, 
DDI-DrugBank.d337.s2.e0,DDI-DrugBank.d337.s2.e1,There were no reports of skeletal myopathy in a placebo-controlled Phase I trial in which 10 healthy subjects on stable drug1 therapy were treated concurrently with drug2,False, 
DDI-DrugBank.d337.s3.e0,DDI-DrugBank.d337.s3.e1,"Experience with co-administration of drug1 and drug2 in patients is limited,therefore,consideration should be given to temporarily suspending use of drug0 in patients receiving drug0",False, 
DDI-DrugBank.d337.s3.e0,DDI-DrugBank.d337.s3.e2,"Experience with co-administration of drug1 and drug0 in patients is limited,therefore,consideration should be given to temporarily suspending use of drug2 in patients receiving drug0",False, 
DDI-DrugBank.d337.s3.e2,DDI-DrugBank.d337.s3.e3,"Experience with co-administration of drug0 and drug0 in patients is limited,therefore,consideration should be given to temporarily suspending use of drug1 in patients receiving drug2",True,advise
DDI-DrugBank.d227.s0.e0,DDI-DrugBank.d227.s0.e1,"drug1 potentiates the muscle relaxant effect of all drug2, most notably drug0",True,effect
DDI-DrugBank.d227.s0.e0,DDI-DrugBank.d227.s0.e2,"drug1 potentiates the muscle relaxant effect of all drug0, most notably drug2",True,effect
DDI-DrugBank.d227.s0.e1,DDI-DrugBank.d227.s0.e2,"drug0 potentiates the muscle relaxant effect of all drug1, most notably drug2",False, 
DDI-DrugBank.d272.s0.e0,DDI-DrugBank.d272.s0.e1,"The risk of using drug1 in combination with other drugs has not been systematically evaluated, but drug2 may potentiate the side effects of drug0",False, 
DDI-DrugBank.d272.s0.e0,DDI-DrugBank.d272.s0.e2,"The risk of using drug1 in combination with other drugs has not been systematically evaluated, but drug0 may potentiate the side effects of drug2",False, 
DDI-DrugBank.d272.s0.e1,DDI-DrugBank.d272.s0.e2,"The risk of using drug0 in combination with other drugs has not been systematically evaluated, but drug1 may potentiate the side effects of drug2",True,effect
DDI-DrugBank.d272.s1.e0,DDI-DrugBank.d272.s1.e1,"drug1 may interact with drug2, drug0",True,int
DDI-DrugBank.d272.s1.e0,DDI-DrugBank.d272.s1.e2,"drug1 may interact with drug0, drug2",True,int
DDI-DrugBank.d272.s1.e1,DDI-DrugBank.d272.s1.e2,"drug0 may interact with drug1, drug2",False, 
DDI-DrugBank.d272.s2.e0,DDI-DrugBank.d272.s2.e1,"Compounds in these categories result in a decreased efficacy of drug1: drug2, drug0, drug0, drug0",True,effect
DDI-DrugBank.d272.s2.e0,DDI-DrugBank.d272.s2.e2,"Compounds in these categories result in a decreased efficacy of drug1: drug0, drug2, drug0, drug0",True,effect
DDI-DrugBank.d272.s2.e0,DDI-DrugBank.d272.s2.e3,"Compounds in these categories result in a decreased efficacy of drug1: drug0, drug0, drug2, drug0",True,effect
DDI-DrugBank.d272.s2.e0,DDI-DrugBank.d272.s2.e4,"Compounds in these categories result in a decreased efficacy of drug1: drug0, drug0, drug0, drug2",True,effect
DDI-DrugBank.d272.s2.e1,DDI-DrugBank.d272.s2.e2,"Compounds in these categories result in a decreased efficacy of drug0: drug1, drug2, drug0, drug0",False, 
DDI-DrugBank.d272.s2.e1,DDI-DrugBank.d272.s2.e3,"Compounds in these categories result in a decreased efficacy of drug0: drug1, drug0, drug2, drug0",False, 
DDI-DrugBank.d272.s3.e0,DDI-DrugBank.d272.s3.e1,Concomitant use of drug1 with other drug2,True,advise
DDI-DrugBank.d240.s0.e0,DDI-DrugBank.d240.s0.e1,drug1 may interact with drug2 or other drug0,True,effect
DDI-DrugBank.d240.s0.e0,DDI-DrugBank.d240.s0.e2,drug1 may interact with drug0 or other drug2,True,effect
DDI-DrugBank.d240.s0.e1,DDI-DrugBank.d240.s0.e2,drug0 may interact with drug1 or other drug2,False, 
DDI-DrugBank.d240.s1.e0,DDI-DrugBank.d240.s1.e1,It may also interact with drug1 or other drug2 or drug0,False, 
DDI-DrugBank.d240.s1.e0,DDI-DrugBank.d240.s1.e2,It may also interact with drug1 or other drug0 or drug2,False, 
DDI-DrugBank.d240.s2.e0,DDI-DrugBank.d240.s2.e1,"drug1 can interact with drug2, increasing the metabolism of drug0",True,mechanism
DDI-DrugBank.d240.s2.e0,DDI-DrugBank.d240.s2.e2,"drug1 can interact with drug0, increasing the metabolism of drug2",False, 
DDI-DrugBank.d240.s2.e1,DDI-DrugBank.d240.s2.e2,"drug0 can interact with drug1, increasing the metabolism of drug2",False, 
DDI-DrugBank.d68.s1.e0,DDI-DrugBank.d68.s1.e1,drug1: Supraventricular arrhythmias may mask the cardiotoxicity associated with excessive drug2,False, 
DDI-DrugBank.d68.s3.e0,DDI-DrugBank.d68.s3.e1,Coadministration of drug1 did not have effects on either the safety or efficacy of drug2,False, 
DDI-DrugBank.d68.s4.e0,DDI-DrugBank.d68.s4.e1,drug1: Coadministration of drug2 did not have any effect on either the safety or efficacy of drug0,False, 
DDI-DrugBank.d68.s4.e0,DDI-DrugBank.d68.s4.e2,drug1: Coadministration of drug0 did not have any effect on either the safety or efficacy of drug2,False, 
DDI-DrugBank.d68.s5.e0,DDI-DrugBank.d68.s5.e1,drug1: Coadministration of drug2 did not have any effect on either the safety or efficacy of drug0,False, 
DDI-DrugBank.d68.s5.e0,DDI-DrugBank.d68.s5.e2,drug1: Coadministration of drug0 did not have any effect on either the safety or efficacy of drug2,False, 
DDI-DrugBank.d72.s0.e0,DDI-DrugBank.d72.s0.e1,drug1 decreases drug2,True,mechanism
DDI-DrugBank.d72.s1.e0,DDI-DrugBank.d72.s1.e1,"drug1, and the drug2 drug0 (drug0) and drug0 (drug0) have all been used with drug0",False, 
DDI-DrugBank.d72.s1.e0,DDI-DrugBank.d72.s1.e2,"drug1, and the drug0 drug2 (drug0) and drug0 (drug0) have all been used with drug0",False, 
DDI-DrugBank.d72.s2.e0,DDI-DrugBank.d72.s2.e1,drug1 increases the clearance of drug2,True,mechanism
DDI-DrugBank.d72.s3.e0,DDI-DrugBank.d72.s3.e1,"Since the pharmacokinetics of drug1 were studied in patients treated with drug2, the clearance of drug0 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with drug0",True,mechanism
DDI-DrugBank.d72.s3.e0,DDI-DrugBank.d72.s3.e2,"Since the pharmacokinetics of drug1 were studied in patients treated with drug0, the clearance of drug2 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with drug0",False, 
DDI-DrugBank.d72.s3.e0,DDI-DrugBank.d72.s3.e3,"Since the pharmacokinetics of drug1 were studied in patients treated with drug0, the clearance of drug0 at the recommended dose may be lower and exposure (AUC) higher in patients not treated with drug2",False, 
DDI-DrugBank.d72.s4.e0,DDI-DrugBank.d72.s4.e1,"Because drug1 is eliminated from the body via conjugation with glutathione, use of drug2 prior to ( 72 hours) or concurrent with drug0 may result in reduced drug0 clearance based upon the known property of drug0",False, 
DDI-DrugBank.d72.s4.e0,DDI-DrugBank.d72.s4.e2,"Because drug1 is eliminated from the body via conjugation with glutathione, use of drug0 prior to ( 72 hours) or concurrent with drug2 may result in reduced drug0 clearance based upon the known property of drug0",False, 
DDI-DrugBank.d72.s4.e1,DDI-DrugBank.d72.s4.e2,"Because drug0 is eliminated from the body via conjugation with glutathione, use of drug1 prior to ( 72 hours) or concurrent with drug2 may result in reduced drug0 clearance based upon the known property of drug0",True,mechanism
DDI-DrugBank.d83.s0.e0,DDI-DrugBank.d83.s0.e1,Patients on drug1 therapy may require dosage adjustment of the anticoagulant during and after drug2,True,advise
DDI-DrugBank.d83.s1.e0,DDI-DrugBank.d83.s1.e1,Concomitant use of drug1 usually depresses drug2,True,effect
DDI-DrugBank.d83.s2.e0,DDI-DrugBank.d83.s2.e1,The concomitant administration of drug1 has been reported to reduce the efficacy of oral drug2,True,effect
DDI-DrugBank.d471.s0.e0,DDI-DrugBank.d471.s0.e1,"drug1 interferes with the absorption of drug2, including drug0",True,mechanism
DDI-DrugBank.d471.s0.e0,DDI-DrugBank.d471.s0.e2,"drug1 interferes with the absorption of drug0, including drug2",True,mechanism
DDI-DrugBank.d471.s0.e1,DDI-DrugBank.d471.s0.e2,"drug0 interferes with the absorption of drug1, including drug2",False, 
DDI-DrugBank.d471.s1.e0,DDI-DrugBank.d471.s1.e1,Administration of drug1 to hypoparathyroid patients who are concurrently being treated with drug2,True,effect
DDI-DrugBank.d57.s0.e0,DDI-DrugBank.d57.s0.e1,In vitro mixing of an drug1 with beta-lactamtype drug2 (drug0 or drug0,True,effect
DDI-DrugBank.d57.s0.e0,DDI-DrugBank.d57.s0.e2,In vitro mixing of an drug1 with beta-lactamtype drug0 (drug2 or drug0,True,effect
DDI-DrugBank.d57.s0.e0,DDI-DrugBank.d57.s0.e3,In vitro mixing of an drug1 with beta-lactamtype drug0 (drug0 or drug2,True,effect
DDI-DrugBank.d57.s0.e1,DDI-DrugBank.d57.s0.e2,In vitro mixing of an drug0 with beta-lactamtype drug1 (drug2 or drug0,False, 
DDI-DrugBank.d57.s0.e1,DDI-DrugBank.d57.s0.e3,In vitro mixing of an drug0 with beta-lactamtype drug1 (drug0 or drug2,False, 
DDI-DrugBank.d57.s1.e0,DDI-DrugBank.d57.s1.e1,"Even when an drug1 and a drug2-type drug are administered separately by different routes, a reduction in drug0",True,mechanism
DDI-DrugBank.d57.s1.e0,DDI-DrugBank.d57.s1.e2,"Even when an drug1 and a drug0-type drug are administered separately by different routes, a reduction in drug2",False, 
DDI-DrugBank.d57.s1.e1,DDI-DrugBank.d57.s1.e2,"Even when an drug0 and a drug1-type drug are administered separately by different routes, a reduction in drug2",False, 
DDI-DrugBank.d63.s0.e0,DDI-DrugBank.d63.s0.e1,"drug1 such as drug2 (e.g., drug0), drug0 (e.g., drug0), drug0 (e.g., drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0): Using these medicines with drug0",False, 
DDI-DrugBank.d63.s0.e0,DDI-DrugBank.d63.s0.e2,"drug1 such as drug0 (e.g., drug2), drug0 (e.g., drug0), drug0 (e.g., drug0), drug0 (e.g., drug0), and drug0 (e.g., drug0): Using these medicines with drug0",False, 
DDI-DrugBank.d363.s0.e0,DDI-DrugBank.d363.s0.e1,"No clinically significant adverse interactions with commonly used preanesthetic drugs, or drugs used during anesthesia (drug1, intravenous agents, and local drug2",False, 
DDI-DrugBank.d363.s2.e0,DDI-DrugBank.d363.s2.e1,"Like drug1, drug2 does not predispose to premature ventricular arrhythmias in the presence of exogenously infused drug0",False, 
DDI-DrugBank.d363.s2.e0,DDI-DrugBank.d363.s2.e2,"Like drug1, drug0 does not predispose to premature ventricular arrhythmias in the presence of exogenously infused drug2",False, 
DDI-DrugBank.d497.s0.e0,DDI-DrugBank.d497.s0.e1,drug1 (drug2 ophthalmic suspension) 1% contains a drug0,False, 
DDI-DrugBank.d497.s0.e0,DDI-DrugBank.d497.s0.e2,drug1 (drug0 ophthalmic suspension) 1% contains a drug2,False, 
DDI-DrugBank.d497.s2.e0,DDI-DrugBank.d497.s2.e1,"However, in patients treated with oral drug1, rare instances of drug interactions have occurred with high-dose drug2",True,int
DDI-DrugBank.d497.s3.e0,DDI-DrugBank.d497.s3.e1,"Therefore, the potential for such drug interaction should be considered in patients receiving drug1 (drug2",False, 
DDI-DrugBank.d269.s1.e0,DDI-DrugBank.d269.s1.e1,"poor metabolizers of drug1: Interactions of drug2 with strong inhibitors of CYP2D6 (such as drug0, drug0, drug0, and drug0) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug0",False, 
DDI-DrugBank.d269.s1.e0,DDI-DrugBank.d269.s1.e2,"poor metabolizers of drug1: Interactions of drug0 with strong inhibitors of CYP2D6 (such as drug2, drug0, drug0, and drug0) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug0",False, 
DDI-DrugBank.d269.s1.e2,DDI-DrugBank.d269.s1.e6,"poor metabolizers of drug0: Interactions of drug0 with strong inhibitors of CYP2D6 (such as drug1, drug0, drug0, and drug0) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug2",True,effect
DDI-DrugBank.d269.s1.e3,DDI-DrugBank.d269.s1.e6,"poor metabolizers of drug0: Interactions of drug0 with strong inhibitors of CYP2D6 (such as drug0, drug1, drug0, and drug0) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug2",True,effect
DDI-DrugBank.d269.s1.e4,DDI-DrugBank.d269.s1.e6,"poor metabolizers of drug0: Interactions of drug0 with strong inhibitors of CYP2D6 (such as drug0, drug0, drug1, and drug0) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug2",True,effect
DDI-DrugBank.d269.s1.e5,DDI-DrugBank.d269.s1.e6,"poor metabolizers of drug0: Interactions of drug0 with strong inhibitors of CYP2D6 (such as drug0, drug0, drug0, and drug1) have not been studied, but these drugs would be expected to increase blood levels of the R(+) enantiomer of drug2",True,effect
DDI-DrugBank.d269.s3.e0,DDI-DrugBank.d269.s3.e1,"Catecholamine-depleting Agents: Patients taking both drug1 and a drug that can deplete catecholamines (e.g., drug2 and drug0",True,effect
DDI-DrugBank.d269.s3.e0,DDI-DrugBank.d269.s3.e2,"Catecholamine-depleting Agents: Patients taking both drug1 and a drug that can deplete catecholamines (e.g., drug0 and drug2",True,effect
DDI-DrugBank.d269.s3.e1,DDI-DrugBank.d269.s3.e2,"Catecholamine-depleting Agents: Patients taking both drug0 and a drug that can deplete catecholamines (e.g., drug1 and drug2",False, 
DDI-DrugBank.d269.s4.e0,DDI-DrugBank.d269.s4.e1,drug1: Concomitant administration of drug2 with drug0,False, 
DDI-DrugBank.d269.s4.e0,DDI-DrugBank.d269.s4.e2,drug1: Concomitant administration of drug0 with drug2,False, 
DDI-DrugBank.d269.s4.e1,DDI-DrugBank.d269.s4.e2,drug0: Concomitant administration of drug1 with drug2,True,effect
DDI-DrugBank.d269.s5.e0,DDI-DrugBank.d269.s5.e1,"When concomitant treatment with drug1 and drug2 is to be terminated, the drug0",True,advise
DDI-DrugBank.d269.s5.e0,DDI-DrugBank.d269.s5.e2,"When concomitant treatment with drug1 and drug0 is to be terminated, the drug2",False, 
DDI-DrugBank.d269.s5.e1,DDI-DrugBank.d269.s5.e2,"When concomitant treatment with drug0 and drug1 is to be terminated, the drug2",False, 
DDI-DrugBank.d269.s7.e0,DDI-DrugBank.d269.s7.e1,drug1: Modest increases in mean trough drug2 concentrations were observed following initiation of drug0,False, 
DDI-DrugBank.d269.s7.e0,DDI-DrugBank.d269.s7.e2,drug1: Modest increases in mean trough drug0 concentrations were observed following initiation of drug2,False, 
DDI-DrugBank.d269.s7.e1,DDI-DrugBank.d269.s7.e2,drug0: Modest increases in mean trough drug1 concentrations were observed following initiation of drug2,True,mechanism
DDI-DrugBank.d269.s8.e0,DDI-DrugBank.d269.s8.e1,"In about 30% of patients, the dose of drug1 had to be reduced in order to maintain drug2",False, 
DDI-DrugBank.d269.s10.e0,DDI-DrugBank.d269.s10.e1,"Due to wide interindividual variability in the dose adjustment required, it is recommended that drug1 concentrations be monitored closely after initiation of drug2 therapy and that the dose of drug0",True,advise
DDI-DrugBank.d269.s10.e0,DDI-DrugBank.d269.s10.e2,"Due to wide interindividual variability in the dose adjustment required, it is recommended that drug1 concentrations be monitored closely after initiation of drug0 therapy and that the dose of drug2",False, 
DDI-DrugBank.d269.s10.e1,DDI-DrugBank.d269.s10.e2,"Due to wide interindividual variability in the dose adjustment required, it is recommended that drug0 concentrations be monitored closely after initiation of drug1 therapy and that the dose of drug2",True,advise
DDI-DrugBank.d269.s11.e0,DDI-DrugBank.d269.s11.e1,drug1: drug2 concentrations are increased by about 15% when drug0 and drug0,False, 
DDI-DrugBank.d269.s11.e0,DDI-DrugBank.d269.s11.e2,drug1: drug0 concentrations are increased by about 15% when drug2 and drug0,False, 
DDI-DrugBank.d269.s11.e2,DDI-DrugBank.d269.s11.e3,drug0: drug0 concentrations are increased by about 15% when drug1 and drug2,True,mechanism
DDI-DrugBank.d269.s12.e0,DDI-DrugBank.d269.s12.e1,Both drug1 and drug2,True,effect
DDI-DrugBank.d269.s13.e0,DDI-DrugBank.d269.s13.e1,"Therefore, increased monitoring of drug1 is recommended when initiating, adjusting, or discontinuing drug2",True,advise
DDI-DrugBank.d269.s14.e0,DDI-DrugBank.d269.s14.e1,Inducers and Inhibitors of Hepatic Metabolism: drug1 reduced plasma concentrations of drug2,True,mechanism
DDI-DrugBank.d269.s16.e0,DDI-DrugBank.d269.s16.e1,drug1: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when drug2 is co-administered with drug0,False, 
DDI-DrugBank.d269.s16.e0,DDI-DrugBank.d269.s16.e2,drug1: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when drug0 is co-administered with drug2,False, 
DDI-DrugBank.d269.s16.e1,DDI-DrugBank.d269.s16.e2,drug0: Isolated cases of conduction disturbance (rarely with hemodynamic compromise) have been observed when drug1 is co-administered with drug2,True,effect
DDI-DrugBank.d269.s17.e0,DDI-DrugBank.d269.s17.e1,"As with other drug1, if drug2 is to be administered orally with drug0 of the drug0 or drug0",False, 
DDI-DrugBank.d269.s17.e0,DDI-DrugBank.d269.s17.e2,"As with other drug1, if drug0 is to be administered orally with drug2 of the drug0 or drug0",False, 
DDI-DrugBank.d269.s17.e1,DDI-DrugBank.d269.s17.e3,"As with other drug0, if drug1 is to be administered orally with drug0 of the drug2 or drug0",True,advise
DDI-DrugBank.d269.s17.e1,DDI-DrugBank.d269.s17.e4,"As with other drug0, if drug1 is to be administered orally with drug0 of the drug0 or drug2",True,advise
DDI-DrugBank.d269.s18.e0,DDI-DrugBank.d269.s18.e1,drug1 or Oral drug2: drug0 may enhance the blood-sugar-reducing effect of drug0 and oral drug0,False, 
DDI-DrugBank.d269.s18.e0,DDI-DrugBank.d269.s18.e2,drug1 or Oral drug0: drug2 may enhance the blood-sugar-reducing effect of drug0 and oral drug0,False, 
DDI-DrugBank.d269.s18.e2,DDI-DrugBank.d269.s18.e3,drug0 or Oral drug0: drug1 may enhance the blood-sugar-reducing effect of drug2 and oral drug0,True,effect
DDI-DrugBank.d269.s18.e2,DDI-DrugBank.d269.s18.e4,drug0 or Oral drug0: drug1 may enhance the blood-sugar-reducing effect of drug0 and oral drug2,True,effect
DDI-DrugBank.d269.s19.e0,DDI-DrugBank.d269.s19.e1,"Therefore, in patients taking drug1 or oral drug2",False, 
DDI-DrugBank.d384.s0.e0,DDI-DrugBank.d384.s0.e1,"Interactions for drug1 (drug2, drug0, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d384.s0.e0,DDI-DrugBank.d384.s0.e2,"Interactions for drug1 (drug0, drug2, drug0, and drug0): drug0: drug0 has been reported to reduce intestinal absorption of drug0",False, 
DDI-DrugBank.d384.s0.e6,DDI-DrugBank.d384.s0.e7,"Interactions for drug0 (drug0, drug0, drug0, and drug0): drug0: drug1 has been reported to reduce intestinal absorption of drug2",True,mechanism
DDI-DrugBank.d384.s2.e0,DDI-DrugBank.d384.s2.e1,"drug1/drug2: The coadministration of drug0 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d384.s2.e0,DDI-DrugBank.d384.s2.e2,"drug1/drug0: The coadministration of drug2 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug0",False, 
DDI-DrugBank.d384.s2.e2,DDI-DrugBank.d384.s2.e5,"drug0/drug0: The coadministration of drug1 or drug0 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug2",True,mechanism
DDI-DrugBank.d384.s2.e3,DDI-DrugBank.d384.s2.e5,"drug0/drug0: The coadministration of drug0 or drug1 will not affect plasma concentrations of drug0, but may reduce endogenous plasma levels of drug2",True,mechanism
DDI-DrugBank.d384.s3.e0,DDI-DrugBank.d384.s3.e1,"Since blood level of drug1/ergocalcitriol will be reduced, higher doses of drug2",False, 
DDI-DrugBank.d384.s4.e0,DDI-DrugBank.d384.s4.e1,drug1: drug2 are known to induce hypercalcemia by the reduction of drug0,False, 
DDI-DrugBank.d384.s4.e0,DDI-DrugBank.d384.s4.e2,drug1: drug0 are known to induce hypercalcemia by the reduction of drug2,False, 
DDI-DrugBank.d384.s5.e0,DDI-DrugBank.d384.s5.e1,Some reports have shown that the concomitant administration of drug1 with drug2,True,effect
DDI-DrugBank.d384.s7.e0,DDI-DrugBank.d384.s7.e1,drug1: drug2 dosage must be determined with care in patients undergoing treatment with drug0,False, 
DDI-DrugBank.d384.s7.e0,DDI-DrugBank.d384.s7.e2,drug1: drug0 dosage must be determined with care in patients undergoing treatment with drug2,False, 
DDI-DrugBank.d384.s7.e1,DDI-DrugBank.d384.s7.e2,drug0: drug1 dosage must be determined with care in patients undergoing treatment with drug2,True,advise
DDI-DrugBank.d384.s8.e0,DDI-DrugBank.d384.s8.e1,drug1: drug2 may inhibit both synthetic and catabolic enzymes of drug0,False, 
DDI-DrugBank.d384.s8.e0,DDI-DrugBank.d384.s8.e2,drug1: drug0 may inhibit both synthetic and catabolic enzymes of drug2,False, 
DDI-DrugBank.d384.s8.e1,DDI-DrugBank.d384.s8.e2,drug0: drug1 may inhibit both synthetic and catabolic enzymes of drug2,True,mechanism
DDI-DrugBank.d384.s10.e0,DDI-DrugBank.d384.s10.e1,"However, in vivo drug interaction studies of drug1 with drug2",False, 
DDI-DrugBank.d384.s11.e0,DDI-DrugBank.d384.s11.e1,"drug1: A relationship of functional antagonism exists between drug2, which promote calcium absorption, and drug0",False, 
DDI-DrugBank.d384.s11.e0,DDI-DrugBank.d384.s11.e2,"drug1: A relationship of functional antagonism exists between drug0, which promote calcium absorption, and drug2",False, 
DDI-DrugBank.d384.s11.e1,DDI-DrugBank.d384.s11.e2,"drug0: A relationship of functional antagonism exists between drug1, which promote calcium absorption, and drug2",True,mechanism
DDI-DrugBank.d384.s13.e0,DDI-DrugBank.d384.s13.e1,drug1: The coadministration of any of the drug2,False, 
DDI-DrugBank.d384.s14.e0,DDI-DrugBank.d384.s14.e1,drug1 Supplements: Uncontrolled intake of additional drug2,False, 
DDI-DrugBank.d384.s15.e0,DDI-DrugBank.d384.s15.e1,"drug1: drug2-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d384.s15.e0,DDI-DrugBank.d384.s15.e2,"drug1: drug0-containing preparations (eg, drug2) may cause hypermagnesemia and should therefore not be taken during therapy with drug0",False, 
DDI-DrugBank.d384.s15.e1,DDI-DrugBank.d384.s15.e3,"drug0: drug1-containing preparations (eg, drug0) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,advise
DDI-DrugBank.d384.s15.e2,DDI-DrugBank.d384.s15.e3,"drug0: drug0-containing preparations (eg, drug1) may cause hypermagnesemia and should therefore not be taken during therapy with drug2",True,advise
DDI-DrugBank.d544.s0.e0,DDI-DrugBank.d544.s0.e1,"No dose adjustment is necessary when drug1 is added to triple-immunosuppression regimens including drug2, drug0, and either drug0 or drug0",False, 
DDI-DrugBank.d544.s0.e0,DDI-DrugBank.d544.s0.e2,"No dose adjustment is necessary when drug1 is added to triple-immunosuppression regimens including drug0, drug2, and either drug0 or drug0",False, 
DDI-DrugBank.d544.s3.e0,DDI-DrugBank.d544.s3.e1,"Total body clearance of drug1 was reduced by an average 22% and 51% when drug2 and drug0, respectively, were added to a regimen consisting of drug0, USP (MODIFIED) and drug0",True,mechanism
DDI-DrugBank.d544.s3.e0,DDI-DrugBank.d544.s3.e2,"Total body clearance of drug1 was reduced by an average 22% and 51% when drug0 and drug2, respectively, were added to a regimen consisting of drug0, USP (MODIFIED) and drug0",True,mechanism
DDI-DrugBank.d544.s3.e0,DDI-DrugBank.d544.s3.e3,"Total body clearance of drug1 was reduced by an average 22% and 51% when drug0 and drug0, respectively, were added to a regimen consisting of drug2, USP (MODIFIED) and drug0",False, 
DDI-DrugBank.d544.s3.e0,DDI-DrugBank.d544.s3.e4,"Total body clearance of drug1 was reduced by an average 22% and 51% when drug0 and drug0, respectively, were added to a regimen consisting of drug0, USP (MODIFIED) and drug2",False, 
DDI-DrugBank.d544.s4.e0,DDI-DrugBank.d544.s4.e1,"Nonetheless, the range of individual drug1 clearance values in the presence of drug2 (12-57 mL/h) or drug0",False, 
DDI-DrugBank.d544.s4.e0,DDI-DrugBank.d544.s4.e2,"Nonetheless, the range of individual drug1 clearance values in the presence of drug0 (12-57 mL/h) or drug2",False, 
DDI-DrugBank.d544.s5.e0,DDI-DrugBank.d544.s5.e1,"The following medications have been administered in clinical trials with drug1 with no increase in adverse reactions: ATG/ALG, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d544.s5.e0,DDI-DrugBank.d544.s5.e2,"The following medications have been administered in clinical trials with drug1 with no increase in adverse reactions: ATG/ALG, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d241.s0.e0,DDI-DrugBank.d241.s0.e1,"Additional reductions in blood pressure may occur when drug1 is administered with drug2, drug0, or other drug0",True,effect
DDI-DrugBank.d241.s0.e0,DDI-DrugBank.d241.s0.e2,"Additional reductions in blood pressure may occur when drug1 is administered with drug0, drug2, or other drug0",True,effect
DDI-DrugBank.d241.s0.e0,DDI-DrugBank.d241.s0.e3,"Additional reductions in blood pressure may occur when drug1 is administered with drug0, drug0, or other drug2",True,effect
DDI-DrugBank.d241.s0.e1,DDI-DrugBank.d241.s0.e2,"Additional reductions in blood pressure may occur when drug0 is administered with drug1, drug2, or other drug0",False, 
DDI-DrugBank.d241.s0.e1,DDI-DrugBank.d241.s0.e3,"Additional reductions in blood pressure may occur when drug0 is administered with drug1, drug0, or other drug2",False, 
DDI-DrugBank.d241.s1.e0,DDI-DrugBank.d241.s1.e1,"When other drug1 or drug2 are used concomitantly, there is the potential for drug0",False, 
DDI-DrugBank.d241.s1.e0,DDI-DrugBank.d241.s1.e2,"When other drug1 or drug0 are used concomitantly, there is the potential for drug2",True,effect
DDI-DrugBank.d241.s1.e1,DDI-DrugBank.d241.s1.e2,"When other drug0 or drug1 are used concomitantly, there is the potential for drug2",True,effect
DDI-DrugBank.d241.s2.e0,DDI-DrugBank.d241.s2.e1,"However, patients receiving infusions of drug1 in clinical trials were maintained on drug2",False, 
DDI-DrugBank.d241.s3.e0,DDI-DrugBank.d241.s3.e1,"In clinical trials, drug1 was used with drug2, drug0, drug0, oral drug0, and supplemental drug0.In a pharmacokinetic substudy in patients with congestive heart failure receiving drug0 or drug0 in whom therapy with drug0 was initiated, apparent oral clearance values for drug0 (n = 23) and drug0",False, 
DDI-DrugBank.d241.s3.e0,DDI-DrugBank.d241.s3.e2,"In clinical trials, drug1 was used with drug0, drug2, drug0, oral drug0, and supplemental drug0.In a pharmacokinetic substudy in patients with congestive heart failure receiving drug0 or drug0 in whom therapy with drug0 was initiated, apparent oral clearance values for drug0 (n = 23) and drug0",False, 
DDI-DrugBank.d241.s3.e6,DDI-DrugBank.d241.s3.e8,"In clinical trials, drug0 was used with drug0, drug0, drug0, oral drug0, and supplemental drug0.In a pharmacokinetic substudy in patients with congestive heart failure receiving drug1 or drug0 in whom therapy with drug2 was initiated, apparent oral clearance values for drug0 (n = 23) and drug0",True,mechanism
DDI-DrugBank.d241.s3.e7,DDI-DrugBank.d241.s3.e8,"In clinical trials, drug0 was used with drug0, drug0, drug0, oral drug0, and supplemental drug0.In a pharmacokinetic substudy in patients with congestive heart failure receiving drug0 or drug1 in whom therapy with drug2 was initiated, apparent oral clearance values for drug0 (n = 23) and drug0",True,mechanism
DDI-DrugBank.d241.s5.e0,DDI-DrugBank.d241.s5.e1,"However, patients on drug1 may show elevations of drug2 concentrations after initiation of therapy with drug0, which may be clinically significant in patients prone to drug0",False, 
DDI-DrugBank.d241.s5.e0,DDI-DrugBank.d241.s5.e2,"However, patients on drug1 may show elevations of drug0 concentrations after initiation of therapy with drug2, which may be clinically significant in patients prone to drug0",True,mechanism
DDI-DrugBank.d241.s5.e0,DDI-DrugBank.d241.s5.e3,"However, patients on drug1 may show elevations of drug0 concentrations after initiation of therapy with drug0, which may be clinically significant in patients prone to drug2",False, 
DDI-DrugBank.d137.s0.e0,DDI-DrugBank.d137.s0.e1,drug1: The concomitant use of drug2 with long- and short-acting drug0,False, 
DDI-DrugBank.d137.s0.e0,DDI-DrugBank.d137.s0.e2,drug1: The concomitant use of drug0 with long- and short-acting drug2,False, 
DDI-DrugBank.d137.s1.e0,DDI-DrugBank.d137.s1.e1,Sublingual drug1 may be taken if necessary for the control of acute angina attacks during drug2,False, 
DDI-DrugBank.d137.s2.e0,DDI-DrugBank.d137.s2.e1,drug1: The concomitant use of drug2 and drug0,False, 
DDI-DrugBank.d137.s2.e0,DDI-DrugBank.d137.s2.e2,drug1: The concomitant use of drug0 and drug2,False, 
DDI-DrugBank.d137.s4.e0,DDI-DrugBank.d137.s4.e1,"drug1: In controlled studies in healthy volunteers, drug2 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum drug0",False, 
DDI-DrugBank.d137.s4.e0,DDI-DrugBank.d137.s4.e2,"drug1: In controlled studies in healthy volunteers, drug0 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum drug2",False, 
DDI-DrugBank.d137.s4.e1,DDI-DrugBank.d137.s4.e2,"drug0: In controlled studies in healthy volunteers, drug1 either had no effect (one study) or was associated with modest increases, about 30% (two studies) in steady-state serum drug2",True,mechanism
DDI-DrugBank.d137.s5.e0,DDI-DrugBank.d137.s5.e1,Limited clinical data in angina patients receiving concomitant drug1 and drug2,False, 
DDI-DrugBank.d137.s7.e0,DDI-DrugBank.d137.s7.e1,Oral drug1: drug2 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for drug0 or oral drug0,False, 
DDI-DrugBank.d137.s7.e0,DDI-DrugBank.d137.s7.e2,Oral drug1: drug0 has been safely used in diabetic patients without significantly lowering their blood glucose levels or altering their need for drug2 or oral drug0,False, 
DDI-DrugBank.d137.s9.e0,DDI-DrugBank.d137.s9.e1,"In general, these are drugs that have one or more pharmacologic activities similar to drug1, including drug2 such as drug0 and drug0, drug0 and drug0",False, 
DDI-DrugBank.d137.s9.e0,DDI-DrugBank.d137.s9.e2,"In general, these are drugs that have one or more pharmacologic activities similar to drug1, including drug0 such as drug2 and drug0, drug0 and drug0",False, 
DDI-DrugBank.d137.s10.e0,DDI-DrugBank.d137.s10.e1,drug1 and drug2 could exaggerate the prolongation of the QT interval observed with drug0,False, 
DDI-DrugBank.d137.s10.e0,DDI-DrugBank.d137.s10.e2,drug1 and drug0 could exaggerate the prolongation of the QT interval observed with drug2,True,effect
DDI-DrugBank.d137.s10.e1,DDI-DrugBank.d137.s10.e2,drug0 and drug1 could exaggerate the prolongation of the QT interval observed with drug2,True,effect
DDI-DrugBank.d137.s11.e0,DDI-DrugBank.d137.s11.e1,drug1 could exaggerate the depression of AV nodal conduction observed with drug2,True,effect
DDI-DrugBank.d119.s2.e0,DDI-DrugBank.d119.s2.e1,drug1    Prolonged action of drug2,False, 
DDI-DrugBank.d119.s4.e0,DDI-DrugBank.d119.s4.e1,drug1    drug2,False, 
DDI-DrugBank.d119.s6.e0,DDI-DrugBank.d119.s6.e1,drug1     drug2,False, 
DDI-DrugBank.d157.s0.e0,DDI-DrugBank.d157.s0.e1,Clinical interaction studies with drug1 and drug2 indicated that the coadministration of drug0,False, 
DDI-DrugBank.d157.s0.e0,DDI-DrugBank.d157.s0.e2,Clinical interaction studies with drug1 and drug0 indicated that the coadministration of drug2,False, 
DDI-DrugBank.d157.s1.e0,DDI-DrugBank.d157.s1.e1,(See CLINICAL PHARMACOLOGY) Coadministration of drug1 and drug2 20 mg daily resulted in a reduction of drug0,True,mechanism
DDI-DrugBank.d157.s1.e0,DDI-DrugBank.d157.s1.e2,(See CLINICAL PHARMACOLOGY) Coadministration of drug1 and drug0 20 mg daily resulted in a reduction of drug2,False, 
DDI-DrugBank.d157.s1.e1,DDI-DrugBank.d157.s1.e2,(See CLINICAL PHARMACOLOGY) Coadministration of drug0 and drug1 20 mg daily resulted in a reduction of drug2,False, 
DDI-DrugBank.d115.s0.e0,DDI-DrugBank.d115.s0.e1,"Drugs that may alter drug1 plasma concentrations Drugs that may increase drug2 plasma concentrations: Caution is recommended when administering drug0 with inhibitors of the CYP3A4 family (e.g., drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d115.s0.e0,DDI-DrugBank.d115.s0.e2,"Drugs that may alter drug1 plasma concentrations Drugs that may increase drug0 plasma concentrations: Caution is recommended when administering drug2 with inhibitors of the CYP3A4 family (e.g., drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d115.s0.e2,DDI-DrugBank.d115.s0.e3,"Drugs that may alter drug0 plasma concentrations Drugs that may increase drug0 plasma concentrations: Caution is recommended when administering drug1 with inhibitors of the CYP3A4 family (e.g., drug2, drug0, drug0, drug0",True,advise
DDI-DrugBank.d115.s0.e2,DDI-DrugBank.d115.s0.e4,"Drugs that may alter drug0 plasma concentrations Drugs that may increase drug0 plasma concentrations: Caution is recommended when administering drug1 with inhibitors of the CYP3A4 family (e.g., drug0, drug2, drug0, drug0",True,advise
DDI-DrugBank.d115.s0.e2,DDI-DrugBank.d115.s0.e5,"Drugs that may alter drug0 plasma concentrations Drugs that may increase drug0 plasma concentrations: Caution is recommended when administering drug1 with inhibitors of the CYP3A4 family (e.g., drug0, drug0, drug2, drug0",True,advise
DDI-DrugBank.d115.s0.e2,DDI-DrugBank.d115.s0.e6,"Drugs that may alter drug0 plasma concentrations Drugs that may increase drug0 plasma concentrations: Caution is recommended when administering drug1 with inhibitors of the CYP3A4 family (e.g., drug0, drug0, drug0, drug2",True,advise
DDI-DrugBank.d115.s2.e0,DDI-DrugBank.d115.s2.e1,There is a significant increase in exposure to drug1 when drug2 is coadministered with drug0,False, 
DDI-DrugBank.d115.s2.e0,DDI-DrugBank.d115.s2.e2,There is a significant increase in exposure to drug1 when drug0 is coadministered with drug2,False, 
DDI-DrugBank.d115.s2.e1,DDI-DrugBank.d115.s2.e2,There is a significant increase in exposure to drug0 when drug1 is coadministered with drug2,True,mechanism
DDI-DrugBank.d115.s3.e0,DDI-DrugBank.d115.s3.e1,Drugs that may decrease drug1 plasma concentrations: Substances that are inducers of CYP3A4 activity may increase metabolism and decrease drug2,False, 
DDI-DrugBank.d115.s4.e0,DDI-DrugBank.d115.s4.e1,"Co-medications that induce CYP3A4 (e.g., drug1, drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d115.s4.e0,DDI-DrugBank.d115.s4.e2,"Co-medications that induce CYP3A4 (e.g., drug1, drug0, drug2, drug0, drug0",False, 
DDI-DrugBank.d115.s6.e0,DDI-DrugBank.d115.s6.e1,"Pretreatment of healthy volunteers with multiple doses of drug1 followed by a single dose of drug2, increased drug0",True,mechanism
DDI-DrugBank.d115.s6.e0,DDI-DrugBank.d115.s6.e2,"Pretreatment of healthy volunteers with multiple doses of drug1 followed by a single dose of drug0, increased drug2",False, 
DDI-DrugBank.d115.s6.e1,DDI-DrugBank.d115.s6.e2,"Pretreatment of healthy volunteers with multiple doses of drug0 followed by a single dose of drug1, increased drug2",False, 
DDI-DrugBank.d115.s8.e0,DDI-DrugBank.d115.s8.e1,"Drugs that may have their plasma concentration altered by drug1 drug2 increases the mean cmax and AUC of drug0 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by drug0",False, 
DDI-DrugBank.d115.s8.e0,DDI-DrugBank.d115.s8.e2,"Drugs that may have their plasma concentration altered by drug1 drug0 increases the mean cmax and AUC of drug2 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by drug0",False, 
DDI-DrugBank.d115.s8.e1,DDI-DrugBank.d115.s8.e2,"Drugs that may have their plasma concentration altered by drug0 drug1 increases the mean cmax and AUC of drug2 (CYP3A4 substrate) 2- and 3.5-fold, respectively, suggesting an inhibition of the CYP3A4 by drug0",True,mechanism
DDI-DrugBank.d115.s9.e0,DDI-DrugBank.d115.s9.e1,"Particular caution is recommended when administering drug1 with CYP3A4 substrates that have a narrow therapeutic window (e.g., drug2 or drug0",True,advise
DDI-DrugBank.d115.s9.e0,DDI-DrugBank.d115.s9.e2,"Particular caution is recommended when administering drug1 with CYP3A4 substrates that have a narrow therapeutic window (e.g., drug0 or drug2",True,advise
DDI-DrugBank.d115.s9.e1,DDI-DrugBank.d115.s9.e2,"Particular caution is recommended when administering drug0 with CYP3A4 substrates that have a narrow therapeutic window (e.g., drug1 or drug2",False, 
DDI-DrugBank.d115.s10.e0,DDI-DrugBank.d115.s10.e1,"drug1 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-drug2, drug0, certain drug0",True,mechanism
DDI-DrugBank.d115.s10.e0,DDI-DrugBank.d115.s10.e2,"drug1 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-drug0, drug2, certain drug0",True,mechanism
DDI-DrugBank.d115.s10.e0,DDI-DrugBank.d115.s10.e3,"drug1 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-drug0, drug0, certain drug2",True,mechanism
DDI-DrugBank.d115.s10.e1,DDI-DrugBank.d115.s10.e2,"drug0 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-drug1, drug2, certain drug0",False, 
DDI-DrugBank.d115.s10.e1,DDI-DrugBank.d115.s10.e3,"drug0 will increase plasmaconcentration of other CYP3A4 metabolized drugs (e.g., triazolo-drug1, drug0, certain drug2",False, 
DDI-DrugBank.d115.s11.e0,DDI-DrugBank.d115.s11.e1,"Because drug1 is metabolized by CYP2C9 and CYP3A4, patients who require anticoagulation should receive low-molecular weight or standard drug2",False, 
DDI-DrugBank.d115.s16.e0,DDI-DrugBank.d115.s16.e1,Systemic exposure to drug1 is expected to be increased when coadministered with drug2,True,mechanism
DDI-DrugBank.d66.s0.e0,DDI-DrugBank.d66.s0.e1,drug1 - Concomitant use of drug2 and drug0,False, 
DDI-DrugBank.d66.s0.e0,DDI-DrugBank.d66.s0.e2,drug1 - Concomitant use of drug0 and drug2,False, 
DDI-DrugBank.d66.s0.e1,DDI-DrugBank.d66.s0.e2,drug0 - Concomitant use of drug1 and drug2,True,mechanism
DDI-DrugBank.d66.s2.e0,DDI-DrugBank.d66.s2.e1,drug1 - Concomitant use of drug2 and drug0 may ameliorate increased intestinal permeability caused by drug0,False, 
DDI-DrugBank.d66.s2.e0,DDI-DrugBank.d66.s2.e2,drug1 - Concomitant use of drug0 and drug2 may ameliorate increased intestinal permeability caused by drug0,False, 
DDI-DrugBank.d66.s2.e1,DDI-DrugBank.d66.s2.e2,drug0 - Concomitant use of drug1 and drug2 may ameliorate increased intestinal permeability caused by drug0,True,effect
DDI-DrugBank.d66.s5.e0,DDI-DrugBank.d66.s5.e1,drug1 - There is one report that drug2 may decrease the possible effectiveness of supplemental drug0,False, 
DDI-DrugBank.d66.s5.e0,DDI-DrugBank.d66.s5.e2,drug1 - There is one report that drug0 may decrease the possible effectiveness of supplemental drug2,False, 
DDI-DrugBank.d66.s5.e1,DDI-DrugBank.d66.s5.e2,drug0 - There is one report that drug1 may decrease the possible effectiveness of supplemental drug2,True,effect
DDI-DrugBank.d66.s6.e0,DDI-DrugBank.d66.s6.e1,"In another report, nine patients with breast cancer were reported to have decreased symptoms of drug1-related toxicity when given supplemental drug2",True,effect
DDI-DrugBank.d66.s7.e0,DDI-DrugBank.d66.s7.e1,"drug1 - In one report, drug2 at a dose of 10 grams three times daily, given 24 hours after receiving drug0, appeared to prevent the development of myalgia and arthralgia, adverse reactions of drug0",False, 
DDI-DrugBank.d66.s7.e0,DDI-DrugBank.d66.s7.e2,"drug1 - In one report, drug0 at a dose of 10 grams three times daily, given 24 hours after receiving drug2, appeared to prevent the development of myalgia and arthralgia, adverse reactions of drug0",False, 
DDI-DrugBank.d66.s7.e1,DDI-DrugBank.d66.s7.e2,"drug0 - In one report, drug1 at a dose of 10 grams three times daily, given 24 hours after receiving drug2, appeared to prevent the development of myalgia and arthralgia, adverse reactions of drug0",True,effect
DDI-DrugBank.d519.s3.e0,DDI-DrugBank.d519.s3.e1,Laboratory Tests Response to drug1 should be monitored by measuring serum total drug2,False, 
DDI-DrugBank.d161.s1.e0,DDI-DrugBank.d161.s1.e1,For information on the pharmacokinetics of drug1 and drug2,False, 
DDI-DrugBank.d489.s0.e0,DDI-DrugBank.d489.s0.e1,"The following drugs have been coadministered with drug1 and have not altered its pharmacokinetics: drug2, drug0, drug0, and drug0",False, 
DDI-DrugBank.d489.s0.e0,DDI-DrugBank.d489.s0.e2,"The following drugs have been coadministered with drug1 and have not altered its pharmacokinetics: drug0, drug2, drug0, and drug0",False, 
DDI-DrugBank.d489.s1.e0,DDI-DrugBank.d489.s1.e1,Concomitant administration of drug1 with the oral drug2 drug0 has been shown not to potentiate the anticoagulant effect of drug0,False, 
DDI-DrugBank.d489.s1.e0,DDI-DrugBank.d489.s1.e2,Concomitant administration of drug1 with the oral drug0 drug2 has been shown not to potentiate the anticoagulant effect of drug0,False, 
DDI-DrugBank.d489.s2.e0,DDI-DrugBank.d489.s2.e1,"Catecholamine-depleting drugs (e.g., drug1) may have an additive effect when given with drug2",True,effect
DDI-DrugBank.d489.s4.e0,DDI-DrugBank.d489.s4.e1,"Should it be decided to discontinue therapy in patients receiving drug1 and drug2 concurrently, the drug0 should be discontinued slowly over several days before the gradual withdrawal of drug0",True,advise
DDI-DrugBank.d489.s4.e0,DDI-DrugBank.d489.s4.e2,"Should it be decided to discontinue therapy in patients receiving drug1 and drug0 concurrently, the drug2 should be discontinued slowly over several days before the gradual withdrawal of drug0",False, 
DDI-DrugBank.d489.s4.e0,DDI-DrugBank.d489.s4.e3,"Should it be decided to discontinue therapy in patients receiving drug1 and drug0 concurrently, the drug0 should be discontinued slowly over several days before the gradual withdrawal of drug2",False, 
DDI-DrugBank.d489.s4.e2,DDI-DrugBank.d489.s4.e3,"Should it be decided to discontinue therapy in patients receiving drug0 and drug0 concurrently, the drug1 should be discontinued slowly over several days before the gradual withdrawal of drug2",True,advise
DDI-DrugBank.d489.s5.e0,DDI-DrugBank.d489.s5.e1,Literature reports suggest that oral drug1 may be used in combination with drug2,True,advise
DDI-DrugBank.d489.s6.e0,DDI-DrugBank.d489.s6.e1,"Hypotension, AV conduction disturbances, and left ventricular failure have been reported in some patients receiving drug1 when an oral drug2",True,effect
DDI-DrugBank.d489.s7.e0,DDI-DrugBank.d489.s7.e1,"Hypotension was more likely to occur if the drug1 were a drug2, e.g., drug0, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either drug0 or drug0",False, 
DDI-DrugBank.d489.s7.e0,DDI-DrugBank.d489.s7.e2,"Hypotension was more likely to occur if the drug1 were a drug0, e.g., drug2, while left ventricular failure and AV conduction disturbances, including complete heart block, were more likely to occur with either drug0 or drug0",False, 
DDI-DrugBank.d489.s8.e0,DDI-DrugBank.d489.s8.e1,"Risk of Anaphylactic Reaction: Although it is known that patients on drug1 may be refractory to drug2 in the treatment of anaphylactic shock, drug0",True,effect
DDI-DrugBank.d489.s8.e0,DDI-DrugBank.d489.s8.e2,"Risk of Anaphylactic Reaction: Although it is known that patients on drug1 may be refractory to drug0 in the treatment of anaphylactic shock, drug2",False, 
DDI-DrugBank.d489.s8.e1,DDI-DrugBank.d489.s8.e2,"Risk of Anaphylactic Reaction: Although it is known that patients on drug0 may be refractory to drug1 in the treatment of anaphylactic shock, drug2",False, 
DDI-DrugBank.d42.s0.e0,DDI-DrugBank.d42.s0.e1,"The potential for clinically significant drug-drug interactions posed by drug1 and drug2 appears to be low for drugs commonly used in chemotherapy or surgery, because drug0",False, 
DDI-DrugBank.d42.s0.e0,DDI-DrugBank.d42.s0.e2,"The potential for clinically significant drug-drug interactions posed by drug1 and drug0 appears to be low for drugs commonly used in chemotherapy or surgery, because drug2",False, 
DDI-DrugBank.d42.s1.e0,DDI-DrugBank.d42.s1.e1,"Blood levels of drug1 increased 24% when drug2 was coadministered with drug0 (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of drug0",False, 
DDI-DrugBank.d42.s1.e0,DDI-DrugBank.d42.s1.e2,"Blood levels of drug1 increased 24% when drug0 was coadministered with drug2 (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of drug0",False, 
DDI-DrugBank.d42.s1.e1,DDI-DrugBank.d42.s1.e2,"Blood levels of drug0 increased 24% when drug1 was coadministered with drug2 (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of drug0",True,mechanism
DDI-DrugBank.d42.s1.e1,DDI-DrugBank.d42.s1.e3,"Blood levels of drug0 increased 24% when drug1 was coadministered with drug0 (nonselective inhibitor of cytochrome P-450) for 7 days, and decreased 28% with coadministration of drug2",True,mechanism
DDI-DrugBank.d42.s4.e0,DDI-DrugBank.d42.s4.e1,"In patients taking drug1, drug2, drug0, drug0, drug0, drug0, drug0, and various chemotherapy agents, no effect was shown on the clearance of drug0",False, 
DDI-DrugBank.d42.s4.e0,DDI-DrugBank.d42.s4.e2,"In patients taking drug1, drug0, drug2, drug0, drug0, drug0, drug0, and various chemotherapy agents, no effect was shown on the clearance of drug0",False, 
DDI-DrugBank.d42.s5.e0,DDI-DrugBank.d42.s5.e1,Clearance of drug1 decreased by about 27% when drug2 was administered intravenously concomitantly with drug0,False, 
DDI-DrugBank.d42.s5.e0,DDI-DrugBank.d42.s5.e2,Clearance of drug1 decreased by about 27% when drug0 was administered intravenously concomitantly with drug2,False, 
DDI-DrugBank.d42.s5.e1,DDI-DrugBank.d42.s5.e2,Clearance of drug0 decreased by about 27% when drug1 was administered intravenously concomitantly with drug2,True,mechanism
DDI-DrugBank.d42.s7.e0,DDI-DrugBank.d42.s7.e1,"drug1 did not inhibit the antitumor activity of four drug2 (drug0, drug0, drug0, drug0",False, 
DDI-DrugBank.d42.s7.e0,DDI-DrugBank.d42.s7.e2,"drug1 did not inhibit the antitumor activity of four drug0 (drug2, drug0, drug0, drug0",False, 
DDI-DrugBank.d167.s1.e0,DDI-DrugBank.d167.s1.e1,"drug1 (neostgmine, drug2), drug0, drug0, drug0",False, 
DDI-DrugBank.d167.s1.e0,DDI-DrugBank.d167.s1.e2,"drug1 (neostgmine, drug0), drug2, drug0, drug0",False, 
DDI-DrugBank.d167.s2.e0,DDI-DrugBank.d167.s2.e1,"In addition, neuromuscular blocking action is enhanced by general drug1, local drug2 like drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d167.s2.e0,DDI-DrugBank.d167.s2.e2,"In addition, neuromuscular blocking action is enhanced by general drug1, local drug0 like drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-DrugBank.d439.s0.e0,DDI-DrugBank.d439.s0.e1,drug1 may accentuate the electrolyte loss associated with drug2,True,effect
DDI-DrugBank.d211.s2.e0,DDI-DrugBank.d211.s2.e1,"drug1: drug2, drug0, drug0, or drug0 may interfere with the bactericidal effect of drug0",False, 
DDI-DrugBank.d211.s2.e0,DDI-DrugBank.d211.s2.e2,"drug1: drug0, drug2, drug0, or drug0 may interfere with the bactericidal effect of drug0",False, 
DDI-DrugBank.d211.s2.e1,DDI-DrugBank.d211.s2.e5,"drug0: drug1, drug0, drug0, or drug0 may interfere with the bactericidal effect of drug2",True,effect
DDI-DrugBank.d211.s2.e2,DDI-DrugBank.d211.s2.e5,"drug0: drug0, drug1, drug0, or drug0 may interfere with the bactericidal effect of drug2",True,effect
DDI-DrugBank.d211.s2.e3,DDI-DrugBank.d211.s2.e5,"drug0: drug0, drug0, drug1, or drug0 may interfere with the bactericidal effect of drug2",True,effect
DDI-DrugBank.d211.s2.e4,DDI-DrugBank.d211.s2.e5,"drug0: drug0, drug0, drug0, or drug1 may interfere with the bactericidal effect of drug2",True,effect
DDI-DrugBank.d211.s5.e0,DDI-DrugBank.d211.s5.e1,drug1: May decrease renal tubular secretion of drug2 resulting in increased blood levels and/or drug0,True,mechanism
DDI-DrugBank.d211.s5.e0,DDI-DrugBank.d211.s5.e2,drug1: May decrease renal tubular secretion of drug0 resulting in increased blood levels and/or drug2,False, 
DDI-DrugBank.d211.s5.e1,DDI-DrugBank.d211.s5.e2,drug0: May decrease renal tubular secretion of drug1 resulting in increased blood levels and/or drug2,False, 
DDI-DrugBank.d211.s6.e0,DDI-DrugBank.d211.s6.e1,"Drug/Laboratory Test Interaction After treatment with drug1, a false-positive reaction for glucose in the urine may occur with drug2",False, 
DDI-DrugBank.d565.s1.e0,DDI-DrugBank.d565.s1.e1,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using drug1 or drug2 concomitantly with drug0,False, 
DDI-DrugBank.d565.s1.e0,DDI-DrugBank.d565.s1.e2,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using drug1 or drug0 concomitantly with drug2,True,effect
DDI-DrugBank.d565.s1.e1,DDI-DrugBank.d565.s1.e2,Pharmacologic studies indicate that there may be additive effects in prolonging AV conduction when using drug0 or drug1 concomitantly with drug2,True,effect
DDI-DrugBank.d565.s7.e0,DDI-DrugBank.d565.s7.e1,Controlled and uncontrolled domestic studies suggest that concomitant use of drug1 and drug2,False, 
DDI-DrugBank.d565.s8.e0,DDI-DrugBank.d565.s8.e1,Administration of drug1 concomitantly with drug2 in five normal volunteers resulted in increased drug0 levels in all subjects and bioavailability of drug0,True,mechanism
DDI-DrugBank.d565.s8.e0,DDI-DrugBank.d565.s8.e2,Administration of drug1 concomitantly with drug0 in five normal volunteers resulted in increased drug2 levels in all subjects and bioavailability of drug0,False, 
DDI-DrugBank.d565.s8.e0,DDI-DrugBank.d565.s8.e3,Administration of drug1 concomitantly with drug0 in five normal volunteers resulted in increased drug0 levels in all subjects and bioavailability of drug2,False, 
DDI-DrugBank.d565.s9.e0,DDI-DrugBank.d565.s9.e1,"In vitro, drug1 appears to be displaced from its binding sites by drug2",True,mechanism
DDI-DrugBank.d565.s10.e0,DDI-DrugBank.d565.s10.e1,"If combination therapy is initiated or withdrawn in conjunction with drug1, an adjustment in the drug2",False, 
DDI-DrugBank.d565.s12.e0,DDI-DrugBank.d565.s12.e1,A study in six healthy volunteers has shown a significant increase in peak drug1 plasma levels (58%) and AUC (53%) after a 1-week course of drug2 1200 mg/day and a single dose of drug0,False, 
DDI-DrugBank.d565.s12.e0,DDI-DrugBank.d565.s12.e2,A study in six healthy volunteers has shown a significant increase in peak drug1 plasma levels (58%) and AUC (53%) after a 1-week course of drug0 1200 mg/day and a single dose of drug2,False, 
DDI-DrugBank.d565.s12.e1,DDI-DrugBank.d565.s12.e2,A study in six healthy volunteers has shown a significant increase in peak drug0 plasma levels (58%) and AUC (53%) after a 1-week course of drug1 1200 mg/day and a single dose of drug2,True,mechanism
DDI-DrugBank.d565.s14.e0,DDI-DrugBank.d565.s14.e1,"The effect may be mediated by drug1s known inhibition of hepatic cytochrome P-450, the enzyme system responsible for the first-pass metabolism of drug2",True,mechanism
DDI-DrugBank.d565.s15.e0,DDI-DrugBank.d565.s15.e1,Patients currently receiving drug1 therapy should be carefully monitored for a change in pharmacological effect when initiating and discontinuing therapy with drug2,True,advise
DDI-DrugBank.d565.s18.e0,DDI-DrugBank.d565.s18.e1,Administration of drug1 with drug2 in 24 healthy male subjects increased plasma drug0,True,mechanism
DDI-DrugBank.d565.s18.e0,DDI-DrugBank.d565.s18.e2,Administration of drug1 with drug0 in 24 healthy male subjects increased plasma drug2,False, 
DDI-DrugBank.d565.s18.e1,DDI-DrugBank.d565.s18.e2,Administration of drug0 with drug1 in 24 healthy male subjects increased plasma drug2,False, 
DDI-DrugBank.d565.s20.e0,DDI-DrugBank.d565.s20.e1,"Since there have been conflicting results regarding the effect of drug1 levels, it is recommended that drug2 levels be monitored when initiating, adjusting, and discontinuing drug0",False, 
DDI-DrugBank.d565.s20.e0,DDI-DrugBank.d565.s20.e2,"Since there have been conflicting results regarding the effect of drug1 levels, it is recommended that drug0 levels be monitored when initiating, adjusting, and discontinuing drug2",False, 
DDI-DrugBank.d565.s20.e1,DDI-DrugBank.d565.s20.e2,"Since there have been conflicting results regarding the effect of drug0 levels, it is recommended that drug1 levels be monitored when initiating, adjusting, and discontinuing drug2",True,advise
DDI-DrugBank.d565.s22.e0,DDI-DrugBank.d565.s22.e1,"The depression of cardiac contractility, conductivity, and automaticity as well as the vascular dilation associated with drug1 may be potentiated by drug2",True,effect
DDI-DrugBank.d565.s23.e0,DDI-DrugBank.d565.s23.e1,"When used concomitantly, drug1 and drug2",True,advise
DDI-DrugBank.d565.s25.e0,DDI-DrugBank.d565.s25.e1,A pharmacokinetic interaction between drug1 and drug2,True,int
DDI-DrugBank.d565.s26.e0,DDI-DrugBank.d565.s26.e1,"In renal and cardiac transplant recipients, a reduction of drug1 dose ranging from 15% to 48% was necessary to maintain drug2 trough concentrations similar to those seen prior to the addition of drug0",False, 
DDI-DrugBank.d565.s26.e0,DDI-DrugBank.d565.s26.e2,"In renal and cardiac transplant recipients, a reduction of drug1 dose ranging from 15% to 48% was necessary to maintain drug0 trough concentrations similar to those seen prior to the addition of drug2",True,mechanism
DDI-DrugBank.d565.s26.e1,DDI-DrugBank.d565.s26.e2,"In renal and cardiac transplant recipients, a reduction of drug0 dose ranging from 15% to 48% was necessary to maintain drug1 trough concentrations similar to those seen prior to the addition of drug2",False, 
DDI-DrugBank.d565.s27.e0,DDI-DrugBank.d565.s27.e1,"If these agents are to be administered concurrently, drug1 concentrations should be monitored, especially when drug2",True,advise
DDI-DrugBank.d565.s28.e0,DDI-DrugBank.d565.s28.e1,The effect of drug1 on drug2,False, 
DDI-DrugBank.d565.s30.e0,DDI-DrugBank.d565.s30.e1,Concomitant administration of drug1 with drug2 has been reported to result in elevated serum levels of drug0,True,mechanism
DDI-DrugBank.d565.s30.e0,DDI-DrugBank.d565.s30.e2,Concomitant administration of drug1 with drug0 has been reported to result in elevated serum levels of drug2,False, 
DDI-DrugBank.d565.s30.e1,DDI-DrugBank.d565.s30.e2,Concomitant administration of drug0 with drug1 has been reported to result in elevated serum levels of drug2,False, 
DDI-DrugBank.d565.s33.e0,DDI-DrugBank.d565.s33.e1,Studies showed that drug1 increased the AUC of drug2 and drug0,True,mechanism
DDI-DrugBank.d565.s33.e0,DDI-DrugBank.d565.s33.e2,Studies showed that drug1 increased the AUC of drug0 and drug2,True,mechanism
DDI-DrugBank.d565.s33.e1,DDI-DrugBank.d565.s33.e2,Studies showed that drug0 increased the AUC of drug1 and drug2,False, 
DDI-DrugBank.d565.s34.e0,DDI-DrugBank.d565.s34.e1,The elimination half life of drug1 and drug2 also increased (1.5-2.5 fold) during coadministration with drug0,False, 
DDI-DrugBank.d565.s34.e0,DDI-DrugBank.d565.s34.e2,The elimination half life of drug1 and drug0 also increased (1.5-2.5 fold) during coadministration with drug2,True,mechanism
DDI-DrugBank.d565.s34.e1,DDI-DrugBank.d565.s34.e2,The elimination half life of drug0 and drug1 also increased (1.5-2.5 fold) during coadministration with drug2,True,mechanism
DDI-DrugBank.d565.s35.e0,DDI-DrugBank.d565.s35.e1,"These pharmacokinetic effects seen during drug1 coadministration can result in increased clinical effects (e.g., prolonged sodation)of both drug2 and drug0",True,effect
DDI-DrugBank.d565.s35.e0,DDI-DrugBank.d565.s35.e2,"These pharmacokinetic effects seen during drug1 coadministration can result in increased clinical effects (e.g., prolonged sodation)of both drug0 and drug2",True,effect
DDI-DrugBank.d565.s35.e1,DDI-DrugBank.d565.s35.e2,"These pharmacokinetic effects seen during drug0 coadministration can result in increased clinical effects (e.g., prolonged sodation)of both drug1 and drug2",False, 
DDI-DrugBank.d565.s37.e0,DDI-DrugBank.d565.s37.e1,"In a ten-subject study, coadministration of drug1 (120 mg bid) with drug2 resulted in a 3-4 times increase in mean drug0 AUC and Cmax vs. drug0",True,mechanism
DDI-DrugBank.d565.s37.e0,DDI-DrugBank.d565.s37.e2,"In a ten-subject study, coadministration of drug1 (120 mg bid) with drug0 resulted in a 3-4 times increase in mean drug2 AUC and Cmax vs. drug0",False, 
DDI-DrugBank.d565.s37.e0,DDI-DrugBank.d565.s37.e3,"In a ten-subject study, coadministration of drug1 (120 mg bid) with drug0 resulted in a 3-4 times increase in mean drug0 AUC and Cmax vs. drug2",False, 
DDI-DrugBank.d565.s38.e0,DDI-DrugBank.d565.s38.e1,no change in drug1 AUC and Cmax was observed during drug2,False, 
DDI-DrugBank.d565.s39.e0,DDI-DrugBank.d565.s39.e1,drug1 plasma levels were not significantly affected by drug2 or drug0,False, 
DDI-DrugBank.d565.s39.e0,DDI-DrugBank.d565.s39.e2,drug1 plasma levels were not significantly affected by drug0 or drug2,False, 
DDI-DrugBank.d565.s41.e0,DDI-DrugBank.d565.s41.e1,Coadministration of drug1 with drug2 lowered the drug0,True,mechanism
DDI-DrugBank.d565.s41.e0,DDI-DrugBank.d565.s41.e2,Coadministration of drug1 with drug0 lowered the drug2,False, 
DDI-DrugBank.d565.s41.e1,DDI-DrugBank.d565.s41.e2,Coadministration of drug0 with drug1 lowered the drug2,False, 
DDI-DrugBank.d565.s42.e0,DDI-DrugBank.d565.s42.e1,Coadministration of drug1 with drug2,True,advise
DDI-DrugBank.d419.s0.e0,DDI-DrugBank.d419.s0.e1,The concurrent administration of drug1 and drug2 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving drug0,True,effect
DDI-DrugBank.d419.s0.e0,DDI-DrugBank.d419.s0.e2,The concurrent administration of drug1 and drug0 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving drug2,False, 
DDI-DrugBank.d419.s0.e1,DDI-DrugBank.d419.s0.e2,The concurrent administration of drug0 and drug1 increases substantially the incidence of rashes in patients receiving both drugs as compared to patients receiving drug2,False, 
DDI-DrugBank.d419.s1.e0,DDI-DrugBank.d419.s1.e1,It is not known whether this potentiation of drug1 rashes is due to drug2,True,effect
DDI-DrugBank.d419.s2.e0,DDI-DrugBank.d419.s2.e1,"In controlled clinical trials of drug1, 22 patients received concomitant drug2 and drug0",False, 
DDI-DrugBank.d419.s2.e0,DDI-DrugBank.d419.s2.e2,"In controlled clinical trials of drug1, 22 patients received concomitant drug0 and drug2",False, 
DDI-DrugBank.d419.s4.e0,DDI-DrugBank.d419.s4.e1,"However, this sample size is too small to allow for any conclusions to be drawn regarding the risk of rashes with concomitant drug1 and drug2",False, 
DDI-DrugBank.d419.s5.e0,DDI-DrugBank.d419.s5.e1,"In common with other drug1, drug2 may reduce the efficacy of oral drug0",False, 
DDI-DrugBank.d419.s5.e0,DDI-DrugBank.d419.s5.e2,"In common with other drug1, drug0 may reduce the efficacy of oral drug2",True,effect
DDI-DrugBank.d419.s5.e1,DDI-DrugBank.d419.s5.e2,"In common with other drug0, drug1 may reduce the efficacy of oral drug2",True,effect
DDI-DrugBank.d316.s0.e0,DDI-DrugBank.d316.s0.e1,drug1 Inhibitors Felodipine is metabolized by drug2,False, 
DDI-DrugBank.d316.s1.e0,DDI-DrugBank.d316.s1.e1,"Co-administration of CYP3A4 inhibitors (eg, drug1, drug2, drug0, grapefruit juice, drug0) with drug0 may lead to several- fold increases in the plasma levels of drug0",False, 
DDI-DrugBank.d316.s1.e0,DDI-DrugBank.d316.s1.e2,"Co-administration of CYP3A4 inhibitors (eg, drug1, drug0, drug2, grapefruit juice, drug0) with drug0 may lead to several- fold increases in the plasma levels of drug0",False, 
DDI-DrugBank.d316.s3.e0,DDI-DrugBank.d316.s3.e1,These effects have been observed with co-administration of drug1 (a potent drug2,False, 
DDI-DrugBank.d316.s4.e0,DDI-DrugBank.d316.s4.e1,Caution should be used when drug1 inhibitors are co-administered with drug2,False, 
DDI-DrugBank.d316.s6.e0,DDI-DrugBank.d316.s6.e1,"The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of drug1 with drug2 resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of drug0",False, 
DDI-DrugBank.d316.s6.e0,DDI-DrugBank.d316.s6.e2,"The following specific interactions have been reported: Itraconazole Co-administration of another extended release formulation of drug1 with drug0 resulted in approximately 8-fold increase in the AUC, more than 6- fold increase in the Cmax, and 2-fold prolongation in the half- life of drug2",False, 
DDI-DrugBank.d316.s7.e0,DDI-DrugBank.d316.s7.e1,"Erythromycin Co-administration of drug1 (drug2) with drug0 resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of drug0",False, 
DDI-DrugBank.d316.s7.e0,DDI-DrugBank.d316.s7.e2,"Erythromycin Co-administration of drug1 (drug0) with drug2 resulted in approximately 2.5- fold increase in the AUC and Cmax, and about 2- fold prolongation in the half- life of drug0",False, 
DDI-DrugBank.d316.s8.e0,DDI-DrugBank.d316.s8.e1,"Grapefruit juice Co-administration of drug1 with grapefruit juice resulted in more than 2-fold increase in the AUC and Cmax, but no prolongation in the half- life of drug2",False, 
DDI-DrugBank.d316.s9.e0,DDI-DrugBank.d316.s9.e1,"Cimetidine Co-administration of drug1 with drug2 (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of drug0",False, 
DDI-DrugBank.d316.s9.e0,DDI-DrugBank.d316.s9.e2,"Cimetidine Co-administration of drug1 with drug0 (a non-specific CYP-450 inhibitor) resulted in an increase of approximately 50% in the AUC and the Cmax, of drug2",False, 
DDI-DrugBank.d316.s10.e0,DDI-DrugBank.d316.s10.e1,Beta-Blocking Agents  A pharmacokinetic study of drug1 in conjunction with drug2 demonstrated no significant effects on the pharmacokinetics of drug0,False, 
DDI-DrugBank.d316.s10.e0,DDI-DrugBank.d316.s10.e2,Beta-Blocking Agents  A pharmacokinetic study of drug1 in conjunction with drug0 demonstrated no significant effects on the pharmacokinetics of drug2,False, 
DDI-DrugBank.d316.s12.e0,DDI-DrugBank.d316.s12.e1,"In controlled clinical trials, however, drug1 including drug2 were concurrently administered with drug0",False, 
DDI-DrugBank.d316.s12.e0,DDI-DrugBank.d316.s12.e2,"In controlled clinical trials, however, drug1 including drug0 were concurrently administered with drug2",False, 
DDI-DrugBank.d316.s13.e0,DDI-DrugBank.d316.s13.e1,Digoxin  When given concomitantly with drug1 the pharmacokinetics of drug2,False, 
DDI-DrugBank.d316.s14.e0,DDI-DrugBank.d316.s14.e1,"drug1: In a pharmacokinetic study, maximum plasma concentrations of drug2 were considerably lower in epileptic patients on long-term drug0 therapy (eg, drug0, drug0, or drug0",False, 
DDI-DrugBank.d316.s14.e0,DDI-DrugBank.d316.s14.e2,"drug1: In a pharmacokinetic study, maximum plasma concentrations of drug0 were considerably lower in epileptic patients on long-term drug2 therapy (eg, drug0, drug0, or drug0",False, 
DDI-DrugBank.d316.s14.e1,DDI-DrugBank.d316.s14.e2,"drug0: In a pharmacokinetic study, maximum plasma concentrations of drug1 were considerably lower in epileptic patients on long-term drug2 therapy (eg, drug0, drug0, or drug0",True,mechanism
DDI-DrugBank.d316.s14.e1,DDI-DrugBank.d316.s14.e3,"drug0: In a pharmacokinetic study, maximum plasma concentrations of drug1 were considerably lower in epileptic patients on long-term drug0 therapy (eg, drug2, drug0, or drug0",True,mechanism
DDI-DrugBank.d316.s14.e1,DDI-DrugBank.d316.s14.e4,"drug0: In a pharmacokinetic study, maximum plasma concentrations of drug1 were considerably lower in epileptic patients on long-term drug0 therapy (eg, drug0, drug2, or drug0",True,mechanism
DDI-DrugBank.d316.s14.e1,DDI-DrugBank.d316.s14.e5,"drug0: In a pharmacokinetic study, maximum plasma concentrations of drug1 were considerably lower in epileptic patients on long-term drug0 therapy (eg, drug0, drug0, or drug2",True,mechanism
DDI-DrugBank.d316.s17.e0,DDI-DrugBank.d316.s17.e1,Tacrolimus  drug1 may increase the blood concentration of drug2,False, 
DDI-DrugBank.d316.s18.e0,DDI-DrugBank.d316.s18.e1,"When given concomitantly with drug1, the drug2",False, 
DDI-DrugBank.d316.s19.e0,DDI-DrugBank.d316.s19.e1,Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when drug1 was given concomitantly with drug2 or drug0,False, 
DDI-DrugBank.d316.s19.e0,DDI-DrugBank.d316.s19.e2,Other Concomitant Therapy  In healthy subjects there were no clinically significant interactions when drug1 was given concomitantly with drug0 or drug2,False, 
DDI-DrugBank.d236.s0.e0,DDI-DrugBank.d236.s0.e1,"drug1: drug2 (drug0, drug0, drug0, drug0, fruit juices, etc.) lower absorption of drug0",False, 
DDI-DrugBank.d236.s0.e0,DDI-DrugBank.d236.s0.e2,"drug1: drug0 (drug2, drug0, drug0, drug0, fruit juices, etc.) lower absorption of drug0",False, 
DDI-DrugBank.d236.s0.e1,DDI-DrugBank.d236.s0.e6,"drug0: drug1 (drug0, drug0, drug0, drug0, fruit juices, etc.) lower absorption of drug2",True,mechanism
DDI-DrugBank.d236.s0.e2,DDI-DrugBank.d236.s0.e6,"drug0: drug0 (drug1, drug0, drug0, drug0, fruit juices, etc.) lower absorption of drug2",True,mechanism
DDI-DrugBank.d236.s0.e3,DDI-DrugBank.d236.s0.e6,"drug0: drug0 (drug0, drug1, drug0, drug0, fruit juices, etc.) lower absorption of drug2",True,mechanism
DDI-DrugBank.d236.s0.e4,DDI-DrugBank.d236.s0.e6,"drug0: drug0 (drug0, drug0, drug1, drug0, fruit juices, etc.) lower absorption of drug2",True,mechanism
DDI-DrugBank.d236.s0.e5,DDI-DrugBank.d236.s0.e6,"drug0: drug0 (drug0, drug0, drug0, drug1, fruit juices, etc.) lower absorption of drug2",True,mechanism
DDI-DrugBank.d236.s1.e0,DDI-DrugBank.d236.s1.e1,"drug1 (drug2, drug0, etc.) increase the concentration of the ionized species of the drug0",False, 
DDI-DrugBank.d236.s1.e0,DDI-DrugBank.d236.s1.e2,"drug1 (drug0, drug2, etc.) increase the concentration of the ionized species of the drug0",False, 
DDI-DrugBank.d236.s1.e0,DDI-DrugBank.d236.s1.e3,"drug1 (drug0, drug0, etc.) increase the concentration of the ionized species of the drug2",True,mechanism
DDI-DrugBank.d236.s1.e1,DDI-DrugBank.d236.s1.e3,"drug0 (drug1, drug0, etc.) increase the concentration of the ionized species of the drug2",True,mechanism
DDI-DrugBank.d236.s1.e2,DDI-DrugBank.d236.s1.e3,"drug0 (drug0, drug1, etc.) increase the concentration of the ionized species of the drug2",True,mechanism
DDI-DrugBank.d236.s3.e0,DDI-DrugBank.d236.s3.e1,drug1: drug2 are inhibited by drug0,False, 
DDI-DrugBank.d236.s3.e0,DDI-DrugBank.d236.s3.e2,drug1: drug0 are inhibited by drug2,False, 
DDI-DrugBank.d236.s3.e1,DDI-DrugBank.d236.s3.e2,drug0: drug1 are inhibited by drug2,True,effect
DDI-DrugBank.d236.s4.e0,DDI-DrugBank.d236.s4.e1,"Alkalinizing agents: Gastrointestinal alkalinizing agents (drug1, etc.) increase absorption of drug2",True,mechanism
DDI-DrugBank.d236.s5.e0,DDI-DrugBank.d236.s5.e1,"Urinary alkalinizing agents (drug1, some drug2) increase the concentration of the non-ionized species of the drug0",False, 
DDI-DrugBank.d236.s5.e0,DDI-DrugBank.d236.s5.e2,"Urinary alkalinizing agents (drug1, some drug0) increase the concentration of the non-ionized species of the drug2",True,mechanism
DDI-DrugBank.d236.s5.e1,DDI-DrugBank.d236.s5.e2,"Urinary alkalinizing agents (drug0, some drug1) increase the concentration of the non-ionized species of the drug2",True,mechanism
DDI-DrugBank.d236.s7.e0,DDI-DrugBank.d236.s7.e1,"drug1, drug2: drug0 may enhance the activity of drug0 or drug0",False, 
DDI-DrugBank.d236.s7.e0,DDI-DrugBank.d236.s7.e2,"drug1, drug0: drug2 may enhance the activity of drug0 or drug0",False, 
DDI-DrugBank.d236.s7.e2,DDI-DrugBank.d236.s7.e3,"drug0, drug0: drug1 may enhance the activity of drug2 or drug0",True,effect
DDI-DrugBank.d236.s7.e2,DDI-DrugBank.d236.s7.e4,"drug0, drug0: drug1 may enhance the activity of drug0 or drug2",True,effect
DDI-DrugBank.d236.s8.e0,DDI-DrugBank.d236.s8.e1,drug1 with drug2 or drug0 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d236.s8.e0,DDI-DrugBank.d236.s8.e2,drug1 with drug0 or drug2 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d236.s8.e0,DDI-DrugBank.d236.s8.e3,drug1 with drug0 or drug0 and possibly other drug2 cause striking and sustained increases in the concentration of drug0,True,mechanism
DDI-DrugBank.d236.s8.e0,DDI-DrugBank.d236.s8.e4,drug1 with drug0 or drug0 and possibly other drug0 cause striking and sustained increases in the concentration of drug2,False, 
DDI-DrugBank.d236.s8.e1,DDI-DrugBank.d236.s8.e2,drug0 with drug1 or drug2 and possibly other drug0 cause striking and sustained increases in the concentration of drug0,False, 
DDI-DrugBank.d236.s10.e0,DDI-DrugBank.d236.s10.e1,"drug1: drug2, as well as a metabolite of drug0, slow drug0",False, 
DDI-DrugBank.d236.s10.e0,DDI-DrugBank.d236.s10.e2,"drug1: drug0, as well as a metabolite of drug2, slow drug0",False, 
DDI-DrugBank.d236.s10.e1,DDI-DrugBank.d236.s10.e3,"drug0: drug1, as well as a metabolite of drug0, slow drug2",True,mechanism
DDI-DrugBank.d236.s10.e2,DDI-DrugBank.d236.s10.e3,"drug0: drug0, as well as a metabolite of drug1, slow drug2",True,mechanism
DDI-DrugBank.d236.s14.e0,DDI-DrugBank.d236.s14.e1,drug1: drug2 may counteract the sedative effect of drug0,False, 
DDI-DrugBank.d236.s14.e0,DDI-DrugBank.d236.s14.e2,drug1: drug0 may counteract the sedative effect of drug2,False, 
DDI-DrugBank.d236.s14.e1,DDI-DrugBank.d236.s14.e2,drug0: drug1 may counteract the sedative effect of drug2,True,effect
DDI-DrugBank.d236.s15.e0,DDI-DrugBank.d236.s15.e1,drug1: drug2 may antagonize the hypotensive effects of drug0,False, 
DDI-DrugBank.d236.s15.e0,DDI-DrugBank.d236.s15.e2,drug1: drug0 may antagonize the hypotensive effects of drug2,False, 
DDI-DrugBank.d236.s15.e1,DDI-DrugBank.d236.s15.e2,drug0: drug1 may antagonize the hypotensive effects of drug2,True,effect
DDI-DrugBank.d236.s16.e0,DDI-DrugBank.d236.s16.e1,"drug1: drug2 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug0, and can be used to treat drug0",False, 
DDI-DrugBank.d236.s16.e0,DDI-DrugBank.d236.s16.e2,"drug1: drug0 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug2, and can be used to treat drug0",False, 
DDI-DrugBank.d236.s16.e1,DDI-DrugBank.d236.s16.e2,"drug0: drug1 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug2, and can be used to treat drug0",True,effect
DDI-DrugBank.d236.s17.e0,DDI-DrugBank.d236.s17.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d236.s17.e0,DDI-DrugBank.d236.s17.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d236.s17.e1,DDI-DrugBank.d236.s17.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d236.s18.e0,DDI-DrugBank.d236.s18.e1,"drug1: drug2 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug0",False, 
DDI-DrugBank.d236.s18.e0,DDI-DrugBank.d236.s18.e2,"drug1: drug0 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug2",False, 
DDI-DrugBank.d236.s18.e1,DDI-DrugBank.d236.s18.e2,"drug0: drug1 blocks dopamine and norepinephrine reuptake, thus inhibiting the central stimulant effects of drug2",True,effect
DDI-DrugBank.d236.s19.e0,DDI-DrugBank.d236.s19.e1,drug1: The stimulatory effects of drug2 may be inhibited by drug0,False, 
DDI-DrugBank.d236.s19.e0,DDI-DrugBank.d236.s19.e2,drug1: The stimulatory effects of drug0 may be inhibited by drug2,False, 
DDI-DrugBank.d236.s19.e1,DDI-DrugBank.d236.s19.e2,drug0: The stimulatory effects of drug1 may be inhibited by drug2,True,effect
DDI-DrugBank.d236.s20.e0,DDI-DrugBank.d236.s20.e1,drug1: drug2 potentiate the analgesic effect of drug0,False, 
DDI-DrugBank.d236.s20.e0,DDI-DrugBank.d236.s20.e2,drug1: drug0 potentiate the analgesic effect of drug2,False, 
DDI-DrugBank.d236.s20.e1,DDI-DrugBank.d236.s20.e2,drug0: drug1 potentiate the analgesic effect of drug2,True,effect
DDI-DrugBank.d236.s21.e0,DDI-DrugBank.d236.s21.e1,"drug1 therapy: Urinary excretion of drug2 is increased, and efficacy is reduced, by drug0 used in drug0",False, 
DDI-DrugBank.d236.s21.e0,DDI-DrugBank.d236.s21.e2,"drug1 therapy: Urinary excretion of drug0 is increased, and efficacy is reduced, by drug2 used in drug0",False, 
DDI-DrugBank.d236.s21.e1,DDI-DrugBank.d236.s21.e2,"drug0 therapy: Urinary excretion of drug1 is increased, and efficacy is reduced, by drug2 used in drug0",True,mechanism
DDI-DrugBank.d236.s22.e0,DDI-DrugBank.d236.s22.e1,drug1: drug2 enhance the adrenergic effect of drug0,False, 
DDI-DrugBank.d236.s22.e0,DDI-DrugBank.d236.s22.e2,drug1: drug0 enhance the adrenergic effect of drug2,False, 
DDI-DrugBank.d236.s22.e1,DDI-DrugBank.d236.s22.e2,drug0: drug1 enhance the adrenergic effect of drug2,True,effect
DDI-DrugBank.d236.s23.e0,DDI-DrugBank.d236.s23.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d236.s23.e0,DDI-DrugBank.d236.s23.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d236.s23.e1,DDI-DrugBank.d236.s23.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d236.s25.e0,DDI-DrugBank.d236.s25.e1,drug1: drug2 may delay intestinal absorption of drug0,False, 
DDI-DrugBank.d236.s25.e0,DDI-DrugBank.d236.s25.e2,drug1: drug0 may delay intestinal absorption of drug2,False, 
DDI-DrugBank.d236.s25.e1,DDI-DrugBank.d236.s25.e2,drug0: drug1 may delay intestinal absorption of drug2,True,mechanism
DDI-DrugBank.d236.s27.e0,DDI-DrugBank.d236.s27.e1,"drug1: In cases of drug2 overdosage, drug0",False, 
DDI-DrugBank.d236.s27.e0,DDI-DrugBank.d236.s27.e2,"drug1: In cases of drug0 overdosage, drug2",False, 
DDI-DrugBank.d236.s27.e1,DDI-DrugBank.d236.s27.e2,"drug0: In cases of drug1 overdosage, drug2",True,effect
DDI-DrugBank.d236.s28.e0,DDI-DrugBank.d236.s28.e1,drug1: drug2 inhibit the hypotensive effect of drug0,False, 
DDI-DrugBank.d236.s28.e0,DDI-DrugBank.d236.s28.e2,drug1: drug0 inhibit the hypotensive effect of drug2,False, 
DDI-DrugBank.d236.s28.e1,DDI-DrugBank.d236.s28.e2,drug0: drug1 inhibit the hypotensive effect of drug2,True,effect
DDI-DrugBank.d320.s0.e0,DDI-DrugBank.d320.s0.e1,drug1   should be used with caution in patients receiving other local drug2,True,advise
DDI-DrugBank.d320.s1.e0,DDI-DrugBank.d320.s1.e1,In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of drug1 to drug2 and drug0,False, 
DDI-DrugBank.d320.s1.e0,DDI-DrugBank.d320.s1.e2,In vitro studies indicate CYP3A4 isoform and CYP1A2 isoform mediate the metabolism of drug1 to drug0 and drug2,False, 
DDI-DrugBank.d320.s2.e0,DDI-DrugBank.d320.s2.e1,Thus agents likely to be concomitantly administered with drug1 that are metabolized by this isoenzyme family may potentially interact with drug2,False, 
DDI-DrugBank.d320.s3.e0,DDI-DrugBank.d320.s3.e1,"Although no clinical studies have been conducted, it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers (such as drug2, drug0, drug0), CYP3A4 inhibitors (azole antimycotics e.g., drug0",True,mechanism
DDI-DrugBank.d320.s3.e0,DDI-DrugBank.d320.s3.e2,"Although no clinical studies have been conducted, it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers (such as drug0, drug2, drug0), CYP3A4 inhibitors (azole antimycotics e.g., drug0",True,mechanism
DDI-DrugBank.d320.s3.e0,DDI-DrugBank.d320.s3.e3,"Although no clinical studies have been conducted, it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers (such as drug0, drug0, drug2), CYP3A4 inhibitors (azole antimycotics e.g., drug0",True,mechanism
DDI-DrugBank.d320.s3.e0,DDI-DrugBank.d320.s3.e4,"Although no clinical studies have been conducted, it is likely that the metabolism of drug1 may be affected by the known CYP3A4 inducers (such as drug0, drug0, drug0), CYP3A4 inhibitors (azole antimycotics e.g., drug2",True,mechanism
DDI-DrugBank.d320.s3.e1,DDI-DrugBank.d320.s3.e2,"Although no clinical studies have been conducted, it is likely that the metabolism of drug0 may be affected by the known CYP3A4 inducers (such as drug1, drug2, drug0), CYP3A4 inhibitors (azole antimycotics e.g., drug0",False, 
DDI-DrugBank.d320.s3.e1,DDI-DrugBank.d320.s3.e3,"Although no clinical studies have been conducted, it is likely that the metabolism of drug0 may be affected by the known CYP3A4 inducers (such as drug1, drug0, drug2), CYP3A4 inhibitors (azole antimycotics e.g., drug0",False, 
DDI-DrugBank.d320.s5.e0,DDI-DrugBank.d320.s5.e1,"drug1 e.g., drug2",False, 
DDI-DrugBank.d320.s6.e0,DDI-DrugBank.d320.s6.e1,"and drug1 e.g., drug2), CYP1A2 inducers (drug0) and CYP1A2 inhibitors (drug0 and drug0",False, 
DDI-DrugBank.d320.s6.e0,DDI-DrugBank.d320.s6.e2,"and drug1 e.g., drug0), CYP1A2 inducers (drug2) and CYP1A2 inhibitors (drug0 and drug0",False, 
DDI-DrugBank.d320.s7.e0,DDI-DrugBank.d320.s7.e1,Dosage adjustment may be warranted when drug1 is concurrently administered with CYP3A4 inhibitors and CYP1A2 inhibitors as systemic drug2,False, 
DDI-DrugBank.d538.s0.e0,DDI-DrugBank.d538.s0.e1,"Known drug interactions include drug1, drug2, and drug0",False, 
DDI-DrugBank.d538.s0.e0,DDI-DrugBank.d538.s0.e2,"Known drug interactions include drug1, drug0, and drug2",False, 
DDI-DrugBank.d538.s1.e0,DDI-DrugBank.d538.s1.e1,"drug1 and drug2 may interact with drug0 In studies with male rats, drug0",False, 
DDI-DrugBank.d538.s1.e0,DDI-DrugBank.d538.s1.e2,"drug1 and drug0 may interact with drug2 In studies with male rats, drug0",True,int
DDI-DrugBank.d538.s1.e0,DDI-DrugBank.d538.s1.e3,"drug1 and drug0 may interact with drug0 In studies with male rats, drug2",False, 
DDI-DrugBank.d538.s1.e1,DDI-DrugBank.d538.s1.e2,"drug0 and drug1 may interact with drug2 In studies with male rats, drug0",True,int
DDI-DrugBank.d76.s1.e0,DDI-DrugBank.d76.s1.e1,In patients receiving another drug1 in combination with drug2 (drug0,True,effect
DDI-DrugBank.d76.s1.e0,DDI-DrugBank.d76.s1.e2,In patients receiving another drug1 in combination with drug0 (drug2,True,effect
DDI-DrugBank.d76.s1.e1,DDI-DrugBank.d76.s1.e2,In patients receiving another drug0 in combination with drug1 (drug2,False, 
DDI-DrugBank.d76.s4.e0,DDI-DrugBank.d76.s4.e1,"Therefore, it is recommended that drug1 Tablets not be used in combination with drug2, or within 14 days of discontinuing treatment with a drug0",True,advise
DDI-DrugBank.d76.s4.e0,DDI-DrugBank.d76.s4.e2,"Therefore, it is recommended that drug1 Tablets not be used in combination with drug0, or within 14 days of discontinuing treatment with a drug2",True,advise
DDI-DrugBank.d76.s4.e1,DDI-DrugBank.d76.s4.e2,"Therefore, it is recommended that drug0 Tablets not be used in combination with drug1, or within 14 days of discontinuing treatment with a drug2",False, 
DDI-DrugBank.d76.s5.e0,DDI-DrugBank.d76.s5.e1,"After stopping drug1 Tablets, at least 2 weeks should be allowed before starting a drug2",True,advise
DDI-DrugBank.d76.s6.e0,DDI-DrugBank.d76.s6.e1,"Potential drug1, drug2, and drug0",False, 
DDI-DrugBank.d76.s6.e0,DDI-DrugBank.d76.s6.e2,"Potential drug1, drug0, and drug2",False, 
DDI-DrugBank.d76.s7.e0,DDI-DrugBank.d76.s7.e1,"drug1, drug2 and drug0 are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that drug0",False, 
DDI-DrugBank.d76.s7.e0,DDI-DrugBank.d76.s7.e2,"drug1, drug0 and drug2 are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that drug0",False, 
DDI-DrugBank.d76.s7.e0,DDI-DrugBank.d76.s7.e3,"drug1, drug0 and drug0 are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that drug2",True,mechanism
DDI-DrugBank.d76.s7.e1,DDI-DrugBank.d76.s7.e3,"drug0, drug1 and drug0 are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that drug2",True,mechanism
DDI-DrugBank.d76.s7.e2,DDI-DrugBank.d76.s7.e3,"drug0, drug0 and drug1 are all metabolized by the cytochrome P450IIIA4 isozyme, and it has been demonstrated that drug2",True,mechanism
DDI-DrugBank.d76.s8.e0,DDI-DrugBank.d76.s8.e1,"Increased plasma concentrations of drug1, drug2, and drug0",False, 
DDI-DrugBank.d76.s8.e0,DDI-DrugBank.d76.s8.e2,"Increased plasma concentrations of drug1, drug0, and drug2",False, 
DDI-DrugBank.d76.s9.e0,DDI-DrugBank.d76.s9.e1,"As noted below, a sub- for drug1 in combination with drug2",False, 
DDI-DrugBank.d76.s10.e0,DDI-DrugBank.d76.s10.e1,"Although it has not been definitively demonstrated that drug1 is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of drug2 with drug0",False, 
DDI-DrugBank.d76.s10.e0,DDI-DrugBank.d76.s10.e2,"Although it has not been definitively demonstrated that drug1 is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of drug0 with drug2",False, 
DDI-DrugBank.d76.s10.e1,DDI-DrugBank.d76.s10.e2,"Although it has not been definitively demonstrated that drug0 is a potent IIIA4 inhibitor, it is likely to be, given the substantial interaction of drug1 with drug2",True,int
DDI-DrugBank.d76.s11.e0,DDI-DrugBank.d76.s11.e1,"Consequently, it is recommended that drug1 not be used in combination with either drug2, drug0, or drug0",True,advise
DDI-DrugBank.d76.s11.e0,DDI-DrugBank.d76.s11.e2,"Consequently, it is recommended that drug1 not be used in combination with either drug0, drug2, or drug0",True,advise
DDI-DrugBank.d76.s11.e0,DDI-DrugBank.d76.s11.e3,"Consequently, it is recommended that drug1 not be used in combination with either drug0, drug0, or drug2",True,advise
DDI-DrugBank.d76.s11.e1,DDI-DrugBank.d76.s11.e2,"Consequently, it is recommended that drug0 not be used in combination with either drug1, drug2, or drug0",False, 
DDI-DrugBank.d76.s11.e1,DDI-DrugBank.d76.s11.e3,"Consequently, it is recommended that drug0 not be used in combination with either drug1, drug0, or drug2",False, 
DDI-DrugBank.d76.s12.e0,DDI-DrugBank.d76.s12.e1,"Other Potentially Important Drug Interactions: drug1: drug2 metabolized by hepatic oxidation (e.g., drug0, drug0, drug0 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug0",False, 
DDI-DrugBank.d76.s12.e0,DDI-DrugBank.d76.s12.e2,"Other Potentially Important Drug Interactions: drug1: drug0 metabolized by hepatic oxidation (e.g., drug2, drug0, drug0 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug0",False, 
DDI-DrugBank.d76.s12.e1,DDI-DrugBank.d76.s12.e5,"Other Potentially Important Drug Interactions: drug0: drug1 metabolized by hepatic oxidation (e.g., drug0, drug0, drug0 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug2",True,mechanism
DDI-DrugBank.d76.s12.e2,DDI-DrugBank.d76.s12.e5,"Other Potentially Important Drug Interactions: drug0: drug0 metabolized by hepatic oxidation (e.g., drug1, drug0, drug0 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug2",True,mechanism
DDI-DrugBank.d76.s12.e3,DDI-DrugBank.d76.s12.e5,"Other Potentially Important Drug Interactions: drug0: drug0 metabolized by hepatic oxidation (e.g., drug0, drug1, drug0 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug2",True,mechanism
DDI-DrugBank.d76.s12.e4,DDI-DrugBank.d76.s12.e5,"Other Potentially Important Drug Interactions: drug0: drug0 metabolized by hepatic oxidation (e.g., drug0, drug0, drug1 elc.) should be used with caution because the clearance of these drugs is likely to be reduced by drug2",True,mechanism
DDI-DrugBank.d76.s13.e0,DDI-DrugBank.d76.s13.e1,"The clearance of drug1 metabolized by glucuronidation (e. g., drug2, drug0, drug0) is unlikely to be affected by drug0",False, 
DDI-DrugBank.d76.s13.e0,DDI-DrugBank.d76.s13.e2,"The clearance of drug1 metabolized by glucuronidation (e. g., drug0, drug2, drug0) is unlikely to be affected by drug0",False, 
DDI-DrugBank.d76.s14.e0,DDI-DrugBank.d76.s14.e1,"drug1: When drug2 (100 mg qd) and drug0 (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of drug0 were approximately twice those observed when drug0",False, 
DDI-DrugBank.d76.s14.e0,DDI-DrugBank.d76.s14.e2,"drug1: When drug0 (100 mg qd) and drug2 (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of drug0 were approximately twice those observed when drug0",False, 
DDI-DrugBank.d76.s14.e1,DDI-DrugBank.d76.s14.e2,"drug0: When drug1 (100 mg qd) and drug2 (1 mg q.d. were co-administered to steady state, plasma concentration and other pharmacokinetics parameters (AUC, Cmax, T1/2,) of drug0 were approximately twice those observed when drug0",True,mechanism
DDI-DrugBank.d76.s17.e0,DDI-DrugBank.d76.s17.e1,"This interaction, which has not been investigated using higher doses of drug1, may be more pronounced if a 300 mg daily dose is co-administered, particularly since drug2 exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If drug0 is co-administered with drug0 Tablets, the initial drug0",False, 
DDI-DrugBank.d76.s17.e0,DDI-DrugBank.d76.s17.e2,"This interaction, which has not been investigated using higher doses of drug1, may be more pronounced if a 300 mg daily dose is co-administered, particularly since drug0 exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If drug2 is co-administered with drug0 Tablets, the initial drug0",False, 
DDI-DrugBank.d76.s17.e2,DDI-DrugBank.d76.s17.e3,"This interaction, which has not been investigated using higher doses of drug0, may be more pronounced if a 300 mg daily dose is co-administered, particularly since drug0 exhibits non-linear pharmacokinetics over the dosage range 100-300 mg. If drug1 is co-administered with drug2 Tablets, the initial drug0",True,advise
DDI-DrugBank.d76.s19.e0,DDI-DrugBank.d76.s19.e1,drug1: The co-administration of drug2 Tablets and drug0,False, 
DDI-DrugBank.d76.s19.e0,DDI-DrugBank.d76.s19.e2,drug1: The co-administration of drug0 Tablets and drug2,False, 
DDI-DrugBank.d76.s19.e1,DDI-DrugBank.d76.s19.e2,drug0: The co-administration of drug1 Tablets and drug2,True,advise
DDI-DrugBank.d76.s20.e0,DDI-DrugBank.d76.s20.e1,"Because drug1 reduces the clearance of both drug2 and its active metabolite, drug0",True,mechanism
DDI-DrugBank.d76.s20.e0,DDI-DrugBank.d76.s20.e2,"Because drug1 reduces the clearance of both drug0 and its active metabolite, drug2",True,mechanism
DDI-DrugBank.d76.s20.e1,DDI-DrugBank.d76.s20.e2,"Because drug0 reduces the clearance of both drug1 and its active metabolite, drug2",False, 
DDI-DrugBank.d76.s21.e0,DDI-DrugBank.d76.s21.e1,Evidence supporting the conclusion that it is inadvisable to co-administer drug1 and drug2 is derived from a study in which healthy volunteers taking 150 mg/day of drug0 were administered a single oral dose of 10 mg of drug0,True,advise
DDI-DrugBank.d76.s21.e0,DDI-DrugBank.d76.s21.e2,Evidence supporting the conclusion that it is inadvisable to co-administer drug1 and drug0 is derived from a study in which healthy volunteers taking 150 mg/day of drug2 were administered a single oral dose of 10 mg of drug0,False, 
DDI-DrugBank.d76.s21.e0,DDI-DrugBank.d76.s21.e3,Evidence supporting the conclusion that it is inadvisable to co-administer drug1 and drug0 is derived from a study in which healthy volunteers taking 150 mg/day of drug0 were administered a single oral dose of 10 mg of drug2,False, 
DDI-DrugBank.d76.s22.e0,DDI-DrugBank.d76.s22.e1,"In these subjects (R= B), the clearance of drug1 was reduced by 65% and that of drug2",False, 
DDI-DrugBank.d76.s24.e0,DDI-DrugBank.d76.s24.e1,"Moreover, as noted with drug1, the effect of drug2",True,effect
DDI-DrugBank.d76.s25.e0,DDI-DrugBank.d76.s25.e1,"Accordingly, drug1 and drug2",True,advise
DDI-DrugBank.d76.s26.e0,DDI-DrugBank.d76.s26.e1,drug1: The effect of steady-state drug2 l50 mg bid on the pharmacokinetics of a single dose of drug0 (375 mg) as 442 mg drug0,False, 
DDI-DrugBank.d76.s26.e0,DDI-DrugBank.d76.s26.e2,drug1: The effect of steady-state drug0 l50 mg bid on the pharmacokinetics of a single dose of drug2 (375 mg) as 442 mg drug0,False, 
DDI-DrugBank.d76.s28.e0,DDI-DrugBank.d76.s28.e1,"Therefore, if drug1 is co-administered with drug2, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drug0",True,advise
DDI-DrugBank.d76.s28.e0,DDI-DrugBank.d76.s28.e2,"Therefore, if drug1 is co-administered with drug0, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drug2",False, 
DDI-DrugBank.d76.s28.e1,DDI-DrugBank.d76.s28.e2,"Therefore, if drug0 is co-administered with drug1, its dose should be reduced to one third of the usual daily maintenance dose and plasma concentrations of drug2",False, 
DDI-DrugBank.d76.s30.e0,DDI-DrugBank.d76.s30.e1,"drug1: When drug2 (50 mg tid) was administered concomitantly with drug0 for two weeks, drug0",False, 
DDI-DrugBank.d76.s30.e0,DDI-DrugBank.d76.s30.e2,"drug1: When drug0 (50 mg tid) was administered concomitantly with drug2 for two weeks, drug0",False, 
DDI-DrugBank.d76.s30.e1,DDI-DrugBank.d76.s30.e2,"drug0: When drug1 (50 mg tid) was administered concomitantly with drug2 for two weeks, drug0",True,mechanism
DDI-DrugBank.d76.s31.e0,DDI-DrugBank.d76.s31.e1,Thus patients receiving oral drug1 and drug2 Tablets should have their prothrombin time monitored and their drug0,True,advise
DDI-DrugBank.d76.s31.e0,DDI-DrugBank.d76.s31.e2,Thus patients receiving oral drug1 and drug0 Tablets should have their prothrombin time monitored and their drug2,False, 
DDI-DrugBank.d76.s31.e1,DDI-DrugBank.d76.s31.e2,Thus patients receiving oral drug0 and drug1 Tablets should have their prothrombin time monitored and their drug2,False, 
DDI-DrugBank.d20.s1.e0,DDI-DrugBank.d20.s1.e1,"A pharmacokinetic study evaluating the administration of a single dose of drug1 100 mg with drug2 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of drug0 and a 5.4-fold increase in AUC of drug0",True,mechanism
DDI-DrugBank.d20.s1.e0,DDI-DrugBank.d20.s1.e2,"A pharmacokinetic study evaluating the administration of a single dose of drug1 100 mg with drug0 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of drug2 and a 5.4-fold increase in AUC of drug0",False, 
DDI-DrugBank.d20.s1.e0,DDI-DrugBank.d20.s1.e3,"A pharmacokinetic study evaluating the administration of a single dose of drug1 100 mg with drug0 200 mg BID, a potent inhibitor of the CYP3A4 pathway, showed a 1.7-fold increase in Cmax of drug0 and a 5.4-fold increase in AUC of drug2",False, 
DDI-DrugBank.d20.s3.e0,DDI-DrugBank.d20.s3.e1,"Administration of drug1 with other CYP3A4 inhibitors (e.g., drug2 500 mg BID, drug0 240 mg QD, drug0 1200 mg TID, drug0 200 mg QD) resulted in increases in Cmax of drug0",True,mechanism
DDI-DrugBank.d20.s3.e0,DDI-DrugBank.d20.s3.e2,"Administration of drug1 with other CYP3A4 inhibitors (e.g., drug0 500 mg BID, drug2 240 mg QD, drug0 1200 mg TID, drug0 200 mg QD) resulted in increases in Cmax of drug0",True,mechanism
DDI-DrugBank.d20.s3.e0,DDI-DrugBank.d20.s3.e3,"Administration of drug1 with other CYP3A4 inhibitors (e.g., drug0 500 mg BID, drug0 240 mg QD, drug2 1200 mg TID, drug0 200 mg QD) resulted in increases in Cmax of drug0",True,mechanism
DDI-DrugBank.d20.s3.e0,DDI-DrugBank.d20.s3.e4,"Administration of drug1 with other CYP3A4 inhibitors (e.g., drug0 500 mg BID, drug0 240 mg QD, drug0 1200 mg TID, drug2 200 mg QD) resulted in increases in Cmax of drug0",True,mechanism
DDI-DrugBank.d20.s3.e0,DDI-DrugBank.d20.s3.e5,"Administration of drug1 with other CYP3A4 inhibitors (e.g., drug0 500 mg BID, drug0 240 mg QD, drug0 1200 mg TID, drug0 200 mg QD) resulted in increases in Cmax of drug2",False, 
DDI-DrugBank.d20.s3.e1,DDI-DrugBank.d20.s3.e2,"Administration of drug0 with other CYP3A4 inhibitors (e.g., drug1 500 mg BID, drug2 240 mg QD, drug0 1200 mg TID, drug0 200 mg QD) resulted in increases in Cmax of drug0",False, 
DDI-DrugBank.d20.s4.e0,DDI-DrugBank.d20.s4.e1,"drug1 and drug2 (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving drug0 25 to 50 mg also received drug0 or drug0 (drug0/drug0",False, 
DDI-DrugBank.d20.s4.e0,DDI-DrugBank.d20.s4.e2,"drug1 and drug0 (Congestive Heart Failure Post-Myocardial Infarction)- In EPHESUS, 3020 (91%) patients receiving drug2 25 to 50 mg also received drug0 or drug0 (drug0/drug0",False, 
DDI-DrugBank.d20.s5.e0,DDI-DrugBank.d20.s5.e1,Rates of patients with maximum potassium levels  5.5 mEq/L were similar regardless of the use of drug1/drug2,False, 
DDI-DrugBank.d20.s6.e0,DDI-DrugBank.d20.s6.e1,"drug1 and drug2 (Hypertension)- In clinical studies of patients with hypertension, the addition of drug0 50 to 100 mg to drug0 and drug0",False, 
DDI-DrugBank.d20.s6.e0,DDI-DrugBank.d20.s6.e2,"drug1 and drug0 (Hypertension)- In clinical studies of patients with hypertension, the addition of drug2 50 to 100 mg to drug0 and drug0",False, 
DDI-DrugBank.d20.s6.e2,DDI-DrugBank.d20.s6.e3,"drug0 and drug0 (Hypertension)- In clinical studies of patients with hypertension, the addition of drug1 50 to 100 mg to drug2 and drug0",True,effect
DDI-DrugBank.d20.s6.e2,DDI-DrugBank.d20.s6.e4,"drug0 and drug0 (Hypertension)- In clinical studies of patients with hypertension, the addition of drug1 50 to 100 mg to drug0 and drug2",True,effect
DDI-DrugBank.d20.s7.e0,DDI-DrugBank.d20.s7.e1,In a study in diabetics with microalbuminuria drug1 200 mg combined with the drug2 drug0 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on drug0,False, 
DDI-DrugBank.d20.s7.e0,DDI-DrugBank.d20.s7.e2,In a study in diabetics with microalbuminuria drug1 200 mg combined with the drug0 drug2 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on drug0,True,effect
DDI-DrugBank.d20.s7.e0,DDI-DrugBank.d20.s7.e3,In a study in diabetics with microalbuminuria drug1 200 mg combined with the drug0 drug0 10 mg increased the frequency of hyperkalemia (serum potassium  5.5 mEq/L) from 17% on drug2,False, 
DDI-DrugBank.d20.s8.e0,DDI-DrugBank.d20.s8.e1,drug1-A drug interaction study of drug2 with drug0,False, 
DDI-DrugBank.d20.s8.e0,DDI-DrugBank.d20.s8.e2,drug1-A drug interaction study of drug0 with drug2,False, 
DDI-DrugBank.d20.s9.e0,DDI-DrugBank.d20.s9.e1,Serum drug1 levels should be monitored frequently if drug2 is administered concomitantly with drug0,False, 
DDI-DrugBank.d20.s9.e0,DDI-DrugBank.d20.s9.e2,Serum drug1 levels should be monitored frequently if drug0 is administered concomitantly with drug2,False, 
DDI-DrugBank.d20.s9.e1,DDI-DrugBank.d20.s9.e2,Serum drug0 levels should be monitored frequently if drug1 is administered concomitantly with drug2,True,advise
DDI-DrugBank.d20.s10.e0,DDI-DrugBank.d20.s10.e1,drug1 (drug2)-A drug interaction study of drug0 with an drug0,False, 
DDI-DrugBank.d20.s10.e0,DDI-DrugBank.d20.s10.e2,drug1 (drug0)-A drug interaction study of drug2 with an drug0,False, 
DDI-DrugBank.d20.s11.e0,DDI-DrugBank.d20.s11.e1,The administration of other drug1 with drug2,True,effect
DDI-DrugBank.d20.s12.e0,DDI-DrugBank.d20.s12.e1,"Therefore, when drug1 and drug2",True,advise
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e1,"drug1 in combination with other drug2, general drug0, drug0, drug0, drug0, or other drug0 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e2,"drug1 in combination with other drug0, general drug2, drug0, drug0, drug0, or other drug0 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e3,"drug1 in combination with other drug0, general drug0, drug2, drug0, drug0, or other drug0 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e4,"drug1 in combination with other drug0, general drug0, drug0, drug2, drug0, or other drug0 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e5,"drug1 in combination with other drug0, general drug0, drug0, drug0, drug2, or other drug0 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e6,"drug1 in combination with other drug0, general drug0, drug0, drug0, drug0, or other drug2 (including drug0",True,effect
DDI-DrugBank.d464.s0.e0,DDI-DrugBank.d464.s0.e7,"drug1 in combination with other drug0, general drug0, drug0, drug0, drug0, or other drug0 (including drug2",True,effect
DDI-DrugBank.d464.s0.e1,DDI-DrugBank.d464.s0.e2,"drug0 in combination with other drug1, general drug2, drug0, drug0, drug0, or other drug0 (including drug0",False, 
DDI-DrugBank.d464.s0.e1,DDI-DrugBank.d464.s0.e3,"drug0 in combination with other drug1, general drug0, drug2, drug0, drug0, or other drug0 (including drug0",False, 
DDI-DrugBank.d487.s1.e0,DDI-DrugBank.d487.s1.e1,"Drugs that induce hepatic enzymes such as drug1, drug2 and drug0 may increase the clearance of drug0 and may require increases in drug0",False, 
DDI-DrugBank.d487.s1.e0,DDI-DrugBank.d487.s1.e2,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug2 may increase the clearance of drug0 and may require increases in drug0",False, 
DDI-DrugBank.d487.s1.e0,DDI-DrugBank.d487.s1.e3,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug0 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d487.s1.e0,DDI-DrugBank.d487.s1.e4,"Drugs that induce hepatic enzymes such as drug1, drug0 and drug0 may increase the clearance of drug0 and may require increases in drug2",True,advise
DDI-DrugBank.d487.s1.e1,DDI-DrugBank.d487.s1.e3,"Drugs that induce hepatic enzymes such as drug0, drug1 and drug0 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d487.s1.e1,DDI-DrugBank.d487.s1.e4,"Drugs that induce hepatic enzymes such as drug0, drug1 and drug0 may increase the clearance of drug0 and may require increases in drug2",True,advise
DDI-DrugBank.d487.s1.e2,DDI-DrugBank.d487.s1.e3,"Drugs that induce hepatic enzymes such as drug0, drug0 and drug1 may increase the clearance of drug2 and may require increases in drug0",True,mechanism
DDI-DrugBank.d487.s1.e2,DDI-DrugBank.d487.s1.e4,"Drugs that induce hepatic enzymes such as drug0, drug0 and drug1 may increase the clearance of drug0 and may require increases in drug2",True,advise
DDI-DrugBank.d487.s2.e0,DDI-DrugBank.d487.s2.e1,Drugs such as drug1 and drug2 may inhibit the metabolism of drug0,False, 
DDI-DrugBank.d487.s2.e0,DDI-DrugBank.d487.s2.e2,Drugs such as drug1 and drug0 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d487.s2.e1,DDI-DrugBank.d487.s2.e2,Drugs such as drug0 and drug1 may inhibit the metabolism of drug2,True,mechanism
DDI-DrugBank.d487.s4.e0,DDI-DrugBank.d487.s4.e1,drug1 may increase the clearance of chronic high dose drug2,True,effect
DDI-DrugBank.d487.s5.e0,DDI-DrugBank.d487.s5.e1,This could lead to decreased drug1 serum levels or increase the risk of drug2 toxicity when drug0,False, 
DDI-DrugBank.d487.s5.e0,DDI-DrugBank.d487.s5.e2,This could lead to decreased drug1 serum levels or increase the risk of drug0 toxicity when drug2,False, 
DDI-DrugBank.d487.s5.e1,DDI-DrugBank.d487.s5.e2,This could lead to decreased drug0 serum levels or increase the risk of drug1 toxicity when drug2,True,effect
DDI-DrugBank.d487.s6.e0,DDI-DrugBank.d487.s6.e1,drug1 should be used cautiously in conjunction with drug2,True,advise
DDI-DrugBank.d487.s7.e0,DDI-DrugBank.d487.s7.e1,The effect of drug1 on oral drug2,True,effect
DDI-DrugBank.d487.s8.e0,DDI-DrugBank.d487.s8.e1,There are reports of enhanced as well as diminished effects of drug1 when given concurrently with drug2,True,effect
DDI-DrugBank.d41.s0.e0,DDI-DrugBank.d41.s0.e1,drug1 and drug2 Administration of drug0 or drug0 in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of drug0,False, 
DDI-DrugBank.d41.s0.e0,DDI-DrugBank.d41.s0.e2,drug1 and drug0 Administration of drug2 or drug0 in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of drug0,False, 
DDI-DrugBank.d41.s0.e2,DDI-DrugBank.d41.s0.e4,drug0 and drug0 Administration of drug1 or drug0 in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of drug2,True,mechanism
DDI-DrugBank.d41.s0.e3,DDI-DrugBank.d41.s0.e4,drug0 and drug0 Administration of drug0 or drug1 in patients (n=13) and volunteers (n=96) resulted in a rapid and significant decrease in plasma M1 (the active metabolite of drug2,True,mechanism
DDI-DrugBank.d41.s3.e0,DDI-DrugBank.d41.s3.e1,In a small (n=30) combination study of drug1 with drug2,True,effect
DDI-DrugBank.d41.s9.e0,DDI-DrugBank.d41.s9.e1,"drug1: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of drug2 and drug0",False, 
DDI-DrugBank.d41.s9.e0,DDI-DrugBank.d41.s9.e2,"drug1: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of drug0 and drug2",False, 
DDI-DrugBank.d41.s12.e0,DDI-DrugBank.d41.s12.e1,"drug1: In in vitro studies, M1 was shown to cause increases ranging from 13 - 50% in the free fraction of drug2",False, 
DDI-DrugBank.d41.s14.e0,DDI-DrugBank.d41.s14.e1,"drug1: Following concomitant administration of a single dose of drug2 to subjects receiving multiple doses of drug0, M1 peak levels were increased (~40%) over those seen when drug0",False, 
DDI-DrugBank.d41.s14.e0,DDI-DrugBank.d41.s14.e2,"drug1: Following concomitant administration of a single dose of drug0 to subjects receiving multiple doses of drug2, M1 peak levels were increased (~40%) over those seen when drug0",False, 
DDI-DrugBank.d41.s14.e1,DDI-DrugBank.d41.s14.e2,"drug0: Following concomitant administration of a single dose of drug1 to subjects receiving multiple doses of drug2, M1 peak levels were increased (~40%) over those seen when drug0",True,mechanism
DDI-DrugBank.d41.s15.e0,DDI-DrugBank.d41.s15.e1,"Because of the potential for drug1 levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both drug2 and drug0",False, 
DDI-DrugBank.d41.s15.e0,DDI-DrugBank.d41.s15.e2,"Because of the potential for drug1 levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both drug0 and drug2",False, 
DDI-DrugBank.d41.s15.e1,DDI-DrugBank.d41.s15.e2,"Because of the potential for drug0 levels to continue to increase with multiple dosing, caution should be used if patients are to be receiving both drug1 and drug2",True,advise
DDI-DrugBank.d41.s16.e0,DDI-DrugBank.d41.s16.e1,drug1: Increased INR (International Normalized Ratio) when drug2 and drug0,False, 
DDI-DrugBank.d41.s16.e0,DDI-DrugBank.d41.s16.e2,drug1: Increased INR (International Normalized Ratio) when drug0 and drug2,False, 
DDI-DrugBank.d41.s16.e1,DDI-DrugBank.d41.s16.e2,drug0: Increased INR (International Normalized Ratio) when drug1 and drug2,True,effect
DDI-DrugBank.d426.s1.e0,DDI-DrugBank.d426.s1.e1,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug1-containing or drug2 (like drug0 or drug0) and drug0",False, 
DDI-DrugBank.d426.s1.e0,DDI-DrugBank.d426.s1.e2,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug1-containing or drug0 (like drug2 or drug0) and drug0",False, 
DDI-DrugBank.d426.s1.e0,DDI-DrugBank.d426.s1.e4,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug1-containing or drug0 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d426.s1.e1,DDI-DrugBank.d426.s1.e4,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug0-containing or drug1 (like drug0 or drug0) and drug2",True,advise
DDI-DrugBank.d426.s1.e2,DDI-DrugBank.d426.s1.e4,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug0-containing or drug0 (like drug1 or drug0) and drug2",True,advise
DDI-DrugBank.d426.s1.e3,DDI-DrugBank.d426.s1.e4,"Due to a theoretical risk of a pharmacodynamic interaction, use of drug0-containing or drug0 (like drug0 or drug1) and drug2",True,advise
DDI-DrugBank.d426.s3.e0,DDI-DrugBank.d426.s3.e1,"drug1 (drug2) (e.g., drug0, drug0, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug0",False, 
DDI-DrugBank.d426.s3.e0,DDI-DrugBank.d426.s3.e2,"drug1 (drug0) (e.g., drug2, drug0, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug0",False, 
DDI-DrugBank.d426.s3.e0,DDI-DrugBank.d426.s3.e6,"drug1 (drug0) (e.g., drug0, drug0, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s3.e1,DDI-DrugBank.d426.s3.e6,"drug0 (drug1) (e.g., drug0, drug0, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s3.e2,DDI-DrugBank.d426.s3.e6,"drug0 (drug0) (e.g., drug1, drug0, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s3.e3,DDI-DrugBank.d426.s3.e6,"drug0 (drug0) (e.g., drug0, drug1, drug0, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s3.e4,DDI-DrugBank.d426.s3.e6,"drug0 (drug0) (e.g., drug0, drug0, drug1, drug0) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s3.e5,DDI-DrugBank.d426.s3.e6,"drug0 (drug0) (e.g., drug0, drug0, drug0, drug1) have been reported, rarely, to cause weakness, hyperreflexia, and incoordination when coadministered with drug2",True,effect
DDI-DrugBank.d426.s4.e0,DDI-DrugBank.d426.s4.e1,If concomitant treatment with drug1 and an drug2,True,advise
DDI-MedLine.d103.s1.e0,DDI-MedLine.d103.s1.e1,Two different types of therapy with drug1 are used: physiological oral drug2 supplementation which is totally atoxic since it palliates drug0 deficiencies by simply normalizing the drug0 intake and pharmacological drug0 therapy which may induce toxicity since it creates iatrogenic drug0,False, 
DDI-MedLine.d103.s1.e0,DDI-MedLine.d103.s1.e2,Two different types of therapy with drug1 are used: physiological oral drug0 supplementation which is totally atoxic since it palliates drug2 deficiencies by simply normalizing the drug0 intake and pharmacological drug0 therapy which may induce toxicity since it creates iatrogenic drug0,False, 
DDI-MedLine.d103.s2.e0,DDI-MedLine.d103.s2.e1,Primary and secondary drug1 deficiencies constitute the sole indication of physiological oral drug2,False, 
DDI-MedLine.d103.s3.e0,DDI-MedLine.d103.s3.e1,It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of drug1 deficit and to discriminate between drug2 deficiency due to an insufficient drug0 intake which only requires oral physiological supplementation and drug0 depletion related to a dysregulation of the control mechanisms of drug0,False, 
DDI-MedLine.d103.s3.e0,DDI-MedLine.d103.s3.e2,It is therefore necessary to be well acquainted with the clinical and paraclinical pattern of drug1 deficit and to discriminate between drug0 deficiency due to an insufficient drug2 intake which only requires oral physiological supplementation and drug0 depletion related to a dysregulation of the control mechanisms of drug0,False, 
DDI-MedLine.d103.s4.e0,DDI-MedLine.d103.s4.e1,Physiological oral drug1 load constitutes the best tool for diagnosis of drug2,False, 
DDI-MedLine.d103.s5.e0,DDI-MedLine.d103.s5.e1,Physiological oral drug1 supplementation (5 mg/kg/day) is easy and can be carried out in the diet or with drug2,False, 
DDI-MedLine.d103.s6.e0,DDI-MedLine.d103.s6.e1,"Specific and aspecific treatments of drug1 depletion are tricky using for example drug2, pharmacological doses of drug0, physiological doses of drug0 and of drug0",False, 
DDI-MedLine.d103.s6.e0,DDI-MedLine.d103.s6.e2,"Specific and aspecific treatments of drug1 depletion are tricky using for example drug0, pharmacological doses of drug2, physiological doses of drug0 and of drug0",False, 
DDI-MedLine.d103.s8.e0,DDI-MedLine.d103.s8.e1,"There are 3 types of indications: specific (for the treatment of some forms of drug1 deficit i.e. acute), pharmacological (i.e. without alterations of drug2",False, 
DDI-MedLine.d103.s15.e0,DDI-MedLine.d103.s15.e1,"Lastly local use of the mucocutaneous and cytoprotective properties of drug1 is still valid, in drug2",False, 
DDI-MedLine.d111.s2.e0,DDI-MedLine.d111.s2.e1,"drug1, drug2, drug0, drug0, drug0, and drug0",False, 
DDI-MedLine.d111.s2.e0,DDI-MedLine.d111.s2.e2,"drug1, drug0, drug2, drug0, drug0, and drug0",False, 
DDI-MedLine.d111.s4.e0,DDI-MedLine.d111.s4.e1,The following eight target drug/added drug combinations were studied: drug1/drug2,False, 
DDI-MedLine.d111.s5.e0,DDI-MedLine.d111.s5.e1,"drug1/drug2, drug0/drug0, drug0/drug0, drug0/drug0, drug0/drug0, drug0/drug0, and drug0/drug0",False, 
DDI-MedLine.d111.s5.e0,DDI-MedLine.d111.s5.e2,"drug1/drug0, drug2/drug0, drug0/drug0, drug0/drug0, drug0/drug0, drug0/drug0, and drug0/drug0",False, 
DDI-MedLine.d111.s7.e0,DDI-MedLine.d111.s7.e1,"Similarly dialyzed were drug1, drug2, and drug0, both alone at therapeutic concentrations in serum and with drug0",False, 
DDI-MedLine.d111.s7.e0,DDI-MedLine.d111.s7.e2,"Similarly dialyzed were drug1, drug0, and drug2, both alone at therapeutic concentrations in serum and with drug0",False, 
DDI-MedLine.d111.s9.e0,DDI-MedLine.d111.s9.e1,drug1 diminished the binding of drug2,True,mechanism
DDI-MedLine.d111.s10.e0,DDI-MedLine.d111.s10.e1,drug1 decreased the binding of drug2,True,mechanism
DDI-MedLine.d111.s12.e0,DDI-MedLine.d111.s12.e1,drug1 diminished binding of drug2,True,mechanism
DDI-MedLine.d111.s14.e0,DDI-MedLine.d111.s14.e1,"Coingestion of drug1 with drug2, drug0 with drug0, and drug0 with drug0",True,effect
DDI-MedLine.d111.s14.e0,DDI-MedLine.d111.s14.e2,"Coingestion of drug1 with drug0, drug2 with drug0, and drug0 with drug0",False, 
DDI-MedLine.d111.s14.e0,DDI-MedLine.d111.s14.e3,"Coingestion of drug1 with drug0, drug0 with drug2, and drug0 with drug0",False, 
DDI-MedLine.d111.s14.e2,DDI-MedLine.d111.s14.e3,"Coingestion of drug0 with drug0, drug1 with drug2, and drug0 with drug0",True,effect
DDI-MedLine.d111.s14.e4,DDI-MedLine.d111.s14.e5,"Coingestion of drug0 with drug0, drug0 with drug0, and drug1 with drug2",True,effect
DDI-MedLine.d88.s0.e0,DDI-MedLine.d88.s0.e1,"The effects of drug1, drug2 and drug0",False, 
DDI-MedLine.d88.s0.e0,DDI-MedLine.d88.s0.e2,"The effects of drug1, drug0 and drug2",False, 
DDI-MedLine.d88.s1.e0,DDI-MedLine.d88.s1.e1,Studies on two strains of pointer dogs have demonstrated that administration of a drug1 (drug2,False, 
DDI-MedLine.d88.s4.e0,DDI-MedLine.d88.s4.e1,The concomitant administration of either drug1 or drug2,False, 
DDI-MedLine.d86.s0.e0,DDI-MedLine.d86.s0.e1,Pharmacokinetic interaction between single oral doses of drug1 and drug2,True,mechanism
DDI-MedLine.d86.s1.e0,DDI-MedLine.d86.s1.e1,"AIM AND BACKGROUND: The pharmacokinetic interaction between drug1, a drug2 metabolized by CYP3A4, and the drug0 drug0",False, 
DDI-MedLine.d86.s1.e0,DDI-MedLine.d86.s1.e2,"AIM AND BACKGROUND: The pharmacokinetic interaction between drug1, a drug0 metabolized by CYP3A4, and the drug2 drug0",False, 
DDI-MedLine.d86.s2.e0,DDI-MedLine.d86.s2.e1,Several clinically important interactions have previously been reported for other drug1 that are metabolized by the same enzyme and for drug2,False, 
DDI-MedLine.d86.s3.e0,DDI-MedLine.d86.s3.e1,"METHODS: Healthy subjects who were 20 to 43 years old participated in an open, three-period, randomized, crossover study of the pharmacokinetics of a single 10-mg oral dose of drug1, a single oral 120-mg dose of drug2",False, 
DDI-MedLine.d86.s5.e0,DDI-MedLine.d86.s5.e1,"RESULTS: The geometric mean (90% confidence interval) whole blood drug1 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with drug2 coadministration, whereas the mean elimination half-life of drug0",True,mechanism
DDI-MedLine.d86.s5.e0,DDI-MedLine.d86.s5.e2,"RESULTS: The geometric mean (90% confidence interval) whole blood drug1 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with drug0 coadministration, whereas the mean elimination half-life of drug2",False, 
DDI-MedLine.d86.s5.e1,DDI-MedLine.d86.s5.e2,"RESULTS: The geometric mean (90% confidence interval) whole blood drug0 area under the plasma concentration time-curve increased 60% (35%-90%), from 736 to 1178 ng x h/mL, and maximum concentration increased 43% (14%-81%), from 67 to 96 ng/mL, with drug1 coadministration, whereas the mean elimination half-life of drug2",False, 
DDI-MedLine.d86.s6.e0,DDI-MedLine.d86.s6.e1,"Apparent oral clearance and volume of distribution of drug1 decreased with 38% and 45%, respectively, when drug2 was given with drug0",False, 
DDI-MedLine.d86.s6.e0,DDI-MedLine.d86.s6.e2,"Apparent oral clearance and volume of distribution of drug1 decreased with 38% and 45%, respectively, when drug0 was given with drug2",False, 
DDI-MedLine.d86.s6.e1,DDI-MedLine.d86.s6.e2,"Apparent oral clearance and volume of distribution of drug0 decreased with 38% and 45%, respectively, when drug1 was given with drug2",True,mechanism
DDI-MedLine.d86.s7.e0,DDI-MedLine.d86.s7.e1,"The plasma maximum concentration and area under the plasma concentration-time curve of drug1, drug2, and drug0 were unchanged after coadministration of drug0, and no potentiation of the effects of drug0",False, 
DDI-MedLine.d86.s7.e0,DDI-MedLine.d86.s7.e2,"The plasma maximum concentration and area under the plasma concentration-time curve of drug1, drug0, and drug2 were unchanged after coadministration of drug0, and no potentiation of the effects of drug0",False, 
DDI-MedLine.d86.s8.e0,DDI-MedLine.d86.s8.e1,"CONCLUSIONS: Single-dose drug1 coadministration leads to higher drug2 exposure, presumably by inhibition of the first-pass metabolism of drug0",True,mechanism
DDI-MedLine.d86.s8.e0,DDI-MedLine.d86.s8.e2,"CONCLUSIONS: Single-dose drug1 coadministration leads to higher drug0 exposure, presumably by inhibition of the first-pass metabolism of drug2",False, 
DDI-MedLine.d86.s8.e1,DDI-MedLine.d86.s8.e2,"CONCLUSIONS: Single-dose drug0 coadministration leads to higher drug1 exposure, presumably by inhibition of the first-pass metabolism of drug2",False, 
DDI-MedLine.d86.s9.e0,DDI-MedLine.d86.s9.e1,"Because of the pronounced intersubject variability in the extent of the drug1-drug2 interaction, whole blood drug0",True,advise
DDI-MedLine.d86.s9.e0,DDI-MedLine.d86.s9.e2,"Because of the pronounced intersubject variability in the extent of the drug1-drug0 interaction, whole blood drug2",False, 
DDI-MedLine.d86.s9.e1,DDI-MedLine.d86.s9.e2,"Because of the pronounced intersubject variability in the extent of the drug0-drug1 interaction, whole blood drug2",False, 
DDI-MedLine.d79.s0.e0,DDI-MedLine.d79.s0.e1,"If taken 1 hour before drug1 (drug2), drug0 does not affect drug0",False, 
DDI-MedLine.d79.s0.e0,DDI-MedLine.d79.s0.e2,"If taken 1 hour before drug1 (drug0), drug2 does not affect drug0",False, 
DDI-MedLine.d79.s1.e0,DDI-MedLine.d79.s1.e1,"Concurrent administration of drug1 and drug2 significantly reduces the level of exposure to drug0, but it is unclear how soon after drug0 administration drug0",True,mechanism
DDI-MedLine.d79.s1.e0,DDI-MedLine.d79.s1.e2,"Concurrent administration of drug1 and drug0 significantly reduces the level of exposure to drug2, but it is unclear how soon after drug0 administration drug0",False, 
DDI-MedLine.d79.s1.e0,DDI-MedLine.d79.s1.e3,"Concurrent administration of drug1 and drug0 significantly reduces the level of exposure to drug0, but it is unclear how soon after drug2 administration drug0",False, 
DDI-MedLine.d79.s2.e0,DDI-MedLine.d79.s2.e1,We compared drug1 pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of drug2 alone versus 800 mg of drug0 administered 1 h after drug0,False, 
DDI-MedLine.d79.s2.e0,DDI-MedLine.d79.s2.e2,We compared drug1 pharmacokinetics and gastric pH in 12 human immunodeficiency virus-positive patients by use of 800 mg of drug0 alone versus 800 mg of drug2 administered 1 h after drug0,False, 
DDI-MedLine.d79.s3.e0,DDI-MedLine.d79.s3.e1,Median gastric pH was significantly higher when drug1 was taken after drug2,True,mechanism
DDI-MedLine.d79.s5.e0,DDI-MedLine.d79.s5.e1,drug1 may be taken with a light meal 1 h following the administration of 400 mg of drug2,True,advise
DDI-MedLine.d57.s1.e0,DDI-MedLine.d57.s1.e1,"The literature provides considerable evidence indicating that several, but not all drug1, are indeed drug2 and some are drug0",False, 
DDI-MedLine.d57.s1.e0,DDI-MedLine.d57.s1.e2,"The literature provides considerable evidence indicating that several, but not all drug1, are indeed drug0 and some are drug2",False, 
DDI-MedLine.d57.s2.e0,DDI-MedLine.d57.s2.e1,"Those for which effectiveness is reported includes drug1, drug2, drug0, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-MedLine.d57.s2.e0,DDI-MedLine.d57.s2.e2,"Those for which effectiveness is reported includes drug1, drug0, drug2, drug0, drug0, drug0, drug0, and drug0",False, 
DDI-MedLine.d120.s0.e0,DDI-MedLine.d120.s0.e1,Molecular basis for the selective toxicity of drug1 for yeast and drug2,False, 
DDI-MedLine.d120.s1.e0,DDI-MedLine.d120.s1.e1,"Among the drug1, many, like drug2",False, 
DDI-MedLine.d120.s3.e0,DDI-MedLine.d120.s3.e1,Both the toxicity of drug1 and the therapeutic value of drug2 can be rationalized at the cellular and molecular level by the following observations: (i) these drug0,False, 
DDI-MedLine.d120.s3.e0,DDI-MedLine.d120.s3.e2,Both the toxicity of drug1 and the therapeutic value of drug0 can be rationalized at the cellular and molecular level by the following observations: (i) these drug2,False, 
DDI-MedLine.d120.s4.e0,DDI-MedLine.d120.s4.e1,"drug1 was more potent in lysing human red blood cells, whereas drug2",False, 
DDI-MedLine.d120.s5.e0,DDI-MedLine.d120.s5.e1,"and (ii) the effects of drug1 were more efficiently inhibited by added cholesterol, the major membrane sterol in human cells, whereas the effects of drug2",False, 
DDI-MedLine.d21.s2.e0,DDI-MedLine.d21.s2.e1,Treatment with drug1 can directly interfere with blood glucose levels or may interact with drug2,True,int
DDI-MedLine.d21.s6.e0,DDI-MedLine.d21.s6.e1,"drug1 (5 mg/kg), drug2 (30 mg/kg), drug0 (0.25 mg/kg), drug0 (20 mg/kg) drug0",False, 
DDI-MedLine.d21.s6.e0,DDI-MedLine.d21.s6.e2,"drug1 (5 mg/kg), drug0 (30 mg/kg), drug2 (0.25 mg/kg), drug0 (20 mg/kg) drug0",False, 
DDI-MedLine.d21.s8.e0,DDI-MedLine.d21.s8.e1,An oral drug1 overload of 1 ml of a 50% drug2,False, 
DDI-MedLine.d21.s9.e0,DDI-MedLine.d21.s9.e1,drug1 and drug2,False, 
DDI-MedLine.d21.s10.e0,DDI-MedLine.d21.s10.e1,drug1 and drug2 increased blood drug0,False, 
DDI-MedLine.d21.s10.e0,DDI-MedLine.d21.s10.e2,drug1 and drug0 increased blood drug2,False, 
DDI-MedLine.d21.s11.e0,DDI-MedLine.d21.s11.e1,drug1 neutralized the increase of glycemia induced by oral drug2,False, 
DDI-MedLine.d21.s12.e0,DDI-MedLine.d21.s12.e1,"In the second experiment, non-diabetic and streptozotocin-induced diabetic rats were fasted, and the same procedures were followed for estimation of drug1 tolerance 30 min after drug2",False, 
DDI-MedLine.d21.s13.e0,DDI-MedLine.d21.s13.e1,"Again, drug1 neutralized the increase in glycemia after drug2",False, 
DDI-MedLine.d55.s0.e0,DDI-MedLine.d55.s0.e1,Increased hepatotoxicity of drug1 by concomitant administration of drug2,True,effect
DDI-MedLine.d55.s1.e0,DDI-MedLine.d55.s1.e1,"Since drug1 is frequently co-administered with drug2, it is of clinical interest to study the effect of drug0 on the hepatotoxicity of drug0",False, 
DDI-MedLine.d55.s1.e0,DDI-MedLine.d55.s1.e2,"Since drug1 is frequently co-administered with drug0, it is of clinical interest to study the effect of drug2 on the hepatotoxicity of drug0",False, 
DDI-MedLine.d55.s4.e0,DDI-MedLine.d55.s4.e1,Careful observations on hepatotoxicity are suggested when drug1 is prescribed with drug2,True,effect
DDI-MedLine.d139.s0.e0,DDI-MedLine.d139.s0.e1,[Quantitative approach to treatment with incisive drug1 by therapeutic monitoring]; The problems encountered during the longterm treatment of psychotic patients with drug2,False, 
DDI-MedLine.d16.s0.e0,DDI-MedLine.d16.s0.e1,Interaction of drug1 and drug2,True,int
DDI-MedLine.d16.s1.e0,DDI-MedLine.d16.s1.e1,The interaction of intramuscularly injected drug1 and its N-demethylated metabolite (metabolite I) with drug2,False, 
DDI-MedLine.d16.s3.e0,DDI-MedLine.d16.s3.e1,"However, drug1 anesthetic requirement (i.e., MAC) was depressed in a dose-dependent fashion as much as 56% 1-2 hours and as much as 14% 5-6 hours after injection of drug2",True,mechanism
DDI-MedLine.d16.s4.e0,DDI-MedLine.d16.s4.e1,"The reduction in MAC was correlated with brain levels of drug1 or metabolite I, suggesting a drug2",False, 
DDI-MedLine.d16.s5.e0,DDI-MedLine.d16.s5.e1,The half-life of drug1 in plasma and brain was longer in the presence of drug2 than when drug0,True,mechanism
DDI-MedLine.d16.s5.e0,DDI-MedLine.d16.s5.e2,The half-life of drug1 in plasma and brain was longer in the presence of drug0 than when drug2,False, 
DDI-MedLine.d16.s5.e1,DDI-MedLine.d16.s5.e2,The half-life of drug0 in plasma and brain was longer in the presence of drug1 than when drug2,False, 
DDI-MedLine.d16.s6.e0,DDI-MedLine.d16.s6.e1,It is concluded that drug1 is not a short-acting drug and that concomitant use with drug2,True,effect
DDI-MedLine.d93.s4.e0,DDI-MedLine.d93.s4.e1,Thirty male rats of the Fischer-344 strain were divided into three equal groups and were given injections of drug1 (drug2,False, 
DDI-MedLine.d93.s6.e0,DDI-MedLine.d93.s6.e1,The 20% v/v solution of drug1 was prepared in water from a stock solution of 95% drug2,False, 
DDI-MedLine.d93.s9.e0,DDI-MedLine.d93.s9.e1,These results suggest that exposure to environmental drug1 may alter the biological and behavioral responsiveness of an animal to drug2,True,effect
DDI-MedLine.d102.s0.e0,DDI-MedLine.d102.s0.e1,Influence of drug1 and drug2 on the sensitivity of rat thoracic aorta to drug0,False, 
DDI-MedLine.d102.s0.e0,DDI-MedLine.d102.s0.e2,Influence of drug1 and drug0 on the sensitivity of rat thoracic aorta to drug2,False, 
DDI-MedLine.d102.s1.e0,DDI-MedLine.d102.s1.e1,"The aim of this study was to investigate the effects of low and high doses of drug1, and of drug2 on the response to drug0",False, 
DDI-MedLine.d102.s1.e0,DDI-MedLine.d102.s1.e2,"The aim of this study was to investigate the effects of low and high doses of drug1, and of drug0 on the response to drug2",False, 
DDI-MedLine.d102.s3.e0,DDI-MedLine.d102.s3.e1,"injection of vehicle (corn oil, 0.1 mL/day), drug1 (10 microg/kg/day or 4 mg/kg/day) and/or drug2",False, 
DDI-MedLine.d102.s5.e0,DDI-MedLine.d102.s5.e1,Aortic rings with intact endothelium from the high-dose (4 mg/kg/day) drug1 group were supersensitive to drug2,True,effect
DDI-MedLine.d102.s6.e0,DDI-MedLine.d102.s6.e1,"Endothelium-intact aortic rings from high-drug1 rats were supersensitive to drug2 when compared to vehicle-, drug0- and drug0 + high-drug0",True,effect
DDI-MedLine.d102.s6.e0,DDI-MedLine.d102.s6.e2,"Endothelium-intact aortic rings from high-drug1 rats were supersensitive to drug0 when compared to vehicle-, drug2- and drug0 + high-drug0",False, 
DDI-MedLine.d102.s6.e0,DDI-MedLine.d102.s6.e3,"Endothelium-intact aortic rings from high-drug1 rats were supersensitive to drug0 when compared to vehicle-, drug0- and drug2 + high-drug0",False, 
DDI-MedLine.d76.s1.e0,DDI-MedLine.d76.s1.e1,"The purpose of this study was to evaluate the effect of drug1 (drug2) and drug0 (drug0) conjugates on the intestinal permeation of drug0 (drug0) and model peptide drugs, drug0 and drug0",False, 
DDI-MedLine.d76.s1.e0,DDI-MedLine.d76.s1.e2,"The purpose of this study was to evaluate the effect of drug1 (drug0) and drug2 (drug0) conjugates on the intestinal permeation of drug0 (drug0) and model peptide drugs, drug0 and drug0",False, 
DDI-MedLine.d76.s2.e0,DDI-MedLine.d76.s2.e1,drug1 was covalently linked to carbodiimide activated drug2,False, 
DDI-MedLine.d76.s5.e0,DDI-MedLine.d76.s5.e1,Unmodified drug1 (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of drug2 to 1.3 and 1% (m/v) drug0 conjugated with drug0,False, 
DDI-MedLine.d76.s5.e0,DDI-MedLine.d76.s5.e2,Unmodified drug1 (1% m/v) significantly improved the transport ratio (R= P(app) polymer/ P(app) control) of drug0 to 1.3 and 1% (m/v) drug2 conjugated with drug0,False, 
DDI-MedLine.d76.s7.e0,DDI-MedLine.d76.s7.e1,"Decreasing the concentration of drug1, exhibiting 7.3% (m/m) of immobilised drug2 (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of drug0",False, 
DDI-MedLine.d76.s7.e0,DDI-MedLine.d76.s7.e2,"Decreasing the concentration of drug1, exhibiting 7.3% (m/m) of immobilised drug0 (CMC-Cys7.3) from 1% (m/v) to 0.5% (m/v) decreased the R-value of drug2",False, 
DDI-MedLine.d76.s8.e0,DDI-MedLine.d76.s8.e1,drug1 at 1% (m/v) in the presence of free drug2 had no significant effect on the R-value of drug0 compared to drug0,False, 
DDI-MedLine.d76.s8.e0,DDI-MedLine.d76.s8.e2,drug1 at 1% (m/v) in the presence of free drug0 had no significant effect on the R-value of drug2 compared to drug0,False, 
DDI-MedLine.d76.s9.e0,DDI-MedLine.d76.s9.e1,"Formulation of fluorescence labelled drug1 and drug2 in unconjugated drug0 (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) drug0",False, 
DDI-MedLine.d76.s9.e0,DDI-MedLine.d76.s9.e2,"Formulation of fluorescence labelled drug1 and drug0 in unconjugated drug2 (1% m/v) did not significantly improve the permeation, however in the presence of 1% (m/v) drug0",False, 
DDI-MedLine.d76.s10.e0,DDI-MedLine.d76.s10.e1,Conjugation at drug1 with drug2 moieties significantly improves the intestinal permeation of the hydrophilic molecule drug0 and the model peptide drugs drug0 and drug0,False, 
DDI-MedLine.d76.s10.e0,DDI-MedLine.d76.s10.e2,Conjugation at drug1 with drug0 moieties significantly improves the intestinal permeation of the hydrophilic molecule drug2 and the model peptide drugs drug0 and drug0,False, 
DDI-MedLine.d11.s4.e0,DDI-MedLine.d11.s4.e1,"This article looks at five commonly used drug1 in turn (drug2, drug0, drug0, drug0, drug0",False, 
DDI-MedLine.d11.s4.e0,DDI-MedLine.d11.s4.e2,"This article looks at five commonly used drug1 in turn (drug0, drug2, drug0, drug0, drug0",False, 
DDI-MedLine.d87.s0.e0,DDI-MedLine.d87.s0.e1,"drug1, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous drug2",True,effect
DDI-MedLine.d87.s1.e0,DDI-MedLine.d87.s1.e1,drug1 is a novel drug2 that may selectively prevent drug0,False, 
DDI-MedLine.d87.s1.e0,DDI-MedLine.d87.s1.e2,drug1 is a novel drug0 that may selectively prevent drug2,True,effect
DDI-MedLine.d87.s1.e1,DDI-MedLine.d87.s1.e2,drug0 is a novel drug1 that may selectively prevent drug2,False, 
DDI-MedLine.d87.s2.e0,DDI-MedLine.d87.s2.e1,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous drug1 (0.05 mg x kg(-1)), and oral drug2 (4 mg) and intravenous drug0",False, 
DDI-MedLine.d87.s2.e0,DDI-MedLine.d87.s2.e2,"Gastrointestinal transit time (lactulose hydrogen breath test) was measured in 14 volunteers with oral and intravenous placebo, oral placebo and intravenous drug1 (0.05 mg x kg(-1)), and oral drug0 (4 mg) and intravenous drug2",False, 
DDI-MedLine.d87.s4.e0,DDI-MedLine.d87.s4.e1,drug1 prolonged gastrointestinal transit time from 69 to 103 minutes (P = .005); this was prevented by drug2,True,effect
DDI-MedLine.d87.s5.e0,DDI-MedLine.d87.s5.e1,"Postoperatively, 45 patients were randomly assigned in a double-blind fashion to receive drug1 (4 mg) or placebo and intravenous drug2",False, 
DDI-MedLine.d87.s7.e0,DDI-MedLine.d87.s7.e1,drug1 analgesia and pupil constriction were unaffected by drug2,False, 
DDI-MedLine.d87.s8.e0,DDI-MedLine.d87.s8.e1,We conclude that drug1 prevents drug2,True,effect
DDI-MedLine.d20.s0.e0,DDI-MedLine.d20.s0.e1,Interaction between drug1 and drug2,True,effect
DDI-MedLine.d20.s4.e0,DDI-MedLine.d20.s4.e1,The successive application of drug1 (5 or 10 mg/kg egg weight (e.w.) and drug2 (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drug0,True,effect
DDI-MedLine.d20.s4.e0,DDI-MedLine.d20.s4.e2,The successive application of drug1 (5 or 10 mg/kg egg weight (e.w.) and drug0 (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drug2,False, 
DDI-MedLine.d20.s4.e1,DDI-MedLine.d20.s4.e2,The successive application of drug0 (5 or 10 mg/kg egg weight (e.w.) and drug1 (15 mg/kg e.w.) in a 10 min interval significantly increased the activation of spontaneous motility of 17-day-old chick embryos in comparison with the effect of drug2,False, 
DDI-MedLine.d47.s0.e0,DDI-MedLine.d47.s0.e1,Activity of drug1 alone and in combination with drug2 and drug0,False, 
DDI-MedLine.d47.s0.e0,DDI-MedLine.d47.s0.e2,Activity of drug1 alone and in combination with drug0 and drug2,False, 
DDI-MedLine.d47.s1.e0,DDI-MedLine.d47.s1.e1,The in vitro anti-cryptosporidial activity of drug1 alone and in combination with drug2 and drug0,False, 
DDI-MedLine.d47.s1.e0,DDI-MedLine.d47.s1.e2,The in vitro anti-cryptosporidial activity of drug1 alone and in combination with drug0 and drug2,False, 
DDI-MedLine.d47.s3.e0,DDI-MedLine.d47.s3.e1,"Moreover, its activity was enhanced when it was combined with either drug1 or drug2",False, 
DDI-MedLine.d47.s4.e0,DDI-MedLine.d47.s4.e1,drug1 may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either drug2 or drug0,True,effect
DDI-MedLine.d47.s4.e0,DDI-MedLine.d47.s4.e2,drug1 may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either drug0 or drug2,True,effect
DDI-MedLine.d47.s4.e1,DDI-MedLine.d47.s4.e2,drug0 may be active in inhibiting Cryptosporidium parvum growth in vitro upon combination with either drug1 or drug2,False, 
DDI-MedLine.d8.s0.e0,DDI-MedLine.d8.s0.e1,"In vitro activity of drug1, either singly or in combination with drug2",False, 
DDI-MedLine.d8.s1.e0,DDI-MedLine.d8.s1.e1,"The antimicrobial effect of a drug1, drug2, either alone or in combination with drug0",False, 
DDI-MedLine.d8.s1.e0,DDI-MedLine.d8.s1.e2,"The antimicrobial effect of a drug1, drug0, either alone or in combination with drug2",False, 
DDI-MedLine.d8.s5.e0,DDI-MedLine.d8.s5.e1,"ulcerans was between 0.012 and 0.025 mg/l, while corresponding values for drug1 and drug2",False, 
DDI-MedLine.d8.s6.e0,DDI-MedLine.d8.s6.e1,"When combined with drug1, drug2 exhibited strong synergistic activity while only additive effects were observed with the combination of drug0 (or drug0) and drug0",True,effect
DDI-MedLine.d8.s6.e0,DDI-MedLine.d8.s6.e2,"When combined with drug1, drug0 exhibited strong synergistic activity while only additive effects were observed with the combination of drug2 (or drug0) and drug0",False, 
DDI-MedLine.d8.s6.e0,DDI-MedLine.d8.s6.e3,"When combined with drug1, drug0 exhibited strong synergistic activity while only additive effects were observed with the combination of drug0 (or drug2) and drug0",False, 
DDI-MedLine.d8.s6.e2,DDI-MedLine.d8.s6.e4,"When combined with drug0, drug0 exhibited strong synergistic activity while only additive effects were observed with the combination of drug1 (or drug0) and drug2",True,effect
DDI-MedLine.d8.s6.e3,DDI-MedLine.d8.s6.e4,"When combined with drug0, drug0 exhibited strong synergistic activity while only additive effects were observed with the combination of drug0 (or drug1) and drug2",True,effect
DDI-MedLine.d4.s0.e0,DDI-MedLine.d4.s0.e1,[The effect of drug1 on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the drug2--the drug drug0,False, 
DDI-MedLine.d4.s0.e0,DDI-MedLine.d4.s0.e2,[The effect of drug1 on the activity of mixed-function mono-oxidases in the liver microsomes] The effects of the drug0--the drug drug2,False, 
DDI-MedLine.d7.s0.e0,DDI-MedLine.d7.s0.e1,Enhanced drug1 clearance secondary to drug2,True,mechanism
DDI-MedLine.d7.s1.e0,DDI-MedLine.d7.s1.e1,This report describes two cases in which drug1 clearance accelerated markedly with concomitant drug2,True,mechanism
DDI-MedLine.d7.s4.e0,DDI-MedLine.d7.s4.e1,"With combined use, clinicians should be aware, when drug1 is added, of the potential for reexacerbation of pulmonary symptomatology due to lowered serum drug2",True,effect
DDI-MedLine.d19.s4.e0,DDI-MedLine.d19.s4.e1,"Numerous drug interactions are possible with some drug1, such as drug2 and drug0",False, 
DDI-MedLine.d19.s4.e0,DDI-MedLine.d19.s4.e2,"Numerous drug interactions are possible with some drug1, such as drug0 and drug2",False, 
DDI-MedLine.d115.s0.e0,DDI-MedLine.d115.s0.e1,"Concomitant drug1, drug2, drug0, and drug0 chemotherapy plus drug0",False, 
DDI-MedLine.d115.s0.e0,DDI-MedLine.d115.s0.e2,"Concomitant drug1, drug0, drug2, and drug0 chemotherapy plus drug0",False, 
DDI-MedLine.d115.s2.e0,DDI-MedLine.d115.s2.e1,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the drug1, drug2, drug0, and drug0 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., drug0, drug0, drug0, and drug0 with drug0 plus drug0) without receiving drug0",False, 
DDI-MedLine.d115.s2.e0,DDI-MedLine.d115.s2.e2,"To evaluate the impact of chemotherapy plus HAART on the clinical course of patients with HIV-related, systemic, non-Hodgkin lymphoma (HIV-NHL), the authors compared retrospectively a group of 24 patients with HIV-NHL who were treated with the drug1, drug0, drug2, and drug0 (CHOP) chemotherapy regimen plus HAART with a group of 80 patients who were treated with CHOP chemotherapy or a CHOP-like regimen (i.e., drug0, drug0, drug0, and drug0 with drug0 plus drug0) without receiving drug0",False, 
DDI-MedLine.d115.s5.e0,DDI-MedLine.d115.s5.e1,drug1 regimens consisted of two drug2 and one drug0,False, 
DDI-MedLine.d115.s5.e0,DDI-MedLine.d115.s5.e2,drug1 regimens consisted of two drug0 and one drug2,False, 
DDI-MedLine.d115.s14.e0,DDI-MedLine.d115.s14.e1,"However, careful attention must be directed to cross toxicity and possible pharmacokinetic interactions between drug1 and drug2",True,advise
DDI-MedLine.d56.s0.e0,DDI-MedLine.d56.s0.e1,Dual effect of drug1 on the drug2,False, 
DDI-MedLine.d56.s1.e0,DDI-MedLine.d56.s1.e1,drug1 (drug2,False, 
DDI-MedLine.d56.s2.e0,DDI-MedLine.d56.s2.e1,"In the presence of drug1 (10(-5) M), drug2",True,effect
DDI-MedLine.d56.s5.e0,DDI-MedLine.d56.s5.e1,"When drug1 was applied to the muscle in the presence of drug2, both first and second contractile responses to drug0",True,effect
DDI-MedLine.d56.s5.e0,DDI-MedLine.d56.s5.e2,"When drug1 was applied to the muscle in the presence of drug0, both first and second contractile responses to drug2",False, 
DDI-MedLine.d56.s5.e1,DDI-MedLine.d56.s5.e2,"When drug0 was applied to the muscle in the presence of drug1, both first and second contractile responses to drug2",False, 
DDI-MedLine.d56.s8.e0,DDI-MedLine.d56.s8.e1,Exposure of the muscle to drug1 (10(-5) M) markedly increased the drug2,True,effect
DDI-MedLine.d56.s10.e0,DDI-MedLine.d56.s10.e1,"The second response is due to a release of norepinephrine from nerves and was potentiated by drug1 through the increase in the norepinephrine release, whereas the first response was not due to the norepinephrine release but presumably to a direct action on smooth muscle cell and was inhibited by drug2",False, 
DDI-MedLine.d12.s0.e0,DDI-MedLine.d12.s0.e1,drug1 and drug2 similarly inhibit and stimulate drug0- or drug0,False, 
DDI-MedLine.d12.s0.e0,DDI-MedLine.d12.s0.e2,drug1 and drug0 similarly inhibit and stimulate drug2- or drug0,True,effect
DDI-MedLine.d12.s0.e0,DDI-MedLine.d12.s0.e3,drug1 and drug0 similarly inhibit and stimulate drug0- or drug2,True,effect
DDI-MedLine.d12.s0.e1,DDI-MedLine.d12.s0.e2,drug0 and drug1 similarly inhibit and stimulate drug2- or drug0,True,effect
DDI-MedLine.d12.s0.e1,DDI-MedLine.d12.s0.e3,drug0 and drug1 similarly inhibit and stimulate drug0- or drug2,True,effect
DDI-MedLine.d12.s0.e2,DDI-MedLine.d12.s0.e3,drug0 and drug0 similarly inhibit and stimulate drug1- or drug2,False, 
DDI-MedLine.d12.s1.e0,DDI-MedLine.d12.s1.e1,"Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing drug1 (1 microgram/ml), drug2 (10 ng/ml), and drug0",False, 
DDI-MedLine.d12.s1.e0,DDI-MedLine.d12.s1.e2,"Prostatic epithelium proliferates in a defined medium consisting of basal medium RPMI1640 containing drug1 (1 microgram/ml), drug0 (10 ng/ml), and drug2",False, 
DDI-MedLine.d12.s2.e0,DDI-MedLine.d12.s2.e1,"Although neither drug1 nor drug2 affected the proliferation of prostatic epithelium in RPMI1640 containing drug0 alone, they modify the mitogenic effect of drug0 and drug0",False, 
DDI-MedLine.d12.s2.e0,DDI-MedLine.d12.s2.e2,"Although neither drug1 nor drug0 affected the proliferation of prostatic epithelium in RPMI1640 containing drug2 alone, they modify the mitogenic effect of drug0 and drug0",False, 
DDI-MedLine.d12.s2.e0,DDI-MedLine.d12.s2.e3,"Although neither drug1 nor drug0 affected the proliferation of prostatic epithelium in RPMI1640 containing drug0 alone, they modify the mitogenic effect of drug2 and drug0",True,effect
DDI-MedLine.d12.s2.e0,DDI-MedLine.d12.s2.e4,"Although neither drug1 nor drug0 affected the proliferation of prostatic epithelium in RPMI1640 containing drug0 alone, they modify the mitogenic effect of drug0 and drug2",True,effect
DDI-MedLine.d12.s2.e1,DDI-MedLine.d12.s2.e3,"Although neither drug0 nor drug1 affected the proliferation of prostatic epithelium in RPMI1640 containing drug0 alone, they modify the mitogenic effect of drug2 and drug0",True,effect
DDI-MedLine.d12.s2.e1,DDI-MedLine.d12.s2.e4,"Although neither drug0 nor drug1 affected the proliferation of prostatic epithelium in RPMI1640 containing drug0 alone, they modify the mitogenic effect of drug0 and drug2",True,effect
DDI-MedLine.d12.s3.e0,DDI-MedLine.d12.s3.e1,drug1 at 10(-10) M or drug2 at about 3 X 10(-9) M inhibits proliferation stimulated by drug0,False, 
DDI-MedLine.d12.s3.e0,DDI-MedLine.d12.s3.e2,drug1 at 10(-10) M or drug0 at about 3 X 10(-9) M inhibits proliferation stimulated by drug2,True,effect
DDI-MedLine.d12.s3.e1,DDI-MedLine.d12.s3.e2,drug0 at 10(-10) M or drug1 at about 3 X 10(-9) M inhibits proliferation stimulated by drug2,True,effect
DDI-MedLine.d12.s4.e0,DDI-MedLine.d12.s4.e1,Higher concentrations of drug1 (10(-8) - 10(-6) M) or drug2 (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of drug0,False, 
DDI-MedLine.d12.s4.e0,DDI-MedLine.d12.s4.e2,Higher concentrations of drug1 (10(-8) - 10(-6) M) or drug0 (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of drug2,True,effect
DDI-MedLine.d12.s4.e1,DDI-MedLine.d12.s4.e2,Higher concentrations of drug0 (10(-8) - 10(-6) M) or drug1 (3 X 10(-8) - 10(-7) M) enhance the mitogenic activity of drug2,True,effect
DDI-MedLine.d12.s5.e0,DDI-MedLine.d12.s5.e1,drug1 had a similar effect in the presence of drug2,False, 
DDI-MedLine.d12.s6.e0,DDI-MedLine.d12.s6.e1,"However, drug1 stimulated, but did not significantly inhibit, proliferation in the presence of drug2",True,effect
DDI-MedLine.d12.s7.e0,DDI-MedLine.d12.s7.e1,"These results suggest that both drug1 and drug2, and possibly other drug0 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug0",False, 
DDI-MedLine.d12.s7.e0,DDI-MedLine.d12.s7.e2,"These results suggest that both drug1 and drug0, and possibly other drug2 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug0",False, 
DDI-MedLine.d12.s7.e0,DDI-MedLine.d12.s7.e4,"These results suggest that both drug1 and drug0, and possibly other drug0 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug2 and drug0",True,effect
DDI-MedLine.d12.s7.e0,DDI-MedLine.d12.s7.e5,"These results suggest that both drug1 and drug0, and possibly other drug0 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug2",True,effect
DDI-MedLine.d12.s7.e1,DDI-MedLine.d12.s7.e4,"These results suggest that both drug0 and drug1, and possibly other drug0 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug2 and drug0",True,effect
DDI-MedLine.d12.s7.e1,DDI-MedLine.d12.s7.e5,"These results suggest that both drug0 and drug1, and possibly other drug0 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug2",True,effect
DDI-MedLine.d12.s7.e2,DDI-MedLine.d12.s7.e4,"These results suggest that both drug0 and drug0, and possibly other drug1 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug2 and drug0",True,effect
DDI-MedLine.d12.s7.e2,DDI-MedLine.d12.s7.e5,"These results suggest that both drug0 and drug0, and possibly other drug1 and drug0, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug2",True,effect
DDI-MedLine.d12.s7.e3,DDI-MedLine.d12.s7.e4,"These results suggest that both drug0 and drug0, and possibly other drug0 and drug1, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug2 and drug0",True,effect
DDI-MedLine.d12.s7.e3,DDI-MedLine.d12.s7.e5,"These results suggest that both drug0 and drug0, and possibly other drug0 and drug1, may regulate the proliferation of prostate epithelium by a dose-dependent modification of the activity of drug0 and drug2",True,effect
DDI-MedLine.d116.s0.e0,DDI-MedLine.d116.s0.e1,drug1 and drug2,True,int
DDI-MedLine.d116.s1.e0,DDI-MedLine.d116.s1.e1,The drug interaction between drug1 and drug2,True,int
DDI-MedLine.d116.s2.e0,DDI-MedLine.d116.s2.e1,drug1 has been reported to increase the drug2,True,mechanism
DDI-MedLine.d116.s3.e0,DDI-MedLine.d116.s3.e1,The concomitant administration of drug1 and drug2 resulted in the need for an unusually high maintenance dose of drug0,True,mechanism
DDI-MedLine.d116.s3.e0,DDI-MedLine.d116.s3.e2,The concomitant administration of drug1 and drug0 resulted in the need for an unusually high maintenance dose of drug2,False, 
DDI-MedLine.d116.s3.e1,DDI-MedLine.d116.s3.e2,The concomitant administration of drug0 and drug1 resulted in the need for an unusually high maintenance dose of drug2,False, 
DDI-MedLine.d116.s4.e0,DDI-MedLine.d116.s4.e1,Withdrawal of drug1 decreased the drug2,True,mechanism
DDI-MedLine.d116.s5.e0,DDI-MedLine.d116.s5.e1,"This effect may be mediated by the ability of drug1 to induce microsomal enzymes and, thus, the catabolism of drug2",True,mechanism
DDI-MedLine.d116.s6.e0,DDI-MedLine.d116.s6.e1,The effect of drug1 on the drug2 requirement of our patient appeared to be maximal 5 to 7 days after the initiation of drug0 and extended a similar length of time after drug0,True,effect
DDI-MedLine.d116.s6.e0,DDI-MedLine.d116.s6.e2,The effect of drug1 on the drug0 requirement of our patient appeared to be maximal 5 to 7 days after the initiation of drug2 and extended a similar length of time after drug0,False, 
DDI-MedLine.d116.s6.e0,DDI-MedLine.d116.s6.e3,The effect of drug1 on the drug0 requirement of our patient appeared to be maximal 5 to 7 days after the initiation of drug0 and extended a similar length of time after drug2,False, 
DDI-MedLine.d118.s0.e0,DDI-MedLine.d118.s0.e1,drug1: mammalian target of drug2,False, 
DDI-MedLine.d118.s2.e0,DDI-MedLine.d118.s2.e1,"drug1 works differently from the drug2 currently available, and except for increased lipid levels, the adverse reaction profile of drug0 does not appear to overlap to any great extent with that associated with drug0 or drug0",False, 
DDI-MedLine.d118.s2.e0,DDI-MedLine.d118.s2.e2,"drug1 works differently from the drug0 currently available, and except for increased lipid levels, the adverse reaction profile of drug2 does not appear to overlap to any great extent with that associated with drug0 or drug0",False, 
DDI-MedLine.d118.s3.e0,DDI-MedLine.d118.s3.e1,"While additional research is needed, the initial clinical data in kidney recipients suggest that drug1, in combination with drug2 or drug0, might have the potential to reduce the frequency of rejection episodes, permit reductions in drug0 or drug0",False, 
DDI-MedLine.d118.s3.e0,DDI-MedLine.d118.s3.e2,"While additional research is needed, the initial clinical data in kidney recipients suggest that drug1, in combination with drug0 or drug2, might have the potential to reduce the frequency of rejection episodes, permit reductions in drug0 or drug0",False, 
DDI-MedLine.d46.s0.e0,DDI-MedLine.d46.s0.e1,Influence of coadministration of drug1 on drug2,False, 
DDI-MedLine.d46.s1.e0,DDI-MedLine.d46.s1.e1,STUDY OBJECTIVE: To evaluate the effect of drug1 on the pharmacokinetics and cardiovascular safety of drug2,False, 
DDI-MedLine.d46.s9.e0,DDI-MedLine.d46.s9.e1,and phase 3 (days 45-52): drug1 10 mg 4 times/day (days 45-51) plus drug2,False, 
DDI-MedLine.d46.s13.e0,DDI-MedLine.d46.s13.e1,Coadministration of drug1 significantly decreased drug2,True,mechanism
DDI-MedLine.d46.s14.e0,DDI-MedLine.d46.s14.e1,There were no clinically significant changes in corrected QT intervals during administration of drug1 alone or with drug2,False, 
DDI-MedLine.d46.s15.e0,DDI-MedLine.d46.s15.e1,drug1 was well tolerated when administered alone or with drug2,False, 
DDI-MedLine.d46.s16.e0,DDI-MedLine.d46.s16.e1,CONCLUSION: drug1 can be administered safely to patients receiving low therapeutic dosages of drug2,False, 
DDI-MedLine.d112.s0.e0,DDI-MedLine.d112.s0.e1,Effect of drug1 on the pharmacokinetics of drug2,False, 
DDI-MedLine.d112.s1.e0,DDI-MedLine.d112.s1.e1,The effect of drug1 on the steady-state pharmacokinetics of drug2,False, 
DDI-MedLine.d112.s2.e0,DDI-MedLine.d112.s2.e1,Five days of drug1 treatment did not significantly affect steady-state pharmacokinetic variables of drug2,False, 
DDI-MedLine.d112.s3.e0,DDI-MedLine.d112.s3.e1,"therefore, the use of drug1 does not necessitate an adjustment in drug2",False, 
DDI-MedLine.d123.s2.e0,DDI-MedLine.d123.s2.e1,"Here we show that a combination of drug1 or 3,7-dihydroxyflavone with drug2",False, 
DDI-MedLine.d107.s1.e0,DDI-MedLine.d107.s1.e1,Little has been studied of the adverse effects of the exposure of the liver to the interaction of drug1 with its congeners and drug2,False, 
DDI-MedLine.d107.s3.e0,DDI-MedLine.d107.s3.e1,"Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing drug1, drug2, higher drug0 and drug0",False, 
DDI-MedLine.d107.s3.e0,DDI-MedLine.d107.s3.e2,"Two groups (SH/DA; SH/FA) were submitted to daily treatment with synthetic hydroalcoholic solutions containing drug1, drug0, higher drug2 and drug0",False, 
DDI-MedLine.d107.s9.e0,DDI-MedLine.d107.s9.e1,These results suggest that the hepatoxicity of drug1 in alcoholic beverages is enhanced by interaction with its congeners and drug2,True,effect
DDI-MedLine.d85.s0.e0,DDI-MedLine.d85.s0.e1,drug1 protects mouse tumour and normal tissues from the toxicity of oral drug2,True,effect
DDI-MedLine.d85.s1.e0,DDI-MedLine.d85.s1.e1,"Because the drug1 drug2 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral drug0, either alone or in combination with the chemosensitizer drug0",False, 
DDI-MedLine.d85.s1.e0,DDI-MedLine.d85.s1.e2,"Because the drug1 drug0 is given exclusively by the oral route in man, we have carried out studies in mice on the antitumour activity, acute toxicity and pharmacokinetics of oral drug2, either alone or in combination with the chemosensitizer drug0",False, 
DDI-MedLine.d85.s7.e0,DDI-MedLine.d85.s7.e1,drug1 reduced the antitumour activity of oral drug2,True,effect
DDI-MedLine.d85.s9.e0,DDI-MedLine.d85.s9.e1,drug1 has a complex effect on oral drug2,True,mechanism
DDI-MedLine.d85.s14.e0,DDI-MedLine.d85.s14.e1,We propose these pharmacokinetic changes to be the underlying mechanism for the reduction of oral drug1 cytotoxicity by drug2,True,mechanism
DDI-MedLine.d100.s5.e0,DDI-MedLine.d100.s5.e1,"drug1, such as drug2, drug0 and drug0",False, 
DDI-MedLine.d100.s5.e0,DDI-MedLine.d100.s5.e2,"drug1, such as drug0, drug2 and drug0",False, 
DDI-MedLine.d73.s0.e0,DDI-MedLine.d73.s0.e1,Neurochemical and functional consequences following drug1 (drug2) and drug0,False, 
DDI-MedLine.d73.s0.e0,DDI-MedLine.d73.s0.e2,Neurochemical and functional consequences following drug1 (drug0) and drug2,False, 
DDI-MedLine.d73.s1.e0,DDI-MedLine.d73.s1.e1,The neurochemical and functional consequences following drug1 administration to the rat were evaluated and compared to similar effects following drug2,False, 
DDI-MedLine.d73.s2.e0,DDI-MedLine.d73.s2.e1,It was observed that drug1 induced long lasting depletions of striatal dopamine concentrations and this neurotoxic effect could be prevented by drug2,True,effect
DDI-MedLine.d73.s3.e0,DDI-MedLine.d73.s3.e1,The drug1-induced neuronal damage produced a tolerance to the disruptive effects of drug2 and a supersensitivity to the disruptive effects of drug0,True,effect
DDI-MedLine.d73.s3.e0,DDI-MedLine.d73.s3.e2,The drug1-induced neuronal damage produced a tolerance to the disruptive effects of drug0 and a supersensitivity to the disruptive effects of drug2,True,effect
DDI-MedLine.d73.s3.e1,DDI-MedLine.d73.s3.e2,The drug0-induced neuronal damage produced a tolerance to the disruptive effects of drug1 and a supersensitivity to the disruptive effects of drug2,False, 
DDI-MedLine.d73.s4.e0,DDI-MedLine.d73.s4.e1,"drug1, like drug2, produced depletions of striatal dopamine but these actions were potentiated by drug0",False, 
DDI-MedLine.d73.s4.e0,DDI-MedLine.d73.s4.e2,"drug1, like drug0, produced depletions of striatal dopamine but these actions were potentiated by drug2",True,effect
DDI-MedLine.d73.s4.e1,DDI-MedLine.d73.s4.e2,"drug0, like drug1, produced depletions of striatal dopamine but these actions were potentiated by drug2",False, 
DDI-MedLine.d95.s4.e0,DDI-MedLine.d95.s4.e1,drug1 (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with drug2 (8 micromol/l) or drug0,False, 
DDI-MedLine.d95.s4.e0,DDI-MedLine.d95.s4.e2,drug1 (5-35 micromol/l) induced concentration-dependent relaxation of mesenteric arteries preconstricted with drug0 (8 micromol/l) or drug2,False, 
DDI-MedLine.d95.s6.e0,DDI-MedLine.d95.s6.e1,"However, drug1 (100 and 300 micromol/l) did not alter the effects of drug2",False, 
DDI-MedLine.d95.s7.e0,DDI-MedLine.d95.s7.e1,drug1 was also ineffective in altering drug2,False, 
DDI-MedLine.d95.s8.e0,DDI-MedLine.d95.s8.e1,"In drug1-precontracted arteries from dietary-obese rats, responses to drug2",False, 
DDI-MedLine.d95.s9.e0,DDI-MedLine.d95.s9.e1,"This study indicates that: (a) the maximal effects of drug1 on resistance arteries from lean and dietary-obese rats are not effected by endothelial dysfunction, and (b) the effects of drug2",False, 
DDI-MedLine.d9.s3.e0,DDI-MedLine.d9.s3.e1,"For the drug1 now available in the United States (drug2, drug0 and drug0",False, 
DDI-MedLine.d9.s3.e0,DDI-MedLine.d9.s3.e2,"For the drug1 now available in the United States (drug0, drug2 and drug0",False, 
DDI-MedLine.d9.s5.e0,DDI-MedLine.d9.s5.e1,by the nonlinear kinetic characteristics for drug1 and drug2 (and probably for drug0,False, 
DDI-MedLine.d9.s5.e0,DDI-MedLine.d9.s5.e2,by the nonlinear kinetic characteristics for drug1 and drug0 (and probably for drug2,False, 
DDI-MedLine.d44.s2.e0,DDI-MedLine.d44.s2.e1,"In this study, the effects of drug1 upon chylomicron metabolism was tested by determination of the plasma kinetics of a chylomicron-like emulsion model in 12 patients with coronary artery disease, aged 59+/-11 years, (total cholesterol: 240+/-41 mg/dl; triglycerides: 188+/-42 mg/dl) submitted to a randomized, crossover, double-blind, placebo-controlled study with administration of 1 g per day drug2",False, 
DDI-MedLine.d44.s6.e0,DDI-MedLine.d44.s6.e1,drug1 elicited 62% enhancement of post-drug2,True,effect
DDI-MedLine.d54.s2.e0,DDI-MedLine.d54.s2.e1,"Since photic evoked potential components are representations of neural pathways which are activated during photic stimulation, study of the effects of drug1 on these components may help to trace pathways which are affected by drug2",False, 
DDI-MedLine.d54.s3.e0,DDI-MedLine.d54.s3.e1,"In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, drug1 (2.0 g/kg), drug2 (0.6 mg/kg) or drug0",False, 
DDI-MedLine.d54.s3.e0,DDI-MedLine.d54.s3.e2,"In the present study, evoked potentials were recorded at 5, 20, and 40 min following IP injections of saline, drug1 (2.0 g/kg), drug0 (0.6 mg/kg) or drug2",False, 
DDI-MedLine.d54.s8.e0,DDI-MedLine.d54.s8.e1,"drug1 pretreatment augmented the depressant effect of drug2 on the early components P1 and N1, while attenuating drug0",True,effect
DDI-MedLine.d54.s8.e0,DDI-MedLine.d54.s8.e2,"drug1 pretreatment augmented the depressant effect of drug0 on the early components P1 and N1, while attenuating drug2",True,effect
DDI-MedLine.d54.s8.e1,DDI-MedLine.d54.s8.e2,"drug0 pretreatment augmented the depressant effect of drug1 on the early components P1 and N1, while attenuating drug2",False, 
DDI-MedLine.d54.s10.e0,DDI-MedLine.d54.s10.e1,"drug1, either alone or in combination with drug2",False, 
DDI-MedLine.d94.s11.e0,DDI-MedLine.d94.s11.e1,"The EC50 values for drug1, which is not a substrate for drug2",False, 
DDI-MedLine.d94.s12.e0,DDI-MedLine.d94.s12.e1,The uptake inhibitors drug1 and drug2 (3 mumol/liter) potentiated the positive inotropic effects of drug0,False, 
DDI-MedLine.d94.s12.e0,DDI-MedLine.d94.s12.e2,The uptake inhibitors drug1 and drug0 (3 mumol/liter) potentiated the positive inotropic effects of drug2,True,effect
DDI-MedLine.d94.s12.e1,DDI-MedLine.d94.s12.e2,The uptake inhibitors drug0 and drug1 (3 mumol/liter) potentiated the positive inotropic effects of drug2,True,effect
DDI-MedLine.d94.s13.e0,DDI-MedLine.d94.s13.e1,Radioligand binding experiments using the uptake inhibitor hydrogen-3 drug1 revealed a significant decrease by approximately 30% in drug2,False, 
DDI-MedLine.d94.s16.e0,DDI-MedLine.d94.s16.e1,"This defect in the failing heart can be mimicked by the effects of uptake blocking agents, such as drug1 and drug2",False, 
DDI-MedLine.d94.s17.e0,DDI-MedLine.d94.s17.e1,Compromised drug1 uptake-1 in functional class IV cannot be further increased by drug2 and drug0,False, 
DDI-MedLine.d94.s17.e0,DDI-MedLine.d94.s17.e2,Compromised drug1 uptake-1 in functional class IV cannot be further increased by drug0 and drug2,False, 
DDI-MedLine.d134.s0.e0,DDI-MedLine.d134.s0.e1,[Dose-time effects of competitive displacement of drug1 by drug2 following oral and intravenous administration] The effect of various doses of drug0 in several dose fractions on the extent and the time scale of displacement of drug0,False, 
DDI-MedLine.d134.s0.e0,DDI-MedLine.d134.s0.e2,[Dose-time effects of competitive displacement of drug1 by drug0 following oral and intravenous administration] The effect of various doses of drug2 in several dose fractions on the extent and the time scale of displacement of drug0,False, 
DDI-MedLine.d134.s1.e0,DDI-MedLine.d134.s1.e1,An intravenous dose of 50 mg drug1 was in respect of competitive suppression of organs actively concentrating drug2 as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of drug0,False, 
DDI-MedLine.d134.s1.e0,DDI-MedLine.d134.s1.e2,An intravenous dose of 50 mg drug1 was in respect of competitive suppression of organs actively concentrating drug0 as effective as intravenous 1000 mg ClO-4- simultaneously or 1000 mg orally 30 min before the injection of drug2,False, 
DDI-MedLine.d134.s2.e0,DDI-MedLine.d134.s2.e1,An intravenous injection of drug1 given later also produces a complete and immediately beginning depletion of drug2,True,mechanism
DDI-MedLine.d106.s0.e0,DDI-MedLine.d106.s0.e1,Clinical implications of drug1 interactions with five drug2,True,int
DDI-MedLine.d106.s1.e0,DDI-MedLine.d106.s1.e1,"The intensity, uniformity and time course of drug1 interference by drug2, drug0, drug0, drug0 and drug0 were systematically investigated in 16 patients receiving drug0",False, 
DDI-MedLine.d106.s1.e0,DDI-MedLine.d106.s1.e2,"The intensity, uniformity and time course of drug1 interference by drug0, drug2, drug0, drug0 and drug0 were systematically investigated in 16 patients receiving drug0",False, 
DDI-MedLine.d106.s4.e0,DDI-MedLine.d106.s4.e1,"Anticoagulant inhibition was observed during the administration of drug1, drug2 and drug0",False, 
DDI-MedLine.d106.s4.e0,DDI-MedLine.d106.s4.e2,"Anticoagulant inhibition was observed during the administration of drug1, drug0 and drug2",False, 
DDI-MedLine.d106.s5.e0,DDI-MedLine.d106.s5.e1,there was no significant change in prothrombin test results during the trials of drug1 and drug2,False, 
DDI-MedLine.d106.s6.e0,DDI-MedLine.d106.s6.e1,drug1 and drug2 should not be administered to patients receiving drug0,False, 
DDI-MedLine.d106.s6.e0,DDI-MedLine.d106.s6.e2,drug1 and drug0 should not be administered to patients receiving drug2,True,advise
DDI-MedLine.d106.s6.e1,DDI-MedLine.d106.s6.e2,drug0 and drug1 should not be administered to patients receiving drug2,True,advise
DDI-MedLine.d106.s8.e0,DDI-MedLine.d106.s8.e1,drug1 and drug2 interact pharmacologically with orally administered drug0,False, 
DDI-MedLine.d106.s8.e0,DDI-MedLine.d106.s8.e2,drug1 and drug0 interact pharmacologically with orally administered drug2,True,int
DDI-MedLine.d106.s8.e1,DDI-MedLine.d106.s8.e2,drug0 and drug1 interact pharmacologically with orally administered drug2,True,int
DDI-MedLine.d106.s9.e0,DDI-MedLine.d106.s9.e1,It is concluded that drug1 and drug2 may be administered safely without additional caution in prothrombin test monitoring during oral drug0,False, 
DDI-MedLine.d106.s9.e0,DDI-MedLine.d106.s9.e2,It is concluded that drug1 and drug0 may be administered safely without additional caution in prothrombin test monitoring during oral drug2,False, 
DDI-MedLine.d122.s1.e0,DDI-MedLine.d122.s1.e1,Many people use both drug1 and drug2,False, 
DDI-MedLine.d122.s3.e0,DDI-MedLine.d122.s3.e1,The initiation of drug1 or drug2,False, 
DDI-MedLine.d122.s4.e0,DDI-MedLine.d122.s4.e1,"Moreover, the mechanisms underlying the development of dependence may be similar for drug1 and drug2",False, 
DDI-MedLine.d89.s0.e0,DDI-MedLine.d89.s0.e1,Therapeutic drug monitoring can avoid iatrogenic alterations caused by drug1 (MDP)-drug2,True,effect
DDI-MedLine.d89.s1.e0,DDI-MedLine.d89.s1.e1,drug1 is an drug2,False, 
DDI-MedLine.d89.s2.e0,DDI-MedLine.d89.s2.e1,"Due to its nephrotoxicity, drug1 may cause abnormal renal uptake to be seen on drug2",True,mechanism
DDI-MedLine.d89.s7.e0,DDI-MedLine.d89.s7.e1,"Therapeutic drug monitoring (TDM) of drug1 therapy, and bone scintigraphy employing drug2 as the drug0",False, 
DDI-MedLine.d89.s7.e0,DDI-MedLine.d89.s7.e2,"Therapeutic drug monitoring (TDM) of drug1 therapy, and bone scintigraphy employing drug0 as the drug2",False, 
DDI-MedLine.d89.s8.e0,DDI-MedLine.d89.s8.e1,"The data presented here demonstrate that with serial pharmacokinetic dosing of drug1, the iatrogenic alteration caused by drug2",False, 
DDI-MedLine.d119.s1.e0,DDI-MedLine.d119.s1.e1,drug1 is the first drug2,False, 
DDI-MedLine.d119.s2.e0,DDI-MedLine.d119.s2.e1,"It is structurally distinct from the other currently available drug1 (drug2, drug0, and drug0",False, 
DDI-MedLine.d119.s2.e0,DDI-MedLine.d119.s2.e2,"It is structurally distinct from the other currently available drug1 (drug0, drug2, and drug0",False, 
DDI-MedLine.d119.s15.e0,DDI-MedLine.d119.s15.e1,"drug1, an anionic-binding resin, has a considerable effect in lowering the rate and extent of drug2",True,mechanism
DDI-MedLine.d119.s16.e0,DDI-MedLine.d119.s16.e1,Although this effect was noted even when drug1 was given 4 hours prior to drug2,True,effect
DDI-MedLine.d119.s17.e0,DDI-MedLine.d119.s17.e1,"Further, no effects on either drug1 levels or prothrombin times were observed in a study involving concomitant administration of drug2 and drug0",False, 
DDI-MedLine.d119.s17.e0,DDI-MedLine.d119.s17.e2,"Further, no effects on either drug1 levels or prothrombin times were observed in a study involving concomitant administration of drug0 and drug2",False, 
DDI-MedLine.d119.s18.e0,DDI-MedLine.d119.s18.e1,"Moreover, additional interaction studies with drug1 and drug2 have not demonstrated any effect on drug0 plasma levels, and administration to a patient population chronically receiving drug0 resulted in no difference in the extent of bioavailability of drug0",False, 
DDI-MedLine.d119.s18.e0,DDI-MedLine.d119.s18.e2,"Moreover, additional interaction studies with drug1 and drug0 have not demonstrated any effect on drug2 plasma levels, and administration to a patient population chronically receiving drug0 resulted in no difference in the extent of bioavailability of drug0",False, 
DDI-MedLine.d110.s0.e0,DDI-MedLine.d110.s0.e1,drug1 (drug2) and drug0,False, 
DDI-MedLine.d110.s0.e0,DDI-MedLine.d110.s0.e2,drug1 (drug0) and drug2,False, 
DDI-MedLine.d110.s2.e0,DDI-MedLine.d110.s2.e1,"Like drug1 (40 mg/kg), drug2 (40 mg/kg) decreases the intravenous self-administration of drug0 and drug0 and the oral self-administration of drug0 and drug0",False, 
DDI-MedLine.d110.s2.e0,DDI-MedLine.d110.s2.e2,"Like drug1 (40 mg/kg), drug0 (40 mg/kg) decreases the intravenous self-administration of drug2 and drug0 and the oral self-administration of drug0 and drug0",False, 
DDI-MedLine.d110.s3.e0,DDI-MedLine.d110.s3.e1,"unlike drug1, drug2",False, 
DDI-MedLine.d110.s4.e0,DDI-MedLine.d110.s4.e1,Both drug1 and drug2 ameliorate drug0,False, 
DDI-MedLine.d110.s4.e0,DDI-MedLine.d110.s4.e2,Both drug1 and drug0 ameliorate drug2,False, 
DDI-MedLine.d110.s5.e0,DDI-MedLine.d110.s5.e1,"Both drug1 and drug2 decrease extracellular levels of dopamine in the nucleus accumbens, but only drug0",False, 
DDI-MedLine.d110.s5.e0,DDI-MedLine.d110.s5.e2,"Both drug1 and drug0 decrease extracellular levels of dopamine in the nucleus accumbens, but only drug2",False, 
DDI-MedLine.d110.s6.e0,DDI-MedLine.d110.s6.e1,Both drug1 and drug2 block drug0-induced and drug0,False, 
DDI-MedLine.d110.s6.e0,DDI-MedLine.d110.s6.e2,Both drug1 and drug0 block drug2-induced and drug0,True,effect
DDI-MedLine.d110.s6.e0,DDI-MedLine.d110.s6.e3,Both drug1 and drug0 block drug0-induced and drug2,True,effect
DDI-MedLine.d110.s6.e1,DDI-MedLine.d110.s6.e2,Both drug0 and drug1 block drug2-induced and drug0,True,effect
DDI-MedLine.d110.s6.e1,DDI-MedLine.d110.s6.e3,Both drug0 and drug1 block drug0-induced and drug2,True,effect
DDI-MedLine.d110.s6.e2,DDI-MedLine.d110.s6.e3,Both drug0 and drug0 block drug1-induced and drug2,False, 
DDI-MedLine.d110.s7.e0,DDI-MedLine.d110.s7.e1,only drug1 enhances drug2,True,effect
DDI-MedLine.d110.s8.e0,DDI-MedLine.d110.s8.e1,Both drug1 and drug2,False, 
DDI-MedLine.d110.s9.e0,DDI-MedLine.d110.s9.e1,"drug1 attenuates, but drug2 potentiates, the acute locomotor effects of drug0",False, 
DDI-MedLine.d110.s9.e0,DDI-MedLine.d110.s9.e2,"drug1 attenuates, but drug0 potentiates, the acute locomotor effects of drug2",True,effect
DDI-MedLine.d110.s9.e1,DDI-MedLine.d110.s9.e2,"drug0 attenuates, but drug1 potentiates, the acute locomotor effects of drug2",True,effect
DDI-MedLine.d110.s10.e0,DDI-MedLine.d110.s10.e1,both compounds attenuate drug1-induced locomotion in drug2,False, 
DDI-MedLine.d110.s13.e0,DDI-MedLine.d110.s13.e1,"drug1, but not drug2",False, 
DDI-MedLine.d110.s14.e0,DDI-MedLine.d110.s14.e1,"While drug1 and drug2 have similar affinities for kappa opioid and possibly nicotinic receptors, drug0 has much lower affinities than drug0",False, 
DDI-MedLine.d110.s14.e0,DDI-MedLine.d110.s14.e2,"While drug1 and drug0 have similar affinities for kappa opioid and possibly nicotinic receptors, drug2 has much lower affinities than drug0",False, 
DDI-MedLine.d110.s15.e0,DDI-MedLine.d110.s15.e1,"Both drug1 and drug2 are sequestered in fat and, like drug0, drug0",False, 
DDI-MedLine.d110.s15.e0,DDI-MedLine.d110.s15.e2,"Both drug1 and drug0 are sequestered in fat and, like drug2, drug0",False, 
DDI-MedLine.d110.s16.e0,DDI-MedLine.d110.s16.e1,The data suggest that drug1 has a narrower spectrum of actions and will have a substantially greater therapeutic index than drug2,False, 
DDI-MedLine.d5.s0.e0,DDI-MedLine.d5.s0.e1,"Repeated oral administration of drug1 in sheep: interactions of drug2 with drug0, drug0, and drug0",False, 
DDI-MedLine.d5.s0.e0,DDI-MedLine.d5.s0.e2,"Repeated oral administration of drug1 in sheep: interactions of drug0 with drug2, drug0, and drug0",False, 
DDI-MedLine.d5.s1.e0,DDI-MedLine.d5.s1.e1,"Interactions between treatments with drug1, drug2 (an drug0), drug0 (an drug0), and drug0",False, 
DDI-MedLine.d5.s1.e0,DDI-MedLine.d5.s1.e2,"Interactions between treatments with drug1, drug0 (an drug2), drug0 (an drug0), and drug0",False, 
DDI-MedLine.d5.s2.e0,DDI-MedLine.d5.s2.e1,A daily dose of 2 mg of drug1/kg of body weight for 6 days did not affect the plasma enzymes or the antiprothrombinemic effect of drug2,False, 
DDI-MedLine.d5.s3.e0,DDI-MedLine.d5.s3.e1,"The treatment of ewes with an intravenous (IV) injection of drug1, insufficient to produce significant inhibition of erythrocyte acetylcholinesterase (AChE) activity, appeared to produce additive effects with those produced by subsequent treatment with 4 mg of drug2",True,effect
DDI-MedLine.d5.s4.e0,DDI-MedLine.d5.s4.e1,"In ewes given 40 mg of drug1/kg for 5 days intraperitoneally (IP), the anticholinesterase effect of 4 mg of drug2",True,effect
DDI-MedLine.d15.s0.e0,DDI-MedLine.d15.s0.e1,"[Stimulation by drug1--an analog of the octapeptide cholecystokinin--of drug2 binding after the long-term administration of drug0] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of drug0 (0.25 mg/kg) and drug0 (0.25 mg/kg) resulted in the reduced interaction between drug0 and low affinity binding sites for drug0 in subcortical structures, whereas drug0 binding with high affinity binding sites for drug0",False, 
DDI-MedLine.d15.s0.e0,DDI-MedLine.d15.s0.e2,"[Stimulation by drug1--an analog of the octapeptide cholecystokinin--of drug0 binding after the long-term administration of drug2] It has been established in experiments on white male rats that prolonged administration (twice a day for 14 days) of drug0 (0.25 mg/kg) and drug0 (0.25 mg/kg) resulted in the reduced interaction between drug0 and low affinity binding sites for drug0 in subcortical structures, whereas drug0 binding with high affinity binding sites for drug0",False, 
DDI-MedLine.d15.s1.e0,DDI-MedLine.d15.s1.e1,"After prolonged administration of drug1 the displacing effect of drug2, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on drug0",False, 
DDI-MedLine.d15.s1.e0,DDI-MedLine.d15.s1.e2,"After prolonged administration of drug1 the displacing effect of drug0, an analog of cholecystokinin octapeptide, was replaced by the stimulant action on drug2",False, 
DDI-MedLine.d15.s2.e0,DDI-MedLine.d15.s2.e1,It is assumed that increased interaction between drug1 and high affinity binding sites for drug2 on dopamine2- and serotonin2-receptors underlies the antipsychotic action of drug0,False, 
DDI-MedLine.d15.s2.e0,DDI-MedLine.d15.s2.e2,It is assumed that increased interaction between drug1 and high affinity binding sites for drug0 on dopamine2- and serotonin2-receptors underlies the antipsychotic action of drug2,False, 
DDI-MedLine.d1.s1.e0,DDI-MedLine.d1.s1.e1,"Since the arrival of oral drug1, patients want to know how safe sexual activity is in cardiovascular disease in general and during use of drug2",False, 
DDI-MedLine.d1.s5.e0,DDI-MedLine.d1.s5.e1,drug1 is contraindicated in patients using drug2 or who may need to use drug0,True,advise
DDI-MedLine.d1.s5.e0,DDI-MedLine.d1.s5.e2,drug1 is contraindicated in patients using drug0 or who may need to use drug2,True,advise
DDI-MedLine.d1.s5.e1,DDI-MedLine.d1.s5.e2,drug0 is contraindicated in patients using drug1 or who may need to use drug2,False, 
DDI-MedLine.d1.s6.e0,DDI-MedLine.d1.s6.e1,"No interactions have been observed with drug1, drug2, drug0 and drug0 and drug0",False, 
DDI-MedLine.d1.s6.e0,DDI-MedLine.d1.s6.e2,"No interactions have been observed with drug1, drug0, drug2 and drug0 and drug0",False, 
DDI-MedLine.d13.s7.e0,DDI-MedLine.d13.s7.e1,"On the basis of the estimated number of regular users of intravenous drug1 in Ontario, the mortality rate in such users is at least four times as high as in the general population of the same age, and is comparable to that in alcoholics and drug2",False, 
DDI-MedLine.d13.s8.e0,DDI-MedLine.d13.s8.e1,"However, the absolute number of drug1-related deaths is far greater than the number of deaths in drug2 or drug0",False, 
DDI-MedLine.d13.s8.e0,DDI-MedLine.d13.s8.e2,"However, the absolute number of drug1-related deaths is far greater than the number of deaths in drug0 or drug2",False, 
DDI-MedLine.d68.s0.e0,DDI-MedLine.d68.s0.e1,[The effect of drug1 on the renal excretion of drug2 and drug0 in dogs] The intravenous injection of drug0 in a dose of 20 mg/kg enhanced drug0 and drug0,False, 
DDI-MedLine.d68.s0.e0,DDI-MedLine.d68.s0.e2,[The effect of drug1 on the renal excretion of drug0 and drug2 in dogs] The intravenous injection of drug0 in a dose of 20 mg/kg enhanced drug0 and drug0,False, 
DDI-MedLine.d68.s0.e3,DDI-MedLine.d68.s0.e4,[The effect of drug0 on the renal excretion of drug0 and drug0 in dogs] The intravenous injection of drug1 in a dose of 20 mg/kg enhanced drug2 and drug0,True,mechanism
DDI-MedLine.d68.s0.e3,DDI-MedLine.d68.s0.e5,[The effect of drug0 on the renal excretion of drug0 and drug0 in dogs] The intravenous injection of drug1 in a dose of 20 mg/kg enhanced drug0 and drug2,True,mechanism
DDI-MedLine.d68.s1.e0,DDI-MedLine.d68.s1.e1,The higher drug1 and drug2,False, 
DDI-MedLine.d68.s2.e0,DDI-MedLine.d68.s2.e1,"In dogs, drug1 unchanged the secretion of drug2",False, 
DDI-MedLine.d68.s3.e0,DDI-MedLine.d68.s3.e1,Possible extrarenal mechanisms of action of drug1 on drug2 and drug0,False, 
DDI-MedLine.d68.s3.e0,DDI-MedLine.d68.s3.e2,Possible extrarenal mechanisms of action of drug1 on drug0 and drug2,False, 
DDI-MedLine.d129.s0.e0,DDI-MedLine.d129.s0.e1,drug1 as potent drug2,False, 
DDI-MedLine.d129.s3.e0,DDI-MedLine.d129.s3.e1,"drug1 showed the most potent inhibition (66% inhibition at 10 microM), which was far more potent than that of crude drug2",False, 
DDI-MedLine.d66.s0.e0,DDI-MedLine.d66.s0.e1,Changes in urinary homocysteine following drug1drug2 estrogen and ,False, 
DDI-MedLine.d66.s1.e0,DDI-MedLine.d66.s1.e1,The present work involved the administration of both drug1 and drug2,False, 
DDI-MedLine.d66.s2.e0,DDI-MedLine.d66.s2.e1,The results indicate that a statistically significant difference exists between the excreted levels of homocysteine in the urine of both control and drug1-treated rats and the levels shown by rats treated with drug2,False, 
DDI-MedLine.d83.s1.e0,DDI-MedLine.d83.s1.e1,"drug1, a drug2, is a drug0",False, 
DDI-MedLine.d83.s1.e0,DDI-MedLine.d83.s1.e2,"drug1, a drug0, is a drug2",False, 
DDI-MedLine.d83.s3.e0,DDI-MedLine.d83.s3.e1,"In large, well controlled trials in patients with schizophrenia or related psychoses, drug1 5 to 20 mg/day was significantly superior to drug2",False, 
DDI-MedLine.d83.s4.e0,DDI-MedLine.d83.s4.e1,The 1-year risk of relapse (rehospitalisation) was significantly lower with drug1 than with drug2,False, 
DDI-MedLine.d83.s5.e0,DDI-MedLine.d83.s5.e1,"In the first double-blind comparative study (28-week) of drug1 and drug2, drug0 10 to 20 mg/day proved to be significantly more effective than drug0",False, 
DDI-MedLine.d83.s5.e0,DDI-MedLine.d83.s5.e2,"In the first double-blind comparative study (28-week) of drug1 and drug0, drug2 10 to 20 mg/day proved to be significantly more effective than drug0",False, 
DDI-MedLine.d83.s6.e0,DDI-MedLine.d83.s6.e1,"In contrast, preliminary results from an 8-week controlled study suggested drug1 2 to 6 mg/day was superior to drug2",False, 
DDI-MedLine.d83.s7.e0,DDI-MedLine.d83.s7.e1,"Improvements in general cognitive function seen with drug1 treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either drug2 or drug0",False, 
DDI-MedLine.d83.s7.e0,DDI-MedLine.d83.s7.e2,"Improvements in general cognitive function seen with drug1 treatment in a 1-year controlled study of patients with early-phase schizophrenia, were significantly greater than changes seen with either drug0 or drug2",False, 
DDI-MedLine.d83.s8.e0,DDI-MedLine.d83.s8.e1,"However, preliminary results from an 8-week trial showed comparable cognitive enhancing effects of drug1 and drug2",False, 
DDI-MedLine.d83.s9.e0,DDI-MedLine.d83.s9.e1,"Several studies indicate that drug1 has benefits against symptoms of aggression and agitation, while other studies strongly support the effectiveness of drug2",False, 
DDI-MedLine.d83.s10.e0,DDI-MedLine.d83.s10.e1,drug1 is associated with significantly fewer extrapyramidal symptoms than drug2 and drug0,False, 
DDI-MedLine.d83.s10.e0,DDI-MedLine.d83.s10.e2,drug1 is associated with significantly fewer extrapyramidal symptoms than drug0 and drug2,False, 
DDI-MedLine.d83.s11.e0,DDI-MedLine.d83.s11.e1,"In addition, drug1 is not associated with a risk of agranulocytosis as seen with drug2 or clinically significant hyperprolactinaemia as seen with drug0",False, 
DDI-MedLine.d83.s11.e0,DDI-MedLine.d83.s11.e2,"In addition, drug1 is not associated with a risk of agranulocytosis as seen with drug0 or clinically significant hyperprolactinaemia as seen with drug2",False, 
DDI-MedLine.d83.s13.e0,DDI-MedLine.d83.s13.e1,"In comparison with drug1, the adverse events reported significantly more frequently with drug2 in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with drug0, only bodyweight gain occurred significantly more frequently with drug0",False, 
DDI-MedLine.d83.s13.e0,DDI-MedLine.d83.s13.e2,"In comparison with drug1, the adverse events reported significantly more frequently with drug0 in > or = 3.5% of patients were dry mouth, bodyweight gain and increased appetite and compared with drug2, only bodyweight gain occurred significantly more frequently with drug0",False, 
DDI-MedLine.d83.s15.e0,DDI-MedLine.d83.s15.e1,"Pharmacoeconomic analyses indicate that drug1 does not significantly increase, and may even decrease, the overall direct treatment costs of schizophrenia, compared with drug2",False, 
DDI-MedLine.d83.s16.e0,DDI-MedLine.d83.s16.e1,"Compared with drug1, drug2",False, 
DDI-MedLine.d83.s17.e0,DDI-MedLine.d83.s17.e1,"drug1 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than drug2, and to broadly the same extent as drug0",False, 
DDI-MedLine.d83.s17.e0,DDI-MedLine.d83.s17.e2,"drug1 treatment improves quality of life in patients with schizophrenia and related psychoses to a greater extent than drug0, and to broadly the same extent as drug2",False, 
DDI-MedLine.d83.s18.e0,DDI-MedLine.d83.s18.e1,CONCLUSIONS: drug1 demonstrated superior antipsychotic efficacy compared with drug2,False, 
DDI-MedLine.d83.s19.e0,DDI-MedLine.d83.s19.e1,The reduced risk of adverse events and therapeutic superiority compared with drug1 and drug2 in the treatment of negative and depressive symptoms support the choice of drug0,False, 
DDI-MedLine.d83.s19.e0,DDI-MedLine.d83.s19.e2,The reduced risk of adverse events and therapeutic superiority compared with drug1 and drug0 in the treatment of negative and depressive symptoms support the choice of drug2,False, 
DDI-MedLine.d133.s0.e0,DDI-MedLine.d133.s0.e1,Suppression by drug1 of drug2-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drug0,True,effect
DDI-MedLine.d133.s0.e0,DDI-MedLine.d133.s0.e2,Suppression by drug1 of drug0-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drug2,False, 
DDI-MedLine.d133.s0.e1,DDI-MedLine.d133.s0.e2,Suppression by drug0 of drug1-enhanced peritoneal metastasis of intestinal adenocarcinomas induced by drug2,False, 
DDI-MedLine.d133.s1.e0,DDI-MedLine.d133.s1.e1,"BACKGROUND: The effects of combined administration of drug1 and drug2 (drug0), a drug0, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drug0 (drug0",False, 
DDI-MedLine.d133.s1.e0,DDI-MedLine.d133.s1.e2,"BACKGROUND: The effects of combined administration of drug1 and drug0 (drug2), a drug0, on the incidence of peritoneal metastasis of intestinal adenocarcinomas induced by drug0 (drug0",False, 
DDI-MedLine.d133.s2.e0,DDI-MedLine.d133.s2.e1,"METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of drug1 (7.4 mg/kg body weight) and subcutaneous injections of drug2 (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of drug0",False, 
DDI-MedLine.d133.s2.e0,DDI-MedLine.d133.s2.e2,"METHODS: From the beginning of the experiment, rats were given 10 weekly subcutaneous injections of drug1 (7.4 mg/kg body weight) and subcutaneous injections of drug0 (40 microg/kg body weight) every other day, and from week 16, intraperitoneal injections of drug2",False, 
DDI-MedLine.d133.s4.e0,DDI-MedLine.d133.s4.e1,Although drug1 administered at either dose had little or no effect on the enhancement of intestinal carcinogenesis by drug2,False, 
DDI-MedLine.d133.s5.e0,DDI-MedLine.d133.s5.e1,"drug1 also significantly decreased the incidence of lymphatic invasion of adenocarcinomas, which was enhanced by drug2",True,effect
DDI-MedLine.d18.s0.e0,DDI-MedLine.d18.s0.e1,"Note: dissolution of aerosol particles of drug1 in drug2, a model drug0",False, 
DDI-MedLine.d18.s0.e0,DDI-MedLine.d18.s0.e2,"Note: dissolution of aerosol particles of drug1 in drug0, a model drug2",False, 
DDI-MedLine.d18.s1.e0,DDI-MedLine.d18.s1.e1,"The effect of a drug1 extract from bovine lung, drug2, on the dissolution rate of aerosol particles of drug0",False, 
DDI-MedLine.d18.s1.e0,DDI-MedLine.d18.s1.e2,"The effect of a drug1 extract from bovine lung, drug0, on the dissolution rate of aerosol particles of drug2",False, 
DDI-MedLine.d18.s2.e0,DDI-MedLine.d18.s2.e1,Aerosol particles of drug1 were generated from an drug2,False, 
DDI-MedLine.d18.s6.e0,DDI-MedLine.d18.s6.e1,drug1 increased the extent of dissolution of drug2,False, 
DDI-MedLine.d18.s7.e0,DDI-MedLine.d18.s7.e1,"drug1 also increased rate of dissolution, in a manner similar to drug2",False, 
DDI-MedLine.d18.s8.e0,DDI-MedLine.d18.s8.e1,Analysis of the concentration of drug1 following ultracentrifugation indicated that there is rapid equilibration of drug2 between the drug0,False, 
DDI-MedLine.d18.s8.e0,DDI-MedLine.d18.s8.e2,Analysis of the concentration of drug1 following ultracentrifugation indicated that there is rapid equilibration of drug0 between the drug2,False, 
DDI-MedLine.d84.s0.e0,DDI-MedLine.d84.s0.e1,Antimicrobial activity of drug1 alone and in combination with some drug2,False, 
DDI-MedLine.d84.s3.e0,DDI-MedLine.d84.s3.e1,"To investigate the effects of antimicrobial combinations of drug1 with four kinds of drug2 (drug0, drug0, drug0 and drug0",False, 
DDI-MedLine.d84.s3.e0,DDI-MedLine.d84.s3.e2,"To investigate the effects of antimicrobial combinations of drug1 with four kinds of drug0 (drug2, drug0, drug0 and drug0",False, 
DDI-MedLine.d84.s4.e0,DDI-MedLine.d84.s4.e1,The antimicrobial combinations of drug1 with four drug2,True,effect
DDI-MedLine.d84.s5.e0,DDI-MedLine.d84.s5.e1,Synergism was observed when drug1 was combined with drug2,True,effect
DDI-MedLine.d59.s4.e0,DDI-MedLine.d59.s4.e1,drug1 at 10 microM preferentially blocked the secretory effect of drug2,True,effect
DDI-MedLine.d59.s5.e0,DDI-MedLine.d59.s5.e1,drug1 inhibited the drug2,True,effect
DDI-MedLine.d81.s0.e0,DDI-MedLine.d81.s0.e1,Hypothermia as an index of the drug1-drug2,False, 
DDI-MedLine.d81.s1.e0,DDI-MedLine.d81.s1.e1,Decreased core temperature in female rats was investigated as one possible index of the drug1-drug2,False, 
DDI-MedLine.d81.s2.e0,DDI-MedLine.d81.s2.e1,Core temperature was decreased in rats in a dose-dependent manner when drug1 was administered to rats treated with drug2 8 hours before the drug0,True,effect
DDI-MedLine.d81.s2.e0,DDI-MedLine.d81.s2.e2,Core temperature was decreased in rats in a dose-dependent manner when drug1 was administered to rats treated with drug0 8 hours before the drug2,False, 
DDI-MedLine.d81.s2.e1,DDI-MedLine.d81.s2.e2,Core temperature was decreased in rats in a dose-dependent manner when drug0 was administered to rats treated with drug1 8 hours before the drug2,False, 
DDI-MedLine.d81.s3.e0,DDI-MedLine.d81.s3.e1,"The decrease in temperature began within 20 minutes after drug1 administration, reaching a maximal decrease between 60 and 120 minutes post drug2",False, 
DDI-MedLine.d81.s6.e0,DDI-MedLine.d81.s6.e1,"Maximal hypotension was found 120 minutes post drug1, and returned to normal 300 minutes after drug2",False, 
DDI-MedLine.d25.s0.e0,DDI-MedLine.d25.s0.e1,Rhabdomyolysis secondary to a drug interaction between drug1 and drug2,True,effect
DDI-MedLine.d25.s1.e0,DDI-MedLine.d25.s1.e1,OBJECTIVE: To report a case of rhabdomyolysis resulting from concomitant use of drug1 and drug2,False, 
DDI-MedLine.d25.s9.e0,DDI-MedLine.d25.s9.e1,"DISCUSSION: drug1 is a potent inhibitor of CYP3A4, the major enzyme responsible for drug2",True,mechanism
DDI-MedLine.d25.s10.e0,DDI-MedLine.d25.s10.e1,The concomitant administration of drug1 and other drug2,True,effect
DDI-MedLine.d25.s12.e0,DDI-MedLine.d25.s12.e1,"CONCLUSIONS: drug1 inhibit the metabolism of drug2 that are metabolized by CYP3A4 (i.e., drug0, drug0, drug0, drug0",False, 
DDI-MedLine.d25.s12.e0,DDI-MedLine.d25.s12.e2,"CONCLUSIONS: drug1 inhibit the metabolism of drug0 that are metabolized by CYP3A4 (i.e., drug2, drug0, drug0, drug0",True,mechanism
DDI-MedLine.d25.s12.e0,DDI-MedLine.d25.s12.e3,"CONCLUSIONS: drug1 inhibit the metabolism of drug0 that are metabolized by CYP3A4 (i.e., drug0, drug2, drug0, drug0",True,mechanism
DDI-MedLine.d25.s12.e0,DDI-MedLine.d25.s12.e4,"CONCLUSIONS: drug1 inhibit the metabolism of drug0 that are metabolized by CYP3A4 (i.e., drug0, drug0, drug2, drug0",True,mechanism
DDI-MedLine.d25.s12.e0,DDI-MedLine.d25.s12.e5,"CONCLUSIONS: drug1 inhibit the metabolism of drug0 that are metabolized by CYP3A4 (i.e., drug0, drug0, drug0, drug2",True,mechanism
DDI-MedLine.d25.s12.e1,DDI-MedLine.d25.s12.e2,"CONCLUSIONS: drug0 inhibit the metabolism of drug1 that are metabolized by CYP3A4 (i.e., drug2, drug0, drug0, drug0",False, 
DDI-MedLine.d48.s3.e0,DDI-MedLine.d48.s3.e1,"drug1, at pH 7.0, was used to chemically modify exposed histidine residues on drug2",False, 
DDI-MedLine.d48.s4.e0,DDI-MedLine.d48.s4.e1,Modification of drug1 with drug2,False, 
DDI-MedLine.d48.s5.e0,DDI-MedLine.d48.s5.e1,Treatment of drug1 with [(14)C]-drug2,False, 
DDI-MedLine.d48.s6.e0,DDI-MedLine.d48.s6.e1,The effects of drug1 could be reversed by drug2,False, 
DDI-MedLine.d48.s11.e0,DDI-MedLine.d48.s11.e1,"Exposed histidines on drug1 are available for drug2 chelation, and these have been exploited in the development of a novel purification protocol for drug0 using drug0",False, 
DDI-MedLine.d48.s11.e0,DDI-MedLine.d48.s11.e2,"Exposed histidines on drug1 are available for drug0 chelation, and these have been exploited in the development of a novel purification protocol for drug2 using drug0",False, 
DDI-MedLine.d130.s0.e0,DDI-MedLine.d130.s0.e1,High-dose drug1 with drug2,True,effect
DDI-MedLine.d130.s2.e0,DDI-MedLine.d130.s2.e1,drug1 is a neutralizing agent for drug2,True,effect
DDI-MedLine.d130.s3.e0,DDI-MedLine.d130.s3.e1,"To determine whether injection of drug1 would permit larger doses of drug2 to be administered, a fixed 9.9-g/m2 dose of drug0 was given intravenously over three hours concurrently with escalating doses of drug0",False, 
DDI-MedLine.d130.s3.e0,DDI-MedLine.d130.s3.e2,"To determine whether injection of drug1 would permit larger doses of drug0 to be administered, a fixed 9.9-g/m2 dose of drug2 was given intravenously over three hours concurrently with escalating doses of drug0",False, 
DDI-MedLine.d130.s4.e0,DDI-MedLine.d130.s4.e1,drug1 was administered over the last two hours of the drug2,False, 
DDI-MedLine.d130.s6.e0,DDI-MedLine.d130.s6.e1,"Comparison of drug1 pharmacokinetics in patients treated with 202.5 mg/m2 plus drug2 to those in patients treated with 100 mg/m2 without drug0 indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of drug0",False, 
DDI-MedLine.d130.s6.e0,DDI-MedLine.d130.s6.e2,"Comparison of drug1 pharmacokinetics in patients treated with 202.5 mg/m2 plus drug0 to those in patients treated with 100 mg/m2 without drug2 indicated that there were no changes in the elimination rate constant, volume of distribution, or total body clearance of drug0",False, 
DDI-MedLine.d130.s8.e0,DDI-MedLine.d130.s8.e1,This study demonstrates that concurrent administration of drug1 permits at least a twofold increase in dose and total exposure to drug2,True,mechanism
DDI-MedLine.d82.s1.e0,DDI-MedLine.d82.s1.e1,The intestinal absorption of drug1(drug2,False, 
DDI-MedLine.d82.s2.e0,DDI-MedLine.d82.s2.e1,"By this procedure, it was observed that drug1 is rapidly and essentially completely absorbed (80-95%) from the lumen at drug2",False, 
DDI-MedLine.d82.s4.e0,DDI-MedLine.d82.s4.e1,"At stable drug1 concentrations greater than 1 mM, fractional mucosal cell accumulation of drug2",False, 
DDI-MedLine.d82.s5.e0,DDI-MedLine.d82.s5.e1,"However, total mucosal accumulation of drug1 and that transferred to the body increase in a linear logarithmic fashion from 0.05 to 5 mm drug2",False, 
DDI-MedLine.d82.s7.e0,DDI-MedLine.d82.s7.e1,"Furthermore, drug1 and drug2",False, 
DDI-MedLine.d82.s8.e0,DDI-MedLine.d82.s8.e1,drug1 administration to rachitic chicks was effective in significantly elevating duodenal drug2,True,mechanism
DDI-MedLine.d114.s1.e0,DDI-MedLine.d114.s1.e1,The effects of drug1 (drug2) on drug0 (drug0,False, 
DDI-MedLine.d114.s1.e0,DDI-MedLine.d114.s1.e2,The effects of drug1 (drug0) on drug2 (drug0,False, 
DDI-MedLine.d114.s3.e0,DDI-MedLine.d114.s3.e1,Administering drug1 together with drug2,True,effect
DDI-MedLine.d114.s4.e0,DDI-MedLine.d114.s4.e1,Pretreatment of megakaryocytes with extracellular drug1 (50 microM) also inhibited drug2,True,effect
DDI-MedLine.d114.s6.e0,DDI-MedLine.d114.s6.e1,"In contrast, in isolated single pancreatic acinar cells, drug1 had no effect on drug2",False, 
DDI-MedLine.d114.s8.e0,DDI-MedLine.d114.s8.e1,"In addition, we have shown that drug1 is a useful pharmacological tool with which to examine the drug2",False, 
DDI-MedLine.d27.s0.e0,DDI-MedLine.d27.s0.e1,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug1 (1 mg/kg) removes the antiedematous action of drug2, drug0, drug0 and drug0 and reduces the action of drug0",True,effect
DDI-MedLine.d27.s0.e0,DDI-MedLine.d27.s0.e2,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug1 (1 mg/kg) removes the antiedematous action of drug0, drug2, drug0 and drug0 and reduces the action of drug0",True,effect
DDI-MedLine.d27.s0.e0,DDI-MedLine.d27.s0.e3,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug1 (1 mg/kg) removes the antiedematous action of drug0, drug0, drug2 and drug0 and reduces the action of drug0",True,effect
DDI-MedLine.d27.s0.e0,DDI-MedLine.d27.s0.e4,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug1 (1 mg/kg) removes the antiedematous action of drug0, drug0, drug0 and drug2 and reduces the action of drug0",True,effect
DDI-MedLine.d27.s0.e0,DDI-MedLine.d27.s0.e5,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug1 (1 mg/kg) removes the antiedematous action of drug0, drug0, drug0 and drug0 and reduces the action of drug2",True,effect
DDI-MedLine.d27.s0.e1,DDI-MedLine.d27.s0.e2,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug0 (1 mg/kg) removes the antiedematous action of drug1, drug2, drug0 and drug0 and reduces the action of drug0",False, 
DDI-MedLine.d27.s0.e1,DDI-MedLine.d27.s0.e3,"[The GABA-ergic system and brain edema] It has been shown in rats with experimental toxic and traumatic edemas that drug0 (1 mg/kg) removes the antiedematous action of drug1, drug0, drug2 and drug0 and reduces the action of drug0",False, 
DDI-MedLine.d109.s0.e0,DDI-MedLine.d109.s0.e1,Effect of drug1 on the pharmacokinetics of drug2,False, 
DDI-MedLine.d109.s1.e0,DDI-MedLine.d109.s1.e1,"The authors examined the effect of the cyclooxygenase-2 (COX-2) inhibitor, drug1, at steady state on the pharmacokinetics of drug2",False, 
DDI-MedLine.d109.s5.e0,DDI-MedLine.d109.s5.e1,Samples for plasma and urine immunoreactive drug1 concentrations were collected through 120 hours following the drug2,False, 
DDI-MedLine.d109.s7.e0,DDI-MedLine.d109.s7.e1,"For drug1 AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (drug2 + drug0/placebo + drug0",False, 
DDI-MedLine.d109.s7.e0,DDI-MedLine.d109.s7.e2,"For drug1 AUC(0-infinity), AUC(0-24), and Cmax, the geometric mean ratios (90% confidence interval) for (drug0 + drug2/placebo + drug0",False, 
DDI-MedLine.d109.s9.e0,DDI-MedLine.d109.s9.e1,The harmonic mean elimination half-life was 45.7 and 43.4 hours for drug1 + drug2 and placebo + drug0,False, 
DDI-MedLine.d109.s9.e0,DDI-MedLine.d109.s9.e2,The harmonic mean elimination half-life was 45.7 and 43.4 hours for drug1 + drug0 and placebo + drug2,False, 
DDI-MedLine.d109.s11.e0,DDI-MedLine.d109.s11.e1,The mean (SD) cumulative urinary excretion of immunoreactive drug1 after concurrent treatment with drug2,False, 
DDI-MedLine.d109.s13.e0,DDI-MedLine.d109.s13.e1,drug1 did not influence the plasma pharmacokinetics or renal elimination of a single oral dose of drug2,False, 
DDI-MedLine.d131.s0.e0,DDI-MedLine.d131.s0.e1,Interaction on the antinociceptive effect between drug1 and drug2 or drug0,True,effect
DDI-MedLine.d131.s0.e0,DDI-MedLine.d131.s0.e2,Interaction on the antinociceptive effect between drug1 and drug0 or drug2,True,effect
DDI-MedLine.d131.s0.e1,DDI-MedLine.d131.s0.e2,Interaction on the antinociceptive effect between drug0 and drug1 or drug2,False, 
DDI-MedLine.d131.s1.e0,DDI-MedLine.d131.s1.e1,"The aim of this paper was to study the interaction between drug1 and both drug2 or its synthetic analogue drug0, or drug0",False, 
DDI-MedLine.d131.s1.e0,DDI-MedLine.d131.s1.e2,"The aim of this paper was to study the interaction between drug1 and both drug0 or its synthetic analogue drug2, or drug0",False, 
DDI-MedLine.d131.s3.e0,DDI-MedLine.d131.s3.e1,It was shown that drug1 antagonized evidently the antinociceptive effect of drug2,True,effect
DDI-MedLine.d131.s4.e0,DDI-MedLine.d131.s4.e1,"On the contrary, drug1 and drug2",True,effect
DDI-MedLine.d131.s5.e0,DDI-MedLine.d131.s5.e1,It is concluded that drug1 modulates in an opposite way the function of the enkephalinergic neurons and the central action of drug2,True,effect
DDI-MedLine.d30.s1.e0,DDI-MedLine.d30.s1.e1,The behavioral effects of the stereoisomers of drug1 (drug2) were compared with those of drug0 (drug0,False, 
DDI-MedLine.d30.s1.e0,DDI-MedLine.d30.s1.e2,The behavioral effects of the stereoisomers of drug1 (drug0) were compared with those of drug2 (drug0,False, 
DDI-MedLine.d30.s2.e0,DDI-MedLine.d30.s2.e1,Intermediate doses of drug1 or drug2,False, 
DDI-MedLine.d30.s6.e0,DDI-MedLine.d30.s6.e1,"In monkeys, drug1 was about 10 times more potent than drug2 in decreasing responding, whereas in pigeons drug0 was about equipotent with drug0",False, 
DDI-MedLine.d30.s6.e0,DDI-MedLine.d30.s6.e2,"In monkeys, drug1 was about 10 times more potent than drug0 in decreasing responding, whereas in pigeons drug2 was about equipotent with drug0",False, 
DDI-MedLine.d30.s7.e0,DDI-MedLine.d30.s7.e1,"In both species, drug1, but not drug2, antagonized the rate-decreasing effects of drug0",False, 
DDI-MedLine.d30.s7.e0,DDI-MedLine.d30.s7.e2,"In both species, drug1, but not drug0, antagonized the rate-decreasing effects of drug2",True,effect
DDI-MedLine.d30.s7.e1,DDI-MedLine.d30.s7.e2,"In both species, drug0, but not drug1, antagonized the rate-decreasing effects of drug2",False, 
DDI-MedLine.d30.s8.e0,DDI-MedLine.d30.s8.e1,"In monkeys, the effects of drug1, but not drug2 or drug0, were antagonized by drug0",False, 
DDI-MedLine.d30.s8.e0,DDI-MedLine.d30.s8.e2,"In monkeys, the effects of drug1, but not drug0 or drug2, were antagonized by drug0",False, 
DDI-MedLine.d30.s8.e0,DDI-MedLine.d30.s8.e3,"In monkeys, the effects of drug1, but not drug0 or drug0, were antagonized by drug2",True,effect
DDI-MedLine.d30.s9.e0,DDI-MedLine.d30.s9.e1,the doses of drug1 required to antagonize the effects of drug2 were more than 100 times higher than those required to antagonize the effects of drug0,True,effect
DDI-MedLine.d30.s9.e0,DDI-MedLine.d30.s9.e2,the doses of drug1 required to antagonize the effects of drug0 were more than 100 times higher than those required to antagonize the effects of drug2,True,effect
DDI-MedLine.d30.s9.e1,DDI-MedLine.d30.s9.e2,the doses of drug0 required to antagonize the effects of drug1 were more than 100 times higher than those required to antagonize the effects of drug2,False, 
DDI-MedLine.d30.s10.e0,DDI-MedLine.d30.s10.e1,"In pigeons, drug1 did not systematically alter the effects of drug2, drug0 or drug0",False, 
DDI-MedLine.d30.s10.e0,DDI-MedLine.d30.s10.e2,"In pigeons, drug1 did not systematically alter the effects of drug0, drug2 or drug0",False, 
DDI-MedLine.d30.s11.e0,DDI-MedLine.d30.s11.e1,"drug1 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug2 or drug0 in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug0",True,effect
DDI-MedLine.d30.s11.e0,DDI-MedLine.d30.s11.e2,"drug1 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug0 or drug2 in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug0",True,effect
DDI-MedLine.d30.s11.e0,DDI-MedLine.d30.s11.e3,"drug1 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug0 or drug0 in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug2",False, 
DDI-MedLine.d30.s11.e1,DDI-MedLine.d30.s11.e2,"drug0 reduced or eliminated the increases in FI responding produced by intermediate doses of either drug1 or drug2 in pigeons, but did not antagonize the decreases in FI or FR responding produced by high doses of PCP or either stereoisomer of drug0",False, 
DDI-MedLine.d17.s0.e0,DDI-MedLine.d17.s0.e1,In vitro interaction of drug1 and drug2,True,int
DDI-MedLine.d17.s1.e0,DDI-MedLine.d17.s1.e1,The interaction of drug1 and synthetic drug2,False, 
DDI-MedLine.d17.s3.e0,DDI-MedLine.d17.s3.e1,In seven experiments reactions to drug1 and drug2 were drug0,False, 
DDI-MedLine.d17.s3.e0,DDI-MedLine.d17.s3.e2,In seven experiments reactions to drug1 and drug0 were drug2,False, 
DDI-MedLine.d17.s4.e0,DDI-MedLine.d17.s4.e1,drug1 produced significantly increased vasoconstriction after a single administration of drug2,True,effect
DDI-MedLine.d17.s9.e0,DDI-MedLine.d17.s9.e1,There is thus an enhancement effect of drug1 upon the reaction of placental vessels to drug2,True,effect
DDI-MedLine.d140.s0.e0,DDI-MedLine.d140.s0.e1,"Longitudinal assessment of drug1 in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on drug2",False, 
DDI-MedLine.d140.s1.e0,DDI-MedLine.d140.s1.e1,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of drug1 and drug2 (INN, drug0",False, 
DDI-MedLine.d140.s1.e0,DDI-MedLine.d140.s1.e2,"OBJECTIVE: Our objective was to characterize the steady-state pharmacokinetics of drug1 and drug0 (INN, drug2",False, 
DDI-MedLine.d140.s2.e0,DDI-MedLine.d140.s2.e1,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive drug1 tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with drug2 and drug0",False, 
DDI-MedLine.d140.s2.e0,DDI-MedLine.d140.s2.e2,"METHOD: This study was a multicenter randomized double-blind study of 101 patients who were randomly assigned 1:1:1 to receive drug1 tablets at doses of 0.5 mg, 1 mg, or 2 mg twice daily with drug0 and drug2",False, 
DDI-MedLine.d140.s3.e0,DDI-MedLine.d140.s3.e1,Blood sampling for the pharmacokinetics of drug1 and drug2,False, 
DDI-MedLine.d140.s6.e0,DDI-MedLine.d140.s6.e1,Potential differences in drug1 dosing and pharmacokinetics at different levels of drug2,False, 
DDI-MedLine.d140.s13.e0,DDI-MedLine.d140.s13.e1,"drug1 doses, trough concentrations, and AUC exhibited similar temporal patterns during the course of the study regardless of the co-administered drug2",False, 
DDI-MedLine.d140.s15.e0,DDI-MedLine.d140.s15.e1,For a 4-fold range of drug1 doses there were no differential effects on drug2,False, 
DDI-MedLine.d80.s1.e0,DDI-MedLine.d80.s1.e1,"In order to provide information for the appropriate package insert labeling of drug1 (drug2) in the US, a comprehensive review was made of drug0 (0.075 mg) and drug0",False, 
DDI-MedLine.d80.s1.e0,DDI-MedLine.d80.s1.e2,"In order to provide information for the appropriate package insert labeling of drug1 (drug0) in the US, a comprehensive review was made of drug2 (0.075 mg) and drug0",False, 
DDI-MedLine.d3.s0.e0,DDI-MedLine.d3.s0.e1,Pharmacokinetic Interaction between drug1 and drug2 or drug0,False, 
DDI-MedLine.d3.s0.e0,DDI-MedLine.d3.s0.e2,Pharmacokinetic Interaction between drug1 and drug0 or drug2,False, 
DDI-MedLine.d3.s1.e0,DDI-MedLine.d3.s1.e1,The objective of this study was to determine if there is a pharmacokinetic interaction when drug1 is given with drug2 or drug0,False, 
DDI-MedLine.d3.s1.e0,DDI-MedLine.d3.s1.e2,The objective of this study was to determine if there is a pharmacokinetic interaction when drug1 is given with drug0 or drug2,False, 
DDI-MedLine.d3.s3.e0,DDI-MedLine.d3.s3.e1,"All subjects received drug1 (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either drug2 (300 mg once a day [QD]) (cohort 1) or drug0",False, 
DDI-MedLine.d3.s3.e0,DDI-MedLine.d3.s3.e2,"All subjects received drug1 (1,200 mg twice a day) for 4 days, followed by a 7-day washout period, followed by either drug0 (300 mg once a day [QD]) (cohort 1) or drug2",False, 
DDI-MedLine.d3.s4.e0,DDI-MedLine.d3.s4.e1,"Cohort 1 then received drug1 plus drug2 for 10 days, and cohort 2 received drug0 plus drug0",False, 
DDI-MedLine.d3.s4.e0,DDI-MedLine.d3.s4.e2,"Cohort 1 then received drug1 plus drug0 for 10 days, and cohort 2 received drug2 plus drug0",False, 
DDI-MedLine.d3.s5.e0,DDI-MedLine.d3.s5.e1,"Serial plasma and urine samples for measurement of drug1, drug2, and drug0 and their drug0",False, 
DDI-MedLine.d3.s5.e0,DDI-MedLine.d3.s5.e2,"Serial plasma and urine samples for measurement of drug1, drug0, and drug2 and their drug0",False, 
DDI-MedLine.d3.s6.e0,DDI-MedLine.d3.s6.e1,drug1 did not significantly affect drug2,False, 
DDI-MedLine.d3.s7.e0,DDI-MedLine.d3.s7.e1,drug1 significantly increased the area under the curve at steady state (AUC(ss)) of drug2 by 2.93-fold and the AUC(ss) of drug0,True,mechanism
DDI-MedLine.d3.s7.e0,DDI-MedLine.d3.s7.e2,drug1 significantly increased the area under the curve at steady state (AUC(ss)) of drug0 by 2.93-fold and the AUC(ss) of drug2,True,mechanism
DDI-MedLine.d3.s7.e1,DDI-MedLine.d3.s7.e2,drug0 significantly increased the area under the curve at steady state (AUC(ss)) of drug1 by 2.93-fold and the AUC(ss) of drug2,False, 
DDI-MedLine.d3.s8.e0,DDI-MedLine.d3.s8.e1,"drug1 significantly decreased the AUC(ss) of drug2 by 82%, but drug0 had no effect on drug0",True,mechanism
DDI-MedLine.d3.s8.e0,DDI-MedLine.d3.s8.e2,"drug1 significantly decreased the AUC(ss) of drug0 by 82%, but drug2 had no effect on drug0",False, 
DDI-MedLine.d3.s8.e0,DDI-MedLine.d3.s8.e3,"drug1 significantly decreased the AUC(ss) of drug0 by 82%, but drug0 had no effect on drug2",False, 
DDI-MedLine.d3.s10.e0,DDI-MedLine.d3.s10.e1,The results of the ERMBT after 2 weeks of drug1 and drug2,False, 
DDI-MedLine.d3.s11.e0,DDI-MedLine.d3.s11.e1,drug1 plus drug2,False, 
DDI-MedLine.d3.s12.e0,DDI-MedLine.d3.s12.e1,drug1 plus drug2,True,effect
DDI-MedLine.d3.s13.e0,DDI-MedLine.d3.s13.e1,drug1 markedly increases the metabolic clearance of drug2,True,mechanism
DDI-MedLine.d3.s14.e0,DDI-MedLine.d3.s14.e1,drug1 significantly decreases clearance of drug2 and drug0,True,mechanism
DDI-MedLine.d3.s14.e0,DDI-MedLine.d3.s14.e2,drug1 significantly decreases clearance of drug0 and drug2,True,mechanism
DDI-MedLine.d3.s14.e1,DDI-MedLine.d3.s14.e2,drug0 significantly decreases clearance of drug1 and drug2,False, 
DDI-MedLine.d3.s15.e0,DDI-MedLine.d3.s15.e1,"drug1 inhibits the ERMBT, and drug2 and drug0",False, 
DDI-MedLine.d3.s15.e0,DDI-MedLine.d3.s15.e2,"drug1 inhibits the ERMBT, and drug0 and drug2",False, 
DDI-MedLine.d2.s0.e0,DDI-MedLine.d2.s0.e1,Failure of drug1 to modify drug2,False, 
DDI-MedLine.d2.s1.e0,DDI-MedLine.d2.s1.e1,"Studies in rats have shown that drug1 administration attenuates certain types of drug2 dependent hypertension, including drug0",False, 
DDI-MedLine.d2.s1.e0,DDI-MedLine.d2.s1.e2,"Studies in rats have shown that drug1 administration attenuates certain types of drug0 dependent hypertension, including drug2",True,effect
DDI-MedLine.d2.s1.e1,DDI-MedLine.d2.s1.e2,"Studies in rats have shown that drug0 administration attenuates certain types of drug1 dependent hypertension, including drug2",False, 
DDI-MedLine.d2.s2.e0,DDI-MedLine.d2.s2.e1,The effects of oral drug1 on drug2,False, 
DDI-MedLine.d2.s3.e0,DDI-MedLine.d2.s3.e1,drug1 has no effect on the blood pressure or metabolic responses to drug2,False, 
DDI-MedLine.d63.s0.e0,DDI-MedLine.d63.s0.e1,Differential actions of intrathecal drug1 on blocking the tail-flick inhibition induced by intraventricular drug2 and drug0,False, 
DDI-MedLine.d63.s0.e0,DDI-MedLine.d63.s0.e2,Differential actions of intrathecal drug1 on blocking the tail-flick inhibition induced by intraventricular drug0 and drug2,False, 
DDI-MedLine.d63.s2.e0,DDI-MedLine.d63.s2.e1,The blockade of the spinal endorphinergic system by intrathecal drug1 on the production of tail-flick inhibition induced by intraventricular drug2 and drug0,False, 
DDI-MedLine.d63.s2.e0,DDI-MedLine.d63.s2.e2,The blockade of the spinal endorphinergic system by intrathecal drug1 on the production of tail-flick inhibition induced by intraventricular drug0 and drug2,False, 
DDI-MedLine.d63.s3.e0,DDI-MedLine.d63.s3.e1,Intraventricular injection of drug1 and drug2,False, 
DDI-MedLine.d63.s4.e0,DDI-MedLine.d63.s4.e1,"Intrathecal injection of drug1 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug2, and a high dose of drug0 (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular drug0",True,effect
DDI-MedLine.d63.s4.e0,DDI-MedLine.d63.s4.e2,"Intrathecal injection of drug1 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug0, and a high dose of drug2 (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular drug0",False, 
DDI-MedLine.d63.s4.e0,DDI-MedLine.d63.s4.e3,"Intrathecal injection of drug1 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug0, and a high dose of drug0 (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular drug2",False, 
DDI-MedLine.d63.s4.e2,DDI-MedLine.d63.s4.e3,"Intrathecal injection of drug0 at doses of 0.4 to 40 micrograms caused a dose-related blockade of the inhibition of the tail-flick response induced by intraventricular injection of drug0, and a high dose of drug1 (40 micrograms) completely blocked the tail-flick inhibition induced by intraventricular drug2",True,effect
DDI-MedLine.d63.s5.e0,DDI-MedLine.d63.s5.e1,"On the other hand, intrathecal drug1 (12-120 micrograms) had only a very weak effect on the tail-flick inhibition induced by intraventricular drug2",True,effect
DDI-MedLine.d63.s6.e0,DDI-MedLine.d63.s6.e1,Intraventricular injection of drug1 at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drug2 and drug0,True,effect
DDI-MedLine.d63.s6.e0,DDI-MedLine.d63.s6.e2,Intraventricular injection of drug1 at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drug0 and drug2,True,effect
DDI-MedLine.d63.s6.e1,DDI-MedLine.d63.s6.e2,Intraventricular injection of drug0 at doses of 1.2 to 12 micrograms equally antagonized in a dose-dependent manner the tail-flick inhibition induced by intraventricular drug1 and drug2,False, 
DDI-MedLine.d63.s7.e0,DDI-MedLine.d63.s7.e1,"The results indicate that a spinal drug1-sensitive endorphinergic system is involved in the production of drug2 but not drug0-induced tail-flick inhibition, and suggest that intraventricular drug0 and drug0",False, 
DDI-MedLine.d63.s7.e0,DDI-MedLine.d63.s7.e2,"The results indicate that a spinal drug1-sensitive endorphinergic system is involved in the production of drug0 but not drug2-induced tail-flick inhibition, and suggest that intraventricular drug0 and drug0",False, 
DDI-MedLine.d63.s8.e0,DDI-MedLine.d63.s8.e1,descending epsilon and mu systems for drug1 and drug2,False, 
DDI-MedLine.d49.s0.e0,DDI-MedLine.d49.s0.e1,Interaction of drug1 and drug2,True,int
DDI-MedLine.d49.s1.e0,DDI-MedLine.d49.s1.e1,The minimal inhibitory concentrations of drug1 and drug2,False, 
DDI-MedLine.d49.s3.e0,DDI-MedLine.d49.s3.e1,drug1 did not interfere with the activity of drug2,False, 
DDI-MedLine.d49.s6.e0,DDI-MedLine.d49.s6.e1,Combinations of drug1 and drug2,True,effect
DDI-MedLine.d49.s7.e0,DDI-MedLine.d49.s7.e1,"All 20 strains of enterococcus, three strains of Clostridium, three strains of Escherichia coli, and one strain of Proteus rettgeri were resistant to both drug1 (minimal inhibitory concentration greater than 3.1 mug/ml) and drug2",False, 
DDI-MedLine.d49.s8.e0,DDI-MedLine.d49.s8.e1,Combinations of drug1 and drug2,True,effect
DDI-MedLine.d45.s0.e0,DDI-MedLine.d45.s0.e1,Selective survival in drug1 and drug2,False, 
DDI-MedLine.d45.s1.e0,DDI-MedLine.d45.s1.e1,"The growth of Pseudomonas aeruginosa, particularly serotype O11, in drug1 and drug2",False, 
DDI-MedLine.d45.s5.e0,DDI-MedLine.d45.s5.e1,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in drug1, but not in drug2 and drug0",False, 
DDI-MedLine.d45.s5.e0,DDI-MedLine.d45.s5.e2,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in drug1, but not in drug0 and drug2",False, 
DDI-MedLine.d45.s5.e1,DDI-MedLine.d45.s5.e2,"Twelve strains of Staphylococcus aureus (a frequent cause of infection in drug0, but not in drug1 and drug2",True,effect
DDI-MedLine.d45.s6.e0,DDI-MedLine.d45.s6.e1,"Dose-response curves (derived from the results of using the tablets as well as pure powders) showed that drug1 was responsible for the inhibitory activity, which was partially antagonized by drug2",True,effect
DDI-MedLine.d45.s9.e0,DDI-MedLine.d45.s9.e1,"aureus, to survive in drug1 and drug2",False, 
DDI-MedLine.d58.s3.e0,DDI-MedLine.d58.s3.e1,"In this study we investigated the effect of drug1 on high threshold voltage-dependent Ca(2+) channel subtypes using their drug2 drug0 (L-type), drug0 (N-type), or drug0",False, 
DDI-MedLine.d58.s3.e0,DDI-MedLine.d58.s3.e2,"In this study we investigated the effect of drug1 on high threshold voltage-dependent Ca(2+) channel subtypes using their drug0 drug2 (L-type), drug0 (N-type), or drug0",False, 
DDI-MedLine.d58.s6.e0,DDI-MedLine.d58.s6.e1,drug1 had no effect on drug2,False, 
DDI-MedLine.d58.s7.e0,DDI-MedLine.d58.s7.e1,"These data suggest that drug1 are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an drug2-sensitive (N-type) channel, an drug0-sensitive (P-type) channel and drug0/drug0/drug0",False, 
DDI-MedLine.d58.s7.e0,DDI-MedLine.d58.s7.e2,"These data suggest that drug1 are negatively coupled to three types of calcium channels in bovine chromaffin cell, including an drug0-sensitive (N-type) channel, an drug2-sensitive (P-type) channel and drug0/drug0/drug0",False, 
DDI-MedLine.d58.s8.e0,DDI-MedLine.d58.s8.e1,"Thus, the selective regulation of voltage-dependent Ca(2+) subtypes by drug1 in bovine chromaffin cell could be the cellular basis of antistress effects induced by drug2",False, 
DDI-MedLine.d74.s2.e0,DDI-MedLine.d74.s2.e1,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of drug1 (20mM), drug2 (100 or 150 mg. per 100 ml.), and drug0",False, 
DDI-MedLine.d74.s2.e0,DDI-MedLine.d74.s2.e2,"To study the pancreatic effects of other agents, dynamic insulin and glucagon release was measured from the in vitro perfused pancreases of normal and diabetic Chinese hamsters in response to various combinations of drug1 (20mM), drug0 (100 or 150 mg. per 100 ml.), and drug2",False, 
DDI-MedLine.d74.s4.e0,DDI-MedLine.d74.s4.e1,"drug1, alone and in the presence of drug2",False, 
DDI-MedLine.d74.s5.e0,DDI-MedLine.d74.s5.e1,"drug1, in the presence of drug2 and drug0",False, 
DDI-MedLine.d74.s5.e0,DDI-MedLine.d74.s5.e2,"drug1, in the presence of drug0 and drug2",False, 
DDI-MedLine.d74.s6.e0,DDI-MedLine.d74.s6.e1,"drug1, in the absence of drug2 or drug0",False, 
DDI-MedLine.d74.s6.e0,DDI-MedLine.d74.s6.e2,"drug1, in the absence of drug0 or drug2",False, 
DDI-MedLine.d74.s11.e0,DDI-MedLine.d74.s11.e1,"Further, these results confirm that the diabetic Chinese hamster's alpha and beta cells respond normally to drug1, but are relatively insensitive to drug2",False, 
DDI-MedLine.d28.s7.e0,DDI-MedLine.d28.s7.e1,"The drug1 (drug2 and drug0), a new class of oral drug0",False, 
DDI-MedLine.d28.s7.e0,DDI-MedLine.d28.s7.e2,"The drug1 (drug0 and drug2), a new class of oral drug0",False, 
DDI-MedLine.d104.s0.e0,DDI-MedLine.d104.s0.e1,The effects of drug1 and drug2 upon drug0 (drug0,False, 
DDI-MedLine.d104.s0.e0,DDI-MedLine.d104.s0.e2,The effects of drug1 and drug0 upon drug2 (drug0,False, 
DDI-MedLine.d104.s2.e0,DDI-MedLine.d104.s2.e1,injection of drug1 (drug2,False, 
DDI-MedLine.d104.s3.e0,DDI-MedLine.d104.s3.e1,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, drug1 and drug2, on the above behavioral changes induced by drug0",False, 
DDI-MedLine.d104.s3.e0,DDI-MedLine.d104.s3.e2,"Then, the effects of metabotropic glutamate receptor (mGluR) agonists, drug1 and drug0, on the above behavioral changes induced by drug2",False, 
DDI-MedLine.d104.s4.e0,DDI-MedLine.d104.s4.e1,The effects of drug1 were very strong and completely depressed the drug2,True,effect
DDI-MedLine.d104.s8.e0,DDI-MedLine.d104.s8.e1,"In order to examine some molecular mechanisms of drug1-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with drug2, drug0, and drug0",False, 
DDI-MedLine.d104.s8.e0,DDI-MedLine.d104.s8.e2,"In order to examine some molecular mechanisms of drug1-induced behavioral changes, Northern blot analysis of total RNA from prefrontal cortical tissues of mice treated with drug0, drug2, and drug0",False, 
DDI-MedLine.d127.s6.e0,DDI-MedLine.d127.s6.e1,Concomitantly given drug1 did not interfere with the absorption of a tablet of drug2,False, 
DDI-MedLine.d99.s0.e0,DDI-MedLine.d99.s0.e1,drug1 inhibits the CYP2C9 catalyzed biotransformation of drug2,True,mechanism
DDI-MedLine.d99.s1.e0,DDI-MedLine.d99.s1.e1,OBJECTIVE: Our objective was to examine the interaction between drug1 and drug2 to confirm that drug0,False, 
DDI-MedLine.d99.s1.e0,DDI-MedLine.d99.s1.e2,OBJECTIVE: Our objective was to examine the interaction between drug1 and drug0 to confirm that drug2,False, 
DDI-MedLine.d99.s8.e0,DDI-MedLine.d99.s8.e1,"Plasma was analyzed for drug1, and urine was analyzed for drug2 and its two metabolites, drug0 and drug0",False, 
DDI-MedLine.d99.s8.e0,DDI-MedLine.d99.s8.e2,"Plasma was analyzed for drug1, and urine was analyzed for drug0 and its two metabolites, drug2 and drug0",False, 
DDI-MedLine.d99.s9.e0,DDI-MedLine.d99.s9.e1,"RESULTS: During treatment with drug1, there was a statistically significant decrease in the median of the total clearance of drug2",True,mechanism
DDI-MedLine.d99.s11.e0,DDI-MedLine.d99.s11.e1,"The clearance by means of drug1 and drug2 was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of drug0 per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of drug0",False, 
DDI-MedLine.d99.s11.e0,DDI-MedLine.d99.s11.e2,"The clearance by means of drug1 and drug0 was significantly reduced in both groups (ie, from 901 mL/h to 318 mL/h in the group that received 150 mg of drug2 per day and from 723 mL/h to 457 mL/h in the group that received 75 mg of drug0",False, 
DDI-MedLine.d22.s2.e0,DDI-MedLine.d22.s2.e1,"By contrast, drug1 (1 mM) and drug2",False, 
DDI-MedLine.d22.s3.e0,DDI-MedLine.d22.s3.e1,"drug1, and to a lesser extent, drug2",False, 
DDI-MedLine.d61.s0.e0,DDI-MedLine.d61.s0.e1,Pharmacokinetic evaluation of the drug1-drug2,False, 
DDI-MedLine.d61.s1.e0,DDI-MedLine.d61.s1.e1,drug1 is known to raise serum drug2,True,mechanism
DDI-MedLine.d61.s3.e0,DDI-MedLine.d61.s3.e1,"The pharmacokinetic variables for drug1 were determined after a 1.0 mg intravenous dose of drug2 in each subject, before and after oral drug0",False, 
DDI-MedLine.d61.s3.e0,DDI-MedLine.d61.s3.e2,"The pharmacokinetic variables for drug1 were determined after a 1.0 mg intravenous dose of drug0 in each subject, before and after oral drug2",False, 
DDI-MedLine.d61.s4.e0,DDI-MedLine.d61.s4.e1,"During drug1 administration, systemic clearance of drug2",True,mechanism
DDI-MedLine.d61.s8.e0,DDI-MedLine.d61.s8.e1,"drug1 caused a three- to fivefold increase in serum reverse triiodothyronine levels, but changes in thyroid function were not quantitatively related to the changes in drug2",False, 
DDI-MedLine.d61.s9.e0,DDI-MedLine.d61.s9.e1,These alterations in drug1 pharmacokinetics produced by drug2 explain the increase in serum drug0,True,mechanism
DDI-MedLine.d61.s9.e0,DDI-MedLine.d61.s9.e2,These alterations in drug1 pharmacokinetics produced by drug0 explain the increase in serum drug2,False, 
DDI-MedLine.d61.s9.e1,DDI-MedLine.d61.s9.e2,These alterations in drug0 pharmacokinetics produced by drug1 explain the increase in serum drug2,False, 
DDI-MedLine.d23.s0.e0,DDI-MedLine.d23.s0.e1,The effects of drug1 and of drug2 anesthesia on drug0,False, 
DDI-MedLine.d23.s0.e0,DDI-MedLine.d23.s0.e2,The effects of drug1 and of drug0 anesthesia on drug2,False, 
DDI-MedLine.d23.s1.e0,DDI-MedLine.d23.s1.e1,"In a comparison of drug1 tolerance in dogs anesthetized with drug2, drug0, or drug0, the dosage of drug0 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of drug0, with drug0 or drug0 than with drug0",False, 
DDI-MedLine.d23.s1.e0,DDI-MedLine.d23.s1.e2,"In a comparison of drug1 tolerance in dogs anesthetized with drug0, drug2, or drug0, the dosage of drug0 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of drug0, with drug0 or drug0 than with drug0",False, 
DDI-MedLine.d23.s1.e1,DDI-MedLine.d23.s1.e4,"In a comparison of drug0 tolerance in dogs anesthetized with drug1, drug0, or drug0, the dosage of drug2 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of drug0, with drug0 or drug0 than with drug0",True,effect
DDI-MedLine.d23.s1.e2,DDI-MedLine.d23.s1.e4,"In a comparison of drug0 tolerance in dogs anesthetized with drug0, drug1, or drug0, the dosage of drug2 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of drug0, with drug0 or drug0 than with drug0",True,effect
DDI-MedLine.d23.s1.e3,DDI-MedLine.d23.s1.e4,"In a comparison of drug0 tolerance in dogs anesthetized with drug0, drug0, or drug1, the dosage of drug2 needed to cause ventricular tachycardia was significantly higher, as was the LD50 of drug0, with drug0 or drug0 than with drug0",True,effect
DDI-MedLine.d23.s2.e0,DDI-MedLine.d23.s2.e1,"Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug2, drug0, or drug0 but not after administration of drug0 alone or after drug0",True,effect
DDI-MedLine.d23.s2.e0,DDI-MedLine.d23.s2.e2,"Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug0, drug2, or drug0 but not after administration of drug0 alone or after drug0",True,effect
DDI-MedLine.d23.s2.e0,DDI-MedLine.d23.s2.e3,"Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug0, drug0, or drug2 but not after administration of drug0 alone or after drug0",True,effect
DDI-MedLine.d23.s2.e0,DDI-MedLine.d23.s2.e4,"Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug0, drug0, or drug0 but not after administration of drug2 alone or after drug0",False, 
DDI-MedLine.d23.s2.e0,DDI-MedLine.d23.s2.e5,"Ventricular tachycardia induced by drug1 was generally converted to sinus rhythm following administration of drug0, drug0, or drug0 but not after administration of drug0 alone or after drug2",False, 
DDI-MedLine.d113.s0.e0,DDI-MedLine.d113.s0.e1,Acid-catalyzed ethanolysis of drug1 in anhydrous and aqueous drug2,True,mechanism
DDI-MedLine.d113.s1.e0,DDI-MedLine.d113.s1.e1,The drug1 are a family of drug2 and drug0,False, 
DDI-MedLine.d113.s1.e0,DDI-MedLine.d113.s1.e2,The drug1 are a family of drug0 and drug2,False, 
DDI-MedLine.d113.s3.e0,DDI-MedLine.d113.s3.e1,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between drug1 (a drug2) and drug0",False, 
DDI-MedLine.d113.s3.e0,DDI-MedLine.d113.s3.e2,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between drug1 (a drug0) and drug2",True,mechanism
DDI-MedLine.d113.s3.e1,DDI-MedLine.d113.s3.e2,"In addition to this pharmacological interaction, this report describes a novel chemical reaction between drug0 (a drug1) and drug2",False, 
DDI-MedLine.d113.s5.e0,DDI-MedLine.d113.s5.e1,The results raise the possibility that the ethanolysis reaction may occur in the stomach of people who consume drug1 and drug2,True,mechanism
DDI-MedLine.d36.s0.e0,DDI-MedLine.d36.s0.e1,drug1 overdose recognized by a drug2,False, 
DDI-MedLine.d36.s2.e0,DDI-MedLine.d36.s2.e1,We report the case of an adolescent with altered consciousness caused by drug1 overdose with a positive drug2 level to alert clinicians to the cross-reactivity of drug0 with a toxicology screen for drug0,True,effect
DDI-MedLine.d36.s2.e0,DDI-MedLine.d36.s2.e2,We report the case of an adolescent with altered consciousness caused by drug1 overdose with a positive drug0 level to alert clinicians to the cross-reactivity of drug2 with a toxicology screen for drug0,False, 
DDI-MedLine.d36.s2.e0,DDI-MedLine.d36.s2.e3,We report the case of an adolescent with altered consciousness caused by drug1 overdose with a positive drug0 level to alert clinicians to the cross-reactivity of drug0 with a toxicology screen for drug2,False, 
DDI-MedLine.d36.s2.e2,DDI-MedLine.d36.s2.e3,We report the case of an adolescent with altered consciousness caused by drug0 overdose with a positive drug0 level to alert clinicians to the cross-reactivity of drug1 with a toxicology screen for drug2,True,advise
DDI-MedLine.d34.s0.e0,DDI-MedLine.d34.s0.e1,Interactions of drug1 and drug2,True,mechanism
DDI-MedLine.d34.s1.e0,DDI-MedLine.d34.s1.e1,"The effects of supplementary oral drug1 and drug2, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of drug0 and 48 or 446 mg/kg of drug0",False, 
DDI-MedLine.d34.s1.e0,DDI-MedLine.d34.s1.e2,"The effects of supplementary oral drug1 and drug0, as well as the interaction between both at the absorption site, fecal and urinary excretion as well as the retention of these trace elements were determined by using four diets containing either 9 or 63 micrograms/kg of drug2 and 48 or 446 mg/kg of drug0",False, 
DDI-MedLine.d34.s4.e0,DDI-MedLine.d34.s4.e1,drug1 excretion was enhanced by supplementary drug2,False, 
DDI-MedLine.d34.s7.e0,DDI-MedLine.d34.s7.e1,Additional drug1 significantly inhibited the absorption of drug2 in both dietary drug0,True,mechanism
DDI-MedLine.d34.s7.e0,DDI-MedLine.d34.s7.e2,Additional drug1 significantly inhibited the absorption of drug0 in both dietary drug2,True,mechanism
DDI-MedLine.d34.s7.e1,DDI-MedLine.d34.s7.e2,Additional drug0 significantly inhibited the absorption of drug1 in both dietary drug2,False, 
DDI-MedLine.d34.s8.e0,DDI-MedLine.d34.s8.e1,The lower rate of absorption in the groups receiving 446 mg drug1 instead of 48 mg of drug2 per kg diet resulted in a decreased renal excretion of drug0,False, 
DDI-MedLine.d34.s8.e0,DDI-MedLine.d34.s8.e2,The lower rate of absorption in the groups receiving 446 mg drug1 instead of 48 mg of drug0 per kg diet resulted in a decreased renal excretion of drug2,True,mechanism
DDI-MedLine.d34.s8.e1,DDI-MedLine.d34.s8.e2,The lower rate of absorption in the groups receiving 446 mg drug0 instead of 48 mg of drug1 per kg diet resulted in a decreased renal excretion of drug2,False, 
DDI-MedLine.d34.s9.e0,DDI-MedLine.d34.s9.e1,"Consequently, the effect of drug1 on the retention of drug2",True,mechanism
DDI-MedLine.d34.s11.e0,DDI-MedLine.d34.s11.e1,"Because of the low dietary drug1 concentration as compared to the drug2 contents of the diets, no effect of drug0 on drug0",False, 
DDI-MedLine.d34.s11.e0,DDI-MedLine.d34.s11.e2,"Because of the low dietary drug1 concentration as compared to the drug0 contents of the diets, no effect of drug2 on drug0",False, 
DDI-MedLine.d34.s12.e0,DDI-MedLine.d34.s12.e1,"Differences in drug1 balance were only observed between both dietary concentrations, showing a higher absolute but a lower relative absorption as well as retention in the groups fed further drug2",False, 
DDI-MedLine.d75.s3.e0,DDI-MedLine.d75.s3.e1,"The percentage of neurons hyperpolarized by drug1, drug2, and drug0",False, 
DDI-MedLine.d75.s3.e0,DDI-MedLine.d75.s3.e2,"The percentage of neurons hyperpolarized by drug1, drug0, and drug2",False, 
DDI-MedLine.d78.s1.e0,DDI-MedLine.d78.s1.e1,The drug1 are a rapidly growing class of drug2,False, 
DDI-MedLine.d78.s2.e0,DDI-MedLine.d78.s2.e1,"These agents, including drug1, drug2, drug0, drug0, and drug0",False, 
DDI-MedLine.d78.s2.e0,DDI-MedLine.d78.s2.e2,"These agents, including drug1, drug0, drug2, drug0, and drug0",False, 
DDI-MedLine.d78.s3.e0,DDI-MedLine.d78.s3.e1,"Advantages offered by this class of drug1 include optimal pharmacokinetics, effectiveness against multidrug-resistant organisms, and oral administration even when parenteral drug2",False, 
DDI-MedLine.d97.s8.e0,DDI-MedLine.d97.s8.e1,"Among the risk factors studied, two appear to increase the risk of ARE: the prescription of drug1 to treat strongyloidiasis during the drug2",True,effect
DDI-MedLine.d97.s10.e0,DDI-MedLine.d97.s10.e1,"Recommendations were to avoid administration of diffusible drug1 treatment during the cure, and to improve the general conditions of patients before the cure of drug2",False, 
DDI-MedLine.d62.s1.e0,DDI-MedLine.d62.s1.e1,"As immediate-early genes (IEGs) are thought to play a critical role in mediating stimulus-induced neural plasticity, IEG response induced by drug1 (drug2",False, 
DDI-MedLine.d62.s4.e0,DDI-MedLine.d62.s4.e1,"Using in situ hybridization, we observed that drug1 caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist drug2 but not by an drug0 drug0",True,effect
DDI-MedLine.d62.s4.e0,DDI-MedLine.d62.s4.e2,"Using in situ hybridization, we observed that drug1 caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist drug0 but not by an drug2 drug0",False, 
DDI-MedLine.d62.s4.e0,DDI-MedLine.d62.s4.e3,"Using in situ hybridization, we observed that drug1 caused a rapid and transient dose-dependent increase in arc mRNA level in the striatum and cortex that was abolished by pretreatment with the specific dopamine D1 receptor antagonist drug0 but not by an drug0 drug2",False, 
DDI-MedLine.d38.s0.e0,DDI-MedLine.d38.s0.e1,Acute drug1 administration does not affect subjective responses to drug2,False, 
DDI-MedLine.d38.s2.e0,DDI-MedLine.d38.s2.e1,"However, the effects of stress and drug1 on the subjective and behavioral effects of drug2",False, 
DDI-MedLine.d38.s3.e0,DDI-MedLine.d38.s3.e1,OBJECTIVES: To examine the effects of acute drug1 pretreatment on the subjective and behavioral effects of drug2,False, 
DDI-MedLine.d38.s4.e0,DDI-MedLine.d38.s4.e1,METHODS: drug1 (100 mg) and drug2,False, 
DDI-MedLine.d38.s8.e0,DDI-MedLine.d38.s8.e1,"However, drug1 pretreatment did not affect any of the physiological, behavioral, or subjective effects of drug2",False, 
DDI-MedLine.d38.s9.e0,DDI-MedLine.d38.s9.e1,"CONCLUSIONS: In contrast to the effects of drug1 in rodent studies, these results indicate that an acute increase in cortisol does not enhance the psychostimulant effects of drug2",False, 
DDI-MedLine.d42.s4.e0,DDI-MedLine.d42.s4.e1,"METHODS: Clinical studies, case reports, and commentaries and editorials concerning drug1 published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms drug2, drug0",False, 
DDI-MedLine.d42.s4.e0,DDI-MedLine.d42.s4.e2,"METHODS: Clinical studies, case reports, and commentaries and editorials concerning drug1 published in the international literature between January 1999 and August 2000 were identified through searches of MEDLINE, PREMEDLINE, and International Pharmaceutical Abstracts, using the terms drug0, drug2",False, 
DDI-MedLine.d42.s5.e0,DDI-MedLine.d42.s5.e1,"RESULTS: drug1 has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, drug2 [drug0",False, 
DDI-MedLine.d42.s5.e0,DDI-MedLine.d42.s5.e2,"RESULTS: drug1 has demonstrated effectiveness in men with erectile dysfunction associated with prostatectomy, radiation therapy, diabetes mellitus, certain neurologic disorders, and drug therapy (eg, drug0 [drug2",False, 
DDI-MedLine.d42.s9.e0,DDI-MedLine.d42.s9.e1,"however, patients with moderate to severe cardiovascular disease or those taking drug1 therapy are at increased risk for potentially serious cardiovascular adverse effects with drug2",True,effect
DDI-MedLine.d42.s10.e0,DDI-MedLine.d42.s10.e1,"In addition, patients taking drugs that inhibit the cytochrome P450 3A4 isozyme, which metabolizes drug1, may experience increased drug concentrations and possible toxicity from normal doses of drug2",False, 
DDI-MedLine.d67.s0.e0,DDI-MedLine.d67.s0.e1,"Effect of drug1 and drug2 on the antinociceptive effect of drug0, drug0 and drug0",False, 
DDI-MedLine.d67.s0.e0,DDI-MedLine.d67.s0.e2,"Effect of drug1 and drug0 on the antinociceptive effect of drug2, drug0 and drug0",False, 
DDI-MedLine.d67.s1.e0,DDI-MedLine.d67.s1.e1,"The influence of drug1 and drug2 on antinociceptive effect of drug0 (10 mg/kg), drug0 (500 mg/kg) and drug0",False, 
DDI-MedLine.d67.s1.e0,DDI-MedLine.d67.s1.e2,"The influence of drug1 and drug0 on antinociceptive effect of drug2 (10 mg/kg), drug0 (500 mg/kg) and drug0",False, 
DDI-MedLine.d67.s3.e0,DDI-MedLine.d67.s3.e1,drug1 were administered to mice 30 min before applying the drug2,False, 
DDI-MedLine.d67.s5.e0,DDI-MedLine.d67.s5.e1,drug1 at doses of 0.25 mg/kg and 2.5 mg/kg injected with drug2 was found to decrease the antinociceptive effect of drug0,True,effect
DDI-MedLine.d67.s5.e0,DDI-MedLine.d67.s5.e2,drug1 at doses of 0.25 mg/kg and 2.5 mg/kg injected with drug0 was found to decrease the antinociceptive effect of drug2,False, 
DDI-MedLine.d67.s5.e1,DDI-MedLine.d67.s5.e2,drug0 at doses of 0.25 mg/kg and 2.5 mg/kg injected with drug1 was found to decrease the antinociceptive effect of drug2,False, 
DDI-MedLine.d67.s6.e0,DDI-MedLine.d67.s6.e1,"Similarly, drug1 decreased the antinociceptive effect of drug2 (only in the tail-flick test) and drug0",True,effect
DDI-MedLine.d67.s6.e0,DDI-MedLine.d67.s6.e2,"Similarly, drug1 decreased the antinociceptive effect of drug0 (only in the tail-flick test) and drug2",True,effect
DDI-MedLine.d67.s6.e1,DDI-MedLine.d67.s6.e2,"Similarly, drug0 decreased the antinociceptive effect of drug1 (only in the tail-flick test) and drug2",False, 
DDI-MedLine.d67.s7.e0,DDI-MedLine.d67.s7.e1,"drug1 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug2, drug0 (only in the tail-flick test) and drug0",True,effect
DDI-MedLine.d67.s7.e0,DDI-MedLine.d67.s7.e2,"drug1 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug0, drug2 (only in the tail-flick test) and drug0",True,effect
DDI-MedLine.d67.s7.e0,DDI-MedLine.d67.s7.e3,"drug1 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug0, drug0 (only in the tail-flick test) and drug2",True,effect
DDI-MedLine.d67.s7.e1,DDI-MedLine.d67.s7.e2,"drug0 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug1, drug2 (only in the tail-flick test) and drug0",False, 
DDI-MedLine.d67.s7.e1,DDI-MedLine.d67.s7.e3,"drug0 used at doses of 1.25 mg/kg and 2.5 mg/kg decreased the antinociceptive effect of drug1, drug0 (only in the tail-flick test) and drug2",False, 
DDI-MedLine.d98.s0.e0,DDI-MedLine.d98.s0.e1,Behavioral responses to repeated drug1 exposure in mice selectively bred for differential sensitivity to drug2,False, 
DDI-MedLine.d98.s1.e0,DDI-MedLine.d98.s1.e1,"Mice from the 20th generation of three lines divergently selected for response to drug1-induced sedation times [long-sedation time (LST), short sedation time (SST), and randomly bred control (RBC)] were used to study drug2",False, 
DDI-MedLine.d69.s0.e0,DDI-MedLine.d69.s0.e1,"Differential regulation of tyrosine phosphorylation in tumor cells by drug1, a homodimeric disintegrin, and monomeric disintegrins drug2 and drug0",False, 
DDI-MedLine.d69.s0.e0,DDI-MedLine.d69.s0.e2,"Differential regulation of tyrosine phosphorylation in tumor cells by drug1, a homodimeric disintegrin, and monomeric disintegrins drug0 and drug2",False, 
DDI-MedLine.d69.s1.e0,DDI-MedLine.d69.s1.e1,The homodimeric disintegrin drug1 was compared directly to the monomeric disintegrins drug2 and drug0,False, 
DDI-MedLine.d69.s1.e0,DDI-MedLine.d69.s1.e2,The homodimeric disintegrin drug1 was compared directly to the monomeric disintegrins drug0 and drug2,False, 
DDI-MedLine.d69.s3.e0,DDI-MedLine.d69.s3.e1,"drug1 alone had no effect on tyrosine phosphorylation in T24 cells, but dose-dependently inhibits the effects of drug2",True,effect
DDI-MedLine.d69.s5.e0,DDI-MedLine.d69.s5.e1,"drug1 alone was found to have no effect on CAS, but can completely block drug2",True,effect
DDI-MedLine.d0.s0.e0,DDI-MedLine.d0.s0.e1,The effects of concomitant drug1 administration on the steady-state pharmacokinetics of drug2,False, 
DDI-MedLine.d0.s1.e0,DDI-MedLine.d0.s1.e1,drug1 ('drug2') is a newly introduced drug0,False, 
DDI-MedLine.d0.s1.e0,DDI-MedLine.d0.s1.e2,drug1 ('drug0') is a newly introduced drug2,False, 
DDI-MedLine.d0.s4.e0,DDI-MedLine.d0.s4.e1,This study demonstrated that the potent cytochrome P450 enzyme-inducer drug1 did indeed have a marked effect on the metabolism of drug2,True,mechanism
